<SEC-DOCUMENT>0001493152-24-010091.txt : 20240315
<SEC-HEADER>0001493152-24-010091.hdr.sgml : 20240315
<ACCEPTANCE-DATETIME>20240315160604
ACCESSION NUMBER:		0001493152-24-010091
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240315
DATE AS OF CHANGE:		20240315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Azitra, Inc.
		CENTRAL INDEX KEY:			0001701478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464478536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41705
		FILM NUMBER:		24754725

	BUSINESS ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405
		BUSINESS PHONE:		(203) 489-0183

	MAIL ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Azitra Inc
		DATE OF NAME CHANGE:	20170320
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:AZTR="http://azitrainc.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_AZTR_azitrainc.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001701478 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AmendmentFlag" id="ixv-12788">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-12789">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCentralIndexKey" id="ixv-12790">0001701478</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:EmployeeRetentionCredit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ForgivenessOfAccountsPayable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0475" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0477" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0479" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0491" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0493" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0495" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ForgivenessOfAccountsPayable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:PaymentsToAcquireCapitalizationOfLicenses" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:PaymentOfDeferredOfferingCosts" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0602" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ObtainingRightofuseAssetInExchangeForLeaseLiability" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ConversionOfNoteToCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ConversionOfNoteToConvertiblePreferredStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-012023-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember" id="xdx2ixbrl0825" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" id="xdx2ixbrl0833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0851" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember" id="xdx2ixbrl0863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31_us-gaap_LicensingAgreementsMember" id="xdx2ixbrl0873" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31_custom_TwentyTwentyOneConvertibleNotesMember" id="xdx2ixbrl0976" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoConvertibleNotesMember" id="xdx2ixbrl0980" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1241" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1243" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember" id="xdx2ixbrl1298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember" id="xdx2ixbrl1299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1346" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1348" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1497" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:DeferredTaxLiabilitiesDepreciationAndAmortization" contextRef="AsOf2023-12-31" id="xdx2ixbrl1525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:DeferredTaxLiabilitiesDepreciationAndAmortization" contextRef="AsOf2022-12-31" id="xdx2ixbrl1526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl1528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" id="xdx2ixbrl1529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2021-05-31_custom_GrotonCTMember" id="xdx2ixbrl1583" name="us-gaap:LesseeOperatingLeaseTermOfContract">P1Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2021-05-31_custom_GrotonCTMember" id="xdx2ixbrl1585" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P3Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31" id="xdx2ixbrl1597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2023-12-31" id="xdx2ixbrl1599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" id="xdx2ixbrl1629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AZTR:FinanceLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2023-12-31" id="xdx2ixbrl1631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember" id="xdx2ixbrl1691" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aztr-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-17_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-17_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CARESEmployeeRetentionCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AZTR:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AZTR:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_BuildingImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_BuildingImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwentyTwentyOneConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-17_custom_ForwardStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AZTR:ForwardStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ForwardStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AZTR:ForwardStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AZTR:TwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_SeriesA1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesA1PreferredStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YearTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YearTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YearTwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember101770734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandSixteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember101773265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember101773703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember101773718">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2036Through2037Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2036Through2037Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_NoExpirationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:NoExpirationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2037Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2037Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2036Through2038Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2036Through2038Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_country_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_country_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BranfordCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:BranfordCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_GrotonCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_GrotonCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_GrotonCTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_UnderwriterMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001701478</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_904_edei--DocumentType_c20230101__20231231_ziUMn8WfF691"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentType" id="ixv-14617">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentAnnualReport_c20230101__20231231_zFx0irKh7dn"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="ixv-14618">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20230101__20231231_zH7Mhq8ie7u7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-42"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20230101__20231231_zw4G4DhiDYI8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="ixv-14619">December 31</ix:nonNumeric></span>, <span id="xdx_908_edei--DocumentFiscalYearFocus_c20230101__20231231_zaocbAVcaxZf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-14620">2023</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentTransitionReport_c20230101__20231231_zV7JH0o4ZPdg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="ixv-14621">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from __________ to __________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <span id="xdx_90A_edei--EntityFileNumber_c20230101__20231231_zDh4hEO27V5g"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-14622">001-41705</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="height: 100px; width: 300px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20230101__20231231_zUZPet8IMG5k"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-14623">Azitra,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zXf0jr10BYj6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-14624">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230101__20231231_zWc8gx6xaGE5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-14625">46-4478536</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or Other Jurisdiction of<br/>
    Incorporation or Organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<br/>
    Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20230101__20231231_zW43ganXuXK5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-14626">21
Business Park Drive</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20230101__20231231_z6adIFKjqF3b"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-14627">Branford</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressStateOrProvince_c20230101__20231231_zdLtvpCkUoQ3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressStateOrProvince" id="ixv-14628">CT</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20230101__20231231_zvkwwafV3Api"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-14629">06405</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--CityAreaCode_c20230101__20231231_zKNHNbhYabq8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:CityAreaCode" id="ixv-14630">(203)</ix:nonNumeric></span>
<span id="xdx_901_edei--LocalPhoneNumber_c20230101__20231231_z11x5Mpa5QZ8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-14631">646-6446</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20230101__20231231_zdLTLNLiXgVk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:Security12bTitle" id="ixv-14632">Common
    stock: Par value $0.0001</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20230101__20231231_z6cFNw51Nu73"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:TradingSymbol" id="ixv-14633">AZTR</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20230101__20231231_zYYtDm5BFA95"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-14634">NYSE
    American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_904_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zmS8pVMPBGf7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-14635">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes &#9744; <span id="xdx_900_edei--EntityVoluntaryFilers_c20230101__20231231_zHXGT108ZK5g"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityVoluntaryFilers" id="ixv-14636">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20230101__20231231_zuLf1hssoSN5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-14637">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20230101__20231231_zlR9Z8qu3CGa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-14638">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20230101__20231231_zNyUfWFGcTwj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-14639">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntitySmallBusiness_c20230101__20231231_zpxh4CU4GNug"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="ixv-14640">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20230101__20231231_z0nNfkQHThgg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="ixv-14641">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_906_edei--EntityExTransitionPeriod_c20230101__20231231_zCMpdPiNbKXd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="ixv-14642">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zdtFS5Oz9JWa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" id="ixv-14643">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_z86NqKoLteAb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-14644">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <span id="xdx_90C_edei--EntityShellCompany_dbF_c20230101__20231231_z5nYJWhxa8Tj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="ixv-14645">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter: $<span id="xdx_90C_edei--EntityPublicFloat_iI_c20230630_zbuszk7AN2Oe"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14646">20,042,404</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of the registrant&#8217;s common stock outstanding as of March 15, 2024 was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_pid_c20240315_zQmRtWYbrnLa"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-15" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14647">28,804,643</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--DocumentsIncorporatedByReferenceTextBlock_c20230101__20231231_zcJx4WyYOEik"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-14648">The
registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended
December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.7in"><a href="#T_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#T_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#T_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_001">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_002">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_003">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_004">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_005">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_006">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_007">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Repurchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_008">Reserved</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_010">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_011">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_018">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_019">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_020">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_021">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_022">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_023">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_024">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_025">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_026">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_027">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_028">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_029">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_030">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_031">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include our expectations, beliefs,
intentions and strategies regarding the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other factors that may affect our financial results are discussed more fully in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this report. Moreover, we operate in a very
competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties
and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ
materially and adversely from those anticipated or implied in our forward-looking statements. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance
or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other
person assumes responsibility for the accuracy and completeness of the forward-looking statements. We caution readers not to place undue
reliance on any forward-looking statements. We do not undertake, and specifically disclaim any obligation, to update or revise such statements
to reflect new circumstances or unanticipated events as they occur, and we urge readers to review and consider disclosures we make in
this and other reports that discuss factors germane to our business. See in particular our reports on Forms 10-K, 10-Q, and 8-K subsequently
filed from time to time with the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all share and share price in this report gives effect to a forward stock split effected on May 17, 2023 at a
ratio of one for 7.1 for one.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>INDUSTRY
AND MARKET DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report, particularly the section &#8220;Business,&#8221; contains observations, statistical data, estimates, and forecasts that are based
on independent industry, government and non-government organization publications or other publicly available information, as well as
other information based on our internal sources. Although we believe that the third-party sources referred to in this report are reliable,
estimates as they relate to projections involve numerous assumptions, are subject to risks and uncertainties, and are subject to change
based on various factors, including those discussed under the section titled &#8220;<i>Risk Factors</i>&#8221; and elsewhere in this
report. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent
parties and by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information in the text of this report is contained in independent industry government and non-governmental organizational publications.
The sources of these publications are provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
                                            and Belkaid Study, <i>Apollo Stacy and Yasmine </i>Belkaid, Microbial Guardians of Skin Health.
                                            Science, 2019 Jan 18;363(6424):227-228. Doi: 10.1126/science.aat4326. PMID: 30655428</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oh
                                            Study, Zhou W, Spoto M, Hardy R, Guan C, Fleming E, Larson PJ, Brown JS, Oh J. Host-Specific
                                            Evolutionary and Transmission Dynamics Shape the Functional Diversification of Staphylococcus
                                            epidermidis in Human Skin. Cell. 2020 Feb 6;180(3):454-470.e18. doi: 10.1016/j.cell.2020.01.006.
                                            Epub 2020 Jan 30. PMID: 32004459; PMCID</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satoh
                                            Study, Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, Rordorf T, Maul
                                            JT, Hafner J, Navarini AA, Contassot E, French LE. IL-36&#947; drives skin toxicity induced
                                            by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020 Mar 2;130(3):1417-1430.
                                            doi: 10.1172/JCI128678. PMID: 31805013; PMCID: PMC7269569</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barbati
                                            Study, Netherton Syndrome in Children: Management and Future Perspectives, Federica Barbati,
                                            Mattia Giovannini Teresa Oranges, Lorenzo Lodi, Simona Barni, Elio Novembre, Ermanno Baldo,
                                            Mario Cristofolini, Stefano Stagi, Silvia Ricci, Francesca Mori, Cesare Filippeschi, Chiara
                                            Azzari and Giuseppe Indol; Frontiers in Pediatrics, May 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sun
                                            Study, Netherton syndrome: A case report and review of the literature, Joannie D. Sun, MD,
                                            and Kenneth G. Linden, PhD, MD, International Journal of Dermatology 2006</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphanet,
                                            Netherton Syndrome, Orphanet: Netherton syndrome</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those described in &#8220;Risk Factors&#8221; in this Annual Report
on Form 10-K. These risks include, but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are an early-stage clinical biopharmaceutical company with limited operating history;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a history of significant operating losses and anticipate continued operating losses
                                            for the foreseeable future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            expect we will need additional financing to execute our business plan and fund operations,
                                            which additional financing may not be available on reasonable terms, or at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            clinical and commercial utility of our microbial library and genetic engineering platform
                                            is uncertain and may never be realized;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates are in early stages of development, and therefore they will require extensive
                                            additional preclinical and clinical testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to grow the size of our organization, and we may experience difficulties in managing
                                            this growth;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            currently have no sales and marketing organization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will be completely dependent for the foreseeable future on third parties to manufacture our
                                            product candidates for commercial sale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business model includes the potential out-licensing of strains from our proprietary microbial
                                            library or our product candidates to other pharmaceutical companies; however, technology
                                            licensing in the pharmaceutical industry is a lengthy process and subject to several risks
                                            and factors outside of our control;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business may suffer with the loss of key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            product liability lawsuits are brought against us, we may incur substantial liabilities and
                                            may be required to limit commercialization of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business operations could suffer in the event of information technology systems&#8217; failures
                                            or security breaches;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face significant competition from other biotechnology and pharmaceutical companies targeting
                                            medical dermatological indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            success is entirely dependent on our ability to obtain the marketing approval for our product
                                            candidates by the FDA and the regulatory authorities in foreign jurisdictions in which we
                                            intend to market our product candidates, of which there can be no assurance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of
                                            our product candidates or any future product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            of preclinical studies of our product candidates may not be predictive of the results of
                                            future preclinical studies or clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we receive regulatory approval for any of our product candidates, we may not be able to
                                            successfully commercialize the product and the revenue that we generate from its sales, if
                                            any, may be limited;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            and future legislation may increase the difficulty and cost for us to obtain marketing approval
                                            of and commercialize our product candidates and affect the prices we may obtain;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is difficult and costly to protect our intellectual property rights, and we cannot ensure
                                            the protection of these rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates may infringe the intellectual property rights of others, which could increase
                                            our costs and delay or prevent our development and commercialization efforts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            active, liquid and orderly trading market for our shares may not develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
                                            capital raises may dilute your ownership and have other adverse effects on our operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            market price of our shares may be subject to fluctuation and volatility;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            failure to meet the continued listing requirements of the NYSE American could result in a
                                            delisting of our common stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we fail to maintain an effective system of internal control over financial reporting, we
                                            may not be able to accurately report our financial results or prevent fraud;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            ratified certain corporate actions pursuant to Section 204 of the Delaware General Corporate
                                            Law, or DGCL; however, there can be no assurance that claims will not be made to challenge
                                            the validity of the ratification or the related corporate actions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="T_001"></span>PART
I</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="T_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc. was formed as a Delaware corporation on January 2, 2014 for the purpose of developing innovative therapies for precision dermatology
using engineered proteins and topical live biotherapeutic products. Since our formation, we have built a proprietary platform that includes
a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our
library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the
transformation of previously genetically intractable strains. We have not commenced commercial operations. Unless otherwise indicated,
the terms &#8220;Azitra,&#8221; Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Azitra, Inc. and its
wholly-owned subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered
proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by
an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like
molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically
intractable strains. Our initial focus is on the development of genetically engineered strains of <i>Staphylococcus epidermidis, </i>or
<i>S. epidermidis, </i>which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The
particular species demonstrates a number of well-described properties in the skin. As of the date of this report, we have identified,
among our microbial library, over 60 distinct bacterial species that we believe are capable of being engineered to create living organisms
or engineered proteins with significant therapeutic effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineering bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal
microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or
peptides to treat skin diseases. Our initial focus is on the development of our current product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-12</b>,
                                            a genetically modified strain of <i>S. epidermidis </i>for treating the orphan disease, Netherton
                                            syndrome, a chronic and sometimes fatal disease of the skin estimated to affect approximately
                                            one to nine in every 100,000, but its prevalence may be underestimated due to misdiagnosis
                                            caused by similarities to other skin diseases. We received Pediatric Rare Disease Designation
                                            for ATR-12 by the United States Food and Drug Administration, or FDA, in 2019. In December
                                            2022, we submitted an investigational new drug application, or IND, for a Phase 1b clinical
                                            trial of ATR-12 in Netherton syndrome patients, and on January 27, 2023 we received notification
                                            from the FDA that the &#8220;study may proceed&#8221; with respect to the proposed Phase
                                            1b clinical trial. After submitting post-IND manufacturing reports, we have commenced operating
                                            activities for our Phase 1b clinical trial in December 2023. We expect to report initial
                                            safety results in the second half of 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-04</b>,
                                            a genetically modified strain of <i>S. epidermidis </i>for treating the papulopustular rash
                                            experienced by cancer patients undergoing epidermal growth factor receptor inhibitor, or
                                            EGFRi, targeted therapy. We intend to submit an IND for a Phase 1b clinical trial in certain
                                            cancer patients undergoing EGFRi targeted therapy by mid-2024. Subject to FDA clearance of
                                            our IND, we expect to commence our Phase 1b clinical trial in the fourth quarter of 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-01</b>,
                                            an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a chronic,
                                            xerotic (abnormally dry), scaly skin disease with an estimated incidence and prevalence of
                                            1 in 250, which suggests a total patient population of 1.3 million in the United States.
                                            We are planning to complete lead optimization and IND-enabling studies in 2024 to support
                                            an IND filing targeted for the second half of 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
                                            separate strains of bacterial microbes are being investigated and developed by us and Bayer
                                            Consumer Care AG, the consumer products division of Bayer AG, or Bayer, the international
                                            life science company. We entered into a Joint Development Agreement, or JDA, with Bayer in
                                            December 2019. Under the terms of the JDA, we are responsible for testing our library of
                                            bacterial strains and their natural products for key preclinical properties. After screening
                                            through hundreds of strains, we and Bayer have selected two particular strains to move forward
                                            into further development. Bayer holds the exclusive option to license the patent rights to
                                            these strains. In December 2020, Bayer purchased $8 million of our Series B preferred stock,
                                            which converted into 1,449,743 shares of our common stock, representing approximately 12.0%
                                            of our outstanding shares of common stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred Hutch, two
of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team takes advantage of the power
of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel, drug like peptides and
proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules made by microbes from
their genetic sequences. The system then compares the predictions to the products actually made through tandem mass spectroscopy and/or
nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly available 2D and 3D protein
databases to select drug like structures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyMPL technologies for all fields of genetic engineering,
including to discover, develop and commercialize engineered microbial therapies and microbial-derived peptides and proteins for skin
diseases. We are utilizing our licensed patent rights to build plasmids that in order to make genetic transformations that have never
been previously achieved. Our collaboration with Fred Hutch is led by Dr. Christopher Johnston, an expert in microbial engineering, and
the innovator behind the SyMPL technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused
on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing
the development of biologics for precision dermatology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_013.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Business Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered
proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
                                            a sustainable precision dermatology company. </i></b>Our goal is to build a leading precision
                                            dermatology company with a sustainable pipeline of product candidates. To that end, we are
                                            focused on rapidly advancing our current pipeline of live biotherapeutic candidates while
                                            actively developing additional product candidates. Each of our current product candidates
                                            are proprietary and subject to pending patent applications. We expect that most, if not all,
                                            genetically engineered product candidates we develop will be eligible for patent protection.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
                                            our lead product candidates, ATR-12 and ATR-04, through clinical trials.</i></b> We expect
                                            to report initial safety results of our Phase 1b clinical trial for our ATR-12 in Netherton
                                            syndrome patients in the second half of 2024 and are currently planning to commence a Phase
                                            1b trial of our ATR-04 in certain cancer patients undergoing EGFRi therapy in the fourth
                                            quarter of 2024. We have a cleared IND for ATR-12 and expect to file an IND for ATR-04 in
                                            mid-2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Broaden
                                            our platform by selectively exploring strategic partnerships that maximize the potential
                                            of our precision dermatology programs.</i></b> We intend to maintain significant rights to
                                            all of our core technologies and product candidates. However, we will continue to evaluate
                                            partnering opportunities in which a strategic partner could help us to accelerate development
                                            of our technologies and product candidates, provide access to synergistic combinations, or
                                            provide expertise that could allow us to expand into the treatment of different types of
                                            skin diseases. We may also broaden the reach of our platform by selectively in-licensing
                                            technologies or product candidates. In addition, we will consider potentially out-licensing
                                            certain of our proprietary technologies for indications and industries that we are not ourselves
                                            pursuing. We believe our genetic engineering techniques and technologies have applicability
                                            outside of the field of medicine, including cosmetics and in the generation of clean fuels
                                            and bioremediation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage
                                            our academic partnerships. </i></b>We currently have partnerships with investigators at the
                                            Fred Hutchinson Cancer Center, Yale University, Jackson Laboratory for Genomic Medicine,
                                            and Carnegie Mellon University. We have an exclusive license from the Fred Hutchinson Cancer
                                            Center covering DNA technologies, which enable the genetic transformation of strains that
                                            have previously been genetically intractable. Our collaboration with investigators at Carnegie
                                            Mellon University builds on an artificial intelligence and machine learning technology to
                                            predict the drug like molecules made by the microbes in our library. We have an ongoing scientific
                                            advisory board contract with Dr. Julia Oh of the Jackson Laboratories and have historically
                                            worked with Jackson Laboratories through sponsored research agreements for mouse experiments.
                                            We expect to leverage these partnerships and potentially expand them or form other academic
                                            partnerships to bolster our engineering platforms and expand our research and development
                                            pipeline.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Experienced
                                            management team and Board of Directors</i></b>. We are led by Francisco D. Salva, our chief
                                            executive officer, and Travis Whitfill, our co-founder and chief operating officer, who have
                                            more than 35 years of combined experience in the management of biotechnology companies and
                                            healthcare investing. Mr. Salva was previously a co-founder of Acerta Pharma, which was sold
                                            to AstraZeneca for approximately $6.3 billion in a staged acquisition beginning in 2016.
                                            He also worked on the turnaround of Pharmacyclics, which subsequently sold to Abbvie for
                                            approximately $21 billion in 2015. Before that, Mr. Salva spent almost a decade in life sciences
                                            venture capital. Mr. Whitfill served as associate research scientist and currently serves
                                            as assistant professor adjunct at Yale University with appointments in the Departments of
                                            Pediatrics and Emergency Medicine. He spent nearly a decade in venture capital as a partner
                                            in a biotech-focused venture capital fund, Bios Partners. He has led numerous grant-funded
                                            projects, holds nearly a dozen patents and has co-authored over 60 publications. Our board
                                            of directors, or Board, is comprised of renowned group of senior executives, scientists and
                                            investors in the biotechnology industry<b><i>.</i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Microbial Library and Microbial Drug Delivery Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commensal
microorganisms reside on either the surface of the body or in the mucosa without harming human health. They act on the host&#8217;s immune
system to induce protective responses that prevent colonization and invasion by infectious pathogens, and thereby play a crucial role
in maintaining human health across a number of organ systems, particularly in the skin. Diverse communities of microorganisms populate
the skin, and a square centimeter can contain up to a billion microorganisms. These diverse communities of bacteria, fungi, mites and
viruses can provide protection against disease and form dynamic, yet distinct niches on the skin. Together, they make up the skin microbiome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
genetically driven human diseases are systemically or partially related to the dysfunction of specific proteins that are missing or functionally
inert due to a mutation. Since approximately 1982, the biopharmaceutical industry has been genetically engineering recombinant proteins
in bacterial microorganisms for purposes providing therapies that mimic or support the body&#8217;s normally functioning proteins and
peptides. For decades, the vast majority of genetic engineering has been limited to primary <i>E. coli</i> and a handful of other bacterial
species, many of which can become pathogenic, inducing infection. In contrast, we have chosen to focus on <i>S. epidermidis</i> because
of its beneficial effects as a commensal, naturally occurring microbe on the skin. Our goal is to leverage our platform and internal
microbial library of over 60 bacterial species to engineer and deliver commensal skin bacteria directly to the target through the stratum
corneum of the skin. At these deeper levels in the skin, engineered microbes can produce the missing or inert proteins and thereby resolve
the underlying disease cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>S.
epidermidis and Our Proprietary Microbial Library</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>S.
epidermidis</i> is a strong therapeutic candidate species due to a number of well-described properties in the skin. <i>S. epidermidis
</i>is a gram-positive bacterium that is ubiquitous in the human skin and mucosal flora. As one of the earliest colonizers of the skin,
<i>S. epidermidis</i> plays an important role in cutaneous immunity and maintaining microbial community homeostasis. <i>S. epidermidis
</i>is known to have a beneficial relationship with its host as a skin commensal. The species has shown inhibition of the pathogenic
strain, <i>Staphylococcus aureus, or S. aureus,</i> as well as the strain <i>Propionibacterium acnes</i>, or <i>P. acnes</i>. <i>S. epidermidis
</i>induces keratinocytes to produce antimicrobial peptides and produces non-inflammatory T cell accumulation of both CD4+ and CD8+ T
cells via immune cell signaling. The T cell responses induce re-epithelization of the skin after injury, accelerating repair and wound
closure. For these reasons, we believe <i>S. epidermidis</i> offers several advantages as a vector for topical delivery of therapeutic
proteins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
their 2019 study, Stacy and Belkaid, world-leading experts in the skin microbiome, described <i>S. epidermidis</i> as &#8220;a &#8216;poster
child&#8217; of the skin microbiota to illustrate the remarkable diversity of functions a microbe can exert on skin physiology and health.&#8221;
We believe that <i>S. epidermidis</i> has enormous strain diversity that can be exploited for therapeutic purposes. In the 2020 Oh Study,
Julia Oh&#8217;s lab reported that 1,482 unique strains of <i>S. epidermidis</i> were present on only five individuals. These strains
had not only significant genetic diversity but also large phenotypic diversity. We believe this large inter-strain variation among <i>S.
epidermidis </i>can be exploited. To that end, we collected samples from healthy volunteers to develop and characterize our own strain
library of <i>S. epidermidis</i> that includes over 900 unique <i>S. epidermidis</i> strains with potential for therapeutic use. We have
used this microbial library to screen against selected properties, including antimicrobial peptide secretion, <i>S. aureus</i> killing,
antibiotic sensitivity, and other therapeutically relevant characteristics. We have also collected other species in our library that
includes roughly 60 different skin commensal species that can also be screened for therapeutic purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
1. Representative Species in Azitra Microbial Library</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Predictive
Analysis of Our Microbial Library</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry has seen success in identifying and isolating thousands of bacterial species. Yet only a relatively few such
species, believed to be less than 20, have been engineered to produce proteins or peptides with therapeutic potential. We have partnered
with Chemia Biosciences, Inc., a research and development group from Carnegie Mellon University. Through our collaboration with Chemia
Biosciences, we are able to use their proprietary genomic and peptidomic artificial intelligence and machine learning system, NRPMiner,
to develop and confirm natural product predictions of the proteins, peptides and small molecules that are generated by our proprietary
bacterial library. These predictions are confirmed via tandem mass spectroscopy or nuclear magnetic resonance. The information is then
fed back into the machine learning algorithm to refine the predictions. It can also be compared to existing 2D and 3D protein databases
to look for structural homology of our products to existing protein and peptide drugs. We believe our collaboration with the Carnegie
Mellon based team provides us with a scalable and modification tolerant way to accelerate therapeutic discoveries within our microbial
library.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Delivery of our Microbially Produced Drugs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of genetically engineered proteins to the subcutaneous target sites is hindered by the natural barrier and the defenses of the
stratum corneum. This is the skin&#8217;s outermost layer, which acts as a barrier that prevents unwanted materials from entering the
body. To address this challenge, we have developed a proprietary process capable of facilitating protein delivery in a manner that bypasses
the normally impenetrable stratum corneum. The strategy utilizes the ability of particular microbes to infiltrate into the deeper layers
of the skin. There, the genetically modified microbes act as miniature factories to produce a therapeutic protein or molecule where it
is needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
protein delivery capability for treating skin conditions is based on engineering <i>S. epidermidis</i> and other microbes to secrete
proteins for drug delivery into the skin. We believe any number of proteins can be engineered and encoded by our bacteria to be produced
and delivered to the skin to treat a variety of skin conditions. We have also added key proprietary features in its platform to facilitate
protein delivery. A key feature of this system is that it bypasses the normally impenetrable skin barrier, a problem of topical protein
delivery. The skin barrier, composed of the stratum corneum, is sealed by enucleated keratinocytes and formed by numerous structural,
physical, and biochemical properties. Other transdermal delivery challenges arise due to susceptibility of protein to enzymatic digestion
by proteases and solubility and diffusion impediments due the hydrophobic surface and the layers of linked corneocytes comprising the
stratum corneum. We address this issue by leveraging the natural homing of <i>S. epidermidis</i> to layers below the stratum corneum.
In preclinical studies, we have shown that <i>S. epidermidis</i> homes to layers below the stratum corneum and delivers proteins into
the deeper epidermis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
expand upon our recombinant protein construction capabilities, we have acquired an exclusive license to proprietary technology that disguises
our genetically engineered DNA sequences to enable the production of proteins in previously intractable bacterial species. The technology
from the Fred Hutchinson Cancer Center or Fred Hutch, expands the universe of bacterial species that can be genetically modified. It
is based upon a restriction modification system-silent SyMPL toolset. The SyMPL technology platform makes human-made DNA invisible to
the bacteria&#8217;s defenses. In theory, the method can be applied to any type of bacteria. Our current product candidates do not incorporate
the SyMPL technology platform, but we expect that some or all of our future product candidates will do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virtually
all strains of naturally occurring bacteria have defense mechanisms called restriction modification systems. The four types of restriction
modification systems recognize and defend against insertion of foreign DNA used to code recombinant proteins. Functional genetic engineering
of S<i>. epidermidis </i>(as well as <i>S. aureus</i>) has previously been limited due to the presence of Type I and IV restriction systems
in virtually all strains of these bacterial species. These restriction systems recognize methylated cytosine bases in DNA from standard
clone expansion systems (such as <i>E. coli)</i> and hinder incorporation of foreign DNA in the microbe. <i>S. epidermidis</i> was once
believed to be an &#8220;untransformable&#8221; strain due to its genetic intractability. However, we have been able to overcome <i>S.
epidermidis&#8217; </i>defenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
genetic engineering processes add specific modifications to disguise human made DNA to trick the bacterium into thinking the intruder
is a part of its own DNA. This approach often takes considerable time and resources to try to match the right disguise to each particular
recognition motif. In contrast, Fred Hutch&#8217;s SyMPL technology platform is a systematic &#8220;stealth-by-engineering&#8221; approach
to overcome restriction modification defense systems. These restriction modification defense systems protect microbes from foreign DNA
and hinder the vast majority of genetic engineering approaches. The SyMPL technology platform is based on the ability to build minicircle
DNA plasmids which lack any of the target recognition motifs for the microbe&#8217;s defense systems to identify. The technology uses
the genome and methylome from a target bacteria&#8217;s genomic sequence to identify the restriction modification target motifs. They
are then eliminated from the nucleotide sequence of the genetic tool <i>in silico</i>. The resulting sequence is used to build the restriction
modification, SyMPL tools. These are propagated and then used for genetic transformations. Not only does the &#8220;stealth by engineering&#8221;
approach enable transformations in genetically intractable bacterial strains, but it has also been shown to drastically increase transformational
efficiency. Proof of principle experiments have shown improvements of over 10,000x in yields of genetically engineered colonies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, Fred Hutch granted us an exclusive worldwide, royalty bearing license to the patent rights, and a non-exclusive worldwide,
royalty bearing license to the related know-how, for the SyMPL technology platform in all fields of use. For more information related
to the intellectual property acquired pursuant to the Fred Hutch license agreement, see the section titled &#8220;<i>Business-Licenses
and Intellectual Property Rights</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATR-12
for the treatment of Netherton syndrome</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-12
is our proprietary and patent-pending drug candidate that contains a novel strain of <i>S. epidermidis</i> which has been genetically
modified to express and secrete an active fragment of the full-length protein called the lympho-epithelial Kazal-type related inhibitor,
or LEKTI. It has also been engineered to be auxotrophic, meaning that it requires the D-alanine nutrient in its formulation to survive
and propagate. This provides an additional level of safety against potential systemic infection. ATR-12 is a topical application intended
to address the underlying cause of Netherton syndrome, by replacing deficient LEKTI with an active segment of human recombinant LEKTI,
or rhLEKTI-D6, to counter the dysregulated skin serine protease activity observed in Netherton syndrome patients. The uncontrolled serine
protease activity leads to a profound skin barrier defect and the release of pro-inflammatory and pro-allergic mediators by keratinocytes
and immune cells. As of the date of this report, there is no known therapy for the cure or effective treatment of Netherton syndrome.
We believe ATR-12 has the potential to be the first therapy to effectively treat this disease of the skin. Based on the Barbati and Sun
Studies, we believe that ATR-12 represents a potential $250 million global sales opportunity by mid-2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Netherton
syndrome overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherton
syndrome is a rare, autosomal recessive disease estimated to affect approximately one in every 200,000, but its prevalence may be underestimated
due to misdiagnosis. It is a chronic disease of the skin, characterized by severe inflammation, pruritus, scaling, red, and dehydrated
skin. Infants born with Netherton syndrome may suffer from a failure to thrive, and it has been reported that approximately one in ten
infants with Netherton syndrome die in their first year of life. Those that survive face a lifetime of skin disease challenges including
red, scaly skin, hair defects and an ongoing higher than normal risk for infection and allergy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherton
syndrome is caused by mutations in the <i>SPINK5</i> gene, which codes for the serine protease inhibitor Lympho-epithelial Kazal-type
related inhibitor, or LEKTI. The function of LEKTI is to inhibit enzymes in the epidermis, such as kallikreins 5, 7 and 14, or KLK5,
KLK7 and KLK14, which facilitate the shedding of skin cells in a process known as desquamation. When LEKTI is absent or has reduced activity,
excess shedding results and the skin is sensitive, open, and appears red and scaly. This is accompanied by the detachment of the stratum
corneum, leading to severe barrier dysfunction, dehydration and potential exposure to environmental agents, such as chemicals. Histopathology
and immunofluorescence staining of skin from a Netherton syndrome patient compared to healthy volunteer reveal an absence of LEKTI and
abnormalities in the skin such hyperkeratosis, epidermal thickening, and reduction of the basophilic keratohyalin granules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
2: Netherton syndrome pathophysiology and LETKI deficiency</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherton
syndrome can range in severity from mild, such as red patchy areas of the skin, to life threatening. The degree of severity of the disease
correlates directly with the extent of loss of function of LEKTI on the skin. Netherton syndrome appears shortly after birth and is most
severe in the first year of an infant&#8217;s life. Survival beyond the first year is common in most cases, but the implications of the
disease are a lifelong challenge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, there is no known cure for Netherton syndrome and treatment options are limited. Dermatologic interventions
to treat the severe skin manifestations of Netherton syndrome include moisturizers, topical corticosteroids, and calcineurin inhibitors,
all of which are limited in that they do not provide sustained remediation. Given the severity of disease during neonatal stages, fluid/electrolyte
and diet support are needed in addition to treating infections that often arise in these patients. While immunoglobulin therapy to address
immunodeficiencies associated with Netherton syndrome has shown limited success, a sustained remediation of skin barrier defects, induced
by dysregulation of LEKTI, is currently unavailable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
solution &#8211; ATR-12 for the treatment of Netherton syndrome</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-12
is a topical ointment containing an <i>S. epidermidis</i> strain, SE351, that has been genetically modified to express LEKTI from the
chromosome. The SE351 strain has also been engineered to be auxotrophic for D-alanine, which means it cannot survive without the exogenous
D-alanine nutrient provided in the formulation. ATR-12 is intended to address the underlying cause of Netherton syndrome by replacing
deficient/dysfunctional LEKTI with an active, recombinant, human fragment of the full-length protein, rhLEKTI-D6. The treatment consists
of applying ATR-12 to affected areas. rhLEKTI-D6 produced by SE351 will counter the dysregulated skin serine protease activity observed
in Netherton syndrome patients, to restore skin barrier function and reduce inflammation. We believe that among the important advantages
of this approach is the potential to deliver rhLEKTI-D6 over time into the lower layers of the stratum corneum and epidermis, the primary
sites of dysregulation in patients with Netherton syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<i>S. epidermidis</i> strain selected to deliver rhLEKTI-D6 to the skin, SE351, was selected from our proprietary strain collection.
This strain is characterized by low virulence and is a non-biofilm forming host strain. To further enhance the safety of ATR-12, we have
engineered the microbe for D-alanine to be auxotrophic. The key advantage to engineering auxotrophy is the ability to control growth
and halt potential infection. Full length human LETKI, a 15-domain protein (145 kDa), is too large for reliable bacterial expression
and secretion. Given evidence that fragments of the full-length protein are sufficient to counter the dysregulated skin serine protease
activity observed in Netherton syndrome patients, we selected D6 for recombinant expression in <i>S. epidermidis</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, we received Rare Pediatric Disease Designation from the FDA for ATR-12. As a result, if we are able to obtain approval for
ATR-12 from the FDA in pediatrics, we will be eligible to receive a Priority Review Voucher, which can be used by us to obtain FDA review
of a New Drug Application or Biologics License Application for this or another drug candidate in an expedited period of six months. These
vouchers are often transferable, and some have been sold for over $100 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
data for ATR-12</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have conducted several <i>in vivo</i> and <i>ex vivo </i>experiments that collectively support the potential
efficacy of ATR-12 as a disease modifying therapy for patients with Netherton syndrome. The genetically engineered strain of S. epidermidis
used in the formulated ATR-12 drug product is called SE351. In 2021, we conducted <i>in vitro</i> studies to assess the ability of exogenously
applied SE351 to colonize sterile reconstructed human epidermis. SE351 successfully colonized the reconstructed human epidermis and,
furthermore, no <i>S. epidermidis </i>colonization occurred without D-alanine present, confirming that D-alanine must be supplied for
SE351 growth on skin. These data suggest that SE351 is capable of colonizing human skin, and that colonization can be controlled with
D-alanine supplementation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
<i>in vitro </i>studies using tape stripped skin from healthy volunteers spiked with KLK5 to mimic Netherton syndrome showed that diluted
SE351 culture supernatant dose-dependently inhibited trypsin-like activity (KLK5 activity). Trypsin-like activity in the Netherton syndrome
surrogates returned to normal healthy levels when a solution containing &#8805;0.5% of the SE351 culture supernatant was added.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 192px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
3: <i>In Vitro</i> Netherton Syndrome Model Using Human Skin Tape Strip Extracts Supplemented with Disease Level KLK5 Activity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, results from an <i>ex vivo</i> pig skin model demonstrate that a single topical dose of ATR-12 at 3 dose levels led to secretion
of active rhLEKTI-D6. Finally, data from an <i>ex vivo</i> healthy human skin model demonstrate that a single topical dose of ATR-12
administered at the maximum intended dose of 10<sup>9</sup> CFU/g delivers enough active rhLEKTI-D6 into the lower layers of the stratum
corneum to effectively inhibit the protease, kallikrein 5 (&#8220;KLK5&#8221;), at levels typically observed in patients with Netherton
syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, data from an <i>ex vivo</i> healthy human skin model demonstrate that a single topical dose of ATR-12 administered at the
maximum intended dose of 10<sup>9</sup> Colony Forming Units per gram (CFU/g) delivers enough active rhLEKTI-D6 into the lower layers
of the stratum corneum to effectively inhibit KLK5 at levels typically observed in patients with Netherton syndrome. Amounts of LEKTI
activity in layers extracted were from tape strip samples from <i>ex vivo</i> human skin treated with placebo and ATR-12. The collection
proceeded right after skin application (T = 0 hours, white bars) or after 8 hours incubation at 30&#176;C (T = 8 hours, black bars). Total
LEKTI activity levels were obtained by adding the pmol amounts through layers 1 to 30 of placebo (grey bars) or ATR-12 (black bars) samples.
Data are the average &#177; a standard deviation (SD) of 3 independent samples (N = 3). Statistical analysis was carried out using
two-way ANOVA, and ** represents p &lt;0.01.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt="" style="height: 185px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
4: LETKI activity in Placebo and ATR-12-Treated Skin Samples Following 0- and 8-hour Incubation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a single therapeutic dose of ATR-12 over 24-hour incubation yielded ~2-fold higher LEKTI activity compared to 8-hour incubation.
This indicates continuous production of functional rhLEKTI-D6 by ATR-12 over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="height: 182px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
5: LETKI activity in Placebo and ATR-12-Treated Skin Samples Following 24-hour Incubation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
vitro</i> stoichiometry work performed by Azitra indicates that KLK5 requires 2 molar equivalents on the rhLEKTI-D6 protein for inhibition
(as measured by IC<sub>50</sub>). Historical studies have indicated that Netherton syndrome patients to show up to ~6 fold the amount
of KLK5 that the amounts found in normal skin. This equates to 60 pmol of KLK5 per given area. The studies shown above indicate that
SE351 delivered 350 pmol of rhLEKTI-D6 at 8 hours and it delivered 700 pmol of rhLEKTI-D6 at 24 hours. This represents a 5- to 11-fold
amount above the predicted amount required for activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_007.jpg" alt="" style="height: 210px; width: 279px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
6: <i>In vitro</i> stoichiometry of LEKTI-D6 to inhibit KLK5</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, we obtained pre-IND correspondence with the FDA for purposes of discussing our proposed regulatory pathway for ATR-12 and obtaining
guidance from the FDA on the preclinical plan leading to the filing and acceptance of an IND application for ATR-12. In December 2022,
we filed an IND for a first-in-human trial of ATR-12 in Netherton syndrome patients. Our IND proposes a Phase 1b multi-center, randomized,
double-blind, single dose level, placebo-controlled clinical study of ATR-12 in patients with Netherton syndrome. The primary endpoint
is safety and secondary endpoints will include signals of efficacy and pharmacokinetics. Exploratory endpoints include immune and inflammatory
mechanism biomarkers. On January 27, 2023, we received notification from the FDA that the &#8220;study may proceed&#8221; with respect
to the proposed Phase 1b clinical trial with initial safety results expected in the second half of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATR-04
for the Treatment of EGFRi-Associated Rash</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-04
is our proprietary and patent-pending drug candidate that contains a novel strain of <i>S. epidermidis</i>, SE484, which has been genetically
modified to be auxotrophic tor D-alanine. ATR-04 is a topical application intended to address the papulopustular rash experienced by
cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy. We believe this product candidate
represents a potential $1 billion global sales opportunity by 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>EGFRi-Associated
Rash Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targeted
cancer therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types, but they are also
associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant physical and psychological discomfort
for patients. Prevention and management of these toxicities may allow patients to tolerate treatments better, remain on therapy longer
and thereby potentially receive maximum clinical benefit from the drug. One such class of targeted cancer therapy includes EGFR inhibitors.
EGFR is a protein on the surface of cells that helps them grow and divide. It is also a key factor in certain malignancies, and its activity
enhances tumor growth, invasion, and metastasis. While systemic exposure to EGFRi agents suppresses EGFR at the target cancer site, it
also suppresses EGFR throughout the body. In the skin, EGFR regulates multiple keratinocyte functions including proliferation, adhesion
and migration, survival, and differentiation. Consequently, inhibition of EGFR in the skin results in adverse skin reactions, which make
it difficult for patients to stay on these effective therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermatologic
toxicities are amongst the most prevalent side effects seen with EGFRi-targeted therapies. The papulopustular rash is the earliest and
most common dermatologic adverse event of EGFRi treatment, often occurring in 50-80% of patients, depending on the drug, the cancer being
treated, and the treatment regimen. The appearance of the papulopustular rash is a dose-dependent skin drug reaction, which usually develops
in the first one to two weeks and peaks at three to four weeks on therapy. The intensity of the rash may start to decrease after two
weeks but can persists over the entire course of EGFRi treatment. The rash is characterized clinically as tender erythematous papules,
which after a few days evolve into pustules and then into crusts on the face, scalp, chest, and upper back. The rash is often accompanied
by severe xerosis and at times serious cutaneous bacterial infection, primarily <i>S. aureus</i>. While most skin rash episodes are considered
mild to moderate, some are severe. In many cases the rash leads to severe quality of life issues and can even lead to the interruption
or cessation of the EGFRi treatment<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current standard of care for rash treatment in patients undergoing EGFRi treatment varies depending on the rash severity. Typically,
skin moisturizers, topical steroids and doxycycline are administered prophylactically from the start of EGFRi therapy and are continued
throughout the entire treatment period. If the rash continues to advance, oral steroids and/or antibiotics are administered. However,
there are known systemic adverse events associated with these adjunctive therapies, and we believe that physicians and patients try to
limit their use. In addition, research indicates that oral antibiotics lead to a disruption in the gut microbiome, which in turn leads
to a decrease in the effectiveness of targeted therapies, including EGFRi. Given the high incidence rate of rash that continues with
these patients, as well as the concerns related to potential impacts of antibiotics on these therapies, we believe there is a clear unmet
medical need for additional safe and effective adjunctive therapies for addressing papulopustular skin rash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on studies conducted by Satoh and Lichtenberger, the cytokine, Interleukin-36 gamma, or IL-36&#947;, and <i>S. aureus</i> are linked
to and play a significant role in the rashes experienced by patients treated with EGFRis. IL-36&#947;, is elevated in the skin of patients
undergoing EGFRi therapy. In 2020, Satoh used gene expression profiling to identify IL-36&#947; as a candidate driver of EGFRi/MEKi
skin toxicity. It is induced by EGFR inhibition and <i>Cutibacterium acnes</i> that synergistically induce IL-36&#947; in the skin and
subsequently IL-8 and NF-&#954;B, which leads to cutaneous neutrophilia. IL-36&#947; could be a key therapeutic target in treating
EGFRi-induced rashes. In 2013, Lichtenberger noted high rates (70%) of bacterial infection in patients (n=107) on EGFRi and proposed
a mechanism of EGFR ablation leading to <i>S. aureus-</i>induced infection in mice. The study noted a majority of the patients were positive
with <i>S. aureus </i>(54%). Mechanistically, the authors noted that EGFRi therapy impairs host defense: impaired expression of antimicrobial
peptides, especially against <i>S. aureus</i>; and lowered expression of tight junctions. Also, the study revealed EGFR ablation leads
to skin barrier defects as well as impaired cutaneous immune response and cytokine expression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
solution &#8211; ATR-04 for the treatment of EGFRi-associated rash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-04
is our formulated, drug product candidate for the treatment of EGFRi associated rash. It includes a novel auxotrophic strain of <i>S.
epidermidis</i> strain that was selected from our microbial strain library, based on desired properties of IL-36&#947; reduction and
inhibition of <i>S. aureus</i> and its biofilms. The current lead strain is called SE484. We then genetically engineered SE484 to be
auxotrophic tor D-alanine and to create our drug product candidate, ATR-04.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SE484
was chosen from our microbial library based on key characteristics such as inhibition of IL-36&#947; as well as its effect against <i>S.
aureus</i>. Together, we expect these mechanisms of action to lead to significant reductions in rash severity among patients undergoing
EGFRi therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that ATR-04 has the potential to address current limitations to treatment of EGFRi-associated rash:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reduced
                                            antibiotic use. </b>From our surveys of clinicians and key opinion leaders, practitioners
                                            are reluctant to prescribe systemic antibiotics to patients undergoing EGFRi therapy. These
                                            patients can often be prescribed antibiotics for more than 12 months and suffer from antibiotic-related
                                            adverse events. We believe ATR-04 would reduce the need for antibiotics in these patients
                                            and lead to fewer adverse events due to EGFRi and antibiotic use.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Better
                                            EGFRi compliance. </b>Up to 20% of patients undergoing EGFRi therapy discontinue due to adverse
                                            events, primarily due to rashes. We believe we can reduce discontinuation rate in patients
                                            undergoing EGFRi therapy and thus increase compliance.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Higher
                                            quality of life. </b>Many patients on EGFRi therapy report a poor quality of life due to
                                            adverse events and papulopustular rashes. Current treatment options fail to adequately reduce
                                            these adverse events. We believe ATR-04 therapy in patients undergoing EGFRi therapy will
                                            have reduced rash severity and thus a higher quality of life.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
data of ATR-04</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
screened over 100 strains based on safety (e.g., lack of antibiotic resistance) and biological activity (e.g., IL-36&#947; inhibition
and activity versus <i>S. aureus</i>) and designated SE484 as our lead candidate strain. After engineering this strain to be auxotrophic
for D-alanine, we nominated this candidate for use as the active microbe in the ATR-04 drug product formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EGFRi-associated
rash is a condition that is characterized by redness, itchiness, and irritation of the skin, and is induced by certain cancer treatments.
It was shown, by gene expression profiling (Satoh et al 2020), that skin biopsy samples from patients suffering from EGFRi-associated
rash had elevated levels of cytokines IL-36&#947; (IL-36 gamma) and IL-8 compared to skin from healthy donors. These are proinflammatory
cytokines that are signaling molecules of the immune system that increase the intensity of an immune response and can cause tissue damage.
In addition to elevated cytokine levels, EGFRi-treated patients have impaired skin barrier function. Infection with pathogenic strains
of <i>S. aureus</i> exacerbates the EGFRi-induced cutaneous disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
work was focused on identifying a <i>Staphylococcus epidermidis</i> strain, a skin commensal, that reduces IL-36&#947; levels and thus
reduces the rash associated with EGFRi. We reasoned that many species of bacteria that live on human skin probably survive there because
they have evolved ways to reduce the human immune system&#8217;s response to their presence, and we might be able to identify a resident
human skin commensal bacteria that survives thereby specifically reducing IL-36&#947; activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
identify such a <i>Staphylococcus epidermidis</i> strain, we developed an <i>in vitro</i> assay to measure the levels of IL-36&#947;
and IL-8 that are produced by human skin cells that are grown in culture. The cell line we used is called HaCaT and is derived from human
keratinocytes, which are a cell type in the epidermis. In order to simulate the inflammatory phenotype of EGFRi-related disease of the
skin, HaCaT cells were stimulated with an immunostimulant, polyinosinic:polycytidylic acid, or poly I:C, which causes them to secrete
elevated levels of IL-36&#947; and IL-8. This assay was used to identify and evaluate the ability of different <i>S. epidermidis</i>
strains to lower IL-36&#947; and IL-8 levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
screened over 100 strains based on safety (e.g., lack of antibiotic resistance) and biological activity (IL-36&#947; inhibition and
activity against <i>S. aureus</i>) and designated SE484 as our lead candidate strain. After engineering this strain to be auxotrophic
for D-alanine, so that it will grow only if provided with D-alanine, we also eliminated an anti-biotic resistance gene. Then, we nominated
this candidate for use as the active microbe in the ATR-04 drug product formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
test the ability of SE484 to reduce IL-36&#947; on a skin-like model, erlotinib was used to induce IL-36&#947; secretion on reconstructed
human epidermis, or RHE. Simultaneous application of SE484 with erlotinib reduced IL-36&#947; to a level comparable RHE that had not
been treated with erlotinib, showing that SE484 acts on a skin-like model to reduce this pro-inflammatory cytokine. Figure 7 shows the
results of two experiments to measure IL-36&#947; reduction by SE484. In Figure 7A, a cell-free supernatant (CFS) from a culture of
SE484 was applied to RHE, while in Figure 7B live cells of SE484 (either 1x10<sup>8</sup> CFU or 1x10<sup>9</sup> CFU) were applied to
RHE to measure the ability of SE484 to reduce IL-36&#947;. In both cases, cell-free supernatant or SE484 cells, erlotinib-induced IL-36&#947;
levels were reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="height: 262px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
7. The anti-IL-36g activity of SE484 on RHE</b>. Reconstructed human epidermis, or RHE, was treated for 72 hours with 1 mM erlotinib
alone or with cell-free supernatant (CFS) from SE484 culture (A), or with approximately 10<sup>8</sup> or 10<sup>9</sup> CFU of SE484
(B). RHE feeding media was then assayed by ELISA for IL-36&#947; levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_009.jpg" alt="" style="height: 314px; width: 340px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
8. IL-8 induction by Poly I:C is Reduced by CS of SE484</b>. The presence of culture medium from SE484 prevents the stimulation and release
of IL-8 by poly I:C (red arrow). An inhibitor of poly I:C is used as control (blue arrow). Data are representative of two independent
experiments. CS = culture supernatant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
8 shows the inhibitory effect of SE484 culture supernatant on the induction of IL-8 by poly I:C. Similar to IL-36&#947;, when poly I:C
is added to HaCaT cells, IL-8 is also secreted, several fold above background (as seen in untreated HaCaT and SE484-treated HaCaT). However,
in the presence of SE484, lower levels of IL-8 were detected, thus further demonstrating the efficacy of SE484 to inhibiting the proinflammatory
pathway involved in EGFRi-related rash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results show that culture media of <i>S. epidermidis strain</i> SE484, which was isolated from a healthy human volunteer, can reduce
the level of IL-36&#947; and IL-8 produced by HaCaT cells (Figure 7 and Figure 8, respectively) and thus help in the treatment of EGFRi-
related rash. In addition to its anti-IL-36&#947; property, SE484 also has broad activity against different methicillin-resistant <i>S.
aureus</i>, or MRSA, strain types as well as methicillin sensitive <i>S. aureus</i>, or MSSA. The ability of SE484 to reduce IL-36&#947;/IL-8
levels as well as its activity against <i>S. aureus</i> and the engineered D-alanine auxotrophy enabled us to nominate strain SE484 for
use as the active microbe in the ATR-04 drug product formulation to form the basis of a treatment and reduce the severity of EGFRi rash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also shown that SE484 leads to <i>in vitro</i> inhibition of known virulent strains USA300, which is resistant to methicillin, and
MSSA, which is sensitive to methicillin. The following data show that ATR-04 reduces the ability of the pathogenic <i>S. aureus</i> bacterial
species to grow and instigate infections that are seen in patients with EGFRi rash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><img src="form10-k_010.jpg" alt="" style="height: 235px; width: 572px"/></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
9. Epidermin-expressing SE484 kills <i>S. aureus</i> with similar activity as mupirocin on in vitro agar plates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are proposing an initial study of SE484 in the ATR-04 formulation in patients. It is contemplated to be a Phase 1b multi-center, randomized,
double-blind, single-dose, placebo-controlled trial in patients with colorectal or head and neck cancer who are initiating EGFRi therapies.
The primary endpoint is safety, and secondary endpoints will include efficacy and Quality of Life, or QoL We are planning to submit an
IND by mid-2024. Subject to FDA clearance of our IND, we expect to commence our Phase 1b clinical trial in fourth quarter of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATR-01
for the treatment of ichthyosis vulgaris</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-01
is our drug product candidate intended to treat ichthyosis vulgaris. The program is currently investigating a proprietary and patent-pending
novel engineering segment of human filaggrin protein. ATR-01 is being developed as a topical application intended to address ichthyosis
vulgaris, a chronic scaly skin disease with an estimated incidence and prevalence of 1 in 250, which gives a total patient population
of 1.3 million in the United States. Ichthyosis vulgaris is caused by loss-of-function mutations in the gene encoding filaggrin Using
synthetic biology tools for protein engineering, we attached a cell penetrating peptide to filaggrin, which helps facilitate deeper skin
delivery for filaggrin. This is designed to overcome the impenetrability of the skin barrier, which would otherwise limit topical protein
delivery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ichthyosis
vulgaris overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ichthyosis
vulgaris, or IV, is a chronic, xerotic, scaly skin disease with an estimated incidence and prevalence of 1 in 250, which gives a total
patient population of 1.3 million in the United States. Clinical features of IV usually appear at around 2 months of age and include
generalized xerosis and fine, white to gray scales that are prominent on the abdomen, chest, and extensor surfaces of the extremities.
Although rare, some IV patients also experience hypohidrosis and heat intolerance. The pathogenesis of IV has long been identified as
a decrease in the size or number, or even a complete absence of, epidermal keratohyaline granules. In addition, patients with IV are
at increased risk for atopic dermatitis, asthma and allergies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ichthyosis
vulgaris is an autosomal semidominant disease caused by loss-of-function mutations in the gene encoding filaggrin. Filaggrin is an essential
structural protein that is derived from profilaggrin, which breaks down into individual filaggrin units in the stratum corneum. These
reinforce the skin barrier by binding to keratins and other intermediate filament proteins in the keratinocyte cytoskeleton. Many studies
have identified loss-of-function mutations in <i>FLG </i>in IV patients, and these mutations are associated with disorganized keratin
filaments, skin barrier defects and microfractures in the stratum corneum leading to enhanced percutaneous allergen sensitization. Moreover,
filaggrin and its breakdown products have significant additional functions in the skin including moisturizing the skin (via hygroscopic
amino acids or &#8220;natural moisturizing factors&#8221;), effecting production of antimicrobial molecules (particularly against <i>S.
aureus</i>) and maintaining both a beneficial lipid profile and pH in the skin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are few effective therapies for the treatment of IV. Current treatment options for IV include primarily topical water evaporation suppressants
(e.g., sodium chloride, urea, lactic acid, salicylic acid), and, to a lesser extent, moisturizers (e.g., glycerol, propylene glycol,).
Topical retinoids may also be prescribed in an effort to slow the body&#8217;s production of skin cells. However, long-term retinoid
use is not ideal. Of particular concern is the teratogenic effect of all retinoids, which limits their use in women of child-bearing
potential. Chronic toxicities from long term therapy with retinoids may result in skeletal abnormalities. Furthermore, the chronic use
of retinoids in children may inhibit their growth. Notably, many patients with IV experience a significantly reduced quality of life,
due to self-consciousness and social embarrassment, and see a negative impact on domestic life, educational/professional lives and even
leisure/sports activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
solution &#8211; ATR-01 for the treatment of ichthyosis vulgaris</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is now known that IV is caused by loss-of-function mutations in the gene encoding filaggrin, leading to disorganized keratin filaments,
skin barrier defects and microfractures in the stratum corneum, and resulting in enhanced percutaneous allergen sensitization as well
as bacterial and viral skin infection. We are developing ATR-01 as a novel treatment modality for IV that directly addresses the disease
pathophysiology. ATR-01 consists of FLG9-10 functional unit of the human FLG protein with an attached cell penetrating peptide. The goal
is to supplement the skin with stable delivery of hFLG via topical application and deeper skin penetration with a cell penetrating peptide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
data for ATR-01</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
FLG units (domains 9-10) were evaluated on human skin explants (from plastic surgery) <i>ex vivo</i>. The skin barrier of the explants
was compromised by repeated tape-stripping such that transepidermal water loss, or TEWL values were significantly increased compared
to normal skin. As shown in the example below, daily topical application of a human filaggrin unit with a cell penetrating peptide for
five days resulted in a dose-dependent (not shown) rapid improvement in TEWL, suggesting improved skin barrier. Thus, topical delivery
of a recombinant hFLG unit coupled with a cell penetrating peptide can improve/accelerate the repair of damaged human skin barrier.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_011.jpg" alt="" style="height: 254px; width: 576px"/></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
10: Topical filaggrin application on tape stripped <i>ex vivo</i> human skin following human filaggrin application.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
we have shown that topical filaggrin can improve skin barrier defects in filaggrin-deficient mouse models. Recombinant mouse filaggrin,
or mFlg, was applied to the tail of flaky tail, or FT, mice (a mouse model that has a knockout in the <i>filaggrin</i> gene) once daily
for 2 weeks (50 &#181;g total protein/tail sections or 15.2 &#181;g total protein/cm<sup>2</sup>). Daily treatment with mFlg significantly
improved transepidermal water loss in FT mice when treated (FT+FLG group) compared to vehicle (&#8220;baseline&#8221; group). The third
group on the X-axis is a normal, control, wild type group (WT) that does not have the <i>filaggrin</i> gene knocked out. Treatment of
damaged mouse skin with recombinant mFlg combined to a cell penetrating peptide improved damaged mouse skin barrier (Figure A below).
Additionally, histological analysis of the epidermis of the mouse tail sections showed tendency for improved stratum corneum thickness
with mFlg treatment (Figure B below). In this graph, the Y-axis represents thickening of the stratum corneum, which starts to fractionate
or scale after growing past a normal thickness. Treatment with mFlg improved the thickness in four of six of the samples.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_012.jpg" alt="" style="height: 234px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Potential Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates, our goal is to develop a broad portfolio of product candidates focused on expanding the application
of our platforms for precision dermatology. We have a proprietary platform for discovering and developing therapeutic products for precision
dermatology. Our platform is built around a microbial library comprised of approximately 1,500 unique bacterial strains to allow screening
for unique therapeutic characteristics and utilizes microbial genetic technology that analyzes, predicts and engineers the proteins,
peptides and molecules made by skin microbes. Our ability to genetically engineer intractable microbial species is uniquely leveraged
by our exclusive license to the SyMPL technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bayer
Joint Development Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, we entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which we agreed to the joint development
of certain strains selected from our proprietary microbial library. We and Bayer have agreed to cooperate in the identification and <i>in
vitro</i> and <i>ex vivo</i> characterization of microbial strains for topical formulations. Bayer paid us a one-time $150,000 payment
upon execution of the JDA and has agreed to reimburse us for our development costs. In October 2021, Bayer expanded the option agreement
and paid us $375,000 for additional characterization work. We have granted Bayer an option to acquire an exclusive royalty bearing license
for up to six strains subject to development activities under the JDA, including an exclusive royalty bearing license to any related
patent rights. After screening through hundreds of strains, we and Bayer have selected two particular strains to move forward with <i>in
vitro</i> and <i>ex vivo</i> characterization, which we intend to develop as potential over-the-counter cosmetic products. We completed
the characterization work and delivered the data to Bayer in the fourth quarter of 2023, at which time Bayer has 12 months to exercise
its option to license the strains and related patents. Upon the conclusion of the characterization studies and our delivery of the data
to Bayer, the JDA will end, but Bayer has the option to license the strains and related patents. As of the date of this report, we have
not negotiated a commercial license agreement with Bayer and we will not do so until such time, if ever, as Bayer exercises its option
to acquire an exclusive royalty bearing license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, Bayer&#8217;s venture capital group, LEAPS by Bayer, purchased $8 million of our Series B preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our stage of development, we have not yet established a commercial organization or distribution capabilities. We plan to build focused
capabilities in the United States to commercialize our development programs focused on live biotherapeutic products and recombinant proteins
for the treatment of skin diseases, where we believe the patient populations and medical specialists for the indications we are targeting
are sufficiently concentrated to allow us to effectively promote our products, if approved for commercial sale, with a targeted sales
team. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue strategic collaborations
with third parties in order to maximize the commercial potential of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of our current product candidates. We currently rely on third-party
contract manufacturers for all of our required raw materials, manufacturing devices and active pharmaceutical ingredients and for our
preclinical research and clinical trials. Although we are able to manufacture finished product in our Groton Connecticut facility for
our clinical trials, we will rely on third parties for the manufacture of our finished product for commercial sale. We do not have long-term
agreements with any of these third parties. We also do not have any current contractual relationship for the manufacture of Phase 3 clinical
trials or commercial supplies. We intend to enter into agreements with third-party contract manufacturers and one or more backup manufacturers
for future production. We are analyzing the feasibility of building manufacturing capabilities for future development and commercial
quantities of any products that we develop. Such products will need to be manufactured in facilities, and by processes, that comply with
the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential
competition from many different sources, including other biopharmaceutical companies, academic institutions and governmental agencies
as well as public and private research institutions. Any drug candidates that we successfully develop and commercialize will compete
with existing treatments and new treatments that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Netherton
syndrome</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Netherton syndrome, no drug has been approved by the FDA, specifically for Netherton syndrome, to date. Standard of care includes
cleansing of the skin with a gentle/soft non-detergent liquid cleansing oil, preferably with an acidic pH (5). Because Netherton syndrome
patient skin is most often dry, scaly and peeling, emollients and moisturizers are also often used. Keratolytics such as salicylic acid,
urea or alpha-hydroxy acids are often irritative and not well tolerated by Netherton syndrome patients. The skin of Netherton syndrome
patients is prone to frequent bacterial infections. Limited infections are treated with topical antibiotics for a short period of up
to 2 weeks. Oral antibiotics may also be used to treat the pathogenic <i>Staphylococcus aureus</i> and <i>Streptococcus</i> strains that
can drive more extreme infections. Bleach baths are also recommended two to three times a week for their antimicrobial effects. Topical
corticosteroids are often used to treat the inflammatory and hyperproliferation associated with non-infected Netherton syndrome lesions,
but due to their adverse effects, must be limited. These adverse events include aminoaciduria, Cushing syndrome, skin atrophy, adrenal
insufficiency, growth retardation, hypertension and weakness. Overuse of topical steroids can even aggravate the defective skin barrier
by inducing loss of the stratum corneum. Systemic retinoids have shown varying degrees of efficacy in Netherton syndrome, but also carry
bone toxicity and teratogenicity as adverse effects. Topical calcineurin inhibitors have been used to reduce erythema (redness) but patients
have shown a tachyphylaxis and reduced efficacy with prolonged treatment. These immunomodulators also carry risks of serious adverse
effects including increased risk of infections, swelling, burning sensations and tingling. Phototherapy (narrowband UVB (NB-UVB) and
psoralen-UVA (PUVA)) has also been investigated in Netherton syndrome patients but has been limited due to its potential to cause erythema
and increases in the risk of skin cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aware that Sixera Pharma initiated a clinical trial in Europe with SXR-1096, a topical small molecule KLK inhibitor in December
2021 for Netherton syndrome. In addition, Quoin Pharmaceuticals initiated two clinical trials with QRX003, a topical small molecule broad-spectrum
serine protease inhibitor, in December 2022 and March 2023. Boehringer Ingelheim is also recruiting for a Phase 2/3 clinical trial for
Netherton syndrome with spesolimab, an IL-36 inhibitor. Krystal Biotech, MatriSys, and BridgeBio have reported they are developing Netherton
syndrome programs that are at a preclinical stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than ATR-12 or any other drug that we may develop.
Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for our drug,
which could result in our competitors establishing a strong market position before we are able to enter the market. Many of the companies
against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical
trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>EGFRi-Associated
Rash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, no drug has been specifically approved by the FDA for the treatment of EGFRi-associated rash. The majority of patients (estimated
to be up to 90%) treated continuously with anti-EGFR therapies suffer from dermatological adverse events, especially papulopustular rash,
pruritus (itching), xerosis (dryness), and paronychia (nail infections). Papulopustular or acneiform rash is the most common adverse
event of EGFRis on the skin. This rash negatively impacts compliance with EGFRi treatment in many patients. Dose modification or discontinuation
treatment occurs in severe cases. Because evidence-based controlled trials are still very sparse, treatment of EGFRi skin toxicity primarily
relies on physician experience, and recommendations from expert consensus conferences. As a result, there are geographical variations
and even inconsistencies in the clinical treatment of EGFRi skin rash. Topical corticosteroids are avoided in Europe with respect to
acneiform rash but are often used in the United States. Furthermore, topical treatment is frequently customized to the individual patient
and may change on a case-by-case basis. No topical treatment scheme is universally applicable for all patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are aware of the following Phase 2 programs developing investigational drug candidates for EGFRi associated rash. Lutris Pharma is developing
LUT014, a topical B-Raf inhibitor, in the US and Israel. Daewoong Pharmaceutical Co. Ltd. is developing DWP708 in Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
actively seek to protect our proprietary technology, inventions, improvements to inventions and other intellectual property that is commercially
important to the development of our business by a variety of means, such as seeking, maintaining and defending patent rights, whether
developed internally or licensed from third parties. We also may rely on trade secrets and know-how relating to our proprietary technology
platform, on continuing technological innovation and on future in-licensing opportunities to develop, strengthen and maintain the strength
of our position in the field of gene therapy that may be important for the development of our business. Additional regulatory protection
may also be afforded through data exclusivity, market exclusivity and patent-term extensions where available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we own or exclusively license three issued U.S. patents, 12 pending U.S. patent applications, three pending
PCT application and 57 other foreign patents and patent applications that are important to the development of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to file patent applications to protect proprietary technology, inventions and improvements to inventions and other intellectual
property that may be commercially important to the development of our business. We also intend to seek additional patent protection or
rely upon know-how or trade secret rights to protect other technologies that may be used to manufacture and develop our live biotherapeutic
products. As described below, we are a party to exclusive license agreements that grant us rights to use specific technologies in our
live biotherapeutic products and in the manufacturing and development of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Patent Portfolio</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio has broad coverage for therapeutic bacteria pharmaceutical compositions containing these therapeutic bacteria for treating
abnormal skin conditions and methods of making and using these recombinant bacteria. In our broadest filing, we have secured a US patent
that protects pharmaceutical compositions for treating abnormal skin conditions using a bacterial strain expressing a therapeutically
effective amount of a recombinant polypeptide. This patent expires in May 2035. Specifically, this issued patent covers a pharmaceutical
composition containing one or more of the following bacterial strains: Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus,
Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, wherein the bacterial strain has
been engineered to produce a therapeutical polypeptide for treating the abnormal skin conditions. We believe that this patent gives us
broad protection for using recombinant bacteria to treat skin diseases and disorders. through its expiration in May 2035.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications directed to our most advanced programs are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATR-12</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ATR-12 product candidate is subject to three issued US patents, seven pending US patent applications, and 31 pending foreign patents
and patent applications. These patents and patent applications represent ten families of claims covering, among other aspects, the pharmaceutical
composition of <i>S. epidermidis </i>expressing a recombinant therapeutic polypeptide, the auxotrophic strain of <i>S. epidermidis</i>,
and the recombinant <i>S. epidermidis </i>strain expressing a therapeutic LEKTI protein, and formulations of ATR-12. One of the issued
US patents covers a recombinant bacterial strain containing a therapeutic polypeptide for treating abnormal skin conditions and expires
in 2035. The second issued US patent covers an auxotrophic <i>S. epidermidis </i>that will expire in 2039. If additional patents were
to grant from the pending patent applications, they would expire between 2035 and 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATR-04</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ATR-12 product candidate is subject to one issued US patent, two pending US patent applications, and 17 pending foreign applications.
These patents and patent applications represent two families of claims directed to auxotrophic strains of bacteria and their therapeutic
use for treating disease. We have one issued US patent that covers ATR-04. If additional patents were to grant, they would also expire
in 2039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Term and Term Extension</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the
legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United
States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in
certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office,
or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review
period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend
the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension,
and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. The duration of
foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective
filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must
be timely paid in order for the patent to remain in force during this period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual protection afforded by a patent may vary on a product-by-product basis, from country to country, and can depend upon many factors,
including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal
remedies in a particular country and the validity and enforceability of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and
protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise
violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled
&#8220;<i>Risk Factors&#8212;Risks Related to Our Intellectual Property</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Secrets and Know-How</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on trade secrets, know-how, continuing technological innovation and confidential information to develop and maintain our
proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection, including our proprietary processes for manufacturing our live biotherapeutic products. We seek to protect our proprietary
technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants,
scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us
inventions made during the term of their employment or term of service. These agreements may be breached, and we may not have adequate
remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To
the extent that our contractors, commercial partners, collaborators, employees, and consultants use intellectual property owned by others
in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, see
the section titled &#8220;<i>Risk Factors&#8212;Risks Related to Our Intellectual Property</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises
and physical and electronic security of our information technology systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
License Agreement with Fred Hutchison Cancer Center</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into an Exclusive License Agreement with the Fred Hutchinson Cancer Center, or Fred Hutch. Pursuant to our agreement
with Fred Hutch, we obtained an exclusive worldwide license under certain patents related to SyMPL technologies developed and owned by
Fred Hutch to develop, make, manufacture, have manufactured, distribute, have distributed, use, research, improve, import, offer to sell
and sell and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained
by Fred Hutch and the U.S. government. The patent rights licensed to us by Fred Hutch consist of two families of patent applications
directed to methods of bypassing restriction modification systems in order to more easily introduce xenogeneic DNA into engineered microbes.
These patents applications and any patents that issue from these applications will allow us to produce more modified microbes for the
treatment of disease. Our current product candidates do not incorporate the SyMPL technology platform, but we expect that some or all
of our future product candidates will do so. If issued, these two families will expire in 2037 and 2040, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the license granted to us under the Fred Hutch license agreement, we paid Fred Hutch a nominal upfront payment. In addition,
we are required to pay Fred Hutch certain development and commercial milestone payments and running single digit royalty on net sales
of the licensed products. The Fred Hutch agreement also requires us to reimburse Fred Hutch for the cost of the prosecution and maintenance
of the licensed patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Fred Hutch license agreement, we are required to use commercially reasonable efforts to bring a licensed product to market through
a vigorous and diligent program for exploitation of the licensed patent rights. The term of the Fred Hutch license agreement will continue
until the later of (i) the expiration of the licensed patents or (ii) ten years from the first sale of a licensed product. We may terminate
the Fred Hutch license agreement at will at any time upon prior written notice to Fred Hutch. Fred Hutch has the right to terminate the
Fred Hutch license agreement if we materially breach the agreement and fail to cure such breach within a specified cure period or if
we become bankrupt or insolvent. For more information related to the intellectual property acquired pursuant to the Fred Hutch license
agreement, see the section titled &#8220;<i>Business-Licenses and Intellectual Property Rights</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also hold registered trademarks for our corporate name and design in the U.S. and in seven foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by foreign, federal, state and local agencies, such as the U.S. FDA, and various similar
agencies in most countries worldwide. The research, development, testing, manufacture, distribution, packaging, labeling, storage, recordkeeping,
marketing and sale of pharmaceutical products are subject to government regulation in the U.S. and various foreign countries. Additionally,
in the U.S., we must follow rules and regulations established by the FDA requiring the presentation of data indicating that our product
candidates are safe and effective and are manufactured in accordance with cGMP regulations. If we do not comply with applicable requirements,
we may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market our product candidates,
and we may be criminally prosecuted. We, our manufacturers and clinical research organizations may also be subject to regulations under
other foreign, federal, state and local laws, including, but not limited to, the U.S. Occupational Safety and Health Act, the Resource
Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other
countries. The U.S. government has increased its enforcement activity regarding illegal marketing practices domestically and internationally.
As a result, pharmaceutical companies must ensure their compliance with the Foreign Corrupt Practices Act and federal healthcare fraud
and abuse laws, including the False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
regulatory requirements impact our operations and differ from one country to another, so that securing the applicable regulatory approvals
of one country does not imply the approval of another country. The approval procedures involve high costs and are manpower intensive,
usually extend over many years and require highly skilled and professional resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Market Approval Process</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., our product candidates are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public
Health Service Act, or PHSA, and regulations promulgated by the FDA. The failure to comply with the applicable requirements at any time
during the product development process, including preclinical testing, clinical testing, the approval process or post-approval process,
may subject an applicant to delays in the conduct of clinical trials, regulatory review and approval, and/or administrative or judicial
sanctions. These sanctions may include, but are not limited to, the FDA&#8217;s refusal to allow an applicant to proceed with clinical
testing, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, adverse
publicity, customer notification, product recalls, product seizures, refusal to grant export or import approval, total or partial suspension
of production or distribution, consent decrees, injunctions, fines, and civil or criminal investigations and penalties brought by the
FDA or the U.S. Department of Justice, or other governmental entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps usually required to be taken before a new biologic may be marketed in the U.S. generally include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s
                                            current Good Laboratory Practices regulation;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an IND, which must become effective before clinical trials may begin and must
                                            be updated annually or when significant changes are made;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an independent Institutional Review Board, or IRB, or ethics committee at each treatment
                                            site before the trial is commenced;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well controlled human clinical trials to establish the safety, purity and
                                            potency of the proposed biologic product candidate for its proposed indication for use;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            of data supporting safety and efficacy as well as detailed information on the manufacture
                                            and composition of the product in clinical development and proposed labeling;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
                                            of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination by the FDA within 60 days of its receipt of a BLA to file the application for
                                            review;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                            at which the proposed product is produced to assess compliance with cGMP standards and to
                                            assure that the facilities, methods and controls are adequate to preserve the biological
                                            product&#8217;s continued safety, purity and potency, and of selected clinical investigation
                                            sites to assess compliance with Good Clinical Practices, or GCP;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance
                                            with CGP requirements and the integrity of clinical data in support of the BLA;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of user fees and securing FDA approval of the BLA for the proposed indication for use;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            review and approval of the BLA to permit commercial marketing of the product for particular
                                            indications for use in the United States; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                            with any post-approval requirements, including REMS and any post-approval studies required
                                            by the FDA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Studies and Investigational New Drug Application</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential
for efficacy and toxicity in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with
federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data,
are submitted to the FDA as part of an IND application. Some preclinical tests may continue even after submission of the IND application.
The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions
about the product or conduct of the proposed clinical trial, including concerns that human research volunteers will be exposed to unreasonable
health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, submission of the IND may result in the FDA not allowing the clinical trials to commence or allowing the clinical trial to
commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial
30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. This order issued
by the FDA would delay either a proposed clinical trial or cause delay in initiation of a phase of an ongoing clinical trial, until all
outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could
cause significant delays or difficulties in completing planned clinical trials in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated
under the supervision of a qualified principal investigator in accordance with good clinical practice, or GCP, requirements. Clinical
studies are conducted under protocols detailing, among other things, the objectives of the study, what types of patients may enter the
study, schedules of tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety,
and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted
to the FDA as part of the IND process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial
under an IND. If a clinical trial outside the U.S. is not conducted under an IND, the sponsor may submit data from the clinical trial
to the FDA in support of a BLA so long as the clinical trial is conducted consistent with the spirit of GCP and in compliance with an
international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations
of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in
the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IRB, either centrally or individually, must also review each clinical trial at each institution at which the clinical trial will be conducted.
The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects,
the possible liability of the institution, and, where appropriate, the protection of privacy of the human subjects. An IRB must operate
in compliance with the FDA regulations. The FDA, IRB, or the clinical trial sponsor, or the principal investigator may suspend or discontinue
a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with
FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive
GCP rules and the requirements for informed consent. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether
or not a trial may move forward at designated check points based on access to certain data from the study. The clinical study sponsor
may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are usually conducted in three sequential phases, but the phases may overlap or be combined. Annual progress detailing the results
of the clinical trial phases must be submitted to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            1</i> clinical trials are normally conducted in small groups of healthy volunteers to assess
                                            safety and tolerability of various dosing regimens and pharmacokinetics. For some products
                                            for orphan, severe or life-threatening diseases, especially if the product may be too toxic
                                            to administer to healthy humans, the initial clinical trials may be conducted in individuals
                                            having a specific disease for which use the tested product is indicated. These trials in
                                            patients are often referred to as Phase 1b trials. If they include a design to establish
                                            a particular dose, they are commonly referred to as Phase 1b/2a clinical trials. Nevertheless,
                                            additional Phase 2 (sometimes called Phase 2b) clinical trials are often necessary to refine
                                            the final dose chosen to take into a pivotal Phase 3 clinical trial.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            2</i> clinical trials are generally conducted in a limited patient population to identify
                                            possible adverse effects and safety risks, evaluate the efficacy of the product candidate
                                            for specific targeted indications and determine does tolerance and optimal dosage. Multiple
                                            Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
                                            larger and more costly Phase 3 clinical trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
                                            3</i> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range
                                            of the product candidate is potentially effective and has an acceptable safety profile. Phase
                                            3 clinical trials are undertaken to further evaluate, in a larger number of patients, dosage,
                                            provide substantial evidence of clinical efficacy and further test for safety in an expanded
                                            and diverse patient population at multiple, geographically dispersed clinical trial sites.
                                            A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data
                                            that regulatory authorities will use to decide whether or not to approve, and, if approved,
                                            how to appropriately label a drug: such Phase 3 studies are referred to as &#8220;pivotal.&#8221;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary or permanent discontinuation of a clinical study at any time or impose other sanctions if it believes that
the clinical study is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable
health risk. In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical
trials to further assess the drug&#8217;s safety and effectiveness after BLA approval. Such post-approval trials are typically referred
to as Phase 4 clinical trials. These studies are used to gain additional experience data from the treatment of patients in the intended
therapeutic indication and to document a clinical benefit in the case of drugs or biologics approved under accelerated approval regulations.
If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able
to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the
product labeling. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval
for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with cGMP Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a product candidate moves through the clinical testing phases, manufacturing processes are further defined, refined, controlled and validated.
The level of control and validation required by the FDA increases as clinical studies progress. The FDA typically will not approve a
BLA application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and
able to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing
control for products like biologics whose attributes cannot be precisely defined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the third-party manufacturers on which we rely for the manufacture of our product candidates and their respective components (including
the active pharmaceutical ingredient, or API) are subject to requirements that drugs be manufactured, packaged and labeled in conformity
with cGMPs. To comply with cGMP requirements, manufacturers must continue to spend time, money and effort to meet requirements relating
to personnel, facilities, equipment, production and process, labeling and packaging, quality control, recordkeeping and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain
state regulatory bodies. Both U.S. and non-U.S. manufacturing establishments must register and provide additional information to the
FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not
registered, whether U.S. or non-U.S., is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections
by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221;
that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic
or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product
being deemed to be adulterated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BLA
Submission and Review</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
completion of all required testing in accordance with all applicable regulatory requirements, detailed information on the product candidate
is submitted to the FDA in the form of a BLA, requesting approval to market the product for one or more indications, together with payment
of a user fee, unless waived. A BLA includes all relevant data available from pertinent nonclinical and clinical studies, including negative
or ambiguous results as well as positive findings, together with detailed information on the chemistry, manufacture, controls and proposed
labeling, among other things. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish
the safety and efficacy of the product candidate for its intended use to the satisfaction of the FDA. The FDA also conducts a pre-approval
inspection of the manufacturer and laboratory prior to approval of the BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a BLA submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the Prescription Drug User Fee Act, or PDUFA,
the FDA&#8217;s goal is to complete its initial review and respond to the applicant within ten months of submission, unless the application
relates to an unmet medical need, or is for a serious or life-threatening indication, in which case the goal may be within six months
of BLA submission. However, PDUFA goal dates are not legal mandates, and the FDA response often occurs several months beyond the original
PDUFA goal date. Further, the review process and the target response date under PDUFA may be extended if the FDA requests or the BLA
sponsor otherwise provides additional information or clarification regarding information already provided in the BLA. The BLA review
process can, accordingly, be very lengthy. During its review of a BLA, the FDA may refer the application to an advisory committee for
review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of
an advisory committee, but it typically follows such recommendations. Data from clinical studies are not always conclusive and the FDA
and/or any advisory committee it appoints may interpret data differently than the applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the BLA and inspects manufacturing facilities where the drug product and/or its API will be produced and tested, it
will either approve commercial marketing of the drug product with prescribing information for specific indications or issue a complete
response letter indicating that the application is not ready for approval and stating the conditions that must be met in order to secure
approval of the BLA. If the complete response letter requires additional data and the applicant subsequently submits that data, the FDA
nevertheless may ultimately decide that the BLA does not satisfy its criteria for approval. The FDA could also approve the BLA with a
Risk Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications,
or a commitment to conduct post-marketing testing. Such post-marketing testing may include Phase 4 clinical trials and surveillance to
further assess and monitor the product&#8217;s safety and efficacy after approval. Regulatory approval of products for serious or life-threatening
indications may require that participants in clinical studies be followed for long periods to determine the overall survival benefit
of the drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA approves one of our product candidates, we will be required to comply with a number of post-approval regulatory requirements.
We would be required to report, among other things, certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling for any of our product candidates.
Also, quality control and manufacturing procedures must continue to conform to cGMPs after approval, and the FDA periodically inspects
manufacturing facilities to assess compliance with cGMPs, which imposes extensive procedural, substantive and record keeping requirements.
If we seek to make certain changes to an approved product, such as certain manufacturing changes, we may need FDA review and approval
before the change can be implemented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication
that has not been approved. Securing FDA approval for new indications is similar to the process for approval of the original indication
and requires, among other things, submitting data from adequate and well-controlled studies that demonstrate the product&#8217;s safety
and efficacy in the new indication. Even if such studies are conducted, the FDA may not approve any change in a timely fashion, or at
all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also require post-marketing testing, or Phase 4 testing, as well as risk minimization action plans and surveillance to monitor
the effects of an approved product or place conditions or an approval that could otherwise restrict the distribution or use of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fast
Track, Breakthrough Therapy and Priority Review Designations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition, or in the event of an emergency. These programs are fast track designation, breakthrough
therapy designation and priority review designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products,
for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs
for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate
review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available
if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.
The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must
pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last
section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that
the designation is no longer supported by data emerging in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory
scheme allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a
breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide
a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents
a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and
to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Secretary of Health and Human Services may authorize unapproved drugs and biologics to be marketed in the event an actual or potential
emergency has been designated by the U.S. government. After an emergency has been designated, the FDA may issue an Emergency Use Authorization,
or EUA, for the use of a specific product based on criteria established by the FDCA. An EUA is product specific and is subject to specific
conditions and restrictions. Once the emergency underlying the EUA ends, then the EUA terminates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Rare Disease Designation and Priority Review Vouchers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, as amended, the FDA incentivizes the development of drugs and biologics that meet the definition of a &#8220;rare pediatric
disease,&#8221; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily
affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects
200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United
States a drug or biologic for such disease or condition will be received from sales in the United States of such drug or biologic. The
sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review
for a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product, referred to
as a priority review voucher, or PRV. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of
its NDA or BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or
BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval
of their marketing application if they request such a voucher in their original. marketing application and meet all of the eligibility
criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program until
September 30, 2024, with the potential for PRVs to be granted until 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to
comply with post-approval regulatory requirements, including any post-approval requirements that the FDA may have imposed as a condition
of approval. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and
certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including
cGMP regulations, which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, the sponsor and
its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMP regulations and other regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of
the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples
of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the
manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some
products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity,
potency, and effectiveness of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among
other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning letters or holds on post-approval clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation
                                            of product license approvals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics
may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drug Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than
200,000 individuals in the United States, or in other limited cases. Orphan drug designation (ODD) provides for seven years of market
exclusivity, independent of patent protection, to the company with ODD that brings a particular product to market. In addition, companies
developing orphan drugs are eligible for certain incentives, including tax credits for qualified clinical testing. In addition, a BLA
for a product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes
an indication other than the rare disease or condition for which the drug was designated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
gain exclusivity, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition
for which it has such designation, the product is entitled to the orphan drug exclusivity, which means that the FDA may not approve any
other applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as
another drug&#8217;s showing of clinical superiority over the drug with orphan exclusivity. In addition, doctors may prescribe products
for off-label uses and undermine our exclusivity. Orphan drug exclusivity could block the approval of one of our product candidates for
seven years if a competitor obtains approval for the same active moiety for the same indication before we do, unless we are able to demonstrate
that our product is clinically superior.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product.
In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan
drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its
product may be clinically superior to the first, approved product. More than one sponsor may receive orphan drug designation for the
same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for
designation, and only the first sponsor that obtains approval for that drug for the orphan indication will obtain market exclusivity,
effectively preventing the FDA from approving products under development by competitors for the same drug and same indication, unless
the competitor is able to demonstrate that the product under development is clinically superior to the approved product or the approved
product is not available in sufficient quantities. To permit the FDA to end another manufacturer&#8217;s orphan exclusivity period, the
FDA must determine that the manufacturer has demonstrated clinical superiority by showing the later drug is safer, more effective, or
otherwise makes a major contribution to patient care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for
which the product has been designated. The FDA may approve a second application for the same product for a different use or a subsequent
application for a different drug for the same indication. Orphan drug designation neither shortens the development time or regulatory
review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may plan to pursue orphan drug designation and exclusivity for some of our product candidates in the United States, European Union, and
other geographies of interest for specific products. We cannot guarantee that we will obtain orphan drug designation for any products
in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be sure that such product will be
approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we will be able to maintain any exclusivity
that is granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, or ACA, which was signed into law on March 23, 2010, included a subtitle called the Biologics
Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars
and interchangeable biosimilars. The FDA has issued several draft guidance documents outlining an approach to review and approval of
biosimilars. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes
by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable
with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar
product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product
in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the
agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for
products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered
without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until 4 years following the date of approval of the
reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved.
Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version
of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity
periods for biosimilars approved as interchangeable products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
Outside the United States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements
of other countries and jurisdictions regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing
authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other
countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country
or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country
or jurisdiction may negatively impact the regulatory process in others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
and Marketing Authorization in the European Union</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Medicines Agency, or EMA, is the scientific agency of the European Union, or EU, that coordinates the evaluation and monitoring
of new and approved medicinal products such as drugs and biologics. It is responsible for the scientific evaluation of applications for
EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process regarding approval of medicinal products in the EU follows roughly the same lines as in the United States and likewise generally
involves satisfactorily completing each of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
                                            laboratory tests, animal studies and formulation studies all performed in accordance with
                                            the applicable EU Good Laboratory Practice regulations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the relevant regulatory agencies in EU member states, or national authorities, of a clinical
                                            trial application, or CTA, for each clinical trial, which must be approved before human clinical
                                            trials may begin;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled clinical trials to establish the safety and efficacy of the
                                            product for each proposed indication;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the relevant national authorities of a Marketing Authorisation Application, or MAA, which
                                            includes the data supporting safety and efficacy as well as detailed information on the manufacture
                                            and composition of the product in clinical development and proposed labeling;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an inspection by the relevant national authorities of the manufacturing facility
                                            or facilities, including those of third parties, at which the product is produced to assess
                                            compliance with cGMP;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            audits of the non-clinical and clinical trial sites that generated the data in support of
                                            the MAA; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
                                            and approval by the relevant national authority of the MAA before any commercial marketing,
                                            sale or shipment of the product.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Studies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential efficacy
and toxicity in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant
EU regulations and requirements. The results of the preclinical tests, together with relevant manufacturing information and analytical
data, are submitted as part of the CTA when seeking approval to start a clinical trial, and with the MAA when seeking marketing authorization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements
for the conduct of clinical trials in the EU including cGCP, are implemented in the currently Clinical Trials Directive 2001/20/EC and
the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical
trials in the EU has been implemented through national legislation of the EU member states. Under this system, approval must be obtained
from the competent national authority in which a trial is planned to be conducted, or in multiple member states if the clinical trial
is to be conducted in a number of member states. To this end, a CTA is submitted, which must be supported by an investigational medicinal
product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable
guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion
on the clinical trial application in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2022, the Clinical Trials Regulation (EU) No. 536/2014 replaced the current Clinical Trials Directive 2001/20/EC. To ensure
that the rules for clinical trials are identical throughout the EU, the Clinical Trials Regulation (EU) No. 536/2014 was passed as a
regulation which is directly applicable in all EU member states. The Clinical Trials Directive 2001/20/EC will, however, still apply
three years from the date of entry into application of the Clinical Trials Regulation to (i) clinical trials applications submitted before
the entry into application and (ii) clinical trials applications submitted within one year after the entry into application if the sponsor
opts for the old system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
(EU) No 536/2014 aims to simplify and streamline the approval of clinical trial in the EU. The main characteristics of the regulation
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            streamlined application procedure via a single entry point, known as the Clinical Trials
                                            Information System;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            single set of documents to be prepared and submitted for the application as well as simplified
                                            reporting procedures which will spare sponsors from submitting broadly identical information
                                            separately to various and different national authorities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            harmonized procedure for the assessment of applications for clinical trials, which is divided
                                            in two parts;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strictly
                                            defined deadlines for the assessment of clinical trial application; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            involvement of the ethics committees in the assessment procedure in accordance with the national
                                            law of the member state concerned but within the overall timelines defined by the Regulation
                                            (EU) No 536/2014.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
Authorization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
to market a product in the member states of the EU proceeds under one of four procedures: a centralized procedure, a mutual recognition
procedure, a decentralized procedure or a national procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Centralized
Procedure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure enables applicants to obtain a marketing authorization that is valid in all EU member states based on a single
application. Certain medicinal products, including products developed by means of biotechnological processes must undergo the centralized
authorization procedure for marketing authorization, which, if granted by the European Commission, based on the opinion of the EMA, is
automatically valid in all EU member states. Sponsors may elect to file an MAA through the centralized procedures for other classes of
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure is mandatory for certain types of products such as, medicines derived from biotechnology processes such as genetic
engineering, advanced-therapy medicines such as gene-therapy or tissue engineered medicine, orphan medicines, and medicinal products
containing a new active substance indicated for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative disorders, autoimmune
and other immune dysfunctions, and viral diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized authorization procedure is optional for other medicinal products if they contain a new active substance, if the applicant
shows that the medicinal product concerned constitutes a significant therapeutic, scientific or technical innovation, or that the granting
of authorization is in the public interest of the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration
Procedure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure, the EMA&#8217;s Committee for Human Medicinal Products, or CHMP serves as the scientific committee that renders
opinions about the safety, efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed of experts
nominated by each member state&#8217;s national authority for medicinal products, with one of them appointed to act as Rapporteur for
the co-ordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After
approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP has 210 active days to adopt an opinion
as to whether a marketing authorization should be granted. The process usually takes longer in case additional information is requested,
which triggers clock-stops in the procedural timelines. The process is complex and involves extensive consultation with the regulatory
authorities of member states and a number of experts. When an application is submitted for a marketing authorization in respect of a
drug which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation,
the applicant may, pursuant to Article 14(9) Regulation (EC) No 726/2004, request an accelerated assessment procedure. If the CHMP accepts
such request, the time-limit of 210 days will be reduced to 150 days, but it is possible that the CHMP can revert to the standard time-limit
for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. Once the procedure
is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds
on which this conclusion was reached. After the adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission,
after consulting the EU member states, which in total can take more than 60 days. After a drug has been authorized and launched, it is
a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditional
Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
specific circumstances, EU legislation (Article 14(7) Regulation (EC) No. 726/2004 and Regulation (EC) No. 507/2006 on Conditional Marketing
Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining
the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted
for products (including medicines designated as orphan medicinal products), if&#8201; (1) the risk-benefit balance of the product is
positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) the
product fulfills unmet medical needs, and (4) the benefit to public health of the immediate availability on the market of the medicinal
product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization
may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion
of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid
for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional
or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect
to the review by the CHMP of applications for a conditional marketing authorization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
Authorization Under Exceptional Circumstances</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
per Article 14(8) Regulation (EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with
the requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the
legislation) might be eligible for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually
to reassess the risk-benefit balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization
under exceptional circumstances is aimed at the provision of information on the safe and effective use of the product and will normally
not lead to the completion of a full dossier/approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Studies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved
Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific
waiver, (2) a class waiver, or (3) a deferral for one or more of the measures included in the PIP. The respective requirements for all
marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement
also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already
authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development
of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also
grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the
elderly population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies
actually comply with the agreed studies and measures listed in each relevant PIP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Period
of Authorization and Renewals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing authorization will be valid for five years in principle, and the marketing authorization may be renewed after five years on
the basis of a re-evaluation of the risk-benefit balance by the EMA or by a national authority. To this end, the marketing authorization
holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization
ceases to be valid. Once renewed, the marketing authorization will be valid for an unlimited period, unless the European Commission or
the national authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.
Any authorization that is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the
market of the authorizing member state within three years after authorization will cease to be valid, the so-called &#8220;sunset clause.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drug Designation and Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Commission can grant orphan medicinal product designation to products for which the sponsor can establish that it is intended
for the diagnosis, prevention, or treatment of&#8201; (1) a life-threatening or chronically debilitating condition affecting not more
than five in 10,000 people in the EU, or (2) a life threatening, seriously debilitating or serious and chronic condition in the EU and
that without incentives it is unlikely that sales of the drug in the EU would generate a sufficient return to justify the necessary investment.
In addition, the sponsor must establish that there is no other satisfactory method approved in the EU of diagnosing, preventing or treating
the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized
EU marketing authorization (see &#8220;&#8212;Government Regulation and Product Approval&#8212;Regulation Outside the United States&#8212;Centralized
Authorization Procedure&#8221;), as well as 10 years of market exclusivity following a marketing authorization. During this market exclusivity
period, neither the EMA, nor the European Commission nor the Member States can accept an application or grant a marketing authorization
for a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and
which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may be
reduced to six years if, at the end of the fifth year, it is established that the orphan drug designation criteria are no longer met,
including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition,
a competing similar medicinal product may be authorized prior to the expiration of the market exclusivity period, including if it is
shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug or if the holder of the marketing
authorization for the already approved orphan drug is unable to supply sufficient quantities of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the MAA of a medicinal product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed
PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity
will be extended to twelve years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
Data Protection</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU
legislation also provides for a system of regulatory data and market exclusivity. Upon receiving marketing authorization, new chemical
entities approved on the basis of complete independent data package benefit from eight years of data exclusivity and an additional two
years of market exclusivity. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to
assess a generic or biosimilar (abbreviated) application. During the additional two-year period of market exclusivity, a generic or biosimilar
marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product
can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years
if, during the first eight years of those 10 years, the marketing authorization holder, or MAH, obtains an authorization for one or more
new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical
benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the innovator is able
to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained
marketing authorization based on an MAA with a complete independent data package of pharmaceutical test, preclinical tests and clinical
trials. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years
of orphan market exclusivity (see also &#8220;Item 4.B&#8212;Government Regulation and Product Approval&#8212;Regulation and Marketing
Authorization in the European Union&#8212;Orphan Drug Designation and Exclusivity&#8221;). Depending upon the timing and duration of
the EU marketing authorization process, products may be eligible for up to five years&#8217; supplementary protection certificates, or
SPCs. Such SPCs extend the rights under the basic patent for the drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
Requirements After a Marketing Authorization Has Been Obtained</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain authorization for a medicinal product in the EU, we will be required to comply with a range of requirements applicable to the
manufacturing, marketing, promotion and sale of medicinal products:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacovigilance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will, for example, have to comply with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization
studies and additional monitoring obligations can be imposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
requirements relate to, for example, the manufacturing of products and APIs in accordance with good manufacturing practice standards.
EU regulators may conduct inspections to verify our compliance with applicable requirements, and we will have to continue to expend time,
money and effort to remain compliant. Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with
requirements related to the development of products for the pediatric population, can also result in significant financial penalties
in the EU. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of individual personal data can also
lead to significant penalties and sanctions. Individual EU member states may also impose various sanctions and penalties in case we do
not comply with locally applicable requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing of authorized drugs, for which a separate manufacturer&#8217;s license is mandatory, must be conducted in compliance with
the EMA&#8217;s cGMP requirements and comparable requirements of other national authorities, which mandate the methods, facilities and
controls used in manufacturing, processing and packing of drugs to assure their safety and identity. The EMA enforces its cGMP requirements
through mandatory registration of facilities and inspections of those facilities. The EMA may have a coordinating role for these inspections
while the responsibility for carrying them out rests with the member states competent authority under whose responsibility the manufacturer
falls. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues,
and could subject the applicant to potential legal or regulatory action, including but not limited to warning letters, suspension of
manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
and Promotion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward
the prescribers of drugs and/or the general public, are strictly regulated in the EU. The applicable regulations aim to ensure that information
provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately reflects the safety and
efficacy claims authorized by the EMA or by the national authority of the authorizing member state. Failure to comply with these requirements
can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
U.S. Healthcare Laws and Compliance Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
products distributed in the United States, we will also be subject to additional healthcare regulation and enforcement by the federal
government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly
                                            and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly,
                                            in cash or in kind, to induce or reward either the referral of an individual for, or the
                                            purchase, order, or recommendation of, any good or service, for which payment may be made
                                            under federal healthcare programs such as Medicare, Medicaid, or other governmental programs.
                                            A person or entity does not need to have actual knowledge of the federal anti-kickback statute
                                            or specific intent to violate it to have committed a violation; in addition, items or services
                                            resulting from a violation of the federal anti-kickback statute may constitute a false or
                                            fraudulent claim for purposes of the False Claims Act;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding
                                            regulations, prohibit physicians from referring patients for designated health services (including
                                            outpatient drugs) reimbursed under the Medicare or Medicaid programs to entities with which
                                            the physicians or their immediate family members have a financial relationship or an ownership
                                            interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting
                                            claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            federal False Claims Act imposes criminal and civil penalties, including civil whistleblower
                                            or qui tam actions, against individuals or entities for knowingly presenting, or causing
                                            to be presented, to the federal government claims for payment that are false or fraudulent
                                            or making a false statement to avoid, decrease, or conceal an obligation to pay money to
                                            the federal government;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
                                            Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability
                                            for executing a scheme to defraud any healthcare benefit program and also imposes obligations,
                                            including mandatory contractual terms, with respect to safeguarding the privacy, security
                                            and transmission of individually identifiable health information. This statute also prohibits
                                            knowingly and willfully falsifying, concealing or covering up a material fact or making any
                                            materially false statement in connection with the delivery of or payment for healthcare benefits,
                                            items, or services;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            federal false statements statute prohibits knowingly and willfully falsifying, concealing
                                            or covering up a material fact or making any materially false statement in connection with
                                            the delivery of or payment for health care benefits, items or services;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Physician Payments Sunshine Act, created under the ACA, and its implementing regulations,
                                            which requires specified manufacturers of drugs, devices, biologics and medical supplies
                                            for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
                                            Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid
                                            Services, or CMS, information related to payments or other &#8220;transfers of value&#8221;
                                            made to physicians. All such reported information is publicly available; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
                                            state laws and regulations, such as state anti-kickback and false claims laws, may apply
                                            to sales or marketing arrangements and claims involving healthcare items or services reimbursed
                                            by non-governmental third-party payors, including private insurers, and some state laws require
                                            pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
                                            guidelines and the relevant compliance guidance promulgated by the federal government.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these
laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or
restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found
to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government funded health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates in the United States may depend, in part, on the extent to which the costs of the product candidates may be
covered by third-party payers, such as government health programs, commercial insurance and managed health care organizations. These
third-party payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment of
health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The
United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment
programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of
price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit our net revenue and results. If these third-party payers do not consider our product candidates to be cost-effective
compared to other available therapies, they may not cover our product candidates after approval as a benefit under their plans or, if
they do, the level of payment may not be sufficient to allow us to sell our product candidates on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain
FDA, EMA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective.
A payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on
our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. The conduct of such studies could be expensive and result in delays
in our commercializing efforts. The EU provides options for its member states to restrict the range of drug products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states
may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of
the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but
monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance
that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing
arrangements for any of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party
payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing
regulation may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Healthcare
Reform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The
ACA was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including,
for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed
care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share
of sales to federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013 and, due to subsequent legislative amendments to the
statute, will stay in effect through 2027, unless additional Congressional action is taken; however, pursuant to the CARES Act, and subsequent
legislation, these reductions are suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. The FDA released a final rule
on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from
Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected
at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
recently, on August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. Among other things, the IRA directs
the Department of Health and Human Services, or the HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics
covered under Medicare. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price
representing a significant discount from average prices to wholesalers and direct purchasers. The law will also, beginning in 2023, penalize
drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. Further, the
IRA eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary
maximum out-of-pocket cost and creating a new manufacturer discount program. The IRA permits the Secretary of the HHS, to implement many
of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update
guidance as these programs are implemented, although the IRA may be subject to legal challenges. It is currently unclear how the IRA
will be implemented but is likely to have a significant impact on the pharmaceutical industry In addition, in response to the Biden administration&#8217;s
October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare
and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality
of care. It is unclear whether the models will be utilized in any health reform measures in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a number of these, and other proposed measures may require authorization through additional legislation to become effective, Congress
has indicated that it will continue to seek new legislative measures to control drug costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological
products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition
Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of
treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.
Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures
to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
We expect that additional state and federal healthcare reform measures will be adopted in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted
in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result
in reduced demand for our product candidates or additional pricing pressures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have 10 employees and full-time consultants, including our executive officers, providing management and
financial services, and general administrative responsibilities. We believe that we maintain a satisfactory working relationship with
our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations. None
of our employees are represented by a labor union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and
reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website is located at www.azitrainc.com. The information on or accessible through our website is not part of this annual report on Form
10-K. A copy of this annual report on Form 10-K is located at the SEC&#8217;s Public Reference Room at 100 F Street, NE, Washington,
D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The SEC also
maintains an internet site that contains reports and other information regarding our filings at www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="T_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. Before purchasing our common stock, you should read and consider carefully the following
risk factors as well as all other information contained in this report, including our financial statements and the related notes. Each
of these risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our common stock. There may be additional risks that we do not presently know
of or that we currently believe are immaterial, which could also impair our business and financial position. If any of the events described
below were to occur, our financial condition, our ability to access capital resources, our results of operations and/or our future growth
prospects could be materially and adversely affected and the market price of our common stock could decline. As a result, you could lose
some or all of any investment you may make in our common stock.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an early-stage clinical biopharmaceutical company with limited operating history</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company incorporated on January 2, 2014, and have limited operating history. We have not
commenced revenue-producing operations apart from limited grant and service revenue. To date, our operations have consisted of the development
of our proprietary microbial library, the identification, characterization, genetic engineering and testing of certain bacterial species
to provide therapeutic effect and the development of our initial product candidates. Our limited operating history makes it difficult
for potential investors to evaluate our technology or prospective operations. As an early-stage clinical biopharmaceutical company, we
are subject to all the risks inherent in the organization, financing, expenditures, complications and delays involved with a new business.
Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by
companies in the early stages of development, especially early-stage clinical-stage biopharmaceutical companies such as ours. Potential
investors should carefully consider the risks and uncertainties that a company with a limited operating history will face. In particular,
potential investors should consider that we may be unable to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            implement or execute our business plan, or that our business plan is sound;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            complete preclinical and clinical trials and obtain regulatory approval for the marketing
                                            of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            demonstrate a favorable differentiation between our precision dermatological product candidates
                                            and the current products on the market;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            contract for the manufacture of our clinical drug products and establish a commercial drug
                                            supply;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure
                                            market exclusivity or adequate intellectual property protection for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            and retain an experienced management and advisory team; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
                                            sufficient funds in the capital markets to effectuate our business plan, including product
                                            and clinical development, regulatory approval and commercialization for our product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
should evaluate an investment in us in light of the uncertainties encountered by developing companies in a competitive environment. There
can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability. If we cannot successfully
execute any one of the foregoing, our business may not succeed and your investment will be adversely affected. You must be prepared to
lose all of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of significant operating losses and anticipate continued operating losses for the foreseeable future</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal years ended December 31, 2023 and 2022, we incurred a net loss of $12.6 million and $13.4 million, respectively. As of December
31, 2023, we had an accumulated deficit of $48.6 million. We expect to continue to incur substantial expenses without any meaningful
revenues unless and until we are able to obtain regulatory approval and successfully commercialize at least one of our product candidates.
We also believe that, at a minimum, it will take us four to six years from the date of this report for us to obtain regulatory approval
of our first drug candidates, assuming we are able to get regulatory approval at all. Even if we are able to commercialize our product
candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to have significant research, regulatory and development expenses as we advance our product candidates towards commercialization.
As a result, we expect to incur substantial losses for the foreseeable future, and these losses will be increasing. We are uncertain
when or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. Failure to become and remain profitable may impair our ability to sustain operations and adversely
affect our business and our ability to raise capital. If we are unable to generate positive cash flow within a reasonable period of time,
we will be unable to further pursue our business plan or continue operations, in which case you may lose your entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm for the year ended December 31, 2023 states that due to our accumulated deficit,
recurring and negative cash flow from operations there is substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect we will need additional financing to execute our business plan and fund operations, which additional financing may not be available
on reasonable terms or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had total assets of $5.1 million and working capital of $932,384. On February 16, 2024, we completed a public
offering of 16,667,000 shares of our common stock, at an offering price of $0.30 per share, in which we received net proceeds of approximately
$4.4 million, after deducting underwriter discounts and offering expenses. We believe that our cash on hand as of the date of this report
will not be sufficient to cover our proposed plan of operations over the next 12 months. We intend to seek additional funds through various
financing sources, including the sale of our equity, licensing fees for our technology and joint ventures with industry partners. In
addition, we will consider alternatives to our current business plan that may enable us to achieve revenue producing operations and
meaningful commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available
on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue
our business plan and we may be unable to continue operations, in which case you may lose your entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
clinical and commercial utility of our microbial library and genetic engineering platform is uncertain and may never be realized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can
be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence, machine learning and genetic
engineering technologies. To date, our focus is on the development of genetically engineered strains of <i>S. epidermidis, </i>which
we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. However, we believe that the genetic
engineering of <i>S. epidermidis</i> is a novel and unproven mode of therapy. We recently initiated our Phase 1b clinical trial for ATR-12
and expect to enroll our first patient in the first half of 2024 and expect to file an IND for a Phase 1b clinical trial of ATR-04 by
mid-2024. However, as of the date of this report, we have tested and evaluated our proprietary strains of <i>S. epidermidis</i> in preclinical
studies and have not conducted any clinical trials designed to evaluate safety, tolerability or efficacy. Furthermore, success in early
clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. Even after the
completion of our proposed Phase 1b clinical trials, our initial product candidates will have only been tested in a small number of patients.
Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our product candidates
or our as we expand into larger clinical trials. Until such time, if ever, as we are able to provide the FDA with substantial clinical
evidence to support a claim of safety, efficacy, purity and potency sufficient to enable the FDA to approve our proprietary product candidates
for any indication, our proprietary microbial library and genetic engineering platform will remain unproven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are in early-stage clinical trials or early stages of preclinical development, and therefore they will require extensive
additional preclinical and clinical testing. Success in preclinical studies or early-stage clinical trials may not be indicative of results
in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient
for the necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our product candidates are in early stages clinical trials or of preclinical development, they will require extensive preclinical and
clinical testing. We recently initiated our Phase 1b clinical trial for ATR-12 and expect to enroll our first patient in the first half
of 2024, and expect to file an IND for a Phase 1b clinical trial of ATR-04 by mid-2024. However, we have not conducted meaningful preclinical
studies for any of our other product candidates. Success in preclinical testing and early-stage clinical trials does not ensure that
later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product
candidate. Preclinical studies and Phase 1b clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics
and to understand the side effects of product candidates at various doses and schedules. Phase 1b clinical trials also test how well
a certain disease responds to a new treatment. Success in preclinical studies and earlier clinical trials does not ensure that later
efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and
efficacy in clinical development despite positive results in preclinical studies or even if they successfully advance through earlier
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design
of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience
designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks, including failure in late-stage clinical trials even
after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities
are subject to varying interpretations, which may delay, limit or prevent regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we cannot predict with any certainty if or when we might submit a Biologics License Application, or BLA, for regulatory approval for
any of our product candidates or whether any such BLA will be accepted for review by the FDA, or whether any BLA will be approved upon
review. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed indications.
Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot
be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The clinical
trial process may fail to demonstrate that our product candidates are safe and effective for their proposed uses. This failure could
cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical
trials will delay and possibly preclude the filing of any BLAs with the FDA and, ultimately, our ability to commercialize our product
candidates and generate product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development and commercialization plans and strategies develop, we will need to expand the size of our employee and consultant/contractor
base. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit,
maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount of its
attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future
financial performance and our ability to commercialize our product candidates and any other future product candidates and our ability
to compete effectively will depend, in part, on our ability to effectively manage our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business
strategy. In addition, the loss of the services of our senior management would adversely impact our business prospects</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has expertise in many different aspects of drug development and commercialization. However, our ability to compete in
the highly competitive pharmaceuticals industry depends in large part upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. We will need to hire additional personnel as we further develop our product candidates. Competition
for skilled personnel in our market is intense and competition for experienced scientists may limit our ability to hire and retain highly
qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management, scientific and
medical teams may terminate their employment with us on short notice. The loss of the services of any of our executive officers or other
key employees, or our inability to hire targeted executives, could potentially harm our business, operating results or financial condition.
In particular, we believe that the loss of the services of our chief executive officer would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
biopharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk
profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career
advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable
to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product candidates
would be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no sales and marketing organization. If we are unable to establish satisfactory sales and marketing capabilities or secure
a third-party sales and marketing relationship, we may not be able to successfully commercialize any of our product candidates</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, we have no sales or marketing personnel. Upon and subject to initial receipt of the requisite regulatory approvals for one or
more of our drug products, we plan to build focused capabilities in the United States to commercialize our development programs focused
on live biotherapeutic products and recombinant proteins for the treatment of skin diseases, where we believe the patient populations
and medical specialists for the indications we are targeting are sufficiently concentrated to allow us to effectively promote our products
with a targeted sales team. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue
strategic collaborations with third parties in order to maximize the commercial potential of our product candidates. In some cases, we
may pursue the licensing of our microbial library or patent rights or enter into a joint development arrangement. If we are not successful
in recruiting sales and marketing personnel and building a sales and marketing infrastructure or entering into appropriate collaboration
arrangements with third parties, we will have difficulty successfully commercializing our product candidates, which would adversely affect
our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we enter into third-party marketing and distribution arrangements, we may have limited or no control over the sales, marketing and
distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties.
In terms of establishing a sales and marketing infrastructure, we will have to compete with established and well-funded pharmaceutical
and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to
build an internal sales organization or enter into collaboration arrangements with third parties include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability of sales personnel to obtain access to or persuade adequate numbers of physicians
                                            to prescribe any of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            lack of complementary products to be offered by sales personnel, which may put us at a competitive
                                            disadvantage relative to companies with more extensive product lines; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
                                            costs and expenses associated with creating an internal sales and marketing organization.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will be completely dependent for the foreseeable future on third parties to manufacture our product candidates for commercial sale, and
the commercialization of our product candidates could be halted, delayed or made less profitable if those third parties fail to obtain
manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our
product candidates or fail to do so at acceptable quality levels or prices</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the commercial production of our current product candidates. We currently rely on
third-party contract manufacturers for all of our required raw materials, manufacturing devices, and active pharmaceutical ingredients
for our preclinical research and clinical trials. Although we are able to manufacture finished product in our Groton Connecticut facility
for our clinical trials, we will rely on third parties for the manufacture of our finished product for commercial sale. We do not have
long-term agreements with any of these third parties. We also do not have any current contractual relationship for commercial supplies.
We intend to enter into agreements with third-party contract manufacturers and one or more backup manufacturers for future production.
We are analyzing the feasibility of building manufacturing capabilities for future development and commercial quantities of any products
that we develop. Such products will need to be manufactured in facilities, and by processes, that comply with the requirements of the
FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. In the meantime, we will be obligated to rely
on contract manufacturers for our preclinical research and clinical trials and commercial production, if and when any of our product
candidates are approved for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by us or any contract manufacturer to manufacture our raw materials, manufacturing devices, active pharmaceutical ingredients
and finished products must be approved by the FDA or comparable foreign regulatory authorities. Such approvals are subject to inspections
that will be conducted after we submit a BLA to the FDA or their equivalents to other relevant regulatory authorities. Until such time,
if ever, as we establish our own manufacturing facilities, we will not control the manufacturing process of our product candidates and
will be completely dependent on our contract manufacturing partners for compliance with Current Good Manufacturing Practices, or cGMPs,
for manufacture of our raw materials, manufacturing devices, active pharmaceutical ingredients and finished products. These cGMP regulations
cover all aspects of the manufacturing, testing, quality control, storage, distribution and record keeping relating to our product candidates.
If our contract manufacturers do not successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or others, we will not be able to secure or maintain regulatory approval for product made at their manufacturing
facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product
candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which could
significantly delay our clinical trials and impact our ability to develop, manufacture, obtain regulatory approval for or market our
product candidates, if approved. Likewise, we could be negatively impacted if any of our contract manufacturers elect to discontinue
their business relationship with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies
for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&#8217; compliance
with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result
in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product
candidates, delays, suspensions or withdrawals of approvals, inability to supply product, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect our business. In addition, we will not have control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers
to comply with or maintain any of these standards could adversely affect our ability to develop, manufacture, obtain regulatory approval
for or market any of our product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for any reason, these third parties are unable or unwilling to perform we may not be able to locate alternative manufacturers or formulators
or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity
to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product experiences any significant
difficulties in its respective manufacturing processes for our required raw materials, manufacturing devices, active pharmaceutical ingredients
or finished product or should cease doing business with us for any reason, we could experience significant delays in our clinical trials
and significant interruptions in the supply of any of our product candidates or may not be able to create a supply of our product candidates
at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in development and clinical
trial delays and lost sales. Additionally, we will rely on third parties to supply the raw materials needed to manufacture our product
candidates. Any such reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and
reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to the operation of
one of our contract manufacturers caused by problems with suppliers could delay our shipment of any of our product candidates, increase
our cost of goods sold and result in delays in clinical trials or lost sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business model includes the potential out-licensing of strains from our proprietary microbial library or our product candidates to other
biopharmaceutical companies, however technology licensing in the biopharmaceutical industry is a lengthy process and subject to several
risks and factors outside of our control, and we cannot forecast our ability to successfully out-license our technology or the length
of time it takes to establish a new licensing relationship.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model includes the potential out-licensing or joint development of strains from our proprietary microbial library or our product
candidates to other biopharmaceutical companies. Any such arrangement would typically begin with preliminary feasibility testing and
evaluation by our potential partner or licensee. Assuming the feasibility testing is successful, our ability to convert the successful
test into a commercial license or joint development agreement is dependent on a number of risks and factors, many of which are outside
our control, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            rate of adoption and incorporation of new technologies, by members of the pharmaceutical
                                            industry generally;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential licensee&#8217;s internal evaluation of the economic benefits of marketing a dermatological
                                            product that may be competitive with other products currently in development or commercial
                                            sale by our potential partner or licensee regardless of the perceived benefits or advantages
                                            of our technology or product;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential partner&#8217;s/licensee&#8217;s internal budgetary and product development issues,
                                            including their ability to commit the capital and human resources towards the development
                                            and commercialization of our technology or product; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential partner&#8217;s/licensee&#8217;s willingness to accept our requirements for upfront
                                            fees and ongoing royalties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we believe that in many cases our potential partners or licensee may engage with us in the early-stage feasibility testing
as part of their evaluation of multiple drug and drug delivery options and prior to making any decision or commitment to the development
of a new drug product. Consequently, even if our platform is successful in early feasibility studies, our potential partner/licensee
may decide, for reasons unrelated to the performance of our technology, not to enter into a license agreement with us. Therefore, we
are unable to predict the degree to which our proposed licensing model will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our product candidates</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will face a potential risk of product liability as a result of the clinical testing of our product candidates and will face an even greater
risk of such liability if we commercialize any of our product candidates. For example, we may be sued if any product we develop, including
any of our product candidates, or any materials that we use in our product candidates allegedly causes injury or is found to be otherwise
unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach
of warranties. In the U.S., claims could also be asserted against us under state consumer protection acts. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of
our product candidates. Even successful defense of these claims would require us to employ significant financial and management resources.
Regardless of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
                                            demand for any of our product candidates or any future products that we may develop;</span></td></tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
                                            to our reputation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to obtain regulatory approval for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
                                            of participants in our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            associated with our defense of the related litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            diversion of our management&#8217;s time and our resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
                                            monetary awards to trial participants or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability to commercialize some or all of our product candidates; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decline in the value of our stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we carry product liability insurance that we consider adequate for our current level of clinical testing
and development. However, we will need additional product liability coverage at the time we commence commercial sale of our initial product.
Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. Although we will endeavor to obtain and maintain
such insurance in coverage amounts we deem adequate, any claim that may be brought against us could result in a court judgment or settlement
in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage.
Our insurance policies would also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.
As a result, we may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or
that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our internal computer systems and those of our current
and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system
failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result
in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary
information or other similar disruptions. For example, the loss of clinical trial data could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were
to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates
could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of
information maintained in the information systems and networks of our company and our vendors, including personal information of our
employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems
or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order
to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses,
phishing and other cyberattack. The number and complexity of these threats continue to increase over time. If a material breach of, or
accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception
of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required
to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could
be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related
to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure
of data, as well as unfair or deceptive practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate
threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating
as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the
possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage
in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks
will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can
be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#8217; efforts
to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration
or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security
breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and
our operating results will suffer if we fail to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dermatological therapies market is highly competitive and led by significant technologic developments. We anticipate that, if we are
successful in obtaining regulatory approval of our candidates, we will face significant competition from other approved therapies or
drugs that will become available in our industry. Even if another branded, generic, or OTC product is less effective, it may be quickly
adopted by physicians and patients than our product based upon cost or convenience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Product Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory
authorities in foreign jurisdictions in which we intend to market our product candidates, of which there can be no assurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval
of a BLA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United States,
the FDA generally requires the completion of clinical trials of each biologic to establish its safety and efficacy and extensive pharmaceutical
development to ensure its quality before a BLA is approved. Of the large number of biologics in development, only a small percentage
result in the submission of a BLA to the FDA and even fewer are eventually approved for commercialization. As of the date of this report,
we have not submitted a BLA to the FDA or comparable applications to other regulatory authorities for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain
and subject to a number of risks, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            authorities may disagree with the number, design, size, conduct or implementation of our
                                            clinical trials or any of our collaborators&#8217; clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            authorities may disagree with our interpretation of data from preclinical studies or clinical
                                            trials or the use of results from studies that served as precursors to our current or future
                                            product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of toxicology studies may not support the filing of an Investigational New Drug Application,
                                            or IND, or a BLA for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRBs,
                                            may disagree with the design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to provide acceptable evidence of our product candidates&#8217; safety and
                                            efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of our clinical trials may not be satisfactory or may not meet the level of statistical
                                            or clinical significance required by the FDA, European Medicines Agency, or EMA, or other
                                            regulatory agencies for us to receive marketing approval for any of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            dosing of our product candidates in a particular clinical trial may not be at an optimal
                                            level;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            in our clinical trials may suffer adverse effects for reasons that may or may not be related
                                            to our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials may not be sufficient to support the submission of a
                                            BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
                                            of approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
                                            or facilities of third-party manufacturers with which we contract for clinical and commercial
                                            supplies; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering our clinical data insufficient for approval
                                            of our product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially
based upon, among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory
approval is sought and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during the development
period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product application
may cause delays in the approval or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily
mean that a product candidate will receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to
obtain approval in one jurisdiction may negatively impact our ability to seek approval in a different jurisdiction. Failure to obtain
regulatory approval for our product candidates for the foregoing, or any other reasons, will prevent us from commercializing our product
candidates, and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA, EMA or other regulatory agencies may also approve a product candidate for fewer or more limited indications than we
request, may impose significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications
or may grant approval contingent on the performance of costly post-marketing clinical trials or risk mitigation requirements. The FDA,
EMA or other regulatory agencies may also not accept the labeling claims that we believe would be necessary or desirable for the successful
commercialization of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, the U.S. Congress enacted a new law, the Modernization of Cosmetics Regulation Act of 2022, or MOCRA. MOCRA will require
a cosmetic manufacturer or importer to: ensure that it has on hand substantiation of the safety of its products and ingredients; meet
increased registration, record-keeping and reporting requirements; include fragrance and allergen information on its labeling; and be
prepared to meet FDA&#8217;s to be promulgated good manufacturing practices requirements. These additional requirements may impact budgets
and timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product
candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model depends entirely on the successful development, regulatory approval and commercialization of our product candidates, which
may never occur. We recently initiated our Phase 1b clinical trial for ATR-12 and expect to enroll our first patient in the first half
of 2024 and expect to file an IND for a Phase 1b clinical trial of ATR-04 by mid-2024. However, all of our other product candidates are
in the early stages of development and as of the date of this report we have not progressed any of our product candidates, other than
ATR-12 and ATR-04, beyond performance characterization and animal testing We may not be successful in obtaining approval from the FDA
or comparable foreign regulatory authorities to start clinical trials for ATR-04 or any of our other product candidates. If we do not
obtain such approvals as presently planned, the time in which we expect to commence clinical programs for any product candidate will
be extended and such extension will increase our expenses, delay our potential receipt of any revenues and increase our need for additional
capital. Moreover, there is no guarantee that we will receive approval to commence human clinical trials or, if we do receive approval,
that our clinical trials will be successful or that we will continue clinical development in support of an approval from the FDA or comparable
foreign regulatory authorities for any indication. We note that most product candidates never reach the clinical development stage and
even those that do commence clinical development have only a small chance of successfully completing clinical development and gaining
regulatory approval. Success in early phases of preclinical and clinical trials does not ensure that later clinical trials will be successful,
and interim results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can
occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize our product candidates. Therefore, our business currently
depends entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of preclinical studies of our product candidates may not be predictive of the results of future preclinical studies or clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe, pure, and potent in humans. Before an IND can be submitted to the FDA
and become effective, which is a prerequisite for conducting clinical trials on human subjects in the United States, a product candidate
must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation
studies in accordance with Good Laboratory Practices. Success in preclinical studies does not ensure that later preclinical studies or
clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant
setbacks in clinical trials, even after positive results in earlier preclinical studies. These setbacks have been caused by, among other
things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including
previously unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product,
and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Further, we or our investigators
may have little control over whether subjects comply with important aspects of clinical trial protocols. In addition, preclinical and
clinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier
studies, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies may
not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may
fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to receive positive results in preclinical studies or clinical trials of our product candidates, the development timeline and
regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and
financial prospects would be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates
for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial
prospects</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or a comparable foreign regulatory authority failing to grant permission to proceed and
                                            placing the clinical study on hold;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            facility manufacturing any of our product candidates being ordered by the FDA or other government
                                            or regulatory authorities to temporarily or permanently shut down due to violations of cGMP
                                            requirements or other applicable requirements, or cross-contaminations of product candidates
                                            in the manufacturing process;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            changes to our manufacturing process that may be necessary or desired;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            choosing an alternative treatment for the indications for which we are developing our product
                                            candidates, or participating in competing clinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            experiencing severe or unexpected drug-related adverse effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
                                            from clinical testing on similar technologies and products raising safety and/or efficacy
                                            concerns;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            clinical investigators losing their license or permits necessary to perform our clinical
                                            trials, not performing our clinical trials on our anticipated schedule or employing methods
                                            consistent with the clinical trial protocol, cGMP requirements, or other third parties not
                                            performing data collection and analysis in a timely or accurate manner;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
                                            of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding
                                            regulatory violations that require us to undertake corrective action, result in suspension
                                            or termination of one or more sites or the imposition of a clinical hold on the entire study,
                                            or that prohibit us from using some or all of the data in support of our marketing applications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            contractors becoming debarred or suspended or otherwise penalized by the FDA or other government
                                            or regulatory authorities for violations of regulatory requirements, in which case we may
                                            need to find a substitute contractor, and we may not be able to use some or any of the data
                                            produced by such contractors in support of our marketing applications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
                                            or more IRBs refusing to approve, suspending or terminating the study at an investigational
                                            site, precluding enrollment of additional subjects, or withdrawing its approval of the trial;
                                            reaching agreement on acceptable terms with prospective contract research organizations,
                                            or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation
                                            and may vary significantly among different CROs and trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deviations
                                            of the clinical sites from trial protocols or dropping out of a trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
                                            new clinical trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability of the CRO to execute any clinical trials for any reason; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
                                            or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination
                                            of a trial.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
development costs for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more
or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend
study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory
authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience
delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical
study sites suspend or terminate any of our clinical studies of any of our product candidates, its commercial prospects may be materially
harmed and our ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs,
slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead
to, termination or suspension of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial
of regulatory approval of our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able
to bring competing products to market before we do, and the commercial viability of any of our affected product candidates could be significantly
reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and
the revenue that we generate from its sales, if any, may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical
community, including physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will
depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
                                            of clinical safety and efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience, dosing burden and ease of administration;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any adverse effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of physicians to prescribe our product candidates, and the target patient population
                                            to try new therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
                                            of our product candidates compared to competing products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            introduction of any new products that may in the future become available targeting indications
                                            for which our product candidates may be approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
                                            procedures or therapies that may reduce the incidences of any of the indications in which
                                            our product candidates may show utility;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
                                            and cost-effectiveness;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inclusion or omission of our product candidates in applicable therapeutic and vaccine guidelines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            or warnings contained in approved labeling from regulatory authorities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain sufficient third-party coverage or reimbursement from government
                                            health care programs, including Medicare and Medicaid, private health insurers and other
                                            third-party payors or to receive the necessary pricing approvals from government bodies regulating
                                            the pricing and usage of therapeutics; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
                                            or government pricing approvals.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and
patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the
medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be
successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other
companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be
limited or subject to restrictions or post-approval commitments that render our product candidates not commercially viable. For example,
regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve
the price we intend to charge for any of our product candidates, may grant approval contingent on the performance of costly post-marketing
clinical trials, or may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable
for the successful commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions
on approvals or require risk management plans or a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the drug.
Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial
marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory
review, which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other
restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if
we experience unanticipated problems with our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose
significant restrictions on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially
costly and time-consuming post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and
efficacy. Our product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging,
storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market
information. These requirements include registration with the FDA, as well as continued compliance with current Good Clinical Practices
regulations, or cGCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities
are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current cGMPs,
requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has the authority to require a REMS as part of an BLA or after approval, which may impose further requirements or restrictions on
the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone
specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or
enrollment in a registry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to sales and marketing activities related to our product candidates, advertising and promotional materials must comply with FDA
rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in other countries.
In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug
Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change.
We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without
limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed
sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal
Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and
regulations regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state
consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our product candidates are approved for a particular indication, our product labeling, advertising and promotion
would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that
may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected
in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless legally
prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such
off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the
laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged
improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies
enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or a regulatory agency discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity
or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable
regulatory requirements, we may be subject to the following administrative or judicial sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of the product, withdrawal of the product from the market,
                                            or voluntary or mandatory product recalls;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of warning letters or untitled letters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            holds;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties or monetary fines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or withdrawal of regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            of any ongoing clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            to approve pending applications or supplements to approved applications filed by us, or suspension
                                            or revocation of product license approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or imposition of restrictions on operations, including costly new manufacturing requirements;
                                            or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention or refusal to permit the import or export of product.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.
Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product
liability exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
action, either in the United States or abroad, and compliance with such regulation may be expensive and consume substantial financial
and management resources. If we or any future marketing collaborators or contract manufacturers are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies or are not able to maintain regulatory compliance, it could
delay or prevent the promotion, marketing or sale of our products, which would adversely affect our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may
have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product
candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of
the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies
conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the
United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some
cases, the price that we intend to charge for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and
costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the
regulatory requirements in international markets and/ or to receive applicable marketing approvals, our target market will be reduced
and our ability to realize the full market potential of our product candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that in some cases our products candidates may qualify for the FDA&#8217;s orphan drug status. There is no guarantee that the
FDA will grant any future application for orphan drug designation for any of our product candidates, which would make us ineligible for
the additional exclusivity and other benefits of orphan drug designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered
from sales of the product. Orphan drug designation must be requested before submitting an BLA. After the FDA grants orphan drug designation,
the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does
not convey any advantage in or shorten the duration of regulatory review and approval process. In addition to the potential period of
exclusivity, orphan designation makes a company eligible for grant funding of up to $650,000 per year for four years to defray costs
of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market
the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&#8217;s orphan designation
is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#8217;s
product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of
clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives
marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be
no assurance that we will receive orphan drug designation for any of our product candidates in the indications for which we think they
might qualify, if we elect to seek such applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
and affect the prices we may obtain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact
of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress
of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product
labeling and post-marketing testing and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The
legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average
sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they
can limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal
coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives
and other provisions of this legislation could decrease the coverage and price that we receive for our product candidates and could seriously
harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or,
collectively, the ACA, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA revised the definition of &#8220;average
manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. The law also imposed
a significant annual fee on companies that manufacture or import branded prescription drug products. Further, on August 16, 2022, President
Biden signed the Inflation Reduction Act of 2022, or IRA, into law which, among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating
a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration
will impact the ACA and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the U.S.
Congress enacted the Budget Control Act of 2011, or the Budget Control Act, which included provisions intended to reduce the federal
deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and,
due to subsequent legislative amendments to the statute, will remain in effect through 2027 absent additional congressional action. However,
pursuant to the CARES Act, and subsequent legislation, these reductions are suspended from May 1, 2020 through March 31, 2022 due to
the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced
Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which
could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. If government
spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue
to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development,
manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop.
In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs
that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort
or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. On September 24, 2020, the FDA
released a final rule providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November
20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price
reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless
the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale,
as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022,
Congress enacted the Inflation Reduction Act of 2022 which contains several provisions relating to prescription drug costs, including
requirements for federal government price negotiations, rebate requirements, and caps on out-of-pocket spending for Medicare Part D enrollees.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 20, 2020, the HHS Office of Inspector General finalized further modifications to the federal Anti-Kickback Statute. Under the
final rules, the HHS Office of Inspector General added safe harbor protections under the Anti-Kickback Statute for certain coordinated
care and value-based arrangements among clinicians, providers, and others, yet removed safe harbor protection for price reductions from
pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction
is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor
for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. This rule (with exceptions) became effective
January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business. CMS issued a final rule, effective
on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological products, for which payment is
available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that
drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription drugs
and biological products that are in violation of these requirements will be included on a public list. Any adopted health reform measure
could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the United
States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products
and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal
healthcare reform measures will be adopted in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of healthcare in the European Union, or EU, including the establishment and operation of health services and the pricing and
reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health
service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products
in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on
the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory
burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict
or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. Both
in the United States and in the EU, legislative and regulatory proposals have been made to expand post-approval requirements and restrict
sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted,
or whether the regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals
of our product candidates, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully market our product candidates will depend in part on the level of reimbursement that government health administration
authorities, private health coverage insurers and other organizations provide for the cost of our product candidates and related treatments.
Countries in which any of our product candidates are sold through reimbursement schemes under national health insurance programs frequently
require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price
increases. In certain countries, including the United States, government-funded and private medical care plans can exert significant
indirect pressure on prices. We may not be able to sell our product candidates profitably if adequate prices are not approved or coverage
and reimbursement is unavailable or limited in scope. Increasingly, third-party payors attempt to contain health care costs in ways that
are likely to impact our development of products including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
                                            to approve or challenging the prices charged for health care products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introducing
                                            reimportation schemes from lower priced jurisdictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            both coverage and the amount of reimbursement for new therapeutic products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">denying
                                            or limiting coverage for products that are approved by the regulatory agencies but are considered
                                            to be experimental or investigational by third-party payors; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
                                            to provide coverage when an approved product is used in a way that has not received regulatory
                                            marketing approval.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers and payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which, if violated, could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual
damages, reputational harm and diminished profits and future earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and others will play a primary role in the recommendation and prescription of any products for which we obtain
marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse
and other healthcare laws and regulations, primarily in the United States, that may constrain the business or financial arrangements
and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under
applicable healthcare laws and regulations, include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute prohibits, among other things, the knowing and willful offer,
                                            payment, solicitation or receipt of any form of remuneration in return for, or to induce,
                                            (i) the referral of a person, (ii) the furnishing or arranging for the furnishing of items
                                            or services reimbursable under the Medicare, Medicaid or other governmental programs, or
                                            (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering
                                            of any item or service reimbursable under the Medicare, Medicaid or other governmental programs.
                                            A person or entity does not need to have actual knowledge of the statute or specific intent
                                            to violate it in order to have committed a violation. In addition, the government may assert
                                            that a claim including items or services resulting from a violation of the federal Anti-Kickback
                                            Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal False Claims Act imposes civil penalties, and provides for civil whistleblower or
                                            qui tam actions, against individuals or entities for knowingly presenting, or causing to
                                            be presented, to the federal government, claims for payment that are false or fraudulent
                                            or making a false statement to avoid, decrease or conceal an obligation to pay money to the
                                            federal government;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
                                            imposes criminal and civil liability for executing a scheme to defraud any health care benefit
                                            program or making false statements relating to health care matters. Similar to the federal
                                            Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
                                            or specific intent to violate it in order to have committed a violation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal false statements statute prohibits knowingly and willfully falsifying, concealing
                                            or covering up a material fact or making any materially false statement in connection with
                                            the delivery of or payment for health care benefits, items or services;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Physician Payments Sunshine Act, created under the ACA, and its implementing regulations,
                                            which requires specified manufacturers of drugs, devices, biologics and medical supplies
                                            for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
                                            Program, with specific exceptions, to report annually to CMS information related to payments
                                            or other &#8220;transfers of value&#8221; made to physicians. All such reported information
                                            is publicly available;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                            state and non-U.S. laws and regulations, such as certain state anti-kickback and false claims
                                            laws which may apply to items or services reimbursed by any third-party payor, including
                                            commercial insurers; state laws that require pharmaceutical companies to comply with the
                                            industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated
                                            by the federal government or otherwise restrict payments that may be made to healthcare providers
                                            and other potential referral sources; state laws that require drug manufacturers to report
                                            information related to payments and other transfers of value to physicians and other healthcare
                                            providers or marketing expenditures; and state laws governing the privacy and security of
                                            health information in certain circumstances, many of which differ from each other in significant
                                            ways and may not have the same effect, thus complicating compliance efforts; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulation
                                            by CMS and enforcement by the HHS Office of Inspector General or the U.S. Department of Justice.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare
and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom
we expect to do business with are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Intellectual Property Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on our ability to prosecute and defend, if necessary, our patent rights against third-party
challenges and successfully enforcing these patent rights against third party competitors. The patent positions of biotech companies
can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved.
Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly,
we cannot predict the breadth of claims that may be allowable or enforceable in any patent applications filed by us or our licensors
of patent rights. The patents and patent applications held by or licensed to us relating to our microbial platform and related technologies
may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or
technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by the patent rights held by or licensed to us is uncertain, because legal means afford only limited
protection and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive
advantage at all. We cannot be certain that any patent application owned by a third party will not have priority over patent applications
filed by us or in which we hold license rights or that we will not be involved in interference, opposition or invalidity proceedings
before United States or foreign patent offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we were to initiate legal proceedings against a third party to enforce a patent covering any of our product candidates, the defendant
could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of
several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include
allegations that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark
Office, or the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative
bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review
and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment
of patents held by or licensed to us in such a way that they no longer cover our product candidates or competitive products. The outcome
following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain
that there is no invalidating prior art, of which, we, any licensor of our patent rights or the patent examiner were unaware during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all,
of the patent protection on any of our product candidates. Such a loss of patent protection would have a material adverse impact on our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 59; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on know-how and trade secrets to protect technology, especially in cases where we believe patent protection is not appropriate or
obtainable. However, know-how and trade secrets are difficult to protect. While we require employees, academic collaborators, consultants
and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary
or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and information in which
we may have rights. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time
consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties
could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate
revenues and attain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development
and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized
by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may
be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences in terminology among
patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications
are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization
of any of our product candidates or any future product candidate. There may be certain issued patents and patent applications claiming
subject matter that we may be required to license in order to research, develop or commercialize any of our product candidates, and we
do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims
of patent infringement asserted by third parties would be time-consuming and may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
                                            in costly litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divert
                                            the time and attention of our technical personnel and management;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevent
                                            us from commercializing a product until the asserted patent expires or is held finally invalid
                                            or not infringed in a court of law;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to cease or modify our use of the technology and/or develop non-infringing technology;
                                            or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into royalty or licensing agreements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may hold proprietary rights that could prevent any of our product candidates from being marketed. Any patent-related legal action
against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes could
subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any of our product
candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or that any license required
under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we
could redesign our product candidates or any future product candidates or processes to avoid infringement, if necessary. Accordingly,
an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from
developing and commercializing any of our product candidates or a future product candidate, which could harm our business, financial
condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 60; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that there are other companies, including major biopharmaceutical companies, working in the areas competitive to our proposed
product candidates which either has resulted, or may result, in the filing of patent applications that may be deemed related to our activities.
If we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption
of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present clear
and convincing evidence as to the invalidity of the patent&#8217;s claims. If we were to challenge the validity of these or any issued
United States patent in an administrative trial before the Patent Trial and Appeal Board in the USPTO, we would have to prove that the
claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on
questions of infringement, validity or enforceability. Even if we are successful, litigation could result in substantial costs and be
a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used
or disclosed alleged confidential information or trade secrets of their former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is commonplace in our industry, we will employ individuals who were previously employed at other biopharmaceutical companies, including
our competitors or potential competitors. Although no claims against us are currently pending, we may be subject in the future to claims
that our employees or prospective employees are subject to a continuing obligation to their former employers (such as non-competition
or non-solicitation obligations) or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or
other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Owning Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control.
Since shares of our common stock were sold in our initial public offering, or IPO, in June 2023 at a price of $5.00 per share, the reported
high and low sales prices of our common stock have ranged from $5.18 to $0.20 through February 29, 2024. The market price of our shares
on the NYSE American may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated variations in our and our competitors&#8217; results of operations and financial
                                            condition;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in earnings estimates or recommendations by securities analysts, if our shares are covered
                                            by analysts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            acceptance of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
                                            of technological innovations or new competitive products by others;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of technological innovations or new products by us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                            of the results of preclinical or clinical trials for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            by us to achieve a publicly announced milestone;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            between our expenditures to develop and market new or enhanced products and the generation
                                            of sales from those products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            concerning intellectual property rights, including our involvement in litigation brought
                                            by or against us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            developments and the decisions of regulatory authorities as to the approval or rejection
                                            of new or modified products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the amounts that we spend to develop, acquire or license new products, technologies or
                                            businesses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in our expenditures to promote our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            sale or proposed sale, or the sale by our significant stockholders, of our shares or other
                                            securities in the future;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 61; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
                                            or failure of our research and development projects or those of our competitors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            trading volume of our shares; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic and market conditions and other factors, including factors unrelated to our operating
                                            performance.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial
losses being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted
securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert
the resources and attention of our management from our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to meet the continued listing requirements of the NYSE American could result in a delisting of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to satisfy the continued listing requirements of the NYSE American, such as the corporate governance requirements or the minimum
closing bid price requirement, the NYSE American may take steps to delist our common stock. Such a delisting would likely have a negative
effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In
the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would
allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common
stock from dropping below the NYSE American&#8217;s minimum bid price requirement or prevent future non-compliance with the NYSE American&#8217;s
listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
capital raises may dilute your ownership and/or have other adverse effects on our operations</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, our existing stockholders&#8217; percentage ownership will be reduced and these
stockholders may experience substantial dilution. If we raise additional funds by issuing debt securities, these debt securities would
have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions on
our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may
be required to relinquish some rights to our intellectual property or candidate products, or to grant licenses on terms that are not
favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
eligible for future sale may adversely affect the market for our common stock</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have 28,804,643 shares of common stock issued and outstanding, all of which are eligible for sale by means
of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain
limitations under Rule 144, except for approximately 925,774 shares of common stock held by our officers and directors which are subject
to IPO lock-ups expiring in August 2024. We have granted demand and piggyback registration rights to the former holders of our convertible
preferred stock and convertible promissory notes pursuant to which they may request the registration for resale of up to 9,542,519 shares
of common stock. Any substantial sale of our common stock pursuant to Rule 144 or pursuant to any resale report may have a material adverse effect on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable
to emerging growth companies will make our common stock less attractive to investors</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act and we may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies&#8221; including,
but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes-Oxley Act;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 62; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            disclosure obligations regarding executive compensation in our periodic reports and proxy
                                            statements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
                                            from the requirements of holding a nonbinding advisory vote on executive compensation and
                                            stockholder approval of any golden parachute payments; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended
                                            transition periods available for complying with new or revised accounting standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have chosen to take advantage of all of the benefits available under the JOBS Act, including the exemptions discussed above. We cannot
predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an &#8220;emerging growth company&#8221; for up to five years, although we will lose that status sooner if our revenues exceed
$1.235 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common
stock that is held by non-affiliates exceeds $700 million as of June 30 in any future year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
status as an &#8220;emerging growth company&#8221; under the JOBS Act may make it more difficult to raise capital as and when we need
it</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the exemptions from various reporting requirements provided to us as an &#8220;emerging growth company,&#8221; we may be less attractive
to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our
business with other companies in our industry if they believe that our reporting is not as transparent as other companies in our industry.
If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially
and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not paid dividends on our common stock in the past and have no immediate plans to pay such dividends</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to reinvest all of our earnings, to the extent we have earnings, to cover operating costs and otherwise become and remain competitive.
We do not plan to pay any cash dividends with respect to our common stock in the foreseeable future. We cannot assure you that we would,
at any time, generate sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend.
Therefore, you should not expect to receive cash dividends on our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our
shares, the price of our shares could decline</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our shares will rely in part on the research and reports that equity research analysts publish about us and our business,
if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The
price of our shares could decline if no research reports are published about us or our business, or if one or more equity research analysts
downgrades our shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be at an increased risk of securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
securities class action litigation has often been brought against a company following a decline in the market price of its securities.
This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility
in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources,
which could harm our business. We maintain director and officer insurance that we regard as reasonably adequate to protect us from potential
claims; however, we are responsible for meeting certain deductibles under the policies and, in any event, we cannot assure you that the
insurance coverage will adequately protect us from claims made. Further, the costs of insurance may increase and the availability of
coverage may decrease. As a result, we may not be able to maintain our current levels of insurance at a reasonable cost, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 63; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our amended and restated certificate of incorporation and amended and restated bylaws and applicable provisions of Delaware law may
delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions
in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem
to be in their best interests. The provisions in our amended and restated certificate of incorporation and amended and restated bylaws:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            who may call stockholder meetings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
                                            our stockholders from bringing matters before our annual meeting of stockholders or from
                                            making nominations for directors at our annual meeting of stockholders if the proper procedures
                                            are not followed;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not provide for stockholder action by written consent;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not provide for cumulative voting rights; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
                                            that all board vacancies may be filled by the affirmative vote of a majority of directors
                                            then in office, even if less than a quorum.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 of the DGCL may limit our ability to engage in any business combination with a person who beneficially owns 15% or more of our outstanding
voting stock unless certain conditions are satisfied. This restriction lasts for a period of three years following the share acquisition.
These provisions may have the effect of entrenching our management team and may deprive you of the opportunity to sell your shares to
potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price
of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially
impact reporting of our financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations
we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based
compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their
interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant
volatility to our reported or expected financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act could have a material adverse effect on our business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP. Under standards established by the
Public Company Accounting Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the design
or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent
or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim
financial statements will not be prevented, or detected and corrected, on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness
of our internal control over financial reporting for our second annual report on Form 10-K filed with the SEC and in each year thereafter.
Our auditors will also need to attest to the effectiveness of our internal control over financial reporting at such time as we are an
accelerated filed or large accelerated filer and no longer an emerging growth company or smaller reporting company. If we are unable
to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered
public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting,
investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be
adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material
adverse effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
limited amount of public company experience of our management team could adversely impact our ability to comply with the reporting requirements
of U.S. securities laws, which could have a materially adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such
as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures
on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply
with the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, which is necessary to maintain our public
company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy
in which event you could lose your entire investment in our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in
the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements.
If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting,
our ability to accurately and timely report our financial results could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection
with Section 404 of the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm when required,
may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require
prospective or retrospective changes to our financial statements or identify other areas for further attention or improvement. Inferior
internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our shares of common stock. There is also a risk that neither we nor our independent registered public accounting
firm (when applicable in the future) will be able to conclude within the prescribed timeframe that internal controls over financial reporting
is effective as required by Section 404. As a result, investors could lose confidence in our financial and other public reporting, which
would harm our business and the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the preparation of our financial statements included in this report, we and our independent registered public accounting firm identified
a material weakness as it relates to a lack of adequate segregation of accounting functions. We are in the process of implementing measures
designed to improve our internal control over financial reporting and remediate this material weakness. We intend to increase staffing
within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed
upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial
results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material
weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely
affect our reputation, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 65; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have and will continue to incur significant increased costs as a result of being a public company that reports to the SEC and our management
will be required to devote substantial time to meet compliance obligations</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company reporting to the SEC, we will continue to incur significant legal, accounting and other expenses
that we did not incur as a private company. We are subject to reporting requirements of the Exchange Act and the reporting and governance
provisions of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules subsequently implemented
by the SEC, that impose significant requirements on public companies, including requiring establishment and maintenance of effective
disclosure and financial controls and changes in corporate governance practices. There are significant corporate governance and reporting
provisions in these laws that will increase our legal and financial compliance costs, make some activities more difficult, time-consuming
or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel will need to devote
a substantial amount of time to these regulations. In addition, we expect these rules and regulations to make it more difficult and more
expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and
retain qualified people to serve on our Board our Board committees or as executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by conditions in the U.S. and global economies, the United States and global financial markets and
adverse geopolitical and macroeconomic developments, including rising inflation rates, the continuing adverse impacts of the COVID-19
pandemic, the Ukrainian/Russian and Israeli/Palestinian conflicts and related sanctions, bank failures, and economic uncertainties related
to these conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation
may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit
or otherwise raise capital on acceptable terms, if at all. In response to rising inflation, the U.S. Federal Reserve has raised, and
may again raise, interest rates, which, coupled with reduced government spending and volatility in financial markets, may have the effect
of further increasing economic uncertainty and heightening these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
financial markets around the world experienced volatility following the invasion of Ukraine by Russia in February 2022 and the eruption
of the Israeli/Palestinian conflict in October 2023, including as a result of economic sanctions and export controls against Russia and
countermeasures taken by Russia. The full economic and social impact of these sanctions and countermeasures, in addition to the ongoing
military conflicts in Ukraine and Gaza, which could conceivably expand, remains uncertain; however, both the conflicts and related sanctions
have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, and/or supply chain
continuity, in both Europe and globally, and has introduced significant uncertainty into global markets. While we do not currently operate
in Russia, Ukraine or the Middle East, as the adverse effects of these conflicts continue to develop our business and results of operations
may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_001"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_002"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
Management and Strategy</i>. We employ processes for assessing, identifying, and managing material risks from cybersecurity threats.
In conjunction with EBM, Inc., we employ best in class Endpoint Detection and Response with 24/7 SOC at the Endpoints. We also utilize
MFA and Geolocation enforcement where available. We continuously monitor and maintain our network infrastructure including consistent
vulnerability monitoring and remediation. We also engage in quarterly phishing campaigns as well as cybersecurity awareness training
to our end users to keep them vigilant in being able to detect threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we develop and maintain systems and controls designed to prevent cybersecurity threats from occurring, and we have a process to identify
and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring
and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our
efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to
vendors, engage in more electronic transactions with service providers and patients, and rely more on cloud-based information systems,
the related security risks will increase and we will need to expend additional resources to protect our technology and information systems.
In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our
consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns,
service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in
the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial,
legal, business or reputational harm. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we are not aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of
operations, or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i>.
Our senior management team conducts the regular assessment and management of material risks from cybersecurity threats, including review
with our IT team and third-party service providers. All employees and consultants are directed to report to our senior management any
irregular or suspicious activity that could indicate a cybersecurity threat or incident. The Audit Committee of our Board of Directors
evaluates our cybersecurity assessment and management policies, including quarterly interviews with our senior officers and independent
registered accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_003"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive offices are located in approximately 12,030 square feet of leased office and laboratory space at 21 Business Park Drive, Branford,
Connecticut 06405. The lease expires in 2027, subject to our option to extend the lease for two additional five-year terms. We currently
pay $14,035 per month under the lease, which will increase to $14,385 in 2024, plus our pro rata share of certain operating expenses
of the property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease approximately 1,093 square feet of additional laboratory space, which is located at 93 Shennecossett Road, Groton, Connecticut
06340. The lease expires in April 2024, subject to our option to extend the lease for an additional one-year term. We pay $7,235 per
month under the lease plus our pro rata share of certain operating expenses of the property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease approximately 1,868 square feet of office and laboratory space, which is located at 500 Cartier Boulevard, Laval, Quebec,
Canada. We pay $6,515 per month under the lease. The lease expires in April 2024, subject to our option to extend the lease for an additional
one-year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our facilities are adequate to meet our current needs and that additional space can be obtained on commercially reasonable
terms as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_004"></span>Item
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to
time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties
and outcomes and are not predictable with assurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_005"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="di_006"></span>PART
II</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_007"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Repurchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has trades on the NYSE American Stock Exchange under the symbol &#8220;AZTR.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Record</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 15, 2024, there were 34 holders of record of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We presently intend to retain earnings to finance the operation and expansion
of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted the Azitra, Inc. 2016 Stock Incentive Plan, or 2016 Plan, providing for the grant of non-qualified stock options and incentive
stock options to purchase shares of our common stock and for the grant of restricted and unrestricted share grants and restricted stock
units. We currently have reserved 242,340 shares of our common stock under the 2016 Plan. The purpose of the 2016 Plan is to provide
eligible participants with an opportunity to acquire an ownership interest in our company. All officers, directors, employees and consultants
to our company are eligible to participate under the 2016 Plan. The 2016 Plan provides that options may not be granted at an exercise
price less than the fair market value of our shares of common stock on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, our Board and stockholders approved and adopted the Azitra, Inc. 2023 Stock Incentive Plan, or 2023 Plan, providing for the
grant of non-qualified stock options and incentive stock options to purchase shares of our common stock and for the grant of restricted
and unrestricted share grants and restricted stock units. We currently have reserved 2,000,000 shares of our common stock under the 2023
Plan. The purpose of the 2023 Plan is to provide eligible participants with an opportunity to acquire an ownership interest in our company.
All officers, directors, employees and consultants to our company are eligible to participate under the 2023 Plan. The 2023 Plan provides
that options may not be granted at an exercise price less than the fair market value of our shares of common stock on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information as of December 31, 2023 about our 2016 Plan and 2023 Plan under which our equity securities
are authorized for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(a)<br/> Number of Securities to be Issued Upon Exercise of Outstanding Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(b)<br/> Weighted-<br/> Average Exercise Price of Outstanding Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(c)<br/> Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected In Column (a))</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,288,255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,202,340</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,288,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,202,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sale of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the close of our initial public offering on June 21, 2023, we issued 8,951,526 shares of our common stock in connection with the
conversion of all outstanding shares of preferred stock convertible notes. We believe the offers, sales and issuances of the above securities
by us were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder
as transactions not involving a public offering. All of the investors were sophisticated and accredited investors as such term is defined
in Rule 501 under the Securities Act and represented their intentions to acquire the securities for investment only and not with a view
to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates, notes and
warrants issued in these transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Proceeds from IPO</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, our registration statement on Form S-1, as amended (File No. 333-269876) was declared effective by the SEC in connection
with our initial public offering of common stock, pursuant to which we issued and sold, on June 15, 2023, 1,500,000 shares of common
stock at a public offering price of $5.00 per share for total gross proceeds of $7.5 million and net proceeds of $6.0 million, after
deducting underwriting discounts and offering expenses borne by us. The IPO was underwritten by ThinkEquity LLC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we estimate that we have used approximately $4,661,707 of the net proceeds from our IPO for our clinical trials
and product development, research and development, clinical manufacturing as well as for working capital and other general corporate
purposes. Substantially all of the unused net proceeds from the offering are held in interest bearing accounts. There has been no material
change in our use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities
Act with the SEC on June 21, 2023. Other than payments in the ordinary course of business for compensation of officers and to non-employee
directors as compensation for board or board committee service, none of the net proceeds from our IPO used by us were direct or indirect
payments to any of (i) our directors or officers or their associates, (ii) persons owning 10 percent or more of our common stock, or
(iii) our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_008"></span>Item
6. Reserved</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_009"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations Cautionary Statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis should be read in conjunction with our consolidated audited financial statements and the related notes
thereto contained elsewhere in this report. The information contained in this annual report on Form 10-K is not a complete description
of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various
disclosures made by us in this report and in our other filings with the Securities and Exchange Commission, or SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this report we make, and from time to time we otherwise make written and oral statements regarding our business and prospects, such as
projections of future performance, statements of management&#8217;s plans and objectives, forecasts of market trends, and other matters
that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements containing the words or phrases &#8220;will likely result,&#8221; &#8220;are expected to,&#8221; &#8220;will
continue,&#8221; &#8220;is anticipated,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221;
&#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;plans,&#8221; &#8220;objective,&#8221;
&#8220;should&#8221; or similar expressions identify forward-looking statements, which may appear in our documents, reports, filings
with the SEC, and news releases, and in written or oral presentations made by officers or other representatives to analysts, stockholders,
investors, news organizations and others, and in discussions with management and other of our representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future results, including results related to forward-looking statements, involve a number of risks and uncertainties, including those
risks included in the &#8220;Risk Factors&#8221; section in this report. No assurance can be given that the results reflected in any
forward-looking statements will be achieved. Any forward-looking statement speaks only as of the date on which such statement is made.
Our forward-looking statements are based upon assumptions that are sometimes based upon estimates, data, communications and other information
from suppliers, government agencies and other sources that may be subject to revision. Except as required by law, we do not undertake
any obligation to update or keep current either (i) any forward-looking statement to reflect events or circumstances arising after the
date of such statement or (ii) the important factors that could cause our future results to differ materially from historical results
or trends, results anticipated or planned by us, or which are reflected from time to time in any forward-looking statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were formed in January 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using
engineered proteins and live biotherapeutic products. We are an early-stage clinical biopharmaceutical company and have not commenced
commercial operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have capitalized our operations primarily through a series of private placements of our convertible preferred stock and convertible
promissory notes and our initial public offering, or IPO, of common stock which closed on June 21, 2023. In connection with our IPO,
we issued 1.5 million shares of our common stock at a public offering price of $5 per share. Concurrent with the close of our IPO, all
of our outstanding shares of convertible preferred stock and convertible promissory notes converted into a total of 8,951,526 shares
of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2024, we completed a public offering of 16,667,000 shares of our common stock at an offering price of $0.30 per share. We
received gross proceeds of approximately $5 million and net proceeds of approximately $4.4 million, after deducting underwriting discounts
and offering-related expenses. We have granted the underwriter an overallotment option to purchase an additional 2,500,000 shares of
our common stock, at the public offering less the underwriter&#8217;s discount, for a 45-day period ending March 29, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all share and share price amounts in this report give effect to a forward stock split effected on May 17, 2023
at a ratio of 7.1-for-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 70; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.
We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that
can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning
technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed
genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Our initial focus
is on the development of genetically engineered strains of <i>Staphylococcus epidermidis, or S. epidermidis</i>, which we consider to
be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of
well-described properties in the skin. As of the date of this report, we have identified among our microbial library over 60 distinct
bacterial species that we believe are capable of being engineered to create living organisms or engineered proteins with significant
therapeutic effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineered bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal
microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or
peptides to treat skin diseases. Our initial focus is on the development of our current product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-12</b>,
                                            a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton
                                            syndrome, a chronic and sometimes fatal disease of the skin estimated to affect approximately
                                            one in every 100,000, but its prevalence may be underestimated due to misdiagnosis caused
                                            by similarities to other skin diseases. In December 2022, we submitted an investigational
                                            new drug application, or IND, for a Phase 1b clinical trial of ATR-12 in Netherton syndrome
                                            patients&#8204;, and in January 2023 we received notification from the FDA that the &#8220;study
                                            may proceed&#8221; with respect to the proposed Phase 1b clinical trial. After submitting
                                            post-IND manufacturing reports, we commenced operating activities for our Phase 1b clinical
                                            trial in December 2023. We expect to report initial safety results in the second half of
                                            2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-04</b>,
                                            a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced
                                            by cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted
                                            therapy. We intend to submit an IND for a Phase 1b clinical trial in certain cancer patients
                                            undergoing EGFRi targeted therapy in mid-2024. Subject to FDA clearance of our IND, we expect
                                            to commence our Phase 1b clinical trial in the fourth quarter of 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATR-01</b>,
                                            an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a chronic,
                                            xerotic (abnormally dry), scaly skin disease with an estimated incidence and prevalence of
                                            1 in 250, which suggests a total patient population of 1.3 million in the United States.
                                            We are planning to complete lead optimization and IND-enabling studies in 2024 to support
                                            an IND filing targeted for the second half of 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
                                            separate strains of bacterial microbes being investigated and developed by us and Bayer Consumer
                                            Care AG, the consumer products division of Bayer AG, or Bayer, the international life science
                                            company. We entered into a Joint Development Agreement, or JDA, with Bayer in December 2019.
                                            Under the terms of the JDA, we are responsible for testing our library of bacterial strains
                                            and their natural products for key preclinical properties. After screening through hundreds
                                            of strains, we and Bayer have selected two particular strains to move forward into further
                                            development. Bayer holds the exclusive option to license the patent rights to these strains.
                                            In December 2020, Bayer purchased $8 million of our Series B preferred stock, which converted
                                            into 1,449,743 shares of our common stock, representing approximately 4.5%, of our outstanding
                                            common shares as of the date of this report.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_014.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred Hutch, two
of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team also takes advantage of the
power of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel, drug like peptides
and proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules made by microbes
from their genetic sequences. The system then compares the predictions to the products actually made through tandem mass spectroscopy
and/or nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly available 2D and
3D protein databases to select drug like structures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyngenicDNA Minicircle Plasmid, or SyMPL, technologies
for all fields of genetic engineering, including to discover, develop and commercialize engineered microbial therapies and microbial-derived
peptides and proteins for skin diseases. We are utilizing our licensed patent rights to build plasmids in order to make genetic transformations
that have never been previously achieved. To date, our team has successfully engineered our lead therapeutic candidates without the SyMPL
technology. However, we believe that SyMPL will open up the ability to make genetic transformations of an expanded universe of microbial
species, and we expect that some or all of our future product candidates will incorporate the SyMPL technology. Our collaboration with
Fred Hutch is led by Dr. Christopher Johnston, an expert in microbial engineering, and the innovator behind the SyMPL technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused
on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing
the development of biologics for precision dermatology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered
proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
                                            a sustainable precision dermatology company</i></b>. Our goal is to build a leading precision
                                            dermatology company with a sustainable pipeline of product candidates. To that end, we are
                                            focused on rapidly advancing our current pipeline of live biotherapeutic candidates while
                                            actively developing additional product candidates. Each of our current product candidates
                                            are proprietary and subject to pending patent applications. We expect that most, if not all,
                                            genetically engineered product candidates we develop will be eligible for patent protection.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
                                            our lead product candidates, ATR-12 and ATR-04, through clinical trials</i></b>. We expect
                                            to report initial safety results of our Phase 1b clinical trial for our ATR-12 in Netherton
                                            syndrome patients in the second half of 2024 and are currently planning to commence a Phase
                                            1b trial of our ATR-04 in certain cancer patients undergoing EGFRi therapy in the second
                                            half of 2024. We have a cleared IND for ATR-12 and expect to file an IND for ATR-04 in mid-2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Broaden
                                            our platform by selectively exploring strategic partnerships that maximize the potential
                                            of our precision dermatology programs</i></b>. We intend to maintain significant rights to
                                            all of our core technologies and product candidates. However, we will continue to evaluate
                                            partnering opportunities in which a strategic partner could help us to accelerate development
                                            of our technologies and product candidates, provide access to synergistic combinations, or
                                            provide expertise that could allow us to expand into the treatment of different types of
                                            skin diseases. We may also broaden the reach of our platform by selectively in-licensing
                                            technologies or product candidates. In addition, we will consider potentially out-licensing
                                            certain of our proprietary technologies for indications and industries that we are not ourselves
                                            pursuing. We believe our genetic engineering techniques and technologies have applicability
                                            outside of the field of medicine, including cosmetics and in the generation of clean fuels
                                            and bioremediation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage
                                            our academic partnerships</i></b>. We currently have partnerships with investigators at the
                                            Fred Hutchinson Cancer Center, Yale University, Jackson Laboratory for Genomic Medicine,
                                            and Carnegie Mellon University. We expect to leverage these partnerships and potentially
                                            expand them or form other academic partnerships to bolster our engineering platforms and
                                            expand our research and development pipeline.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand
                                            on our other potential product candidates</i></b>. Beyond our three lead product candidates,
                                            our goal is to develop a broad portfolio of product candidates focused on expanding the application
                                            of our platforms for precision dermatology. We have a proprietary platform for discovering
                                            and developing therapeutic products for precision dermatology. Our platform is built around
                                            a microbial library comprised of approximately 1,500 unique bacterial strains to allow screening
                                            for unique therapeutic characteristics and utilizes a microbial genetic technology that analyzes,
                                            predicts and engineers the proteins, peptides and molecules made by skin microbes. Our ability
                                            to genetically engineer intractable microbial species is uniquely leveraged by our exclusive
                                            license to the SyMPL technology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company, formed in January 2014, and have limited operating history. We have not commenced
revenue-producing operations apart from limited service revenue derived through our JDA with Bayer. Under the terms of the JDA, we are
responsible for testing our library of microbial strains and their natural products for key preclinical properties and Bayer reimburses
us for our development costs. To date, our operations have consisted of the development of our proprietary microbial library, the identification,
characterization and testing of certain bacterial species from our microbial library that we believe are capable of being engineered
to provide significant therapeutic effect and the development of our initial product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2023 Compared to Year Ended December 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations with respect to the items set forth below for the years ended December 31, 2023
and 2022 together with the percentage change for those items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Service revenue - related party</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">686,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">284,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">402,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">142</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,493,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,639,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,809,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,097,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,288,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,302,395</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,737,604</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,435,212</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,616,395</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,453,604</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,837,209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non operating income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,241</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(167,726</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(251,891</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employee retention credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(229,813</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65,849</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forgiveness of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,630,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,250,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,380,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,351</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(455</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,650,078</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,226,762</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,423,316</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,266,473</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,680,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(586,107</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,283,781</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,680,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(603,415</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,355,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,768,984</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,413,637</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,639,128</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,449,350</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">810,222</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Service
Revenue - Related Party</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated $0.7 million of service revenue under the Bayer JDA during the year ended December 31, 2023 compared to service revenue of
$0.3 million under the JDA for the year ended December 31, 2022. The increase of $0.4 million in service revenue is attributable to an
increase in the amount of reimbursable development costs in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs during the year ended December 31, 2023 increased by $854,000, or 23%, to $4.5 million from the prior year period.
The increase was primarily related to an increase of $856,00 of expenses related to our public company emergence, including $216,000
in additional administrative costs related to accounting and finance, $200,000 in increased legal costs, $110,000 of listing fees with
the NYSE American Stock Exchange, a $233,000 increase in premiums for directors and officers insurance, and $97,000 in investor and public
relations costs. The increase in year-over-year general and administrative costs also included $354,000 in IP legal costs due to the
impairment and expensing of certain patent families offset by a decrease of $378,000 in payroll and related costs due to certain positions
not filled for partial year and a net increase of $22,000 in other overhead expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include salaries and benefits of all research personnel, payments to contract research organizations, payments
to research consultants, and the purchase of lab supplies. These expenses are offset by income earned from government grant payments.
We generate grant revenue on contracts with various federal agencies and nonprofit research institutions for general research conducted
by us. These grant arrangements also do not meet the criteria for revenue recognition and amounts earned under these grant contracts
are recorded as a negative research and development expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, research and development expenses decreased by $2.3 million, or 37%, to $3.8 million from the prior
year period. The decrease was primarily related to a decrease of $1.9 million in research and development related costs attributable
to our Netherton program as the program transitions into the clinic, a net decrease in payroll and related costs of $556,000 attributable
to a reduction in staff, a decrease of $183,000 attributable to a decrease in the utilization of consultants offset by an increase of
$378,000 in research and development costs attributable to advancing our CTAR program and a net increase of $39,000 of other costs. There
was $0 and $4,426 government and nonprofit grant revenue received by us during fiscal year 2023 or 2022; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase in the future due primarily to our planned clinical trial activity
and continued development of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-operating
income (expense)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
non-operating income (expense) consists of refundable research and development credits, valuation of warrants, amortization of debt issuance
costs, forgiveness of accounts payable, loss on foreign currency translation, employee retention credit,
change in fair value of the convertible note, interest income, and interest expense. During the year ended December 31, 2023, non-operating
income (expense) increased by $2.4 million, or 198%, compared to the comparable period in fiscal 2022. The increase was primarily related
to an increase of $2.4 million attributable to the change in fair value of the convertible note and a decrease of $0.2 million income
attributable to the employee retention credit. This was partially offset by an increase of $0.1 million in income attributable to forgiveness
of accounts payable and a net increase of $0.1 million attributable to other income (expense).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Condition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had total assets of approximately $5.1 million and working capital of approximately $0.9 million. As of
December 31, 2023, our liquidity included approximately $1.8 million of cash and cash equivalents. On February 15, 2024, we
completed a public offering of 16,667,000 shares of our common stock, at an offering price of $0.30 per share, in which we received
net proceeds of approximately $4.4 million, after deducting underwriting discounts and offering-related expenses. After giving
effect to the February 2024 public offering, we believe that our cash on hand as of the date of this report will not be sufficient
to cover our proposed plan of operations over the next 12 months. We intend to seek additional funds through various financing
sources, including the sale of our equity, licensing fees for our technology and joint ventures with industry partners. In addition,
we will consider alternatives to our current business plan that may enable us to achieve revenue producing operations and meaningful
commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available on
commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further
pursue our business plan and we may be unable to continue operations, in which case you may lose your entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 75; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we raise additional capital through the sale of equity or convertible debt securities, our common stockholders&#8217;
ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures
or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs
or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through
equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product
development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of this filing, management has determined there is substantial
doubt about our ability to continue as a going concern based on our lack of revenue from commercial operations, significant losses and
the need to raise additional capital to support on-going operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows a summary of our cash flows for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,362,375</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(8,349,469</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(318,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(336,761</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,983,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,134,624</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,696,667</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,551,606</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, operating activities used $7.4 million of cash primarily driven by our net loss of $11.3 million offset
by non-cash items of $3.9 million. During the comparable period of fiscal 2022, operating activities used $8.3 million of cash primarily
driven by our net loss of $10.7 million offset by non-cash items of $2.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, investing activities used $0.3 million of cash primarily driven by $0.3 million of deferred patent
costs and patent and trademark costs. During the comparable period of fiscal 2022, investing activities used $0.3 million of cash primarily
driven by $0.3 million of deferred patent costs and patent and trademark costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, financing activities provided $6.0 million in cash primarily driven by proceeds from our initial public
offering. During the comparable period of fiscal 2022, financing activities provided $4.1 million in cash primarily driven by the proceeds
from the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgements and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements and related public financial information are based on the application of accounting principles generally accepted
in the United States (&#8220;GAAP&#8221;). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations
of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also
affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial
condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively
applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant
estimates made during the preparation of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies
impact on our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be
critical are those policies that have the most significant impact on our financial statements and require management to use a greater
degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and
circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results
of operations, financial position or liquidity for the periods presented in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with U.S. GAAP. Under standards established by the Public Company Accounting
Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the design or operation of a control
does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements
on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not
be prevented, or detected and corrected, on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the preparation of our financial statements for the years ended December 31, 2023 and 2022, we and our independent registered public
accounting firm identified a material weakness as it relates to a lack of adequate segregation of accounting functions. We are in the
process of implementing measures designed to improve our internal control over financial reporting and remediate this material weakness.
We intend to increase staffing within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions
and to enable appropriate review of our internally prepared financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2 to our audited financial statements included elsewhere in this report, under Accounting Standards Codification, or
ASC, 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or
services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform
the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services
in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction
price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) we satisfy
each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect consideration
it is entitled to in exchange for the goods or services it transfers to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
optional goods or services are offered, we assess the options to determine whether the options grant the customer a material right. This
determination includes whether the option is priced at an amount that the customer would not have received without entering into the
contract. If we conclude the option conveys a material right, it is accounted for as a separate performance obligation. In identifying
performance obligations in a contract, we identify those promises that are distinct. Promised goods or services are considered distinct
when the customer can benefit from the goods or services on their own, or together with readily available resources, and the goods or
services are separately identifiable from other promises in the contract. If a promise is not distinct, it is combined with other promises
in the contract until the combined group of promises is capable of being distinct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 77; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement
that includes variable consideration, we evaluate the amount of the potential payments and the likelihood that the payments will be received.
If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.
For contracts that include sales-based royalties for licensed compounds, we recognize revenue at the date when the related sales occur.
Finally, we determine whether the contract contains a significant financing component by analyzing the promised consideration relative
to the standalone selling price of the promised goods and services and the timing of payment relative to the transfer of the promised
goods and services. At each reporting date, we reassess the transaction price and probability of achievement of the performance obligations
and the associated constraints on transaction price. If necessary, we adjust the transaction price, recording a cumulative catch-up based
on progress for the amount that was previously constrained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when (or as) control of a performance obligation is transferred to the customer. When combined performance obligations
contain a promised license and related services or other promises, management judgment is required to determine the appropriate timing
of revenue recognition. In doing so, we must identify the predominant promise or promises in the contract to determine whether revenue
is recognized at a point in time or over time. If over time, we must determine the appropriate measure of progress. If a license is deemed
to be the predominant promise in a performance obligation, we must determine the nature of the license, whether functional or symbolic
intellectual property, to conclude whether point-in-time or over-time revenue recognition is most appropriate. The determination of functional
or symbolic intellectual property requires an assessment of whether the customer is able to exploit and benefit from the license in its
current condition, or if the utility of the license is dependent on or influenced by our ongoing activities or being associated with
us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, we calculate the measure of progress for the performance obligations transferred over time. The calculation generally
uses an input measure based on costs incurred to date relative to estimated total costs to complete the transfer of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense
research and development costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue an expense for preclinical studies and clinical trial activities performed by our vendors based upon estimates of the proportion
of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions
with our internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and
the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to
risks and may change depending upon a number of factors, including our clinical development plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our prepaid/accrued expenses as of each balance sheet date in our financial statements based upon facts and circumstances
known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust
the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development
or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred
and recognized as expense in the period that the related goods are consumed, or services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 78; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date.
We use the Black-Scholes option pricing model to value our share-based awards. We recognize compensation expense on a straight-line basis
over the requisite service period, which is generally the vesting period of the award. We have not issued awards for which vesting is
subject to market or performance conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price volatility and the
fair value of the underlying common stock on the date of grant. See Note 10 to our audited financial statements included elsewhere in
this report for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model
to determine the estimated fair value of our awards granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimating
the Fair Value of Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize a Black-Scholes method to value our outstanding warrants at each reporting period, with changes in fair value recognized in the
statement of operations. The estimated fair value of the warrant liabilities is determined using Level 3 inputs. Inherent in a Black-Scholes
model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. We estimate
the volatility of our common stock based on market participant assumptions and matches the volatility used to value our stock options.
The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected
remaining life of the warrants. The expected life of our outstanding warrants is assumed to be equivalent to their remaining contractual
term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our audited financial statements found elsewhere in this report for a description of recent accounting pronouncements applicable
to our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_010"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_011"></span>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_012">Report of Independent Registered Public Accounting Firm (PCAOB ID No. <span id="xdx_909_edei--AuditorFirmId_c20230101__20231231_zamStYqj8a36"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorFirmId" id="ixv-14649">606</ix:nonNumeric></span>)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_013">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_014">Consolidated Statements of Operations for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_015">Consolidated Statements of Changes in Stockholders&#8217; Deficit for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_016">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#di_017">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_012"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grassi &amp; Co. CPAs, P.C.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jericho, New York</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Azitra, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related
statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred
to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity
with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Substantial
Doubt Regarding the Company&#8217;s Ability to Continue as a Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that Azitra, Inc., will continue as a going concern. As discussed in Note
1 to the financial statements, the Company&#8217;s significant operating losses raise substantial doubt regarding the entity&#8217;s
ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions, and management&#8217;s plans regarding
those matters, are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty. Our opinion is not modified with respect to this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><img src="form10-k_015.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorName_c20230101__20231231_z1EMvfek1PN1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorName" id="ixv-14650">GRASSI
&amp; CO., CPAs, P.C.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--AuditorLocation_c20230101__20231231_zZNKBSlmNe13"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorLocation" id="ixv-14651">Jericho,
New York</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
23, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_013"></span>AZITRA,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_zYhiRcsNLhB8" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zLUgsk5f4jdl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zBUbYz30fPqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zsN1tECXOPbj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zR52IKzohRKe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzOI1_zzkpTOpJqpyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14652">1,795,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14653">3,492,656</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zxXT9LduxdZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14654">8,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14655">7,820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zST8m6QWjwA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14656">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14657">175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzOI1_zM3ICRIRQQM6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-left: 10pt; text-align: left">Accounts receivable </td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14658">90,000</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14659">175,000</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--TaxCreditsReceivable_i02I_maACzOI1_zeQR3S3BIEQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax credits receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:TaxCreditsReceivable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14660">118,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:TaxCreditsReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14661">69,666</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReceivable_i02I_maACzOI1_zrqc4Jp4CRg9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Income tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReceivable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14662">6,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14663">13,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredOfferingCosts_i02I_maACzOI1_zaYkg2HATcm8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14664">67,859</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14665">216,886</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_i02I_maACzOI1_zBDzi2VYfBb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14666">448,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14667">160,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_mtACzOI1_maAzugi_maAzEbL_zsbto2iK6g1d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14668">2,535,579</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14669">4,135,883</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzugi_maAzEbL_z0fxMoRvBQe3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14670">710,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14671">846,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAsset_i02I_maAzugi_maAzEbL_zLjMCb7js5Mk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14672">40,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maAzugi_maAzEbL_zvcPD14s1ULb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14673">828,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14674">1,116,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maAzugi_maAzEbL_zw1p8hNZl2Ua" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14675">210,881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14676">219,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredCosts_i02I_maAzugi_maAzEbL_zWjjGr04uIPa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred patent costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14677">742,229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14678">800,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherAssets_i01I_maAzEbL_zVkUKjv5Vz35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14679">47,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14680">47,507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_iTI_mtAzEbL_zQHkk4DlxYy6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total assets</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14681">5,115,486</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14682">7,167,443</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES, PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYDwlxRMa8jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maLCzTED_zYmJJGNkd5ie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14683">897,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14684">784,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzTED_z5FmCSx5nWTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current financing lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14685">14,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzTED_zPasqM4Mbnp4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14686">307,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14687">287,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzTED_z1jAevvZRcF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14688">383,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14689">993,961</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzTED_zaGDkj3FBIR3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Contract liabilities - related party</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14690">156,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzTED_maLztg1_zuq5YVdnXIB7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14691">1,603,195</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14692">2,222,032</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maLztg1_zuDDYfZG9mXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Long-term financing lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14693">26,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maLztg1_zGN22qjZjdf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14694">537,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14695">840,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_maLztg1_zEAjlqUYiuha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14696">35,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14697">70,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleLongTermNotesPayable_iI_maLztg1_zRLZBrs10Gvd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14698">6,600,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_iTI_mtLztg1_maLASEz6Wt_maLASEzpV6_zzqofFfO3Rge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14699">2,202,340</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14700">9,733,211</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_iI_maLASEz6Wt_maLASEzpV6_zvPXmaV5W1vi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (Note 14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0138">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0139">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--TemporaryEquityAbstract_iB_zdXGoD04nUG3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdrpv9THdxIg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Series A convertible preferred stock; $<span id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z6xDughz1Kwd" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4H6YNUocpg7" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14701"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14702">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_906_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdbxvr1nyh1d" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--TemporaryEquitySharesAuthorized_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14703"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14704">205,385</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and 2022; <span id="xdx_909_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zi9mRMH7QYQi" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4rQNcdCm2Rh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14705"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14706">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKnmhX32P5c2" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zHfRmpGrwh96" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14707"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14708">205,385</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2023 and 2022 respectively; liquidation value of $<span id="xdx_907_eus-gaap--TemporaryEquityLiquidationPreference_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3zYJLpnoFY4" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14709">0</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--TemporaryEquityLiquidationPreference_iI_pp0p0_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYznwVQ5gpO3" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14710">3,337,506</ix:nonFraction></span> at December 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14711">3,272,944</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zxkekPTlMIBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series A-1 convertible preferred stock; $<span id="xdx_90C_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zvZUV7LpmHpb" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zcXWcBTGNSXj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14712"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14713">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90B_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_z5mN3O91hNP" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--TemporaryEquitySharesAuthorized_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14714"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14715">380,657</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and 2022; <span id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zbmKODsqkqXf" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zR21clHIj3lk" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14716"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14717">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zvVisA6DAZ5b" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_z5nuDzqMPG7e" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14718"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14719">380,657</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2023 and 2022 respectively; liquidation value of $<span id="xdx_90C_eus-gaap--TemporaryEquityLiquidationPreference_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zzk4DqGOSx2b" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14720">0</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--TemporaryEquityLiquidationPreference_iI_pp0p0_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zFeOHGk8HeA6" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14721">14,274,638</ix:nonFraction></span> as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14722">14,100,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA6Egg7OSUBa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Series B convertible preferred stock; $<span id="xdx_909_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zCfrNGEzCO0g" title="Preferred stock, par value"><span id="xdx_906_eus-gaap--TemporaryEquityParOrStatedValuePerShare_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14723"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14724">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_906_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zhlSYc5dz1G6" title="Preferred stock, shares authorized"><span id="xdx_906_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zoduIBCMdhy9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14725"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14726">851,108</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and 2022; <span id="xdx_902_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zDiYQ6WVh2il" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zx0chVk9nvT2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14727"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14728">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zGizoPagA5sj" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z3kR6ZEWqqa4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14729"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14730">391,303</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 3023 and 2022, respectively; liquidation value of $<span id="xdx_900_eus-gaap--TemporaryEquityLiquidationPreference_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_ztsqxu0Heqhl" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14731">0</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--TemporaryEquityLiquidationPreference_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_pp0p0" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-14732">17,000,159</ix:nonFraction></span> as of December 31, 2023 and 2022 respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14733">16,321,065</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEzNms_maLASEzpV6_zwsaXzDBhCbf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: left">Preferred stock value</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14734">16,321,065</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_iB_zD768D6rbJ28" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i01I_maSEz8P3_maSEzNms_maSEzu3Z_z0g7mE8V6a6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock; $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zqZjVJcSEoKe" title="Common stock, par value"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zZOxkThknaub" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14735"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14736">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zvnolinPGc8c" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zYsMZQr2DgZ" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14737"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14738">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2023 and 2022, <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20231231_zk9KbckeJV19" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zfq0wxLIisae" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14739"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14740">12,097,643</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231_zOLsxaFREgXk" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14741"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14742">1,043,988</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14743">1,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14744">104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i01I_maCzAVQ_maSEzNms_maSEzu3Z_zYrS3vkhOkXf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14745">51,510,269</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14746">1,054,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzAVQ_maSEzNms_maSEzu3Z_zBWbJxAPGbXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14747">48,598,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14748">37,314,552</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_iTI_mtSEzu3Z_maLASEzpV6_z1uMGOYFQ7Te" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total stockholders&#8217; equity (deficit)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14749">2,913,146</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14750">36,260,310</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzpV6_zwDXFGrh9S9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14751">5,115,486</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14752">7,167,443</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_014"></span>AZITRA,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zbhgbUjw4iwg" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zvD2zTvHQxh5" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zM9FyJoY8Lcb" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2022</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzkJ9_zt2uhfxHU9Nj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Service revenue - related party</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14753">686,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14754">284,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_iT_mtCzkJ9_maCz2Cf_z4EudZJuh7hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14755">686,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14756">284,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zNylLi7fnsCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzx8t_zFXVvOqkzN17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14757">4,493,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14758">3,639,666</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzx8t_zg01FHNDDO2a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14759">3,809,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14760">6,097,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_iT_mtCzx8t_msCz2Cf_zzetQqF2UIW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14761">8,302,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14762">9,737,604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtCz2Cf_maCzf4S_maILFCOzcTp_z9KmxgqjbPS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14763">7,616,395</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14764">9,453,604</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zGY0c2JvPv9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-operating income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestIncomeOther_i01_maCzKxI_maNIEz4O2_ztLroqtn9FS5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14765">1,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14766">4,818</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestExpense_i01N_di_msCzKxI_msNIEz4O2_zWXWJhsCtmze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14767">167,726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14768">251,891</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--EmployeeRetentionCredit_i01_maCzKxI_maNIEz4O2_zgtHvwaRT6u1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employee retention credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:EmployeeRetentionCredit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14769">229,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherIncome_i01_maONIEzI85_maNIEz4O2_zIjPjAclFOD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14770">65,849</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ForgivenessOfAccountsPayable_i01_maCzKxI_maNIEz4O2_zk7PfZAxchel" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forgiveness of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:ForgivenessOfAccountsPayable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14771">56,285</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfConvertibleNote_i01_maCzKxI_maNIEz4O2_zPDRK4OUJQk6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14772">3,630,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14773">1,250,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzUQn_maNIEz4O2_zZX4qWvE6r25" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14774">89,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14775">25,351</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEz4O2_maILFCOzcTp_zoPkYGEixg1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14776">3,650,078</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14777">1,226,762</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzcTp_maNILzrPj_zSMFTg7du4r5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14778">11,266,473</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14779">10,680,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzqww_msNILzrPj_zY7SR6JCNaJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14780">17,308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_maCzzq2_mtNILzrPj_zSYy2iU0Xiz" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14781">11,283,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14782">10,680,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msCzzq2_zSda2OO5D3K6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividends on preferred stock</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14783">1,355,347</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14784">2,768,984</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtCzzq2_zX9dQ89pErPg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to common shareholders</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14785">12,639,128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14786">13,449,350</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zENJsdT68JX" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zg7WJDlb6zb5" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-14787"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-14788">1.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zoCEfqWuP9xj" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_z64Eigln5Lw9" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-14789"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-14790">12.74</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zK7cUUMw2iqe" title="Weighted average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z9NjWVGJbnNc" title="Weighted average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14791"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14792">6,924,453</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zHfATdBeH8I6" title="Weighted average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zT4oEwNsIBCb" title="Weighted average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14793"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14794">1,055,399</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_015"></span>AZITRA,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zYcVK6ozgxSe" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Shares</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zJRV2XtslTLc" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Shares</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementClassOfStockAxis_custom--SeriesA1ConvertiblePreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zOUCLrhB0gn" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Shares</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zHZk4gWG6NNj" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Shares</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zbfCz31BC4h3" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zy3SYUfpP05d" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Capital</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zPWBPtuX8cp6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Deficit</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B1_zNqwKkRza9E2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">(Deficit)</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Convertible Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A-1 Convertible Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B Convertible Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-in-</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total <br/>
Stockholders&#8217;<br/>
 Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z5umxmFWC1v9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: bold">Balance - December 31, 2021</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5HY93Zl97Q4" title="Balance, shares" style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14795">205,385</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14796">3,272,944</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zJCo31FPb2ng" title="Balance, shares" style="width: 3%; font-weight: bold; text-align: right">&#160;<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14797">380,657</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14798">14,100,533</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zIM0tSgMKoY6" title="Balance, shares" style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14799">391,303</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14800">16,321,065</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXfEvuc4siK8" title="Balance, shares" style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14801">1,043,103</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14802">104</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14803">868,163</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14804">26,634,186</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 3%; font-weight: bold; text-align: right">&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14805">25,765,919</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zy0uiPAHwzy" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14806">184,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14807">184,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zVmCe4s8npni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHwzquWQRkd9" title="Exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14808">888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14809">1,510</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14810">1,510</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zdGBsIEb8SNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14811">10,680,366</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14812">10,680,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iS_z5Wa9x91RIZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - December 31, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zRKLzsuqfcA" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14813">205,385</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14814">3,272,944</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zaKfhZceIPdb" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14815">380,657</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14816">14,100,533</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zM5ma5pOTz73" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14817">391,303</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14818">16,321,065</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx1lZ6vN8iw7" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14819">1,043,991</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14820">104</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14821">1,054,138</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14822">37,314,552</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14823">36,260,310</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zhjfHg7kvc2f" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold">Balance </td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYZiBS2MEL18" title="Balance, shares" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14824">205,385</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14825">3,272,944</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_ztgIERJcL5l8" title="Balance, shares" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14826">380,657</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14827">14,100,533</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI62rYW5yPRl" title="Balance, shares" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14828">391,303</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14829">16,321,065</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYdlzlFqDCV8" title="Balance, shares" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14830">1,043,991</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14831">104</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14832">1,054,138</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14833">37,314,552</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">)</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="display: none; font-weight: bold; text-align: left">$</td><td style="display: none; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14834">36,260,310</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_z2Qb67E6CsJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Series B Convertible Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231_zZKfz6Fg34Rh" title="Issuance of Series B Convertible Preferred Stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14835">23,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14836">1,124,759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zjYNZHAvtGA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOyqvYiKXpv8" title="Conversion of convertible notes payable, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14837">1,846,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14838">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14839">9,494,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14840">9,495,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zfZjatYgKz8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231_zhgVRA1TxEL6" title="Conversion of preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares" id="ixv-14841">205,385</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14842">3,272,944</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zliEpgcJr767" title="Conversion of preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares" id="ixv-14843">380,657</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14844">14,100,533</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zksr0vO238Ma" title="Conversion of preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares" id="ixv-14845">414,735</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14846">17,445,824</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCMMLsQirUVg" title="Conversion of preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14847">7,707,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14848">771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14849">34,818,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14850">34,819,301</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z6MgNwZSo8Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial public offering, net of issuance costs of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20230101__20231231_zJ9CTeajIr11" title="Net of issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14851">1,508,641</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA9gwZO1Fvf3" title="Initial public offering, net of issuance costs of $1,508,791, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14852">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14853">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14854">5,991,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14855">5,991,359</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zLBH4ekt9X01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14856">151,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14857">151,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_z8NAFd6ouAtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14858">11,283,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14859">11,283,781</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zVYMZU2HJs4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance - December 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVoV7W6EzKhe" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zmwob1EzCeB7" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z8BvoojQtOZ8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxRbzIkKCYBi" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14860">12,097,643</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14861">1,210</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14862">51,510,269</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14863">48,598,333</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14864">2,913,146</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zzZDneoNpZbh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-weight: bold">Balance </td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zb8B275yx721" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA1ConvertiblePreferredStockMember_zvSgThoNipN7" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z9QqAaNfkuh6" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVjmfEoBWqM1" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14865">12,097,643</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14866">1,210</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14867">51,510,269</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14868">48,598,333</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">)</td><td style="display: none; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14869">2,913,146</ix:nonFraction></td><td style="display: none; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_016"></span>AZITRA,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zapIod4P9lp2" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zv0suwmDviK4" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zsg2n2MXCEK7" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2022</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zACl7KU67ne5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUzGR6_maNCPBUzFOQ_zhXwzcmbQnM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14870">11,283,781</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14871">10,680,366</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zuMzQR5Et93c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzGR6_maNCPBUzFOQ_z0yR2Rnek2vf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14872">129,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14873">125,885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzGR6_maNCPBUzFOQ_zVTH0PLx7Gx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14874">7,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_maNCPBUzFOQ_zp5cn02eZq2b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14875">295,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14876">280,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedInterestOnConvertibleNotes_i02_maNCPBUzFOQ_zEFqJUZFH4Pd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued interest on convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:AccruedInterestOnConvertibleNotes" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14877">166,019</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:AccruedInterestOnConvertibleNotes" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14878">164,611</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_maNCPBUzFOQ_zTfnEI6zzXqd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14879">151,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14880">184,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzFOQ_z4YLhOj5fD6d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14881">34,830</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14882">821</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfConvertibleNote_i02N_di_msNCPBUzFOQ_zPv2UNpOxYn6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14883">3,630,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14884">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForgivenessOfAccountsPayable_i02N_di_msNCPBUzFOQ_zUPIGzgXzaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Forgiveness of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:ForgivenessOfAccountsPayable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14885">56,285</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msNCPBUzFOQ_zqTiL4x5j1y4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14886">41,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14887">7,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i02_maNCPBUzFOQ_zJmF4ClddSN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Impairment of intangible assets and deferred patent costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14888">351,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zwej7YOnhKck" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzFOQ_zR1O9f6yvCId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14889">84,565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14890">21,953</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzFOQ_z5sgViAjPAO4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14891">288,124</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14892">49,844</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_msNCPBUzFOQ_zXbTkckVHbH4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14893">253</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14894">694</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxCreditsAndAdjustments_i02_maNCPBUzFOQ_zento32ihvXb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax credits receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14895">48,717</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14896">103,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzFOQ_zxeuzHzH4rJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14897">68,684</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14898">420,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msNCPBUzFOQ_zAj3dANrxzQi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Income tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14899">6,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14900">15,024</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzFOQ_zR3T1WfyriHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14901">283,102</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14902">268,509</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInCommodityContractAssetsAndLiabilities_i02N_di_msNCPBUzFOQ_zMBWX45WFOLj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14903">156,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14904">141,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzFOQ_maCCERCzzy8_zageE4Y6Auk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14905">7,362,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14906">8,349,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zhyA2rLalHAf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzqOY_z5IEp9xnRjxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14907">26,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14908">33,101</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzqOY_zXj8dkBUBY3j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14909">4,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PaymentsToAcquireCapitalizationOfDeferredPatentCosts_i01N_di_msNCPBUzqOY_z4Jge7DR31h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capitalization of deferred patent costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14910">214,152</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14911">180,802</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--PaymentsToAcquireCapitalizationOfLicenses_i01N_di_msNCPBUzqOY_zcU9KCnE8n04" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Capitalization of licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:PaymentsToAcquireCapitalizationOfLicenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14912">65,510</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquireOtherProductiveAssets_i01N_di_msNCPBUzqOY_zILWEUZkoaoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Capitalization of patent and trademark costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14913">77,563</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14914">61,598</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUzqOY_maCCERCzzy8_z7HQ8RKR6cF6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14915">318,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14916">336,761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zTrktDUbbDJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_i01_maNCPBUzWJb_zts8WTJEhWnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from convertible notes, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14917">4,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PaymentOfDeferredOfferingCosts_i01N_di_msNCPBUzWJb_zF6BAyxE7n46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payment of deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AZTR:PaymentOfDeferredOfferingCosts" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14918">216,886</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzWJb_zOObnPiYj9T7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Principal payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14919">7,392</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maNCPBUzWJb_zdKZXlelik7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from initial public offering, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14920">5,991,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzWJb_z3WWJvmw7P94" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14921">1,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzWJb_maCCERCzzy8_zAwJPg8BvFqc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14922">5,983,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14923">4,134,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_mtCCERCzzy8_z4mlEPkLwLGi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14924">1,696,667</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14925">4,551,606</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zJ5W19DCKwM6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14926">3,492,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14927">8,044,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zx1ZlokDo3Xl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14928">1,795,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14929">3,492,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zEkNdG6bnYi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of non-cash investing and financing information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ObtainingRightofuseAssetInExchangeForLeaseLiability_i01_zW1yXWZNe4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Obtaining a right-of-use asset in exchange for lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AZTR:ObtainingRightofuseAssetInExchangeForLeaseLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14930">1,418,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability_i01_zNHKrUmPAMXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Obtaining a right-of-use asset in exchange for financing lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AZTR:ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14931">46,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ConversionOfNoteToCommonStock_i01_zELhG5rZaxz3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of note to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AZTR:ConversionOfNoteToCommonStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14932">9,495,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ConversionOfNoteToConvertiblePreferredStock_i01_zkbh9ANr8VHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of note to Series B Convertible Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AZTR:ConversionOfNoteToConvertiblePreferredStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14933">1,124,759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock_i01_zlnQkjcQB5x7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of Series A, A-1, and B Convertible Preferred Stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AZTR:ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14934">34,819,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_017"></span>AZITRA,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-8418"><p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zyGpxj2Qg7gb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<span id="xdx_826_zzgaE43ZUfg2">Organization and Nature of Operations</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc. was founded on January 2, 2014. It is a synthetic biology company focused on screening and genetically engineering microbes of the
skin. The mission is to discover and develop novel therapeutics to create a new paradigm for treating skin disease. The Company&#8217;s
discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced
and engineered to make cellular therapies, recombinant therapeutic proteins, peptides and small molecules for precision treatment of
dermatology diseases. On May 17, 2023, the Company changed its name to from &#8220;Azitra Inc&#8221; to &#8220;Azitra, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a location in Montreal, Canada for certain research activities. This location and operations conducted there remained
consistent throughout 2022 and 2023. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
Stock Split, Change in Par Value, and Initial Public Offering</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company completed its initial public offering (IPO) in which it issued and sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230601__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNTL6bAsINvb" title="Shares of common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-06-012023-06-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-14935">1,500,000</ix:nonFraction></span> shares of its common stock at
a price to the public of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zW1UvWuhXVsl" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14936">5.00</ix:nonFraction></span> per share. The shares began trading on the NYSE American on June 16, 2023 under the symbol &#8220;AZTR&#8221;.
The net proceeds received by the Company from the offering were $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvhItHSJllvl" title="Proceeds from initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-06-30_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14937">6.0</ix:nonFraction></span> million, after deducting underwriting discounts, commissions and
other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the effectiveness of the Company&#8217;s registration statement, the Company effected a <span id="xdx_901_eus-gaap--StockholdersEquityNoteStockSplit_c20230101__20230630_z83ahAlzuYhj" title="Forward stock split"><ix:nonNumeric contextRef="From2023-01-012023-06-30" name="us-gaap:StockholdersEquityNoteStockSplit" id="ixv-14938">7.1-for-1 forward stock split</ix:nonNumeric></span> of its
issued and outstanding shares of common stock (the Forward Stock Split). On May 17, 2023, the Company changed the par value of its capital
stock from $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MaximumMember_z6I6mWIxmA3e" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-17_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14939">0.01</ix:nonFraction></span> to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MinimumMember_zr05IHCaqIei" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-17_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-14940">0.0001</ix:nonFraction></span>. Accordingly, all share and per share amounts for all periods presented in the accompanying audited consolidated
financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the Forward Stock
Split. Refer to Note 8 for additional details relating to the Forward Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
Concern Matters</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation
for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to
continue as a going concern. As of and for the year ended December 31, 2023, the Company has an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zhK13gazNIp2" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD" id="ixv-14941">48.6</ix:nonFraction></span> million,
a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zNIDC5NrkPkd" title="Loss from operations"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD" id="ixv-14942">7.6</ix:nonFraction></span> million and used $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zUa4erHCXZp7" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD" id="ixv-14943">7.4</ix:nonFraction></span> million to fund operations. These factors among others raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
plans to continue to raise funds through equity and debt financing to fund operating and working capital needs; however, the Company
will require a significant amount of additional funds to complete the development of its products and to fund additional losses which
the Company expects to incur over the next few years as the Company does not yet have product revenue. There can be no assurance that
the Company will be successful in securing additional financing to meet its operating needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
conditions and events create uncertainty about the ability of the Company to continue as a going concern for twelve months from the date
that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary
should the Company be unable to continue as a going concern.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-8491"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zu2k2EAJDC54" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<span id="xdx_826_zo2DKJIjEhE9">Summary of Significant Accounting Policies</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-8497"><p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zMtiHuRO9Al6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zZqaCW4rAPe7">Basis
of Accounting</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:UseOfEstimates" id="ixv-8507"><p id="xdx_847_eus-gaap--UseOfEstimates_zuAKEAiSIOZi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_z5isAYtCIGSh">Use
of Estimates</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
These estimates and assumptions are based on current facts, historical experience, and various other factors believed to be reasonable
under the circumstances, the results which form the basis for making judgements about the carrying values of assets and liabilities and
the recording of expenses that are not readily apparent from other sources. While management believes the estimates and assumptions are
appropriate, actual results may differ materially and adversely from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-8517"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbhO8K0SBAj5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_ziWQJ4TFc4bh">Cash
and Cash Equivalents</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-8527"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6JZhm12qyoe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zUG5HvOzVEsb">Property
and Equipment</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zxxdutHi8g2c" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14944">3</ix:nonNumeric></span> to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zYHSrbr4mOdl" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14945">10</ix:nonNumeric></span> years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-8539"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zilBeWaVDAg7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zXgQuPq5jsw">Accounts
Receivable</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries its accounts receivable at cost less an allowance for expected credit losses. On a periodic basis, the Company evaluates
its accounts receivable and establishes an allowance for expected credit losses based on a history of past write-offs, collections and
current conditions. There was no allowance for credit losses at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="AZTR:DeferredOfferingCostsPolicyTextBlock" id="ixv-8549"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zXnFt8Rbwac4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zfbgB7kzjFId">Deferred
Offering Costs</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&#8217;s initial public offering. In June 2023, the Company consummated its IPO and recorded
such amounts against the gross proceeds of its IPO within the statements of stockholders&#8217; equity. During the fourth quarter the
Company incurred $67,859 of costs related to a follow-on offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-8559"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zNXhjUSSL1Oe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zZGESRvACDc4">Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;).
ASU 2016-02 requires lessees to present right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either
operating or financing leases based on the economic substance of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$<span id="xdx_90F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220101_ztnyfb3ehQyi" title="Right-of-use asset and lease liability"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-012022-01-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14946">1,418,502</ix:nonFraction></span> as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&#8217;s
option to extend certain leases ranges from <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zSeo4zMg8uZj" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="ixv-14947">36</ix:nonNumeric></span> &#8211; <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_z2il98dePDgc" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="ixv-14948">52</ix:nonNumeric></span> months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. The Company utilizes a weighted
average discount rate of <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zcnGnCh3Kx9i" title="Operating lease, weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-14949">4.25</ix:nonFraction></span>% and <span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zJ7LSKGJNpPa" title="Finance lease, weighted average discount rate"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-14950">9.60</ix:nonFraction></span>% for its operating and finance leases, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had operating right-of-use assets with a net value of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zMn2w1U4xA33" title="Operating lease right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14951">828,960</ix:nonFraction></span> and current and long-term operating lease
liabilities of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zx5EewTQfpAl" title="Current operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14952">307,655</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zd3AkaCmHbAc" title="Long-term operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14953">537,523</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has
a term of <span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtM_c20231231_z2QaJxzUGq8j" title="Finance lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:durmonth" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="ixv-14954">36</ix:nonNumeric></span> months. At December 31, 2023, the Company had financing right-of-use assets with a net value of $<span id="xdx_906_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_zuCS5CAC1OXl" title="Long term finance lease liability"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14955">40,002</ix:nonFraction></span> and current and
long-term operating lease liabilities of $<span id="xdx_90D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zP39DMziATy4" title="Finance lease liability current"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14956">14,600</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zskZ2wli7W8j" title="Long term finance lease liability"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14957">26,169</ix:nonFraction></span>, respectively.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-8623"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziNUhc5MFc5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zOMApwqfbtN7">Intangible
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, <i>Goodwill and Other Intangible Assets</i>
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were $<span id="xdx_900_ecustom--ImpairmentOfLicenseAgreements_c20230101__20231231_zWv6Tn88ESZ" title="Impairment of license agreements"><ix:nonFraction name="AZTR:ImpairmentOfLicenseAgreements" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14958">78,606</ix:nonFraction></span> and
$<span id="xdx_909_ecustom--ImpairmentOfLicenseAgreements_c20220101__20221231_zfjusyt3FGCc" title="Impairment of license agreements"><ix:nonFraction name="AZTR:ImpairmentOfLicenseAgreements" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14959">0</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively, and are included in general and administrative expenses on the accompanying
consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="AZTR:DeferredPatentCostsPolicyTextBlock" id="ixv-8640"><p id="xdx_841_ecustom--DeferredPatentCostsPolicyTextBlock_z4b4ly3qt0Z" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zxQIkWopin63">Deferred
Patent Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating
to deferred patent costs during the years ended December 31, 2023 and 2022 were $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqi1vsaTWV6" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14960">272,754</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHx7Xqou0uCe" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14961">0</ix:nonFraction></span>, respectively, and are included in general
and administrative expenses on the accompanying consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-8652"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUr7PcCCf6Pf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zq5aIFmoUVhl">Impairment
of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets (ASC 360-10), the Company&#8217;s policy
is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets.
The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition
of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value
of the net future operating cash flows generated by the asset.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Summary of Significant Accounting Policies (continued)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-8688"><p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zPW2TWZB4w42" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zjkuYKwT7Bxh">Convertible
Debt and Warrant Accounting</span></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income (Expense).</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
debt</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &#8211; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&#8217;s
conversion features require bifurcation in accordance with ASC 815 &#8211; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
The Convertible Notes were converted into the Company&#8217;s common stock on the Closing Date of the Company&#8217;s IPO. Under 815-15-25,
the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825.
The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to
be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change
based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized
as a non-cash gain or loss in Other Income (Expense) on the statements of operations. The Company elected the fair value option for the
2022 Convertible Notes and recorded the notes at their initial fair values with subsequent changes in fair value recorded in earnings.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="AZTR:ConvertiblePreferredStockPolicyTextBlock" id="ixv-8716"><p id="xdx_841_ecustom--ConvertiblePreferredStockPolicyTextBlock_zoDaQ41gDDYe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zWfXmquYxeSi">Convertible
Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in Note 8, at the Closing Date of the Company&#8217;s IPO, the Convertible Preferred stock converted into shares of the Company&#8217;s
common stock.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-8730"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zSZKzFW576J" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zlP1wXMBJkAg">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the <i>five</i> steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers
(&#8220;ASC 606&#8221;), which are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>1</i>: Identify the contract(s) with a customer</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>2</i>: Identify the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>3</i>: Determine the transaction price</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>4</i>: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>5</i>: Recognize revenue when (or as) a performance obligation is satisfied</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-8817"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z5TWStwucIwl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zBHxvW101E84">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, <i>Research
and Development</i>. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Advance payments for goods and services that will be used in future research and development
activities are expensed when the activity has been performed or when the goods have been received. Research and development costs incurred
were $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zroj86IPyoQb" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14962">3,809,063</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zE3vq10NMPol" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14963">6,097,938</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company has a state tax credit receivable of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20231231_ztPBBt1if2c1" title="State tax credit receivable"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14964">86,778</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20221231_zyQ9FwNbN8xl" title="State tax credit receivable"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14965">32,459</ix:nonFraction></span>, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2023 and 2022, the Company has
$<span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_z3MIXlO8Zl1c" title="Pending refunds related to research and experimental development"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14966">20,040</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zJUPVx5KHOC" title="Pending refunds related to research and experimental development"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14967">28,925</ix:nonFraction></span>, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits.
At December 31, 2023 and 2022, the Company has also recorded $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20231231_zwPd68iTdYma" title="Refunds tax amount"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14968">11,565</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20221231_z8DHBFkcmAy5" title="Refunds tax amount"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14969">8,282</ix:nonFraction></span>, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-8840"><p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLmBzSEROH7k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zLzLqCWaK226">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved. The Company recognizes the effect of forfeitures when the forfeitures occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&#8217;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, <i>Improvements to Nonemployee Share-Based Payment Accounting</i>, which expands the scope of ASC
718 to include share-based payment transactions to non-employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>. The expected volatility of the Company&#8217;s shares is estimated based on the average volatility of peer companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underlying
Common Stock Value</i>. The underlying common stock value of the Company&#8217;s shares is estimated by a third-party valuation expert
up until the Company&#8217;s IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
Interest Rate</i>. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-8914"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zUHeCzIdfisg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zK0UNWqj7YP5">Income
Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, <i>Accounting for Income Taxes</i>. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2023 and December 31, 2022. The Company&#8217;s income
tax returns have not been examined by tax authorities through December 31, 2023.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-8952"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zc2sDqE0Fo3l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z6nfOQDLexIc">Net
Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per weighted average share attributable to common stockholders using the weighted average number of shares
of common stock outstanding during the period. The Company computes diluted net loss per weighted average share attributable to common
stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period.
Potential common shares outstanding consist of stock options, warrants and preferred stock and are excluded if their effect is anti-dilutive.
Diluted weighted average common shares did not include any incremental shares for the fiscal year ended December 31, 2023 and 2022.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="AZTR:CertainRisksAndUncertaintiesPolicyTextBlock" id="ixv-8962"><p id="xdx_848_ecustom--CertainRisksAndUncertaintiesPolicyTextBlock_zxGQWdOD9QCh" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zTVzLJ61m7Gg">Certain
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding
to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical
industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on
key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-8972"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztEoDnBavlIc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zVmQr5aENLK">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &#8211; Inputs are based upon observable or quoted prices for identical instruments traded
                                            in active markets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &#8211; Inputs are based upon quoted prices for similar instruments in active markets,
                                            quoted prices for identical or similar instruments in markets that are not active, and model-based
                                            valuation techniques for which all significant assumptions are observable in the market or
                                            can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &#8211; Inputs are generally unobservable and typically reflect management&#8217;s estimates
                                            of assumptions that market participants would use in pricing the asset or liability. The
                                            fair values are therefore determined using model-based techniques that include option pricing
                                            models, discounted cash flow models, and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-9007"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1wB1vi2kIA7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zVuLsQuwtdtg">Financial
Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term
maturities of such instruments. The estimated fair value of the Company&#8217;s long-term debt approximates carrying value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-9017"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z4b5eMa24sd1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zLSkO6OaZs5e">Concentration
of Credit Risk and Off- Balance Sheet Risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash
equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and
accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated
with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The
Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances
in the form of a money market account with a financial institution that management believes to be creditworthy.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-9052"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCsompK9GpOf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zY6TggQUom35">Recent
Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes</i> (Topic 740): <i>Simplifying the Accounting for Income Taxes</i>.
This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing
additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted
this standard effective January 1, 2022, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 1026-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (ASC 326)</i>, which replaces the incurred loss methodology with the expected loss methodology. This standard is referred
to as the current expected credit loss (&#8220;CECL&#8221;) methodology. CECL This standard is effective for the Company on January 1,
2023. The Company has adopted this standard effective January 1, 2023, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</span></p>

</ix:nonNumeric><p id="xdx_858_zhfFJXBdUUYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-9073"><p id="xdx_805_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zBvN6RCxo9V9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<span id="xdx_82B_zQ2fuRdozvYf">Employee Retention Credit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CARES Act provides an employee retention credit (&#8220;CARES Employee Retention credit&#8221;), which is a refundable tax credit against
certain employment taxes of up to $<span id="xdx_900_ecustom--RefundableTaxCredit_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zFUbl7aEOpT1" title="Refundable tax credit"><ix:nonFraction name="AZTR:RefundableTaxCredit" contextRef="AsOf2023-12-31_custom_CARESEmployeeRetentionCreditMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14970">5,000</ix:nonFraction></span> per employee for eligible employers. The tax credit is equal to <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MinimumMember_zc0neqHDL2j" title="Tax credit percent"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-14971">50</ix:nonFraction></span>% of qualified wages paid
to employees during a quarter, capped at $<span id="xdx_901_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zAUFQSnawIF3" title="Payments to employees"><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14972">10,000</ix:nonFraction></span> of qualified wages per employee through December 31, 2020. Additional relief provisions
were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September
30, 2021. Based on these additional provisions, the tax credit is now equal to <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MaximumMember_zycnb2CGuTx5" title="Tax credit percent"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-14973">70</ix:nonFraction></span>% of qualified wages paid to employees during a quarter,
and the limit on qualified wages per employee has been increased to $<span id="xdx_900_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_z78u0QxiVU68" title="Payments to employees wages"><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14974">10,000</ix:nonFraction></span> of qualified wages per quarter. In April 2022, the Company
determined it qualified for the tax credit under the CARES Act and recorded a receivable for $<span id="xdx_90B_ecustom--EmployeeRetentionCredit_c20220401__20220430_zBKsn1N6sBGe" title="Employee retention credit"><ix:nonFraction name="AZTR:EmployeeRetentionCredit" contextRef="From2022-04-012022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14975">229,813</ix:nonFraction></span> and recognized the amounts as other
income on the statement of operations. The Company received full payment for the amount in September 2022.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-9089"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zslLWzaeL29i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span id="xdx_821_z6zNl2UHX9r9">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-9095"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvzIVcCNTZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zhpgQy9pfYuk" style="display: none">Schedule of Property And Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zNAL2YgfmwE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zIjSyKKYbC0b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zuC6SM2kvHa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LabEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14976">1,013,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_LabEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14977">1,034,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVm6VIlXmUW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14978">30,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14979">30,825</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd02iNHTOvzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14980">24,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14981">24,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1lRbxZsED2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14982">28,855</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14983">28,855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znhsWhNZQxMf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Building equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_BuildingImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14984">14,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14985">14,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFzA_zDejBdfUkalj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14986">1,112,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14987">1,133,507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFzA_zqxxiUqswxzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation &amp; amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14988">401,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14989">286,549</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFzA_zQii0gDfTlD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14990">710,075</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14991">846,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zGcz3xiuQAn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">4. Property and Equipment (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90C_eus-gaap--Depreciation_c20230101__20231231_z3s2fT1ANBLd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14992">122,010</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20220101__20221231_zJZC3Q4S9AVc" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14993">120,651</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022 there were losses on disposal of property and equipment recorded of $<span id="xdx_905_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20230101__20231231_z4yIhyN2T153" title="Losses on disposal of property and equipment"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14994">41,417</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20220101__20221231_zGRV3dcPaiK2" title="Losses on disposal of property and equipment"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-14995">7,923</ix:nonFraction></span>, respectively,
and are included in other income (expense) on the accompanying consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-9229"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zVdcVEe2kTi6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span id="xdx_82E_zIAL8Gb7y7hl">Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="ixv-9235"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zM3kuxjk4HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zxrrCXioz30b" style="display: none">Schedule of Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_901_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDbfGwolEBIg" title="Estimated Useful Life"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_TrademarksMember" name="AZTR:FiniteLivedIntangibleAssetUsefulLives" id="ixv-14996">Indefinite</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zy3fFZEzZ4i6" title="Gross Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14997">57,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztfG906mrQC5" title="Accumulated Amortization" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zS0kweJv22ek" title="Impairement of intangible asset" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1FgkZk9Spm" title="Net Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-14998">57,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziHF1SdrAmua" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-14999">17</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zksXf151TqY3" title="Gross Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15000">169,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zTz2l95V2Oil" title="Accumulated Amortization" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15001">15,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeWgY3CSdip5" title="Impairement of intangible asset" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztiUx2PBENf2" title="Net Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15002">153,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zClj2XepS3we" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-15003">17</ix:nonNumeric></span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQavO1GiYWxi" title="Gross Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15004">78,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zFFzyn5mP5Ud" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpW3Pt6wclrf" title="Impairment of intangible asset" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15005">78,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9vZYtq0A4Cc" title="Net Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_zVQsw5yPtnz7" title="Gross Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15006">305,270</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zRMH75DR6O5c" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15007">15,783</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231_zJqlewJv4bIe" title="Impairment of intangible asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15008">78,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_ziaQ7SuYurh9" title="Net Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15009">210,881</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_90D_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV1YCRMn1jC" title="Estimated Useful Life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_TrademarksMember" name="AZTR:FiniteLivedIntangibleAssetUsefulLives" id="ixv-15010">Indefinite</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQyNzZsqxFLb" title="Gross Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15011">53,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zzP801sPs0a5" title="Accumulated Amortization" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zH1tv1jdc154" title="Impairement of intangible asset" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zitqpRkuAcJ9" title="Net Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15012">53,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zspge0w8Yn3g" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-15013">17</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCCQnEujbfj" title="Gross Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15014">108,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJgplqHK3zK6" title="Accumulated Amortization" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15015">8,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6B2SLwkSvza" title="Impairement of intangible asset" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNMXtmTPYg7a" title="Net Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15016">100,058</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_znZcSRqWHOJ6" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-15017">17</ix:nonNumeric></span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z7zYmOdIk2i3" title="Gross Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15018">65,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zNALvIHma669" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSywPZlK9lof" title="Impairment of intangible asset" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zdlSqPfJUS27" title="Net Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15019">65,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zf2Zzk4pJClh" title="Gross Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15020">227,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zB30cLLzzPJa" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15021">8,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231_zUDcSeorX2J2" title="Impairment of intangible asset" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zEymGA2twQPj" title="Net Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15022">219,567</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zn1DKLlaTTL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, amortization expense related to intangible assets was $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z9eSQ5cwYqp" title="Amortization expenses of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15023">7,643</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zvKGvxYdD9Zj" title="Amortization expenses of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15024">5,234</ix:nonFraction></span>, respectively. During
the third quarter, the Company recorded an impairment of $<span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_zwA8EYqjk4gk" title="Impairment loss"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15025">78,606</ix:nonFraction></span> to licensing costs, recorded within general and administrative expenses
on the consolidated statements of operations, as there is uncertainty as to the likelihood of the patent being granted. All subsequent
licensing costs have been expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-9471"><p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z0gkRTPy8i7f" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<span id="xdx_823_zYTs3kO8NeK4">Accrued Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-9477"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAYvX5tAdQO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5Gx6qiSRuXl" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zBRNgjoHnx2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zksyM47zs8Mg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_maALCzSIF_z2R8dtyly0m9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Employee payroll and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15026">207,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15027">371,010</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_maALCzSIF_zbcqAwmeI9x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15028">31,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15029">27,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedResearchAndDevelopmentProjects_iI_maALCzSIF_zV6cWh29dGqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:AccruedResearchAndDevelopmentProjects" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15030">85,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:AccruedResearchAndDevelopmentProjects" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15031">316,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPayableCurrent_iI_maALCzSIF_zNQEbXEkezP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15032">223,792</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzSIF_z4EFnNrFEoz4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15033">35,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15034">24,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzSIF_zzaR84ou17L9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15035">23,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15036">31,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzSIF_zbJBjtGopUVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15037">383,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15038">993,961</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zJZThjKQ5he6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">6. Accrued Expenses (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and
efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and
non-clinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of
services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services
will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced
any material differences between accrued costs and actual costs incurred since its inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-9604"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zB4NxjGNUwD5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span id="xdx_826_z1Y1bwMuhc82">Convertible Debt</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zsuFUQHPerUi" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15039">2,000,000</ix:nonFraction></span> of convertible promissory notes. On the
same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zVyS6HtvEZl9" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15040">1,000,000</ix:nonFraction></span>. The 2021
Convertible Note bears interest at a rate of <span id="xdx_909_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zHJjg8kupXyc" title="Bearing interest, percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15041">6</ix:nonFraction></span>% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note
automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal
and accrued interest divided by the conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zIE6kvIzX2x3" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15042">48.00</ix:nonFraction></span>, which is subject to adjustment as defined in the note agreement. The
2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in
control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zfos0GvtY81e" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15043">15,613</ix:nonFraction></span> related to the 2021 Convertible
Note, which has been recorded as a debt discount and will be amortized over the term of the 2021 Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zmRQNoH25j6c" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15044">4,500,000</ix:nonFraction></span> convertible
promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors
totaling $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwDCSA3ABfW" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15045">4,350,000</ix:nonFraction></span>. The 2022 Convertible Notes mature on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0vTRnHLAF71" title="Maturity date"><ix:nonNumeric contextRef="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15046">January 13, 2023</ix:nonNumeric></span> or the occurrence of an Event of Default (as defined) and
bear interest at a rate of <span id="xdx_908_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zoHoqlUjg6k8" title="Bearing interest, percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15047">8</ix:nonFraction></span>% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding
principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of
a Qualified Financing resulting in gross proceeds to the Company of at least $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pn6n6_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0I1sjOfHoIk" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-15048">20</ix:nonFraction></span> million into securities issued in connection with the
Qualified Financing, at a discount of <span id="xdx_901_ecustom--DebtInstrumentDiscountPercentage_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zmHenJ7sYyod" title="Debt discount, percentage"><ix:nonFraction name="AZTR:DebtInstrumentDiscountPercentage" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15049">30</ix:nonFraction></span>% per share; b) upon the closing of a Change of Control event into shares of capital stock of
the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued
to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public
offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the
holders, at the maturity date into a new class of Company&#8217;s Preferred Stock (Series C Preferred) equal to the quotient of the outstanding
principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of $<span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pn6n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zcedl9DQgwUe" title="Capitalization amount"><ix:nonFraction name="us-gaap:CapitalizationLongtermDebtAndEquity" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-15050">30</ix:nonFraction></span>
million divided by the Company Capitalization, as defined in the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company elected to convert the 2021 Convertible Note, including interest accrued but not yet paid of $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSr0jJyHaTK8" title="Interest accrued"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD" id="ixv-15051">124,759</ix:nonFraction></span> at a
conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp0p0_c20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3wCAXeZOA2" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares" id="ixv-15052">48.00</ix:nonFraction></span> into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyblRmCvggv3" title="Issuance of conversion shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares" id="ixv-15053">23,432</ix:nonFraction></span> shares of its Series B Preferred Stock in accordance with the terms outlined in the Note Purchase
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the 2022 Convertible Notes were amended to extend the maturity date to<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zY3frpMLGlN1" title="Maturity date"> <ix:nonNumeric contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15054">March 31, 2023</ix:nonNumeric></span> and to change the conversion price
upon a Qualified Financing or Change in Control event to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn6n6_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zfV9vY8m4tv7" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-15055">30</ix:nonFraction></span> million divided by the number of shares of the Company&#8217;s common stock
issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">7. Convertible Debt (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
April and June 2023, the 2022 Convertible Notes were further amended to extend the maturity date to<span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zC791egVMhRe" title="Maturity date"> <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zgKSytheB3v" title="Maturity date"><ix:nonNumeric contextRef="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15056"><ix:nonNumeric contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15057">September 30, 2023</ix:nonNumeric></ix:nonNumeric></span></span> and allow for
the sale of additional notes of $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zJtomlTHO8R4" title="Sale of additional notes"><span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zvMDubOEXtr6" title="Sale of additional notes"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfNotesReceivable" contextRef="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15058"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfNotesReceivable" contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15059">500,000</ix:nonFraction></ix:nonFraction></span></span> for a total aggregate principal of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zSKRImPURgTb" title="Aggregate principal"><span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z2EPv5hSuP65" title="Aggregate principal"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15060"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15061">4,850,000</ix:nonFraction></ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 21, 2023, the 2022 Convertible Notes, including accrued interest of $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFr6MT17Q612" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15062">265,052</ix:nonFraction></span>, were converted to <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_dd_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z34nLXIhKu5g" title="Converted shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15063">1,846,020</ix:nonFraction></span> shares of the Company&#8217;s
common stock equal to $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_iN_ddi_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z6puenIbVVSe" title="Conversion of convertible notes payable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15064">9,495,072</ix:nonFraction></span>. Upon conversion, the Company recorded a change in fair value of $<span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20230101__20231231_zx8NOxYGl8Fi" title="Change in fair value of convertible note"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15065">3,630,100</ix:nonFraction></span> and $<span id="xdx_900_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20220101__20221231_ze9bQ2dD0vuc" title="Change in fair value of convertible note"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNote" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15066">1,250,000</ix:nonFraction></span> for the years
ended December 31, 2023 and 2022, respectively, which was recognized as a non-cash change in fair value in Other Income (Expense) on
the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the
accounting considerations under ASC 480 &#8211; Distinguishing Liabilities from Equity, and ASC 815 &#8211; Derivatives and Hedging.
The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company
also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria
for bifurcation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-9691"><p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zbwDcoZihTbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zwa2WTYnxfB9" style="display: none">Schedule of Convertible
Notes Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">2021 Convertible Note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zQAWEoHtTA06" title="Convertible notes payable" style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zG8PFsoAyOz1" title="Convertible notes payable" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31_custom_TwentyTwentyOneConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15067">1,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z9Ve8MgvcpP8" title="Convertible notes payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwROubSS7hKl" title="Convertible notes payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15068">5,600,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total convertible notes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231_zCulOaH45P72" title="Convertible notes payable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231_z52LDFTUSHk" title="Convertible notes payable, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15069">6,600,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zXilFwMjPPMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense was $<span id="xdx_900_eus-gaap--InterestAndDebtExpense_c20230101__20231231_zShQKNn3X0g6" title="Interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15070">166,019</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20220101__20221231_z4N6Q1pyAnAa" title="Interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15071">172,592</ix:nonFraction></span> and included debt issuances costs of $<span id="xdx_902_eus-gaap--DeferredFinanceCostsGross_iI_c20231231_zmHfnCGKve5a" title="Debt issuances costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15072">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DeferredFinanceCostsGross_iI_c20221231_zLdkGoflxCTe" title="Debt issuances costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15073">7,981</ix:nonFraction></span> during the years ended December 31, 2023 and 2022,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-9749"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfmmAZWhREfd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span id="xdx_82B_zVMTzpFF7aa2">Stockholders&#8217; Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2023, the Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20230516__20230517_zMYfgkr4HJqd" title="Forward stock split"><ix:nonNumeric contextRef="From2023-05-162023-05-17" name="us-gaap:StockholdersEquityNoteStockSplit" id="ixv-15074">7.1-for-1 forward stock split</ix:nonNumeric></span> (the &#8220;Forward Stock Split&#8221;) of its issued and outstanding
shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred
stock. The par value of the common stock was adjusted as a result of the Forward Stock Split from $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230517__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zXVQFmTN3KL" title="Common stock, par value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-17_custom_ForwardStockSplitMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15075">0.01</ix:nonFraction></span> to $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zckVq9mHkygl" title="Common stock, par value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ForwardStockSplitMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15076">0.0001</ix:nonFraction></span> and the authorized
shares were increased to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_z0wIOsHVc0Rc" title="Common stock shares authorized in connection with forward stock split"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ForwardStockSplitMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15077">100,000,000</ix:nonFraction></span> shares of common stock in connection with the Forward Stock Split. Fractional shares resulting
from the Forward Stock Split were rounded down to the next whole share and in lieu of any fractional shares the Company will pay a cash
amount to the holder of such fractional shares. The accompanying financial statements and notes to the financial statements give retroactive
effect to the Forward Stock Split for all periods presented. Shares of common stock underlying outstanding stock-based awards and other
equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately
decreased in accordance with the terms of the agreements governing such securities.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, per the Company&#8217;s amended and restated Certificate of Incorporation, the Company was authorized to
issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zBjt3kSc1eV6" title="Common stock shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNjdTzKwbSeg" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15078"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15079">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zd9xYndwQNKj" title="Common stock, par value per share"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zneYIyPgWZQ5" title="Common stock, par value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15080"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15081">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--CommonStockVotingRights_c20230101__20231231_zJzVE0wEGHr7" title="Common stock voting rights description"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="us-gaap:CommonStockVotingRights" id="ixv-15082">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zEMOAyWLcmDf" title="Common stock shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15083">1,611,991</ix:nonFraction></span> shares of common stock reserved for future issuance for the potential exercise of stock options and warrants
outstanding at December 31, 2023.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">8. Stockholders&#8217; Equity (continued)</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, per the Company&#8217;s amended and restated Certificate of Incorporation, the Company has authorized <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zFe6uTMidezb" title="Preferred stock shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zanALIvFt061" title="Preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15084"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15085">1,437,150</ix:nonFraction></ix:nonFraction></span></span>
shares of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zt3kncZx0Ota" title="Preferred stock, par value per share"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zQT3TikYGNx9" title="Preferred stock, par value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15086"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15087">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zVVnUOzsR8pa" title="Convertible preferred stock shares issued"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15088">23,432</ix:nonFraction></span> shares of its Series B Preferred Stock related to conversion of the 2021 Convertible Note at
a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zjLtM0FCi1jb" title="Convertible preferred stock conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15089">48.00</ix:nonFraction></span> per share (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A, Series A-1, and Series B Preferred Stock had the following rights, preferences and privileges :</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock was converted, at the option of the holder, into common shares based upon a predefined formula. The holders of preferred
stock converted such shares into common shares upon the Company&#8217;s IPO. For purpose of conversion, the initial conversion price
was $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7WmJ8tNwJmh" title="Original issue price per share of series A preferred stock"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15090">16.25</ix:nonFraction></span> per share (original issue price) for Series A Preferred Stock, $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zbKyqBCcOQ3d" title="Original issue price per share of series A-1 preferred stock"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-01-31_custom_SeriesA1PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15091">37.50</ix:nonFraction></span> per share (original issue price) for Series A-1 Preferred
Stock, and $<span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7BoPie7HAK5" title="Original issue price per share of series B preferred stock"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15092">43.45</ix:nonFraction></span> per share (original issue price) for Series B Preferred Stock, and was subject to adjustment as described in the Certificate
of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Company&#8217;s IPO in June 2023, all of the outstanding preferred stock converted to common stock, resulting in the issuance of
<span id="xdx_900_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqmhSe3ZQBh6" title="Convertible series A preferred stock shares issued"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15093">1,458,233</ix:nonFraction></span>, <span id="xdx_90C_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFRdpE43WVj4" title="Convertible series A-1 preferred stock shares issued"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_custom_SeriesA1PreferredStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15094">2,964,849</ix:nonFraction></span>, and <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zJMxbiTAyI5c" title="Convertible series B preferred stock shares issued"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15095">3,284,553</ix:nonFraction></span> shares of common stock in exchange for outstanding Series A, Series A-1, and Series B Preferred Stock,
respectively. There was no gain or loss upon conversion.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Series A, Series A-1, and Series B Preferred Stock were entitled to vote on any matter presented to the stockholders of
the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of preferred stock was entitled to cast the number of votes equal to the number
of whole shares of Common Stock into which the shares of preferred stock held by such holder converted as of the record date for determining
stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock were each entitled to elect
one director of the Corporation. The holders of the Series B Stock were entitled to elect two members of the Board. Each class of preferred
stock could have removed such directors from office and to fill any vacancy caused by the resignation, death or removal of such directors
under certain circumstances as described in the Certificate of Incorporation.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A Preferred Stock were entitled to receive dividends at a rate of <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLw0zrVdj0B2" title="Dividend percentage on series A preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15096">8</ix:nonFraction></span>% per annum of the Series A original issue price
of $<span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znVMn8l6vnl5" title="Original issue price per share of series A preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15097">16.25</ix:nonFraction></span> per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends accumulated
from the original date of issuance of the Series A Preferred Stock, were cumulative and were payable upon declaration of the Board of
Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series A Preferred Stock as there
was no longer any Series A Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A-1 Stock were entitled to receive dividends at a rate of <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_ztBd3BNB8Gu4" title="Dividend percentage on series A-1 preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15098">8</ix:nonFraction></span>% per annum of the Series A-1 original issue price of $<span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zzkCvOlJPWl3" title="Original issue price per share of series A-1 preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15099">37.50</ix:nonFraction></span>
per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends were cumulative and were payable
upon declaration of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on
Series A-1 Preferred Stock as there was no longer any Series A-1 Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">8. Stockholders&#8217; Equity (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B Stock were entitled to receive dividends at a rate of <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaVJD4xCAc8j" title="Dividend percentage on series B preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15100">8</ix:nonFraction></span>% per annum of the Series B original issue price of $<span id="xdx_903_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zH19oPIj8Ws8" title="Original issue price per share of series B preferred stock"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15101">43.45</ix:nonFraction></span>
per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to the Series B Preferred Stock). Dividends were cumulative and were payable upon declaration
of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series B Preferred
Stock as there was no longer any Series B Preferred Stock outstanding.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock were entitled to receive,
prior to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock
original issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment
of all preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation
available for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock,
pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted
into Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="AZTR:WarrantsTextBlock" id="ixv-9913"><p id="xdx_80D_ecustom--WarrantsTextBlock_z7ZL09p17T2i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<span id="xdx_828_zNloBHkOS3R8">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued warrants to purchase <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl8FR2llnrmh" title="Number of warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15102">6,745</ix:nonFraction></span> shares of common stock in 2018 in conjunction with convertible debt financing that have a redemption
provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it has converted into)
at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent appraiser.
As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based on ASC 480
&#8211; Distinguishing Liabilities from Equity. These warrants have an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zGUeVATmqlV2" title="Exercise price of warrants per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15103">0.48</ix:nonFraction></span> per share and a term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zVNTfymJH4qc" title="Maturity term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15104">10</ix:nonNumeric></span> years. The
warrants are marked to market each reporting period. The fair value is $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlBQpdkEen9" title="Fair value of warrants"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15105">35,453</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3p8YgMIYdDl" title="Fair value of warrants"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15106">70,283</ix:nonFraction></span> at December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead
meet equity classification criteria. The <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZMXNdQLIKh" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15107">11,466</ix:nonFraction></span> warrants issued in 2016 had a weighed average exercise price of $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpW4FIoFM0d3" title="Weighed average exercise price"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15108">0.01</ix:nonFraction></span> and a weighted
average term of <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_dtY_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkfifuOkytud" title="Weighted average term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt-sec:duryear" name="AZTR:SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" id="ixv-15109">9.7</ix:nonNumeric></span> years and expired upon the initial public offering in June 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-9935"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQBju39i6ktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants outstanding at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zPZXVjgU03Q2" style="display: none">Schedule
of Information about Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2018</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zkCdwpqzeEc" title="Exercise price of warrants" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_YearTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15110">0.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zqwmz86hzsfi" title="Number of warrants outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15111">47,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zZQB7cZI9yQd" title="Weighted Average Remaining Contractual Life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15112">4.5</ix:nonNumeric></span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDzgr0Jg8Ltd" title="Weighted Average Exercise Price, Outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15113">0.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_ziu9fUMDi1jc" title="Number of warrants exercisable" style="width: 9%; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15114">47,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zFum6EmXhFEc" title="Weighted Average Remaining Contractual Life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt-sec:duryear" name="AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15115">4.5</ix:nonNumeric></span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDZIfgEPrF4g" title="Weighted Average Exercise Price, Exercisable"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15116">0.48</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zp59YIvl2e7l" title="Exercise price of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_YearTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15117">5.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zI69yuzjnSla" title="Number of warrants outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15118">215,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zlnYOwUWtjh6" title="Weighted Average Remaining Contractual Life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15119">2.4</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zIDZkPocI7ah" title="Weighted Average Exercise Price, Outstanding" style="text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15120">5.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zRxszl8YDn92" title="Number of warrants exercisable" style="text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15121">215,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zO4D9DbLSszc" title="Weighted Average Remaining Contractual Life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt-sec:duryear" name="AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15122">2.4</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zYZ23YLUv4n5" title="Weighted Average Exercise Price, Exercisable"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15123">5.28</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zoUrwgmKzUhk" title="Exercise price of warrants" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_YearTwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15124">6.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zyvRh2JSCFQf" title="Number of warrants outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15125">60,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zt1XkaHM9rfl" title="Weighted Average Remaining Contractual Life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15126">4.7</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zh8jG0wWUC5k" title="Weighted Average Exercise Price, Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15127">6.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zAJs7XeX8rM4" title="Number of warrants exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15128">60,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_ztKvjweQ94Y1" title="Weighted Average Remaining Contractual Life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt-sec:duryear" name="AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15129">4.7</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zCfJMwwPkhC2" title="Weighted Average Exercise Price, Exercisable"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15130">6.25</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7xK4duS2j36" title="Number of warrants outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15131">323,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRNfZFq6smlb" title="Weighted Average Exercise Price, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15132">4.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBz0QE0X97Hb" title="Number of warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15133">323,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxcQjjPXULUg" title="Weighted Average Exercise Price, Exercisable"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15134">4.75</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zSFicp98Qbg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueOptionTextBlock" id="ixv-10146"><p id="xdx_80F_eus-gaap--FairValueOptionTextBlock_ztthSgv6sYdb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<span id="xdx_820_zvYjWmmeT4s2">Stock Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company&#8217;s Board of Directors and stockholders approved the 2023 Stock Incentive Plan (&#8220;2023 Plan&#8221;).
The 2023 Plan allows the Committee to grant up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230301__20230331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzPMcaWcSdL"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15135">2,000,000</ix:nonFraction></span> shares of Common Stock in the form of incentive and non-statutory stock options,
restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and non-employees. As of December
31, 2023, options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEeOuRQC5yHj" title="Stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15136">40,000</ix:nonFraction></span> shares of common stock had been granted and were outstanding under the 2023 Plan and <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEtzj3orjm1" title="Stock options available for grants"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15137">1,960,000</ix:nonFraction></span> shares
of common stock were available for grant under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, the Company established the Azitra Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options and
restricted shares to the Company&#8217;s employees, officers, directors, advisors and consultants. As of December 31, 2023, options to
purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD9scnGAjqX3" title="Stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15138">1,248,255</ix:nonFraction></span> shares of common stock had been granted and were outstanding under the 2016 Plan and <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CfoIW3sj06" title="Stock options available for grants"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" contextRef="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15139">242,340</ix:nonFraction></span> shares of common stock
were available for grant under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recognized stock compensation expense of $<span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgh4WNwNWMni" title="Stock compensation expense"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15140">125,555</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFuIFefi7ape" title="Stock compensation expense"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15141">25,950</ix:nonFraction></span>, included in general and
administrative and research and development on the accompanying statement of operations, respectively. During the year ended December
31, 2022, the Company recognized stock compensation expense of $<span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZdNmpXreBda" title="Stock compensation expense"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15142">131,185</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRjfKE3yoZE5" title="Stock compensation expense"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15143">53,280</ix:nonFraction></span>, included in general and administrative and research
and development on the accompanying statement of operations, respectively, relating to the issuance of service-based stock options. At
December 31, 2023, there was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQWLNqwXgBUl" title="Performance stock options shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15144">326,438</ix:nonFraction></span> of unamortized compensation expense that will be amortized over a remaining weighted-average period
for the 2016 Plan and 2023 Plan of approximately <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zt124Q1nIaK8" title="Weighted average period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="ixv-15145">1.32</ix:nonNumeric></span> and <span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember_zRIjwwgBicja" title="Weighted average period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandTwentyThreeStockIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="ixv-15146">3.58</ix:nonNumeric></span> years, respectively. At December 31, 2023 and 2022, there were <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z9dtWmEXgX76" title="Number of stock options outstanding"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNNUGhdowyf4" title="Number of stock options outstanding"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15147"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15148">13,120</ix:nonFraction></ix:nonFraction></span></span>
performance-based options outstanding with a fair value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5EfcXfS8wZ6" title="Fair value of stock options"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDliqpi9yO6" title="Fair value of stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15149"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15150">109,551</ix:nonFraction></ix:nonFraction></span></span>. During the years ended December 31, 2023 and 2022, the Company did
not recognize any compensation expense for performance-based options. The Company determined the options qualified as plain vanilla under
the provisions of SAB 107 and the simplified method was used to estimate the expected option life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="ixv-10180"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_z0IW86DeXVh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about options outstanding and exercisable at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zIyC4GBKAWC3" style="display: none">Schedule of Information about Options Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_z8alUhhaGHvf" title="Number of options exercise price" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_StockOptionOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15151">0.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zxyowzgtjtj" title="Number of options outstanding" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15152">246,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR3Ann5Ixp79" title="Weighted Average Remaining Contractual Life, Options outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15153">2.0</ix:nonNumeric></span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zt9pjLBKdbci" title="Weighted Average Exercise Price, Options outstanding" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2023-12-31_custom_StockOptionOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15154">0.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zo8WiVuiKYZ7" title="Number of options exercisable" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_StockOptionOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15155">246,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zYT3Df1fOJ71" title="Weighted Average Remaining Contractual Life, Options exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15156">2.0</ix:nonNumeric></span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR9c35belXWj" title="Weighted Average Exercise Price, Options exercisable" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15157">0.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_z230LJtrVUte" title="Number of options exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_StockOptionTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15158">0.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zG1uZTAAOHKi" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15159">202,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEpD9VstCDi4" title="Weighted Average Remaining Contractual Life, Options outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15160">2.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zTBl3sDX1S83" title="Weighted Average Exercise Price, Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2023-12-31_custom_StockOptionTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15161">0.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEz0aNcZOps9" title="Number of options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_StockOptionTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15162">202,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zaBAK7ymcR3" title="Weighted Average Remaining Contractual Life, Options exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15163">2.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zebXAPfhb2Qj" title="Weighted Average Exercise Price, Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15164">0.93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNplBbt1s6i" title="Number of options exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_StockOptionThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15165">1.70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zjdmUFeW7k" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15166">800,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNyXrER7XRx2" title="Weighted Average Remaining Contractual Life, Options outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15167">7.3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zQpwkXxVK3rf" title="Weighted Average Exercise Price, Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2023-12-31_custom_StockOptionThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15168">1.70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zTTtxALwWwpl" title="Number of options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_StockOptionThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15169">572,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zhRU9mi8Ph2b" title="Weighted Average Remaining Contractual Life, Options exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15170">7.0</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zu2hHQ7pyKbi" title="Weighted Average Exercise Price, Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15171">1.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_ziJR95ZKgtO6" title="Number of options exercise price" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_StockOptionFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15172">2.07</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zmQXbPGAObYc" title="Number of options outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15173">40,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zSRjIM5YVT7h" title="Weighted Average Remaining Contractual Life, Options outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15174">9.7</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zinJOCaNbm2l" title="Weighted Average Exercise Price, Options outstanding" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2023-12-31_custom_StockOptionFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15175">2.07</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_z7fmXVkMUUQg" title="Number of options exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_StockOptionFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15176">4,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zNrZYLH8kxX3" title="Weighted Average Remaining Contractual Life, Options exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15177">9.7</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zg0wp74KBlKi" title="Weighted Average Exercise Price, Options exercisable" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15178">2.07</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zurrTuXFjww2" title="Number of options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15179">1,288,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z5EguCpa9YGg" title="Number of options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15180">1,025,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zsBU4Knl9oV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-10375"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znzMZ8DIaDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
stock option activity for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z8jQ1C39P195" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zSNcOmTFKIEk" title="Number of Options, Outstanding Beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15181">1,381,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zugnGEAh2Rc4" title="Weighted Average Exercise Price, Outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15182">1.34</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zC3Aneb4tN5i" title="Number of Options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15183">888</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zCIG5MDvbj1e" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15184">1.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_zesRlD2lIsAe" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15185">90,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zL7rTaF8BFSl" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15186">5.91</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zV4J4DYMImTi" title="Number of Options, Outstanding Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15187">1,290,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_z0zusWSFR2l4" title="Weighted Average Exercise Price, Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15188">1.33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zyVwOyA2CMY9" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15189">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zEW8hL496vA8" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15190">2.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zUM7hFyG2jj2" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zXJUrtb9U9Y5" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zi0Q53h4PbQ6" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15191">42,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zxDSVZ0EUXHg" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15192">0.87</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z2xIL8GpDF76" title="Number of Options, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15193">1,288,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOGJvImz7sfl" title="Weighted Average Exercise Price, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15194">1.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z6oqf11p9Ps7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">10. Stock Options (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBKxZCmf8BQh" title="Shares available for future grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15195">242,340</ix:nonFraction></span> shares available for future grant under the 2016 Plan and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z83BldKcWmz4" title="Shares available for future grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15196">1,960,000</ix:nonFraction></span> available under the 2023 Plan at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" id="ixv-10505"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_zh1YyAYYvNZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
intrinsic value for the 2016 plan for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_zyUPIhhTgClk" style="display: none">Schedule of Total Intrinsic Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Value of Stock at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zrkBRiqqQy2i" title="Options Outstanding Value of Stock" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15197">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--OptionsExcercisableSharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zOoksrDCpKWd" title="Options Exercisable Value of Stock" style="width: 16%; text-align: right"><ix:nonFraction name="AZTR:OptionsExcercisableSharePrice" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15198">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zb8PSyGiExx6" title="Options Outstanding Exercise Price" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15199">0.48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zNQKltQxeIx7" title="Options Exercisable Exercise Price" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15200">0.48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Intrinsic Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zEuooQLcCDTa" title="Options Outstanding Intrinsic Value Per Share" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15201">0.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z78JkwIjJ5Yg" title="Options Excercisable Intrinsic Value Per Share" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15202">0.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options O/S</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zyBSUf7Rfjac" title="Options Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15203">246,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z2BQQGDGzlWh" title="Options Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15204">246,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Intrinsic Value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zPFMR5g23Ftb" title="Options Outstanding Intrinsic Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15205">108,300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z6O0lcqKxIFc" title="Options Exercisable Intrinsic Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15206">108,300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zh8qcwh0tcE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="ixv-10572"><p id="xdx_802_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zpZPvJubsqMj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<span id="xdx_823_zqiV7bvlq3G6">Fair Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-10578"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBKPHKKuW5vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_ziY5xp84EIgb" style="display: none">Schedule of Fair Value Measurements for Assets and Liabilities</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2e8yspYLvIh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zk6TsCYXF1Rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zstjytY83pPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKGa7vl2qWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zHlPqQZ1mqmc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15207">35,453</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15208">35,453</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z3EYgVVW1NU9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15209">35,453</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15210">35,453</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFv6jSbplQ79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoS2fezKmjEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxPBFbWHocb9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9zxz54b4MHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zIEMn0IQf2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15211">70,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15212">70,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNoteMember_zYi48rZhccb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15213">5,600,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15214">5,600,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z8XA51UIyGpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15215">5,670,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15216">5,567,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zuTmJjT7RD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-10762"><p id="xdx_89B_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z0kZpwkZv4If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zncfXAazObO" style="display: none">Schedule
of Changes in Level 3 Instruments Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1p34BQtPLUl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_z1q7e27CglDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15217">71,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zurp5fkLQ478" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15218">821</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfConvertibleNotes_z1NKCLvE1QTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:IssuanceOfConvertibleNotes" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15219">4,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zH3s99L4a9gi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNotes" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15220">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_ztNUsYSMFtuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15221">5,670,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zXKBGPbrt20d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15222">34,830</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zvSvJ0XeOJO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:ChangeInFairValueOfConvertibleNotes" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15223">3,630,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConversionConvertibleNotes_zHJuLjed3EO4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Conversion of 2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AZTR:ConversionConvertibleNotes" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15224">9,230,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zve30gNh3qe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15225">35,453</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zmd6jwOWj7Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">11. Fair Value Measurements (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="ixv-10856"><p id="xdx_899_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zoOSLa7v7TR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zhFxpIcLF5B4" style="display: none">Schedule
of Fair Value of Warrants Using Black Scholes Option Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Underlying common stock value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zUDDyoy1CJh3" title="Dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15226">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231_zXTl2VrkBAci" title="Dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15227">1.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zYkWaZCcl9El" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15228">4.29</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zpLwB0ubkzwj" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15229">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_z7tZJPnP41E4" title="Expected volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15230">99</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zfcaq46ibAla" title="Expected volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15231">86</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zN4HKuQkBTmk" title="Risk free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15232">4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zm0mVHMFB1P2" title="Risk free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15233">3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zePJz5kqEL6l" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zOnRUNZeT7x1" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zY5Wyo7xpau6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuation
in the fair value of the Company&#8217;s Common stock is the primary driver for the change in the Common Stock Warrant liability valuation
during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to their redemption, fluctuations in the various inputs, including the enterprise value, time to liquidity, volatility, and discount
rate are the primary drivers for the changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the
enterprise value, estimated time to liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible
Notes generally increases.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-10937"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zBMkOwBVb9Cg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<span id="xdx_82C_z6xU1tXD7XL3">Net Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share were calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-10947"><p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zJNFCSMaVIi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
numerator for basic and diluted net loss per share is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zfpFVNqOTC3h" style="display: none">Schedule of Numerator for Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zCPJVc2TksLi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zFZDXGfH5KHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILFCzCGP_zULqagYfRwO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15234">11,283,781</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15235">10,680,366</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPreferredStockStock_iN_di_msNILFCzCGP_zLM3gIHiY3X5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStockStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15236">1,355,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStockStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15237">2,768,984</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_iT_mtNILFCzCGP_zyXj41tpGmj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15238">12,639,128</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15239">13,449,350</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zxpTpRC9P2D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="ixv-11007"><p id="xdx_89B_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zGsT9DCsnp34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zLTGJPpLz6f1" style="display: none">Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Weighted average common stock outstanding, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2coApmHoYv8" title="Weighted average common stock outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNNh9KEXWE6" title="Weighted average common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15240"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15241">6,919,081</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtNwCylC15" title="Weighted average common stock outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRK3MfNeG5cg" title="Weighted average common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15242"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15243">1,043,932</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">$0.01 warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYb2ti6mWI6" title="$0.01 warrants, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRX72Go7aqmb" title="$0.01 warrants, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember101773265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15244"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember101773265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15245">5,372</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfL9UvMbNNf" title="$0.01 warrants, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuNTI8EmtUc" title="$0.01 warrants, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15246"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15247">11,467</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zz3A9PtZqQIb" title="Total, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z8ZlPbMj0mz2" title="Total, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15248"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15249">6,924,453</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zCJ9KcRdEP7h" title="Total, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zGwOsO0x3oxg" title="Total, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15250"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15251">1,055,399</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zkKnj9BZ0Eq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">12. Net Loss Per Share (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="ixv-11096"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zzHwGgy3Dqw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share, basic and diluted is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zQbWsCUzCHU6" style="display: none">Schedule of Net Loss Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net Loss per share, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBYfdHL8e44c" title="Net loss per share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zUH004Uqwkt5" title="Net loss per share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-15252"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-15253">1.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zB02apJBBhYe" title="Net loss per share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_z6yPSgVg12Z6" title="Net loss per share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-15254"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-15255">12.74</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zJ90GOUSIsv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-11132"><p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRfdJ1Q0gWp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbnsigDYV59l" style="display: none">Schedule of Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zsXLrmvpRAp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zQGqz7S0BhKb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_ziBSQNCoJAC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15256">1,288,255</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15257">1,290,318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z03y5jLiEog7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember101773703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15258">323,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember101773718" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15259">263,743</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zAc0GXMqIWO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15260">1,611,991</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15261">1,554,061</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zEsyP8793r51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-11192"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zoJBeGCYKQrg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<span id="xdx_823_z92Mn21tNel9">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-11198"><p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zpfbBNL4YGPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
(benefit) provision for income taxes for the years ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zIOjfXsCBFq7" style="display: none">Schedule
of (Benefit) Provision for Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zGYtHGstCgd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zIgjC1BHdPmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzw8s_z4hkGu6sJr1f" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1415">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzw8s_zUhSNJnkiHp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Foreign</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15262">17,308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzw8s_zyeb7u5WOyHa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1421">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzw8s_maITEBzwVq_zB0CcPiU7ny4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15263">17,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBz8IL_z8oA38GMc7rj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBz8IL_zaTfkcSR9up2" style="vertical-align: bottom; background-color: White">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBz8IL_zB05kIboZfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1432">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBz8IL_maITEBzwVq_zvyM8uXgmD7k" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total deferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzwVq_zCoJbq6tBkO6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15264">17,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_zKkc3ULkV2R3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-11351"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8TNnX7OuLJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax computed using the U.S. federal statutory tax rate compared to that reflected in operations for the years
ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zr6AjcBdvpN2" style="display: none">Schedule
of Reconciliation of Income Tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Income taxes using U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20230101__20231231_zBQWfu5NiH14" title="Income taxes using U.S. statutory rate, amount" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15265">2,401,761</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20230101__20231231_zFQvJdlBxaKh" title="Income taxes using U.S. statutory rate, percent" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15266">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zqldSVBsjYSl" title="Income taxes using U.S. statutory rate, amount" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15267">2,205,649</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20220101__20221231_zAwHWYPwvQP6" title="Income taxes using U.S. statutory rate, percent" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15268">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt fair value adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20230101__20231231_zT1v6mNoWBh9" title="Debt fair value adjustment, amount" style="text-align: right"><ix:nonFraction name="AZTR:IncomeTaxReconciliationDebtFairValueAdjustment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15269">762,321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20230101__20231231_zgKlhvb28D4d" title="Debt fair value adjustment, percent" style="text-align: right">(<ix:nonFraction name="AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15270">6.67</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20220101__20221231_zI8sHpMERyk8" title="Debt fair value adjustment, amount" style="text-align: right"><ix:nonFraction name="AZTR:IncomeTaxReconciliationDebtFairValueAdjustment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15271">262,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20220101__20221231_zoNgeEc5sgYg" title="Debt fair value adjustment, percent" style="text-align: right">(<ix:nonFraction name="AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15272">2.50</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zNPf6YVQdqC5" title="State taxes, net of federal benefit, amount" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15273">538,268</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20230101__20231231_zCyc8KELZeT1" title="State taxes, net of federal benefit, percent" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15274">4.71</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20220101__20221231_zRZzEZj1GPF7" title="State taxes, net of federal benefit, amount" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15275">602,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20220101__20221231_zl6sZEUwzwI7" title="State taxes, net of federal benefit, percent" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15276">5.73</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zmt64MMj3WUk" title="Research and development tax credit, amount" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15277">356,237</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20230101__20231231_zSRVv2461cDi" title="Research and development tax credit, percent" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15278">3.11</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231_zJk1BxhkFHU9" title="Research and development tax credit, amount" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15279">433,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20220101__20221231_zYx5r1gOzZol" title="Research and development tax credit, percent" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15280">4.13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_z9PXm5o8mZp5" title="Change in valuation allowance, amount" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15281">2,502,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20230101__20231231_zOZZNI679Ft" title="Change in valuation allowance, percent" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15282">21.88</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zlk32p46zGq5" title="Change in valuation allowance, amount" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15283">2,889,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20220101__20221231_zjfN5GrkvOh3" title="Change in valuation allowance, percent" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15284">27.51</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zE16s75wjxec" title="Other, net, amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15285">48,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20230101__20231231_zvrRd69wLQ6a" title="Other, net, percent" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15286">0.42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20220101__20221231_zKZfGx0xO2H" title="Other, net, amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15287">89,367</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20220101__20221231_zQ6NWxkGQcEd" title="Other, net, percent" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15288">0.85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expenses (benefit)</span></td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_zpyz6dkPwVt9" title="Income tax expenses" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15289">17,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20230101__20231231_zL0JtloCgzrf" title="U.S. federal statutory tax rate" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure" id="ixv-15290">0.15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)%</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231_zP9O6vp9zrB" title="Income tax expenses" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><p id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20220101__20221231_zf6GfF1mv82j" title="U.S. federal statutory tax rate" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></b></span></p></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zY4expNN5Ga3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">13. Income Taxes (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-11537"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhpaIW6z2iL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2023 and 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_ziXVB3Yf6517" style="display: none">Schedule
of Deferred Income Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zocL4cblOKt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zQ4I8w2dCtHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zOv3kUhmi6Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_zMbnYKMXCjah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15291">8,755,690</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15292">7,870,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_ziW2rjLHPgd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15293">2,155,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15294">1,729,421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_maDTAGzRjT_maDTAGzJN6_zM2Ib0xs56Se" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:DeferredTaxAssetsDepreciationAndAmortization" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15295">2,372,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AZTR:DeferredTaxAssetsDepreciationAndAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15296">1,189,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzJN6_z9YiDw1wHPg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15297">89,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15298">81,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJN6_zfEkFsSKHIDa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15299">30,572</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15300">28,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJN6_maDTALNzcbS_zIm003X3ZEN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15301">13,402,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15302">10,899,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zmBM7rBQJGs8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzJtH_zVpXKUZeRN8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzJtH_msDTALNzcbS_z78OE6dfDKr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1528">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzcbS_zJkpwGa5FF7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15303">13,402,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15304">10,899,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcbS_zOn5cvxwIoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1535">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zVyNMELdCeEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZh3XhJkHwc" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15305">32,529,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmqoxOoMuZI5" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15306">29,192,000</ix:nonFraction></span> for the tax years ending December 31,
2023 and 2022, respectively, of which $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2037Member_zBlYMv8JZY95" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2036Through2037Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15307">1,285,000</ix:nonFraction></span> will expire in tax years 2036 through 2037 and approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--NoExpirationMember_zIeXdvwHMsr4" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_NoExpirationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15308">31,244,000</ix:nonFraction></span> which does
not expire. The Company has state net operating loss carryforwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_zOLPNzCv4gEj" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15309">32,484,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_z4Sg90sEegR3" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15310">29,374,000</ix:nonFraction></span> for the tax years ending
December 31, 2023 and 2022, respectively, which will expire in tax years 2037 through 2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal research tax credits of approximately $<span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_z4chqDCa37m1" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15311">1,524,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_znkq3rpIqId2" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15312">1,235,000</ix:nonFraction></span> for the tax years ending December 31, 2023 and 2022,
respectively, which expire in tax years 2039 through 2043. The Company has state research tax credits of approximately $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkZR3vZ6PAf2" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15313">466,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zxEm7BwfiKWg" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15314">350,000</ix:nonFraction></span>
for the tax years ending December 31, 2023 and 2022, respectively, of which $<span id="xdx_901_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2038Member_zzPIAC2tvgEi" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2036Through2038Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15315">312,000</ix:nonFraction></span> will expire in tax year 2036 through 2038 and the
remainder can be carried forward indefinitely. The Company has Canadian research tax credits of approximately $<span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zCjOgZ53X0yl" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15316">263,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zfOX7ceMxKYa" title="Research tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15317">218,000</ix:nonFraction></span> for
the tax years ending December 31, 2023 and 2022, respectively, which expire in tax years 2039 through 2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Internal Revenue Code Section 382 imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership
change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company undergoes an ownership
change exceeding the 50% limitation threshold imposed by Section 382, the Company&#8217;s net operating loss carryforwards may be significantly
limited as to the amount of use in a particular year. In addition, all or a portion of the Company&#8217;s net operating loss carryforwards
incurred before 2018, may expire unutilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">13. Income Taxes (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate future taxable income during the periods
in which the temporary differences become deductible. Based on the Company&#8217;s recent earnings history and projected future U.S.
earnings, management believes that it is more likely than not that its federal and state deferred tax assets will not be fully realized
in the foreseeable future. As a result of this assessment, management believes that a full valuation allowance against its net federal
and state deferred tax assets is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 740-10 to account for uncertain tax positions. ASC 740-10 addresses the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the
Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be
sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that it
has no significant uncertain tax positions requiring recognition and measurement under ASC 740-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income tax, Connecticut state income tax and Canada branch tax. The Company has not been audited by
the IRS, state, or foreign tax authorities in connection with income taxes. The Company&#8217;s tax years remain open to examination
for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statute of limitations
have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize interest and penalties related to unrecognized tax benefits, if applicable, as a component of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-11769"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zifvlu3ZAqx1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span id="xdx_82F_zvhYM1tSkWi1">Commitments and Contingencies</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions
or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on
its financial position, results of operations or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 26, 2022, the Company entered into an Exclusive License Agreement (the License Agreement) with an unrelated third party. Under
the License Agreement, the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how.
The License Agreement continues until the later of the expiration of the last to expire licensed patent or ten years after the first
commercial sale of the first licensed therapeutic or non-therapeutic product. The Company may terminate the License Agreement at any
time by providing at least 30 days written notice to the third party. The License Agreement is also terminated upon breach of a material
obligation under the agreement or bankruptcy. Upon any termination of the License Agreement, neither party is relieved of obligations
incurred prior to the termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company capitalized payments made under this license agreement in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromLicenseFeesReceived_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z72gFpn1c2T6" title="Capitalized License agreement amount"><ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15318">13,096</ix:nonFraction></span>
and $<span id="xdx_90A_eus-gaap--ProceedsFromLicenseFeesReceived_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsZqhBt4Ty41" title="Capitalized License agreement amount"><ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="From2022-01-012022-12-31_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15319">65,510</ix:nonFraction></span>, respectively. During the fourth quarter, the license agreement was subsequently written off as discussed in Note 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-11797"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zFSlWNltB9S3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span id="xdx_82D_z5r1stsCw0kd">Operating Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company&#8217;s leases expire at various dates
through May 31, 2027. Most leases are for a fixed term and for a fixed amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019, the Company entered into a new lease agreement for office and laboratory space in Laval, Canada. The Laval lease required monthly
lease payments of $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20190101__20191231__srt--StatementGeographicalAxis__country--CA_zHfhzd5bcFw7" title="Lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-012019-12-31_country_CA" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15320">5,221</ix:nonFraction></span> which increased approximately 10% per year upon renewal. The Laval lease is initially for a <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zqXHyIhVsKqb" title="Lease term"><ix:nonNumeric contextRef="AsOf2019-12-31_country_CA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-15321">one year</ix:nonNumeric></span> term with
additional <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zy288uYbnRn6" title="Lease term renewal"><ix:nonNumeric contextRef="AsOf2019-12-31_country_CA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-15322">one year</ix:nonNumeric></span> renewal terms available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">15. Operating Leases (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company entered into a new lease agreement for the Company&#8217;s primary office and laboratory space in Branford, CT. The
Branford lease requires monthly payments of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20200101__20201231__dei--LegalEntityAxis__custom--BranfordCTMember_ztNfo4aiBSYf" title="Lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-012020-12-31_custom_BranfordCTMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15323">13,033</ix:nonFraction></span> for the first year of the lease, which increases approximately 2% in each of the
following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments
of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210501__20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zHbsjix5ybUk" title="Lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-05-012021-05-31_custom_GrotonCTMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15324">4,234</ix:nonFraction></span>, which was increased to $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210901__20210930__dei--LegalEntityAxis__custom--GrotonCTMember_zuxsbB8Pvie8" title="Lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-09-012021-09-30_custom_GrotonCTMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15325">6,824</ix:nonFraction></span> in September 2021 upon leasing additional space. The Groton lease is initially for a <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zJhR1BwhlHhb" title="Lease term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1583">one</span></span>-year
term, with up to <span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zYKptnyscBfb" title="Lease term renewal::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1585">three</span></span> additional years renewal available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="ixv-11852"><p id="xdx_899_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zm3Zqunk70Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zob4Grp0Rvqj" style="display: none">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231231_z1D2ts613384" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrWe_zjlwdIEbroUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15326">338,254</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrWe_z7DrqcLsQMvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15327">279,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrWe_zXEyNoTI7hVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15328">206,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzrWe_zTrAKc8MM941" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15329">74,273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzrWe_zUfTXVdcqED8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzrWe_zS79ur35KmVf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrWe_z7zMVNGc8NBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15330">898,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zOMi14Eml617" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15331">53,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_z1IjGrF02Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15332">845,178</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zNEn7N8peqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for all operating leases was $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231_zBuQc4khLhC5" title="Operating lease rental expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15333">338,856</ix:nonFraction></span> for the year ended December 31, 2023. The weighted average lease term for all operating
leases is <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhpEHfdTr034" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-15334">2.9</ix:nonNumeric></span> years. The weighted average discount rate for all operating leases is <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zoPCxLsEmD8f" title="Operating lease discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15335">4.25</ix:nonFraction></span>%.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company entered into an agreement with Hewlett Packard to lease equipment. The lease requires monthly payments of $<span id="xdx_90E_ecustom--FinanceLeaseMonthlyPayments_c20230101__20231231_zDvxF2ZSq0Wf" title="Finance lease monthly payments"><ix:nonFraction name="AZTR:FinanceLeaseMonthlyPayments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15336">1,478</ix:nonFraction></span>, including
tax. The lease is for a <span id="xdx_900_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtY_c20231231_zvbDls2Dae5l" title="Finance lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="ixv-15337">3</ix:nonNumeric></span>-year term with option of purchase or extension at term end. The remaining lease term is <span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231_zZvLtWRlkSjk" title="Finance lease remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="ixv-15338">2.8</ix:nonNumeric></span> years and the discount
rate is <span id="xdx_901_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20231231_zSny5LKEl3Ei" title="Finance lease discount rate"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-15339">9.60</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="ixv-11942"><p id="xdx_895_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z5RhecIKj2Nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zcxhdypVpmpk" style="display: none">Schedule of Future Minimum Payments Under Finance  Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231231_zMJCYukla8a3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzipE_zJL5lA5gQv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15340">17,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzipE_zCbpu78uBcl2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15341">17,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maFLLPDzipE_zfCFk8yxAvJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15342">10,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_maFLLPDzipE_zwkoILUcXhGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_maFLLPDzipE_zIKCOXOMpCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1631">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzipE_zDfAaJeCiqDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15343">45,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinanceLeaseInterest_iI_zMiM7sWvZM2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AZTR:FinanceLeaseInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-15344">5,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_zM4OQTtL0yy5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15345">40,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zLZ81GFREmbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for the finance lease was $<span id="xdx_901_ecustom--FinanceLeaseExpense_c20230101__20231231_zbDozcIynbM3" title="Finance lease expense"><ix:nonFraction name="AZTR:FinanceLeaseExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15346">6,450</ix:nonFraction></span> for the year ended December 31, 2023. Interest expense for the finance lease was $<span id="xdx_903_eus-gaap--FinanceLeaseInterestExpense_c20230101__20231231_z5zNtz9BbdQi" title="Interest expense"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15347">1,707</ix:nonFraction></span> for
the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-12032"><p id="xdx_806_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zRE4H9qmGaB2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<span id="xdx_82D_zuQUAq08qS63">Retirement Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2019, <span id="xdx_90F_eus-gaap--DefinedBenefitPlansGeneralInformation_c20190101__20190101_z4RVtfH34xPa" title="Retirement plan general information"><ix:nonNumeric contextRef="From2019-01-012019-01-01" name="us-gaap:DefinedBenefitPlansGeneralInformation" id="ixv-15348">the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed.</ix:nonNumeric></span> Total employer matching
contributions was $<span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zwMjNzjIaEW9" title="Employer contribution"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15349">11,803</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zExiK3gn2iZ9" title="Employer contribution"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15350">23,466</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-12045"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPQxsf05F055" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<span id="xdx_824_zH5hw2pZx1D">Related Parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
related party revenue was $<span id="xdx_906_eus-gaap--Revenues_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJ6GYsF7317" title="Revenues from related party"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15351">686,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--Revenues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zxV5CvQmG3bj" title="Revenues from related party"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15352">284,000</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively. Accounts receivable due
from the related party was $<span id="xdx_904_eus-gaap--OtherReceivables_iI_c20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfYaJuF77Asa" title="Accounts receivable due from related party"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15353">90,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--OtherReceivables_iI_c20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zyvtKjoo2TZf" title="Accounts receivable due from related party"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15354">175,000</ix:nonFraction></span> at December 31, 2023 and 2022, respectively. Contract liabilities from the related party
was $<span id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2XJDWac3P93" title="Contract liabilities due from related party"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15355">0</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiability_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zizPJ7LWVFJi" title="Contract liabilities due from related party"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15356">156,000</ix:nonFraction></span> at December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a convertible promissory note totaling $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zjCVaA2flTu7" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15357">4,350,000</ix:nonFraction></span> of which $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmrbhSzkVKxc" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15358">4,000,000</ix:nonFraction></span> was attributable to an
entity who was also an investor in the Company&#8217;s Series A, A-1, and B Preferred Stock financing (See Note 7). This entity received
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFfnJALfFUG9" title="Stock issued during conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15359">1,697,490</ix:nonFraction></span> shares of common stock upon conversion of the promissory notes for principal and interest of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zKNXV1gHOQ19" title="Stock issued during conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-15360">4,243,726</ix:nonFraction></span>.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-12069"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zIAx15YVBe5j" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<span id="xdx_82B_zsgAIsHlB3yl">Subsequent Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2024, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPLCAm867Vii" title="Number of shares of public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15361">16,667,000</ix:nonFraction></span> shares of its common stock at an offering price of $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoyTmekfbsWc" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15362">0.30</ix:nonFraction></span> per
share. The Company received gross proceeds of approximately $<span id="xdx_90A_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn6n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPcULtCzU8qg" title="Gross proceeds from public offering"><ix:nonFraction name="AZTR:GrossProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-15363">5</ix:nonFraction></span> million and net proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zO19jNoEZ8Zk" title="Net proceeds from issuance of public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD" id="ixv-15364">4.4</ix:nonFraction></span> million, after deducting
underwriting discounts and offering-related expenses. The Company granted the underwriter an overallotment option to purchase an additional
<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0THcsCXJGp6" title="Number of shares purchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_UnderwriterMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15365">2,500,000</ix:nonFraction></span> shares of its common stock, at the public offering of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zOuze0LPKIo8" title="Public offering price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15366">0.30</ix:nonFraction></span> per share less the underwriter&#8217;s discount, for a 45-day period
ending March 29, 2024. In connection with the public offering, the Company issued to the underwriter, as additional underwriting compensation,
a warrant to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z5XzkSKemx2e" title="Warrants to purchase of common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-15367">666,680</ix:nonFraction></span> shares of its common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zX0HrsOOyMNd" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-15368">0.375</ix:nonFraction></span> per share over a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z4dnWQ8EU9q2" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1691">five</span></span>-year period.</span></p>

</ix:nonNumeric><p id="xdx_812_zR1zGionhSng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_018"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_019"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(a)
Evaluation of Disclosure Controls and Procedures.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure
controls and procedures pursuant to Rule 13a-15(e) under the Exchange Act as of December 31, 2023. In the course of that evaluation,
we identified a material weakness as it relates to a lack of adequate segregation of accounting functions. We intend to increase staffing
within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions and to enable appropriate review
of our internally prepared financial statements. Based upon the foregoing, our chief executive officer and chief financial officer concluded
that our disclosure controls and procedures were not effective as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)
Changes in internal control over financial reporting.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes to our internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act that occurred during
the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(c)
Management&#8217;s report on internal controls over financial reporting.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation
report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission
for newly public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_020"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_021"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Options: NewSection; Value: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="di_022"></span>PART
III</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_023"></span>Item
10. Directors, Executive Officers and Corporate Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required under this item will be contained in the 2024 Proxy Statement and is hereby incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_024"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required under this item will be contained in the 2024 Proxy Statement and is hereby incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_025"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required under this item will be contained in the 2024 Proxy Statement and is hereby incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_026"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required under this item will be contained in the 2024 Proxy Statement and is hereby incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_027"></span>Item
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required under this item will be contained in the 2024 Proxy Statement and is hereby incorporated by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="di_028"></span>PART
IV</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_029"></span>Item
15. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the Index and Financial Statements under Item 8 in Part II hereof where these documents are listed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial statement schedules</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
statement schedules are either not required or the required information is included in the consolidated financial statements or notes
thereto filed under Item 8 in Part II hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exhibits to this Annual Report on Form 10-K are set forth below. The exhibit index indicates each management contract or compensatory
plan or arrangement required to be filed as an exhibit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Method
    of Filing</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223021998/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Certificate of Incorporation of the Registrant</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223021998/ex3-2.htm" style="-sec-extract: exhibit">Second Amended and Restated Bylaws of the Registrant</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223017665/ex4-1.htm" style="-sec-extract: exhibit">Specimen Certificate representing shares of Common Stock</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223005551/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued to Private Placement investors</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223017665/ex1-1.htm" style="-sec-extract: exhibit">Form of Representative&#8217;s Warrant dated June 20, 2023 issued to ThinkEquity LLC</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315224006365/ex1-1.htm" style="-sec-extract: exhibit">Form of Representative&#8217;s Warrant dated February 16, 2024 issued to ThinkEquity LLC (attached to Underwriting Agreement between the Registrant and ThinkEquity, LLC dated February 13, 2024)</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Current Report on Form 8-K filed on February 14, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex4-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315222035618/filename7.htm" style="-sec-extract: exhibit">Azitra Inc. 2016 Stock Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223008274/ex10-5.htm" style="-sec-extract: exhibit">Azitra Inc. 2023 Stock Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315222035618/filename9.htm" style="-sec-extract: exhibit">Executive Employment Agreement dated April 22, 2021 between the Registrant and Francisco D. Salva</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315224002993/ex10-4.htm" style="-sec-extract: exhibit">Executive Employment Agreement dated July 5, 2023 between the Registrant and Travis Whitfill</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on January 19, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315222035618/filename6.htm" style="-sec-extract: exhibit">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315222035618/filename8.htm" style="-sec-extract: exhibit">Second Amended and Restated Investors&#8217; Rights Agreement dated September 10, 2020 between the Registrant and each of the investors named therein</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Form S-1 filed on June 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1701478/000149315223008274/ex21-1.htm" style="-sec-extract: exhibit">List of Subsidiaries of the Registrant</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Company&#8217;s Form S-1 filed
on March 20, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of Grassi &amp; Co., CPAs, P.C., Independent Registered Public Accounting Firm</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification under Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification under Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex97-1.htm">Azitra, Inc. Executive Officer Clawback Policy</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    electronically herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates management compensatory plan, contract or arrangement.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="di_030"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="di_031"></span>SIGNATURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this annual report
on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AZITRA,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 15, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Francisco D. Salva</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    D. Salva,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Francisco D. Salva</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    D. Salva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Executive Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Norman Staskey</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Treasurer and Secretary</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norman
    Staskey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Financial and Accounting Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Travis Whitfill</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travis
    Whitfill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew McClary</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    McClary</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Barbara Ryan</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barbara
    Ryan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    John Schroer</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Schroer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Options: NewSection Last; Value: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>ex4-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc. (&ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo;) has one class of securities registered under Section
12 of the Securities Exchange Act of 1934, as amended, namely our common stock, par value $0.0001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the rights of our common and of certain provisions of our Second Amended and Restated Certificate of Incorporation
(&ldquo;Certificate of Incorporation&rdquo;) and Second Amended and Restated Bylaws (&ldquo;Bylaws&rdquo;). For more detailed information,
please see our Certificate of Incorporation and Bylaws, which are incorporated by reference as exhibits to the Annual Report on Form
10-K to which this description is an exhibit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation authorizes us to issue up to 100,000,000 shares of common stock, $0.0001 par value per share. As of March
1, 2024, we had 28,804,643 shares of common stock outstanding, held by 34 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders generally. Stockholders
are entitled to receive such dividends as may be declared from time to time by the Board out of funds legally available therefore, and
in the event of liquidation, dissolution or winding up of the company to share ratably in all assets remaining after payment of liabilities.
The holders of shares of common stock have no preemptive, conversion, subscription rights or cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation authorizes us to issue up to 10,000,000 shares of preferred stock, $0.0001 par value per share, none of
which are issued or outstanding as of March 1, 2024. Our board of directors is authorized to issue from time to time, without stockholder
authorization, in one or more designated series or classes, any or all of the authorized but unissued shares of preferred stock with
such dividend, redemption, conversion and exchange provisions as may be provided in the particular series. Any series of preferred stock
may possess voting, dividend, liquidation and redemption rights superior to that of the common stock. The rights of the holders of common
stock will be subject to and may be adversely affected by the rights of the holders of any preferred stock that may be issued in the
future. Issuance of a new series of preferred stock, while providing desirable flexibility in connection with possible acquisition and
other corporate purposes, could make it more difficult for a third party to acquire, or discourage a third party from acquiring, a majority
of the outstanding voting stock of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock and we do not anticipate the payment of cash dividends on our common stock in the
foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, an anti-takeover law. In general, Section
203 prohibits a publicly held Delaware corporation from engaging in a &ldquo;business combination&rsquo;&rsquo; with an &ldquo;interested
stockholder&rsquo;&rsquo; for a period of three years after the date of the transaction in which such stockholder became an interested
stockholder, unless the business combination is approved in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rsquo;&rsquo;
includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an &ldquo;interested
stockholder&rsquo;&rsquo; is a stockholder who, together with affiliates and associates, owns, or within three years prior, did own,
15% or more of the voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, New York 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-2_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement of Azitra, Inc. on Form S-8 (File No. 333-275876) of our report
dated February 23, 2024 with respect to our audits of the consolidated financial statements of Azitra, Inc. as of December 31, 2023 and
2022 and for each of the two years in the period ended December 31, 2023, which report is included in this Annual Report on Form 10-K
of Azitra, Inc. for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Grassi &amp; Co., CPAs, P.C.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grassi
    &amp; Co., CPAs, P.C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
    New York</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Francisco D. Salva, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Azitra, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably
    likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons
    performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AZITRA,
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 15, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Francisco D. Salva</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    D. Salva, Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Norman Staskey, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Azitra, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably
    likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons
    performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AZITRA,
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 15, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Norman Staskey</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norman
    Staskey, Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. ss.1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Azitra, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December 31, 2023 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Francisco D. Salva, the Chief Executive
Officer, and Norman Staskey, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. &sect;1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Francisco D. Salva</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 15, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    D. Salva</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Norman Staskey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 15, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norman
    Staskey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not
for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>ex97-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AZITRA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officer Clawback Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approved
by the Board of Directors on October 18, 2023 (the &ldquo;Adoption Date&rdquo;) </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purpose</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Azitra, Inc., a Delaware corporation and
any of its direct or indirect subsidiaries (the &ldquo;<B><I>Company</I></B>&rdquo;) will be required to repay or return Erroneously-Awarded
Compensation to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy and any terms used in this Policy shall be construed in accordance with any SEC regulations promulgated to comply with Section
954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules adopted by the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Covered Person of the Company shall sign an Acknowledgement and Agreement to the Clawback Policy in the form attached hereto as <U>Exhibit
A</U> as a condition to his or her participation in any of the Company&rsquo;s incentive-based compensation programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions
    </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, the following capitalized terms shall have the meaning set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Accounting
    Restatement</I></B>&rdquo; shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial
    reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously
    issued financial restatements that is material to the previously issued financial statements (a &ldquo;Big R&rdquo; restatement),
    or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement
    if the error were corrected in the current period or left uncorrected in the current period (a &ldquo;little r&rdquo; restatement).
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Board</I></B>&rdquo;
    shall mean the Board of Directors of the Company. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Clawback-Eligible
    Incentive Compensation</I></B>&rdquo; shall mean, in connection with an Accounting Restatement, any Incentive-Based Compensation
    Received by a Covered Person (regardless of whether such Covered Person was serving at the time that Erroneously-Awarded Compensation
    is required to be repaid) (i) on or after the NYSE American Effective Date, (ii) after beginning service as a Covered Person, (iii)
    while the Company has a class of securities listed on a national securities exchange or national securities association and (iv)
    during the Clawback Period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Clawback
    Period</I></B>&rdquo; shall mean, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding
    the Restatement Date and any transition period (that results from a change in the Company&rsquo;s fiscal year) of less than nine
    months within or immediately following those three completed fiscal years. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Committee</I></B>&rdquo;
    shall mean the Compensation Committee of the Board. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Covered
    Person</I></B>&rdquo; shall mean any person who is, or was at any time, during the Clawback Period, an Executive Officer of the Company.
    For the avoidance of doubt, Covered Person may include a former Executive Officer that left the Company, retired or transitioned
    to an employee role (including after serving as an Executive Officer in an interim capacity) during the Clawback Period. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Erroneously-Awarded
    Compensation</I></B>&rdquo; shall mean the amount of Clawback-Eligible Incentive Compensation that exceeds the amount of Incentive-Based
    Compensation that otherwise would have been Received had it been determined based on the restated amounts. This amount must be computed
    without regard to any taxes paid. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Executive
    Officer</I></B>&rdquo; shall mean the Company&rsquo;s president, principal financial officer, principal accounting officer (or if
    there is no such accounting officer, the controller), any vice-president in charge of a principal business unit, division, or function
    (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including
    an officer of the Company&rsquo;s parent(s) or subsidiaries) who performs similar policy-making functions for the Company. For the
    sake of clarity, at a minimum, all persons who would be executive officers pursuant to Rule 401(b) under Regulation S-K shall be
    deemed &ldquo;Executive Officers&rdquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Financial
    Reporting Measures</I></B>&rdquo; shall mean measures that are determined and presented in accordance with the accounting principles
    used in preparing the Company&rsquo;s financial statements, and all other measures that are derived wholly or in part from such measures.
    For purposes of this Policy, Financial Reporting Measures shall include stock price and total shareholder return (and any measures
    that are derived wholly or in part from stock price or total shareholder return). </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Incentive-Based
    Compensation</I></B>&rdquo; shall have the meaning set forth in Section III below. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>NYSE
    American</I></B>&rdquo; shall mean The NYSE American Stock Exchange.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NYSE
    American Effective Date</I></B>&rdquo; shall mean October 2, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Policy</I></B>&rdquo;
    shall mean this Executive Officer Clawback Policy, as the same may be amended and/or restated from time to time. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Received</I></B>&rdquo;
    shall mean Incentive-Based Compensation received, or deemed to be received, in the Company&rsquo;s fiscal period during which the
    Financial Reporting Measure specified in the Incentive-Based Compensation is attained, even if the payment or grant occurs after
    the fiscal period. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Repayment
    Agreement</I></B>&rdquo; shall have the meaning set forth in Section V below.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Restatement
    Date</I></B>&rdquo; shall mean the earlier of (i) the date the Board, a committee of the Board or the officers of the Company authorized
    to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required
    to prepare an Accounting Restatement, or (ii) the date that a court, regulator or other legally authorized body directs the Company
    to prepare an Accounting Restatement. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>SARs</I></B>&rdquo;
    shall mean stock appreciation rights. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>SEC</I></B>&rdquo;
    shall mean the U.S. Securities and Exchange Commission. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Incentive-Based
    Compensation </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Incentive-Based
Compensation</I></B>&rdquo; shall mean any compensation that is granted, earned or vested wholly or in part upon the attainment of a
Financial Reporting Measure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, specific examples of Incentive-Based Compensation include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-equity
    incentive plan awards that are earned based, wholly or in part, based on satisfaction of a Financial Reporting Measure performance
    goal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses
    paid from a &ldquo;bonus pool,&rdquo; the size of which is determined, wholly or in part, based on satisfaction of a Financial Reporting
    Measure performance goal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    cash awards based on satisfaction of a Financial Reporting Measure performance goal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock, restricted stock units, performance share units, stock options and SARs that are granted or become vested, wholly or in part,
    on satisfaction of a Financial Reporting Measure performance goal; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    received upon the sale of shares acquired through an incentive plan that were granted or vested based, wholly or in part, on satisfaction
    of a Financial Reporting Measure performance goal. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, Incentive-Based Compensation excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    base salaries (except with respect to any salary increases earned, wholly or in part, based on satisfaction of a Financial Reporting
    Measure performance goal); </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses
    paid solely at the discretion of the Committee or Board that are not paid from a &ldquo;bonus pool&rdquo; that is determined by satisfying
    a Financial Reporting Measure performance goal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses
    paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-equity
    incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    awards that vest solely based on the passage of time and/or satisfaction of one or more non-Financial Reporting Measures. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Determination
    and Calculation of Erroneously-Awarded Compensation </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of an Accounting Restatement, the Committee shall promptly determine the amount of any Erroneously-Awarded Compensation for
each Executive Officer in connection with such Accounting Restatement and shall promptly thereafter provide each Executive Officer with
a written notice containing the amount of Erroneously-Awarded Compensation and a demand for repayment or return, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cash
    Awards</U></B>. With respect to cash awards, the Erroneously-Awarded Compensation is the difference between the amount of the cash
    award (whether payable as a lump sum or over time) that was Received and the amount that should have been received applying the restated
    Financial Reporting Measure. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cash
    Awards Paid From Bonus Pools</U></B>. With respect to cash awards paid from bonus pools, the Erroneously-Awarded Compensation is
    the pro rata portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated
    Financial Reporting Measure. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Equity
    Awards</U></B>. With respect to equity awards, if the shares, options or SARs are still held at the time of recovery, the Erroneously-Awarded
    Compensation is the number of such securities Received in excess of the number that should have been received applying the restated
    Financial Reporting Measure (or the value in excess of that number). If the options or SARs have been exercised, but the underlying
    shares have not been sold, the Erroneously-Awarded Compensation is the number of shares underlying the excess options or SARs (or
    the value thereof). If the underlying shares have already been sold, then the Committee shall determine the amount which most reasonably
    estimates the Erroneously-Awarded Compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Compensation
    Based on Stock Price or Total Shareholder Return</U></B>. For Incentive-Based Compensation based on (or derived from) stock price
    or total shareholder return, where the amount of Erroneously-Awarded Compensation is not subject to mathematical recalculation directly
    from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable
    estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based
    Compensation was Received (in which case, the Committee shall maintain documentation of such determination of that reasonable estimate
    and provide such documentation to the NYSE American in accordance with applicable listing standards).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recovery
    of Erroneously-Awarded Compensation</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the Committee has determined the amount of Erroneously-Awarded Compensation recoverable from the applicable Covered Person, the Committee
shall take all necessary actions to recover the Erroneously-Awarded Compensation. Unless otherwise determined by the Committee, the Committee
shall pursue the recovery of Erroneously-Awarded Compensation in accordance with the below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cash
    Awards</U></B>. With respect to cash awards, the Committee shall either (i) require the Covered Person to repay the Erroneously-Awarded
    Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously-Awarded
    Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a Repayment
    Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the
    Committee, the Company shall countersign such Repayment Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unvested
    Equity Awards</U></B>. With respect to those equity awards that have not yet vested, the Committee shall take all necessary action
    to cancel, or otherwise cause to be forfeited, the awards in the amount of the Erroneously-Awarded Compensation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Vested
    Equity Awards</U></B>. With respect to those equity awards that have vested and the underlying shares have not been sold, the Committee
    shall take all necessary action to cause the Covered Person to deliver and surrender the underlying shares in the amount of the Erroneously-Awarded
    Compensation. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that the Covered Person has sold the underlying shares, the Committee shall either (i) require the Covered Person to repay
    the Erroneously-Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal
    to such Erroneously-Awarded Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee,
    offer to enter into a Repayment Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable
    time as determined by the Committee, the Company shall countersign such Repayment Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Repayment
    Agreement</U></B>. &ldquo;Repayment Agreement&rdquo; shall mean an agreement (in a form reasonably acceptable to the Committee) with
    the Covered Person for the repayment of the Erroneously-Awarded Compensation as promptly as possible without unreasonable economic
    hardship to the Covered Person.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effect
    of Non-Repayment</U></B>. To the extent that a Covered Person fails to repay all Erroneously-Awarded Compensation to the Company
    when due (as determined in accordance with this Policy), the Company shall, or shall cause one or more other members of the Company
    to, take all actions reasonable and appropriate to recover such Erroneously-Awarded Compensation from the applicable Covered Person.
    The applicable Covered Person shall be required to reimburse the Company for any and all expenses reasonably incurred (including
    legal fees) by the Company in recovering such Erroneously-Awarded Compensation in accordance with the immediately preceding sentence.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously-Awarded Compensation based on all
applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery.
However, in no event may the Company accept an amount that is less than the amount of Erroneously-Awarded Compensation in satisfaction
of a Covered Person&rsquo;s obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Discretionary
    Recovery</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, the Company shall not be required to take action to recover Erroneously-Awarded Compensation if any
one of the following conditions are met and the Committee determines that recovery would be impracticable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    direct expenses paid to a third party to assist in enforcing this Policy against a Covered Person would exceed the amount to be recovered,
    after the Company has made a reasonable attempt to recover the applicable Erroneously-Awarded Compensation, documented such attempts
    and provided such documentation to the NYSE American;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would
    be impracticable to recover any amount of Erroneously-Awarded Compensation based on violation of home country law, the Company has
    obtained an opinion of home country counsel, acceptable to the NYSE American, that recovery would result in such a violation and
    a copy of the opinion is provided to the NYSE American; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company,
    to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Reporting
                                            and Disclosure Requirements</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including
the disclosure required by the applicable filings required to be made with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effective
                                            Date</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall apply to any Incentive-Based Compensation Received on or after the NYSE American Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IX.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
    Indemnification </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Person against the loss of Erroneously-Awarded Compensation and shall not pay, or reimburse any
Covered Persons for premiums, for any insurance policy to fund such Covered Person&rsquo;s potential recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Administration
    </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee has the sole discretion to administer this Policy and ensure compliance with NYSE American Rules and any other applicable law,
regulation, rule or interpretation of the SEC or NYSE American promulgated or issued in connection therewith. Actions of the Committee
pursuant to this Policy shall be taken by the vote of a majority of its members. The Committee shall, subject to the provisions of this
Policy, make such determinations and interpretations and take such actions as it deems necessary, appropriate or advisable. All determinations
and interpretations made by the Committee shall be final, binding and conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XI.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment;
    Termination </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when
it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or
national securities association on which the Company&rsquo;s securities are then listed. The Board may terminate this Policy at any time.
Notwithstanding anything in this Section XI to the contrary, no amendment or termination of this Policy shall be effective if such amendment
or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination)
cause the Company to violate any federal securities laws, SEC rule, or the rules of any national securities exchange or national securities
association on which the Company&rsquo;s securities are then listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
    Recoupment Rights; No Additional Payments</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement,
equity award agreement or any other agreement entered into on or after the Adoption Date shall, as a condition to the grant of any benefit
thereunder, require a Covered Person to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition
to, and not in lieu of, any other rights under applicable law, regulation or rule or pursuant to the terms of any similar policy in any
employment agreement, equity plan, equity award agreement or similar arrangement and any other legal remedies available to the Company.
However, this Policy shall not provide for recovery of Incentive-Based Compensation that the Company has already recovered pursuant to
Section 304 of the Sarbanes-Oxley Act or other recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XIII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Successors
    </U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGEMENT
AND AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
OFFICER CLAWBACK POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AZITRA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of Azitra, Inc.&rsquo;s
Executive Officer Clawback Policy (the &ldquo;<B><I>Policy</I></B>&rdquo;). Capitalized terms used but not otherwise defined in this
Acknowledgement Form (this &ldquo;<I>A<B>cknowledgement Form</B></I>&rdquo;) shall have the meanings ascribed to such terms in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to
the Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with the Company. Further, by signing
below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously-Awarded
Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner permitted by, the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ()N?"+X)>#[*'7_  OI7CWQ;)$O]H:MKMJMW$9>I6"&4%(T4YP0N\C[Q/0
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M : /Q8_X*?\ _)]'Q._WM._]-MK7O_\ P1%_Y*U\1_\ L!P?^E KP#_@I_\
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M^"<_[*7Q>^%W[6WA'Q'XL^'VMZ%H=K;WRS7UY %BC+VDJ*"<]V8#ZFOV6HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_013.jpg
<TEXT>
begin 644 form10-k_013.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $U IX# 2(  A$! Q$!_\0
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M '\Z M/^9?<AO_"T_$'_ $2'QQ_X/_A5_P#/#H_X6GX@_P"B0^./_!_\*O\
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M'_PJ_P#GAT[Y?0?@,_RZ^_I1\OH/R_GQQ]30%I_S+[D-_P"%I^(/^B0^./\
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MZ_IBT'B@\ GTK@_$'B#5+K4_^$-\&F"3Q/)!!/J^KSP?;=)\#:7>!OL^IZG
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MJ^%'Q6\-^#I_&.J77@+P9\0]'\5_!SX!2>)_&/A#PA<Z3H7B/X@>&_A5X?\
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M=#\,7#<;K?CK]M:/]N_^P+63]H>'0%_:C^'7A[P]\.++X+Z?=?L0ZG^P5??
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M_;A\(7>G:+^W9H_Q%\7?LJ?LY^%?C?\ 'S7_ -H?X9_M MX4_8]\%^)]'O\
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M[._G-Q.TXD*+'B-XPN$W8.&B<Y.XY.><#CBJG_"+:;_?NO\ ON'_ .,5TE%
M'-_\(MIO]^Z_[[A_^,4Y/#&GHZNKW.Y&5AEXL94@C.(,XR.<<UT5% 'A6D_!
MC5-!TVST;1_BGXMM-*TZ(VVGVLN@_#V[>VM%D=X;<W5QX0:XN/)5]@FG=YI
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MYH]G92-+=PV\&C,EQJLK:QJ7V_45BN(_Y[?^(KK_ ()]?]$4_;(_\(+X,_\
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M,?#C_P"8^C_A5_B?_HK?BG_PF/AQ_P#,?7LM% <J[R_\#E_F>-?\*O\ $_\
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M?7LM% <J[R_\#E_F>-?\*O\ $_\ T5OQ3_X3'PX_^8^C_A5_B?\ Z*WXI_\
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M/'.K?$+P]X6NV\"^';FXT#PIK_AG7-#\$>)XO$^N_L9?'BX^,_CG5O 5C:^
M_A(/BM9VGQ%\#:/\4O#6MWGPE^%'B']DWPA^QEX/UW5/%.JW/A4?%_\ :7\
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MQ*UX^*OC--HOC+QUXJU.7[/]M\-_#/Q3I/PO\$_ ?X>:HL&#;7]CX,^$U_\
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M'_(_U0:*_P K[_A]!_P58_Z/G^,O_?CP%_\ ,91_P^@_X*L?]'S_ !E_[\>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+W7Q=NOC1\-X/AA;>)CL \.W'CZ7Q*GA2'729(P-(DU9=0_>)_H_S+G\J?\
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M)TW_ ()^:_X_'[?'C+XA>&IH_#'CKX67EQ<^ /">N0:!_P %"OBU"?%'Q/\
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MB!^P!^V?\/?@-X:^%.FZ#X \>7W[0WC7XF_$G2?A]H7[>GAN]^,/Q"UWQ;X
MN_V9+WP'X<\&WOQ9\::]XBU/P\_BV7Q;X<TK]JZ^L;E@#^T6UNK6^M;:^L;F
MWO+*\MX;JSO+6:.XM;JUN(UFM[FVN(6>*>WGB=)89HG:.6-E=&96!,]?C#^T
MG\%OVK_B+\3/^"3OPN^'GC;]I'X._ BST#XMV_[9>M_ /Q?:> ]1L++PK^S[
MX<U'X5^%/&GB!X[VZTFTUWXHZ*/#$-[HEN=9BAO=9LM*UC0;F_36K3\7O!FG
M_P#!97Q;-\?KO5O^'D7P?\-?$+]F:S\0>*;/6(-6^.OB[X??M(>'OVZ_"%[X
MH\->#KH?%_\ 9P3Q'97G[+FK^)M#UJ^_8)T+]EWPUJ7PS/VWX#^&/B+\7_"*
MWVH ']CI\8>$AXM3P"?%'AT>.I/#LGB^/P6=;TT>+'\)PZE%HTWBA/#AN?[8
M;P[%K$\.DR:VMF=,34YHK!KH7<B1'HJ_BQU7]E?_ (*<?$H:Q\??^$>_;9^%
MOQR^%'_!)K]K+PY\$OB!X;^*^MO\3?B%\<O"O[;-]\2OV9OASXMUOQ+86?Q5
MU3P]XV\"6>C:[IWP-^-1\1_$";P'!HWACXZ^-/'?CFTUC6-0_LR\,3:K<^&_
M#UQKL30ZY/H>DS:S"\:0O#JLMA;R:C$T49,<31WC3(8XR4C(*(=H% &Y1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_DS_M1>
M/M5^%O\ P4B_:K^(>AV&F:GJWA3]L?\ :5U"PLM6GU^SLY)I?BMX\L#(FI>%
M-<\,>+-$U&UCNWN]%\1>%/$OA_Q1X:UJ#3]?\.ZUI>LZ;97T'4ZA_P %-_VG
M[NRU*UL+_P .^'9Y/$-EXC\-7N@7_P 3[8>$;RVL/AUI][(VB7GQ+OO"?Q,U
M;Q _PQT/6O$OC3XZ>'?BM\0-:\5ZWXY\77?BI_$?C+5M2?\ L;^+W_!L!^QG
M\9OBU\4_C%XB^/G[5.F>(?BU\2/'/Q.U[3=$UOX.Q:+IVL^/O%&J>*M4L-'B
MU#X.ZA?QZ79WNK3V^GI?7]]>+:1Q"YN[F??,_GG_ !";_L-?]'%?M>_^#_X(
M_P#SD:QY)=OQ->>+W7RM<_C6L/VR_B!X6USP]KOPM^'WP:^#<WAGXP_#GX[Z
M?:?#KPOXFAANOB5\-9_BW-I>K:UJ/BOQKXJ\1:U9:K'\:?%^EZGIE]KDEOIG
MAVV\.>'/!O\ PBVD:*EM<[>M?MX?&379_$TFH:)X+O8]>TK0](TP:]J7Q<\<
M:GX.MM#^&_Q[^%GF:%XJ^(/Q7\6>,M9GU;PS^TK\6)-3/Q \1>-88]4U72+G
M18=%MM TZRB_L._XA-_V&O\ HXK]KW_P?_!'_P"<C1_Q";_L-?\ 1Q7[7O\
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MM>:/U5HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME'VSQ!XJ\07N_4-<UW4'DN[Z[D/,5O';V\/NDT23PRP2 F.:.2)P"02DBE&
M(Y!VL<$<@\UNKVUW,':^FQ^#O[&G_!:.Z^-O[/G[*/B7Q]^S7\<OBQ\<_BW^
MSY\-OVAOV@K/]CCX1R>./AS^SOX!^+?QI\5_!/P#XO\ $?AWQ/\ $Z?XK:[I
MNOZ[X,\7:P/!7P@TGXY_%#2O"'@7QKXWUCPI9^%M-M=0O/'M*_X+S>*- _9B
M^,?C/XA_LM?$.^^/WA7X<?\ !37XI?!:X\+Z1X&\._LY_''0?^"?7QZ\6_#K
MQ18>&O$/B7X\:I\1[6?X=?#N7P#XZ^-.JZWX8T&UUN+3OB7;_!2R\9>,M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX7O/%.H^)M5T76KSP?X%L;6;7)]/M9([F]'DI=7/)>)O^"I'A5X=0O\ X/\
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M2_\ RWH_X0GP_P#\\]6_\*7Q+_\ +>O@SPEI7[7'[,WB]O&G[0'[6O@WX_\
M[/%K\,?'/BOXJ7/C+X<>$OA7\0_A[KG@?0I/$L^O_"[2_AEX>6U\9>%+NRM-
M0AUSPYXBN'U;0K**UOM.U'4;DRVMUG^$_P#@I3H%T-&OOBA^S]\9?A#H?Q'^
M"7Q&_:#^ M_JTG@;Q;J/QE^'WPN\)6WCSQ1INFZ!X,\4ZOJ/A?XB-X+U#3O$
M>D^"_$0@_M"QNC$=7@OXULY<GEF(FG+"NGC:247[7#MQ3E*_-25/$+#UI5::
MBYU(0IU'&BX5Y.-*5X=,>*,NHJ,,UAB<CQ,IS3PF8PA.<*<90A#$SQ&73S'
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M^'_^>>K?^%+XE_\ EO7Y'_MC_P#!0[XD:5\,_P!H.X_9N^'?Q!T[3/@M\6/
M_P &M6_:;BB^&&K^"-(^)*>/_ =IX[\+1^"/%E[J7B'4]#AT3Q!/X1N/&<7A
M*^T^U\3ZI:0VBV\2Q:]!],ZE_P % _ ^E>!OBCXW;X>>-)[/X6_MGVO[%FH6
M$=[H)O-5\777BOP;X33QGI[R7XA3PN+KQE9W1MKJ1-9,%I<K]D\UHE:7D^8*
MG2J*A?VM14U34X.I"<HPE352//[DJJJ)PA)QJ+>I"FI0<]H\9\/RQ6+PKQKA
M]4P[Q,L14H8B.&K4J<\5#$/#5)8=/$1PTL)4]K5IQGAYMJ.'KXB<*L*?VO\
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M2J4L=]3EBJ>#KT*U'$5*<X6E^B?_  A/A_\ YYZM_P"%+XE_^6]'_"$^'_\
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M <G_ ,(3X?\ ^>>K?^%+XE_^6]'_  A/A_\ YYZM_P"%+XE_^6]=910!R?\
MPA/A_P#YYZM_X4OB7_Y;T?\ "$^'_P#GGJW_ (4OB7_Y;UUE% ')_P#"$^'_
M /GGJW_A2^)?_EO1_P (3X?_ .>>K?\ A2^)?_EO7644 <G_ ,(3X?\ ^>>K
M?^%+XE_^6]'_  A/A_\ YYZM_P"%+XE_^6]=910!R?\ PA/A_P#YYZM_X4OB
M7_Y;T?\ "$^'_P#GGJW_ (4OB7_Y;UUE% ')_P#"$^'_ /GGJW_A2^)?_EO1
M_P (3X?_ .>>K?\ A2^)?_EO7644 <G_ ,(3X?\ ^>>K?^%+XE_^6]'_  A/
MA_\ YYZM_P"%+XE_^6]=910!R?\ PA/A_P#YYZM_X4OB7_Y;T?\ "$^'_P#G
MGJW_ (4OB7_Y;UUE% ')_P#"$^'_ /GGJW_A2^)?_EO1_P (3X?_ .>>K?\
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M_C9\7=3^&-A\//B/\-?AW\/KJU^&>FV7@;0/B9H6I>'-0FU#Q'X?\!:3XO\
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M (2Q_P#H'#_P+_\ N>C_ (2Q_P#H'#_P+_\ N>@#LZ*XS_A+'_Z!P_\  O\
M^YZ/^$L?_H'#_P "_P#[GH [.BN,_P"$L?\ Z!P_\"__ +GH_P"$L?\ Z!P_
M\"__ +GH [.BN,_X2Q_^@</_  +_ /N>C_A+'_Z!P_\  O\ ^YZ .SHKC/\
MA+'_ .@</_ O_P"YZ/\ A+'_ .@</_ O_P"YZ .SHKC/^$L?_H'#_P "_P#[
MGH_X2Q_^@</_  +_ /N>@#LZ*XS_ (2Q_P#H'#_P+_\ N>C_ (2Q_P#H'#_P
M+_\ N>@#LZ*XS_A+'_Z!P_\  O\ ^YZ/^$L?_H'#_P "_P#[GH [.BN,_P"$
ML?\ Z!P_\"__ +GH_P"$L?\ Z!P_\"__ +GH [.BN,_X2Q_^@</_  +_ /N>
MC_A+'_Z!P_\  O\ ^YZ .SHKC/\ A+'_ .@</_ O_P"YZ/\ A+'_ .@</_ O
M_P"YZ .SHKC/^$L?_H'#_P "_P#[GH_X2Q_^@</_  +_ /N>@#LZ*XS_ (2Q
M_P#H'#_P+_\ N>C_ (2Q_P#H'#_P+_\ N>@#LZ*XS_A+'_Z!P_\  O\ ^YZ/
M^$L?_H'#_P "_P#[GH [.BN,_P"$L?\ Z!P_\"__ +GH_P"$L?\ Z!P_\"__
M +GH [.BN,_X2Q_^@</_  +_ /N>C_A+'_Z!P_\  O\ ^YZ .SHKC/\ A+'_
M .@</_ O_P"YZZJSN#=6MO<E=GGQ)+L!W;-ZAMN[ W8SC.!GK@=* +-%%% !
M1110!Y[XD_Y"C?\ 7O!_.2L&M[Q)_P A1O\ KW@_G)6#0 5)#_KH?^NT7_HQ
M:CJ2'_70_P#7:+_T8M GL_1_DSSCX2_\DS\$?]@"U_\ 0I:]#KSSX2_\DS\$
M?]@"U_\ 0I:]#IO=^K_-DP^"/^%?DB8V]P(A<&"<0'I,8I/*/.T8DV[.6&!S
M][Y>O%.:TNU:-6M;E6ER(E:"0-*0,D1@KER 03MS@<GCFOQT\,_L+?&_0O\
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M>]^ '@C_ (*"_'S]M6V\'+\4M:O=9M[[X_\ Q+^-OA[5M,FLY8?L5]X/\&_
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M/_WYE_\ B*F_X4M\$_\ HD/PP_\ #?\ A3_Y4T?\*6^"?_1(?AA_X;_PI_\
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MBK?_  I#X+?]$A^%_P#X0'A3_P"5-'_"D/@M_P!$A^%__A >%/\ Y4T![_\
M<^^7^14^SS_\^\__ 'YD_P#B*/(G_P">$_\ WYE_^(JW_P *0^"W_1(?A?\
M^$!X4_\ E31_PI#X+?\ 1(?A?_X0'A3_ .5- >__ '/OE_D5/(G_ .>$_P#W
MYE_^(H^SS_\ /O/_ -^9/_B*M_\ "D/@M_T2'X7_ /A >%/_ )4T?\*0^"W_
M $2'X7_^$!X4_P#E30'O_P!S[Y?Y%3[/.>MO.?\ MC)_\11Y$_\ SPG_ ._,
MO_Q%6_\ A2'P6_Z)#\+_ /P@/"G_ ,J:/^%(?!;_ *)#\+__  @/"G_RIH#W
M_P"Y]\O\BIY$_P#SPG_[\R__ !%'D3_\\)_^_,O_ ,15O_A2'P6_Z)#\+_\
MP@/"G_RIH_X4A\%O^B0_"_\ \(#PI_\ *F@/?_N??+_(\V\2^)-1345\(>$X
M[>Y\7W-K%>7=Q>PO/I'@O1[AY(X_$7B.%'A>YEN'AFB\-^&HY[>]\27T$Q,M
MEH=CJ^KV.OX:\.:=X7T]K*RDN;J>ZNI=1U?5]2E2YUGQ!K%PL:76M:U>(D2W
M-_<)%%"B11065A906FEZ7:6.EV-E9P>MZ)X)\&^&;233_#?A/PWX=L)KA[R:
MRT+0]-T>TFNY(XXGNI;;3K:VADN&BBBC:=T:4QQ1INVHH&O_ &3IG_/A:_\
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MB/XJ_%%_VJ?"_P )_ WQ1UGQSXKOF<7FHVO@CX'_  P\'^ K'2-/T7PS\/\
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M^+'A_P")EWK\OB[1/C)X5_:!\7:OX\T3QCINIVUII=M]B\#:?H=K\.K.'PD
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M2-(UFS\3:SX0U'QY+<:YHEAX7O/!]S\/8+R_\/?#"]\%>%[^]T2< \5\2_\
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MA"G3A&,8I+4HHHK,Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 0@'J ?J,U\Q?$+]F'0_$OBVZ^)_P[\9>*O@C\6KV"*WU7QMX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #! B8# 2(  A$! Q$!_\0
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M_"ET;_Y,H [6BN*_X63\._\ H>_!W_A2Z-_\FT?\+)^'?_0]^#O_  I=&_\
MDV@#M:*XK_A9/P[_ .A[\'?^%+HW_P FT?\ "R?AW_T/?@[_ ,*71O\ Y-H
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M3QWNQH/])ABEE5BI;\0?A9_P2S\"KXM\9ZI\=OB]\++WPAHME\5O!GP#\$^
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MX63\._\ H>_!W_A2Z-_\FT =K17%?\+)^'?_ $/?@[_PI=&_^3:/^%D_#O\
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M#*S:=\/;E4CB\<W$":HQ30)O,A5=18,HEN[.+RQ<W-O!)'_PU9^S@YU>8?M
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M\66OBW2;*;PY_8.F:WI=SX5T_3[<6.C0:7?VC7%WK6FZEK1BU2( ^L&_;_\
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M9O OP\E\&65CX3TN.VAN+.QU_P =F[OKR\\>^++O5@#V6Q_X*+_L,WRW!?\
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MCT'XKZ7XB_9K\87'CW2/AMIG@WXU3?"VXU;5_%'B(Z?!H]E9:]\&?B+\7_
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MR1/\/^'?^"9O[&'A/3/!^E^%-5^.?AZQ\'Q:9IJ1:5XY^*$0\2Z#IWACX?\
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MVXW.H;LL03H/B,\'JN!HJ  >W? /08 .L^S1?\^T?_?B#_XBC[-%_P ^T?\
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M/_RFH [C8?1?S;_&C8?1?S;_ !KA_P#A/]%_Y\_%'_A)>*?_ )34?\)_HO\
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M]AIEE8FTM[("< ^K]A]%_P#'O\:-A]%_-O\ &N'_ .$_T7_GS\4?^$EXI_\
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M11Y:?W17&_\ "6W_ /T)?B__ , ]&_\ E_1_PEM__P!"7XO_ / /1O\ Y?T
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M_@TG_"6W_P#T)?B__P  ]&_^7] '9>6G]T4>6G]T5QO_  EM_P#]"7XO_P#
M/1O_ )?T?\);?_\ 0E^+_P#P#T;_ .7] '9>6G]T5Y5\9_&4WPX^&GCOQ]9Z
M8^MZAX-\(^)/$FD^'%UFPT ^*=:TK1[FXT7PO#JVJ%K.QN_$&K"TTJRGEM[I
M5O+F%?LUPS"%^C_X2V__ .A+\7_^ >C?_+^N3\:VVC_$3PWK/@OQK\+=5\5>
M$/$VF7FB>)?#'B+0/#NK:-K>CZA$T-Y8ZC87>O-;75G/&0DL$\4JL<$*" 0
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MI'A']D#]G_P?JWC74G^!^I^*5\8S>%=-^P^+O"O@#4=$\.^#O ?@_P 8> _
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MIK_3]=-MX3B_M.ROYH8GOK6Z>6&[92TP)9E(!^=GBO\ X++>#? -GJ\OC_\
M9H^*_@W4["T^(!TC2-6^(7P!N[G7=?\ A?I'@3Q9XY\+PS:+\2]4MK'5_#W@
M#QO?^,+]]2EM].$'P\^(^G0WLUYX9W7>+XA_X+(>#K=-/\1:5\$?B#%X#N-%
M\9ZU9:OK^K_#'2)?%&F> /%=KX#^(/BJWO+SXC0IX0\%_#;Q3-)'KNN>)],
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M2-._\+.+_P"4E ':>4?]C_OD_P"-'E'_ &/^^3_C7%_VUXY_Z$C3O_"SB_\
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M!E<G<.,\]^P!)/ !)%<9_;7CG_H2-._\+.+_ .4E-;7/'(!_XH;3R1@\^,H
MN001\S:+C\<=>G.#0!^=O[6?[:GCKX'_ +1_P[^&WARV^%D?@:Y'P>@^(&L^
M)K#Q+XK\06GB'XV_%>\^'?@?P?J@\'>*]+O/@M_PF.E^'_&5S\+/'/C#P/\
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M_4_XT;%]/U/^-<%_:GQ'_P"A5\,?^%3J/_S,T?VI\1_^A5\,?^%3J/\ \S-
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M>\.V7@75X/#?CKQO:?'K4G\%:9=:MXY\(>&=%^(VEZSXG^!OA"VO_@!-X?\
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MJ O#9S_V>;5;P)FW-ZDLEJ) RD><D#1RE< _ZMU8'!&>W*+'XY<*//\ ">&
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M'?OQS2;E]?RSC\,52U**ZGM)8;*Z^PW4B[8;T6T-X;9\J?-^S3E8I5"!P5+
MY*[03Q7(G0O%_P!Y?'4IR<@?\(OHFX GN25Z#KT/MF@#N]Z^OZ'_  I"ZX.#
MS@XR#C\:X3^Q/&/_ $/4W_A,:%_\<H_L3QC_ -#S-_X3&A?_ !R@#\8?VJO%
MG[94?[7GQNU'X4:'\3KKPQ\./@[X0D^!GA%-4^.^@>!OB)\9[+P9\0/&+WL]
MA\/;K1?A3XR\,:EXWN_AAX.\9V_Q3\1Z8#HFA^)-&T^>WM+M+E/)?BQ\:O\
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M'CAE51@8\+^'R,C )^9V&X$'<5QRY#9^0+-_8?C$<?\ "<S<<?\ (KZ$.G_
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M-Z^OZ'_"C>OK^A_PK@_[$\8_]#U-_P"$QH7_ ,<H_L3QC_T/4W_A,:%_\<H
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M(Y#[7?:Q4,135T[6"[(WC'7595# /H>CQ[\Y^5&;3=K. -SH#N2,I(^U&0D
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M>-5_\%6@_P#ROH_X1[Q%_P!#QJO_ (*M!_\ E?0!V-%<=_PCWB+_ *'C5?\
MP5:#_P#*^C_A'O$7_0\:K_X*M!_^5] '8UQOCR[U^R\+:_=>%M)&O^([31=5
MO-!T$ZQ%X>77=;M-.N[C1M&EU^:&XBT2#5=6CLM,EU>2WN8M+2]:_F@DAMI
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M'=52PU&1+=XO'>IO'="-K>6/3-"FCFBE3=%-&\6GLIMY8_FCN-PA="-CL&%
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M8.#IQ>-@Q"M'*$<_,0K(K$"V.J.AD7QOJS*'$8VZ-H;LTC!0BHJ6#,6=B(@
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ME_\ E=0!WWF#_9_[[6CS!_L_]]K7 _\ ""R?]#CX^_\ "B7_ .5U'_""R?\
M0X^/O_"B7_Y74 ?,W[>OPU\6?&3X"O\ #?P;X7U?Q;-K/CWX<:OKFF>&?B!X
M9^'?B>'1O!/C+2/'=KJ&A:IXW\)>-? ?B)[/Q+X=T";6_A[XYT.?PI\0_"0\
M1^$-3>,ZO 1^4/PP_94_X*LZ!J6A^%-2^*GA[X.?#-?!>@>"/[/^#7BK3(M%
M\"Z#X@UOP_?>+KKPUIWB7Q#XMNG^(OA[7=;\:>+['4&\+ZPG]J::?!/A/Q-;
M?#C5M#\!:-^^I\!.V=WC/X@<[?\ F88SRN2I&=-^4AL-E<$LJDGY17,Z[H>F
M>';?4M0U_P"(WB[2M!L+"\U'5=1USQ9I^F:58:=;0-<:C=7VJ7EA;PZ3I5G9
MPRO=7\MS#%$AD=YD",Z@'X:>*OV8O^"JHU/0;/P]\2/&6K^%M<\'?&75?&5U
MK'[4B7,=KJGQ%\$?'*+P;\(=-9[33X[2/X;Z]JWP/\+Z-\18_#_B?4M8M- \
M1^-/[4\(^(XTO-4[_P#9H_9E_P""B/PI_:)^",>KZU+X<_9?\&7'BN+QA'>?
M&&V\?^(/$OA2_P##FO:3X4T'QQISR:;;^*?&VBO:>!?#VH^-]3T?Q5/%H'AT
MZQX>U_1-0NM6L]2_6#POK?P\\;:7#KW@CXX3>+_#L]E=Z\OB/PQ\4/#>O::=
M(T>YFT^^U6"^TNWN;*71]/U"TN]+U*[+FW2YMYD\\7<4RKUVEZ)9:YIVG:UH
M?COQEJVC:QIZ7^AZOIGB.RN['6;"ZM8[VRNK*]BTF9+^TU"T<7=C=VL\MO<6
MLGGV[N"TM 'XU^(?V=O^"HMM'XL\>>&?C%XNO?'VI^-]5UK1/A_JOQZT"+X?
MZ1HGC)/VA=3O?"^E:7<>")K"VLO!NG:A\!OA;X4M;Y;Z&^U&QUGXD3WJW%K+
M=38O@O\ 9Q_X*BP?#2TU'XC?$WXC^*=;T_6_#O@NY^%'@W]I+1/!FIZW\&W\
M7_&+Q'XCU^S^*5QI^O/HOCF(>(/A+X-T_5=7\2^)O% \'?#_ %2WM_%!USQ%
M?ZF?V@LK/0-7U'5M,TCXJ:YJ^JZ,?LVKV&E>,M+O=5T219FA7^T;2TLKN\T^
M6X$#V0FNDMG,B2A/WNX)NMX/?8RGQ3X]E$A13&=:^:7<Q1C'++HZNK1S(MP4
M20K$I+%%7YJ /PENO@)_P6-EU_QF\GQAU#5]&NOB%X(.B6>F?%KPSHC:WX1\
M%ZIJ]QIUW<:[;:A:7.D--X8L/#]O\1O^$2\'?#M/%_Q"NI]:UCP-XS^&UEK?
M@'Q3L^/?@?\ \%:]7\-Z9:^"_B!XI\+>,M9^)#ZU\4?$^M_'?P-XPTC4[[3]
M#UJ'PIXX^%?A?0=#^%EM\/\ X<:5KFH>'+K5/A1<:GJ%IXQL_"R:;KW@G4$F
MUS4O%?[=KX1D7#'Q9X[!V+&((]>C6.6XL$>22!2=+\LS/]FFDDF4B3?#+&"'
MW8KZMHFEZ5:?;-9^(7BO1;*YN].T];[5O%5CIK-J&HZI;Z;HVF6MU<64:/?:
MGK&I6FEVMAC[1=:EJ%OI,(DN9X8B ?C9-^S]_P %0]-UCP!J6G_%WQCXCBU#
MQW\-?'?Q4L+OX]Z!I>D:;JHUWQGJWCW1](7_ (1NSN]%\":)I?C?PWX0T7PO
MH]KXC\.>(;KX)V_B36?"_B*V^(E_:1_NM8[5FRKGRB+AH(Y!%!/$X8*5"H(D
ME0H2R"XA5XD#$L5SGG/^%?GY2GC;X@)LQO9->ME:1@JKOE_XE9,DC*J-(21N
M8;B,]9/^$"PYD'B_QZ"2I(_X2%=N5&TD V!P67Y7_O#KT% '?B0$ _+R,_?7
M_&CS!_L_]]K7 _\ ""R?]#CX^_\ "B7_ .5U'_""R?\ 0X^/O_"B7_Y74 =]
MY@_V?^^UH\P?[/\ WVM<#_P@LG_0X^/O_"B7_P"5U'_""R?]#CX^_P#"B7_Y
M74 =]Y@_V?\ OM::S[E(!49Q_&O8@]O6N#_X063_ *''Q]_X42__ "NH_P"$
M%D_Z''Q]_P"%$O\ \KJ .OGA+%G#+DK'G=(NU/):5\KG<0TGFD,VUL!%R"!@
M_B#\=_V _BG\0OB1\=/B#X/T#3O FL^//CYX!\=^$?$_@+XE7/@?Q]I?@CX"
M_ *]OO!B6GB33[*:Y\(2?%C]I#3M"T/Q:FFRM>Z;X,O[W77N[I[0QM^Q_P#P
M@LG;QEX^'_<PH?YZ::A;X>NK*P\<?$$X"G8?$%LT;>5RH8OI+E0W&X*RB0@;
M@VT8 /PT\+?L[?\ !7#4/&OC-/BM\;=27P9?7\TXD^'7Q-T?PGJGB/2/ _A;
MXA6O@#PQX4UF]O\ Q%_PA$_B36I_AVOQ&\06?@+PIJ6K/)XEU;4KN_U)]$U'
M0-_PS^S7_P %-?AI-X6U^'XP^._C/-9:A<6_Q \+Z]\?= AA\<^'-,U7X&-<
M+X0EU[PNNB^#]2^(FKZ=\9O&-G<L)U\ :%+%\.+3?:ZQIMQH?[&ZAHFE:7)I
M-GJGQ!\7VUQJ^KQZ-I$6H>+;.*77-5.GWVL)I%A$UFSZCJ2:=I.HZE':6D'V
MD6FGWMVP%O;3%>;T:7P=XEO+VQ\._%J_\57EG)>+?6>A^/\ 0M8U"T-A>VEK
MJ-K=6.GVM]+!-IUW>VT-\CQ+(E_-I]L_D2W ! /S6^ 'PH_X**VD'[0U[\?/
M$&H:AJ7CC]F_1M,\%:';?&G2]3T#3OC_ *GX163Q'HGA9]!T&TN-#\,:/XYO
M=;D\,>-3;>%O$-AI\D.F^)9?'&AV'AFZT'YATG]BS_@I9\,_AGI@^%GQ9\7:
M-X\U_P -^'/"?Q/T#6/C[)XST_5/"?PXT7X#?"3P[_PC=[KM]X?CTSXG^./"
M'@#QG\1_$?Q&TKQKX?U33=:N+KPUO.EZ];Z+#^]%OH=A<ZCJ=I%\0/&-W?Z1
M);1ZK:Q>)]/FN-+;5+43V-O?0)IWVC1FFMRES L^PO'*TMN\XW;4N=$LM*T^
M2]U#XA^+=+M+:ZL8;B_U7Q38P6@::6*TT^"62YTJ&W,>HW5Q;VEK&I\[4)[A
M5@,TS+N /QRT?]D[_@I9J.E^%;[Q]^T_\2D\5-'I-EXLN/!WQ@TK0-#T^2UO
M?@!X9T_7K#PXGA?7K>YN/#/A[1_CQ\4_$FERZIJT'Q \4^)-$\(W=W'IAM[&
MU\R^*OPN_P""K_@?3]-L_#/B[XK>)M0;5OAWX!\/:QX?^.WA/48X?A-XR?0-
M-^)G@K4[/4_AT;JZ^-GAJ75/'^O:1^U?X\NAIWA?P]H/PZ_M"VO]?MO%4OC'
M]V+S0--T:SN=4UWQ[XPTC3K"WQ=ZGJWB:VM-*LX8[LQJMQJ>J:=;P6H:62W\
MR.Z9%D"Q98[54Z,?@NX24R1^+/B,6"PVYAD\1H&W2#<LQ1M$"EL"65W$_E1N
M\B*BAPM 'XAVW['G_!1'4=5NOB%=^.]?L_$NK::?A!I/@7Q/\?X/&^D6_P"S
M7=>%/C-KI\/_ !3U&X\/'1_BS\3=/^(?Q0TO0X?'FH61U >$M-@GT0V<^F27
MFK\_:_LT?\%4O"'PWU[X7^ ]43PWI*7WBSQ/!K?A;XV>"R^NWWQ$\'? ]=0\
M)V=K>Z-X<U72;31/B3IOQXU?6-5L_$G@[4+G1/&,$W@_6-+\4IHVKZ)^\-OX
M*\V9PWBOQ_;R3KY3E_$4._*K*8X@QTS(D4&2<*#O&U7.4CQ6F? ,NS8?&_C\
MX*G?_;]LSG:00K9TG# ]\J<C.: .>^ 6F^-]$^#?POTOXE.S?$/3_A[X.LO'
M@D\26_B\Q^,X-!LD\2Q?\)=!I/AY/%/D:N+J >(?^$?T4ZND:7XTZV\]XU]A
M\P?[/_?:UY['X DB4K_PFWQ"ERVX-)XBB+#C&-R:8I^H;<<]SQ4G_""R?]#C
MX^_\*)?_ )74 =]Y@_V?^^UIC7"IG..-I.&!P&.T$XZ#(/)XXSFN$_X063_H
M<?'W_A1+_P#*ZE'@5MRLWC'QZP5E;8WB!&1MIR X_L\;E)ZC/.!0!W<4\<V=
MC!L -E3N7!_V@,9]LYYZ44V"W6!5422RE4$?F3,'E< YS))@%VSU8\GOD\T4
M 6**HZA90ZA:RVEQ&TL$Z^7+&DLT#,A96($T#QS(,+@A'7=D!B!FN8/@[0,G
M-C=DY.2-9UP#/? _M08&>@H [6D;H>,\'CUXZ=OYUQ7_  AWA_\ Y\+S_P '
M.N?_ "TH_P"$.\/_ //A>?\ @YUS_P"6E 'Q)_P4"_9W^)?[3OPY\"^ OAUK
M&FZ;!X9^./P^^*/C&QU'Q)<^!YO$>@?#^'7-=TK1=)\7VOAGQ>-)OK?XC1>
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M=NPD:MK3963!*'=JJL!MVM("O!Q@.0#3_P#A#_#P&&TZ_55)&3JVN[0%,BC
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M_P#EI0!VU%<3_P (=X?_ .?"\_\ !SKG_P M*/\ A#O#_P#SX7G_ (.=<_\
MEI0!VU(W0X]#_*N,'@WP^02+.Z##H&UG7>O8G&IG )]CT/!KRQ_&'P9BU9M!
M3Q5HYUP>-K;X:Q:'!XMU9M<'Q!?1_P#A(_\ A#VTXZG)<?VPOAR5_$5Q!M A
M\/!M<F9=*0WJ@'E/[:7P-^(WQO\ AQX5TSX.>--)^'WQ7\$?%+P9\0_ OC/7
M=,U'5]-\-7,-CXB\">)KMM.TZ>">YU%/ GCKQ=+HL EM;>[U@65K>2_9I9"?
MRAN?^"4W[1?@OQKX@U/X-?%_1/!^DZ;X7E\*_!/QW)XT^)T/B_X-^#F\9?$C
MQ+JFE3:3H26/AGXE7WCNS\0?#?1-;U'Q1;ZO;Z#<?#[4->CT=[_QD\(_?]_!
MGAUPS_V/?!VB8KG5];#B0B-E#[=1P,E%#%265HR/FWKNX8-\/Y_#]KXI:XC.
MA7UQ!:V>M3ZUXB^R7=W=:M-ID<$*?VEYXNI=1MUMPK1A)F:(1R.1M8 _*;PY
M_P $Z_V@_!_Q4\$ZUX8^-.I6O@?PS\5?"?B^SFU#XK_&/5/%_@SPYX4\6?#G
M7]?T;4Y9M:D@^,NM?&OPSX/\4^"?%%[\0M8NK/P%H_Q/\8VFF+J>G36B1]9\
M6?V!_BM\;?BOXYUGXI^+-(\3_#;Q)\5M+\;/>1?%GXWZ#K6L?"GPSJMGXH^'
MWP<C^'7AS4M)\!^#=,\$:QX=\/WEU\0=!1O&6L:C;3:[%?K>:SKZ7WZOIX,\
M,+YD+:5?,$,C1Q#5=<:5HYY3*'"G5-J1%V927*%71A@;6Q!?Z'X*T?[%_:<<
M.FKJ>HPZ1I@O_$VJ6C:AJ]T&>TTRR6?45-U>WBQ7+6EK;B2YN3;LL$,C.H !
M^$4?_!,7]LO5?"[>%O$O[4T+W$?@[X9>&-6\>:KXN^*GBR[\<VW@_4?V;-=M
M],U?P'K-Y/X4T&/P'JGP:\<V_@[684U?Q%X@N?C'J_B#Q(?[5AU6Z\0,TK_@
MFI^V?:?#+4]'UO\ :'OM9\6K_8B^'+'4/C9\:DT_3U\3ZQH4_P ==4GUOPNW
MA5ICXPM_AQX0\4:'9ZIH'BW3=)U3QQ\;;.XTJ\/BNR72?WP7P3X>);_B57BG
M#$8UC6^0#\HR=44 N/F _AZ-M((#!X,\,#S$_LF]*,=S,NJZTZ2.F6QM.IAC
M*K)RI&%D3&_*J2 ?E?\ L'_L6_M3? ?XS+\0OCU^T)J'Q4TRW^#/A;X?P:?#
MXW\4:UINK:K;>$?A7H\\VI>&]>TN/3[2?PUKO@#Q7KND>)+/5YM2UQOB+K$M
MSI\*W,CP?L;7SS=Z_P#![3_$_P#P@][XCT.P\8))9VDGA^_\4:I!J,,VI'2$
MTVS='U@1QSZI)X@T6#3K-YH[S4I=3M8K""=YHMW7^'-.\&^*](T[Q!H45QJF
MA:Q8076E:G#K/B!(;^RG5I(9(5GU"*545 /]8"22VT@*S$ ]7HKAU\(^''W!
M+.[?8=K$:UK9 ;)!7C5205QE@ZJ0&0@$-D._X0[P_P#\^%Y_X.=<_P#EI0!V
MU%<3_P (=X?_ .?"\_\ !SKG_P M*:?!N@AE=;"ZW(<C.LZY]>O]ILO/(^9&
M_#L =N&!S@YQU]LT57MT"*J#I'&J*=S-\O.,EWD=CP<NSDMU(!S10!.SJ@)8
M@  DDD  # .6)"CJ.I'Z&H_M%OC)GA /<RICGWW8J.]LK34;:6SOH([JUG79
M-;S+OBE7<K .AX8!E!&>A%<[_P ()X-/!\-:01Z&SC(_4'GWZT =+]JMO^?B
M#_O]'_\ %4?:K;_GX@_[_1__ !5<S_P@?@S_ *%G1O\ P!A_^)H_X0/P9_T+
M.C?^ ,/_ ,30!TWVJV_Y^(/^_P!'_P#%50U29Y=/O(].O;*'47MKA;":Y9);
M>&],+BTFN(A+&TL$5QY;SQ*V98E>,<MD9'_"!^#/^A9T;_P!A_\ B:4>!/!R
MG*>&]'4],BRB!QZ9 !]/\* /P\TC_@E!\3;#X5? 'X6/\8O!L,7P7\<Z)XLO
M_$FK^*?C;\4!KVJVR6C:YXXT+P7\3_'.O>"? OBK6KV;Q)K$ND^#-%\/QV>L
M:Y%JOA[Q?X;U;38M0DN^'O\ @D5/+JN@ZKXU\7?">XN_!=[)KGAF\\+^'/$R
MZEJ7Q'D\?_!KQ%=?M#^,[_Q1XHU>+5/CWJ?A#P'\1_!5QXNL-/LI(+#XD6=O
M'<&R\,Z9'9_ML? WA%LAO#FCD'&?]"CW''3YLYXP!]!CI2#P'X- ('AO21G'
M_+HF>/0]1^!'ZT ?@;X _P"")^L6'AS4M,^)W[0]OXSUJXT%]'L=8.ESW[6/
MB?Q!JGP^B^)OQK+2W^@"7XS?$CPQX%DBN/%DMK-KFC>(]:NM3O/$?B;:DZ>@
MP_\ !);6]3TG38/$WC7X,1:UX6DNM?\ "FL^&_!_BA;AOB_+K7P<AD_:)\7S
MZWXRU";Q!\:=:\)>#?BEI6J>*[6/2;S33\2["VL)[Q/#D-W7[:#P/X1  7P[
MI( ];1"?SSG\\DTT>!?!X(/_  CNE$\\FU0C)ZG:<CZ>G04 ?CY\"?\ @FC\
M4/A#\4O''Q O_P!H'1M2N=3_ &0M6_9:\':[HNE?V+XS@O+CP;\)/#6@?$7Q
MKJ5LL%[XAUSPSJ/P[UK7[*YO/$.JW<>H>+=5O;%K&_U+4Y)?-;C_ ().?$7[
M#X"@\/\ Q ^!7@*[\,MHNJB3PAX/\8M#X'^('A;Q=X&\4I\6/AG#JOC*>U'Q
M'^,-G\.]/\#_ !U\3:G8Z7JNI^"_&?CRSLM0UI]5OTUS]RO^$!\&?]"WI?T^
MSC'_ 'SG'Z<=J7_A O!G'_%-:3QG'^BIQGKCTSWQU[T >"_LD? &#]F+X6-\
M,SXJA\3I%KT^H6NH".2SBMM)MM'T/POX?T>""ZU759_+TKP[X:TJ!I&N(TEG
M:9TMH0QW?4/VJV_Y^(/^_P!'_P#%5S7_  @G@T@ ^&M'.!@9LHC@?4@FD_X0
M/P9_T+.C?^ ,/_Q- '3?:K;_ )^(/^_T?_Q5'VJV_P"?B#_O]'_\57,_\('X
M,_Z%G1O_  !A_P#B:/\ A _!G_0LZ-_X P__ !- '3?:K;_GX@_[_1__ !5'
MVJV_Y^(/^_T?_P 57,_\('X,_P"A9T;_ , 8?_B:/^$#\&?]"SHW_@##_P#$
MT =-]JMO^?B#_O\ 1_\ Q5'VJV_Y^(/^_P!'_P#%5S/_  @?@S_H6=&_\ 8?
M_B:/^$#\&?\ 0LZ-_P" ,/\ \30!TWVJV_Y^(/\ O]'_ /%5XE^T5\-9?C=\
M'?&OPGLO$&FZ"GCO3[7P_JNI7UG;ZQ:'PW=ZOIK>*])N=*EGACOK?Q'X7CUC
MP[<12R>5Y&JR&:.:(/!)Z/\ \('X,_Z%G1O_  !A_P#B:4>!?!Z_<\-Z,N>O
M^@Q'..G3'3)H _"71O\ @CIXIT?2["34_C#\-OB1KEGX'^'WPGO]'^(G@[4K
MGX?^)OA'\,M*^)>@_#KP%K^D:?KK7\VB_#"+Q7X0\8>%='$\N@:W\2] \2^,
M_$&F1WOB'2(_#&5XA_X(Y?$BV'PAU/P/\>_A_J'C;P)XEN?'GCWQI\4?"&H^
M*=1^)_CZT\3^'K[0=6UIX=:_MO\ X1RR\%>%=&\!V6@:7XF\,ZGHNBWOCC38
MO$&HZ9X[U-+;][F\!^#WX?PYI)'7'V1!SV/7MSQ[T@\ ^#!P/#6D_P#@*E '
MX#R_\$7OB9'+X MT_:[U35U\ ^&_%FAV/B_7+6:3QVLFIZCXV2TU*'51=76H
M-K?BWP?K'P\\#_$75K37] M+GPO\+=,\*V.AWGA75ETO1??_ -F'_@FAXY_9
M]_:?\-?''5/C'X,\5>&?!O@7Q;X1TK2-!\,Q>%?$NK)XMT71[-K+6[Q(;IY]
M%T+78_%'B6RTF?7[S0K[5_$B:BGA[2M6TJ+4+C]>?^$"\&?]"UI/_@*E)_P@
M/@S_ *%O2SR#S;@X(Z$9)QU[=>^: /P/N_\ @CU\4+YOA*'^,OP@LKKP'XD\
M">+O%OB2Q\(Z]<^*_BE\0_!NI>";KQ+\:/'&K>)M2\2S7_Q:^,VE^$M1TWQ=
MK7AV7P7=>$$\3ZRNBZUXEM[JX@N*W@'_ ((N^)?#_C#PO_;GQ9^%4?PHTKPY
MX=\*^(_ '@KP5)X:;Q9X<TC4?ASXHU7PQ?7=A+IU\V@^)?&W@75->\1Z9J>M
M:SH&IW/C;Q/J$/ANPN[R:&]_?K_A O!G_0MZ3_X"IG\^WX4?\(#X,S_R+>E_
M3[.,?]\YQ^E 'X=^(O\ @C5I$/AC3YOA[X_^'_A7XN:5H'@NTT[XG2^!5GUV
MVU/3?%OQ1^)GQ1V:W_;UQJ-MI_Q;\:?$ZZ\(7<36U\=+^">EV7@&[36;33["
MQ?BO#?\ P1C\=^'_ (?:AX9;XZ^!M1OI_"/C3PCI^BR>'-3M/!EIHGC#XR>/
M?B;'X>>'2M7TFSG\.Z-I/C^[\+6FAW'@V;P:=/TJWTW5O OB7P?J^O>#+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $2 E@# 2(  A$! Q$!_\0
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M$WKZ)_WTM&]?1/\ OI:\[Y!QN8\'JQ[8]"/6@DX^\W4#[S=SCUH^KQ_Y^/\
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MR;4W7@[X30W?Q6OO%7AGX<Z#<C0?";^%O!^AZ9!<V.CP2I\\ZK_P1XL&\0>
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M>M?SLP_\%;_VE[@Y_P"$*_9JM@!EED7Q?(>._P#HOC*50.A))4'/4'BK*?\
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MSC) *DX5@2W_ (1'XV_]%MT+_P -#9__ #8UX!^P)X*N_ /P>U30=2\!ZUX
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M@<!CGJ2,\!Y\)_&S_HMF@]"?^2/V0Z#/4^,P/ID\]!DU[)$'()?8!SR I&>
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M'N.V?&6."03G/((Z9Q[*@WHKN"&.01G Z^IYX/KV/H.%=&7)C;#8Q\WS8]<
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MZ^3VGG>.2SU(-+:W "+>;$\ZUE+ Q2.57YX@R@MN/ SW/,,<,MNYMI8%BN5
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M_P $]'90G_!8_P#8NVO@-&/B%^SU\P#%U55/B7(&YF/3ECD@DU:E_P""H7[
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M<Z??)8:OIM_IETUO,WDWMG<6\H6:)Q7^"QR&P=N<C^$$?B,<CVX_&O\ 8?\
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MU]?7Z"O]B'_@VG_Y0D?L+?\ 8J?%#_U>WQ1K_'?/('&,,.,8_KTY&*_V(/\
M@VG_ .4)'["W_8J?%#_U>WQ1KVY))VB^966NVO4_,EMZ:._=;G[IT445(PHH
MHH **** "BBB@ HHHH 0\#KCIR?<@5GW4KJ(V!&W#N3MR5"X))Y'! (4 $[B
M,\E0;4K!$D9MV RD  DG&S   ).2.F.>P-?G1_P4T_:;?]FS]F3Q'JWAK5&L
MOB+\0I&^'7P]\MWCN[34M9MG.L>(H=H\R+_A&M%6XU*.X"'R[UM/7'[\ U"S
MDHO357;VU>B]6]%T=_)GO<+<.9GQ=Q'DG#.3T98C,L]S3!Y9@:<8RFI5\152
MDZD87:I4J2JUJTK)0I4I3;239_.)_P %/_VHE_:/_:>\0P^'=175/A]\*7N/
MAYX"^QL)K75+FUDC_P"$P\0PB$O'.-4\1026,$XE,4NEZ-ILL9WRLLOYN:[J
M#^'=,O)[6(WFL.L,"1(0@;4;ZYAM-*T6"0'<)+B_DMH;FX7_ %"-+<,BI [I
MK6]Q?V"AX'CG0( R311":1,JS,9X5B;S)/O-)\^YOWF",$\K-Y6J>*OMEN3/
MH/AYC<7 (&8O&FLVDGD6DR\([Z)H5R;E)!E$NO$2LTBO%((O4BN6*BK*RU5U
MO9)Z7NO/;T/^@?@#A#+?#G@+ACA/(?9QHY;E6 P%&ISTYSQN93?M<PQU7DO9
M^T6*K2J33<:DX*3=D7]*TRS\.:1::<\HF: 3->7A0^9JFIWES->:M>B+)<MJ
M6I7-W>&,;0L<Z$*NV,+;ANK"21(\!)&)&V:)HP_!.%+?+NSC"YR1DCH:FNK4
MS^4ZRB.6+>R,0S02*ZJI5T(#*2%!5E!V*1SQBJB:;-(Z>?+$(XW64K$6>1GC
M.5&^4+A>23CYLX !&2%/F5K7Z[?\"Y]]1C"A2A2C*2C!."MUDFY5)VMJJDYR
MDGL[MJRT5Y6:TD,\48DA*%;NV8Y2>%@=\>"<#J""/FSVKD$TS29_%GB.YNM/
MLM4L6T+P8+:XO["UOI+(N_B8/92M=0R-$RJ%)\MHRZXWEN">SED=F\N-/,GG
M+)#&/F9G<Y'88Z[6.=J?Q$ UAZ=)+I_B?Q7IUJT,D_\ 9'@R6[G*+-#&[#Q-
M^Z1&^4L,#+'( )P2>!2NU?RUVT[]=/,Y<9&%2>"A.SA/&034K-2B\-CIOF3=
MFG*G"5FFFX1NK:..;PYX/N&$DFB^'2X 'F1Z9I\3$ #"N%@5<J."-I.,98T^
M'0/"5JK"'0O#BACN<+HVF2222#/)8VQ)YSD9W$\GG.-L17!_Y:QLV,D_8M/(
M(S]Y<VN[;DXR6/)'.<T\?:[?#PRQ&1=K -9V0 <\CA+9#C/WMCC'J1P1**U5
MK[7NE^ILL'@4TW3I)7>GLZ:BW;12]VS77IKJ9MOX9\-QHVJ7_AK08[1,"W@;
M0],$DSDD;BGV495^-@_A&YR2%;/*^'_#^BWFH^-;N[\/Z$TG_":WL<41TFP9
M(8&\+>"Y%MXD-MM" LQ "@,99&Y+BO2&E_MJV-L[+#J-G)YZQCF*XS'(I*]S
MQE2IVB,D#&#D\7X8<^?XS1T9)$\=7<<L)!5E>'PEX*$B=.!\I.>0 =V2.:$F
M[VUT?GT:[_UZG'BL-2EB,!*-"DY1J8Z'\*"]U8%3I<UHKW8U)1FGT>MST'X<
M^/+[X1>-O"GCWP (='\0^!]>M/$6E-IECY5J]]92AYK6=+9 K6FHVQGT_40B
M-YMM<S0LBHYDC_JA\+_\%7OV-=9\-Z%JVL^/]5T+6]1TBRO-9T ^"_%U_P#V
M+K%Q!'+J6E&_LM&DM;LV$SS69N;=W@E$0FB)+*Q_DO-A+;(WE2Q&% &621GB
M=%5BW[R.+ D8$D*\<BNPXRPR*^H/#_['W[1EYHUCJMA\.;Z:SUNSM]8M))=<
M\-6,LEKJ5O'<6[&SO-6BNK;-N\;"*Z@CGC7"S(KAP/+QV8Y=ET%+,,3A\-&4
MDH_6*T*3YI)V:]I.-]$^C7J?SG](3PW\(.*IY%G'B/Q;1X)Q-*KC\)EN-6/P
M&63QU*<,+7Q&7UJF,G:K'"UD\71I1@I4XXF5134*KB_Z2H_^"J7[#YNX[.;X
MLW<,TS2I;1R> _'*-=21PM</%;!O#X,SQP1RS,B!I/+BD900K8:?^"J?[#P8
MAOBSJ"E259'\ >-HG5APRE)M%B?(<,H8H P 8'D@?S4:G^PI^U!JOB'P?K7_
M  AFIZ7:^#];O=9FTRSU_P #2_\ "1Q7?A_4M&AT^>6?5V-I;V\>H1WMS-$\
M!N[*.\M J>;!,.ED_8\_:BNGWS?#-8=Q;$(UOP=<."7.4\ZYUB66<JP96D=2
MSM&Y<APZ)P_ZQ\-6?/F^!U=E#ZS0J)Z)Z.-2^E]4]NS31_,]#P=^BU4Q6*IU
MO&E1I4)4*=.<>)\@BJBK1=YQ_<U;^S:]Y\UU>]DK7_;SXJ_M9_\ !)+XYZFV
MN_&"V\+_ !$UQM"L/#"ZSX@^&7Q$.K6^@:=_PEPM='L]3T[3[.\L-.DB\?>-
M;/4K:PGMTUO3/%&LZ9K*ZA87*VZ<3-\:/^",NMNX?3(;W7+=MW_"6C3_ -H1
M_B%: >'M*\-6XD^)BZN?'\5O!X:T/P]IMA:3^(OLUK!X?T9K.")],M)(OP3^
M(7PQ\?\ PKUNW\._$#0CX=U>YT^+5K2WDAT2]%S83230)<V]WIWVVTD43V\T
M4JQRF1)8GCD2-R"/'M!OI;?Q'X_BN?*FL;C4?#\5PT42121K-X3TV-94,(52
M4?<2I0,,D[<<GUL/4PF,I4\1AZD*V'J-^SJT90G2J6Z1G"\96[*3:VL?HN"^
MACX09]A<!FF0\8\29OEN8SJRPV88?'Y75PM6G3ASN6'G1P\X58MI^]3FTGK*
MVJ/ZYO#'_!2_]@'PIX;\/^$/"7C]_#OA/PCH.D^%_"V@Z5\-O&]II6@>'O#]
MA;Z5H>BZ9;)H.(K#3--M;>RM("SF.WAC7>2NXZ5Q_P %6?V&+5D27XMZD'DV
M!$'P\\<$EI72*%&)T)50RRNL2$GYG(4*<Y'\E>PV<J6LGE.6C+VTB_=N8#\X
MD4\_-R"^2-H/S "N6\6V3RV23P,A,NO>"XY8I,X.WQ=H2H8V4DIE=VY>,^_2
MMW3BFU&+?5KJO6TMK=SV*GT(?#:C'WN*.+HJ*32^LX!1:6CC'_9-K^>[W/Z_
M[;_@JK^P[<NT</Q:U)Y4P3&WPZ\=12!2?DDV2Z$@97X)PVT<C=QFO@?_ (*&
M?\%(OA!\5_@>GPF^ 'BN_P#$%M\2=2%G\0M>BT;6]$AT[P%:1K=W-BDNK6-F
MUVOB2_-K974=HDD<FC6NIQO.K72*?Q;^''P=^(?Q+O=4D\%>'YM>ET&VA74#
M:W>GV$=@-3>86Q-UJTT4<E[*ENTEM%$LLD:PB1H5C*L_5^$_V+/VDO#_ (2\
M-^%[WPI>:Y<:79"RO=?NM5\)6DU_B=B]W);VNL;(%CC9(H8%5DAC_>^81.S#
MT:&5YCB*<*]#+L76I5+QA6IX:M.E=;N,X1:>EU>[6KUNSX&EX=_1:\*O$/*H
M<2>*N#PV=<.UL'F=3)>).+N'L/.CCKO%98L9EE.-&NG-16.P<*]6A*?U2E6U
M5)PJ?,^J:)XDDU"X:^E\ 31B1AIUQJ_A"\U.<V9<M;JUW_; @?<FV5Q J1B8
MEHXXN%7&?P9=E\^5\+4SV3P5>^61Z '7611CC"J!ZU]P3?LL_M$MY=M:_#R:
M.WM4\J&2;6_"ES+*T8P)&$^K2+"1M9AM 8J"<85JY?Q-^S?\;O!V@:IXG\1>
M"FL-!T6V6]U2_BN/#%ZMG9F2. WDD%E<W4[6T32(9IT@=((BTLS+&CNNE3)\
MSA'FJX#%PA%-N3P]:,8JUVW)PLDDKZNR2?1-G].X3QV^C[FV/H9;EOB[PCC<
MQQ^,I8;"8.CQ/EE:OBL3BJM.C0HT84L55DZM;$5H4J4(QC*K5JPA!.32/C_4
M]+O]"T^7438?#"_AL_L[-86G@BZAGFA>[@@>."X.J7*0R"&21A-/"\89%+%B
MQ ]"F\-:#ITTL2>']"DU6998W_XDNF+_ &?;,2/)(^S$K/*%#<DE06 !(S6?
MXQDO;;PMK#H\$@,5KN1[:W0X%_:;E#Q0PO&0,J^TEPP9"H*FNMOG$UQ/JEJ'
ME2XG,5U -S26MT&6...- /,E$QE147F21I$PI+;:\VI.-&$ISDHPIPE.4FU9
M0@_>F[M*R>C>BN[=3]EPV&PF'K8F,9>WP]/"4L1[2K-R?/4E.,H0G-4_=I\K
M]HY17)RSYE:+.9_X1SPM;1M))H/A\8 >1Y-%TN5RY*C/-L6D=CC" Y/)&T<5
MSYCT*T\;>'?L.G6.EM/X;\6)F'2[;3A<$:EX7,2N]M#&975V?8D[,$:1MNT$
MX^V9/V)?VFM0LK>XC^&-U&DB07T#3>(O"4;8DB$L0N;>76(Y$)CE!DB?%S$W
M#(K BN/O?^"?G[5-_P"*]$\1S>#=0M;/3-&UW29="M?$_A&33]3DU6?395U&
MX636U9;RPBTSRHB@8O\ ;8K@XETZ%)O@JGBAP%3JU:4^+<AC*A*:K.>9891I
MRI_Q(R]E7YHRIZ.:G\*\['RF8<;\$1A0CA^(LEGB(9AA%6C2S'!1^KT56DL1
M5<U7:Q$*<(R5;#1]Z<+M-*#;\0\M[.3[5:8655)9",1W$;Y#0D-E7CD7(W$=
M?F7!. O[J)%N[2-S92.$F@ +26%QQN60#Y_L[L&:-R%'ENN,#%?5$G[%W[3N
MP^7\+IY2\9*QCQ1X1Y"D!<G^VU&'4CO@<D?=KP?QAX/\7_"CQ!?^!_%ND2:/
MXQB6PN]2T^Z:VNX+*VO+>*:P>.>UFN+2^$\$H7S8IYHHI$DMW(D@D4>SE7&'
M#&>XJ>$R?B#*LQQ<*<JL\)A,71G4A2IR]G4JN]:55PC/W:DG'EIR]W1:GT>7
M<5\.YQ6EA,ISK+<?BE2G5EAZ&.PM:HJ-.4HRDZ=*K*<H4W:$JJ7*^:*NN76S
M\+_B1K?PC^)O@/XK^$9T3Q5\/?$6F^(=*99O*^V)82LU]H]X8F1WLM9T^:^T
MZ]CR4%O?3D*%)%?WJ_!CXH^%OC3\+?!'Q3\&7T6H^&_'&@6&OZ9+%)',\27J
M$76GW$D1,:WVEWT=QIM_ -K6E[:7%H^'@(K_ #] MPQP9XPS"3=Y-C9$G>&3
M: ]LQ#E263(7#+DLN,'^B7_@B%^TS<8\8?LK^*]39X[+[9\0_A6EP5#+;7=Y
M<7/CWP]:JBJD:VNIW=IXCM8B$#1ZEK3?,;*,/]!6IJ<))VC*F[MNR;LFG?5[
M[=%>UV?Q#].CPF6?<'X+Q)R;#QJ9MPK4>'S:E!*%3$9!B'AZ4JM6:O*<,MQU
M2,L,FK1PM7$33DE*2_H]C."5'W<@CV&.3GW./4=>]351MF9F'S948^OW6R",
MY&&Z!AGMSMS5ZO/:L[?UKJOPL?Y*)WN];<TXI-6:4).'SNXN2?5-!1112&%%
M%% !1110 5$WW/PC_P#0JEJ)ON?A'_Z%4SV7^.(^W^)?E(\#^&,3S>(OVB(X
MYY+:23XS/"EQ&D4DEL\OP:^$R+<Q130W$<D\!/F1))!+#(08YT:)F%?EA^S-
M\=?VC+W]O/Q-\#/&'QD^*7Q6^'OAKQ#\9?!&H^#O$V@^!;7Q)X,MOA]I]M-X
M8^,OQ/U#P+^RQ\//!=O\/?B9J4C:7\,[#PG\67UJ&_U/P]9ZY%XHU*'QYHO@
M;]4?A=N'B;]H3: 6;XUA5!&06/P>^$>T/RN8RV Z*T;29"^8B;B/QT_87@^+
M=Y^W5\<;G4M6T2/PYIW[0/[4$'Q(E^''B[QIX9^'WC+QW;"WTN+[1\ ?'7[>
M?CQO#^KZ7$VER:EXTT7]DG1W\5ZE91^([?78=!UM?$VLZ5?BEZ?^VHY,'_NT
M/\5;_P!/US[^^(WAK2_$/BCXI?VMX>'B"TL?CM*X"OIPN+":X_9V^#T$4]E#
M?L6N[_(+VMO;122$PN[@"-5D\AU7P-#/K=OH>BW%W#I.G:8(=9L=6DEL&>VF
MEB1I5$($U]-<3M9RV4EI%';PV\TT;[&,CK] ^(]9TW0_%GQ:NM2O9+&%_CM:
MIYJQW#P/C]GSX.R-%<R6\;FU$OEB.*X;:8W8A"7< \A::5IUU=V_B"36XH;[
M0[G5[6\\IDET^^M;R*XEDFE-T%>]>S@GN7AC+;?->21MKVZ*"I_$:_N4_P (
M_P!?U<_4^!\RQ6$R.#<ZT,/3Q&.]A&$932KJI7ESQ23<6H*3<E)66C5FSSJ&
MS_X035+?3[#]Y)'(LT5KI>);%4N(K:RTNVLA#)-))H^E0K=W&HW>HS10SW-U
M;WTI=Y/GNVOB#4)E2YU!=0,GB?7;V6;1[O3H##I6I.[+I^JQ,((/L#P&.33(
MD9+A=2EO8+R";:R 8NEZ3J?_  D=Q)X3U[0[_P (>'O[-U7P]XBDDT^YMY[S
M5XIFUGPWXIA @U73?[4TDQ71G@BQ:+#9W,"2M;/'6YK-C=3I>2:V+?2KG1[B
M34+ZRTS6O[1N[>SBN;>\T](A+%#-=&RG^SO%<0@H([A6D2,QR!<Y7MI>^FWX
MGV%;V4I4ZCJ4ZV*J4%5KS5E552HN:,:L;IJI%-7YHJ3NF[Z%U4^R:MH7AB]%
M]_:VL07=CJ!MI+H+]GTVS.I-"\Z.[+;IJ,4R23X96CB9MH0E1V%_LO+Z2^TV
MYEO5TRZO++4[>=EGA>[TY([J<>8[0OB.2;<#,%M-@&(WF#%,2\EMIM9\-^(I
MX9M/U"34+FPN;QB)3;6]U"]C<O;RQ[Q&LDL)6[A(86SF^!!-Q;F30TJS&EW!
MOKC4=1>/6]?2^ F@@:WN%L='DTF60M;1"6?3O$\,HV7=U/+/%*;.YA<V\5P+
M4C)MR:=UT>Z^1Y.,J<U/#UK3A5="-.4;6YY0UE!W5^>&[CHX]?+A-4^'GA/6
M=0\:2:\\E_X7\606&L:EX5TV_N;.YU&'18+![J:9K*[MKK4$U"73]-W0HV^[
M,*6\CRVUP+<8,]]K.C^(4\)G3=7>UO-9OK/1-3@EN]?TV'1)]#M+FSS=?98[
MG0M,TV%;K1Y&U1)+FRN(C;75X5-N:]3U6ULHG\.:J=.@&KV>ERF(R2)!96DC
M6THNK;4;F?"P6AFBM2AF8)#,(L2,5)KSGXC7E[I7A_7]3MH+S5=3M- NKMM%
M@G\M[W4([>ZNYM/@$:*&EB8.(VNHY@YC_P!7%.L<JMM+JE\TKFF72=?$8;GB
MYTYVIJU2,73DI/6UDTTK:^O4_.F_U.;QO\;S9>()FU+0/#OB.^L/#WANZO0-
M.:]L(;5HXYE#+;FTU+44AU;5T599[RTL[F(((I'B;]N/AMX4TSPMX8T^RTZY
MBOY988KO4-75</K%]=!KJ[U"1CF1S=W<MQ.FXKMBD2-HTVJ@_GB\1:[-KLWC
M#Q/HL%[X?O[[4;KQ%IBS3N=3T/6HEM+O+ED&+B&5Y+5HV 862.L@+,-W[&_L
M8>,/$_B+X?1V?B6>5[@65CJ/^D7!DN#?7D+K?R1(TK/%IMR88KNTA,2+;AV2
M-W3.(C)0G%5+SNTTH>\K.[6ROHFF]3[/Q5R6O4X3RW-<'B>3!8"-#"8O!^TM
M!PG1H*-:$$USU9UY57BI:I15*344T<I_P4KS_P ,F_%[)R3\%_VK23P,D_L?
M_'<YP !TQVZY-?XQ)Z+]/ZFO]G/_ (*4AO\ ADSXNDCE?@C^U:3@@\?\,A?'
M#G.<$E02<$]2._/^,8>B_3^IKIK6<[KF2LM):6]#^9=-UM96MM972MY6V$HH
MHK( HHHH *5?O#MR.1P>OKVI*4=1]10!90E2C9/.PX/W<MNRN!C(P",$GD@Y
MSU]<\4%KS38KN6]%PTFF:<8]S;I(4MXS;1VDAXQ-%(CEP1E8=DN0&Y\FA42,
M$ZDG8H!QD\G&3@ >YXX ')KVGQRD5CHFE6<EBMC?QZ79S:DZN"MU<WB;[600
MD[8RUH\+2%2>2SMC.*\S'.3JX-)-M5)MI*[5VE=Z7L[:W=K*]C[_ (2IWR3B
MF=6:AAXX+"R;D[*5:-3$\D-?M<LG)+>S4K:MOPTG)![A\>V,^GX>WZ<?[$/_
M  ;3_P#*$C]A;_L5/BA_ZO;XHU_CO'D@\8++R!C)Y[8'U_$=\U_L0_\ !M/_
M ,H2/V%O^Q4^*'_J]OBC7IVLDO)?D? M\S;UUUUWW?ITL?NG1110(**** "B
MBB@ HHHH ***:3\W7'&>_;/7'^3C%'?R5[=_(3:5K]7;[[_Y%*YD.6BP""H8
M[CM# 8)4'N"N0V.V?2OYP/\ @I1^S!^T1^UU\>(-4\-^(_A]:_#/X<Z._A?P
M38ZGK^N6=^VIW%P+KQCKUW;:?HL]O#=WVH16FFV9%S>>7IVDVKK/F:5!^_7Q
M5\5+X5\+7US%(R:AJ"G3-+(SNCN[@/NN-W#>7;0 S$ C+*B]6%?!^6/.YV/
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M7?M)0,ZS>*/A1);,H\D-KWB)I(Y-[!T0GPZ/DP-P&<KT/&,?T(;?]IOSH&W
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M<6?PLT/7/#OP/\!?%+XJZKXT^'GP*T3Q#9MHVH6GPZT*XM+*]>YMO"K2>"]
MUKQMJOC37_"_@N>[\*>'-2TG0[_4+2[UJZREZ+_TE''A';"Q?:5?_P!/USCO
MBI<RV.J_%S4$BNWMK+]H+2'U(VBF1HK$_ GX-QM,T<D@A(CF,4S.\,TT,<4K
M6K1.7+\W8ZC%K>M>'[B[M;;7-.BF>WTO7FU!;:WO[34I'TQ#<6=Q;K#?M:7
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M>./3@8[<#M7^,0>B_3^IKJK?Q'Z)?F?S-T5[722=M%I?9=%J)11160!1110
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MT/&<8Z<"O78V2VN%DNF2W2UFE>Z>4^7';Q6_F&XDF9W/EQ0B-VD=W"JJEB4
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M=2Y4 =<UX=XLDME:.)(PI56F1\L"RN6,49&Y@-@X5MS$@ $DU[C<7LOA_P
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MF66F:%H>EVY9H[#2=-M)TMK2U$DDLBQQ*%D?+Y:9IGE_%/3/V@-&O8I+Y/\
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M*O\ :?[';7$[DSW0_;Y_8U1) 2-D<44?QCC6*- H&T<'"DE:Y_P__P $3O\
M@H-X4UO2O$OA[Q+^Q_I.NZ%?0:II6I0_M]?L9O/9WUI(9+>YC2?XRRQ%XI"6
MC#1LA8DL'R#7XQ6< F8<*QR.H]#CI@>V![^M=#-96RVLK-&@;9U"*3D<$AL<
M< '.>N?0URP5#!<M&C'EYI)2=M]_/;L_+8]O%RS;BA3S''XAU)8>E+DYY2Y>
M2*<I6M!V>FSNW?=+0_<WQ7_P2Y_X*L>/=!O?"WB_XN_LG:[X?U-K=K_3+O\
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M7;"<QQ85<5\:6:AS<J3$C1&WD>(,P+*CLH,0W;FC=D4SQ1D-,"T1.U@M>X_
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M@,<UQ?B7PAX)\1W7A+7?%OAO1-<O?AKXG'CWP1J6KZ?#>W'@WQ=#H>L>'/\
MA*/#TK@26.LCP_X@US1UNXV5S:ZI<)G=Y<D7UC\=O"2VFJ0>*+:,)'J8^Q:G
ML3Y1J$**EI<''"F[M@$=R!NDMUSS*Q3X^\<ZBUO'#I,3$&XC6ZNU(V?N0["*
M!NH;?M+2*&)^X#G -?R1GF35\DS[%Y6E+EI5:E3"5V^55,'4E5M%.ZM*G&<:
M=G[TDF[.+=_Z&R7,Z.<Y7A\8^7VM2G;%PNKK$P<8N-GT=I2NER[;.P__ (3O
M3?X;'4-N<_\ +L&.>N06D()_BRPR<_*G"(I\=Z:/^7*_].3; #WR\DB@#UP,
M#G<!G/EX (R,]3@DDMU(Y/?OG'!Z]ZCP%#,S!516=R25"(BEW9R#D(J*7E(5
M\1+(60CD8++Z%DK-MM)MMZREV5]K]5H>ES22>KY8JZLHKE76]VM^EO3L>JIX
M\TX,K+9WRL"KJRM:[P5955E*@;3NE0*PYW' .X-MY?PG/\// .F:CHW@;P38
M^$M)U?Q5XJ\<:EIGA^PL=.M+[QCX\UZ^\4>,O$ES;0,!/KGBCQ#JM]JFN7Z%
M9;V_<DQ1P^3;P?FS\4_'G[5,7Q6-E\)_B'^R^/!?BN;P]KGPG\)^,O'.B67B
MGQ#X8\'>%S?_ !/FUJ*2S.HMI?B?6M:L[N._TJ]EN?">EZ%;,;S3SXAE6!E_
M\3/V\M)U#P_I\W@']G+Q!/>VT#>)+O1O$,\'A;PQ=3Z_!HW]F:OK.H_$DW_]
MM0:>U]XJN=*TW2+X2VFE:UI45Q).MI+<>K#A^7L;1KX>*J*-:5.6-Q$):7E&
M,X1I2AS1^RDYJ-VXM-R.!YA#VC7L<1)TY-1G!1<96ZKWDTMU;UN?JBOCO33\
MOV&_8^BF!L@],?-(3D<C!&0<@$<TG_"=Z;@XL[UO]W[&0<E@,$*<CY&(()!
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MU%)7>UGKK<ZHXJE!6C&G%=H1Y%\TI2OZMK32QX7X"T(:MJWVV9-UGI065VY
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M+VXLV_6\>!_"XX_X1G2P/3[)$N!GH 1Q@<<]>O?%'_"$>&/^A:TO_P !8?\
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MEC=W5O;WNM7D^GZ1:R,QFU*]MK"YU6XM;./:3)-!IME>7TZDJ+:WM+AKDPE
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MYZQ?]_K;_P"/5P>!Z#\A1@>@_(4++X+:5O1-?DS+VU7^[]S.\WV7_/6+_O\
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ML#?\&T__ "A(_86_[%3XH_\ J]OBC7^07XAL)HDMKN8EGD!!/\( )&%('8D
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M[C **** "BBB@ HHHH **** "F2+E#UX&>I'3.1D$$9&1[]#D<4^BDTFK/5
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MMIQZ\\ _G@?6@!U%<;<>*6CF>*WMTE1&*>9+(P9RO!*J%&%R,@DX(]SBH/\
MA++GC_0H>1D?O'Y&<9''()Z$<'!QT-2VF[<UFK-ZK6[MRZ[MM;+7L%G:]M+7
MOTMWOM;SO;S.YHKAO^$LN>OV*(#KS(XXW%>X_O @'V)Z T#Q;.<8LHCN4,,3
M,05.S!R%P 3(@!/\3JOWB!5>J:?9JS7DUT:ZKH'IKYH[FLS5-/34;.2V=MI8
M[D<C(211\KX[< J?7>>Y%<P?%TX&?L<(7!.3*^,#D\XQZD>H#8SM;"?\)5<L
MQ'V.(E64;?,DW!FW*$V[<B1AG$?^L93D+MYJ*D(U8RIS5XRB[_EV\QQ;C)5(
MNTHVLT]5K?1==ON* \*ZB!UM#_M&9UW<DAMNQL9SG&?H*3_A%-2];3_P(D_^
M)J__ ,)3,PS]C0@<$B>3'3/=3C@@X]"/49/^$HESC[&F<X $[DDY48 "Y/S.
MBG&<,Z*>64'R5DN#2M^^MY-);O:Z;MKWN=RS/&))*I!I*R<H:Z=[):_(H?\
M"*:EZVG_ ($2?_$T?\(IJ7K:?^!$G_Q-7_\ A*9?^?./T_X^&Y."<#Y>> 2,
M=1@CAER?\)1, #]B3!QSY[XY&1D[>.!GGV]1D62X-;>W_P# D_S0_P"T\;_/
M2_\  &4/^$4U+UM/_ B3_P")H_X134O6T_\  B3_ .)J^?%$H&39H!C.3.X[
M9QRO7L!U+?*!NXH/BB89_P!"7@X.)Y#@X)QPIZ@$CU4%AD#-#R3!/_G_ /\
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M"&)"D3R88@,VU3LPS;4=MJDML4OC;@EP\42][2(<X'[]F!(8*0#M()!9<X/
M.3QS1_8N#>_MOO7^2#^T\;_/2_\  '_D9W_"*:EZVG_@1)_\31_PBFI>MI_X
M$2?_ !-7SXIDY/V6+  )/VD@#.<;N/E)VOP<'Y)#CY'VK_PD\V<?8ESSQY\F
M?E.&XVYX/!XX/6C^Q,%_T_\ _ E_D']IXW^>E_X S/\ ^$4U+UM/_ B3_P")
MH_X134O6T_\  B3_ .)J_P#\)3* 2;.,!>&)N& 4Y088E1MY=.N/O*>A%'_"
M439Q]B7."<>=)G Y8XV?PCEO[H#%L!6PO[$P7_3_ /\  E_D']IXW^>E_P"
M,H?\(IJ7K:?^!$G_ ,31_P (IJ7K:?\ @1)_\35__A*)CS]B3&<9\^3&<[2
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M/0>IKLU((X.?J<GGGK]",>U "T444 %%%<WJNNG3[D01P>=($4N6=D10<$8
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M-8)=R3>7///-(99)G8Q?\)7=?\^4/_?U_P#"C_A*[K_GRA_[^O\ X4 <Q%\
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M[92_%W2KFP>/3+_X#Z_XX@/P7T74H?#<MU';Z3>:O;>+M2\77FK^#_#?[>>
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M1O$,-QXTOM4T^Q\#1Z/X]E\">*M.N;>?5;:+PKJOC^SU[3$O+CPGI?%^'/\
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M&_,;:A%=6%E<Q:@T0A$3:A'/!(M\T7V:U,378F:-K2S="KV=LT0!_/E;?\%
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MF>)?'<&F/-X=TO5XKJV$X!^B%%?FK\'/^"K/[)OQ8U?5M(U;6?%?P=6V\,^
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M_ NE_&#0-<;PQX7\4>,O#=IJLEEJEDVF<GX5_P""4?B/4[+Q+)\5?VJ?B/\
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MSP#IOQ=\42>)]2T*75-+\-^./B)K_@[P5<>(/$%KX0T+1=,FTRTTGYE\'_\
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M\&Q^RS\2_@B_P;_9C^(_QJ\2_LT?"7XXZ3\1I9OAK\./V@_AG<>'/&_P=O\
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M !V@#DJ*ZW_A%&_Y_3_WX7_X[1_PBC?\_I_[\+_\=H Y*BNM_P"$4;_G]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #  D # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#5<Z=9EH6-K!NA):)O+&8R>I7TS5FB@"F
MVD:>T4L;6-J8YG\R13"N';^\1CD^]37  MI<?W#_ "J:HKG_ (]I?]P_RH Y
M+X3?\DYTSZR?^C&KLJXWX3?\DYTSZR?^C&KLJ "BBB@ HHHH **** "BBB@
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M\:NQ$T9VX=?F.!SU/I0 ^BF>=&<?.O+;1SW]*/.C_OKPVWKW]/K0 ^BF>=&
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MQIW_ ",'B?\ ["9_] 6M.O#Q=:<:K29[.&I0=--HQ?\ A#M _P"@9'_WV_\
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M/HH 88D.[*@[A@Y'44>4ASE0<C:<CJ/2GT4 ,\I,YVC.-N<=O2@1*I!"@$#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBJ>B/7R:K.>(M)WT/2A2T@I:\L^J"BBB@ HHHH **** "BBB@ HHHH ****
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MEP/7]XU=B)D.,.OS' YZFN.^%"*WPZTLD E3+@^G[QJ[#R8QC"*-IR..A]:
M#SD./G7EMO7OZ52E\0Z/!,\4VJV$<B':R/<("I]",\5=$*#'RKP=W3OZU\J^
M.N/'6MC_ *?)/_0J /I.[\6Z1;Q;XM0L[AL@>7%=19^O+ 53_P"$ZL/[B_\
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M2E#)X@U9BC;ES/G:?4?G3O/U?_H8]8_\"*=1BCDCV#ZQ4[C?/UC_ *&/6/\
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ML7PG_P!!ZR_[[KBOB9XNT'5[+24T_5;:X:*]#N$;[J[2,FO3/[!TG_H%V/\
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M2EHKN&&*[@>)5A4%DW,'4D=5QM)]LUT/@ZZUVZTZ9O$40CG$F$'E[#C R/<
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "Y D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V)5 4<4[%
M I12W 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $Q2'CMFG5C>++J:T\-7DE
MNS+(0L8=3S&&8*6'T!)_"@#6_ 4H'M7"7FK7D?BL7T3W7]E6$\=A(H!\M]X^
M=SW)5B@'XUT/AFXFE;589F=TM]0ECB=SG*\-@>P)(_"BP&WBC;2T4 )MHVTM
M% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10
M FVC;2T4 )BD.!Z4XUR^NWURNN/;12O%'%I<]PNTXWO]T?\ ?.,_\"HL!TOX
M4HP>U>:)?ZC;V\W^ERX;1/M(,=VTNV5"#EBWW2<XP.N3FO1;*5I[."9U"M)&
MKL/<@&BP$^*-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";
M:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4 )MK/UW4/[(T.]U#;N-O"
MTBJ.Y X'YUHXK+\2Z=)JOAO4+&$@2SP,J9Z;L<?K0!DV>IZKJ6I-IJ30VL]G
M9Q2W4AAW[I9%S@#(  QZU<;4KVS\0:98W?DM'>6\@+1@C$R8/&>Q&>*2VTB9
MY8M4@<V5[<6L<5U&Z;U)4<9']Y<D9J.72[N7Q-H[R,\T&GP2N]Q(!F21@% X
MXZ9-,#H<9I=M"BEI )MHVTM% ";:-M+10 FVFLHQ3Z1NE&P .E+2#I2T +12
M4F[FF ZDI-PJ&ZNHK2VDN+B01PQ*7D<]%4<DF@"Q13588!'>ER* %HI.M+0
M57N[.&^MI;:YC$D$JE'1NA!&"*L44 1+ JQB,*-@&,$5':64-BC);QA%>1I&
M [LQRQ_$FK-% !1110 4444 %%%% !1110 4444 %%%% !129HR* %I*,U ]
MW"EU%;M(JRRAF1#U8+C)'TR/SH L44F:-PH 6BDZTM !52;3X)[N&YDC#30J
MZHQ[*V-P]P<"K=% %&?2+.XM)+9[:-89<;UC 3=@YYQ]*MA=N,"GT4 %%%%
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M$N;]DU!D79M01IY:$ !B.,DCC/-1:]JMS9>*-/MR\R6CJI B8 R.7VE=I&7
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MJ:<A431*X4^:W3(XH UA-IPE,OG6HD(P6WKFCSM/\TRB>U\PC&[>N<9S4?\
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MK+/&TN5<P6XF8K@Y&T^OK6!\/I+B>_NY+I=1#)!'"IN[".W&T$X VDY//.:
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MD-+2'F@#F?$%A]NU!&CP9/L[1;6M_-PI8'<.>.1UK9:R6ZTUK34 DR2(4D4
MA74]NN>E<WXIG%KKD,AM(IYEMCY;_:'C8#<-V<'E>_3KBNLA.Z)&QU4'I[4
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M$WC<@$6XQ_U^+_C6_P""?AYXPT3Q5:WMSY-O'&'!DDE$RC*D?<# GKZUSX\
M_$0J,6U]TX_TY?\ XNO=M(AU2)\:E- \7D1+&L:D$. =^<DY_A[T ,^R:^)(
MB^IV3QK("ZI9LA9<\C<9#C\JV1UH7I2XH 6BBB@ HHHH **** "BBB@ HHHH
M **** "DI:0T <WXCUM-,O[6(V4$[NA823-C W ;5X.3[?2M]6!56VL,@'!X
M(KD?&6IFQU.T1FNV#0LT*6PR5EW !FP#QC(KJ86EN+-6(:"5U_B )4XZXY%
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M%BZ&?XHO_1BUNURGC&RO3I=U<?VG(+;S(C]E\E-N/,3C=C=^M=6.] "T444
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MYA\>?^1-LO\ K^7_ - >O3LYKS'X\_\ (FV7_7\O_H#T >!&N^^"O_)1(/\
MKWE_E7 FN^^"O_)1(/\ KWE_E0!]'4UNE.IK=*3 !TI:0=*7J* .-U^"ZN=<
MNUT^VNHYX[)]LX+!9G9<+&ISM4#&23SG&*TM#^W0:0D<=C&@4OM!E=<\Y'#9
M8 Y/4UO[:-M,#A]3LIY;V]>.SO3;2/&9XP6R65V)(^;Y@<CIT YJSK\FJ6_@
M*XB%DDO_ !+'$[O<;7C/EGMM.X_C77%.,5F^(K>2[\-ZI;P(TDTMK*B(.K$J
M0!0!R7@"^\6R>%'DU*SEGN_-?8;US$^-HV_*5Z9[_6N\MC*;:(SJ%E*@NJ]
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MQ;P/!&)&-Q&%R,XZ@G)KG/CS_P B;9?]?R_^@/7(_ ^^M+'7]3>\NH+=6M0
M99 @)WCIDUT?QMU33[[PC9QVE]:SN+U6*Q3*Y V/S@&@#PVN^^"O_)1(/^O>
M7^5<%CW%=Q\'KJWLO'T,MU/%!$()1OE<*,X]30!])4C=*H)KNE32I%#J=E)(
M[!55+A"Q/H!GFKQZ4F HZ4M(.E+0 M%%%,!*Q_$HD.FKLCGDB\Y?.2%2SE.<
MX YZXZ=LULTAH SM#6YBT&P2^+FZ6W02[SEMVT9R?7-4?&#N-&"P6US<3R2"
M.,0[L(2#\[[>=J]?J!6EJ.H6^E6,MY>2>7!$,NV"<<XZ#D\FI+:[@N[>*>"5
M7BF4-&P/W@: .?TR&>W\2( +JX0P$3W%S%MQA5"E&Z'=\V1R<CM6]J2E]-N5
M7S<M&1^Y&7QCG;ZGTI+?4;6[VFWF60,6 9>5R#@C/KGM5C>O W YZ#/6@#AH
M8=3,NG+%;WD:).H@81LF8Q+\[2#H"T?KUYXKN^>]1>>@F:,G!5023P,'W_"H
MAJ-LU^UDLH-PD8F*?[!) .>G4&@#E9]-9=*OK@V]XAFNR8K>*(N (\J@9?[K
M$$Y&/O#D5UMIYILH?.41RF,;E'\)QR/PJ*UU&VN;F2WBDS+&JNRL"" V<=?]
MTTZ#4+:XE,4<P\T1B1D;A@I) )'U!H XFYM=:BAG11?3?Z9=^6Y4EMY">2V!
MT4'=ST%;/AB._BO;O[<MPI^?S3*#M9S*Q4H3U&S'3VKI0ZC WKSR.>OTJ&.]
MMYY)DCD4F%_+D]FP#C\B/SH YK6C=VVK:I<-;W][:?8H3%##G#2>8WRC;V^Z
M6]J9I]M>V]_H^?M=W,$"SR3Q$1HF&+,K'D,&VK@]NU==YB XWKD=02.*9//%
M;Q222N D:%V]@.IQ0!CZW;7;ZMHTUM)<^2DS>;%'C:05/S-^/3G%<U/;:BNG
M20V5MJ.P.PMI#$T<K2E5(9QV .X;C@=*[BRO;>_5WM93(%(#<$8R PZ^Q%6]
MN>] "#@XSS3Z3%+0 4444 %%%% !1110 C=*YL:O<'Q=)9$QF&.18E3;\V&C
MWE\]>",>E=(1FH3:P?:1<&&/S]NWS-@W8],]<4 2&N9U#5KE=:NK*TNK1FBM
MS,RRJ ML<#86;DY)R>G0?GTV1P,C\ZK'3[1Y9)6M8#+*,2,8QEAC&">_% %;
M0[UK_3R[N[R1RM%(Q P2IYVD8!'O57Q!J<^G26SI*J09!E167S7!8*-H(.1S
MST-:\$,5O"L4$:1Q*,*B* !] *26WAGDC>6&*1XCN1G4$J?4>E &%X5UNXU5
MI4G$840QS*$&/++,X\O\-@///S5J:W<-::3<7$<CQO$I8% I+'L!GCDX%6H;
M>"$R-!%%&93O=HU WMZG'4TZ14D&UU5E)Y!P1[4 8%O=ZA9ZS:VU]<V\BRQH
MC+ %#&;:2S.N,@' P1Z<U;\3:A=:1X<O;ZS6,S01F0&3H .OUK0-K;F[%R8(
MOM &T2[1NQZ;NM/EB2:)HI45T8896 (/U!H Y.]\1WL&JR1HT.W:Z$;1NCVB
M,AR?0[R>>.*VM"O[F_T03OLDF62:,$?*LFQV53QTSM'3UJ^UE:L\CM;0EY4$
M<A,8RZ_W3ZCVJ2*..&)8XE5(U&%50  /0 4 <=;>([^>RL3<SVHOI[Z:W6V1
M,B39)C()QA54$DXST_'9T"_N;F:ZAO)XIIHSNW0,#&%). #C.0!R#WK1:PLW
M*,;2!F0ED)C&5).21Z9/6GP6MO:!Q!#%#O.Y_+0+N/J<=30!S\^IZE)?ZW9+
M+:0FW6#[.7;"@/NSN)'4XZ8Q5?1?$\^H:O;P(<V[N(=K!=Q'D^9YG'&,_+QQ
M7426EO.L@EMXG$H"R!D!W@=,YZXI4L[>.998[>))%3RPZH 0O]T'T]J + Z4
MM(.E+0 4444 )BEHHH **** $-9%_H,.H:A'<RS3*!LWQ+C9)L;<F>,C#8/&
M.E;%)B@"G<Z78WFX75G;S;R"V^('..F?R%._LRR_Y\[;_OTO^%6J#0!4DTZT
M*-BTMRQ''[I?\*HZ#H\-IH.GV]U96ZW$5M&D@\M3A@H!Y[T[Q&TBZ<A7SO*,
MZ"?R02_EYYQCGTSCMFIM :=]$M6NC(9"G648<C)VY]\8S0!/_9EE_P ^=M_W
MZ7_"D-A9#&;2W_[]#_"KE9VN&==#OVM?-^T"!_+\K[^[:<;?>@"KH>C16FFF
M*ZLK=9//F?&Q3\K2LR]O0BM$Z99$\V=N?K$O^%8W@UKEM,N1=>:0+DB+>& V
M;5^[O^;&<]>^>U='0!5_LRQ_Y\K;_OTO^%!TRQ_Y\[;_ +]+_A5JB@"J-.M$
M'%K /I$O^%9BZ0B^)I+O[)#]E-FL0.Q?OAV)X^A%;C=*Y'36U+_A+Y5E-T8O
M-N/,W@^6(OD\G!Z?WNG/7- '2_V?9N/FM(#]8E_PI/[.LUZ6EN#[1+_A5H4$
M9H Q-4T=+FXTMH+2$K!>"67Y%&$\MQ^/)%:7]GV;#FUMR/\ KFO^%<UK#:@/
M&-GY#7 MQY7RJKD');=@CY<=,[O3BNL';TH A33K2-PZ6L"L.05B4$?I4[=*
M=36Z4F "EI!2T +1244P%I#110!E:SI#ZL;./[0\,4,XG?9]YBO*@9R,9ZUD
M6?@^6S6UC^T0W$=LS+%]HCW-&ADWKM/&&&,9]A7648% ''IX(\J!HXIT0*LO
MDD+R)&D\Q';IDJP'U IT7@G9J%G=271D,,:^8/N_O0Q=I%XR-S,<C([5UV!2
M8% &!J'AO[?K3WDLB-"X@!A9<@^6S'Z<[OTK*C\ [%BS/$S0QQ)$WE\Q[)S*
M=OID';7:\48% '&1>!Y5G1FNXC@0CS!&?,3RW9\JW;.['YTV'P(T4:+]H@=O
M*A1R\>0_ERL^T_[+!L$>PKM,"EP* .;T;PJNF:FM[(\<A2)DC0)Q"6<L0GHH
MSBLR^\-7MY?+%Y,;0_:KI]\PWKMDB 4D>QR/PKM\#TI,#TH XQ? *%V,LT<Y
M,C$O)'DLI@\H _1@&_"G1>!Y(T"M=H649,^P^8W[KR]F?^>??'L*[' I<"@#
M#T#2IK"\O9)ONLD$"?[0C3!;\2WZ5N4<44 +1244 +1244 +1244 +1244 +
M36[4M!YH X?5=/UF?Q5_;4%H#%8S111)O(EDB_Y:[!T(._N<_)23Q^(+FU8S
M-J2RQ7<#RK&B!0!)\PB/5EVX/.>GX5W&!2X% '%:8GB.$V-MY+1P7$LAG8(B
M_9PLC-G Z[UVC\S5[PK)KTLMY_;@V@-\J;3@')^Z< %<8]3[UT^!1@4 <3IL
M/B*&RL21/$8S;K);K%&J$,["4D8[+@\8Q5#3]/\ $%GI5M:>1.\7[F0QRQHW
ME-]I.\#_ (!@]R.QKT7 HP* ."LX-=$*6WV:Z^SQF+<D\:'8WF<^7QR-F22<
MX.*;:1^)K"PM[=#?R3(&",RJRO+YASYC'GR]N,'W/-=]@48% ',7XU6+PAK,
MLDTS7;1S&-6 'EJ,[0N!Z?6LHZAK<M_?Q:2]Q+#;RF*)51#"L?D*PP<9W[R,
M9]:[LC)Z<4U(E3[B*H/4 8S0!Q]K!XG@-O(;J[N&+1[HYTC"_-%\^[ !PK],
M>_6JXAUR_;3S?0W3PPW<4LWG*JLCA)!)MQUC&1@G/6N[P*"H(P1F@#*\,[F\
M.6.XL1Y?R$GDIGY<_P# <5K8IH4*    /2G4 %+244 +1244 +1244 +1244
M +1244 +1244 !%&*** %IIQ2TA H 0YZXI=QKDKS1;*?XAVKRVBN'LY)G;!
MP9%= K'MD#I7-P^(=:ALKG[-*8!#;W=R$6V7#NESM .1W4G..>] 'J):C=7"
MZCKNM65A<1I<H3'J A-W+&$$41CW9/RD#YL+G:>OKS6AK-W>-X%AFN7$,\Q@
M6>2(,H4,Z@D @$9'KZT =26P.: ,GZ5PFEW-]9^*+U4ED-K<ZT]N\#IE=OD!
M@P/4<KCTY-;O@R>6;0F$K,ZQW,T<3LVXN@D(!S^GX4 = !BBBB@ Q1BBB@!:
M:W2EI&Z4F T'(&#3LU"GW14E&S!#LT9IM%*X#LT9IM%%P'9HS3:*+@.S1FFT
M47 =FC--HHN [-&:;11<!V:,TVBBX#LT9IM%%P'9HS3:*+@.S1FFT47 =FC-
M-HHN [-&:;11<!V:,TVBBX#LT9IM%%P'9HS3:*+@.S1FFT47 =FC--HHN [-
M&:;11<!V:.*;11<!V:,TVBBX#LT9IM%%P'9HS3:*+@.S1FFT47 =FC--HHN
M[-&:;11<!V:,TVBBX#LT9IM%%P'9HS3:*+@.S1FFT47 4@&C\:;3NQHN F,'
M.>>E1W-M'=0/#.BR1N,,C\@BI!1VHN @7"[?X<8ZTRUMH;2W6&WC6.)?NJHP
D!SFGGO1ZT7 ?FC-,I:+@.S1FFT47 =FD8\4E,DZ?A0@;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MP  +" "V D ! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /9J**********RO[3:;Q"VFVX4B"$37+MSC<2$4>YP2
M3Z >M5--\2?VAXDU#2S#Y2Q1A[68])P"5D(_W7XJYHFJ'45NXIE5+JRG-O.J
MGC( (8>Q4@_C6I1111111111111111112&N0O?%ETNFVNI6BVB6=WJ"V<33Y
M^X6*F0D$=P2!Z8H@\83M9:K=-%;3P:3.%FGMV)CFCP"Q0_WDSR.1QUKKHV5X
MU9""K#(([BG4444444444444444445G:YJBZ1IWG[/,EDD2&&/.-\CD*HSZ9
M//MFLVWUC4-2U6]L;'[(HT[9'<3RHQ$DQ7=M50>  1DDGK4MAK%XNHVMAJ\$
M4%Q=0-+'Y;$C<A =??J"#Z9]*W:6BBBBBBBBBBBBBBBBBBBBBBN<FTZ]M?$F
MHW5F0O\ :5JD:3,NY898]P&X#L0WYCWJL?!QLYM&N]-DAM[JP)\YRK/YZ,N'
M7&>,GYOJ*T/#MA+!<:KJ%PC1OJ-UYJQL,%$551<^A(7./>MRBBBBBBBBBBBB
MBBBBBBD/0UQ4'AB_?0;#2%>*%M*OQ.LDT9=9T5RR8P1U!P?0BEO/"UU%9ZYY
M;I)>:X%@\N"+9! NTJ7(R><$DGOP*["VA6WMHH4SMC0(,^@&*EHHHHHHHHHH
MHHHHHHHHK%\4Z;-J.FP-:KON+.ZBNXX\X\PHV2OXC/XXJO%HUY:ZO=ZGI$\*
M1:D$DN+>ZB;Y7"X#K@@@D8!!].U+_9MS<^*-/N)F=X],@D!F90OFR28' ]
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MV_UK>JN^HV43E)+NW1U."K2J"/UIO]J:?_S_ %M_W^7_ !H_M6P_Y_K;_O\
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MHJ"\MEO+66WD:14E4J6C<JP!]".0:\\\!)Y7B"6-9I(43SE%FYNFVX;KN?\
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M>B?]]"CSH_\ GHG_ 'T*/.C_ .>B?]]"CSH_^>B?]]"CSH_^>B?]]"CSH_\
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;111111111111111112448HQ2T44444445__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MC 23/ON!KMX5\O'.?\FA6L*I'EG)/=.Q:HHHIF84444 %%%% !1110 4444
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I>W]X_G1O;^\?SHHH -[?WC^=#,>>:**RE\+*ZC/\#_,4445R$RW/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
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M!FZ*91D_05?AE2>%)8F#HXRK*<@BGT44444444444444445S7A7_ )#/B?\
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M'_F)C_P&7_&J6I2:B?L>[40?]+CQ_HRC'7FKOGZI_P!!,?\ @,O^-+Y^J?\
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M?^@FL>'_ %$7^X/Y5%/>Q6S['68G&<I"S#\P,51OK^*46NR*[.RYC=O]&DX
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M]:[^BBBBBBBBBJ.M_P#("U#_ *]I/_036/#_ *B/_<'\J?11VHI=-_Y&0?\
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MB# W&% X^;VJW;K<KN^U2Q2$]/+0KC\R:GL/^1BMO^O:;_T*.NBHI"P ))
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M0GIGUE_] J&BBB@5>\-_\@9?^NTW_HUZU:HZW_R M0_Z]I/_ $$UCP_ZB/\
MW!_*GT4"BETS_D9!_P!>;?\ H:UT5(>E<W<76H2ZG?)'?R0QPRA$1(D.!L5N
MI!/5C2>9J7_06G_[\Q?_ !-9$'BZ*ZTV^O[7Q!-<06 )G,<$9(QZ#;SGL:S-
M/\:K:^!(-9.I7HM8L0F-;>+<''&!\O3WS716&I7FIZ?;WMMJUP8;B,2)N@B!
MP?4;:?=7>IVL!F&IRN5=/E:&/!!8 CA<]#75"EHHHHHHI,US?A7_ )#/B?\
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MW>8<?[OUK)T37KC3M1UJ>?P]KQ2]O/.BVV>3M\M5YYX.5-:__"9_]2[XA_\
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M44444445A^)FU1+>,Z4LK.4E0B, D,8R(R<]@V*S)[OQ2NX);*5CD.W9&#O
MW@ \]#A#D8ZT7>I>*H%NA%IT4S($$)5/O';DD_-TSD8[<4T7_BJ.>95L4E0&
M5E9X^2-QV@8..%VXSUR11=_\)'+HUJ;<3_:MUPTG(C;&3Y?'/.,87OT)J.?_
M (2<L?GF\DL<%(\,%\_N,]?+].U==9[OL<.XN6V#)<?-GWJ>BJNI-=IIUPVG
MI')=A#Y2RG"ENV361?G53J=@0)5@\EC,MN"RF7*X!/!QC/7BJ$=WXHCN 9;5
M9!(L38V#:C%5WJ.<@#+?-SRH]:CL[SQ9'(BS6OFJ%4N\D8!8_("  V!U<Y_V
M:N^&[C7FO&CU:!EB*EMSJ/D.$P P/.27[<8KIZH:Y]J&B7G]G[OM?E-Y6SKN
MQQBL&XD\0K'$+&.218VC;$B[6ESOWABQ)"C"?G5>>_\ %>]9(;1F4(=L9B"A
MB">6^;()X&,^]+=7GBM+C=':DB/.-D8*RG$N,J6X!/E]#QG-=$'U$ZK&K0VX
ML#!N=MYWB7(X ],9KGF.O?;=C?;OLHNG+2*@YC(.U0H.0 <#.2#^=,=_%O\
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EI5D89# ]0145A86VF6D=K90I#!&/E11P*LT44444444445__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M@D:$.,[2P !(]<4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !33WIU-/>IEL!$_WJ*'^]14$#UIZTQ:>M..R-&+
M1116@@IK+R#WZ4ZB@#Q3XE?""[\1?'OX3>.=,M["&'P[<:E)JTS#;<31S6,D
M$*+@?/AY,X)XY(ZFOG/3OV*_B/''8O+J/A\W'@BSALO"Y2>79JODZLFH*UV
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MX5=T)..O4]ZYSPS\ ]:\'Z';:3I'Q6\3VME;^88U^Q:>S*79G8[C;YY9V/\
MG- '8_&/'_"G/'G1E_X1_43U.,?99<^G45V/[#O_ ":'\),G/_%/6O\ Z!7#
M?%.UELO@;XSMY[N34)X?#-]')>3JJR3L+.0%VV@#)QV KNOV'?\ DT+X1?\
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M?PV-4N;?3[C0=#DM[VUN8!>7J6BO.SC;=0QM(I>2#^(E!V<@'TM\,_@3X?\
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MV+UK_P"@T >YT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[+]AO_DT'X2?]B];?^@T >YT444 %%%% !1110 4444 %%%% !1110 4444
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M-9_ZJ1JO_HJWH ]448H(S2CE0:0G% ''?&;Y?@[X^_[%W4O_ $EDKLOV&_\
MDT'X2?\ 8O6W_H-<=\9?F^#OC[_L7M1'_DK)_A78_L-_\F@_"3_L7K4_^.T
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M<>(-?E>WD*L\+-J]V2C%25)4DC()'% 'T(W]1_.OCKX%_P#(P?&O_LI&K?\
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MR_+\'?'W_8O:B?\ R5D_QKL?V&_^30?A)_V+UK_Z#7&_&8Y^#OC[_L7=2_\
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MT+2FG_LS38$MK5;B=YG6)0 B[V)9@%  R3P!70HH10HZ#@4BJ5SDYR<_2GT
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MU:73;C4M5U75I8Y-1UG6KYKR]NS&-L:R2MSM1<A4&% )XY.0"_X1^$O@_P
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M.=VT;4C16=RW X- '5>-OB59J_BOPKX<U:V?Q]8Z!/JD-GL,WV;*D022X^4
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6C'=P.,456N%7S/NCIZ45?*C+F9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MUV4D8/3GBMK3_#>G:3->26-C:VAO9C/<F"!5,TA0(7<@?,VU5&3V&* /GO\
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M%?$[QQHWBSX0_$Z'2;U+V?3](U&UN44,FR06\OR_,!NY4C(R,@CL<=I\-_\
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M#C^-5]$7E^\:?:_\AK1O^PC:_P#H]*9_$:?:_P#(:T;_ +"-K_Z/2OS;+/\
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M*5]X7)X!4<YH Q?C]\+?&6H?&B?7?#-SKMY<7_@37=.M?WO^A:=>,D(MQ&
M(Y'8R$.QR<8&<<8_P#_9_P!0U29/$"Z9=>#-.TO68[K0].U2"6.X2%;6W$J-
M&7^6.2Y220C@G![-FOL!EY.3@#GD<CWS2\JIXXYQS@"@#YQ^)7PS\3^!?A/\
M3IO#VI:+!%JUK>WUY97=K,\*AK:7SGB(DW>=*Q+%F)48'RU[=\-^/A[X8ZX_
MLNUQNZ_ZE.M9/QL;;\&?'[ X_P")!?XZ@G%M)6U\-UV_#WPP/^H9;?\ HI:
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M9_*N!TWXK>&8%L[ ZE=33-MA6:ZLIH]S951N8Q@ DD5WBMQFJ4D]A;;GS/\
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MAD#D+I=L/RA2LGXT1[?@SX_.XG_B07XY[8MWK7^')'_"N_"_<?V5:_\ HE:
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MM_%D=4-C.TNSU>":9M3U>/5%?YHPMDMN4;/7Y6.?RK7^$/\ Q[^*O^P]<_\
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MZ^K/_P!*HJ]@KQ_QU_R+,O\ U]6?_I5%7L%>O@_A,*OQ'S-_S,GB[_L.W/\
M):F7M4/_ #,GB[_L.W/\EJ9>U?J6!_W>/H>=+<5?]9^']17KGP1_Y)'X2_[!
ML/\ Z#7D:_ZS\/ZBO7/@C_R2/PE_V#8?_0:\7.OA@:T]CE/BU(6\=:  .NFW
M@SU_Y:VW;\OKQUX!YU=OU!Y//M[^V>3UY)R,FNA^+O\ R/F@9^[_ &9>YS_U
MUM_7_P#5Z\9KGQ\O16)SCOG/^.1]<]<8)73+[>P1,MQS??'#9R?7.?\ 'GZ\
M9[$CK?@;_P ?'C#T_M.+M_TZ05R#8['/!^[TQQ^G3MCD>H!Z[X(_\?7C$9S_
M ,32/OG_ )=8?\^OKSFL\R_@CAN6OCPP'@FW'?\ M2P/7&/])CYSV^O;U%><
M+G.!U' 7'&.!C'<=,#&.@ Q@5Z/\>%SX'MB!EO[5T_\ ]*8_\^OIS7G'"]"O
M<]L=_P .F?U[9KY<W!L,QS@YY.3GCDMR<YSSR?<G(+$W/!@V_%+PH,<[;XG\
M(U_Q_2J>?FSSG/.,YSU_/@^^0/0LMOP;C_A:7A(9&=E\..G^J3I[<?E1T#J>
MX^(O^0'??]<)/_037YBZ#_R![/\ ZXI_Z"*_3OQ%_P @.^_ZXR?^@FOS$T'_
M ) ]G_UQ3_T$5^6\:_PZ?J_R/V7PY_C5?1%^G6O_ "&M&_["-K_Z/2FTZU_Y
M#6C?]A&U_P#1Z5^999_O</\ $OS1^RYO_N57_"_R/TVM_P#4Q?2ID^[4-O\
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M2M_%]*_GR/Q']5R_AH^L_P!B7_D1/$'_ &&I/_1$%?1_^-?.'[$G_(B^(?\
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M#\T\YWJBJB9!)9W11T7+?,0#FI_&OCS2?AWH-QJ^M7"VMNGR(G+/-(02L<:
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MH *3FEI.:B6P#%IZTQ:>M*.R&Q:***T$%%%% !1110 4444 %%%% !1110!
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M+$G ^4 D[5 4< 5U+1DMD-C\*55*C&<^E "1QB-0HZ#I3Z** "BBB@ HHHH
M*3FEI.:B6P#%IZTQ:>M*.R&Q:***T$%%%% !1110 4444 %%%% !1110 444
M4 %%%% "$9IJ*57''X# I]% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%"^LHM2M;FUN42:UFC:*6&50RNK#!!'<$$C!J/3]-@TVQMK.TMX[:VMHUB@A
MB0*D:*NU5 '10. !V%:=% $:J%7 Z#H!VJ2BB@ HHHH **** "BBB@ HHHH
-**** "DYI:*B6P'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #^ D # 2(  A$! Q$!_\0
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M!6/IGA.ZMM?@NY7@6"WDDD18W<YWC& IX7KVKL,48HNP<$ XHHQ2TB@HHHH
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M!IJV/V[4GAB96M]\_-LR]#&<<4 +:>,$N/)1[*43LLSR1Q2++L6/J05^]DD
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MU@Z=QX^US_KVMO\ V:NDKF]._P"1^US_ *]K;_V>@"YXAU"&RTF83$YE4QJ
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M:E_M6#<5*S9%Q]F_U3??QGT^[[]*N@48H HQZO!*\:JL^9)GA7,+#YESG/'
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M6UNDNX%EA.4;H2"*NZO8FSM<L44@.:6F(**** "BBB@ HHHH **** "BBB@
MHHINZ@#G=>_Y&[PS_P!=+C_T771FN<U[_D;O#/\ UTN/_1=='0!0U:P^WZ;)
M"IVR<-&W]UQRI_.HK26/6=+1YXU.]=LL;?PN.&'YUID5BQ#^S=>>$\07V9$]
MI1]X?B.?PHT:U(;<7=%+5I;K0[%ML\C6W17!_>1GL.>H_6IM)UPS6$9CBNKJ
M0_>;:,9^O3%:6IV3W^GR6ZE"7'61<C_]=.TNS:QL8X&\O*<9C& :Y^22GIL=
M?/!T]5J0&;5)A\EM! /61]Q_(5B^(M)OKJ.!I+Q&8R!0@7:H)[UUNWBJEYI5
MO?[!<*S!3D ,1S^%.=+FC:Y-.KR2N5]'O,Q"TFRMS"H5U8]?]H'N#6HIXZU0
MO--66)&A8Q3Q?ZN0<D>Q]126.H&9VM[E1%=1CYD[,/[R^HJXMQT9$ES:HT:*
M8&IV3BM"!2>*0&F[B1]:R[&\O)=3N(9FA\J''W0<G/2IE))I/J4HMIM=#7%+
M3 <'VI=U,D=13=PZ4H-,!*P?$O2U_P!YOY5OU@>)NEK_ +S?RKGQ7\)FV'_B
M(E\,_P#'I-_UU_H*VJQ?#/\ QZ3?]=?Z"MK-/#?PD%?^(Q:*3-+6YB%%%% !
M2-TI:1NE)@ H[4"CM0@.6^(,UE#X5D?44F, FCP\+[&C;/#Y/I5+X8/"^@W'
MEPS)*)QYKS2^8S_(NWG P0N!CMBM;QK!>7'AN6.PGC@<R)YDCLJA8\_,<MQ^
M=4O ,6H0Z-<'4YFE+W!9)&F20D;1DY7C&<X[XQFF!Q\,FBCXC!8H[V25M0^<
MF1-L3;CM &-Q!;)(ZX'I7KB\5YO$VJ?\)X&$4WF-?99!;Q_9OL^T@2"3&3)V
M]>U>CKTS0!PGQG_Y)]<?]=H_YUYY\#/^1TN/^O5OYBO0_C/_ ,D^N/\ KM'_
M #KSSX&?\CI<?]>K?S%)E'OYZ5S7C":[%G]C&FP76GW2,EQ-+<^2L/IDX.,^
MOK7351UI[:+2;A[VV>YMU7+PI'YA<9Z!>],DCT&P32]$M+-(%@2&, 1K(9 G
ML&/45I "O/?">MZMJ&L0C4KK5D9V?-K)IHCA4<[?GZ],&O0EZ"@!-M<[IO\
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MT813]W'?KSFMP5YSK/A_5V\60F&Y>7> T<CO@X7&[(&/_KUUP_MV(#FQN/\
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M^/M;P<_Z+;?^ST =+1110 4444 %%%% !124M !1110 4444 %%%% !1110
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MCZ5V(TSQ- !]FU^WN!V%U9#^:D4 =)D49Q7,3WOBVSAD>33]*N@B$YAN'C/
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MJ[M[:^O(X)K@_NU;//.,GT&<#)H H:]_R-WAG_KI<?\ HNNCKF]=Y\6^&?\
MKI<?^BZZ.@!:**:QQ0 M%5H-0M;E6:&XB<*Q4D..".HJ7SX?^>L?_?0H"Y)2
M8%,^T0_\]8_^^A1]HA_YZQ_]]"@+D@XHS47VF'_GK'_WT*/M,/\ SUC_ .^A
M0!+FC-1_:(?^>L?_ 'T*/M$/_/6/_OH4!<CO8I)[*>*&4PRNA5)!U0D<&N:L
M/#&MVTVD--XCGF6RW>>I3_CX!/ ]L"NI\^'_ )ZQ_P#?0J*:]MK:)I9KB)(U
M&68L.*!7+"C!I:9'(LB*Z,&5AD$'.14E Q,44M% "5@^)>EM_O-_*MZL'Q+]
MVV_WF_E7/BOX3-L/_%1FG2I]:\*WME:3+#,\RLC."5)!5L-CG!Q5OP=X5F\,
M6MS'/>?:6N'60D9P&Q\QY/4G/Z5:\-?\>DW_ %T_H*VP,4\-_#08C^(S"O/!
M/A^_NY;JZTFVEN)6W/(P.6/K6U!#';01PPJ$CC4*JCL!T%245N8A1110 4C=
M*6D;I28 *6D%+0@"BBBF 4E+10!#/;0W*[)XDE3.=KJ",_C44&G6EM)YEO:P
MQ/C&Y$ .*M8HI6 *,44M,!,44M-- !NKG=-Y\?ZY_P!>UM_[/6!:ZWJ+?$66
MV-[,Y-W+";$_<6!8@R/CL2W\5;^@VVI/XAU/4]1LDLUN(XHXT682$[-V22.G
M6@#HBH/49^M 0#@<#VIU% #2*Q]8\):+KUPD^J:?'<2HNQ7)(.WTX-;5% $%
MI:065K%;6L2Q01*%1%& H'85-BEHH 3;1@4M% #2H(QC(-8>F^"M TC4CJ&G
MZ;%!='=^\7.1GK6]10 T# I<4M% " 8-&*6B@!CQK(NUU5AZ,,T)&J#"*%'H
M!@4^B@ HHHH **** "BBB@ HHHH ***:6P* '44T-Q2YH :RYSVK@/$7@?5]
M2FC6._-R9AY<]S(^QECWAPNP## 8..AS7H&11Q0!R&HZ<MKXYT&X%S=2&9Y@
M8Y)2T:8C_A7H*["N<UW_ )&WPU_UTN/_ $771YH 6F2*&&",@]:=FD/:@#)M
MO#&DVJ,L=C%AF+'<,\FIQH6F?\^,'_?-7Z,T7%9&>="TS'_'C!_WS51K70DO
MQ926ULD[('"LH 8$XX]3[5M$UC:GX>34KYKEY &V1JOR9*[9 ^0??&*:$UV*
M4=QX>D5W%AB))/+\UK<A"V[;@'OS4NH?V#ILXAEL5>7;YA2* N57^\<=!0?"
M<:Z7+;PRJES)-YS3[,Y(?> 13;[PY>7N^1K^-+B:+R)F6,@%025(YR&&3WIZ
M$V?8DO4T/3Q;F2P5S< F-8X2Q( R>/I5JST[1K^TBNK:T@>&5=R-LZBH-0\-
MQ:E%8Q3RR.EK&R$DX9\KMSD=#WJ32;'4;&58)YHY;.*%8X]BA3N'4D>XI!:S
MV+7]A:9_SXP?]\5%<^&M)NH'ADL8MK#!VK@_G6H",4M(NR(K>WCM84AA4+&B
MA54=@*EHS1F@8M%(#FEH ;6%XE_Y=O\ >/\ *MTUSGB"&Y$BS.^^V'0!?N'W
M]JY\3=TVD;8>WM%<L^&C_HTW_73^@K;KG_#L-RNZ4OMMF.0A7ECZ_3BN@%/#
M7]FKA7=ZC:%HHHK<Q"BBB@ I&Z4M(W2DP 4M(*6A %%%%, HHHH **** "BB
MB@ I,<TM% $7D1^<91&GF$;2^T;B/3-2 4M% "49]JI:U;3WNBWMM:2B*XFA
M=(Y,D;6(P#D5AVO@/35MHEN)+]I@@#L+Z7!;')^]ZT =52&N<_X0/2/[U_\
M^!TO_P 55+4O -JZVXL)[V-A.C2[KV7YH@?F7KW% '84M<U_P@>D?WK_ /\
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ME0RQZ1:-?,Y$D!NL(B]B&QR?:M[%!Q0!D376LKJ-K'#IUN]FZJ;B5KC#1GN
MN/FQ2076M-?7:3:=;):HI^SRBXRTI[ C'RYK7 %!% &%'>^(CI,LLFD6:Z@)
M,1P"ZRA7U+8X^E/N+S7DBLC;Z7:R22?\?2M<[1$?13CYJVJ,4 98NM7.N&$Z
M?;C3,<7/G_/G']S'KQUJ"VO/$#VUZ]QI5K'-'_QZHMUN$O\ O''RUMXH_&@#
M#EO?$0TF&6/2;1K]G(E@-WA%7L0V.?I4TMUK2ZE:QQ:=;O9N%\^9KC#1D]0%
MQSBM>DQ0!%;M,Z$SQK&VX@!6R-N>#4U(*=0 E-**ZE64$'J"*?10 U5"X
M'3BG444 %%%% !1110 4C=*6D;I28 *6D%+0@"BBBF 4444 %%%% !1110 4
M444 %-R#2YKAO$?B.[349;2U==K Q0F&<;9R1\R;O^6<PZJ#P: +?BCQJ-#G
MM8K1+:X$K,'D>7" KC<FX9P^,G!]*Z>SG6ZMHKA P65 ZAUP0",\CL:Y/P?X
M7B@MHKNZA4.R!=OE[1.HP4DEC(XE'()%=F!B@!:Y7Q];74NE6TMI<7*>5=0E
MH8!_K09%'S8YP!DXKJJ3'- !0>16=?Z]I6ES"'4-1M;61EW!990I(]>:GM=0
MMK[=]DN8IMH5CY;!L!AD?F.: .*UF6.7XDZ?#!+?PRQLCRSDR&(J,@0HH&WY
MLY8GIBN_%(.*:[B-69C@*,DGL* '-VK@_#CD?$'4/LAOVM9('\X7 D'ERA^^
M[@Y!^7;V'-=BVH6?V2*Z-S$+>4J(Y"X"N3TP?>K0!H <.E5M0GGM]/N);2#[
M1<)&3%%G&]L<#-60>*@BNH+EY4AE21HFV2!3G8V,X/H>: .0^'+:J4UA-9AN
MUN/MN\O/C!)09"XXP#Z>HKMZ;CIZ4Z@#G/'D33>%IXENI;17>,/-%$TC*NX9
MX7G'KBG>!WE?PG:>=;-;L"X56+?,NXX;YB6 (YP?6N@(S1B@!:*** "BBB@
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MAW#/<X(S76JH4  8 Z 4U((XF=HXT0NVYBHQN/J?4T 24M%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M^3O_  *U[C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K'&@V:ZY)JXAW:@\(MO.<DE(L@E%
M_N@D G'4@9S@8V** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***\"T7]H"YUS]JV_P#A>EDEMI%EHDUVMQ<03)<7=Y'+#N\LD!/)5)<;
MN=SANF!D ]]HKP[X=_';Q1X@^,$GP_\ &'P[D\$W[Z--K=I<KK4.H)<0QW$<
M+ B-1L.90>?2O<: "BBB@ HHHH *S-:U2WT/2;S4KQS%:6<+W$S@$[412S'
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MK:KYP_;D^'/A7Q-^SK\0?$&M^&M(U;7-'\.WLFFZE?64<T]DPC+!HG924.X
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MP@#Z1>Q7#Z2VK1:ENC,$B)(D;K@-O!#2*,E<$Y_'T"@ HHHH **** "BBB@
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M/^R=7_\ Z<K6OB'_ (+D?\??P?\ ]S5/YVM 'Y:#M]:_3W_@FO\ \F:_&/\
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M+^?8S"X&9IHMB;IH_E;>.!QGZ$(S0%V]Q:*** "BBB@ HHHH \9_;._Y-/\
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MUBY+QAAA@K>9E<@#..N*_?3^<3^E73;5]/L;:WFN9;V2&-8VN9\>9*0 "[8
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M?^B6KU7P]_R M-_Z]HO_ $ 4 :-%%% !1110 4444 )2T4E "T444 )2T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@>I?\
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MD7)ZG NL5\[DG#4LIQ#KNHI:-6MW/J^(N+*>=X94%3<7=.][[(\6_P""Q_\
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MC]XN6.-0BC^S-+X &!_R[5[18V=OI=G;VMK!';VD,:Q10Q*%2-%&%50.
M *T* /C#]J']COXK_%KX.ZQX<TGXUZWKEU,T<@TK6K>TM;2\56!,<DEO"KCU
M&<KE1D=Q\X^-O^"8_P <]8_9Q\"^$XOB)!J]]I-Y-/-X6O+LIIMDLA^4P2B/
M<[+SD-P-[;,<[OU=KG?&'C#2/A_X;U#Q#XBU&#2=&T^/S;F\N&PJ+G ]R22
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M2:WJTBG5(M19D\V.<!0LR,0'C=0IC"^7@J$(]?M[6*SA2""-(8HU"I'&H55
MZ  =!0!%I^GVVFPF&UMHK:$NTACAC"+N9BS-@=RQ))[DDUHT44 %%%% !7,^
M*O OAWQQ_9W_  D.B:?K1TVZCOK(WULDIMIT8,DL98?*P('(]*Z:B@ HHHH
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M47]_]#1]JB_O_H: )J*A^U1?W_T-'VJ+^_\ H: )J*A^U1?W_P!#1]JB_O\
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MB_O_ *&C[5%_?_0T 345#]JB_O\ Z&C[5%_?_0T 345#]JB_O_H:/M47]_\
M0T 345#]JB_O_H:/M47]_P#0T 345#]JB_O_ *&C[5%_?_0T 345#]JB_O\
MZ&C[5%_?_0T 345#]JB_O_H:/M47]_\ 0T 345#]JB_O_H:/M47]_P#0T 34
M5#]JB_O_ *&C[5%_?_0T 345#]JB_O\ Z&C[5%_?_0T 345#]JB_O_H:/M47
9]_\ 0T 345#]JB_O_H:/M47]_P#0T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_014.jpg
<TEXT>
begin 644 form10-k_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^LG5O$5A
MHL\,-V9C),"46*)G) Z]*UJY3Q!I=WJ'BK26@DNK>)(I0]Q!P4ST&?>JBDWJ
M9U')1]W<M2^--)A$&\7>Z9"Z(+5RV <$D8R*OQ:]ILVC2:K'<AK.-2SO@Y7'
M4$=<^U<]>I=:/XJL+LVVH:A#%9-$TL<>]RQ;(ST%9;:3K%Q92V\=@8?[6U$W
M,D4GW(HE .UR.FXCM5\L3#VLTVOT.]T[4+;5;"&]M'WP2C*L1CVZ59R!W%<=
MHECKUF-1TQ6ALV\\7$,RQ&2':WWD7)[&FOHM]=>(]4GF\UYH[*+[+*"4C,^U
MAN SC(./I4\JON:*I*RTU.S!!S@@XZT;E/1A^=>;:7IFJ16]R\37%I<"PD29
MY8S&C2XX)8GYCG/(JK%;-/<K;:?97-O))HTN4:7/FR97YA@GKSSWJN3S(]N[
M+W3TG4=1MM+LWN[IRL2D E1D\G X'N:M!U) R,D9 [UYKJ4.I:J&>+3K](UT
MZ&';+&1F195+<?2I-1L]1GULS1Z?<QS)J,1WJKL6B!&3OS@+C^$"CD7</;N^
MQWUK?VU[Y_V>99/(E:*3'\+#J*L;EV[LC;ZYXKS>71[RWL]7MK2PN(B=3\V3
M:A(EML\!>?F]2*>NF7L=C TEO>S:5]O,DMHL11O+VX&U,YV[N<4N1=QJM+JC
MN[+4;:_>Y6W8L;:8P294C##&?KUJUD$D C(ZBN7\(6<UK9:L!:S6JRWDCP),
M,,%*C::R-)L[BWCCW:1J#ZO''-]JN#*421B#CG^+/&,=*7*KLI57976YWX93
MG# XZ\]* 0<X(XZUY:FG:F8+HVUE=Q"73&1D6)U_>Y!QDDEF]^]7[W1-0MFO
MH],M[E(YM/B,@5C^\<-\X!/\1&:?(NY*KO?E.RN-=LK:YEMV,KRQ(DC+'&6^
M5FV@C'7FI]0U*VTNV^T73E8]RK\HR<L<#@>]>>76F3.^HR:5I5];020VPC5D
M96)$H+8&<CC.:EU73+F6:^2;3;V?46U!9([E03'Y&X8 .<8 [4^1$^VG9Z'I
M&Y<XR,XSBJ]GJ%K?PR2VTRR)'(T;,.S*<$5P4EG?S>(()AI]Q$XU,&9@CMF'
MH27)P5/H!BJRZ-?6UA);Q:?<1Q1ZG(]RHC+"6$Y\O !^8#C@4<B[C=>5]CTX
MLH&2P ]<U'<W,-G;27,[A(HE+.Q[ 5YY-I%X-)L_,2^>))9FBC>W+HJD#"M&
M#N'?!SQ6[<65S>?#IK:XL76Z^S<6^XNP8=.>I-)Q2ZEJJW?3H=%8W\&H645W
M"6$4O*;U*D_@:L9 [BO/;W2G@*I<Z;>3P'3T2S2W#$0S8^;.#\IS@Y-:&BZ+
M>2>(S<:LDSO!:0;&+'890#N/H2*'%;W%&K)NUCL)ID@B:20X506/T'-0V5]!
MJ%C#>6[DPRJ&0L,'!]JY3Q)9R2Z[+)=V-W>6SV12U%N"1'+DYS@\'IR:HZ+X
M?NI[M/MEO<*L6E1+$K$JHFRWZC(HY5:]P=67-9(]!R/7K0&!Z$&O-E35Y;'2
MH([>\M9K*SN8Y9YP40.4P#N)Z>]6/#:QIXITQ;>TGME_LYC*'DW"1\C+\$]?
M7O1R:;B5>[2L=W>7D-A9S75PVV*)"[$#)P!D\4Z"XCN((IHV^25 Z9X)!&:X
M7Q-I\\^I:S]HT^\NVFME73WA!*QG:=PX/!S^=4;G2=5>[Q+%="0Q6XLY(H2W
ME849&<@(0<YSUH4%;<)5I*35CTS(QG(J.>XCMX)9I&^2)2[XY( &:XO^RM5'
MB=K%5E_L_P [[>)R3M\S9@)]-W.*S-,TG5 6\R*[6[6WG6Z)A(64D' +$X8D
M],"CD7<;K2VY3T2TO(+ZS@NX6S%.H>,L,$@].*G+ =2!VKS9M,NDM(EO]-OK
MC.F1162P@_N)@#NS@_*<X.34-S;RR7^HV]_:WE[?+8P+&8"3Y<VWKP>#GO3Y
M%W)]NTM4>GE@.I'I1D'."..M><7^AZE/!K$UQ!<RWJ6]K]G=&;[X WE<=_6G
MZGHNHVT^HP:;!<+8M]G>1%W-Y@'W\<\GU ZTN1=QNM+^4]$# @$$8/0U7N-0
MM;22V2>94:YD\N(?WVQG _*N$MM%NYA91-%=FQ?4=YB:-H@D>WGC.0I/8U')
MH<T2VC2Z;<2P6FM2;4 +,MN1Q@9^[G%'(NX.M*VD3TBBD'08&!2UF=(4444
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M1Y\/_/5/^^A5/[/!_P \8_\ OD4?9X/^>,?_ 'R* +GGP_\ /5/^^A1Y\/\
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M 5)(C#)&F\@$XADZE3_=/J*M03><K97:Z':X[ ^U5566>8\XDZ,PZ1#^ZO\
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MZ_XT[-S_ ,^;_P#?:T[^V]*_Z"=E_P!_U_QH_MO2O^@G9?\ ?]?\: &YN?\
MGS?_ +[6C-S_ ,^;_P#?:T[^V]*_Z"=E_P!_U_QH_MO2O^@G9?\ ?]?\: &Y
MN?\ GS?_ +[6C-S_ ,^;_P#?:T[^V]*_Z"=E_P!_U_QH_MO2O^@G9?\ ?]?\
M: &YN?\ GS?_ +[6C-S_ ,^;_P#?:T[^V]*_Z"=E_P!_U_QH_MO2O^@G9?\
M?]?\: &YN?\ GS?_ +[6C-S_ ,^;_P#?:T[^V]*_Z"=E_P!_U_QH_MO2O^@G
M9?\ ?]?\: &YN?\ GS?_ +[6HWM[F8&22'Y4Y2'</G/N>E3?VWI7_03LO^_Z
M_P"-']MZ5_T$[+_O^O\ C0!7ABND)DDM6:9NK;UP/8>U39N?^?-_^^UIW]MZ
M5_T$[+_O^O\ C5FWNK>[C,EM/%,@.-T;AAGZB@"IFY_Y\W_[[6C-S_SYO_WV
MM:%% &?FY_Y\W_[[6C-S_P ^;_\ ?:UH44 9^;G_ )\W_P"^UHS<_P#/F_\
MWVM:%% &>3=8XLVS[R+44EM=Q)OC02W$G#."!L'MFM6B@#,BCFA38EF^.I)D
M7)/J:?FY_P"?-_\ OM:T** ,_-S_ ,^;_P#?:T9N?^?-_P#OM:T** ,_-S_S
MYO\ ]]K1FY_Y\W_[[6M"B@#/S<_\^;_]]K1FY_Y\W_[[6M"B@#.87<@V)!Y1
M/\;,#M_ 5#):3JP@2!F@ZNP< R'WK7HH S@;@  6; #H ZTN;G_GS?\ [[6M
M"B@#/S<_\^;_ /?:T9N?^?-_^^UK0HH S\W/_/F__?:T9N?^?-_^^UK0HH S
M\W/_ #YO_P!]K1FY_P"?-_\ OM:T** ,TP7%R=DD9BB_B&X$O[<=!42PW1FW
MR69VH<1('7"CU^M:]% &?FY_Y\W_ .^U_P :,W/_ #YO_P!]K6A10!GYN?\
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MYD!"32J&&"%<C(]*&FE955I9&51A06) 'H/:@#IO^$;@C,D,.IW'FDRQLHC
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M]Q;#98CJ>P KL:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!;3_ +^-1_POG5/^@+:?]_&H ]F_L/2?^@79?]^%_P */[#TG_H%V7_?A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6KAXX1'M=@.BLP/(%">$9%D2W-_G3([O[8L'E?/OSNQNSTSSTK;\V]_O6_\
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MPR%6RI_.I/-O?[UO_P!\M_C2YV/V4-[&%_PB%Q!$8[+4A#YUHEI<EH=V]5&
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MR$),?E_,&$OE!#Z,6!Q[ FJ8^)]@U]&XC<:>;1Y&!0^=YXE6,1A>Y)85L2^
M?#TIU9C:,'U29)[AQ(<B1#E67^Z0<GCO3&^'N@20B.6&>0^2T/F/,=W+A]V?
M[VX @]L4 5V^(NG Q0)IVI27S22Q/9I!F6-HU5F##./NL"#WJ$?%'1)98UM+
M74;J.1XHEDAM\J9)%W(G7J>GM1<_#:REOK":"_O85A:XDN)5G;[1</*JKDR?
M1<?2M*T\!Z!8[!;6TD:QW$%RJK*<!XEVH?I@\CO0!F_\+3\/;;0_Z5^^4-*/
M*YMP7*?./]X$<9Z9J&_^*-C!8WTMIIU[++#!<2P>9'LCG,+;9 &]O6M%?ASX
M>CE@DCBG1HB=VV8_O07+[7]1N)J=O >@O D+P2M&B7,84RMTG.9/S[>E #-=
M\62:5X'CUM;95O+A(EM[:=MH,TF JD_4\^PK/M?B58/H&G7LUK<S7-Q;27$\
M%HGF>2(N)2>>@;@>N:W+CPEI-[9Z7:7L<EW!IIW0I<2%PQ"E07!^]@'C-<UK
MGPNM+J+R]%DBL%D,WF*V\A1* &";6&!QG;TS0!;/Q0T3RII5M[XQQ.D(D\G"
MO*X!6,'/WB#GV H/Q3\.C[+@W+&90T@$7-N"^SYQ_O>F>.>E78O &B1Z*^F,
MDS+)-'<F7S"'$R*%#K_=.!].M(?A[H1EM90EPLD"!&<3',RAMV)/[WS<T 49
M/BCI*%]FGZI*@$S+(EOE7$)Q(0<]%ZU87XE:!)J?V*)YW!4XF6/Y"_E^9L]<
M[?PSQ5Q? VAK"(A#,$5+E /.;I<',G\N/2HH?A_H-O>&XABG3,>QHA*=A/E^
M7O(_O;>,T 8US\5+4PVK6&D7\LD\MMM2:/RRT,S;5=?7D$8]:WO$7C;2O#$S
M1ZEYZ'[/]H7:F=X#!2!ZD9!QZ5%-\/M!F@BB,=RGDP001.D[!D6%BT9!]03U
MK1UCPQI6NW-A<:A 99+%F>$[B.67:<^HQ0!RFL_%""S6]FTVU:]CMK>60*5*
M^:4=5)#=-HW5<TWX@K-X@GTS4-.N;<&^6S@E$>5#M$KA7/9N2./2KB?#GPY'
MIL>GK;2BWCLY+)5\YL^6[!FY]<@<U9A\%:1"\<F+F21+Q+[S))V9FF1 @8GO
MP.E $OB:\6SMX9)$:2*+?<.B]7$:EL?C69%\0+.2V@D>VFB::X,!R,[  IWG
M_9RP%;NM02-;1W,4?F26S^9LQG>O1A^56;)K*XM$EM$B\EQQM4#Z@BHA#EE*
M3ZV_!;?J8J7[QQOJ</8:J/#'VB7R-1N!<W7E3"?;_KP"69<=1C'-7+WQ,NH7
MDMNEC/#+8R+*D[_=;#*"!Z_>IG@(P746HP37,5\R3EB2 V.3U]#^O%;>IB+4
M=0M]+MT4A'$MRRCA%!R%^I('Y5V4XJ4[26G7T,,0W[%I/5Z+UZ?Y_(WAR,T4
M45S':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >9?$3_D.P?]>X_F:Q)M
M%N4\QED22.,#YMW7C)Q]*ZKQOH>I:GJ\4MG:/-&(0I92.N3ZFL;^Q_%)0H;&
M0J1@YV^F/7TKV:,TJ<;-'Q>,H2EB:C<)--Z63,T:+<_O%>2-95565"WW@QP#
M_6DM=.OBL4\#HNX_)E^3QGI],FM/^Q_%6[<;*4MC&3MZ9R._K0VC^*6:-OL,
MB^6<H%V@#C'KZ5I[3^\CF^KV=U3E]S,2Y2YM&>VD?@D.=K9!XX.?H:K;F&/F
M/'3FMR?PUXAN)3))ITA8\<%0/YU'_P (GKW_ $#9?S7_ !JU4A;5HPEAJS>D
M)6]&8^YLYW'/UHR<YR<_6MC_ (1/7O\ H&R_FO\ C1_PB>O?] V7\U_QI^TA
MW1'U6O\ R/[F8^X\\GGKSUHW'&,G'IFMC_A$]>_Z!LOYK_C1_P (GKW_ $#9
M?S7_ !H]I#N@^JU_Y']S,?)'0G\ZTM$T2ZUR^$$ VH.9)2.$'^/M5ZS\&:U<
MW<<4UJUO&3\TKD84?@:].TO2[72+%+6U3:HZL>K'U-<]?$Q@K1U9Z6 RNI6G
M>JFHK[V&EZ7:Z19):VJ;5'+,>K'U-7:**\=MMW9]G&,8148JR04444B@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RI]$7SVN+&
MYELIG.7\O!1CZE3QFM6BKC.4=C.I2A45I+^O4YZW\-W$+L1J/DJRA'^S0B-F
M SC)_$UL65A;:?!Y5M'M!.6)Y+'U)[FK-%5*K.2L]ON(AAZ<'S):]VV_S"BB
MBLC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' /$# 2(  A$! Q$!_\0
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M%W<K<W>J7AF\P#&V, !4_#FN?^(EAJ=IXF\,^)](ADGFM9S:7$4:Y+12=3]
M1^M>C4<4 >7!OB%X=CNM#33D\00SLYMM1EGVE QZ2 ^F>U3>(;9],U'X=Z,M
MP3<0W:AF#8+*D1#<>AZ5Z43@$UX_X TG7O$WC^^\:>(D>."V,EMI\$BE=O.-
MP4]!@'GN30!U_P 3HM1O/![Z;IMO+,]_<1VLIB7)2)VPS'V KJ[*UBL;&WM(
M5VQ01K&@] !@5/10!YYXH\!@>&?%LEC<7%Q>ZHZ7FR4Y :([E1?;C%:_ASX@
M>']=T"&_.I6UO)L'GPS2A'B<#D$&NLKE-3^&W@_5[\WM[H=L]PS;G9<KO/N
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B6^_\#Y__ (NMB*)884B3.U %&YB3@>YY-%% #Z*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !D IX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0E-T7.G&,HU*/+RU6UR)O1Z,N4445]P>*%%%% !1110 4444 %%%% !1110
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MXXU2SUW0_%OAV"6$2ZYX=N9I;Z&ZN](CU.72;R.33]8AL;]HK9^^_P""$'[
M/[3G["^C_M16G[1OAOPAH*_$[Q/X.U7P;'X6\;:'XT-W;:)#XC74;F_31?*L
MK2ZC%["I94FN)'4^0\S1LI.,:F63CQGE>,R/*.'YY9F/#\^%J,<LC@,TQ^7S
M=*%::G2K0A5H2IWK>U@IJJIPM>S.?AI9A;AC,,+F^8YI3QN#S_"YQ?$1G3P&
M/6%KXBBZE.-*U.2G!4VI1@E\2N]^,_X(G?MF?M2_M/\ [3/_  4*\#_'GXQZ
MO\4O"/P=\4>'[/X9:#J'AOP-HL'@RQO?B/\ &WP])#8W'ASPQI^M:DTND^&=
M'LYYM7UK4G$-O;S$(UR))/Z5H#GR\*%! ;;S@#8!C'8@@@9YX'J17\CO_!N4
M&3]LC_@JDK;R?^$K\(_,6DD#.WQ6^.N]MTD<9/S9W$YP20Q&#C^N6,8<8[<?
MAN;_  KXKQ&R[!Y9Q9B,#@:%/"8:EE^4N-*CSJ7M*V6X7'5*CJ.<I-SG6E"4
M>7E<=;IMH^P\.\9B<;PUA\9BZ]3%5Z^+S:4JU7D<XQAC70IT5*%.#E3I*+4'
M+6TFFBU1117Q1]R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '$>/6SX)\:[<Y/A7Q&!V 8Z-?8R>>Y!X![\5_'A_P;^>
M ?B_\3/^">/_  4.^'_P'\<Z?\+?C%XM\<Z)H_P[^(%Y>ZK8V/@[Q3J'PET&
M"RUV:\TG2M7U.W6VG1I-]KI=[*!M(@8;D']B/C.&6X\&^+X(UWR3>%]<CB4=
M9)7T:[4(, _>8@#KV'O7\GO_  :\?$GP'X6^#'[7/A'Q+XN\.>'?%4?Q:\!:
MT= \0:WINBZE_9C^ K31FND@O[F$SPPZWI.K:5=2VGVB&VN[)H)9%FD$0_3N
M$ZLZ' 7'-2A0I8K%T,\X+Q-##5:"Q7MHT<PQ\^=T795*/,HJK3:Y9QDXN45*
MY^:\3>RGQKPC#&5'A\%B,HSY5<4I^R='FC@:CI*KKR5)2UB[7CLD]#,_X)D_
M%']O'X?_ /!87Q7^QC^U1^U9XN^.*?#7X>>-/^$GTV#Q'J&K_#S4M=;P%X,\
M5Z/J&FMK?ASP[J]W)IMOXEMAYMWHVE?9]22_CACO+6."[N_EK]KSP+^TO\1O
M^#AWXR^#/V0?B/X=^$GQ^UC3/#DGA#Q[XIO+JUT32+*P_9:\&W'B6UN);/PY
MXKO(I-7TV)(K14T.^B^UQJD[V]O(TB?5'[)GBOP_XX_X.:OVFO$7A?5;'6M$
MO/#OC[3[75-,NH;ZQNKC0?@Y\']$U22SNK=Y+>YM;;5['4K!;B*1D9[3.%,C
M+&:3)G_@ZQ\4Q _*VB*'!W@AD_9&\',I7;(J]7(;>DF0  1GC](CBY8'B+,L
MVHY7EF'Q.)\&<+F>+P2R^E1RYXNOA8JM*>6\T:3IS:5Z#GJWS.39^?XF"QN1
MY;@OK>,K8>GXH/"8?$2Q<YXEX95H.*CBK.;Y;^[)+16LMK_(UCX:_:!_93_X
M*_?LFZC_ ,%:'D_:8\8>+-1\$:?\(?'?A+XDR:CX-\(ZWK7B*;P]X3\>VNCW
M_@CP=_PD>E^"/&LD=S>^&=9MO"AT&ZOY_%6D2^*[^.#P_-^OW_!S'\1)_#/_
M  3LT[P%%F75/BS\>?AUX32-%=A):^';7Q+X]<G[.K2A'U+PCI]O*1 Z"6XB
MC8%'WCX__P""\15?^"F__!,'#;0;_P"':K$H"JOF_M(^$5E<$@DG8CHBR!TC
M\R0@$L<Z_P#P<O:AX@\?_&'_ ()V?LU>"S;7/BSQ?XU^(WC31;*[>TCTW_A)
M[S6OASX$\!W6J/J$=QIL5G::GK/B%KB:\M;[>ES,@MXUC+2<&"C4X@XH\'LY
MQ%/#X:L\CQN98VG@Z%.A@X4>'I9W"A+#8&,G0PU.C3I4ZV)4)R524'6TDM._
M$M9!D_BC@,-"MB(4N(,JPU/ZQ*6*QE2EF<*$<3"6)ERU)RDJM3V<Y1O3>J4G
M9/QG_@M#X"U#]F/X3_\ !%_XJZ%;)IDO[-FG^!/"TE\$WM;7?@G2_A-XVL+*
MZCD6"+;-)X(U:697FC9HS>@H266OZ:OVS?C[^RG\&/@CJ>I?M>^)O"7A[X+?
M$PI\.K]?&NDWWB+POXF_X2;3+N[70KW3--MKI[Z/4-%M[^9C(UHT"HYM;GS$
MCF'\?W_!5+X(_P#!9:Y_98MM>_;W\<_!WQA\%? OBC2HM*M_ -C\.(-7TOQ-
MK^GW_@W2;Z,>%/!>DZI<:;!97>H/?--<P/%)*MN$D\H3G[M_X+&>-+KXN?\
M!#K]A3XKJTUY=ZSK'[-FJ>*;U9)G:#7Y_@+XT\.^(;2]:.VGE-VWBK[?H.ZW
M5IGO"C6J7MRT-E-RXOAC"YXO"W#5<]PF)I5^+.),!C<PX=KK&3IPS.E5S6A%
MU:T:'LL93Q$X6<.9TVIQ7,TYD8+-*^6S\0*4<O=)4^'<FKX3!8S#JM[7V4,-
MA*M2I&;7MJ,<-3Y)0DE%U$JK=TX'@7[77_!/#XH?\$VX=-_X*;?\$M_C9J:_
M J;0O"/B?Q#X-OY;C4=5T+P!XC/VW0;][2[CL-.^)/P2G_M.*/5/#NO/IGC'
MPO\ VA9ZAIEYK5M;S+IW]'G[(/[>?P__ &@/V!?!O[<'Q*AT;X<>&$\'>([G
MXM%I[V_T3PAK/@37-3\*^-3;M#;W%Y-H<FL6#S:5#/;C4XM#NK6"]A:1/*7X
M2_:H^,GPLU3_ (('>(X;7XC^$;NZU+]BGX=>!].M;'Q)I0O[SQ*_A;P=X=7P
M_9V"W.H:C_:[7RBRN+*.)KA7,KE+<$RQ?*'[&VE:O_Q#1_&Y5L;F,:IX._:H
MU>TCC$D;:CIA^*OB-([VR>.-Y&@OH=/NC97,D*R",(YA>-1))Q9GA:W$/"F%
MQ'$Z^KYQDWB#1X'PV:UZ$<-F>+R&4J<?K-:I&-Z\J'-&4,3*+E%I1O+5R]/*
ML5#*N(*U7(:\YY3C^#*^95LLHU/:T:&:1I1=G3;DJ>'G[ZGA5:,K*\URZ\7^
MTI_P2Y^$G[6'AJ3_ (*0_P#!&[XMV_A?QI9:QXM\61^'/ =YKG@OP[XR\4Z'
M-<OXIU'X0ZHNC2:C\/\ Q]<ZC"\$OAG4-+D\">+;K[-:7LOAI+F>^B_3+_@B
M%_P49\=_M^_ ?QE9?&*&SF^-'P0US2/"GC3Q3H]M;:7I_CC3-<T>XN?#_BZ?
M0K:6X@T;6Y!97NE^(8+.>:U75H0+ SV-P;J+R'_@WS^+?PPT/_@F)X<L=?\
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M6HS6T.H:Q<WUM:6T;"*OZ*IFD6&5HMAE$<AB$I81F0(2@D* L$W ;RH+!<D
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MMWLMA]%%%<AU!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 =>M,\N/.=B9R6SM7.YNK9QG)[GJ>]%% 679 (HU7:L:*N,
M;0BA<;0N, 8QM 7_ '0!T H:-&&&1&'7#*",X89P0>S,/HS#N:**  QQDDE$
M)(8$E5R0^W<"<<AMB;AWVKG.T8#%&>#&A&",%%/#%21R.A*J2.A*KGH,%% "
MA5"A JA -H4 !0N,;0N, 8XQC&..E&U<[MJ[L8W8&< @@9QG&0#CID ]J**
M&B&$*%$404%B%$:A06R&(&, L&(8]\G/4THBB 8".,!E"L B@,HW85ACE1O?
M /'S-Q\QR44679?<O\@';5_NK^0IOE1;MWEQ[MQ;=L7=N*["V<9W%/E)SDK\
MIXXHHHVVT] $$,2L76*,.0 6"*&(4L0"P&2 7<@9X+L1]XYDHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>aztr-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaGqbP9z5Z8uekhvWBxbakqPyImlP7qJCnLNOcG0RUH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:AZTR="http://azitrainc.com/20231231" elementFormDefault="qualified" targetNamespace="http://azitrainc.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://azitrainc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" id="StatementsOfChangesInStockholdersDeficitParenthetical">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperations" id="OrganizationAndNatureOfOperations">
          <link:definition>00000008 - Disclosure - Organization and Nature of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/EmployeeRetentionCredit" id="EmployeeRetentionCredit">
          <link:definition>00000010 - Disclosure - Employee Retention Credit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000011 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>00000012 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>00000013 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ConvertibleDebt" id="ConvertibleDebt">
          <link:definition>00000014 - Disclosure - Convertible Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/Warrants" id="Warrants">
          <link:definition>00000016 - Disclosure - Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StockOptions" id="StockOptions">
          <link:definition>00000017 - Disclosure - Stock Options</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>00000018 - Disclosure - Fair Value Measurements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>00000019 - Disclosure - Net Loss Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/OperatingLeases" id="OperatingLeases">
          <link:definition>00000022 - Disclosure - Operating Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/RetirementPlan" id="RetirementPlan">
          <link:definition>00000023 - Disclosure - Retirement Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/RelatedParties" id="RelatedParties">
          <link:definition>00000024 - Disclosure - Related Parties</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000025 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000027 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>00000028 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>00000029 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ConvertibleDebtTables" id="ConvertibleDebtTables">
          <link:definition>00000030 - Disclosure - Convertible Debt (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>00000031 - Disclosure - Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StockOptionsTables" id="StockOptionsTables">
          <link:definition>00000032 - Disclosure - Stock Options (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>00000033 - Disclosure - Fair Value Measurements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
          <link:definition>00000034 - Disclosure - Net Loss Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000035 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
          <link:definition>00000036 - Disclosure - Operating Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" id="OrganizationAndNatureOfOperationsDetailsNarrative">
          <link:definition>00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" id="EmployeeRetentionCreditDetailsNarrative">
          <link:definition>00000039 - Disclosure - Employee Retention Credit (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000040 - Disclosure - Schedule of Property And Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000041 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000042 - Disclosure - Schedule of Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>00000043 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>00000044 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" id="ScheduleOfConvertibleNotesPayableDetails">
          <link:definition>00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" id="ConvertibleDebtDetailsNarrative">
          <link:definition>00000046 - Disclosure - Convertible Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000047 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" id="ScheduleOfInformationAboutWarrantsOutstandingDetails">
          <link:definition>00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
          <link:definition>00000049 - Disclosure - Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" id="ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails">
          <link:definition>00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000051 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" id="ScheduleOfTotalIntrinsicValueDetails">
          <link:definition>00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" id="ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails">
          <link:definition>00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" id="ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails">
          <link:definition>00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" id="ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails">
          <link:definition>00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/StockOptionsDetailsNarrative" id="StockOptionsDetailsNarrative">
          <link:definition>00000056 - Disclosure - Stock Options (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails">
          <link:definition>00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" id="ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails">
          <link:definition>00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" id="ScheduleOfNetLossPerShareBasicAndDilutedDetails">
          <link:definition>00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" id="ScheduleOfCalculationOfDilutedNetLossPerShareDetails">
          <link:definition>00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" id="ScheduleOfBenefitProvisionForIncomeTaxesDetails">
          <link:definition>00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" id="ScheduleOfReconciliationOfIncomeTaxDetails">
          <link:definition>00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000064 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000065 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" id="ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails">
          <link:definition>00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" id="ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails">
          <link:definition>00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>00000068 - Disclosure - Operating Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/RetirementPlanDetailsNarrative" id="RetirementPlanDetailsNarrative">
          <link:definition>00000069 - Disclosure - Retirement Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
          <link:definition>00000070 - Disclosure - Related Parties (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000071 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aztr-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aztr-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aztr-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aztr-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="AZTR_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_CARESEmployeeRetentionCreditMember" name="CARESEmployeeRetentionCreditMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConvertibleNotePurchaseAgreementMember" name="ConvertibleNotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwentyTwentyOneConvertibleNotesMember" name="TwentyTwentyOneConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwentyTwentyTwoConvertibleNotesMember" name="TwentyTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ForwardStockSplitMember" name="ForwardStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwoThousandTwentyOneConvertibleNoteMember" name="TwoThousandTwentyOneConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_YearTwoThousandEighteenMember" name="YearTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_YearTwoThousandNineteenMember" name="YearTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_YearTwoThousandTwentyThreeMember" name="YearTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" name="TwoThousandTwentyThreeStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwoThousandSixteenStockIncentivePlanMember" name="TwoThousandSixteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_StockOptionOneMember" name="StockOptionOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_StockOptionTwoMember" name="StockOptionTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_StockOptionThreeMember" name="StockOptionThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_StockOptionFourMember" name="StockOptionFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TwoThousandTwentyTwoConvertibleNoteMember" name="TwoThousandTwentyTwoConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxYears2036Through2037Member" name="TaxYears2036Through2037Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_NoExpirationMember" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxYears2037Through2043Member" name="TaxYears2037Through2043Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxYears2039Through2043Member" name="TaxYears2039Through2043Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxYears2036Through2038Member" name="TaxYears2036Through2038Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_BranfordCTMember" name="BranfordCTMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_GrotonCTMember" name="GrotonCTMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxCreditsReceivable" name="TaxCreditsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_EmployeeRetentionCredit" name="EmployeeRetentionCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ForgivenessOfAccountsPayable" name="ForgivenessOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ChangeInFairValueOfConvertibleNote" name="ChangeInFairValueOfConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_AccruedInterestOnConvertibleNotes" name="AccruedInterestOnConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" name="PaymentsToAcquireCapitalizationOfDeferredPatentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_PaymentsToAcquireCapitalizationOfLicenses" name="PaymentsToAcquireCapitalizationOfLicenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" name="ObtainingRightofuseAssetInExchangeForLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" name="ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConversionOfNoteToCommonStock" name="ConversionOfNoteToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConversionOfNoteToConvertiblePreferredStock" name="ConversionOfNoteToConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" name="ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DeferredPatentCostsPolicyTextBlock" name="DeferredPatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" name="CertainRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ImpairmentOfLicenseAgreements" name="ImpairmentOfLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_RefundableTaxCredit" name="RefundableTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_FiniteLivedIntangibleAssetUsefulLives" name="FiniteLivedIntangibleAssetUsefulLives" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_AccruedResearchAndDevelopmentProjects" name="AccruedResearchAndDevelopmentProjects" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DebtInstrumentDiscountPercentage" name="DebtInstrumentDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" name="SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_OptionsExcercisableSharePrice" name="OptionsExcercisableSharePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_IssuanceOfConvertibleNotes" name="IssuanceOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ChangeInFairValueOfConvertibleNotes" name="ChangeInFairValueOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ConversionConvertibleNotes" name="ConversionConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" name="IncomeTaxReconciliationDebtFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" name="EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_FinanceLeaseInterest" name="FinanceLeaseInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_FinanceLeaseMonthlyPayments" name="FinanceLeaseMonthlyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_FinanceLeaseExpense" name="FinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_GrossProceedsFromIssuanceInitialPublicOffering" name="GrossProceedsFromIssuanceInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_ExpirationStatusAxis" name="ExpirationStatusAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="AZTR_WillNotExpireMember" name="WillNotExpireMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_WillExpireMember" name="WillExpireMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_TaxYear2037Through2043Member" name="TaxYear2037Through2043Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>aztr-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://azitrainc.com/role/Cover" xlink:href="aztr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheets" xlink:href="aztr-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:href="aztr-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfOperations" xlink:href="aztr-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfCashFlows" xlink:href="aztr-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:href="aztr-20231231.xsd#EmployeeRetentionCredit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipment" xlink:href="aztr-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssets" xlink:href="aztr-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpenses" xlink:href="aztr-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebt" xlink:href="aztr-20231231.xsd#ConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquity" xlink:href="aztr-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/Warrants" xlink:href="aztr-20231231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptions" xlink:href="aztr-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurements" xlink:href="aztr-20231231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShare" xlink:href="aztr-20231231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxes" xlink:href="aztr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:href="aztr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeases" xlink:href="aztr-20231231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlan" xlink:href="aztr-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedParties" xlink:href="aztr-20231231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEvents" xlink:href="aztr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsTables" xlink:href="aztr-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpensesTables" xlink:href="aztr-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtTables" xlink:href="aztr-20231231.xsd#ConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsTables" xlink:href="aztr-20231231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsTables" xlink:href="aztr-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:href="aztr-20231231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShareTables" xlink:href="aztr-20231231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesTables" xlink:href="aztr-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesTables" xlink:href="aztr-20231231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:href="aztr-20231231.xsd#EmployeeRetentionCreditDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aztr-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="aztr-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="aztr-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:href="aztr-20231231.xsd#ConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:href="aztr-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:href="aztr-20231231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aztr-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:href="aztr-20231231.xsd#ScheduleOfTotalIntrinsicValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:href="aztr-20231231.xsd#ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:href="aztr-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:href="aztr-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:href="aztr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aztr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="aztr-20231231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:href="aztr-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:href="aztr-20231231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="aztr-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxCreditsReceivable" xlink:label="loc_AZTRTaxCreditsReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_AZTRTaxCreditsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable" xlink:label="loc_us-gaapIncomeTaxReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapIncomeTaxReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EmployeeRetentionCredit" xlink:label="loc_AZTREmployeeRetentionCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_AZTREmployeeRetentionCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForgivenessOfAccountsPayable" xlink:label="loc_AZTRForgivenessOfAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_AZTRForgivenessOfAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedInterestOnConvertibleNotes" xlink:label="loc_AZTRAccruedInterestOnConvertibleNotes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AZTRAccruedInterestOnConvertibleNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForgivenessOfAccountsPayable" xlink:label="loc_AZTRForgivenessOfAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AZTRForgivenessOfAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaapIncomeTaxCreditsAndAdjustments" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncomeTaxCreditsAndAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:label="loc_AZTRPaymentsToAcquireCapitalizationOfDeferredPatentCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_AZTRPaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:label="loc_AZTRPaymentsToAcquireCapitalizationOfLicenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_AZTRPaymentsToAcquireCapitalizationOfLicenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentOfDeferredOfferingCosts" xlink:label="loc_AZTRPaymentOfDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_AZTRPaymentOfDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:title="00000008 - Disclosure - Organization and Nature of Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:title="00000010 - Disclosure - Employee Retention Credit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpenses" xlink:title="00000013 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebt" xlink:title="00000014 - Disclosure - Convertible Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Warrants" xlink:title="00000016 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurements" xlink:title="00000018 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShare" xlink:title="00000019 - Disclosure - Net Loss Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeases" xlink:title="00000022 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlan" xlink:title="00000023 - Disclosure - Retirement Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedParties" xlink:title="00000024 - Disclosure - Related Parties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:title="00000027 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpensesTables" xlink:title="00000029 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtTables" xlink:title="00000030 - Disclosure - Convertible Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsTables" xlink:title="00000032 - Disclosure - Stock Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShareTables" xlink:title="00000034 - Disclosure - Net Loss Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesTables" xlink:title="00000036 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:title="00000039 - Disclosure - Employee Retention Credit (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000041 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedResearchAndDevelopmentProjects" xlink:label="loc_AZTRAccruedResearchAndDevelopmentProjects" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_AZTRAccruedResearchAndDevelopmentProjects" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:title="00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:title="00000049 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:title="00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000051 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:title="00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:title="00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:title="00000056 - Disclosure - Stock Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:title="00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="loc_us-gaapDividendsPreferredStockStock" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:title="00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:title="00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:title="00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:title="00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:label="loc_AZTREffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AZTREffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:title="00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_AZTRDeferredTaxAssetsDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_AZTRDeferredTaxAssetsDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="loc_AZTRDeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_AZTRDeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000065 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:title="00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_AZTRFinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_AZTRFinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000068 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:title="00000069 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000070 - Disclosure - Related Parties (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000071 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>aztr-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://azitrainc.com/role/Cover" xlink:href="aztr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheets" xlink:href="aztr-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:href="aztr-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfOperations" xlink:href="aztr-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfCashFlows" xlink:href="aztr-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:href="aztr-20231231.xsd#EmployeeRetentionCredit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipment" xlink:href="aztr-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssets" xlink:href="aztr-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpenses" xlink:href="aztr-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebt" xlink:href="aztr-20231231.xsd#ConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquity" xlink:href="aztr-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/Warrants" xlink:href="aztr-20231231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptions" xlink:href="aztr-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurements" xlink:href="aztr-20231231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShare" xlink:href="aztr-20231231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxes" xlink:href="aztr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:href="aztr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeases" xlink:href="aztr-20231231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlan" xlink:href="aztr-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedParties" xlink:href="aztr-20231231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEvents" xlink:href="aztr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsTables" xlink:href="aztr-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpensesTables" xlink:href="aztr-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtTables" xlink:href="aztr-20231231.xsd#ConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsTables" xlink:href="aztr-20231231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsTables" xlink:href="aztr-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:href="aztr-20231231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShareTables" xlink:href="aztr-20231231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesTables" xlink:href="aztr-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesTables" xlink:href="aztr-20231231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:href="aztr-20231231.xsd#EmployeeRetentionCreditDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aztr-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="aztr-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="aztr-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:href="aztr-20231231.xsd#ConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:href="aztr-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:href="aztr-20231231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aztr-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:href="aztr-20231231.xsd#ScheduleOfTotalIntrinsicValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:href="aztr-20231231.xsd#ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:href="aztr-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:href="aztr-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:href="aztr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aztr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="aztr-20231231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:href="aztr-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:href="aztr-20231231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="aztr-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssetsCurrentAbstract_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxCreditsReceivable" xlink:label="loc_AZTRTaxCreditsReceivable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_AZTRTaxCreditsReceivable_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable" xlink:label="loc_us-gaapIncomeTaxReceivable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapIncomeTaxReceivable_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapDeferredOfferingCosts_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapPrepaidExpenseCurrent_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssetsCurrent_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapDeferredCosts_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapOtherAssets_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableCurrent_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrent_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_130" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_130" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies_130" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAbstract_130" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_130" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_130" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommonStockValue_130" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_130" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:title="00000008 - Disclosure - Organization and Nature of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:title="00000010 - Disclosure - Employee Retention Credit" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpenses" xlink:title="00000013 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebt" xlink:title="00000014 - Disclosure - Convertible Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Warrants" xlink:title="00000016 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurements" xlink:title="00000018 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShare" xlink:title="00000019 - Disclosure - Net Loss Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeases" xlink:title="00000022 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlan" xlink:title="00000023 - Disclosure - Retirement Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedParties" xlink:title="00000024 - Disclosure - Related Parties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:title="00000027 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpensesTables" xlink:title="00000029 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtTables" xlink:title="00000030 - Disclosure - Convertible Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsTables" xlink:title="00000032 - Disclosure - Stock Options (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShareTables" xlink:title="00000034 - Disclosure - Net Loss Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesTables" xlink:title="00000036 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ImpairmentOfLicenseAgreements" xlink:label="loc_AZTRImpairmentOfLicenseAgreements_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_AZTRImpairmentOfLicenseAgreements_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther_100" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:title="00000039 - Disclosure - Employee Retention Credit (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CARESEmployeeRetentionCreditMember" xlink:label="loc_AZTRCARESEmployeeRetentionCreditMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRCARESEmployeeRetentionCreditMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_RefundableTaxCredit" xlink:label="loc_AZTRRefundableTaxCredit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_AZTRRefundableTaxCredit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsToEmployees_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EmployeeRetentionCredit" xlink:label="loc_AZTREmployeeRetentionCredit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_AZTREmployeeRetentionCredit_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_LabEquipmentMember" xlink:label="loc_AZTRLabEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AZTRLabEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000041 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FiniteLivedIntangibleAssetUsefulLives" xlink:label="loc_AZTRFiniteLivedIntangibleAssetUsefulLives_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_AZTRFiniteLivedIntangibleAssetUsefulLives_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_170" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:title="00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyOneConvertibleNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyOneConvertibleNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertibleNotePurchaseAgreementMember" xlink:label="loc_AZTRConvertibleNotePurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRConvertibleNotePurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyOneConvertibleNotesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyOneConvertibleNotesMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DebtInstrumentDiscountPercentage" xlink:label="loc_AZTRDebtInstrumentDiscountPercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AZTRDebtInstrumentDiscountPercentage_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="loc_us-gaapCapitalizationLongtermDebtAndEquity_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCapitalizationLongtermDebtAndEquity_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfNotesReceivable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfNotesReceivable_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_190" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForwardStockSplitMember" xlink:label="loc_AZTRForwardStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AZTRForwardStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1PreferredStockMember" xlink:label="loc_AZTRSeriesA1PreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1PreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:label="loc_AZTRTwoThousandTwentyOneConvertibleNoteMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_AZTRTwoThousandTwentyOneConvertibleNoteMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaapPreferredStockDividendRatePerDollarAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePerDollarAmount_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandEighteenMember" xlink:label="loc_AZTRYearTwoThousandEighteenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandEighteenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandNineteenMember" xlink:label="loc_AZTRYearTwoThousandNineteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandNineteenMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandTwentyThreeMember" xlink:label="loc_AZTRYearTwoThousandTwentyThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandTwentyThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:title="00000049 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:label="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:title="00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionOneMember" xlink:label="loc_AZTRStockOptionOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionTwoMember" xlink:label="loc_AZTRStockOptionTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionThreeMember" xlink:label="loc_AZTRStockOptionThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionFourMember" xlink:label="loc_AZTRStockOptionFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000051 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:title="00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandSixteenStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandSixteenStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_OptionsExcercisableSharePrice" xlink:label="loc_AZTROptionsExcercisableSharePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTROptionsExcercisableSharePrice_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CommonStockWarrantsMember" xlink:label="loc_AZTRCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRCommonStockWarrantsMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyTwoConvertibleNoteMember" xlink:label="loc_AZTRTwoThousandTwentyTwoConvertibleNoteMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRTwoThousandTwentyTwoConvertibleNoteMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_IssuanceOfConvertibleNotes" xlink:label="loc_AZTRIssuanceOfConvertibleNotes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRIssuanceOfConvertibleNotes_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNotes" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNotes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNotes_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionConvertibleNotes" xlink:label="loc_AZTRConversionConvertibleNotes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRConversionConvertibleNotes_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:title="00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:title="00000056 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandTwentyThreeStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandTwentyThreeStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandSixteenStockIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandSixteenStockIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_150" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:title="00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:title="00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:title="00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:title="00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:title="00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:title="00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2037Member" xlink:label="loc_AZTRTaxYears2036Through2037Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2036Through2037Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_NoExpirationMember" xlink:label="loc_AZTRNoExpirationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRNoExpirationMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2037Through2043Member" xlink:label="loc_AZTRTaxYears2037Through2043Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2037Through2043Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2039Through2043Member" xlink:label="loc_AZTRTaxYears2039Through2043Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2039Through2043Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2038Member" xlink:label="loc_AZTRTaxYears2036Through2038Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2036Through2038Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch_140" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000065 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ExclusiveLicenseAgreementMember" xlink:label="loc_AZTRExclusiveLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRExclusiveLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:title="00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000068 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_countryCA_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_BranfordCTMember" xlink:label="loc_AZTRBranfordCTMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AZTRBranfordCTMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrotonCTMember" xlink:label="loc_AZTRGrotonCTMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AZTRGrotonCTMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseMonthlyPayments" xlink:label="loc_AZTRFinanceLeaseMonthlyPayments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRFinanceLeaseMonthlyPayments_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaapLesseeFinanceLeaseTermOfContract1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseTermOfContract1_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseExpense" xlink:label="loc_AZTRFinanceLeaseExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRFinanceLeaseExpense_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_90" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:title="00000069 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000070 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertibleNotePurchaseAgreementMember" xlink:label="loc_AZTRConvertibleNotePurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRConvertibleNotePurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapInvestorMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenues_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapContractWithCustomerLiability_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_100" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000071 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_UnderwriterMember" xlink:label="loc_AZTRUnderwriterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AZTRUnderwriterMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_AZTRGrossProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_AZTRGrossProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>aztr-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="AZTR_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesAConvertiblePreferredStockMember" xlink:to="AZTR_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="AZTR_SeriesA1ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:to="AZTR_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="AZTR_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesBConvertiblePreferredStockMember" xlink:to="AZTR_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CARESEmployeeRetentionCreditMember" xlink:label="AZTR_CARESEmployeeRetentionCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_CARESEmployeeRetentionCreditMember" xlink:to="AZTR_CARESEmployeeRetentionCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_CARESEmployeeRetentionCreditMember_lbl" xml:lang="en-US">CARES Employee Retention credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_LabEquipmentMember" xlink:label="AZTR_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_LabEquipmentMember" xlink:to="AZTR_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Building Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertibleNotePurchaseAgreementMember" xlink:label="AZTR_ConvertibleNotePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConvertibleNotePurchaseAgreementMember" xlink:to="AZTR_ConvertibleNotePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConvertibleNotePurchaseAgreementMember_lbl" xml:lang="en-US">Convertible Note Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:label="AZTR_TwentyTwentyOneConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:to="AZTR_TwentyTwentyOneConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwentyTwentyOneConvertibleNotesMember_lbl" xml:lang="en-US">2021 Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="AZTR_TwentyTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:to="AZTR_TwentyTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwentyTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">2022 Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForwardStockSplitMember" xlink:label="AZTR_ForwardStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ForwardStockSplitMember" xlink:to="AZTR_ForwardStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ForwardStockSplitMember_lbl" xml:lang="en-US">Forward Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:label="AZTR_TwoThousandTwentyOneConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:to="AZTR_TwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_TwoThousandTwentyOneConvertibleNoteMember_lbl" xml:lang="en-US">2021 Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1PreferredStockMember" xlink:label="AZTR_SeriesA1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesA1PreferredStockMember" xlink:to="AZTR_SeriesA1PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SeriesA1PreferredStockMember_lbl" xml:lang="en-US">Series A-1 convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandEighteenMember" xlink:label="AZTR_YearTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandEighteenMember" xlink:to="AZTR_YearTwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_YearTwoThousandEighteenMember_lbl" xml:lang="en-US">Year 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandNineteenMember" xlink:label="AZTR_YearTwoThousandNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandNineteenMember" xlink:to="AZTR_YearTwoThousandNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_YearTwoThousandNineteenMember_lbl" xml:lang="en-US">Year 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandTwentyThreeMember" xlink:label="AZTR_YearTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandTwentyThreeMember" xlink:to="AZTR_YearTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_YearTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">Year 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" xlink:label="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" xlink:to="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember_lbl" xml:lang="en-US">2023 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:label="AZTR_TwoThousandSixteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:to="AZTR_TwoThousandSixteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwoThousandSixteenStockIncentivePlanMember_lbl" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionOneMember" xlink:label="AZTR_StockOptionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionOneMember" xlink:to="AZTR_StockOptionOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_StockOptionOneMember_lbl" xml:lang="en-US">Stock Option One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionTwoMember" xlink:label="AZTR_StockOptionTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionTwoMember" xlink:to="AZTR_StockOptionTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_StockOptionTwoMember_lbl" xml:lang="en-US">Stock Option Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionThreeMember" xlink:label="AZTR_StockOptionThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionThreeMember" xlink:to="AZTR_StockOptionThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_StockOptionThreeMember_lbl" xml:lang="en-US">Stock Option Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionFourMember" xlink:label="AZTR_StockOptionFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionFourMember" xlink:to="AZTR_StockOptionFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_StockOptionFourMember_lbl" xml:lang="en-US">Stock Option Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CommonStockWarrantsMember" xlink:label="AZTR_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_CommonStockWarrantsMember" xlink:to="AZTR_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyTwoConvertibleNoteMember" xlink:label="AZTR_TwoThousandTwentyTwoConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyTwoConvertibleNoteMember" xlink:to="AZTR_TwoThousandTwentyTwoConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwoThousandTwentyTwoConvertibleNoteMember_lbl" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2037Member" xlink:label="AZTR_TaxYears2036Through2037Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2036Through2037Member" xlink:to="AZTR_TaxYears2036Through2037Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TaxYears2036Through2037Member_lbl" xml:lang="en-US">Tax Years 2036 Through 2037 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_NoExpirationMember" xlink:label="AZTR_NoExpirationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_NoExpirationMember" xlink:to="AZTR_NoExpirationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_NoExpirationMember_lbl" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2037Through2043Member" xlink:label="AZTR_TaxYears2037Through2043Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2037Through2043Member" xlink:to="AZTR_TaxYears2037Through2043Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TaxYears2037Through2043Member_lbl" xml:lang="en-US">Tax Years 2037 Through 2043 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2039Through2043Member" xlink:label="AZTR_TaxYears2039Through2043Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2039Through2043Member" xlink:to="AZTR_TaxYears2039Through2043Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TaxYears2039Through2043Member_lbl" xml:lang="en-US">Tax Years 2039 Through 2043 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2038Member" xlink:label="AZTR_TaxYears2036Through2038Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2036Through2038Member" xlink:to="AZTR_TaxYears2036Through2038Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TaxYears2036Through2038Member_lbl" xml:lang="en-US">Tax Years 2036 Through 2038 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ExclusiveLicenseAgreementMember" xlink:label="AZTR_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ExclusiveLicenseAgreementMember" xlink:to="AZTR_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_BranfordCTMember" xlink:label="AZTR_BranfordCTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_BranfordCTMember" xlink:to="AZTR_BranfordCTMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_BranfordCTMember_lbl" xml:lang="en-US">Branford. CT [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrotonCTMember" xlink:label="AZTR_GrotonCTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_GrotonCTMember" xlink:to="AZTR_GrotonCTMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_GrotonCTMember_lbl" xml:lang="en-US">Groton. CT [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_UnderwriterMember" xlink:label="AZTR_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_UnderwriterMember" xlink:to="AZTR_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxCreditsReceivable" xlink:label="AZTR_TaxCreditsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxCreditsReceivable" xlink:to="AZTR_TaxCreditsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TaxCreditsReceivable_lbl" xml:lang="en-US">Tax credits receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xml:lang="en-US">Income tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Financing lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Preferred stock:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock; $0.0001 par value, 100,000,000 shares authorized at December 31, 2023 and 2022, 12,097,643 and 1,043,988 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Service revenue - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-operating income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EmployeeRetentionCredit" xlink:label="AZTR_EmployeeRetentionCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_EmployeeRetentionCredit" xlink:to="AZTR_EmployeeRetentionCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_EmployeeRetentionCredit_lbl" xml:lang="en-US">Employee retention credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForgivenessOfAccountsPayable" xlink:label="AZTR_ForgivenessOfAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ForgivenessOfAccountsPayable" xlink:to="AZTR_ForgivenessOfAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ForgivenessOfAccountsPayable_lbl" xml:lang="en-US">Forgiveness of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="AZTR_ChangeInFairValueOfConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNote" xlink:to="AZTR_ChangeInFairValueOfConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ChangeInFairValueOfConvertibleNote_lbl" xml:lang="en-US">Change in fair value of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total non-operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividends on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common stock outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of Series B Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of Series B Convertible Preferred Stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Initial public offering, net of issuance costs of $1,508,641</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Initial public offering, net of issuance costs of $1,508,791, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedInterestOnConvertibleNotes" xlink:label="AZTR_AccruedInterestOnConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_AccruedInterestOnConvertibleNotes" xlink:to="AZTR_AccruedInterestOnConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_AccruedInterestOnConvertibleNotes_lbl" xml:lang="en-US">Accrued interest on convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNote" xlink:to="AZTR_ChangeInFairValueOfConvertibleNote_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AZTR_ChangeInFairValueOfConvertibleNote_2_lbl" xml:lang="en-US">Change in fair value of convertible notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ForgivenessOfAccountsPayable" xlink:to="AZTR_ForgivenessOfAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AZTR_ForgivenessOfAccountsPayable_2_lbl" xml:lang="en-US">Forgiveness of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets and deferred patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Tax credits receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Income tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_lbl" xml:lang="en-US">Capitalization of deferred patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfLicenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfLicenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfLicenses_lbl" xml:lang="en-US">Capitalization of licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Capitalization of patent and trademark costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from convertible notes, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentOfDeferredOfferingCosts" xlink:label="AZTR_PaymentOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentOfDeferredOfferingCosts" xlink:to="AZTR_PaymentOfDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AZTR_PaymentOfDeferredOfferingCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Principal payments on finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from initial public offering, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing information:</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" xlink:to="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability_lbl" xml:lang="en-US">Obtaining a right-of-use asset in exchange for lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" xlink:to="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability_lbl" xml:lang="en-US">Obtaining a right-of-use asset in exchange for financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfNoteToCommonStock" xlink:label="AZTR_ConversionOfNoteToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfNoteToCommonStock" xlink:to="AZTR_ConversionOfNoteToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConversionOfNoteToCommonStock_lbl" xml:lang="en-US">Conversion of note to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfNoteToConvertiblePreferredStock" xlink:label="AZTR_ConversionOfNoteToConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfNoteToConvertiblePreferredStock" xlink:to="AZTR_ConversionOfNoteToConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConversionOfNoteToConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of note to Series B Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" xlink:label="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" xlink:to="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series A, A-1, and B Convertible Preferred Stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Organization and Nature of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Retention Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureWarrantsAbstract" xlink:label="AZTR_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DisclosureWarrantsAbstract" xlink:to="AZTR_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_WarrantsTextBlock" xlink:label="AZTR_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_WarrantsTextBlock" xlink:to="AZTR_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_WarrantsTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionTextBlock" xlink:label="us-gaap_FairValueOptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionTextBlock" xlink:to="us-gaap_FairValueOptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionTextBlock_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="AZTR_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DisclosureOperatingLeasesAbstract" xlink:to="AZTR_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredOfferingCostsPolicyTextBlock" xlink:label="AZTR_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredOfferingCostsPolicyTextBlock" xlink:to="AZTR_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredPatentCostsPolicyTextBlock" xlink:label="AZTR_DeferredPatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredPatentCostsPolicyTextBlock" xlink:to="AZTR_DeferredPatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DeferredPatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible Debt and Warrant Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertiblePreferredStockPolicyTextBlock" xlink:label="AZTR_ConvertiblePreferredStockPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConvertiblePreferredStockPolicyTextBlock" xlink:to="AZTR_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:label="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:to="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Certain Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and Off- Balance Sheet Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Information about Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Information about Options Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Total Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Measurements for Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Numerator for Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share, Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Calculation of Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of (Benefit) Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Income Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Proceeds from initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Forward stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset and lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease, weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance lease, weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Finance lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Long term finance lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance lease liability current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long term finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ImpairmentOfLicenseAgreements" xlink:label="AZTR_ImpairmentOfLicenseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ImpairmentOfLicenseAgreements" xlink:to="AZTR_ImpairmentOfLicenseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ImpairmentOfLicenseAgreements_lbl" xml:lang="en-US">Impairment of license agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US">State tax credit receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Pending refunds related to research and experimental development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Refunds tax amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_RefundableTaxCredit" xlink:label="AZTR_RefundableTaxCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_RefundableTaxCredit" xlink:to="AZTR_RefundableTaxCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_RefundableTaxCredit_lbl" xml:lang="en-US">Refundable tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credit percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Payments to employees wages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation &amp; amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property, plant, and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Losses on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FiniteLivedIntangibleAssetUsefulLives" xlink:label="AZTR_FiniteLivedIntangibleAssetUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FiniteLivedIntangibleAssetUsefulLives" xlink:to="AZTR_FiniteLivedIntangibleAssetUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_FiniteLivedIntangibleAssetUsefulLives_lbl" xml:lang="en-US">Estimated Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Impairment of intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expenses of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Employee payroll and bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedResearchAndDevelopmentProjects" xlink:label="AZTR_AccruedResearchAndDevelopmentProjects" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_AccruedResearchAndDevelopmentProjects" xlink:to="AZTR_AccruedResearchAndDevelopmentProjects_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_AccruedResearchAndDevelopmentProjects_lbl" xml:lang="en-US">Research and development projects</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Bearing interest, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DebtInstrumentDiscountPercentage" xlink:label="AZTR_DebtInstrumentDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DebtInstrumentDiscountPercentage" xlink:to="AZTR_DebtInstrumentDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DebtInstrumentDiscountPercentage_lbl" xml:lang="en-US">Debt discount, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationLongtermDebtAndEquity" xlink:to="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationLongtermDebtAndEquity_lbl" xml:lang="en-US">Capitalization amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Issuance of conversion shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xml:lang="en-US">Sale of additional notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of convertible notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNote" xlink:to="AZTR_ChangeInFairValueOfConvertibleNote_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="AZTR_ChangeInFairValueOfConvertibleNote_3_lbl" xml:lang="en-US">Change in fair value of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuances costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock, par value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible series B preferred stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Original issue price per share of series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend percentage on series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US">Original issue price per share of series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xml:lang="en-US">Number of warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Number of warrants issued to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Maturity term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighed average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_lbl" xml:lang="en-US">Weighted average term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Number of options exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Options, Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Options Outstanding Value of Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_OptionsExcercisableSharePrice" xlink:label="AZTR_OptionsExcercisableSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_OptionsExcercisableSharePrice" xlink:to="AZTR_OptionsExcercisableSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_OptionsExcercisableSharePrice_lbl" xml:lang="en-US">Options Exercisable Value of Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options Outstanding Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options Exercisable Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_lbl" xml:lang="en-US">Options Outstanding Intrinsic Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_lbl" xml:lang="en-US">Options Excercisable Intrinsic Value Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xml:lang="en-US">Options Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options Outstanding Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options Exercisable Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xml:lang="en-US">Balance at December 31, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Changes in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_IssuanceOfConvertibleNotes" xlink:label="AZTR_IssuanceOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_IssuanceOfConvertibleNotes" xlink:to="AZTR_IssuanceOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_IssuanceOfConvertibleNotes_lbl" xml:lang="en-US">Issuance of 2022 Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNotes" xlink:label="AZTR_ChangeInFairValueOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNotes" xlink:to="AZTR_ChangeInFairValueOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ChangeInFairValueOfConvertibleNotes_lbl" xml:lang="en-US">Changes in fair value of 2022 Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionConvertibleNotes" xlink:label="AZTR_ConversionConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionConvertibleNotes" xlink:to="AZTR_ConversionConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ConversionConvertibleNotes_lbl" xml:lang="en-US">Conversion of 2022 Convertible Notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xml:lang="en-US">Balance at December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTable_lbl" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_lbl" xml:lang="en-US">Stock options available for grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xml:lang="en-US">Performance stock options shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Number of stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Dividends on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Total, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Total, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5_lbl" xml:lang="en-US">Options to purchase shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income taxes using U.S. statutory rate, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income taxes using U.S. statutory rate, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" xlink:label="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" xlink:to="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment_lbl" xml:lang="en-US">Debt fair value adjustment, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:label="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:to="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_lbl" xml:lang="en-US">Debt fair value adjustment, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credit, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credit, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other, net, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other, net, percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="AZTR_DeferredTaxAssetsDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Research tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">Capitalized License agreement amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DisclosureOperatingLeasesAbstract" xlink:to="AZTR_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Future Minimum Payments Under Non-cancelable Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DisclosureOperatingLeasesAbstract" xlink:to="AZTR_DisclosureOperatingLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="AZTR_DisclosureOperatingLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Minimum Payments Under Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseInterest" xlink:label="AZTR_FinanceLeaseInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseInterest" xlink:to="AZTR_FinanceLeaseInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_FinanceLeaseInterest_lbl" xml:lang="en-US">Less interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lease term renewal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Operating lease rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Operating lease discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseMonthlyPayments" xlink:label="AZTR_FinanceLeaseMonthlyPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseMonthlyPayments" xlink:to="AZTR_FinanceLeaseMonthlyPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_FinanceLeaseMonthlyPayments_lbl" xml:lang="en-US">Finance lease monthly payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US">Finance lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Finance lease remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance lease discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseExpense" xlink:label="AZTR_FinanceLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseExpense" xlink:to="AZTR_FinanceLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_FinanceLeaseExpense_lbl" xml:lang="en-US">Finance lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansGeneralInformation" xlink:label="us-gaap_DefinedBenefitPlansGeneralInformation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansGeneralInformation" xlink:to="us-gaap_DefinedBenefitPlansGeneralInformation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansGeneralInformation_lbl" xml:lang="en-US">Retirement plan general information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Employer contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Accounts receivable due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities due from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock issued during conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3_lbl" xml:lang="en-US">Stock issued during conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Public offering price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="AZTR_GrossProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="AZTR_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xml:lang="en-US">Net proceeds from issuance of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase of common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxCreditsReceivable" xlink:to="AZTR_TaxCreditsReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxCreditsReceivable_doc" xml:lang="en-US">Tax credits receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesAConvertiblePreferredStockMember" xlink:to="AZTR_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:to="AZTR_SeriesA1ConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SeriesA1ConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesBConvertiblePreferredStockMember" xlink:to="AZTR_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_WarrantsTextBlock" xlink:to="AZTR_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandEighteenMember" xlink:to="AZTR_YearTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_YearTwoThousandEighteenMember_doc" xml:lang="en-US">Year 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandNineteenMember" xlink:to="AZTR_YearTwoThousandNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_YearTwoThousandNineteenMember_doc" xml:lang="en-US">Year 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_YearTwoThousandTwentyThreeMember" xlink:to="AZTR_YearTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_YearTwoThousandTwentyThreeMember_doc" xml:lang="en-US">Year 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options outstanding period increase decrease weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" xlink:to="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwoThousandTwentyThreeStockIncentivePlanMember_doc" xml:lang="en-US">2023 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:to="AZTR_TwoThousandSixteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwoThousandSixteenStockIncentivePlanMember_doc" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredOfferingCostsPolicyTextBlock" xlink:to="AZTR_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_EmployeeRetentionCredit" xlink:to="AZTR_EmployeeRetentionCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_EmployeeRetentionCredit_doc" xml:lang="en-US">Employee retention credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ForgivenessOfAccountsPayable" xlink:to="AZTR_ForgivenessOfAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ForgivenessOfAccountsPayable_doc" xml:lang="en-US">Forgiveness of accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNote" xlink:to="AZTR_ChangeInFairValueOfConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ChangeInFairValueOfConvertibleNote_doc" xml:lang="en-US">Change in fair value of convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredPatentCostsPolicyTextBlock" xlink:to="AZTR_DeferredPatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_DeferredPatentCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Patent Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConvertiblePreferredStockPolicyTextBlock" xlink:to="AZTR_ConvertiblePreferredStockPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConvertiblePreferredStockPolicyTextBlock_doc" xml:lang="en-US">Convertible Preferred Stock [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_AccruedInterestOnConvertibleNotes" xlink:to="AZTR_AccruedInterestOnConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_AccruedInterestOnConvertibleNotes_doc" xml:lang="en-US">Accrued interest on convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_doc" xml:lang="en-US">The cash outflow for purchases of capitalization of deferred patent costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfLicenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfLicenses_doc" xml:lang="en-US">The cash outflow for purchases of capitalization of licenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentOfDeferredOfferingCosts" xlink:to="AZTR_PaymentOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_PaymentOfDeferredOfferingCosts_doc" xml:lang="en-US">Payment of deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" xlink:to="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability_doc" xml:lang="en-US">Obtaining a right-of-use asset in exchange for lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" xlink:to="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability_doc" xml:lang="en-US">Obtaining right of use asset in exchange for financing lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfNoteToCommonStock" xlink:to="AZTR_ConversionOfNoteToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConversionOfNoteToCommonStock_doc" xml:lang="en-US">Conversion of note to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfNoteToConvertiblePreferredStock" xlink:to="AZTR_ConversionOfNoteToConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConversionOfNoteToConvertiblePreferredStock_doc" xml:lang="en-US">Conversion of note to convertible preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionOneMember" xlink:to="AZTR_StockOptionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_StockOptionOneMember_doc" xml:lang="en-US">Stock Option One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionTwoMember" xlink:to="AZTR_StockOptionTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_StockOptionTwoMember_doc" xml:lang="en-US">Stock Option Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionThreeMember" xlink:to="AZTR_StockOptionThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_StockOptionThreeMember_doc" xml:lang="en-US">Stock Option Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_StockOptionFourMember" xlink:to="AZTR_StockOptionFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_StockOptionFourMember_doc" xml:lang="en-US">Stock Option Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" xlink:to="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of series A1 and B convertible preferred stock to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:to="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_CertainRisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Certain Risks And Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_RefundableTaxCredit" xlink:to="AZTR_RefundableTaxCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_RefundableTaxCredit_doc" xml:lang="en-US">Refundable tax credit on realted to employment in refundable to the employees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_CARESEmployeeRetentionCreditMember" xlink:to="AZTR_CARESEmployeeRetentionCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_CARESEmployeeRetentionCreditMember_doc" xml:lang="en-US">CARES Employee Retention credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FiniteLivedIntangibleAssetUsefulLives" xlink:to="AZTR_FiniteLivedIntangibleAssetUsefulLives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_FiniteLivedIntangibleAssetUsefulLives_doc" xml:lang="en-US">Finite lived intangible asset useful lives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding intrinsic value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:to="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options Exercisable intrinsic value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_OptionsExcercisableSharePrice" xlink:to="AZTR_OptionsExcercisableSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_OptionsExcercisableSharePrice_doc" xml:lang="en-US">Options excercisable share price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ChangeInFairValueOfConvertibleNotes" xlink:to="AZTR_ChangeInFairValueOfConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ChangeInFairValueOfConvertibleNotes_doc" xml:lang="en-US">Change in fair value of convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConversionConvertibleNotes" xlink:to="AZTR_ConversionConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConversionConvertibleNotes_doc" xml:lang="en-US">Conversion convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_AccruedResearchAndDevelopmentProjects" xlink:to="AZTR_AccruedResearchAndDevelopmentProjects_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_AccruedResearchAndDevelopmentProjects_doc" xml:lang="en-US">Accrued research and development projects.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ConvertibleNotePurchaseAgreementMember" xlink:to="AZTR_ConvertibleNotePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ConvertibleNotePurchaseAgreementMember_doc" xml:lang="en-US">Convertible Note Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:to="AZTR_TwentyTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwentyTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">2022 Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_IssuanceOfConvertibleNotes" xlink:to="AZTR_IssuanceOfConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_IssuanceOfConvertibleNotes_doc" xml:lang="en-US">Issuance of convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DebtInstrumentDiscountPercentage" xlink:to="AZTR_DebtInstrumentDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_DebtInstrumentDiscountPercentage_doc" xml:lang="en-US">Debt instrument discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:to="AZTR_TwentyTwentyOneConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwentyTwentyOneConvertibleNotesMember_doc" xml:lang="en-US">2021 Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ForwardStockSplitMember" xlink:to="AZTR_ForwardStockSplitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ForwardStockSplitMember_doc" xml:lang="en-US">Forward Stock Split [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:to="AZTR_TwoThousandTwentyOneConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwoThousandTwentyOneConvertibleNoteMember_doc" xml:lang="en-US">2021 Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SeriesA1PreferredStockMember" xlink:to="AZTR_SeriesA1PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SeriesA1PreferredStockMember_doc" xml:lang="en-US">Series A-1 convertible preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" xlink:to="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_IncomeTaxReconciliationDebtFairValueAdjustment_doc" xml:lang="en-US">Income tax reconciliation debt fair value adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:to="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_doc" xml:lang="en-US">Effective income tax rate reconciliation debt fair value adjustment tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxAssetsDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_DeferredTaxAssetsDepreciationAndAmortization_doc" xml:lang="en-US">Deferred tax assets depreciation and amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_doc" xml:lang="en-US">Deferred tax liabilities depreciation and amortization.</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ExpirationStatusAxis" xlink:label="AZTR_ExpirationStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ExpirationStatusAxis" xlink:to="AZTR_ExpirationStatusAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ExpirationStatusAxis_doc" xml:lang="en-US">Expiration Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_WillNotExpireMember" xlink:label="AZTR_WillNotExpireMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_WillNotExpireMember" xlink:to="AZTR_WillNotExpireMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_WillNotExpireMember_doc" xml:lang="en-US">Will Not Expire [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_WillExpireMember" xlink:label="AZTR_WillExpireMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_WillExpireMember" xlink:to="AZTR_WillExpireMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_WillExpireMember_doc" xml:lang="en-US">Will Expire [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYear2037Through2043Member" xlink:label="AZTR_TaxYear2037Through2043Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYear2037Through2043Member" xlink:to="AZTR_TaxYear2037Through2043Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxYear2037Through2043Member_doc" xml:lang="en-US">Tax Year 2037 Through 2043 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2039Through2043Member" xlink:to="AZTR_TaxYears2039Through2043Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxYears2039Through2043Member_doc" xml:lang="en-US">Tax Years 2039 Through 2043 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2036Through2037Member" xlink:to="AZTR_TaxYears2036Through2037Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxYears2036Through2037Member_doc" xml:lang="en-US">Tax Years 2036 Through 2037 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2037Through2043Member" xlink:to="AZTR_TaxYears2037Through2043Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxYears2037Through2043Member_doc" xml:lang="en-US">Tax Years 2037 Through 2043 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TaxYears2036Through2038Member" xlink:to="AZTR_TaxYears2036Through2038Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TaxYears2036Through2038Member_doc" xml:lang="en-US">Tax Years 2036 Through 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ExclusiveLicenseAgreementMember" xlink:to="AZTR_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_BranfordCTMember" xlink:to="AZTR_BranfordCTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_BranfordCTMember_doc" xml:lang="en-US">Branford. CT [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_GrotonCTMember" xlink:to="AZTR_GrotonCTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_GrotonCTMember_doc" xml:lang="en-US">Groton. CT [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee operating lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseMonthlyPayments" xlink:to="AZTR_FinanceLeaseMonthlyPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_FinanceLeaseMonthlyPayments_doc" xml:lang="en-US">Finance lease monthly payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Finance lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseInterest" xlink:to="AZTR_FinanceLeaseInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_FinanceLeaseInterest_doc" xml:lang="en-US">Finance lease interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseExpense" xlink:to="AZTR_FinanceLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_FinanceLeaseExpense_doc" xml:lang="en-US">Finance lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_ImpairmentOfLicenseAgreements" xlink:to="AZTR_ImpairmentOfLicenseAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_ImpairmentOfLicenseAgreements_doc" xml:lang="en-US">Impairment of license agreements.</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment non options weighted average term.</link:label>
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice" xlink:to="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment non options weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyTwoConvertibleNoteMember" xlink:to="AZTR_TwoThousandTwentyTwoConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_TwoThousandTwentyTwoConvertibleNoteMember_doc" xml:lang="en-US">2022 Convertible Notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_NoExpirationMember" xlink:to="AZTR_NoExpirationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_NoExpirationMember_doc" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="AZTR_GrossProceedsFromIssuanceInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_GrossProceedsFromIssuanceInitialPublicOffering_doc" xml:lang="en-US">Gross proceeds from issuance initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_UnderwriterMember" xlink:to="AZTR_UnderwriterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AZTR_UnderwriterMember_doc" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:to="AZTR_TwoThousandTwentyOneConvertibleNoteMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_TwoThousandTwentyOneConvertibleNoteMember_3_lbl" xml:lang="en-US">2021 Convertible Note [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_2_lbl" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Commodity Contract Assets and Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts_3_lbl" xml:lang="en-US">PaymentsToAcquireCapitalizationOfDeferredPatentCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:to="AZTR_PaymentsToAcquireCapitalizationOfLicenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_PaymentsToAcquireCapitalizationOfLicenses_3_lbl" xml:lang="en-US">PaymentsToAcquireCapitalizationOfLicenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_PaymentOfDeferredOfferingCosts" xlink:to="AZTR_PaymentOfDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_PaymentOfDeferredOfferingCosts_3_lbl" xml:lang="en-US">PaymentOfDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_WarrantsTextBlock" xlink:to="AZTR_WarrantsTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_WarrantsTextBlock_3_lbl" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_2_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock, Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxAssetsDepreciationAndAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DeferredTaxAssetsDepreciationAndAmortization_3_lbl" xml:lang="en-US">DeferredTaxAssetsDepreciationAndAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciationAndAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xml:lang="en-US">FinanceLeaseLiabilityPaymentsDueAfterYearFour</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_2_lbl" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>aztr-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://azitrainc.com/role/Cover" xlink:href="aztr-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheets" xlink:href="aztr-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:href="aztr-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfOperations" xlink:href="aztr-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:href="aztr-20231231.xsd#StatementsOfChangesInStockholdersDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StatementsOfCashFlows" xlink:href="aztr-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:href="aztr-20231231.xsd#EmployeeRetentionCredit" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipment" xlink:href="aztr-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssets" xlink:href="aztr-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpenses" xlink:href="aztr-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebt" xlink:href="aztr-20231231.xsd#ConvertibleDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquity" xlink:href="aztr-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/Warrants" xlink:href="aztr-20231231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptions" xlink:href="aztr-20231231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurements" xlink:href="aztr-20231231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShare" xlink:href="aztr-20231231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxes" xlink:href="aztr-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:href="aztr-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeases" xlink:href="aztr-20231231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlan" xlink:href="aztr-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedParties" xlink:href="aztr-20231231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEvents" xlink:href="aztr-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsTables" xlink:href="aztr-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/AccruedExpensesTables" xlink:href="aztr-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtTables" xlink:href="aztr-20231231.xsd#ConvertibleDebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsTables" xlink:href="aztr-20231231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsTables" xlink:href="aztr-20231231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:href="aztr-20231231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/NetLossPerShareTables" xlink:href="aztr-20231231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesTables" xlink:href="aztr-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesTables" xlink:href="aztr-20231231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:href="aztr-20231231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aztr-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:href="aztr-20231231.xsd#EmployeeRetentionCreditDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aztr-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="aztr-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="aztr-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="aztr-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:href="aztr-20231231.xsd#ConvertibleDebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:href="aztr-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:href="aztr-20231231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:href="aztr-20231231.xsd#ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aztr-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:href="aztr-20231231.xsd#ScheduleOfTotalIntrinsicValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:href="aztr-20231231.xsd#ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:href="aztr-20231231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="aztr-20231231.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:href="aztr-20231231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:href="aztr-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:href="aztr-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aztr-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:href="aztr-20231231.xsd#ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="aztr-20231231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:href="aztr-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:href="aztr-20231231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="aztr-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxCreditsReceivable" xlink:label="loc_AZTRTaxCreditsReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_AZTRTaxCreditsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable" xlink:label="loc_us-gaapIncomeTaxReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EmployeeRetentionCredit" xlink:label="loc_AZTREmployeeRetentionCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_AZTREmployeeRetentionCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForgivenessOfAccountsPayable" xlink:label="loc_AZTRForgivenessOfAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_AZTRForgivenessOfAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesAConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_AZTRSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesA1ConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_AZTRSeriesA1ConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AZTRSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_AZTRSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedInterestOnConvertibleNotes" xlink:label="loc_AZTRAccruedInterestOnConvertibleNotes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AZTRAccruedInterestOnConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForgivenessOfAccountsPayable" xlink:label="loc_AZTRForgivenessOfAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AZTRForgivenessOfAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="loc_us-gaapIncomeTaxCreditsAndAdjustments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncomeTaxCreditsAndAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:label="loc_AZTRPaymentsToAcquireCapitalizationOfDeferredPatentCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_AZTRPaymentsToAcquireCapitalizationOfDeferredPatentCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentsToAcquireCapitalizationOfLicenses" xlink:label="loc_AZTRPaymentsToAcquireCapitalizationOfLicenses" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_AZTRPaymentsToAcquireCapitalizationOfLicenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_PaymentOfDeferredOfferingCosts" xlink:label="loc_AZTRPaymentOfDeferredOfferingCosts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_AZTRPaymentOfDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability" xlink:label="loc_AZTRObtainingRightofuseAssetInExchangeForLeaseLiability" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AZTRObtainingRightofuseAssetInExchangeForLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" xlink:label="loc_AZTRObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AZTRObtainingRightofuseAssetInExchangeForFinancingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfNoteToCommonStock" xlink:label="loc_AZTRConversionOfNoteToCommonStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AZTRConversionOfNoteToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfNoteToConvertiblePreferredStock" xlink:label="loc_AZTRConversionOfNoteToConvertiblePreferredStock" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AZTRConversionOfNoteToConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" xlink:label="loc_AZTRConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AZTRConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperations" xlink:title="00000008 - Disclosure - Organization and Nature of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCredit" xlink:title="00000010 - Disclosure - Employee Retention Credit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssets" xlink:title="00000012 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpenses" xlink:title="00000013 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebt" xlink:title="00000014 - Disclosure - Convertible Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/Warrants" xlink:title="00000016 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureWarrantsAbstract" xlink:label="loc_AZTRDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_WarrantsTextBlock" xlink:label="loc_AZTRWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureWarrantsAbstract" xlink:to="loc_AZTRWarrantsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptions" xlink:title="00000017 - Disclosure - Stock Options">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionTextBlock" xlink:label="loc_us-gaapFairValueOptionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueOptionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurements" xlink:title="00000018 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShare" xlink:title="00000019 - Disclosure - Net Loss Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeases" xlink:title="00000022 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="loc_AZTRDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlan" xlink:title="00000023 - Disclosure - Retirement Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedParties" xlink:title="00000024 - Disclosure - Related Parties">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_AZTRDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AZTRDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredPatentCostsPolicyTextBlock" xlink:label="loc_AZTRDeferredPatentCostsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AZTRDeferredPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertiblePreferredStockPolicyTextBlock" xlink:label="loc_AZTRConvertiblePreferredStockPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AZTRConvertiblePreferredStockPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CertainRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_AZTRCertainRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AZTRCertainRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentTables" xlink:title="00000027 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/AccruedExpensesTables" xlink:title="00000029 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtTables" xlink:title="00000030 - Disclosure - Convertible Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureWarrantsAbstract" xlink:label="loc_AZTRDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsTables" xlink:title="00000032 - Disclosure - Stock Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/FairValueMeasurementsTables" xlink:title="00000033 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/NetLossPerShareTables" xlink:title="00000034 - Disclosure - Net Loss Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesTables" xlink:title="00000036 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="loc_AZTRDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ImpairmentOfLicenseAgreements" xlink:label="loc_AZTRImpairmentOfLicenseAgreements" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_AZTRImpairmentOfLicenseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative" xlink:title="00000039 - Disclosure - Employee Retention Credit (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CARESEmployeeRetentionCreditMember" xlink:label="loc_AZTRCARESEmployeeRetentionCreditMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRCARESEmployeeRetentionCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_RefundableTaxCredit" xlink:label="loc_AZTRRefundableTaxCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_AZTRRefundableTaxCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsToEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EmployeeRetentionCredit" xlink:label="loc_AZTREmployeeRetentionCredit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_AZTREmployeeRetentionCredit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000040 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_LabEquipmentMember" xlink:label="loc_AZTRLabEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AZTRLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000041 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FiniteLivedIntangibleAssetUsefulLives" xlink:label="loc_AZTRFiniteLivedIntangibleAssetUsefulLives" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_AZTRFiniteLivedIntangibleAssetUsefulLives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_AccruedResearchAndDevelopmentProjects" xlink:label="loc_AZTRAccruedResearchAndDevelopmentProjects" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_AZTRAccruedResearchAndDevelopmentProjects" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails" xlink:title="00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyOneConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ConvertibleDebtDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertibleNotePurchaseAgreementMember" xlink:label="loc_AZTRConvertibleNotePurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRConvertibleNotePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyOneConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyOneConvertibleNotesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyOneConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DebtInstrumentDiscountPercentage" xlink:label="loc_AZTRDebtInstrumentDiscountPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AZTRDebtInstrumentDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizationLongtermDebtAndEquity" xlink:label="loc_us-gaapCapitalizationLongtermDebtAndEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCapitalizationLongtermDebtAndEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="loc_us-gaapProceedsFromSaleOfNotesReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNote" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNote" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNote" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ForwardStockSplitMember" xlink:label="loc_AZTRForwardStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AZTRForwardStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SeriesA1PreferredStockMember" xlink:label="loc_AZTRSeriesA1PreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AZTRSeriesA1PreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyOneConvertibleNoteMember" xlink:label="loc_AZTRTwoThousandTwentyOneConvertibleNoteMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_AZTRTwoThousandTwentyOneConvertibleNoteMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaapPreferredStockDividendRatePerDollarAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePerDollarAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails" xlink:title="00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureWarrantsAbstract" xlink:label="loc_AZTRDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandEighteenMember" xlink:label="loc_AZTRYearTwoThousandEighteenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandNineteenMember" xlink:label="loc_AZTRYearTwoThousandNineteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandNineteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_YearTwoThousandTwentyThreeMember" xlink:label="loc_AZTRYearTwoThousandTwentyThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_AZTRYearTwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/WarrantsDetailsNarrative" xlink:title="00000049 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureWarrantsAbstract" xlink:label="loc_AZTRDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:label="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRSharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails" xlink:title="00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionOneMember" xlink:label="loc_AZTRStockOptionOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionTwoMember" xlink:label="loc_AZTRStockOptionTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionThreeMember" xlink:label="loc_AZTRStockOptionThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_StockOptionFourMember" xlink:label="loc_AZTRStockOptionFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRStockOptionFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000051 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails" xlink:title="00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandSixteenStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandSixteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_OptionsExcercisableSharePrice" xlink:label="loc_AZTROptionsExcercisableSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTROptionsExcercisableSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails" xlink:title="00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_CommonStockWarrantsMember" xlink:label="loc_AZTRCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyTwoConvertibleNoteMember" xlink:label="loc_AZTRTwoThousandTwentyTwoConvertibleNoteMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AZTRTwoThousandTwentyTwoConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails" xlink:title="00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_IssuanceOfConvertibleNotes" xlink:label="loc_AZTRIssuanceOfConvertibleNotes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRIssuanceOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ChangeInFairValueOfConvertibleNotes" xlink:label="loc_AZTRChangeInFairValueOfConvertibleNotes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRChangeInFairValueOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConversionConvertibleNotes" xlink:label="loc_AZTRConversionConvertibleNotes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_AZTRConversionConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails" xlink:title="00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/StockOptionsDetailsNarrative" xlink:title="00000056 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandTwentyThreeStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandTwentyThreeStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandTwentyThreeStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwoThousandSixteenStockIncentivePlanMember" xlink:label="loc_AZTRTwoThousandSixteenStockIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AZTRTwoThousandSixteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:label="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_AZTRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOptionQuantitativeDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails" xlink:title="00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapDividendsPreferredStockStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails" xlink:title="00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails" xlink:title="00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails" xlink:title="00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails" xlink:title="00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_IncomeTaxReconciliationDebtFairValueAdjustment" xlink:label="loc_AZTRIncomeTaxReconciliationDebtFairValueAdjustment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AZTRIncomeTaxReconciliationDebtFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:label="loc_AZTREffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AZTREffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:title="00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_AZTRDeferredTaxAssetsDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AZTRDeferredTaxAssetsDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="loc_AZTRDeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AZTRDeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2037Member" xlink:label="loc_AZTRTaxYears2036Through2037Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2036Through2037Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_NoExpirationMember" xlink:label="loc_AZTRNoExpirationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRNoExpirationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2037Through2043Member" xlink:label="loc_AZTRTaxYears2037Through2043Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2037Through2043Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2039Through2043Member" xlink:label="loc_AZTRTaxYears2039Through2043Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2039Through2043Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TaxYears2036Through2038Member" xlink:label="loc_AZTRTaxYears2036Through2038Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_AZTRTaxYears2036Through2038Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000065 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ExclusiveLicenseAgreementMember" xlink:label="loc_AZTRExclusiveLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="loc_AZTRDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails" xlink:title="00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="loc_AZTRDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_AZTRFinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_AZTRFinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseInterest" xlink:label="loc_AZTRFinanceLeaseInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_AZTRFinanceLeaseInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000068 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_DisclosureOperatingLeasesAbstract" xlink:label="loc_AZTRDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AZTRDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_countryCA" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_BranfordCTMember" xlink:label="loc_AZTRBranfordCTMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AZTRBranfordCTMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrotonCTMember" xlink:label="loc_AZTRGrotonCTMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AZTRGrotonCTMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseMonthlyPayments" xlink:label="loc_AZTRFinanceLeaseMonthlyPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRFinanceLeaseMonthlyPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="loc_us-gaapLesseeFinanceLeaseTermOfContract1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseTermOfContract1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_FinanceLeaseExpense" xlink:label="loc_AZTRFinanceLeaseExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AZTRFinanceLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RetirementPlanDetailsNarrative" xlink:title="00000069 - Disclosure - Retirement Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansGeneralInformation" xlink:label="loc_us-gaapDefinedBenefitPlansGeneralInformation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlansGeneralInformation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000070 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_ConvertibleNotePurchaseAgreementMember" xlink:label="loc_AZTRConvertibleNotePurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRConvertibleNotePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_TwentyTwentyTwoConvertibleNotesMember" xlink:label="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_AZTRTwentyTwentyTwoConvertibleNotesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapInvestorMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://azitrainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000071 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_UnderwriterMember" xlink:label="loc_AZTRUnderwriterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AZTRUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aztr-20231231.xsd#AZTR_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_AZTRGrossProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_AZTRGrossProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081622592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Azitra,
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001701478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4478536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">21
Business Park Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Branford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">646-6446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock: Par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AZTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,042,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,804,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">The
registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended
December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRASSI
& CO., CPAs, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Jericho,
New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083088960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,795,989<span></span>
</td>
<td class="nump">$ 3,492,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_TaxCreditsReceivable', window );">Tax credits receivable</a></td>
<td class="nump">118,383<span></span>
</td>
<td class="nump">69,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income tax receivable</a></td>
<td class="nump">6,836<span></span>
</td>
<td class="nump">13,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">67,859<span></span>
</td>
<td class="nump">216,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">448,257<span></span>
</td>
<td class="nump">160,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,535,579<span></span>
</td>
<td class="nump">4,135,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">710,075<span></span>
</td>
<td class="nump">846,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease right-of-use asset</a></td>
<td class="nump">40,002<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">828,960<span></span>
</td>
<td class="nump">1,116,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">210,881<span></span>
</td>
<td class="nump">219,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred patent costs</a></td>
<td class="nump">742,229<span></span>
</td>
<td class="nump">800,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">47,760<span></span>
</td>
<td class="nump">47,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,115,486<span></span>
</td>
<td class="nump">7,167,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">897,272<span></span>
</td>
<td class="nump">784,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current financing lease liability</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">307,655<span></span>
</td>
<td class="nump">287,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">383,668<span></span>
</td>
<td class="nump">993,961<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,603,195<span></span>
</td>
<td class="nump">2,222,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term financing lease liability</a></td>
<td class="nump">26,169<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">537,523<span></span>
</td>
<td class="nump">840,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
<td class="nump">35,453<span></span>
</td>
<td class="nump">70,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,202,340<span></span>
</td>
<td class="nump">9,733,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value, 100,000,000 shares authorized at December 31, 2023 and 2022, 12,097,643 and 1,043,988 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">51,510,269<span></span>
</td>
<td class="nump">1,054,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(48,598,333)<span></span>
</td>
<td class="num">(37,314,552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">2,913,146<span></span>
</td>
<td class="num">(36,260,310)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">5,115,486<span></span>
</td>
<td class="nump">7,167,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,272,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,100,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,321,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">8,255<span></span>
</td>
<td class="nump">7,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 156,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_TaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_TaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597084146144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,097,643<span></span>
</td>
<td class="nump">1,043,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,097,643<span></span>
</td>
<td class="nump">1,043,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">205,385<span></span>
</td>
<td class="nump">205,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,337,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">380,657<span></span>
</td>
<td class="nump">380,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">380,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">380,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,274,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">851,108<span></span>
</td>
<td class="nump">851,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">391,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">391,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,000,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079431424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Service revenue - related party</a></td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="nump">$ 284,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,493,332<span></span>
</td>
<td class="nump">3,639,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,809,063<span></span>
</td>
<td class="nump">6,097,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,302,395<span></span>
</td>
<td class="nump">9,737,604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,616,395)<span></span>
</td>
<td class="num">(9,453,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(167,726)<span></span>
</td>
<td class="num">(251,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_EmployeeRetentionCredit', window );">Employee retention credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">229,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ForgivenessOfAccountsPayable', window );">Forgiveness of accounts payable</a></td>
<td class="nump">56,285<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ChangeInFairValueOfConvertibleNote', window );">Change in fair value of convertible note</a></td>
<td class="num">(3,630,100)<span></span>
</td>
<td class="num">(1,250,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">89,886<span></span>
</td>
<td class="num">(25,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(3,650,078)<span></span>
</td>
<td class="num">(1,226,762)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(11,266,473)<span></span>
</td>
<td class="num">(10,680,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(17,308)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,283,781)<span></span>
</td>
<td class="num">(10,680,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividends on preferred stock</a></td>
<td class="num">(1,355,347)<span></span>
</td>
<td class="num">(2,768,984)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (12,639,128)<span></span>
</td>
<td class="num">$ (13,449,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (12.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (12.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">6,924,453<span></span>
</td>
<td class="nump">1,055,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="nump">6,924,453<span></span>
</td>
<td class="nump">1,055,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ChangeInFairValueOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ChangeInFairValueOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee retention credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ForgivenessOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ForgivenessOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082652240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series A-1 Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series B Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 3,272,944<span></span>
</td>
<td class="nump">$ 14,100,533<span></span>
</td>
<td class="nump">$ 16,321,065<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 868,163<span></span>
</td>
<td class="num">$ (26,634,186)<span></span>
</td>
<td class="num">$ (25,765,919)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">205,385<span></span>
</td>
<td class="nump">380,657<span></span>
</td>
<td class="nump">391,303<span></span>
</td>
<td class="nump">1,043,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">184,465<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">184,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,510<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,680,366)<span></span>
</td>
<td class="num">$ (10,680,366)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,272,944<span></span>
</td>
<td class="nump">$ 14,100,533<span></span>
</td>
<td class="nump">$ 16,321,065<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">1,054,138<span></span>
</td>
<td class="num">(37,314,552)<span></span>
</td>
<td class="num">(36,260,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">205,385<span></span>
</td>
<td class="nump">380,657<span></span>
</td>
<td class="nump">391,303<span></span>
</td>
<td class="nump">1,043,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">151,505<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 151,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,283,781)<span></span>
</td>
<td class="num">$ (11,283,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Series B Convertible Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,124,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Series B Convertible Preferred Stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">9,494,887<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,495,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of preferred stock</a></td>
<td class="num">(3,272,944)<span></span>
</td>
<td class="num">$ (14,100,533)<span></span>
</td>
<td class="num">$ (17,445,824)<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">34,818,530<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34,819,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(380,657)<span></span>
</td>
<td class="num">(414,735)<span></span>
</td>
<td class="nump">7,707,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of issuance costs of $1,508,641</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">5,991,209<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,991,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs of $1,508,791, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 51,510,269<span></span>
</td>
<td class="num">$ (48,598,333)<span></span>
</td>
<td class="nump">$ 2,913,146<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,097,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085026048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 1,508,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078695536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,283,781)<span></span>
</td>
<td class="num">$ (10,680,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129,653<span></span>
</td>
<td class="nump">125,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">295,896<span></span>
</td>
<td class="nump">280,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_AccruedInterestOnConvertibleNotes', window );">Accrued interest on convertible notes</a></td>
<td class="nump">166,019<span></span>
</td>
<td class="nump">164,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">151,505<span></span>
</td>
<td class="nump">184,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(34,830)<span></span>
</td>
<td class="num">(821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ChangeInFairValueOfConvertibleNote', window );">Change in fair value of convertible notes</a></td>
<td class="nump">3,630,100<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ForgivenessOfAccountsPayable', window );">Forgiveness of accounts payable</a></td>
<td class="num">(56,285)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">41,417<span></span>
</td>
<td class="nump">7,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets and deferred patent costs</a></td>
<td class="nump">351,360<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">84,565<span></span>
</td>
<td class="num">(21,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(288,124)<span></span>
</td>
<td class="num">(49,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits receivable</a></td>
<td class="num">(48,717)<span></span>
</td>
<td class="nump">103,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(68,684)<span></span>
</td>
<td class="nump">420,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">6,886<span></span>
</td>
<td class="num">(15,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(283,102)<span></span>
</td>
<td class="num">(268,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities', window );">Contract liabilities</a></td>
<td class="num">(156,000)<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,362,375)<span></span>
</td>
<td class="num">(8,349,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(26,544)<span></span>
</td>
<td class="num">(33,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts', window );">Capitalization of deferred patent costs</a></td>
<td class="num">(214,152)<span></span>
</td>
<td class="num">(180,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_PaymentsToAcquireCapitalizationOfLicenses', window );">Capitalization of licenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(65,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Capitalization of patent and trademark costs</a></td>
<td class="num">(77,563)<span></span>
</td>
<td class="num">(61,598)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(318,259)<span></span>
</td>
<td class="num">(336,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from convertible notes, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_PaymentOfDeferredOfferingCosts', window );">Payment of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(216,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(7,392)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of transaction costs</a></td>
<td class="nump">5,991,359<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,983,967<span></span>
</td>
<td class="nump">4,134,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,696,667)<span></span>
</td>
<td class="num">(4,551,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,492,656<span></span>
</td>
<td class="nump">8,044,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,795,989<span></span>
</td>
<td class="nump">3,492,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability', window );">Obtaining a right-of-use asset in exchange for lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,418,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability', window );">Obtaining a right-of-use asset in exchange for financing lease liability</a></td>
<td class="nump">46,452<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ConversionOfNoteToCommonStock', window );">Conversion of note to common stock</a></td>
<td class="nump">9,495,072<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ConversionOfNoteToConvertiblePreferredStock', window );">Conversion of note to Series B Convertible Preferred Stock</a></td>
<td class="nump">1,124,759<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock', window );">Conversion of Series A, A-1, and B Convertible Preferred Stock to common stock</a></td>
<td class="nump">$ 34,819,301<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_AccruedInterestOnConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_AccruedInterestOnConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ChangeInFairValueOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ChangeInFairValueOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ConversionOfNoteToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of note to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ConversionOfNoteToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ConversionOfNoteToConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of note to convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ConversionOfNoteToConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of series A1 and B convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ForgivenessOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ForgivenessOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obtaining right of use asset in exchange for financing lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obtaining a right-of-use asset in exchange for lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of capitalization of deferred patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_PaymentsToAcquireCapitalizationOfLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of capitalization of licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_PaymentsToAcquireCapitalizationOfLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085265104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zyGpxj2Qg7gb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<span id="xdx_826_zzgaE43ZUfg2">Organization and Nature of Operations</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc. was founded on January 2, 2014. It is a synthetic biology company focused on screening and genetically engineering microbes of the
skin. The mission is to discover and develop novel therapeutics to create a new paradigm for treating skin disease. The Company&#8217;s
discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced
and engineered to make cellular therapies, recombinant therapeutic proteins, peptides and small molecules for precision treatment of
dermatology diseases. On May 17, 2023, the Company changed its name to from &#8220;Azitra Inc&#8221; to &#8220;Azitra, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a location in Montreal, Canada for certain research activities. This location and operations conducted there remained
consistent throughout 2022 and 2023. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
Stock Split, Change in Par Value, and Initial Public Offering</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company completed its initial public offering (IPO) in which it issued and sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230601__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNTL6bAsINvb" title="Shares of common stock">1,500,000</span> shares of its common stock at
a price to the public of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zW1UvWuhXVsl" title="Sale of stock price per share">5.00</span> per share. The shares began trading on the NYSE American on June 16, 2023 under the symbol &#8220;AZTR&#8221;.
The net proceeds received by the Company from the offering were $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvhItHSJllvl" title="Proceeds from initial public offering">6.0</span> million, after deducting underwriting discounts, commissions and
other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the effectiveness of the Company&#8217;s registration statement, the Company effected a <span id="xdx_901_eus-gaap--StockholdersEquityNoteStockSplit_c20230101__20230630_z83ahAlzuYhj" title="Forward stock split">7.1-for-1 forward stock split</span> of its
issued and outstanding shares of common stock (the Forward Stock Split). On May 17, 2023, the Company changed the par value of its capital
stock from $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MaximumMember_z6I6mWIxmA3e" title="Sale of stock price per share">0.01</span> to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MinimumMember_zr05IHCaqIei" title="Sale of stock price per share">0.0001</span>. Accordingly, all share and per share amounts for all periods presented in the accompanying audited consolidated
financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the Forward Stock
Split. Refer to Note 8 for additional details relating to the Forward Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
Concern Matters</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation
for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to
continue as a going concern. As of and for the year ended December 31, 2023, the Company has an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zhK13gazNIp2" title="Accumulated deficit">48.6</span> million,
a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zNIDC5NrkPkd" title="Loss from operations">7.6</span> million and used $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zUa4erHCXZp7" title="Net cash used in operating activities">7.4</span> million to fund operations. These factors among others raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
plans to continue to raise funds through equity and debt financing to fund operating and working capital needs; however, the Company
will require a significant amount of additional funds to complete the development of its products and to fund additional losses which
the Company expects to incur over the next few years as the Company does not yet have product revenue. There can be no assurance that
the Company will be successful in securing additional financing to meet its operating needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
conditions and events create uncertainty about the ability of the Company to continue as a going concern for twelve months from the date
that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary
should the Company be unable to continue as a going concern.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085169600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zu2k2EAJDC54" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<span id="xdx_826_zo2DKJIjEhE9">Summary of Significant Accounting Policies</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zMtiHuRO9Al6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zZqaCW4rAPe7">Basis
of Accounting</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zuAKEAiSIOZi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_z5isAYtCIGSh">Use
of Estimates</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
These estimates and assumptions are based on current facts, historical experience, and various other factors believed to be reasonable
under the circumstances, the results which form the basis for making judgements about the carrying values of assets and liabilities and
the recording of expenses that are not readily apparent from other sources. While management believes the estimates and assumptions are
appropriate, actual results may differ materially and adversely from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbhO8K0SBAj5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_ziWQJ4TFc4bh">Cash
and Cash Equivalents</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6JZhm12qyoe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zUG5HvOzVEsb">Property
and Equipment</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zxxdutHi8g2c" title="Property, plant and equipment, useful life">3</span> to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zYHSrbr4mOdl" title="Property, plant and equipment, useful life">10</span> years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zilBeWaVDAg7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zXgQuPq5jsw">Accounts
Receivable</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries its accounts receivable at cost less an allowance for expected credit losses. On a periodic basis, the Company evaluates
its accounts receivable and establishes an allowance for expected credit losses based on a history of past write-offs, collections and
current conditions. There was no allowance for credit losses at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zXnFt8Rbwac4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zfbgB7kzjFId">Deferred
Offering Costs</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&#8217;s initial public offering. In June 2023, the Company consummated its IPO and recorded
such amounts against the gross proceeds of its IPO within the statements of stockholders&#8217; equity. During the fourth quarter the
Company incurred $67,859 of costs related to a follow-on offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zNXhjUSSL1Oe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zZGESRvACDc4">Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;).
ASU 2016-02 requires lessees to present right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either
operating or financing leases based on the economic substance of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$<span id="xdx_90F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220101_ztnyfb3ehQyi" title="Right-of-use asset and lease liability">1,418,502</span> as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&#8217;s
option to extend certain leases ranges from <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zSeo4zMg8uZj" title="Lease term">36</span> &#8211; <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_z2il98dePDgc" title="Lease term">52</span> months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. The Company utilizes a weighted
average discount rate of <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zcnGnCh3Kx9i" title="Operating lease, weighted average discount rate">4.25</span>% and <span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zJ7LSKGJNpPa" title="Finance lease, weighted average discount rate">9.60</span>% for its operating and finance leases, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had operating right-of-use assets with a net value of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zMn2w1U4xA33" title="Operating lease right-of-use asset">828,960</span> and current and long-term operating lease
liabilities of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zx5EewTQfpAl" title="Current operating lease liability">307,655</span> and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zd3AkaCmHbAc" title="Long-term operating lease liability">537,523</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has
a term of <span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtM_c20231231_z2QaJxzUGq8j" title="Finance lease term">36</span> months. At December 31, 2023, the Company had financing right-of-use assets with a net value of $<span id="xdx_906_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_zuCS5CAC1OXl" title="Long term finance lease liability">40,002</span> and current and
long-term operating lease liabilities of $<span id="xdx_90D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zP39DMziATy4" title="Finance lease liability current">14,600</span> and $<span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zskZ2wli7W8j" title="Long term finance lease liability">26,169</span>, respectively.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziNUhc5MFc5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zOMApwqfbtN7">Intangible
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, <i>Goodwill and Other Intangible Assets</i>
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were $<span id="xdx_900_ecustom--ImpairmentOfLicenseAgreements_c20230101__20231231_zWv6Tn88ESZ" title="Impairment of license agreements">78,606</span> and
$<span id="xdx_909_ecustom--ImpairmentOfLicenseAgreements_c20220101__20221231_zfjusyt3FGCc" title="Impairment of license agreements">0</span> during the years ended December 31, 2023 and 2022, respectively, and are included in general and administrative expenses on the accompanying
consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--DeferredPatentCostsPolicyTextBlock_z4b4ly3qt0Z" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zxQIkWopin63">Deferred
Patent Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating
to deferred patent costs during the years ended December 31, 2023 and 2022 were $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqi1vsaTWV6" title="Impairment of intangible assets">272,754</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHx7Xqou0uCe" title="Impairment of intangible assets">0</span>, respectively, and are included in general
and administrative expenses on the accompanying consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUr7PcCCf6Pf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zq5aIFmoUVhl">Impairment
of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets (ASC 360-10), the Company&#8217;s policy
is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets.
The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition
of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value
of the net future operating cash flows generated by the asset.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Summary of Significant Accounting Policies (continued)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zPW2TWZB4w42" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zjkuYKwT7Bxh">Convertible
Debt and Warrant Accounting</span></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income (Expense).</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
debt</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &#8211; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&#8217;s
conversion features require bifurcation in accordance with ASC 815 &#8211; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
The Convertible Notes were converted into the Company&#8217;s common stock on the Closing Date of the Company&#8217;s IPO. Under 815-15-25,
the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825.
The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to
be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change
based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized
as a non-cash gain or loss in Other Income (Expense) on the statements of operations. The Company elected the fair value option for the
2022 Convertible Notes and recorded the notes at their initial fair values with subsequent changes in fair value recorded in earnings.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--ConvertiblePreferredStockPolicyTextBlock_zoDaQ41gDDYe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zWfXmquYxeSi">Convertible
Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in Note 8, at the Closing Date of the Company&#8217;s IPO, the Convertible Preferred stock converted into shares of the Company&#8217;s
common stock.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zSZKzFW576J" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zlP1wXMBJkAg">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the <i>five</i> steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers
(&#8220;ASC 606&#8221;), which are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>1</i>: Identify the contract(s) with a customer</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>2</i>: Identify the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>3</i>: Determine the transaction price</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>4</i>: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>5</i>: Recognize revenue when (or as) a performance obligation is satisfied</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z5TWStwucIwl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zBHxvW101E84">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, <i>Research
and Development</i>. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Advance payments for goods and services that will be used in future research and development
activities are expensed when the activity has been performed or when the goods have been received. Research and development costs incurred
were $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zroj86IPyoQb" title="Research and development">3,809,063</span> and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zE3vq10NMPol" title="Research and development">6,097,938</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company has a state tax credit receivable of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20231231_ztPBBt1if2c1" title="State tax credit receivable">86,778</span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20221231_zyQ9FwNbN8xl" title="State tax credit receivable">32,459</span>, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2023 and 2022, the Company has
$<span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_z3MIXlO8Zl1c" title="Pending refunds related to research and experimental development">20,040</span> and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zJUPVx5KHOC" title="Pending refunds related to research and experimental development">28,925</span>, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits.
At December 31, 2023 and 2022, the Company has also recorded $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20231231_zwPd68iTdYma" title="Refunds tax amount">11,565</span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20221231_z8DHBFkcmAy5" title="Refunds tax amount">8,282</span>, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLmBzSEROH7k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zLzLqCWaK226">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved. The Company recognizes the effect of forfeitures when the forfeitures occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&#8217;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, <i>Improvements to Nonemployee Share-Based Payment Accounting</i>, which expands the scope of ASC
718 to include share-based payment transactions to non-employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>. The expected volatility of the Company&#8217;s shares is estimated based on the average volatility of peer companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underlying
Common Stock Value</i>. The underlying common stock value of the Company&#8217;s shares is estimated by a third-party valuation expert
up until the Company&#8217;s IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
Interest Rate</i>. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zUHeCzIdfisg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zK0UNWqj7YP5">Income
Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, <i>Accounting for Income Taxes</i>. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2023 and December 31, 2022. The Company&#8217;s income
tax returns have not been examined by tax authorities through December 31, 2023.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zc2sDqE0Fo3l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z6nfOQDLexIc">Net
Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per weighted average share attributable to common stockholders using the weighted average number of shares
of common stock outstanding during the period. The Company computes diluted net loss per weighted average share attributable to common
stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period.
Potential common shares outstanding consist of stock options, warrants and preferred stock and are excluded if their effect is anti-dilutive.
Diluted weighted average common shares did not include any incremental shares for the fiscal year ended December 31, 2023 and 2022.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--CertainRisksAndUncertaintiesPolicyTextBlock_zxGQWdOD9QCh" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zTVzLJ61m7Gg">Certain
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding
to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical
industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on
key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztEoDnBavlIc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zVmQr5aENLK">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &#8211; Inputs are based upon observable or quoted prices for identical instruments traded
                                            in active markets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &#8211; Inputs are based upon quoted prices for similar instruments in active markets,
                                            quoted prices for identical or similar instruments in markets that are not active, and model-based
                                            valuation techniques for which all significant assumptions are observable in the market or
                                            can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &#8211; Inputs are generally unobservable and typically reflect management&#8217;s estimates
                                            of assumptions that market participants would use in pricing the asset or liability. The
                                            fair values are therefore determined using model-based techniques that include option pricing
                                            models, discounted cash flow models, and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1wB1vi2kIA7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zVuLsQuwtdtg">Financial
Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term
maturities of such instruments. The estimated fair value of the Company&#8217;s long-term debt approximates carrying value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z4b5eMa24sd1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zLSkO6OaZs5e">Concentration
of Credit Risk and Off- Balance Sheet Risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash
equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and
accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated
with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The
Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances
in the form of a money market account with a financial institution that management believes to be creditworthy.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCsompK9GpOf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zY6TggQUom35">Recent
Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes</i> (Topic 740): <i>Simplifying the Accounting for Income Taxes</i>.
This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing
additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted
this standard effective January 1, 2022, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 1026-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (ASC 326)</i>, which replaces the incurred loss methodology with the expected loss methodology. This standard is referred
to as the current expected credit loss (&#8220;CECL&#8221;) methodology. CECL This standard is effective for the Company on January 1,
2023. The Company has adopted this standard effective January 1, 2023, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</span></p>

<p id="xdx_858_zhfFJXBdUUYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597182079408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retention Credit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Retention Credit</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zBvN6RCxo9V9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<span id="xdx_82B_zQ2fuRdozvYf">Employee Retention Credit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CARES Act provides an employee retention credit (&#8220;CARES Employee Retention credit&#8221;), which is a refundable tax credit against
certain employment taxes of up to $<span id="xdx_900_ecustom--RefundableTaxCredit_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zFUbl7aEOpT1" title="Refundable tax credit">5,000</span> per employee for eligible employers. The tax credit is equal to <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MinimumMember_zc0neqHDL2j" title="Tax credit percent">50</span>% of qualified wages paid
to employees during a quarter, capped at $<span id="xdx_901_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zAUFQSnawIF3" title="Payments to employees">10,000</span> of qualified wages per employee through December 31, 2020. Additional relief provisions
were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September
30, 2021. Based on these additional provisions, the tax credit is now equal to <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MaximumMember_zycnb2CGuTx5" title="Tax credit percent">70</span>% of qualified wages paid to employees during a quarter,
and the limit on qualified wages per employee has been increased to $<span id="xdx_900_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_z78u0QxiVU68" title="Payments to employees wages">10,000</span> of qualified wages per quarter. In April 2022, the Company
determined it qualified for the tax credit under the CARES Act and recorded a receivable for $<span id="xdx_90B_ecustom--EmployeeRetentionCredit_c20220401__20220430_zBKsn1N6sBGe" title="Employee retention credit">229,813</span> and recognized the amounts as other
income on the statement of operations. The Company received full payment for the amount in September 2022.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085091600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zslLWzaeL29i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<span id="xdx_821_z6zNl2UHX9r9">Property and Equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvzIVcCNTZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zhpgQy9pfYuk" style="display: none">Schedule of Property And Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zNAL2YgfmwE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zIjSyKKYbC0b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zuC6SM2kvHa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,013,134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,034,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVm6VIlXmUW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,825</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd02iNHTOvzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1lRbxZsED2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,855</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znhsWhNZQxMf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Building equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFzA_zDejBdfUkalj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,112,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133,507</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFzA_zqxxiUqswxzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation &amp; amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(401,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(286,549</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFzA_zQii0gDfTlD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">710,075</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">846,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zGcz3xiuQAn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">4. Property and Equipment (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90C_eus-gaap--Depreciation_c20230101__20231231_z3s2fT1ANBLd" title="Depreciation expense">122,010</span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20220101__20221231_zJZC3Q4S9AVc" title="Depreciation expense">120,651</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022 there were losses on disposal of property and equipment recorded of $<span id="xdx_905_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20230101__20231231_z4yIhyN2T153" title="Losses on disposal of property and equipment">41,417</span> and $<span id="xdx_907_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20220101__20221231_zGRV3dcPaiK2" title="Losses on disposal of property and equipment">7,923</span>, respectively,
and are included in other income (expense) on the accompanying consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085075824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zVdcVEe2kTi6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<span id="xdx_82E_zIAL8Gb7y7hl">Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zM3kuxjk4HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zxrrCXioz30b" style="display: none">Schedule of Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_901_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDbfGwolEBIg" title="Estimated Useful Life">Indefinite</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zy3fFZEzZ4i6" style="width: 9%; text-align: right" title="Gross Amount">57,474</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztfG906mrQC5" style="width: 9%; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zS0kweJv22ek" style="width: 9%; text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1FgkZk9Spm" style="width: 9%; text-align: right" title="Net Amount">57,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziHF1SdrAmua" title="Estimated Useful Life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zksXf151TqY3" style="text-align: right" title="Gross Amount">169,190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zTz2l95V2Oil" style="text-align: right" title="Accumulated Amortization">15,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeWgY3CSdip5" style="text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztiUx2PBENf2" style="text-align: right" title="Net Amount">153,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zClj2XepS3we" title="Estimated Useful Life">17</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQavO1GiYWxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount">78,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zFFzyn5mP5Ud" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpW3Pt6wclrf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset">78,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9vZYtq0A4Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_zVQsw5yPtnz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount">305,270</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zRMH75DR6O5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">15,783</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231_zJqlewJv4bIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset">78,606</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_ziaQ7SuYurh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount">210,881</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_90D_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV1YCRMn1jC" title="Estimated Useful Life">Indefinite</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQyNzZsqxFLb" style="width: 9%; text-align: right" title="Gross Amount">53,999</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zzP801sPs0a5" style="width: 9%; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zH1tv1jdc154" style="width: 9%; text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zitqpRkuAcJ9" style="width: 9%; text-align: right" title="Net Amount">53,999</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zspge0w8Yn3g" title="Estimated Useful Life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCCQnEujbfj" style="text-align: right" title="Gross Amount">108,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJgplqHK3zK6" style="text-align: right" title="Accumulated Amortization">8,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6B2SLwkSvza" style="text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNMXtmTPYg7a" style="text-align: right" title="Net Amount">100,058</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_znZcSRqWHOJ6" title="Estimated Useful Life">17</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z7zYmOdIk2i3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount">65,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zNALvIHma669" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSywPZlK9lof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zdlSqPfJUS27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount">65,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zf2Zzk4pJClh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount">227,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zB30cLLzzPJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">8,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231_zUDcSeorX2J2" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zEymGA2twQPj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount">219,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zn1DKLlaTTL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, amortization expense related to intangible assets was $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z9eSQ5cwYqp" title="Amortization expenses of intangible assets">7,643</span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zvKGvxYdD9Zj" title="Amortization expenses of intangible assets">5,234</span>, respectively. During
the third quarter, the Company recorded an impairment of $<span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_zwA8EYqjk4gk" title="Impairment loss">78,606</span> to licensing costs, recorded within general and administrative expenses
on the consolidated statements of operations, as there is uncertainty as to the likelihood of the patent being granted. All subsequent
licensing costs have been expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085143664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z0gkRTPy8i7f" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<span id="xdx_823_zYTs3kO8NeK4">Accrued Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAYvX5tAdQO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5Gx6qiSRuXl" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zBRNgjoHnx2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zksyM47zs8Mg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_maALCzSIF_z2R8dtyly0m9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Employee payroll and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">371,010</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_maALCzSIF_zbcqAwmeI9x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,082</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedResearchAndDevelopmentProjects_iI_maALCzSIF_zV6cWh29dGqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">316,389</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPayableCurrent_iI_maALCzSIF_zNQEbXEkezP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,792</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzSIF_z4EFnNrFEoz4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,502</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzSIF_zzaR84ou17L9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzSIF_zbJBjtGopUVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">383,668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,961</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zJZThjKQ5he6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">6. Accrued Expenses (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and
efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and
non-clinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of
services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services
will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced
any material differences between accrued costs and actual costs incurred since its inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085066272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zB4NxjGNUwD5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<span id="xdx_826_z1Y1bwMuhc82">Convertible Debt</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zsuFUQHPerUi" title="Convertible promissory note">2,000,000</span> of convertible promissory notes. On the
same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zVyS6HtvEZl9" title="Convertible promissory note">1,000,000</span>. The 2021
Convertible Note bears interest at a rate of <span id="xdx_909_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zHJjg8kupXyc" title="Bearing interest, percentage">6</span>% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note
automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal
and accrued interest divided by the conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zIE6kvIzX2x3" title="Conversion price per share">48.00</span>, which is subject to adjustment as defined in the note agreement. The
2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in
control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zfos0GvtY81e" title="Debt issuance costs">15,613</span> related to the 2021 Convertible
Note, which has been recorded as a debt discount and will be amortized over the term of the 2021 Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zmRQNoH25j6c" title="Convertible promissory note">4,500,000</span> convertible
promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors
totaling $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwDCSA3ABfW" title="Convertible promissory note">4,350,000</span>. The 2022 Convertible Notes mature on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0vTRnHLAF71" title="Maturity date">January 13, 2023</span> or the occurrence of an Event of Default (as defined) and
bear interest at a rate of <span id="xdx_908_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zoHoqlUjg6k8" title="Bearing interest, percentage">8</span>% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding
principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of
a Qualified Financing resulting in gross proceeds to the Company of at least $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pn6n6_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0I1sjOfHoIk" title="Gross proceeds">20</span> million into securities issued in connection with the
Qualified Financing, at a discount of <span id="xdx_901_ecustom--DebtInstrumentDiscountPercentage_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zmHenJ7sYyod" title="Debt discount, percentage">30</span>% per share; b) upon the closing of a Change of Control event into shares of capital stock of
the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued
to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public
offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the
holders, at the maturity date into a new class of Company&#8217;s Preferred Stock (Series C Preferred) equal to the quotient of the outstanding
principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of $<span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pn6n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zcedl9DQgwUe" title="Capitalization amount">30</span>
million divided by the Company Capitalization, as defined in the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company elected to convert the 2021 Convertible Note, including interest accrued but not yet paid of $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSr0jJyHaTK8" title="Interest accrued">124,759</span> at a
conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp0p0_c20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3wCAXeZOA2" title="Conversion price per share">48.00</span> into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyblRmCvggv3" title="Issuance of conversion shares">23,432</span> shares of its Series B Preferred Stock in accordance with the terms outlined in the Note Purchase
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the 2022 Convertible Notes were amended to extend the maturity date to<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zY3frpMLGlN1" title="Maturity date"> March 31, 2023</span> and to change the conversion price
upon a Qualified Financing or Change in Control event to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn6n6_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zfV9vY8m4tv7" title="Conversion price">30</span> million divided by the number of shares of the Company&#8217;s common stock
issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">7. Convertible Debt (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
April and June 2023, the 2022 Convertible Notes were further amended to extend the maturity date to<span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zC791egVMhRe" title="Maturity date"> <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zgKSytheB3v" title="Maturity date">September 30, 2023</span></span> and allow for
the sale of additional notes of $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zJtomlTHO8R4" title="Sale of additional notes"><span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zvMDubOEXtr6" title="Sale of additional notes">500,000</span></span> for a total aggregate principal of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zSKRImPURgTb" title="Aggregate principal"><span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z2EPv5hSuP65" title="Aggregate principal">4,850,000</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 21, 2023, the 2022 Convertible Notes, including accrued interest of $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFr6MT17Q612" title="Accrued interest">265,052</span>, were converted to <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_dd_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z34nLXIhKu5g" title="Converted shares">1,846,020</span> shares of the Company&#8217;s
common stock equal to $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_iN_ddi_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z6puenIbVVSe" title="Conversion of convertible notes payable">9,495,072</span>. Upon conversion, the Company recorded a change in fair value of $<span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20230101__20231231_zx8NOxYGl8Fi" title="Change in fair value of convertible note">3,630,100</span> and $<span id="xdx_900_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20220101__20221231_ze9bQ2dD0vuc" title="Change in fair value of convertible note">1,250,000</span> for the years
ended December 31, 2023 and 2022, respectively, which was recognized as a non-cash change in fair value in Other Income (Expense) on
the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the
accounting considerations under ASC 480 &#8211; Distinguishing Liabilities from Equity, and ASC 815 &#8211; Derivatives and Hedging.
The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company
also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria
for bifurcation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zbwDcoZihTbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zwa2WTYnxfB9" style="display: none">Schedule of Convertible
Notes Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">2021 Convertible Note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zQAWEoHtTA06" style="width: 16%; text-align: right" title="Convertible notes payable">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zG8PFsoAyOz1" style="width: 16%; text-align: right" title="Convertible notes payable">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z9Ve8MgvcpP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwROubSS7hKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total convertible notes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231_zCulOaH45P72" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231_z52LDFTUSHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable, net">6,600,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zXilFwMjPPMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense was $<span id="xdx_900_eus-gaap--InterestAndDebtExpense_c20230101__20231231_zShQKNn3X0g6" title="Interest expense">166,019</span> and $<span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20220101__20221231_z4N6Q1pyAnAa" title="Interest expense">172,592</span> and included debt issuances costs of $<span id="xdx_902_eus-gaap--DeferredFinanceCostsGross_iI_c20231231_zmHfnCGKve5a" title="Debt issuances costs">0</span> and $<span id="xdx_906_eus-gaap--DeferredFinanceCostsGross_iI_c20221231_zLdkGoflxCTe" title="Debt issuances costs">7,981</span> during the years ended December 31, 2023 and 2022,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085010112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfmmAZWhREfd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<span id="xdx_82B_zVMTzpFF7aa2">Stockholders&#8217; Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2023, the Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20230516__20230517_zMYfgkr4HJqd" title="Forward stock split">7.1-for-1 forward stock split</span> (the &#8220;Forward Stock Split&#8221;) of its issued and outstanding
shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred
stock. The par value of the common stock was adjusted as a result of the Forward Stock Split from $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230517__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zXVQFmTN3KL" title="Common stock, par value per share">0.01</span> to $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zckVq9mHkygl" title="Common stock, par value per share">0.0001</span> and the authorized
shares were increased to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_z0wIOsHVc0Rc" title="Common stock shares authorized in connection with forward stock split">100,000,000</span> shares of common stock in connection with the Forward Stock Split. Fractional shares resulting
from the Forward Stock Split were rounded down to the next whole share and in lieu of any fractional shares the Company will pay a cash
amount to the holder of such fractional shares. The accompanying financial statements and notes to the financial statements give retroactive
effect to the Forward Stock Split for all periods presented. Shares of common stock underlying outstanding stock-based awards and other
equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately
decreased in accordance with the terms of the agreements governing such securities.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, per the Company&#8217;s amended and restated Certificate of Incorporation, the Company was authorized to
issue <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zBjt3kSc1eV6" title="Common stock shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNjdTzKwbSeg" title="Common stock shares authorized">100,000,000</span></span> shares of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zd9xYndwQNKj" title="Common stock, par value per share"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zneYIyPgWZQ5" title="Common stock, par value per share">0.0001</span></span> par value common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--CommonStockVotingRights_c20230101__20231231_zJzVE0wEGHr7" title="Common stock voting rights description">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zEMOAyWLcmDf" title="Common stock shares reserved for future issuance">1,611,991</span> shares of common stock reserved for future issuance for the potential exercise of stock options and warrants
outstanding at December 31, 2023.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">8. Stockholders&#8217; Equity (continued)</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, per the Company&#8217;s amended and restated Certificate of Incorporation, the Company has authorized <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zFe6uTMidezb" title="Preferred stock shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zanALIvFt061" title="Preferred stock shares authorized">1,437,150</span></span>
shares of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zt3kncZx0Ota" title="Preferred stock, par value per share"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zQT3TikYGNx9" title="Preferred stock, par value per share">0.0001</span></span> par value preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zVVnUOzsR8pa" title="Convertible preferred stock shares issued">23,432</span> shares of its Series B Preferred Stock related to conversion of the 2021 Convertible Note at
a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zjLtM0FCi1jb" title="Convertible preferred stock conversion price per share">48.00</span> per share (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A, Series A-1, and Series B Preferred Stock had the following rights, preferences and privileges :</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock was converted, at the option of the holder, into common shares based upon a predefined formula. The holders of preferred
stock converted such shares into common shares upon the Company&#8217;s IPO. For purpose of conversion, the initial conversion price
was $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7WmJ8tNwJmh" title="Original issue price per share of series A preferred stock">16.25</span> per share (original issue price) for Series A Preferred Stock, $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zbKyqBCcOQ3d" title="Original issue price per share of series A-1 preferred stock">37.50</span> per share (original issue price) for Series A-1 Preferred
Stock, and $<span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7BoPie7HAK5" title="Original issue price per share of series B preferred stock">43.45</span> per share (original issue price) for Series B Preferred Stock, and was subject to adjustment as described in the Certificate
of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Company&#8217;s IPO in June 2023, all of the outstanding preferred stock converted to common stock, resulting in the issuance of
<span id="xdx_900_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqmhSe3ZQBh6" title="Convertible series A preferred stock shares issued">1,458,233</span>, <span id="xdx_90C_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFRdpE43WVj4" title="Convertible series A-1 preferred stock shares issued">2,964,849</span>, and <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zJMxbiTAyI5c" title="Convertible series B preferred stock shares issued">3,284,553</span> shares of common stock in exchange for outstanding Series A, Series A-1, and Series B Preferred Stock,
respectively. There was no gain or loss upon conversion.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Series A, Series A-1, and Series B Preferred Stock were entitled to vote on any matter presented to the stockholders of
the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of preferred stock was entitled to cast the number of votes equal to the number
of whole shares of Common Stock into which the shares of preferred stock held by such holder converted as of the record date for determining
stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock were each entitled to elect
one director of the Corporation. The holders of the Series B Stock were entitled to elect two members of the Board. Each class of preferred
stock could have removed such directors from office and to fill any vacancy caused by the resignation, death or removal of such directors
under certain circumstances as described in the Certificate of Incorporation.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A Preferred Stock were entitled to receive dividends at a rate of <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLw0zrVdj0B2" title="Dividend percentage on series A preferred stock">8</span>% per annum of the Series A original issue price
of $<span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znVMn8l6vnl5" title="Original issue price per share of series A preferred stock">16.25</span> per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends accumulated
from the original date of issuance of the Series A Preferred Stock, were cumulative and were payable upon declaration of the Board of
Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series A Preferred Stock as there
was no longer any Series A Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A-1 Stock were entitled to receive dividends at a rate of <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_ztBd3BNB8Gu4" title="Dividend percentage on series A-1 preferred stock">8</span>% per annum of the Series A-1 original issue price of $<span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zzkCvOlJPWl3" title="Original issue price per share of series A-1 preferred stock">37.50</span>
per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends were cumulative and were payable
upon declaration of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on
Series A-1 Preferred Stock as there was no longer any Series A-1 Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">8. Stockholders&#8217; Equity (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B Stock were entitled to receive dividends at a rate of <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaVJD4xCAc8j" title="Dividend percentage on series B preferred stock">8</span>% per annum of the Series B original issue price of $<span id="xdx_903_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zH19oPIj8Ws8" title="Original issue price per share of series B preferred stock">43.45</span>
per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to the Series B Preferred Stock). Dividends were cumulative and were payable upon declaration
of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series B Preferred
Stock as there was no longer any Series B Preferred Stock outstanding.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock were entitled to receive,
prior to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock
original issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment
of all preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation
available for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock,
pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted
into Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085037568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_80D_ecustom--WarrantsTextBlock_z7ZL09p17T2i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<span id="xdx_828_zNloBHkOS3R8">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued warrants to purchase <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl8FR2llnrmh" title="Number of warrants issued to purchase common stock">6,745</span> shares of common stock in 2018 in conjunction with convertible debt financing that have a redemption
provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it has converted into)
at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent appraiser.
As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based on ASC 480
&#8211; Distinguishing Liabilities from Equity. These warrants have an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zGUeVATmqlV2" title="Exercise price of warrants per share">0.48</span> per share and a term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zVNTfymJH4qc" title="Maturity term">10</span> years. The
warrants are marked to market each reporting period. The fair value is $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlBQpdkEen9" title="Fair value of warrants">35,453</span> and $<span id="xdx_902_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3p8YgMIYdDl" title="Fair value of warrants">70,283</span> at December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead
meet equity classification criteria. The <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZMXNdQLIKh" title="Number of warrants issued">11,466</span> warrants issued in 2016 had a weighed average exercise price of $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpW4FIoFM0d3" title="Weighed average exercise price">0.01</span> and a weighted
average term of <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_dtY_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkfifuOkytud" title="Weighted average term">9.7</span> years and expired upon the initial public offering in June 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQBju39i6ktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants outstanding at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zPZXVjgU03Q2" style="display: none">Schedule
of Information about Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2018</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zkCdwpqzeEc" style="width: 9%; text-align: right" title="Exercise price of warrants">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zqwmz86hzsfi" style="width: 9%; text-align: right" title="Number of warrants outstanding">47,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zZQB7cZI9yQd" title="Weighted Average Remaining Contractual Life, Outstanding">4.5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDzgr0Jg8Ltd" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_ziu9fUMDi1jc" style="width: 9%; text-align: right" title="Number of warrants exercisable">47,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zFum6EmXhFEc" title="Weighted Average Remaining Contractual Life, Exercisable">4.5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDZIfgEPrF4g" title="Weighted Average Exercise Price, Exercisable">0.48</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zp59YIvl2e7l" style="text-align: right" title="Exercise price of warrants">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zI69yuzjnSla" style="text-align: right" title="Number of warrants outstanding">215,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zlnYOwUWtjh6" title="Weighted Average Remaining Contractual Life, Outstanding">2.4</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zIDZkPocI7ah" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zRxszl8YDn92" style="text-align: right" title="Number of warrants exercisable">215,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zO4D9DbLSszc" title="Weighted Average Remaining Contractual Life, Exercisable">2.4</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zYZ23YLUv4n5" title="Weighted Average Exercise Price, Exercisable">5.28</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zoUrwgmKzUhk" style="padding-bottom: 1.5pt; text-align: right" title="Exercise price of warrants">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zyvRh2JSCFQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zt1XkaHM9rfl" title="Weighted Average Remaining Contractual Life, Outstanding">4.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zh8jG0wWUC5k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zAJs7XeX8rM4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_ztKvjweQ94Y1" title="Weighted Average Remaining Contractual Life, Exercisable">4.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zCfJMwwPkhC2" title="Weighted Average Exercise Price, Exercisable">6.25</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7xK4duS2j36" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">323,736</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRNfZFq6smlb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">4.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBz0QE0X97Hb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable">323,736</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxcQjjPXULUg" title="Weighted Average Exercise Price, Exercisable">4.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zSFicp98Qbg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085066272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionTextBlock', window );">Stock Options</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--FairValueOptionTextBlock_ztthSgv6sYdb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<span id="xdx_820_zvYjWmmeT4s2">Stock Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company&#8217;s Board of Directors and stockholders approved the 2023 Stock Incentive Plan (&#8220;2023 Plan&#8221;).
The 2023 Plan allows the Committee to grant up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230301__20230331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzPMcaWcSdL">2,000,000</span> shares of Common Stock in the form of incentive and non-statutory stock options,
restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and non-employees. As of December
31, 2023, options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEeOuRQC5yHj" title="Stock options granted">40,000</span> shares of common stock had been granted and were outstanding under the 2023 Plan and <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEtzj3orjm1" title="Stock options available for grants">1,960,000</span> shares
of common stock were available for grant under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, the Company established the Azitra Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options and
restricted shares to the Company&#8217;s employees, officers, directors, advisors and consultants. As of December 31, 2023, options to
purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD9scnGAjqX3" title="Stock options granted">1,248,255</span> shares of common stock had been granted and were outstanding under the 2016 Plan and <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CfoIW3sj06" title="Stock options available for grants">242,340</span> shares of common stock
were available for grant under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recognized stock compensation expense of $<span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgh4WNwNWMni" title="Stock compensation expense">125,555</span> and $<span id="xdx_90A_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFuIFefi7ape" title="Stock compensation expense">25,950</span>, included in general and
administrative and research and development on the accompanying statement of operations, respectively. During the year ended December
31, 2022, the Company recognized stock compensation expense of $<span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZdNmpXreBda" title="Stock compensation expense">131,185</span> and $<span id="xdx_902_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRjfKE3yoZE5" title="Stock compensation expense">53,280</span>, included in general and administrative and research
and development on the accompanying statement of operations, respectively, relating to the issuance of service-based stock options. At
December 31, 2023, there was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQWLNqwXgBUl" title="Performance stock options shares">326,438</span> of unamortized compensation expense that will be amortized over a remaining weighted-average period
for the 2016 Plan and 2023 Plan of approximately <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zt124Q1nIaK8" title="Weighted average period">1.32</span> and <span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember_zRIjwwgBicja" title="Weighted average period">3.58</span> years, respectively. At December 31, 2023 and 2022, there were <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z9dtWmEXgX76" title="Number of stock options outstanding"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNNUGhdowyf4" title="Number of stock options outstanding">13,120</span></span>
performance-based options outstanding with a fair value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5EfcXfS8wZ6" title="Fair value of stock options"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDliqpi9yO6" title="Fair value of stock options">109,551</span></span>. During the years ended December 31, 2023 and 2022, the Company did
not recognize any compensation expense for performance-based options. The Company determined the options qualified as plain vanilla under
the provisions of SAB 107 and the simplified method was used to estimate the expected option life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_z0IW86DeXVh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about options outstanding and exercisable at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zIyC4GBKAWC3" style="display: none">Schedule of Information about Options Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_z8alUhhaGHvf" style="width: 11%; text-align: right" title="Number of options exercise price">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zxyowzgtjtj" style="width: 11%; text-align: right" title="Number of options outstanding">246,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR3Ann5Ixp79" title="Weighted Average Remaining Contractual Life, Options outstanding">2.0</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zt9pjLBKdbci" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Options outstanding">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zo8WiVuiKYZ7" style="width: 10%; text-align: right" title="Number of options exercisable">246,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zYT3Df1fOJ71" title="Weighted Average Remaining Contractual Life, Options exercisable">2.0</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR9c35belXWj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Options exercisable">0.48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_z230LJtrVUte" style="text-align: right" title="Number of options exercise price">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zG1uZTAAOHKi" style="text-align: right" title="Number of options outstanding">202,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEpD9VstCDi4" title="Weighted Average Remaining Contractual Life, Options outstanding">2.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zTBl3sDX1S83" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEz0aNcZOps9" style="text-align: right" title="Number of options exercisable">202,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zaBAK7ymcR3" title="Weighted Average Remaining Contractual Life, Options exercisable">2.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zebXAPfhb2Qj" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable">0.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNplBbt1s6i" style="text-align: right" title="Number of options exercise price">1.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zjdmUFeW7k" style="text-align: right" title="Number of options outstanding">800,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNyXrER7XRx2" title="Weighted Average Remaining Contractual Life, Options outstanding">7.3</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zQpwkXxVK3rf" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding">1.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zTTtxALwWwpl" style="text-align: right" title="Number of options exercisable">572,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zhRU9mi8Ph2b" title="Weighted Average Remaining Contractual Life, Options exercisable">7.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zu2hHQ7pyKbi" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable">1.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_ziJR95ZKgtO6" style="padding-bottom: 1.5pt; text-align: right" title="Number of options exercise price">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zmQXbPGAObYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding">40,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zSRjIM5YVT7h" title="Weighted Average Remaining Contractual Life, Options outstanding">9.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zinJOCaNbm2l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_z7fmXVkMUUQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable">4,167</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zNrZYLH8kxX3" title="Weighted Average Remaining Contractual Life, Options exercisable">9.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zg0wp74KBlKi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zurrTuXFjww2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">1,288,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z5EguCpa9YGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">1,025,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zsBU4Knl9oV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znzMZ8DIaDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
stock option activity for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z8jQ1C39P195" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zSNcOmTFKIEk" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning">1,381,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zugnGEAh2Rc4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding">1.34</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zC3Aneb4tN5i" style="text-align: right" title="Number of Options, Exercised">(888</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zCIG5MDvbj1e" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_zesRlD2lIsAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(90,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zL7rTaF8BFSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">5.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zV4J4DYMImTi" style="text-align: right" title="Number of Options, Outstanding Beginning">1,290,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_z0zusWSFR2l4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">1.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zyVwOyA2CMY9" style="text-align: right" title="Number of Options, Granted">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zEW8hL496vA8" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zUM7hFyG2jj2" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zXJUrtb9U9Y5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zi0Q53h4PbQ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(42,063</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zxDSVZ0EUXHg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z2xIL8GpDF76" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">1,288,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOGJvImz7sfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">1.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z6oqf11p9Ps7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">10. Stock Options (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBKxZCmf8BQh" title="Shares available for future grant">242,340</span> shares available for future grant under the 2016 Plan and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z83BldKcWmz4" title="Shares available for future grant">1,960,000</span> available under the 2023 Plan at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_zh1YyAYYvNZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
intrinsic value for the 2016 plan for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_zyUPIhhTgClk" style="display: none">Schedule of Total Intrinsic Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Value of Stock at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zrkBRiqqQy2i" style="width: 16%; text-align: right" title="Options Outstanding Value of Stock">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--OptionsExcercisableSharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zOoksrDCpKWd" style="width: 16%; text-align: right" title="Options Exercisable Value of Stock">0.92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zb8PSyGiExx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Exercise Price">0.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zNQKltQxeIx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable Exercise Price">0.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Intrinsic Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zEuooQLcCDTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Intrinsic Value Per Share">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z78JkwIjJ5Yg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Excercisable Intrinsic Value Per Share">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options O/S</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zyBSUf7Rfjac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding">246,137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z2BQQGDGzlWh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable">246,137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Intrinsic Value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zPFMR5g23Ftb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Intrinsic Value">108,300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z6O0lcqKxIFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable Intrinsic Value">108,300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zh8qcwh0tcE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a company's election to apply the fair value option for measurement and reporting of eligible financial assets and liabilities (as defined), as well as certain other eligible items (as defined) included in the statement of financial position, whether such option is elected for a single eligible item or a group of similar eligible items and is in addition to other disclosures concerning fair value which the company may be required to provide. Such disclosure might be expected to include: (1) for items included in the statement of financial position: (a) the reasons for electing a fair value option for each eligible item or group of similar eligible items; (b) if the fair value option is elected for some but not all eligible items within a group of similar eligible items: (i) a description of those similar items and the reasons for partial election and (ii) information of how the group of similar items relates to individual balance sheet line items; (c) for each line item in the statement of financial position that includes an item or items for which the fair value option has been elected: (i) information of how each line item in the statement of financial position relates to major categories of assets and liabilities presented in accordance with other fair value disclosures and (ii) the aggregate carrying amount of ineligible items included in each line item in the balance sheet, if any; (d) the difference between the aggregate fair value and the aggregate unpaid principal balance (assuming contractual principal amounts and fair value option elected) of: (i) loans and long-term receivables (other than securities otherwise reported at fair value) and (ii) long-term debt instruments; (e) for loans held as assets for which the fair value option has been elected: (i) the aggregate fair value of loans that are 90 days or more past due, (ii) if the policy is to recognize interest income separately from other changes in fair value, the aggregate fair value of loans in nonaccrual status, and (iii) the difference between the aggregate fair value and the aggregate unpaid principal balance for loans that are 90 days or more past due, in nonaccrual status, or both; (f) for investments that would have been accounted for under the equity method if the entity had not chosen to apply the fair value option, the information required for such investments, if material either individually or in the aggregate; (2) for items included in the income statement: (a) the amounts of gains and losses from fair value changes included in earnings and in which line in the income statement those gains and losses are reported whether or not combined with gains and losses from items required to be accounted for at fair value; (b) a description of how interest and dividends are measured and where they are reported in the income statement; (c) for loans and other receivables held as assets: (i) the estimated amount of gains or losses included in earnings attributable to changes in instrument-specific credit risk and (ii) how the gains or losses attributable to changes in instrument-specific credit risk were determined; (d) for liabilities with fair values that have been significantly affected during the reporting period by changes in the instrument-specific credit risk: (i) the estimated amount of gains and losses from fair value changes included in earnings that are attributable to changes in the instrument-specific credit risk, (ii) qualitative information about the reasons for those changes, and (iii) how the gains and losses attributable to changes in instrument-specific credit risk were determined; and (3) certain other disclosures as required or determined to be provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//825/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597084931760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_802_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zpZPvJubsqMj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<span id="xdx_823_zqiV7bvlq3G6">Fair Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBKPHKKuW5vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_ziY5xp84EIgb" style="display: none">Schedule of Fair Value Measurements for Assets and Liabilities</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2e8yspYLvIh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zk6TsCYXF1Rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zstjytY83pPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKGa7vl2qWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zHlPqQZ1mqmc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">35,453</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">35,453</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z3EYgVVW1NU9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFv6jSbplQ79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoS2fezKmjEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxPBFbWHocb9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9zxz54b4MHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zIEMn0IQf2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">70,283</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">70,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNoteMember_zYi48rZhccb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z8XA51UIyGpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,670,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,567,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zuTmJjT7RD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z0kZpwkZv4If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zncfXAazObO" style="display: none">Schedule
of Changes in Level 3 Instruments Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1p34BQtPLUl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_z1q7e27CglDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">71,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zurp5fkLQ478" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(821</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfConvertibleNotes_z1NKCLvE1QTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zH3s99L4a9gi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_ztNUsYSMFtuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,670,283</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zXKBGPbrt20d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,830</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zvSvJ0XeOJO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,630,100</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConversionConvertibleNotes_zHJuLjed3EO4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Conversion of 2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,230,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zve30gNh3qe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zmd6jwOWj7Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">11. Fair Value Measurements (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zoOSLa7v7TR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zhFxpIcLF5B4" style="display: none">Schedule
of Fair Value of Warrants Using Black Scholes Option Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Underlying common stock value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zUDDyoy1CJh3" style="width: 16%; text-align: right" title="Dividend yield">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231_zXTl2VrkBAci" style="width: 16%; text-align: right" title="Dividend yield">1.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zYkWaZCcl9El" title="Expected term (years)">4.29</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zpLwB0ubkzwj" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_z7tZJPnP41E4" style="text-align: right" title="Expected volatility">99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zfcaq46ibAla" style="text-align: right" title="Expected volatility">86</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zN4HKuQkBTmk" style="text-align: right" title="Risk free interest rate">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zm0mVHMFB1P2" style="text-align: right" title="Risk free interest rate">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zePJz5kqEL6l" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zOnRUNZeT7x1" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zY5Wyo7xpau6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuation
in the fair value of the Company&#8217;s Common stock is the primary driver for the change in the Common Stock Warrant liability valuation
during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to their redemption, fluctuations in the various inputs, including the enterprise value, time to liquidity, volatility, and discount
rate are the primary drivers for the changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the
enterprise value, estimated time to liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible
Notes generally increases.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085040000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zBMkOwBVb9Cg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<span id="xdx_82C_z6xU1tXD7XL3">Net Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share were calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zJNFCSMaVIi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
numerator for basic and diluted net loss per share is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zfpFVNqOTC3h" style="display: none">Schedule of Numerator for Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zCPJVc2TksLi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zFZDXGfH5KHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILFCzCGP_zULqagYfRwO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(11,283,781</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,680,366</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPreferredStockStock_iN_di_msNILFCzCGP_zLM3gIHiY3X5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,355,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,768,984</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_iT_mtNILFCzCGP_zyXj41tpGmj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,639,128</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,449,350</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A1_zxpTpRC9P2D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zGsT9DCsnp34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zLTGJPpLz6f1" style="display: none">Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Weighted average common stock outstanding, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2coApmHoYv8" title="Weighted average common stock outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNNh9KEXWE6" title="Weighted average common stock outstanding, diluted">6,919,081</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtNwCylC15" title="Weighted average common stock outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRK3MfNeG5cg" title="Weighted average common stock outstanding, diluted">1,043,932</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">$0.01 warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYb2ti6mWI6" title="$0.01 warrants, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRX72Go7aqmb" title="$0.01 warrants, diluted">5,372</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfL9UvMbNNf" title="$0.01 warrants, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuNTI8EmtUc" title="$0.01 warrants, diluted">11,467</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zz3A9PtZqQIb" title="Total, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z8ZlPbMj0mz2" title="Total, diluted">6,924,453</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zCJ9KcRdEP7h" title="Total, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zGwOsO0x3oxg" title="Total, diluted">1,055,399</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zkKnj9BZ0Eq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">12. Net Loss Per Share (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zzHwGgy3Dqw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share, basic and diluted is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zQbWsCUzCHU6" style="display: none">Schedule of Net Loss Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net Loss per share, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBYfdHL8e44c" title="Net loss per share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zUH004Uqwkt5" title="Net loss per share, diluted">(1.83</span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zB02apJBBhYe" title="Net loss per share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_z6yPSgVg12Z6" title="Net loss per share, diluted">(12.74</span></span></td><td style="width: 1%; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A3_zJ90GOUSIsv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRfdJ1Q0gWp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbnsigDYV59l" style="display: none">Schedule of Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zsXLrmvpRAp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zQGqz7S0BhKb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_ziBSQNCoJAC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,288,255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,290,318</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z03y5jLiEog7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">323,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,743</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zAc0GXMqIWO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,611,991</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,554,061</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zEsyP8793r51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085066272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zoJBeGCYKQrg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<span id="xdx_823_z92Mn21tNel9">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zpfbBNL4YGPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
(benefit) provision for income taxes for the years ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zIOjfXsCBFq7" style="display: none">Schedule
of (Benefit) Provision for Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zGYtHGstCgd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zIgjC1BHdPmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzw8s_z4hkGu6sJr1f" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1415">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzw8s_zUhSNJnkiHp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Foreign</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">17,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzw8s_zyeb7u5WOyHa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1421">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzw8s_maITEBzwVq_zB0CcPiU7ny4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBz8IL_z8oA38GMc7rj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBz8IL_zaTfkcSR9up2" style="vertical-align: bottom; background-color: White">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBz8IL_zB05kIboZfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1432">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBz8IL_maITEBzwVq_zvyM8uXgmD7k" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total deferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzwVq_zCoJbq6tBkO6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A0_zKkc3ULkV2R3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8TNnX7OuLJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax computed using the U.S. federal statutory tax rate compared to that reflected in operations for the years
ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zr6AjcBdvpN2" style="display: none">Schedule
of Reconciliation of Income Tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Income taxes using U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20230101__20231231_zBQWfu5NiH14" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount">(2,401,761</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20230101__20231231_zFQvJdlBxaKh" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zqldSVBsjYSl" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount">(2,205,649</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20220101__20221231_zAwHWYPwvQP6" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt fair value adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20230101__20231231_zT1v6mNoWBh9" style="text-align: right" title="Debt fair value adjustment, amount">762,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20230101__20231231_zgKlhvb28D4d" style="text-align: right" title="Debt fair value adjustment, percent">(6.67</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20220101__20221231_zI8sHpMERyk8" style="text-align: right" title="Debt fair value adjustment, amount">262,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20220101__20221231_zoNgeEc5sgYg" style="text-align: right" title="Debt fair value adjustment, percent">(2.50</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zNPf6YVQdqC5" style="text-align: right" title="State taxes, net of federal benefit, amount">(538,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20230101__20231231_zCyc8KELZeT1" style="text-align: right" title="State taxes, net of federal benefit, percent">4.71</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20220101__20221231_zRZzEZj1GPF7" style="text-align: right" title="State taxes, net of federal benefit, amount">(602,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20220101__20221231_zl6sZEUwzwI7" style="text-align: right" title="State taxes, net of federal benefit, percent">5.73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zmt64MMj3WUk" style="text-align: right" title="Research and development tax credit, amount">(356,237</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20230101__20231231_zSRVv2461cDi" style="text-align: right" title="Research and development tax credit, percent">3.11</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231_zJk1BxhkFHU9" style="text-align: right" title="Research and development tax credit, amount">(433,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20220101__20221231_zYx5r1gOzZol" style="text-align: right" title="Research and development tax credit, percent">4.13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_z9PXm5o8mZp5" style="text-align: right" title="Change in valuation allowance, amount">2,502,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20230101__20231231_zOZZNI679Ft" style="text-align: right" title="Change in valuation allowance, percent">(21.88</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zlk32p46zGq5" style="text-align: right" title="Change in valuation allowance, amount">2,889,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20220101__20221231_zjfN5GrkvOh3" style="text-align: right" title="Change in valuation allowance, percent">(27.51</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zE16s75wjxec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount">48,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20230101__20231231_zvrRd69wLQ6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent">(0.42</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20220101__20221231_zKZfGx0xO2H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount">89,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20220101__20221231_zQ6NWxkGQcEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent">(0.85</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expenses (benefit)</span></td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_zpyz6dkPwVt9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses">17,308</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20230101__20231231_zL0JtloCgzrf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="U.S. federal statutory tax rate">(0.15</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)%</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231_zP9O6vp9zrB" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><p id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20220101__20221231_zf6GfF1mv82j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></b></span></p></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AE_zY4expNN5Ga3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">13. Income Taxes (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhpaIW6z2iL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2023 and 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_ziXVB3Yf6517" style="display: none">Schedule
of Deferred Income Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zocL4cblOKt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zQ4I8w2dCtHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zOv3kUhmi6Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_zMbnYKMXCjah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,755,690</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,870,665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_ziW2rjLHPgd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,155,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,729,421</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_maDTAGzRjT_maDTAGzJN6_zM2Ib0xs56Se" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,372,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,975</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzJN6_z9YiDw1wHPg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,876</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJN6_zfEkFsSKHIDa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,572</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,057</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJN6_maDTALNzcbS_zIm003X3ZEN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,402,912</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,899,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zmBM7rBQJGs8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzJtH_zVpXKUZeRN8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzJtH_msDTALNzcbS_z78OE6dfDKr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1528">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzcbS_zJkpwGa5FF7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,402,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,899,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcbS_zOn5cvxwIoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1535">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zVyNMELdCeEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZh3XhJkHwc" title="Net operating loss carry forwards">32,529,000</span> and $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmqoxOoMuZI5" title="Net operating loss carry forwards">29,192,000</span> for the tax years ending December 31,
2023 and 2022, respectively, of which $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2037Member_zBlYMv8JZY95" title="Net operating loss carry forwards">1,285,000</span> will expire in tax years 2036 through 2037 and approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--NoExpirationMember_zIeXdvwHMsr4" title="Net operating loss carry forwards">31,244,000</span> which does
not expire. The Company has state net operating loss carryforwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_zOLPNzCv4gEj" title="Net operating loss carry forwards">32,484,000</span> and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_z4Sg90sEegR3" title="Net operating loss carry forwards">29,374,000</span> for the tax years ending
December 31, 2023 and 2022, respectively, which will expire in tax years 2037 through 2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal research tax credits of approximately $<span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_z4chqDCa37m1" title="Research tax credits">1,524,000</span> and $<span id="xdx_903_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_znkq3rpIqId2" title="Research tax credits">1,235,000</span> for the tax years ending December 31, 2023 and 2022,
respectively, which expire in tax years 2039 through 2043. The Company has state research tax credits of approximately $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkZR3vZ6PAf2" title="Research tax credits">466,000</span> and $<span id="xdx_908_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zxEm7BwfiKWg" title="Research tax credits">350,000</span>
for the tax years ending December 31, 2023 and 2022, respectively, of which $<span id="xdx_901_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2038Member_zzPIAC2tvgEi" title="Research tax credits">312,000</span> will expire in tax year 2036 through 2038 and the
remainder can be carried forward indefinitely. The Company has Canadian research tax credits of approximately $<span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zCjOgZ53X0yl" title="Research tax credits">263,000</span> and $<span id="xdx_90C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zfOX7ceMxKYa" title="Research tax credits">218,000</span> for
the tax years ending December 31, 2023 and 2022, respectively, which expire in tax years 2039 through 2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Internal Revenue Code Section 382 imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership
change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company undergoes an ownership
change exceeding the 50% limitation threshold imposed by Section 382, the Company&#8217;s net operating loss carryforwards may be significantly
limited as to the amount of use in a particular year. In addition, all or a portion of the Company&#8217;s net operating loss carryforwards
incurred before 2018, may expire unutilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">13. Income Taxes (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate future taxable income during the periods
in which the temporary differences become deductible. Based on the Company&#8217;s recent earnings history and projected future U.S.
earnings, management believes that it is more likely than not that its federal and state deferred tax assets will not be fully realized
in the foreseeable future. As a result of this assessment, management believes that a full valuation allowance against its net federal
and state deferred tax assets is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 740-10 to account for uncertain tax positions. ASC 740-10 addresses the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the
Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be
sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that it
has no significant uncertain tax positions requiring recognition and measurement under ASC 740-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income tax, Connecticut state income tax and Canada branch tax. The Company has not been audited by
the IRS, state, or foreign tax authorities in connection with income taxes. The Company&#8217;s tax years remain open to examination
for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statute of limitations
have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize interest and penalties related to unrecognized tax benefits, if applicable, as a component of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085033840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zifvlu3ZAqx1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<span id="xdx_82F_zvhYM1tSkWi1">Commitments and Contingencies</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions
or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on
its financial position, results of operations or liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 26, 2022, the Company entered into an Exclusive License Agreement (the License Agreement) with an unrelated third party. Under
the License Agreement, the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how.
The License Agreement continues until the later of the expiration of the last to expire licensed patent or ten years after the first
commercial sale of the first licensed therapeutic or non-therapeutic product. The Company may terminate the License Agreement at any
time by providing at least 30 days written notice to the third party. The License Agreement is also terminated upon breach of a material
obligation under the agreement or bankruptcy. Upon any termination of the License Agreement, neither party is relieved of obligations
incurred prior to the termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company capitalized payments made under this license agreement in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromLicenseFeesReceived_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z72gFpn1c2T6" title="Capitalized License agreement amount">13,096</span>
and $<span id="xdx_90A_eus-gaap--ProceedsFromLicenseFeesReceived_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsZqhBt4Ty41" title="Capitalized License agreement amount">65,510</span>, respectively. During the fourth quarter, the license agreement was subsequently written off as discussed in Note 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085072384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zFSlWNltB9S3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<span id="xdx_82D_z5r1stsCw0kd">Operating Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company&#8217;s leases expire at various dates
through May 31, 2027. Most leases are for a fixed term and for a fixed amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019, the Company entered into a new lease agreement for office and laboratory space in Laval, Canada. The Laval lease required monthly
lease payments of $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20190101__20191231__srt--StatementGeographicalAxis__country--CA_zHfhzd5bcFw7" title="Lease payments">5,221</span> which increased approximately 10% per year upon renewal. The Laval lease is initially for a <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zqXHyIhVsKqb" title="Lease term">one year</span> term with
additional <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zy288uYbnRn6" title="Lease term renewal">one year</span> renewal terms available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">15. Operating Leases (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company entered into a new lease agreement for the Company&#8217;s primary office and laboratory space in Branford, CT. The
Branford lease requires monthly payments of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20200101__20201231__dei--LegalEntityAxis__custom--BranfordCTMember_ztNfo4aiBSYf" title="Lease payments">13,033</span> for the first year of the lease, which increases approximately 2% in each of the
following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments
of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210501__20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zHbsjix5ybUk" title="Lease payments">4,234</span>, which was increased to $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210901__20210930__dei--LegalEntityAxis__custom--GrotonCTMember_zuxsbB8Pvie8" title="Lease payments">6,824</span> in September 2021 upon leasing additional space. The Groton lease is initially for a <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zJhR1BwhlHhb" title="Lease term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1583">one</span></span>-year
term, with up to <span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zYKptnyscBfb" title="Lease term renewal::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1585">three</span></span> additional years renewal available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zm3Zqunk70Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zob4Grp0Rvqj" style="display: none">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231231_z1D2ts613384" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrWe_zjlwdIEbroUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">338,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrWe_z7DrqcLsQMvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrWe_zXEyNoTI7hVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,423</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzrWe_zTrAKc8MM941" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzrWe_zUfTXVdcqED8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzrWe_zS79ur35KmVf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrWe_z7zMVNGc8NBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,424</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zOMi14Eml617" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,246</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_z1IjGrF02Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">845,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zNEn7N8peqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for all operating leases was $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231_zBuQc4khLhC5" title="Operating lease rental expense">338,856</span> for the year ended December 31, 2023. The weighted average lease term for all operating
leases is <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhpEHfdTr034" title="Operating lease term">2.9</span> years. The weighted average discount rate for all operating leases is <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zoPCxLsEmD8f" title="Operating lease discount rate">4.25</span>%.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company entered into an agreement with Hewlett Packard to lease equipment. The lease requires monthly payments of $<span id="xdx_90E_ecustom--FinanceLeaseMonthlyPayments_c20230101__20231231_zDvxF2ZSq0Wf" title="Finance lease monthly payments">1,478</span>, including
tax. The lease is for a <span id="xdx_900_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtY_c20231231_zvbDls2Dae5l" title="Finance lease term">3</span>-year term with option of purchase or extension at term end. The remaining lease term is <span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231_zZvLtWRlkSjk" title="Finance lease remaining lease term">2.8</span> years and the discount
rate is <span id="xdx_901_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20231231_zSny5LKEl3Ei" title="Finance lease discount rate">9.60</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z5RhecIKj2Nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zcxhdypVpmpk" style="display: none">Schedule of Future Minimum Payments Under Finance  Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231231_zMJCYukla8a3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzipE_zJL5lA5gQv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzipE_zCbpu78uBcl2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maFLLPDzipE_zfCFk8yxAvJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,349</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_maFLLPDzipE_zwkoILUcXhGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_maFLLPDzipE_zIKCOXOMpCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1631">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzipE_zDfAaJeCiqDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinanceLeaseInterest_iI_zMiM7sWvZM2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,060</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_zM4OQTtL0yy5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zLZ81GFREmbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
expense for the finance lease was $<span id="xdx_901_ecustom--FinanceLeaseExpense_c20230101__20231231_zbDozcIynbM3" title="Finance lease expense">6,450</span> for the year ended December 31, 2023. Interest expense for the finance lease was $<span id="xdx_903_eus-gaap--FinanceLeaseInterestExpense_c20230101__20231231_z5zNtz9BbdQi" title="Interest expense">1,707</span> for
the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085033840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p id="xdx_806_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zRE4H9qmGaB2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<span id="xdx_82D_zuQUAq08qS63">Retirement Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2019, <span id="xdx_90F_eus-gaap--DefinedBenefitPlansGeneralInformation_c20190101__20190101_z4RVtfH34xPa" title="Retirement plan general information">the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed.</span> Total employer matching
contributions was $<span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zwMjNzjIaEW9" title="Employer contribution">11,803</span> and $<span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zExiK3gn2iZ9" title="Employer contribution">23,466</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085040000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPQxsf05F055" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<span id="xdx_824_zH5hw2pZx1D">Related Parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
related party revenue was $<span id="xdx_906_eus-gaap--Revenues_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJ6GYsF7317" title="Revenues from related party">686,000</span> and $<span id="xdx_908_eus-gaap--Revenues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zxV5CvQmG3bj" title="Revenues from related party">284,000</span> for the years ended December 31, 2023 and 2022, respectively. Accounts receivable due
from the related party was $<span id="xdx_904_eus-gaap--OtherReceivables_iI_c20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfYaJuF77Asa" title="Accounts receivable due from related party">90,000</span> and $<span id="xdx_908_eus-gaap--OtherReceivables_iI_c20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zyvtKjoo2TZf" title="Accounts receivable due from related party">175,000</span> at December 31, 2023 and 2022, respectively. Contract liabilities from the related party
was $<span id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2XJDWac3P93" title="Contract liabilities due from related party">0</span> and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiability_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zizPJ7LWVFJi" title="Contract liabilities due from related party">156,000</span> at December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a convertible promissory note totaling $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zjCVaA2flTu7" title="Convertible promissory note">4,350,000</span> of which $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmrbhSzkVKxc" title="Convertible promissory note">4,000,000</span> was attributable to an
entity who was also an investor in the Company&#8217;s Series A, A-1, and B Preferred Stock financing (See Note 7). This entity received
<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFfnJALfFUG9" title="Stock issued during conversion">1,697,490</span> shares of common stock upon conversion of the promissory notes for principal and interest of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zKNXV1gHOQ19" title="Stock issued during conversion">4,243,726</span>.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085026480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zIAx15YVBe5j" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<span id="xdx_82B_zsgAIsHlB3yl">Subsequent Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2024, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPLCAm867Vii" title="Number of shares of public offering">16,667,000</span> shares of its common stock at an offering price of $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoyTmekfbsWc" title="Share price per share">0.30</span> per
share. The Company received gross proceeds of approximately $<span id="xdx_90A_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn6n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPcULtCzU8qg" title="Gross proceeds from public offering">5</span> million and net proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zO19jNoEZ8Zk" title="Net proceeds from issuance of public offering">4.4</span> million, after deducting
underwriting discounts and offering-related expenses. The Company granted the underwriter an overallotment option to purchase an additional
<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0THcsCXJGp6" title="Number of shares purchased">2,500,000</span> shares of its common stock, at the public offering of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zOuze0LPKIo8" title="Public offering price per share">0.30</span> per share less the underwriter&#8217;s discount, for a 45-day period
ending March 29, 2024. In connection with the public offering, the Company issued to the underwriter, as additional underwriting compensation,
a warrant to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z5XzkSKemx2e" title="Warrants to purchase of common shares">666,680</span> shares of its common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zX0HrsOOyMNd" title="Warrant exercise price per share">0.375</span> per share over a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z4dnWQ8EU9q2" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1691">five</span></span>-year period.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079415424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zMtiHuRO9Al6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zZqaCW4rAPe7">Basis
of Accounting</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zuAKEAiSIOZi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_z5isAYtCIGSh">Use
of Estimates</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
These estimates and assumptions are based on current facts, historical experience, and various other factors believed to be reasonable
under the circumstances, the results which form the basis for making judgements about the carrying values of assets and liabilities and
the recording of expenses that are not readily apparent from other sources. While management believes the estimates and assumptions are
appropriate, actual results may differ materially and adversely from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbhO8K0SBAj5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_ziWQJ4TFc4bh">Cash
and Cash Equivalents</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6JZhm12qyoe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zUG5HvOzVEsb">Property
and Equipment</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zxxdutHi8g2c" title="Property, plant and equipment, useful life">3</span> to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zYHSrbr4mOdl" title="Property, plant and equipment, useful life">10</span> years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zilBeWaVDAg7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zXgQuPq5jsw">Accounts
Receivable</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries its accounts receivable at cost less an allowance for expected credit losses. On a periodic basis, the Company evaluates
its accounts receivable and establishes an allowance for expected credit losses based on a history of past write-offs, collections and
current conditions. There was no allowance for credit losses at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zXnFt8Rbwac4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zfbgB7kzjFId">Deferred
Offering Costs</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&#8217;s initial public offering. In June 2023, the Company consummated its IPO and recorded
such amounts against the gross proceeds of its IPO within the statements of stockholders&#8217; equity. During the fourth quarter the
Company incurred $67,859 of costs related to a follow-on offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zNXhjUSSL1Oe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zZGESRvACDc4">Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;).
ASU 2016-02 requires lessees to present right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either
operating or financing leases based on the economic substance of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
Summary of Significant Accounting Policies (continued)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$<span id="xdx_90F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220101_ztnyfb3ehQyi" title="Right-of-use asset and lease liability">1,418,502</span> as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&#8217;s
option to extend certain leases ranges from <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zSeo4zMg8uZj" title="Lease term">36</span> &#8211; <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_z2il98dePDgc" title="Lease term">52</span> months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. The Company utilizes a weighted
average discount rate of <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zcnGnCh3Kx9i" title="Operating lease, weighted average discount rate">4.25</span>% and <span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zJ7LSKGJNpPa" title="Finance lease, weighted average discount rate">9.60</span>% for its operating and finance leases, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had operating right-of-use assets with a net value of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zMn2w1U4xA33" title="Operating lease right-of-use asset">828,960</span> and current and long-term operating lease
liabilities of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zx5EewTQfpAl" title="Current operating lease liability">307,655</span> and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zd3AkaCmHbAc" title="Long-term operating lease liability">537,523</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has
a term of <span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtM_c20231231_z2QaJxzUGq8j" title="Finance lease term">36</span> months. At December 31, 2023, the Company had financing right-of-use assets with a net value of $<span id="xdx_906_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_zuCS5CAC1OXl" title="Long term finance lease liability">40,002</span> and current and
long-term operating lease liabilities of $<span id="xdx_90D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zP39DMziATy4" title="Finance lease liability current">14,600</span> and $<span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zskZ2wli7W8j" title="Long term finance lease liability">26,169</span>, respectively.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziNUhc5MFc5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zOMApwqfbtN7">Intangible
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, <i>Goodwill and Other Intangible Assets</i>
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were $<span id="xdx_900_ecustom--ImpairmentOfLicenseAgreements_c20230101__20231231_zWv6Tn88ESZ" title="Impairment of license agreements">78,606</span> and
$<span id="xdx_909_ecustom--ImpairmentOfLicenseAgreements_c20220101__20221231_zfjusyt3FGCc" title="Impairment of license agreements">0</span> during the years ended December 31, 2023 and 2022, respectively, and are included in general and administrative expenses on the accompanying
consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DeferredPatentCostsPolicyTextBlock', window );">Deferred Patent Costs</a></td>
<td class="text"><p id="xdx_841_ecustom--DeferredPatentCostsPolicyTextBlock_z4b4ly3qt0Z" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zxQIkWopin63">Deferred
Patent Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating
to deferred patent costs during the years ended December 31, 2023 and 2022 were $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqi1vsaTWV6" title="Impairment of intangible assets">272,754</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHx7Xqou0uCe" title="Impairment of intangible assets">0</span>, respectively, and are included in general
and administrative expenses on the accompanying consolidated statement of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUr7PcCCf6Pf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zq5aIFmoUVhl">Impairment
of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets (ASC 360-10), the Company&#8217;s policy
is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets.
The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition
of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value
of the net future operating cash flows generated by the asset.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022 </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Summary of Significant Accounting Policies (continued)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Debt and Warrant Accounting</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zPW2TWZB4w42" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zjkuYKwT7Bxh">Convertible
Debt and Warrant Accounting</span></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in ASC 480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)
and ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income (Expense).</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
debt</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &#8211; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&#8217;s
conversion features require bifurcation in accordance with ASC 815 &#8211; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
The Convertible Notes were converted into the Company&#8217;s common stock on the Closing Date of the Company&#8217;s IPO. Under 815-15-25,
the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825.
The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to
be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change
based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized
as a non-cash gain or loss in Other Income (Expense) on the statements of operations. The Company elected the fair value option for the
2022 Convertible Notes and recorded the notes at their initial fair values with subsequent changes in fair value recorded in earnings.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p id="xdx_841_ecustom--ConvertiblePreferredStockPolicyTextBlock_zoDaQ41gDDYe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zWfXmquYxeSi">Convertible
Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in Note 8, at the Closing Date of the Company&#8217;s IPO, the Convertible Preferred stock converted into shares of the Company&#8217;s
common stock.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zSZKzFW576J" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zlP1wXMBJkAg">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the <i>five</i> steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers
(&#8220;ASC 606&#8221;), which are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>1</i>: Identify the contract(s) with a customer</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>2</i>: Identify the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>3</i>: Determine the transaction price</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>4</i>: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
                                            <i>5</i>: Recognize revenue when (or as) a performance obligation is satisfied</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z5TWStwucIwl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zBHxvW101E84">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, <i>Research
and Development</i>. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Advance payments for goods and services that will be used in future research and development
activities are expensed when the activity has been performed or when the goods have been received. Research and development costs incurred
were $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zroj86IPyoQb" title="Research and development">3,809,063</span> and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zE3vq10NMPol" title="Research and development">6,097,938</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company has a state tax credit receivable of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20231231_ztPBBt1if2c1" title="State tax credit receivable">86,778</span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20221231_zyQ9FwNbN8xl" title="State tax credit receivable">32,459</span>, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2023 and 2022, the Company has
$<span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_z3MIXlO8Zl1c" title="Pending refunds related to research and experimental development">20,040</span> and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zJUPVx5KHOC" title="Pending refunds related to research and experimental development">28,925</span>, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits.
At December 31, 2023 and 2022, the Company has also recorded $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20231231_zwPd68iTdYma" title="Refunds tax amount">11,565</span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20221231_z8DHBFkcmAy5" title="Refunds tax amount">8,282</span>, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLmBzSEROH7k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zLzLqCWaK226">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with ASC 718, <i>Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved. The Company recognizes the effect of forfeitures when the forfeitures occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&#8217;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, <i>Improvements to Nonemployee Share-Based Payment Accounting</i>, which expands the scope of ASC
718 to include share-based payment transactions to non-employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>. The expected volatility of the Company&#8217;s shares is estimated based on the average volatility of peer companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underlying
Common Stock Value</i>. The underlying common stock value of the Company&#8217;s shares is estimated by a third-party valuation expert
up until the Company&#8217;s IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
Interest Rate</i>. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zUHeCzIdfisg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zK0UNWqj7YP5">Income
Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, <i>Accounting for Income Taxes</i>. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2023 and December 31, 2022. The Company&#8217;s income
tax returns have not been examined by tax authorities through December 31, 2023.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zc2sDqE0Fo3l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z6nfOQDLexIc">Net
Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per weighted average share attributable to common stockholders using the weighted average number of shares
of common stock outstanding during the period. The Company computes diluted net loss per weighted average share attributable to common
stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period.
Potential common shares outstanding consist of stock options, warrants and preferred stock and are excluded if their effect is anti-dilutive.
Diluted weighted average common shares did not include any incremental shares for the fiscal year ended December 31, 2023 and 2022.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_CertainRisksAndUncertaintiesPolicyTextBlock', window );">Certain Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_848_ecustom--CertainRisksAndUncertaintiesPolicyTextBlock_zxGQWdOD9QCh" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zTVzLJ61m7Gg">Certain
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding
to properly execute the Company&#8217;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical
industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on
key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztEoDnBavlIc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zVmQr5aENLK">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &#8211; Inputs are based upon observable or quoted prices for identical instruments traded
                                            in active markets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &#8211; Inputs are based upon quoted prices for similar instruments in active markets,
                                            quoted prices for identical or similar instruments in markets that are not active, and model-based
                                            valuation techniques for which all significant assumptions are observable in the market or
                                            can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &#8211; Inputs are generally unobservable and typically reflect management&#8217;s estimates
                                            of assumptions that market participants would use in pricing the asset or liability. The
                                            fair values are therefore determined using model-based techniques that include option pricing
                                            models, discounted cash flow models, and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1wB1vi2kIA7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zVuLsQuwtdtg">Financial
Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term
maturities of such instruments. The estimated fair value of the Company&#8217;s long-term debt approximates carrying value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off- Balance Sheet Risk</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z4b5eMa24sd1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zLSkO6OaZs5e">Concentration
of Credit Risk and Off- Balance Sheet Risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash
equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and
accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated
with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The
Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances
in the form of a money market account with a financial institution that management believes to be creditworthy.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AZITRA, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">2. Summary of Significant Accounting Policies (continued)</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCsompK9GpOf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zY6TggQUom35">Recent
Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes</i> (Topic 740): <i>Simplifying the Accounting for Income Taxes</i>.
This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing
additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted
this standard effective January 1, 2022, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 1026-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (ASC 326)</i>, which replaces the incurred loss methodology with the expected loss methodology. This standard is referred
to as the current expected credit loss (&#8220;CECL&#8221;) methodology. CECL This standard is effective for the Company on January 1,
2023. The Company has adopted this standard effective January 1, 2023, which did not have a material impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_CertainRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Risks And Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_CertainRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DeferredPatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DeferredPatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085091600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvzIVcCNTZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zhpgQy9pfYuk" style="display: none">Schedule of Property And Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zNAL2YgfmwE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zIjSyKKYbC0b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zuC6SM2kvHa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,013,134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,034,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVm6VIlXmUW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,825</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd02iNHTOvzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1lRbxZsED2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,855</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znhsWhNZQxMf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Building equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFzA_zDejBdfUkalj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,112,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133,507</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFzA_zqxxiUqswxzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation &amp; amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(401,987</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(286,549</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFzA_zQii0gDfTlD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">710,075</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">846,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085086880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zM3kuxjk4HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zxrrCXioz30b" style="display: none">Schedule of Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_901_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDbfGwolEBIg" title="Estimated Useful Life">Indefinite</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zy3fFZEzZ4i6" style="width: 9%; text-align: right" title="Gross Amount">57,474</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztfG906mrQC5" style="width: 9%; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zS0kweJv22ek" style="width: 9%; text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1FgkZk9Spm" style="width: 9%; text-align: right" title="Net Amount">57,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziHF1SdrAmua" title="Estimated Useful Life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zksXf151TqY3" style="text-align: right" title="Gross Amount">169,190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zTz2l95V2Oil" style="text-align: right" title="Accumulated Amortization">15,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeWgY3CSdip5" style="text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0825">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztiUx2PBENf2" style="text-align: right" title="Net Amount">153,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zClj2XepS3we" title="Estimated Useful Life">17</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQavO1GiYWxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount">78,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zFFzyn5mP5Ud" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpW3Pt6wclrf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset">78,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9vZYtq0A4Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_zVQsw5yPtnz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount">305,270</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zRMH75DR6O5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">15,783</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231_zJqlewJv4bIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset">78,606</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_ziaQ7SuYurh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount">210,881</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Trademarks</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_90D_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV1YCRMn1jC" title="Estimated Useful Life">Indefinite</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQyNzZsqxFLb" style="width: 9%; text-align: right" title="Gross Amount">53,999</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zzP801sPs0a5" style="width: 9%; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zH1tv1jdc154" style="width: 9%; text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zitqpRkuAcJ9" style="width: 9%; text-align: right" title="Net Amount">53,999</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zspge0w8Yn3g" title="Estimated Useful Life">17</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCCQnEujbfj" style="text-align: right" title="Gross Amount">108,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJgplqHK3zK6" style="text-align: right" title="Accumulated Amortization">8,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6B2SLwkSvza" style="text-align: right" title="Impairement of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNMXtmTPYg7a" style="text-align: right" title="Net Amount">100,058</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">License agreement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_znZcSRqWHOJ6" title="Estimated Useful Life">17</span> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z7zYmOdIk2i3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount">65,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zNALvIHma669" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSywPZlK9lof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zdlSqPfJUS27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount">65,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zf2Zzk4pJClh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount">227,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zB30cLLzzPJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">8,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231_zUDcSeorX2J2" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zEymGA2twQPj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount">219,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085016288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAYvX5tAdQO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5Gx6qiSRuXl" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zBRNgjoHnx2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zksyM47zs8Mg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_maALCzSIF_z2R8dtyly0m9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Employee payroll and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">371,010</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_maALCzSIF_zbcqAwmeI9x3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,082</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedResearchAndDevelopmentProjects_iI_maALCzSIF_zV6cWh29dGqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">316,389</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPayableCurrent_iI_maALCzSIF_zNQEbXEkezP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,792</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzSIF_z4EFnNrFEoz4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,502</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzSIF_zzaR84ou17L9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzSIF_zbJBjtGopUVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">383,668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,961</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081561408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zbwDcoZihTbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zwa2WTYnxfB9" style="display: none">Schedule of Convertible
Notes Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">2021 Convertible Note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zQAWEoHtTA06" style="width: 16%; text-align: right" title="Convertible notes payable">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zG8PFsoAyOz1" style="width: 16%; text-align: right" title="Convertible notes payable">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z9Ve8MgvcpP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwROubSS7hKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total convertible notes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231_zCulOaH45P72" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231_z52LDFTUSHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable, net">6,600,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085163808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Information about Warrants Outstanding</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQBju39i6ktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants outstanding at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zPZXVjgU03Q2" style="display: none">Schedule
of Information about Warrants Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants at 12/31/2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2018</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zkCdwpqzeEc" style="width: 9%; text-align: right" title="Exercise price of warrants">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zqwmz86hzsfi" style="width: 9%; text-align: right" title="Number of warrants outstanding">47,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zZQB7cZI9yQd" title="Weighted Average Remaining Contractual Life, Outstanding">4.5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDzgr0Jg8Ltd" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_ziu9fUMDi1jc" style="width: 9%; text-align: right" title="Number of warrants exercisable">47,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zFum6EmXhFEc" title="Weighted Average Remaining Contractual Life, Exercisable">4.5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDZIfgEPrF4g" title="Weighted Average Exercise Price, Exercisable">0.48</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zp59YIvl2e7l" style="text-align: right" title="Exercise price of warrants">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zI69yuzjnSla" style="text-align: right" title="Number of warrants outstanding">215,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zlnYOwUWtjh6" title="Weighted Average Remaining Contractual Life, Outstanding">2.4</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zIDZkPocI7ah" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zRxszl8YDn92" style="text-align: right" title="Number of warrants exercisable">215,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zO4D9DbLSszc" title="Weighted Average Remaining Contractual Life, Exercisable">2.4</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zYZ23YLUv4n5" title="Weighted Average Exercise Price, Exercisable">5.28</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zoUrwgmKzUhk" style="padding-bottom: 1.5pt; text-align: right" title="Exercise price of warrants">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zyvRh2JSCFQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zt1XkaHM9rfl" title="Weighted Average Remaining Contractual Life, Outstanding">4.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zh8jG0wWUC5k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding">6.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zAJs7XeX8rM4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_ztKvjweQ94Y1" title="Weighted Average Remaining Contractual Life, Exercisable">4.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zCfJMwwPkhC2" title="Weighted Average Exercise Price, Exercisable">6.25</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7xK4duS2j36" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">323,736</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRNfZFq6smlb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">4.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBz0QE0X97Hb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable">323,736</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxcQjjPXULUg" title="Weighted Average Exercise Price, Exercisable">4.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081833472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Schedule of Information about Options Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_z0IW86DeXVh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about options outstanding and exercisable at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zIyC4GBKAWC3" style="display: none">Schedule of Information about Options Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weight Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_z8alUhhaGHvf" style="width: 11%; text-align: right" title="Number of options exercise price">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zxyowzgtjtj" style="width: 11%; text-align: right" title="Number of options outstanding">246,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR3Ann5Ixp79" title="Weighted Average Remaining Contractual Life, Options outstanding">2.0</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zt9pjLBKdbci" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Options outstanding">0.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zo8WiVuiKYZ7" style="width: 10%; text-align: right" title="Number of options exercisable">246,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zYT3Df1fOJ71" title="Weighted Average Remaining Contractual Life, Options exercisable">2.0</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR9c35belXWj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Options exercisable">0.48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_z230LJtrVUte" style="text-align: right" title="Number of options exercise price">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zG1uZTAAOHKi" style="text-align: right" title="Number of options outstanding">202,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEpD9VstCDi4" title="Weighted Average Remaining Contractual Life, Options outstanding">2.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zTBl3sDX1S83" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEz0aNcZOps9" style="text-align: right" title="Number of options exercisable">202,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zaBAK7ymcR3" title="Weighted Average Remaining Contractual Life, Options exercisable">2.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zebXAPfhb2Qj" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable">0.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNplBbt1s6i" style="text-align: right" title="Number of options exercise price">1.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zjdmUFeW7k" style="text-align: right" title="Number of options outstanding">800,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNyXrER7XRx2" title="Weighted Average Remaining Contractual Life, Options outstanding">7.3</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zQpwkXxVK3rf" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding">1.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zTTtxALwWwpl" style="text-align: right" title="Number of options exercisable">572,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zhRU9mi8Ph2b" title="Weighted Average Remaining Contractual Life, Options exercisable">7.0</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zu2hHQ7pyKbi" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable">1.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_ziJR95ZKgtO6" style="padding-bottom: 1.5pt; text-align: right" title="Number of options exercise price">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zmQXbPGAObYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding">40,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zSRjIM5YVT7h" title="Weighted Average Remaining Contractual Life, Options outstanding">9.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zinJOCaNbm2l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_z7fmXVkMUUQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable">4,167</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zNrZYLH8kxX3" title="Weighted Average Remaining Contractual Life, Options exercisable">9.7</span> years</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zg0wp74KBlKi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable">2.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zurrTuXFjww2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">1,288,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z5EguCpa9YGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">1,025,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znzMZ8DIaDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
stock option activity for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z8jQ1C39P195" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zSNcOmTFKIEk" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning">1,381,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zugnGEAh2Rc4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding">1.34</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zC3Aneb4tN5i" style="text-align: right" title="Number of Options, Exercised">(888</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zCIG5MDvbj1e" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_zesRlD2lIsAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(90,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zL7rTaF8BFSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">5.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zV4J4DYMImTi" style="text-align: right" title="Number of Options, Outstanding Beginning">1,290,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_z0zusWSFR2l4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">1.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zyVwOyA2CMY9" style="text-align: right" title="Number of Options, Granted">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zEW8hL496vA8" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zUM7hFyG2jj2" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zXJUrtb9U9Y5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zi0Q53h4PbQ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(42,063</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zxDSVZ0EUXHg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">0.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z2xIL8GpDF76" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending">1,288,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOGJvImz7sfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">1.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Schedule of Total Intrinsic Value</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_zh1YyAYYvNZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
intrinsic value for the 2016 plan for the year ended December 31, 2023, is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_zyUPIhhTgClk" style="display: none">Schedule of Total Intrinsic Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable at December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Value of Stock at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zrkBRiqqQy2i" style="width: 16%; text-align: right" title="Options Outstanding Value of Stock">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--OptionsExcercisableSharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zOoksrDCpKWd" style="width: 16%; text-align: right" title="Options Exercisable Value of Stock">0.92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zb8PSyGiExx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Exercise Price">0.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zNQKltQxeIx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable Exercise Price">0.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Intrinsic Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zEuooQLcCDTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Intrinsic Value Per Share">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z78JkwIjJ5Yg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Excercisable Intrinsic Value Per Share">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options O/S</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zyBSUf7Rfjac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding">246,137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z2BQQGDGzlWh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable">246,137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Intrinsic Value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zPFMR5g23Ftb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Intrinsic Value">108,300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z6O0lcqKxIFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable Intrinsic Value">108,300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (d)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085903200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurements for Assets and Liabilities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBKPHKKuW5vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_ziY5xp84EIgb" style="display: none">Schedule of Fair Value Measurements for Assets and Liabilities</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2e8yspYLvIh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zk6TsCYXF1Rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zstjytY83pPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKGa7vl2qWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zHlPqQZ1mqmc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">35,453</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">35,453</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z3EYgVVW1NU9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFv6jSbplQ79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoS2fezKmjEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxPBFbWHocb9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9zxz54b4MHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zIEMn0IQf2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Common stock warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">70,283</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">70,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNoteMember_zYi48rZhccb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z8XA51UIyGpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,670,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,567,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z0kZpwkZv4If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zncfXAazObO" style="display: none">Schedule
of Changes in Level 3 Instruments Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1p34BQtPLUl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_z1q7e27CglDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">71,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zurp5fkLQ478" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(821</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfConvertibleNotes_z1NKCLvE1QTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zH3s99L4a9gi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_ztNUsYSMFtuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,670,283</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zXKBGPbrt20d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,830</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zvSvJ0XeOJO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of 2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,630,100</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConversionConvertibleNotes_zHJuLjed3EO4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Conversion of 2022 Convertible Notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,230,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zve30gNh3qe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zoOSLa7v7TR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the
following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zhFxpIcLF5B4" style="display: none">Schedule
of Fair Value of Warrants Using Black Scholes Option Pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Underlying common stock value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zUDDyoy1CJh3" style="width: 16%; text-align: right" title="Dividend yield">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231_zXTl2VrkBAci" style="width: 16%; text-align: right" title="Dividend yield">1.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zYkWaZCcl9El" title="Expected term (years)">4.29</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zpLwB0ubkzwj" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_z7tZJPnP41E4" style="text-align: right" title="Expected volatility">99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zfcaq46ibAla" style="text-align: right" title="Expected volatility">86</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zN4HKuQkBTmk" style="text-align: right" title="Risk free interest rate">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zm0mVHMFB1P2" style="text-align: right" title="Risk free interest rate">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zePJz5kqEL6l" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zOnRUNZeT7x1" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085891968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Numerator for Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zJNFCSMaVIi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
numerator for basic and diluted net loss per share is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zfpFVNqOTC3h" style="display: none">Schedule of Numerator for Basic and Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zCPJVc2TksLi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zFZDXGfH5KHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILFCzCGP_zULqagYfRwO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(11,283,781</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,680,366</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPreferredStockStock_iN_di_msNILFCzCGP_zLM3gIHiY3X5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,355,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,768,984</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_iT_mtNILFCzCGP_zyXj41tpGmj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,639,128</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,449,350</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zGsT9DCsnp34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zLTGJPpLz6f1" style="display: none">Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Weighted average common stock outstanding, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2coApmHoYv8" title="Weighted average common stock outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNNh9KEXWE6" title="Weighted average common stock outstanding, diluted">6,919,081</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtNwCylC15" title="Weighted average common stock outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRK3MfNeG5cg" title="Weighted average common stock outstanding, diluted">1,043,932</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">$0.01 warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYb2ti6mWI6" title="$0.01 warrants, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRX72Go7aqmb" title="$0.01 warrants, diluted">5,372</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfL9UvMbNNf" title="$0.01 warrants, basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuNTI8EmtUc" title="$0.01 warrants, diluted">11,467</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zz3A9PtZqQIb" title="Total, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z8ZlPbMj0mz2" title="Total, diluted">6,924,453</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zCJ9KcRdEP7h" title="Total, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zGwOsO0x3oxg" title="Total, diluted">1,055,399</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Net Loss Per Share, Basic and Diluted</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zzHwGgy3Dqw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share, basic and diluted is as follows for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zQbWsCUzCHU6" style="display: none">Schedule of Net Loss Per Share, Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net Loss per share, basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBYfdHL8e44c" title="Net loss per share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zUH004Uqwkt5" title="Net loss per share, diluted">(1.83</span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zB02apJBBhYe" title="Net loss per share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_z6yPSgVg12Z6" title="Net loss per share, diluted">(12.74</span></span></td><td style="width: 1%; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRfdJ1Q0gWp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zbnsigDYV59l" style="display: none">Schedule of Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zsXLrmvpRAp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zQGqz7S0BhKb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_ziBSQNCoJAC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,288,255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,290,318</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z03y5jLiEog7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">323,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,743</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zAc0GXMqIWO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,611,991</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,554,061</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085904640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of (Benefit) Provision for Income Taxes</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zpfbBNL4YGPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
(benefit) provision for income taxes for the years ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zIOjfXsCBFq7" style="display: none">Schedule
of (Benefit) Provision for Income Taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zGYtHGstCgd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zIgjC1BHdPmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzw8s_z4hkGu6sJr1f" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1415">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzw8s_zUhSNJnkiHp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Foreign</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">17,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzw8s_zyeb7u5WOyHa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1421">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzw8s_maITEBzwVq_zB0CcPiU7ny4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBz8IL_z8oA38GMc7rj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBz8IL_zaTfkcSR9up2" style="vertical-align: bottom; background-color: White">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1430">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBz8IL_zB05kIboZfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1432">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBz8IL_maITEBzwVq_zvyM8uXgmD7k" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total deferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzwVq_zCoJbq6tBkO6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1439">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8TNnX7OuLJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax computed using the U.S. federal statutory tax rate compared to that reflected in operations for the years
ending December 31, 2023 and December 31, 2022 consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zr6AjcBdvpN2" style="display: none">Schedule
of Reconciliation of Income Tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Income taxes using U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20230101__20231231_zBQWfu5NiH14" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount">(2,401,761</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20230101__20231231_zFQvJdlBxaKh" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zqldSVBsjYSl" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount">(2,205,649</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20220101__20221231_zAwHWYPwvQP6" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt fair value adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20230101__20231231_zT1v6mNoWBh9" style="text-align: right" title="Debt fair value adjustment, amount">762,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20230101__20231231_zgKlhvb28D4d" style="text-align: right" title="Debt fair value adjustment, percent">(6.67</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20220101__20221231_zI8sHpMERyk8" style="text-align: right" title="Debt fair value adjustment, amount">262,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20220101__20221231_zoNgeEc5sgYg" style="text-align: right" title="Debt fair value adjustment, percent">(2.50</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zNPf6YVQdqC5" style="text-align: right" title="State taxes, net of federal benefit, amount">(538,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20230101__20231231_zCyc8KELZeT1" style="text-align: right" title="State taxes, net of federal benefit, percent">4.71</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20220101__20221231_zRZzEZj1GPF7" style="text-align: right" title="State taxes, net of federal benefit, amount">(602,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20220101__20221231_zl6sZEUwzwI7" style="text-align: right" title="State taxes, net of federal benefit, percent">5.73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zmt64MMj3WUk" style="text-align: right" title="Research and development tax credit, amount">(356,237</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20230101__20231231_zSRVv2461cDi" style="text-align: right" title="Research and development tax credit, percent">3.11</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231_zJk1BxhkFHU9" style="text-align: right" title="Research and development tax credit, amount">(433,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20220101__20221231_zYx5r1gOzZol" style="text-align: right" title="Research and development tax credit, percent">4.13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_z9PXm5o8mZp5" style="text-align: right" title="Change in valuation allowance, amount">2,502,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20230101__20231231_zOZZNI679Ft" style="text-align: right" title="Change in valuation allowance, percent">(21.88</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zlk32p46zGq5" style="text-align: right" title="Change in valuation allowance, amount">2,889,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20220101__20221231_zjfN5GrkvOh3" style="text-align: right" title="Change in valuation allowance, percent">(27.51</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zE16s75wjxec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount">48,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20230101__20231231_zvrRd69wLQ6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent">(0.42</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20220101__20221231_zKZfGx0xO2H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount">89,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20220101__20221231_zQ6NWxkGQcEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent">(0.85</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expenses (benefit)</span></td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_zpyz6dkPwVt9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses">17,308</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20230101__20231231_zL0JtloCgzrf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="U.S. federal statutory tax rate">(0.15</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)%</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231_zP9O6vp9zrB" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><p id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20220101__20221231_zf6GfF1mv82j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></b></span></p></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhpaIW6z2iL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2023 and 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_ziXVB3Yf6517" style="display: none">Schedule
of Deferred Income Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zocL4cblOKt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zQ4I8w2dCtHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zOv3kUhmi6Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_zMbnYKMXCjah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,755,690</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,870,665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_ziW2rjLHPgd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,155,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,729,421</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_maDTAGzRjT_maDTAGzJN6_zM2Ib0xs56Se" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,372,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,975</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzJN6_z9YiDw1wHPg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,876</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJN6_zfEkFsSKHIDa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,572</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,057</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJN6_maDTALNzcbS_zIm003X3ZEN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,402,912</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,899,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zmBM7rBQJGs8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzJtH_zVpXKUZeRN8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzJtH_msDTALNzcbS_z78OE6dfDKr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1528">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzcbS_zJkpwGa5FF7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,402,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,899,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcbS_zOn5cvxwIoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1535">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085192224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zm3Zqunk70Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zob4Grp0Rvqj" style="display: none">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231231_z1D2ts613384" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrWe_zjlwdIEbroUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">338,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrWe_z7DrqcLsQMvf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrWe_zXEyNoTI7hVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,423</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzrWe_zTrAKc8MM941" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzrWe_zUfTXVdcqED8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzrWe_zS79ur35KmVf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrWe_z7zMVNGc8NBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,424</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zOMi14Eml617" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,246</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_z1IjGrF02Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">845,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments Under Finance Leases</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z5RhecIKj2Nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zcxhdypVpmpk" style="display: none">Schedule of Future Minimum Payments Under Finance  Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231231_zMJCYukla8a3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzipE_zJL5lA5gQv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzipE_zCbpu78uBcl2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maFLLPDzipE_zfCFk8yxAvJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,349</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_maFLLPDzipE_zwkoILUcXhGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_maFLLPDzipE_zIKCOXOMpCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1631">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzipE_zDfAaJeCiqDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinanceLeaseInterest_iI_zMiM7sWvZM2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,060</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_zM4OQTtL0yy5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082924800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,991,359<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Forward stock split</a></td>
<td class="text">7.1-for-1 forward stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7.1-for-1 forward stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,598,333<span></span>
</td>
<td class="nump">37,314,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,616,395<span></span>
</td>
<td class="nump">9,453,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,362,375<span></span>
</td>
<td class="nump">$ 8,349,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081661568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="nump">$ 1,418,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 828,960<span></span>
</td>
<td class="nump">$ 1,116,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,655<span></span>
</td>
<td class="nump">287,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,523<span></span>
</td>
<td class="nump">840,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Long term finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,002<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long term finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,169<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ImpairmentOfLicenseAgreements', window );">Impairment of license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,063<span></span>
</td>
<td class="nump">6,097,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,778<span></span>
</td>
<td class="nump">32,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Pending refunds related to research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,040<span></span>
</td>
<td class="nump">28,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Refunds tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,565<span></span>
</td>
<td class="nump">8,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,754<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">52 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ImpairmentOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ImpairmentOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079411344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retention Credit (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_EmployeeRetentionCredit', window );">Employee retention credit</a></td>
<td class="nump">$ 229,813<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 229,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_CARESEmployeeRetentionCreditMember', window );">CARES Employee Retention credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_RefundableTaxCredit', window );">Refundable tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Payments to employees wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_CARESEmployeeRetentionCreditMember', window );">CARES Employee Retention credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_CARESEmployeeRetentionCreditMember', window );">CARES Employee Retention credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee retention credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_RefundableTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable tax credit on realted to employment in refundable to the employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_RefundableTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AZTR_CARESEmployeeRetentionCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AZTR_CARESEmployeeRetentionCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597084196128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property And Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,112,062<span></span>
</td>
<td class="nump">$ 1,133,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation &amp; amortization</a></td>
<td class="num">(401,987)<span></span>
</td>
<td class="num">(286,549)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant, and equipment, net</a></td>
<td class="nump">710,075<span></span>
</td>
<td class="nump">846,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AZTR_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,013,134<span></span>
</td>
<td class="nump">1,034,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">30,825<span></span>
</td>
<td class="nump">30,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">24,316<span></span>
</td>
<td class="nump">24,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">28,855<span></span>
</td>
<td class="nump">28,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 14,932<span></span>
</td>
<td class="nump">$ 14,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AZTR_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=AZTR_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597086121248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 122,010<span></span>
</td>
<td class="nump">$ 120,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Losses on disposal of property and equipment</a></td>
<td class="nump">$ 41,417<span></span>
</td>
<td class="nump">$ 7,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079467168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Amount</a></td>
<td class="nump">$ 305,270<span></span>
</td>
<td class="nump">$ 227,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">15,783<span></span>
</td>
<td class="nump">8,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible asset</a></td>
<td class="nump">78,606<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 210,881<span></span>
</td>
<td class="nump">$ 219,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_FiniteLivedIntangibleAssetUsefulLives', window );">Estimated Useful Life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Amount</a></td>
<td class="nump">$ 57,474<span></span>
</td>
<td class="nump">$ 53,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">53,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Amount</a></td>
<td class="nump">169,190<span></span>
</td>
<td class="nump">108,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">15,783<span></span>
</td>
<td class="nump">8,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 153,407<span></span>
</td>
<td class="nump">$ 100,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Amount</a></td>
<td class="nump">$ 78,606<span></span>
</td>
<td class="nump">$ 65,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible asset</a></td>
<td class="nump">78,606<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 65,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_FiniteLivedIntangibleAssetUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible asset useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_FiniteLivedIntangibleAssetUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083538880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expenses of intangible assets</a></td>
<td class="nump">$ 7,643<span></span>
</td>
<td class="nump">$ 5,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 78,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083929216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Employee payroll and bonuses</a></td>
<td class="nump">$ 207,556<span></span>
</td>
<td class="nump">$ 371,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Vacation</a></td>
<td class="nump">31,074<span></span>
</td>
<td class="nump">27,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_AccruedResearchAndDevelopmentProjects', window );">Research and development projects</a></td>
<td class="nump">85,767<span></span>
</td>
<td class="nump">316,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">223,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">35,624<span></span>
</td>
<td class="nump">24,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">23,647<span></span>
</td>
<td class="nump">31,186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 383,668<span></span>
</td>
<td class="nump">$ 993,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_AccruedResearchAndDevelopmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_AccruedResearchAndDevelopmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082908384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember', window );">2021 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember', window );">2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079215296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,495,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ChangeInFairValueOfConvertibleNote', window );">Change in fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,630,100<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,019<span></span>
</td>
<td class="nump">172,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuances costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember', window );">2021 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember', window );">2021 Convertible Note [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember', window );">2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Sale of additional notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,850,000<span></span>
</td>
<td class="nump">$ 4,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">1,846,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes payable</a></td>
<td class="nump">$ 9,495,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember', window );">Convertible Note Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember', window );">Convertible Note Purchase Agreement [Member] | 2021 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Bearing interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember', window );">Convertible Note Purchase Agreement [Member] | 2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Bearing interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DebtInstrumentDiscountPercentage', window );">Debt discount, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationLongtermDebtAndEquity', window );">Capitalization amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ChangeInFairValueOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ChangeInFairValueOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DebtInstrumentDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DebtInstrumentDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationLongtermDebtAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationLongtermDebtAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078991952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Forward stock split</a></td>
<td class="text">7.1-for-1 forward stock split<span></span>
</td>
<td class="text">7.1-for-1 forward stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend percentage on series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible series B preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | 2021 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible series B preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend percentage on series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible series B preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1PreferredStockMember', window );">Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend percentage on series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Original issue price per share of series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1PreferredStockMember', window );">Series A-1 convertible preferred stock | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible series B preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,964,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AZTR_ForwardStockSplitMember', window );">Forward Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=AZTR_TwoThousandTwentyOneConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=AZTR_TwoThousandTwentyOneConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AZTR_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=AZTR_ForwardStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=AZTR_ForwardStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082526224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Information about Warrants Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">323,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 4.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Number of warrants exercisable | shares</a></td>
<td class="nump">323,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 4.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandEighteenMember', window );">Year 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandEighteenMember', window );">Year 2018 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">47,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Number of warrants exercisable | shares</a></td>
<td class="nump">47,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandNineteenMember', window );">Year 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandNineteenMember', window );">Year 2019 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">215,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Number of warrants exercisable | shares</a></td>
<td class="nump">215,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandTwentyThreeMember', window );">Year 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandTwentyThreeMember', window );">Year 2023 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Number of warrants exercisable | shares</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding period increase decrease weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=AZTR_YearTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=AZTR_YearTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=AZTR_YearTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=AZTR_YearTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081755504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Maturity term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Number of warrants issued to purchase common stock</a></td>
<td class="nump">6,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of warrants</a></td>
<td class="nump">$ 35,453<span></span>
</td>
<td class="nump">$ 70,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants issued</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighed average exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm', window );">Weighted average term</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment non options weighted average term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078945008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Information about Options Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of options exercise price</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
<td class="nump">1,381,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionOneMember', window );">Stock Option One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of options exercise price</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">246,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price, Options outstanding</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">246,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options exercisable</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionTwoMember', window );">Stock Option Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of options exercise price</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">202,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price, Options outstanding</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">202,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options exercisable</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionThreeMember', window );">Stock Option Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of options exercise price</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">800,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price, Options outstanding</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">572,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionFourMember', window );">Stock Option Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of options exercise price</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price, Options outstanding</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options exercisable</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">1,025,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082604992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding Beginning</a></td>
<td class="nump">1,290,318<span></span>
</td>
<td class="nump">1,381,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(42,063)<span></span>
</td>
<td class="num">(90,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 5.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding Ending</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597081595552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Total Intrinsic Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Exercise Price</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
<td class="nump">1,381,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Options Outstanding Value of Stock</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_OptionsExcercisableSharePrice', window );">Options Exercisable Value of Stock</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Exercise Price</a></td>
<td class="nump">0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable Exercise Price</a></td>
<td class="nump">0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare', window );">Options Outstanding Intrinsic Value Per Share</a></td>
<td class="nump">0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare', window );">Options Excercisable Intrinsic Value Per Share</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">246,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">246,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding Intrinsic Value</a></td>
<td class="nump">$ 108,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable Intrinsic Value</a></td>
<td class="nump">$ 108,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_OptionsExcercisableSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options excercisable share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_OptionsExcercisableSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options Exercisable intrinsic value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding intrinsic value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079062272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Measurements for Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 35,453<span></span>
</td>
<td class="nump">$ 5,567,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">35,453<span></span>
</td>
<td class="nump">70,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | 2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | 2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">35,453<span></span>
</td>
<td class="nump">5,670,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 35,453<span></span>
</td>
<td class="nump">70,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | 2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AZTR_TwoThousandTwentyTwoConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AZTR_TwoThousandTwentyTwoConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597082482112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrants</a></td>
<td class="num">$ (34,830)<span></span>
</td>
<td class="num">$ (821)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at December 31, 2022</a></td>
<td class="nump">5,670,283<span></span>
</td>
<td class="nump">71,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrants</a></td>
<td class="num">(34,830)<span></span>
</td>
<td class="num">(821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_IssuanceOfConvertibleNotes', window );">Issuance of 2022 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ChangeInFairValueOfConvertibleNotes', window );">Changes in fair value of 2022 Convertible Notes</a></td>
<td class="nump">3,630,100<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ConversionConvertibleNotes', window );">Conversion of 2022 Convertible Notes</a></td>
<td class="num">(9,230,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 35,453<span></span>
</td>
<td class="nump">$ 5,670,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ChangeInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ChangeInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ConversionConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ConversionConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_IssuanceOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_IssuanceOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078990032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Dividend yield</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079019632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Performance stock options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Number of stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,551<span></span>
</td>
<td class="nump">$ 109,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,555<span></span>
</td>
<td class="nump">131,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,950<span></span>
</td>
<td class="nump">$ 53,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandTwentyThreeStockIncentivePlanMember', window );">2023 Stock Incentive Plan [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandTwentyThreeStockIncentivePlanMember', window );">2023 Stock Incentive Plan [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandTwentyThreeStockIncentivePlanMember', window );">2023 Stock Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod', window );">Stock options available for grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Performance stock options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod', window );">Stock options available for grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AZTR_TwoThousandTwentyThreeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AZTR_TwoThousandTwentyThreeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AZTR_TwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597084061024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,283,781)<span></span>
</td>
<td class="num">$ (10,680,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Dividends on preferred stock</a></td>
<td class="num">(1,355,347)<span></span>
</td>
<td class="num">(2,768,984)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (12,639,128)<span></span>
</td>
<td class="num">$ (13,449,350)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597086519264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total, basic</a></td>
<td class="nump">6,924,453<span></span>
</td>
<td class="nump">1,055,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total, diluted</a></td>
<td class="nump">6,924,453<span></span>
</td>
<td class="nump">1,055,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total, basic</a></td>
<td class="nump">6,919,081<span></span>
</td>
<td class="nump">1,043,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total, diluted</a></td>
<td class="nump">6,919,081<span></span>
</td>
<td class="nump">1,043,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total, basic</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total, diluted</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597175939904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share, Basic and Diluted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (12.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (12.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597086542960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase shares of common stock</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
<td class="nump">1,381,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">1,611,991<span></span>
</td>
<td class="nump">1,554,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">323,736<span></span>
</td>
<td class="nump">263,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase shares of common stock</a></td>
<td class="nump">1,288,255<span></span>
</td>
<td class="nump">1,290,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">1,025,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597086519840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of (Benefit) Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">17,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">17,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 17,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083138256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes using U.S. statutory rate, amount</a></td>
<td class="num">$ (2,401,761)<span></span>
</td>
<td class="num">$ (2,205,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes using U.S. statutory rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_IncomeTaxReconciliationDebtFairValueAdjustment', window );">Debt fair value adjustment, amount</a></td>
<td class="nump">$ 762,321<span></span>
</td>
<td class="nump">$ 262,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate', window );">Debt fair value adjustment, percent</a></td>
<td class="num">(6.67%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit, amount</a></td>
<td class="num">$ (538,268)<span></span>
</td>
<td class="num">$ (602,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit, percent</a></td>
<td class="nump">4.71%<span></span>
</td>
<td class="nump">5.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit, amount</a></td>
<td class="num">$ (356,237)<span></span>
</td>
<td class="num">$ (433,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit, percent</a></td>
<td class="nump">3.11%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, amount</a></td>
<td class="nump">$ 2,502,918<span></span>
</td>
<td class="nump">$ 2,889,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, percent</a></td>
<td class="num">(21.88%)<span></span>
</td>
<td class="num">(27.51%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net, amount</a></td>
<td class="nump">$ 48,335<span></span>
</td>
<td class="nump">$ 89,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, net, percent</a></td>
<td class="num">(0.42%)<span></span>
</td>
<td class="num">(0.85%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="nump">$ 17,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">U.S. federal statutory tax rate</a></td>
<td class="num">(0.15%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation debt fair value adjustment tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_IncomeTaxReconciliationDebtFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation debt fair value adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_IncomeTaxReconciliationDebtFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083489760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,755,690<span></span>
</td>
<td class="nump">$ 7,870,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">2,155,118<span></span>
</td>
<td class="nump">1,729,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,372,070<span></span>
</td>
<td class="nump">1,189,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">89,462<span></span>
</td>
<td class="nump">81,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">30,572<span></span>
</td>
<td class="nump">28,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">13,402,912<span></span>
</td>
<td class="nump">10,899,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(13,402,912)<span></span>
</td>
<td class="num">(10,899,994)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079096048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="num">$ (356,237)<span></span>
</td>
<td class="num">$ (433,674)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">32,529,000<span></span>
</td>
<td class="nump">29,192,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Years 2036 Through 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">1,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">31,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Years 2039 Through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">1,524,000<span></span>
</td>
<td class="nump">1,235,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">466,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Years 2037 Through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">32,484,000<span></span>
</td>
<td class="nump">29,374,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Years 2036 Through 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Tax Years 2039 Through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="nump">$ 218,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=AZTR_TaxYears2036Through2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=AZTR_TaxYears2036Through2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=AZTR_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=AZTR_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=AZTR_TaxYears2039Through2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=AZTR_TaxYears2039Through2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=AZTR_TaxYears2037Through2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=AZTR_TaxYears2037Through2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=AZTR_TaxYears2036Through2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=AZTR_TaxYears2036Through2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597085146432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Capitalized License agreement amount</a></td>
<td class="nump">$ 13,096<span></span>
</td>
<td class="nump">$ 65,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AZTR_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AZTR_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597083399984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 338,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">279,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">206,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">74,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="nump">898,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less interest</a></td>
<td class="num">(53,246)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 845,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079092928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Payments Under Finance Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 17,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">17,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">10,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="nump">45,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_FinanceLeaseInterest', window );">Less interest</a></td>
<td class="num">(5,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 40,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_FinanceLeaseInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_FinanceLeaseInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597079352448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Operating lease rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_FinanceLeaseMonthlyPayments', window );">Finance lease monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Finance lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_FinanceLeaseExpense', window );">Finance lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AZTR_BranfordCTMember', window );">Branford. CT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AZTR_GrotonCTMember', window );">Groton. CT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="nump">$ 6,824<span></span>
</td>
<td class="nump">$ 4,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_FinanceLeaseMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease monthly payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_FinanceLeaseMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AZTR_BranfordCTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AZTR_BranfordCTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AZTR_GrotonCTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AZTR_GrotonCTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078648848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansGeneralInformation', window );">Retirement plan general information</a></td>
<td class="text">the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,803<span></span>
</td>
<td class="nump">$ 23,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansGeneralInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansGeneralInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078613920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="nump">$ 284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,495,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember', window );">2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="num">$ (9,495,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember', window );">Convertible Note Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember', window );">Convertible Note Purchase Agreement [Member] | 2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember', window );">2022 Convertible Note [Member] | Common Stock [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,243,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Accounts receivable due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member] | Convertible Note Purchase Agreement [Member] | 2022 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AZTR_ConvertibleNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AZTR_TwentyTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140597078838048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,991,359<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of common shares</a></td>
<td class="nump">666,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 0.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="nump">16,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price per share</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AZTR_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from public offering</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of public offering</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Over-Allotment Option [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price per share</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AZTR_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AZTR_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AZTR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AZTR_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AZTR_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MA,D#X/L%I6*W(T]0OF=U^S]02P,$%     @ O8!O6+*Y_TXA"   RBH  !@
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M?F06O3J^'ZGO0=0^]2&:0"_AHX\^HWP["D5Q#MU'I7IE/!Z5SY$$I@GK4VG
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MG<5=,(&W.RD;W(&D3K30;)2W@/0,S1(9FY&\=8\7.7'#XN+&:!I=B[P3-;@
M>Y)8VYD9/&_T]K,/V_AWCCKGP%CB#^?LZ*"A/>7YFZ@?BZH!I5R8AO!]:CS4
MVX.3VQNMUNW9PP>EM5JUETLIYK*V!N;WA5)Z?V./,QZ.KU[_'U!+ P04
M" "]@&]876L>Y_(#  "P$P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;*V878_:.!2&_XJ57:U:J9W8^686D#J,5KL7E5!1NQ>KO3") 6N2F-H&NOOK
M:X=,0DAP$C1S,>3CG-?/,?%YB:<GQE_$CA )?F1I+F;63LK]HVV+>$<R+![8
MGN3JSH;Q#$MURK>VV'."DR(I2VT'PL#.,,VM^;2XMN3S*3O(E.9DR8$X9!GF
M_SV1E)UF%K)>+WRAVYW4%^SY=(^W9$7DU_V2JS.[4DEH1G)!60XXV<RL3^AQ
MX;@ZH8CX1LE)7!P#7<J:L1=]\E<RLZ F(BF)I9; ZN-(%B1-M9+B^%Z*6M68
M.O'R^%7]CZ)X5<P:"[)@Z=\TD;N9%5D@(1M\2.47=OJ3E 7Y6B]FJ2C^@],Y
MUO<L$!^$9%F9K @RFI\_\8]R(BX2T*T$ITQPAB:X94(Q<_:9K"CK&4L\GW)V
M EQ'*S5]4,Q-D:VJH;G^&E>2J[M4Y<GY@N6"I33!DB3@":<XCPE8:3D!WBTQ
M)[G<$4ECG+X''\'7U3-X]^O[J2W5T%K CLMAGL[#.#>&>2;Q W#1!^! Q^U(
M7PQ/=YKIMBJXJMJIJG8*/>]FU5FFGB$UN_'+![#''!QQ>B!==9V%PD)(KXGC
M'#Y "-'4/E[R]X8U.-V*TQW!*7;J^Q  '^2.<?H_2;IXSX+!!0B"Y=\5\I#(
M!K5747OCJ:D0AVYBK\WAP$D8>.X5<$<@]-Q)%'7C^A6N/QY7=3PA<9[0?-O%
M[ ]E[@@T,0<5<V!D7A%.%>4GH-;OD7!)URD!2]4!">=J(:]T+>"?SR1;$_YO
M5P%&>>T=CV*/8S*SE#D(PH_$FO_V"PK@[UV+]XW$&C,15C,1&F>B+GK(:@Z'
MK>;>L 9J5*%&XU '+>BH]00YT'<C_PJY-ZR!/*F0)W<AWU[-DQ;'==]I1YA(
M$:R=#-[%VK.42U43<4>($?G"?-$XY)1^/V@SUK]P;C[$I:AO(FZ'N*X;^C"X
M@5P[)S);YVOG^8CN[CWF$<8VG[=2:\Y'[=#(;-'C^D\IUMN ^N.:N+4U([,W
MW]>#4-MZW0@&?GB-W1O7Q*XM&ID]>GP?0FWG;2V2=HB1MC9G9';G>SM1T(_<
M#C$BURZ*1MKHL$X4]G>B=@CRG- +W!L_@5!MI\CLIV4K>KJ_$1GU1S>B-U)K
MSD;MU&BD59L;T61@(^J-:[Z U6[MW.?6YD;DM)TX\A&"T?7K6&]<$[MV;&>D
M8_<VHE+0M*H[0MP)<J%[@_;B-==LUG<VHE+5B-P.,2+7?NJ,]--!C:@4-36B
MCA 4ZB?9GUPQVQ?;*7HOZS/F6YH+D)*-2H4/H=+@Y^VA\XED^V*'9<VD9%EQ
MN",X(5P'J/L;QN3KB=ZTJ3;IYC\!4$L#!!0    ( +V ;UBEG)O*K@4  #@7
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5AM;]LV$/XKA#<,'=#$
M(B514N88:)QN"["^H%G7#\,^T!)M"Y5$CZ*=Y-_O*,F6+5)L.N2+;<EWI^<Y
MWMU#<?8@Y-=ZP[E"CV51U=>3C5+;J^FT3C>\9/6EV/(*_ED)63(%EW(]K;>2
MLZQQ*HLI\3PZ+5E>3>:SYMY'.9^)G2KRBG^4J-Z5)9-/-[P0#]<3/#G<^)2O
M-TK?F,YG6[;F]UQ]WGZ4<#4]1LGRDE=U+BHD^>IZ\@9?+4BL'1J+OW+^4)_\
M1IK*4HBO^N(NNYYX&A$O>*IT" 9?>[[@1:$C 8Y_NZ"3XS.UX^GO0_1?&_)
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M:W[/'K/ZDWB.>7=#3L-+1%:U_Z/GG:UG35#R6-4B[YSE"/*TV/UE7[N).';
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ML&+)"#9LZ!G[Z?F?_#5(H8"SDVN-;=*=TGAN=2.''8)=!1TA9VS(&?O)^7[
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M5MSH8\Y\@!KFZ:'S25&$^]5H^CV(\/V4Z<"(0881\XR8F(PF4_Z:X.='BXC
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M7=&GIWZ6S*QU49NR4)5>_'QP,7WVZ@CC><!O1M_7P=\*.YF7Y6=\N,I^/IB
M()WKM,$,"?USIR]UGF,B(N.+G?/ +XD7P[_=[&]Y[[27>5+KRS+_W63-ZN>#
MLP.5Z472YLW'\O[OVN[G&/.E95[S?]6]C#TZ/%!I6S?EVKY,%*Q-(?\F7RT?
M@A?.)@^\,+,OS)AN68BI?)TTR<L757FO*HRFV? ';Y7?)N), :'<-!5]:^B]
MYN6-"$.5"W5CEH59F#0I&G61IF5;-*98JNLR-ZG1]8NG#:V'MYZF=NY7,O?L
M@;FG,_5K632K6KTI,IWU)WA*A'IJ9X[:5[-'9WRMT[$ZG,9J-ID=/C+?H=_]
M(<]W^,!\ ]M4_WDQKYN*M.6_AG8L\QT-SP<+>E9ODE3_?$ F4NOJ3A^\_-L/
MTY/)\T>H/?+4'CTV^_]25H_./4SY;!Q]_YKJ55*;.J*!P9>W*QTM3)$4J4ER
M53=)H\FBFQKS-2NM+LOU)BFV*JFTHG4W]&^F#(PU+:N,7M-D#\U*?2I,0]_<
M8():+76AJR3/MQBG-_@FZ=;<5(:6V^0T\*>__7 VFTV>?QK?C*-?+BZN^?/T
M^9.Q^E1KT/JF;LR:)P6I0D+"_L)2.$ ]"$S+ A[1-%LA<'C] 4+I74S;WQ"8
MMM85\98<W9?6D 2B=5*05^3UFI),_K-6VA.;%+3EFCSI!K36-&72J&2Q(%_'
MT],^RHKYL@99O *-UXV\FIMD;G+30&R)O)'1O&[/\R1GUK-;&4?$F?JQQ2$\
M>,9,$=O2MJI \X(LJ([5RI +P\9RI;]N:(N:)HYYBKND,F5+I-&2%8\OJUK-
M=6[T'<U%FYYC(TE=%LD\UU%+3J1B^E)3I>V:Y$%ST1JRX9K\<*WN5R9=*8C&
M[H1T$A_!0 CGCS9;6A5,YA2D9+ZDJK;X]B[)6_THLXHLDN6@GWB%QF)C1:V=
M%(@;1=F \LQ \AMH-3A2E6N[V;IL*R)]K'Y?F5RK0-1V^S73]2C+(YJX*DG9
M:$",Z-82CQT;ULE698;T 1MOB.VBA)@EN],51<6MT-/T93M6ETF]BC 0?Z@W
MI(S$%.871<%HTU:;LM;UH*8(F7TC3S'+@D*_E9,S>+*?VI \Z9T\EU&D/"N:
M(*:@NL9$&>EP;>RL&+6B"$MTYX:(RB)3$)L:68A-D-1L2<::8\=M)?)B,BM-
M+)9 1(I =EE;Y>)E=;?%L;HFCNJJV3('L/D-2Z7W6/O'$+5H BRMH4W5S5B]
MUN1&R&.P%R'M2VG++6RQK:$PX ("#.#""&Y8K76S*LEX[JQZ.VG@#;UH<]KQ
M'?1<=+M*BB4Y50CO4$TGSMO6T4>=:MH)F0K[,L]I4FZP@CEIQX)J-];2+7Q)
M"G"ZO&>APFR@VRE(2<DS&QI5DF$0HS[00 5[+C.3BIGU!:QA2U"IZ,&%P4O2
MEGEN2'V^>^W.U236NW!TVB2TAWL2NQZ5BP410\C(0C\Q6^>82/-H,CP>@T\D
MPOND)HO=6;R_)C&)L(=>STE$#G_P!NB/&41.ED8O1!]@<I#R);&TWI'#QC1)
M;K[1=)D=3X3;\1"!%S$9-05=. \V$]H8;3"CJ) V,040(@WJ1YJ>ZV62QS2^
M7)#T:$_XU(4B\;/L<LAKF2H;D2NBB+70&I+($XY79 N!X! AIZ?/25\H0B'L
M;5H24.HI':NK0OVC);4%#_:-&GB!XQQM_^KZ U/@;"2J6]J="TG)DG*&6CSP
MLB(^8Q^IUAF;K7L?IFUC9M^SD.33SZLRAQ.Q1+-I-EN21ULY4UN0JR7G\*6E
MG8M]>8D0)UN6PH\GI_'9\3G[*Y8;\T9B4$(S0#%&# D<#]Y16"(>7A716SVO
M6B"DV61Z(NQXZR%#@(0HTA=94M'F7I7TCX<F;R]N7CE40MZB;FG9BYM/ZGTY
MYBE'DUGLEG/OW)8;DLC9T<S#F0BOV.$>0K!)0]2T#09UI/T5NYUR,2+7XN?[
M^.&3)R$,?%BU%_[*8M_KL[7 /?/P.F)?3*Q>T_HEN2KPG$R;D@'QP5"@B/!
MVCK]@\L3Z (<U&UDQZ'DX@SPC-PGV04[6.L\H>-ZOK61%YHB5K4&GH.W$5\E
M-N_FC/R<I;,:WDU1%B/9/"8H"X$+I)^D0R[R[7R/*<1XZ<NM52"K)R$XI*A5
MYHCO=8>F(X 2UFNV[KQE8&$!2X<! J7L" "C8_OW)MG:63A\FEIV5#$E5_N@
MF@V/0BF>Q%'(:Q@LD?>-5B/=>%PG^N*W:)CI(JO623.@ %:=$3[3G"8G/B"
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M/EV,Y(IM__ZRW4I07:]M51L-EJ9#YWX3O?XW28'"H^;^F<=>=V(@PU!R<D_
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M_.=*4X9280!]OR@I0MD/6,#_.-K+_P902P,$%     @ O8!O6 @S>M)Z @
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M!L.;L0>J'0KM@F3M&G$MR;2U"PLS1U'9!/,^EY+V"WM /YF3/U!+ P04
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M$*_CZPML_,G"E@QK2MY.4IWC8XP<8I++.,;$-6@"1$6[E4D5(.9)EPS;$G2
MM2GVK4Y8&^:J2B(W:@WB2[=US /(&TDW&>'S+J50:@K$EH)5.7$P'WB"*SS*
M,O,XI@I5UMA3DFM21QQ1<#@\-O&JDE;GBZPSP3J3-3@'\EEQU'7N+05/EK;"
M<'6E1N?^_.#,<Q<]<Y%\HZNSMNSG/8/ZT,FF._E(FX0(97N?WP9C(RPH[;P@
MV21^2<#[;,T71B+3E,K!5\ *W0Y1-;T?:^NJJZ9VNMJ0*BZ-H7,KV5]9;6'!
MK=&&UVZ-SM&MGJ-9^[<+3^A2N>J";W:;Y]&L>A4\B5=OJQMAUE2S%-*45+OM
M\3 $4[U7J@^G"_]&6&E'+PZ_W- 3#PT+T'FJM3M\L('FT3C]#U!+ P04
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MJ#9VL-1@:Z::OIJWS>PZKD:V9_-J\*6KE\I80XIK<O5;@YX+JAHFJP<C"SO
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MA7LT;=F<-*6;*JD#UJR &[[!GR-_[2!2^+^/>A7[]K .E=  SIIB3/KNX#R
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M-8K4#65;B#!&AY662(U\XN,KT.VM3=QFLUQWL+4Y[=KSOH2.G>NYV >] -P
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MW5Q>SSZS^1T6OGR\N9NS3U6M_L,2F#VC7BA56YU@RD<LQ'HH2B/S4B1'K*&
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M9-1ERGV$=C>FV-@/OXO"F"*SEVO!D2[:@.?+HC#U#1EH_A)P_A]02P,$%
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M#(#!C#]@!AI585^^O\@*60G=AM-*49Y.X/E]%_2.#J"@.-K(A984)>BDL/C
MY@J1#AAM\1[+($DVJ=8[-9I\1TRPC-7YVJ4&2^'WBINW%*87\K53+R_9VKS
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MG9[,">AA% ?'JBZT?Z&L&Z9@-N[U0NT3W'ZME-T[_H#Q/<S_ E!+ P04
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MP.P+"+OAFU$4RAH^A-C[BT8CW1C6B>[RVPR1^2)'H^.Z1P&L.@,/)1D1)SD
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MH>2@<)NP!U*TQ^Y?!8LOWLD^NM"<![1K#O.+B85B!8=JO1/<!&66=A/:KTF
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M>M'[;W@M:!W? UQMQP5WA'=W)5SQ4G^Q;D60 GIMQ5UQA: V8S>'2?32RO5
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MIORTQ /T^[*@P&D_8 !_>_3S_P%02P,$%     @ O8!O6'[=X]H: P  [08
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M=C7!FDTWV4!,:XA@#X0?P*4H]5+!^S+%]"F 2WQ:4D%#:AH<1#S'I >AWX7
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MH>D%::<K>K*C- JTOA!"[SZ,@_9/P/0?4$L#!!0    ( +V ;UCHZCA5F@0
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MRJ(6@#4 N]$%\0+@'JB9V)WX$]>CK/-=+PK=21CT3KR^Y\.&2<E*K8!2:Q0
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M2=<XE$:!OL^%T-L7XZ"]&$[_ U!+ P04    " "]@&]82BH!)RP#  #G"
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M(E-?5P0GA,D"XO=%4?"7"]E ?41G]A]02P,$%     @ O8!O6,OY %6Q P
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M$*BZD*PTQR)+)B4K3'.#)$6N'U#W5XS)IPL=H#F*FWX#4$L#!!0    ( +V
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M)?(5HA6PSN71BS-T>8P$UI+L5)*=*^X2SIAE& FL50:W*H,[ZB[AGOD/:]C
MAGGBTZXXP[2<5Y;8M*([[:6[H%&2<6!O=&LOV-!I&@FLI1MK]7^Y=D6_EN C
M56(LM'8I&FT-'M6S)5S3C(;FZJ=;Z\6P-MVZ'<&]?_/>0\;B@&<,<J8/P8N\
M3GM]VX\X>+JNT8;@N@_!QC6=V]OE#"[%2&CM4M0]#NYO<@8[][Q3T4T#VZ?.
MO136IEOW,[B_H7D"\1*UHZ&/'B-!>@^2YP7G]B(.GJZ1T-KZZZX(V]=T[JB]
MTEAH[5+4W1+N[4*&.]<YMZ3K6F=[[J6P-MVZJ\'];<U=%H1^$&\'&+<7</!L
MC836EE]W27AZ3>..VC:-A=8^"ZC[)KVW&1ELW!*N]7YK3HW3M^"+805=M7%Z
M(X_.OA*V#>(4A; 1>=J-(P!8<1I5W'":Y <Z*\HYC?++'1 ?F P0OV\HY<<;
M>494G0EZ_P-02P,$%     @ O8!O6-3KQ_N* @  :@8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&ULK55M3]LP$/XK5C9-(#'RUI2-I9%H"]JD,54@
MM@_3/KC)M;%P[&"[+?S[G9TT:R%T^[ OB5_N>>ZYL^^<;J2ZUR6 (8\5%WKD
ME<;4Y[ZO\Q(JJD]E#0)W%E)5U.!4+7U=*Z"% U7<CX)@Z%>4"2]+W=I,9:E<
M&<X$S!31JZJBZFD,7&Y&7NAM%V[8LC1VP<_2FB[A%LQ=/5,X\SN6@E4@-)."
M*%B,O(OP?))8>V?PG<%&[XR)C60NY;V=?"E&7F % 8?<6 :*OS5,@'-+A#(>
M6DZO<VF!N^,M^Y6+'6.94PT3R7^PPI0C[X-'"EC0%3<W<O,9VGB<P%QR[;YD
MT]@FL4?RE3:R:L&HH&*B^=/'-@\[@'#X"B!J =%SP. 50-P"8A=HH\R%-:6&
M9JF2&Z*L-;+9@<N-0V,T3-A3O#4*=QGB3#93>"&4>2)4%.3R8<5J/")#CJ9@
M*..:?*-*49OI8_*>W-U.R=';X]0WZ-GB_;SU,FZ\1*]X"2-R+84I-;D4!13[
M!#Y*[G1'6]WCZ"#C%/)3$H<G) JBN$?0Y-_AT0$Y<9?&V/'%?TGC"9EQBOG;
MS^;/B[DV"F_LK[[4-<R#?F9;Q>>ZICF,/"Q3#6H-7O;N33@,/O6%_9_(]I(P
MZ)(P.,2.2472G%%7G_"(C49#7\ -2^)8;)=9X_V(@C!(_?5N*'UFP3 ).[,]
MD4DG,CDH\JO4&C1!A073M=24$[D@]6X9P/;@^L0G+U0-PD%X]DS[2ZNSC_:>
M[BGW=\JV K5TW4R37*Z$:2JA6^T:YH7K$\_6Q]A(F[[WAZ;IPM=4+9G0A,,"
M*8/3,Y2DFL[63(RL77.82X.MQ@U+? Q 60/<7TAIMA/KH'M>LM]02P,$%
M  @ O8!O6-78QDBC!   2QD  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULM5EM;]LV$/XKA#8,+;!&(F6].+,-.$[;&4B&H%FV#\4^T!)M"Y5$CZ3C
M=K]^I*1(EDTS?E&^V'JY>_C<Z7AW.@TVE'WC2T($^)ZE.1]:2R%6U[;-HR7)
M,+^B*Y++.W/*,BSD*5O8?,4(C@NE++61X_AVAI/<&@V*:P]L-*!KD28Y>6"
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M2X)CPI2 O#^G5+R<J 7J[R>C_P%02P,$%     @ O8!O6,T-IWR* @  C@8
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MROHSMO5X@;EDVC^A;F+3)(!\I8WD+=@JX%0T;_+8^K %Z T. .(6$#\'] \
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MM?P, :8"Y/N<4O$R43==_V&3_ -02P,$%     @ O8!O6!=+F2R> @  N@H
M !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULK99=;]HP%(;_BI5-4RMU
MY(NDP$*D%30-:9U04;>+:A<F',"J8V>V@?;?SW;2"-0T*U*X(#Z)W]=^<DZL
MDQRX>)1; (6><LKDV-DJ58Q<5V9;R+'L\0*8?K+F(L=*AV+CRD( 7EE13MW
M\V(WQX0Y:6+OS46:\)VBA,%<(+G+<RR>;X#RP]CQG9<;=V2S5>:&FR8%WL "
MU'TQ%SIR:Y<5R8%)PAD2L!X[7_W19&CFVPF_"!SDT1@9DB7GCR:8K<:.9S8$
M%#)E'+"^[&$"E!HCO8V_E:=3+VF$Q^,7]V^67;,LL80)I[_)2FW'SL!!*UCC
M'55W_/ =*I[(^&6<2ON/#N7<2$_.=E+QO!+K'>2$E5?\5+V'(X'??T,05(+@
MO8*P$H06M-R9Q9IBA=-$\ ,29K9V,P/[;JQ:TQ!FLKA00C\E6J?2A2Z+U8X"
MXFLTX6P/0I&E#G]R!1+-\3,VT<44%"947J+/Z'XQ11<?+Q-7Z>6-B9M52]V4
M2P5O+#6%K(="_PH%7A VR"?OEP>G<E=#U^1!31Y8O_!-OZ5",R:5V.FJ5.CA
MAYZ 9@IR^:<)KG3K-[N9CVTD"YS!V-%?DP2Q!R?]],&/O2]-J!V9G8"'-7C8
MYIX>IYG9-!=EFJ\0 ]6$WNK7O%O41%WZ1-;''"_[-(X]\TO<?0-0OP;JMP+I
M@O!?%2]ZN(5\":(QEZU^Y^:R([,3]*A&CSHMXJA+\([,3L#C&CSNN(A;_<XH
MXM(G/BIBWVLIXNL:Z/I_11R<5\2M?N?FLB.S$_1!C3[HM(@'78)W9'8"/JS!
MAQT7<:O?&44\?'421XTGL7O469BN[A:+#6$245AKI=>[UA:B[)3*0/'"-AM+
MKG3K8H=;W5R",!/T\S77G%5@^I>Z74W_ 5!+ P04    " "]@&]8&V*U[.H)
M  !4?   &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RMW>UOHT8>!_!_
M9>0[5:W4KGGP8YI82@(#C+I5U*AW+ZI[,;$G-EH;? -.=JO^\>4IQH/Q&.Z^
M^V(W=I@/L/Z-/?#UP.U[++\D&R%2\G6WC9*[P29-]S?#8;+<B!U//L5[$66_
M>8WECJ?90[D>)GLI^*IHM-L.+<.8#'<\C :+V^*Y)[FXC0_I-HS$DR3)8;?C
M\MN#V,;O=P-S\/'$;^%ZD^9/#!>W>[X6SR+]??\DLT?#H[(*=R)*PC@B4KS>
M#>[-&S8J&A1+_"L4[\G)SR3?E9<X_I(_"%9W R/?(K$5RS0G>/;/FW@4VVTN
M9=OQWPH='->9-SS]^4.GQ<YG._/"$_$8;_\=KM+-W6 V("OQR@_;]+?XW1?5
M#HUS;QEOD^)O\EXN.\T67AZ2--Y5C;,MV(51^2__6OU'G#0P1Q<:6%4#J]E@
M?*&!736PNS8850U&71N,JP;CKOLPJ1I,NJYA6C68-AM,+C2850UF73=I7C68
M=VU@&A^OG%%44/F2%_7B\)0O;F7\3F2^?.;E/Q1%5[3/RB2,\O[QG,KLMV'6
M+ET\QM&;D&GXLA7$$2\I^=X1*0^W"?F52\GSXOV!_$1^?W;(]__\X7:89NO,
M6PZ7E?]8^M8%WR2?XRC=),2-5F+5TMZ_TM[2 ,-L9X][;'WL\8.E%=DA^D0L
M\T=B&9;=MD,=FMO&Q>:.OOG]7FJ;N_KF5+QD&S^[V)Q>V7B>;_SE???TS9_%
M_KCQ5MMKJ6_NB*5V[4'WYFUK9QWVW1@7S4U-'=G'GF,7GGUQ<[+>$D1)*@_9
MYT5*_O@E6X $J=@E_VG9NH=2&[5K^<?@3;+G2W$WR#[G$B'?Q&#QW3_,B?%S
M6XTB,0>)N4B,(C$/B?E(+$!B#(0I?6)T[!,CG;X(DN3 HZ4@\2M9%I\LQ3@J
MV?!L76V=0LOU[11(S$%B+A*C2,Q#8GZ)30HL'YB_+2Q[9&?OU6^GU8Y<)0-A
M2K6/C]4^UE;[8UWAQWHO1U)1G(J$[/DWGCUJJWLMW+?ND9B#Q%PD1I&8A\3\
M$AN?U/U/\]%\;$R;I8]<*P-A2NE/CJ4_T9?^AD=K0<*(O/)0DC>^/8BV3M!6
M^UJY;^TC,0>)N4B,(C$/B?F3L_=\>V(;IF$T2G]RUD=,:VP8S>48:..4JIX>
MJWJJ'[Y$J<C4E(BO>Q$EK=6K%?I6+Q)SD)B+Q"@2\Y"8/SVK7G,R,<QYHWA;
M%IM:XWGC[9V!-DVIW=FQ=F?:VBT.1\-J_)UD;\1)VCKBUBI]ZQ>).4C,16(4
MB7E(S)^=O:LVWW?/EYC.9V:C<$';I!3N_%BX<VWAYJ=CR.EIR%^S<0/YX[/8
MO0C9>B9%Z_4M823F(#$7B5$DYB$Q'XD%2(R!,*57F$9]8MZ GE^L.%"W@&H.
M5'.A&H5J'E3SH5H U1A*4[O'26YE=CWYLI?A4I"]D.6)QM;.H<5Z=PZDYD U
M%ZI1J.9!-1^J!5"-5=KIL&LT.PZZU)*WZI*WN@_Q+X_P]4KO6D=J#E1SH1J%
M:AY4\Z%: -58I2FG=L83T[Y0[G6^:FJCJBL'!N0O\BQDF!WJ/I G*5Z%E&)%
MGM-X^45[\*!?:>_> 0UBH9H+U2A4\Z":#]4"J,90FMJ)ZD#6'&&/(J")+%1S
MH)H+U2A4\Z":#]4"J,90FMH]Z@37[!SA=CF*@,:V4,V!:BY4H^9Y0'HR&JY*
M'IK(0K4 JC&4II9\G=R:^NCV?KF4AVRH%%9A5VNA0S-:J.9 -1>J4;,MY1Q-
MQ_-FL4,C6*@60#6&TM1BKP-=\TJBV_<+:7JO=^5# UZHYD(U:IY'I"W?_?*@
M*_6A6@#5&$I3"[].@TU]')Q_1[I?JJ8'>U<^-!J&:BY4HU#-@VH^5 N@&D-I
M:@>I4V=SCCTPAJ;.4,V!:BY4HU#-@VH^5 N@&D-IZARI.GVVM/'=XC-/#S),
MOY$5;_\6I[Y]W_YP96N.$X\NS[KZ/P'WZO^'+"<?79YY!<V1H9H/U0*HQE":
M6NAUCFSI<^0NA\-ZHG>MGV>#UF1LC!MC90>Z5A>J4:CF034?J@50C:$TM=CK
M!-G2)\C-TYVMQ0Z-CZ&: ]5<ZSRXM(WRC]H5*72]'E3SH5H U1A*4\N]3I M
M?8+\S+?%F1^^6H7YU1CXMIR9U5KVT%RXTDY/AXQ;"LNIEAM?6<Z%;AV%:AY4
M\Z%: -482E/+N<YR+6T8MKA?KZ589^/Q_,T[6H9[OFVM9&B$6VEJ=M,R<<?I
MNJ +W3X*U3RHYD.U *HQE*;6<AV\6EV"US0;>%\^%U\1RK2;V6AB6(V*>M2O
MJ_<@ YJD0C4*U3RHYD.U *HQE*96>YVY6E>FR_[O,\6M\TBQ=6[QHWX3>G<"
M:,H*U2A4\Z":#]4"J,90FMH)ZBS6TF>Q9VG4TT$N-SP1Y#X;UXCR++PFH-+S
MO<<UT&@6JKE0C4(U#ZKY4"V :@REJ=VE3G"M&32@LJ#Y+51SH)H+U2A4\Z":
M#]4"J,90FMH]ZOS6TD\;/OTTV<MX%R9)++]=O.B(7NO=.Z#Q+51SH1J%:EZE
M*><(VLYW^=#5!E"-59KR5:?&66/U@H)UZ&KK0\8^(R3R%^D_<UZ__KZ] *HY
M4,V%:A2J>5#-AVH!5&,H3>U/=;9KF] AE W->:&: ]5<J$:AF@?5?*@60#6&
MTM3N4:?!=I<TN/,02J_U[AW08!BJN5"-0C4/JOE0+8!JS&Z95ZP=9YU<N5F?
M"S\(+L-H??S.SX_YM*]E]@G!U^V5C[UV,_;BS=BK-V,OWXR]?C/V L[8*SAC
M+^%<:OD55HZE;WPR)A?JO@Z0;7V W/_XPNIY? &-GJ&: ]5<J$:AF@?5?*@6
M0#6&TM3^5(?8]AA[? &=/PS5'*CF0C4*U3RHYD.U *HQE*9VCSKUMKNDWMV/
M+Z"3CJ&: ]5<J$:AFF>??]]@9+=\C<N'KC: :@REJ85?)]VV/NGN?7P!3;:A
MF@/57*A&H9I7:<U1]ZQ9]]#(&JHQE*;6?1U9V_I)QU<GC>G;]RYT:$8-U5RH
M1J&:=^55+&Z49=J7I[KYT,T)H!I#:6H7J&-I6Q]+>S).DGRTLQ1BU?JM5CW0
MNP] DVBHYD(U"M4\^SR)MEKG_OC0]090C:$T]69?=5X]TN?5Q?'O*DR6\2&Z
M.LC16WWK'JHY4,V%:A2J>976&.38C9J'KC. :@REJ35?9\JC*]>=YOLPY=OP
M3U[>WW>7UWYKO4/#9*CF0#47JE&HYHW.)UNWS_'TH>L-H!I#:67-#T]N%[P3
M<EW<GCJ_94Q6R>7]3X_/'F^!?5_<^+GQ_*-YXYDMS_OF35#>X+KFR_MM?^9R
M'48)V8K7;%7&IVGVPLCR%M;E@S3>%S<K?HG3--X5/VX$7PF9+Y#]_C6.TX\'
M^0J.-Q)?_ U02P,$%     @ O8!O6-*BPO0="   ,E   !D   !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&ULO9Q;;]LV&(;O]RL(;R@V8(TE2CZD30PTD8AU
M6-M@P;:+81>,3<="=7 I.FF'_?A1AYBB8]/6\*Z]:&5;W_-)?"D>WE*\>"SD
MQW(EA"*?LS0O+P<KI=:OAL-ROA(9+\^*M<CU+\M"9ESIC_)^6*ZEX(LZ*$N'
MU//&PXPG^6!V47]W(V<7Q4:E22YN)"DW6<;EERN1%H^7 W_P],6OR?U*55\,
M9Q=K?B]NA?IM?2/UI^&6LD@RD9=)D1,IEI>#-_XK%M(JH#[C]T0\EIUC4MW*
M75%\K#Z\75P.O.J*1"KFJD)P_<^#N!9I6I'T=7QJH8-MSBJP>_Q$9_7-ZYNY
MXZ6X+M(_DH5:70ZF [(02[Y)U:_%XT^BO:%1Q9L7:5G_31Z;<\>3 9EO2E5D
M;;"^@BS)FW_YY[8@.@&!=R" M@'TU("@#0AV J:' L(V(-P)\,,# :,V8'1J
MP+@-&-=EWQ167=(15WQV(8M'(JNS-:TZJ.6JHW4!)WE5LVZ5U+\F.D[-;E4Q
M_[@JTH60Y8MOI]2?O";QITVBOI#O(Z%XDI;D/9>25Q7@!_*2?$>&I%QQ*<J+
MH=(74&&&\S;9=9.,'D@V)N^*7*U*$N<+L=@3'[GC?>H #/6=;V^?/MW^%742
MW_$OQ)_\2*A'@WWWXX[^>9.?D< [&!ZYPR,QU^'^P?#X2':>.\/9Z=FIHRB#
M;4T*:EYP@'>=\K(DQ9+458K\^8O^G;Q5(BO_VG-Q5PTLW ^KVM-7Y9K/Q>5
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M= *E3<LWRM5V%O8'PV!/K5@(03>%:MWLF>H=A7;G5OU>Y.JW^YHDX%,\/PR
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M^@;U_9PQN3W1!LI7Z)/_ %!+ P04    " "]@&]8D8+//5(#  "5#   &0
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M/3P<FN&^I*OB#%:<P0(/M>#5"VWAI>1O 62G:B[4J"\T9]6#2\P3#G[<R G
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M);R]1$5H)M_!>_AR?PEO7[\;N4HS-/.X2<5F4K()#K#Q [CA3*TD?&0IIKL
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MEP/%U[8EG7.E&UQ[N=+_05"8 /U\P?4R5P,S0?VO)OX+4$L#!!0    ( +V
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MM7IZ5XNR?I8=Q0M;@F9<Z8)FFZG^Y4!A O3\G'.U[Y@%JI^8Z ]02P,$%
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M971S+W-H965T-3DN>&ULK55=;],P%/TK5P$AD+:F2=JU&FVDM1T"B:%J%?"
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M'J3--FQVX,[&H8T;RNU77&EI5JG!Z71ERB*O&8+8P!=3-)^%4K!$":N"2+R
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M6)A? 4J;8-8W0NA#8#=H?R[I'U!+ P04    " "]@&]8AGDU-FH#  "T#P
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M6G7=P+6!>K]D3!X'>H&VCY_\ U!+ P04    " "]@&]8.D<U#64#  #&#
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M):/TONH52!>G9+!:&$3)(:>A%4F-F9M3VG-*QP^@T)3;.G&8*EP\T^&VA9.
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MWUE-JFFNS<3(VO>GF32VV_EA9>\C5"[ ?I]+:383MT%WP^5_ %!+ P04
M" "]@&]8XW\%B,H"   T"   &0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6R55EMOFS 4_BL6FZ9.6@LQUW0)TMJJVJ1VBYIU>W;@D%@U-K--TO[[V4!9
MU!"BO03?OLOQY9S,=D(^J0V 1L\EXVKN;+2N+EU791LHB;H0%7 S4PA9$FVZ
M<NVJ2@+)&U#)7.QYD5L2RIUTUHPM9#H3M6:4PT(B59<ED2]7P,1N[DR<UX$'
MNMYH.^"FLXJL80GZL5I(TW-[EIR6P!45'$DHYLZ7R>75I $T*WY1V*F]-K*A
MK(1XLIUO^=SQK"-@D&E+0<QG"]? F&4R/OYTI$ZO:8'[[5?VVR9X$\R**+@6
M[#?-]6;N) [*H2 UTP]B]Q6Z@$++EPFFFE^TZ]9Z#LIJI479@8V#DO+V2YZ[
MC=@#8'P$@#L ;GRW0HW+&Z)).I-BAZ1=;=ALHPFU01MSE-M366II9JG!Z71I
MCCFO&2!1H-M:UQ+0/>6TK$NT("]F^[5"CSP'B;X+?IX1G@$C*[/^1P62:,K7
MZ [,KBAT=@.:4*8^SEQMC%EZ-^M,7+4F\!$3-Y!=('_R"6$/^^AQ>8/.WK^A
M<4U<?7"X#PXWO/X1WK<>AYRU#,$P@WT3EZHB&<P=<^D5R"TXZ8=WD\C[/.+/
M[_WY8^RI"3<8\M2BP@9EG]4V]?T$AV;M=D MZ-6"4VKAD%J+BO;4<#P-XG!8
M+>S5PE-JT9!:>*CF10'VA]6B7BTZI18/J44':G& XR-B<2\6GQ)+AL1&4<-7
M"8W<HJ2WDXS:^;D!DX\+#7+(U"CV_TU->U/3<5-"$X:*-J/4/*<J$S77D"-F
MGR*JNN0R9'EZ<&C)- GPD>L_\?ZE.F_4TQTHA:@Q82+5@UG*.U ^#WT<1$>4
M]Y+L9%1Y8?>6:[0EK&Y2;=GEV-.;T3'O)X,D""=Q\L:3NU<#;#V])W)-N3(*
MA0%Z%[%AD&V):CM:5$U96 EMBDS3W)BR#M(N,/.%$/JU8RM-_T<A_0M02P,$
M%     @ O8!O6!VFY6.I @  K0<  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C<N>&ULE55;;YLP%/XK%INF3MK*)5R2CB"MBZI-:K6H6;=G%P[!JK&9;9+V
MW\\VE$4M(=L+V,;?Y1QSCM,]%P^R E#HL:9,+IU*J>;"=65>08WE.6^ Z2\E
M%S56>BJVKFP$X,*":NH&GA>[-2;,R5*[MA99REM%"8.U0+*M:RR>+H'R_=+Q
MG>>%6[*ME%EPL[3!6]B NFO60L_<@:4@-3!).$,"RJ7SV;^X]#T#L#M^$MC+
M@S$RH=QS_F FWXJEXQE'0"%7A@+KUPZ^ *6&2?OXW9,Z@Z8!'HZ?V:]L\#J8
M>RSA"Z>_2*&JI3-W4 $E;JFZY?NOT <4&;Z<4VF?:-_MC1,'Y:U4O.[!VD%-
M6/?&CWTB#@!!< 00](# ^NZ$K,L55CA+!=\C879K-C.PH5JT-D>8.96-$OHK
MT3B5;?0Q%RT%Q$MTU:I6 +HAC-1MC=;X2:=?273'"A#HBC#,<D#7H),@T=D*
M%"94OD]=I7T8-C?O-2\[S>"(Y@KR<S3S/Z# "V;H;K-"9V]?T+@ZC"&68(@E
ML+RS([S?&Q!8$;;M/8XYZQC"<093 A>RP3DL'?V/2Q [<+)W;_S8^S3A;S;X
MFTVQ9SK<<,Q3AXHLRE31+O.3)/12=S<B%@YBX2FQ:$RL0\7_)A8-8M$IL7A,
M+'HMYLW"Q;A8/(C%I\22,;%)U/C1HHE3308[R:2='Q7H=E@J$&.F)K'_;VH^
MF)I/F^(*4U1V!=VR@LB<MTQ!@:@I#=3TM3UF>?[JT,)H'APYM,5@:#%IZ!JD
M1$0[T&&J,=7%*]6/D1<?^2]][V][\R9UUR:M3*$=IJUM<G7?W4[GH6<^K,O0
M2^*7B7 /FJ^YR&ZPV!(FM4"I<=YYH@E$=S=T$\4;VX_ON=+=W0XK?9^",!OT
M]Y)S]3PQ+7ZXH;,_4$L#!!0    ( +V ;UA ,98>$ 4   ,G   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;*V:6X_B-AS%OXJ55M6NU)(X";<I( T8
MMROM;$<[W?:AZH,'#$2;Q-0Q,'S[.A<2P@1#I/_+3&[G9SLGMI.#1P<AOR<;
MSA5ZB\(X&5L;I;8/MITL-CQB24=L>:S/K(2,F-*[<FTG6\G9,A-%H>TZ3L^.
M6!!;DU%V[%E.1F*GPB#FSQ(ENRAB\CCEH3B,+6R=#GP-UAN5'K GHRU;\Q>N
MOFV?I=ZS2\HRB'B<!")&DJ_&UB-^H&XFR*[X*^"'Y&P;I4UY%>)[NO-I.;:<
MM$8\Y N5(IC^M^<S'H8I2=?COP)JE66FPO/M$YUFC=>->64)GXGP[V"I-F-K
M8*$E7[%=J+Z*P^^\:% WY2U$F&1_T2&_UN];:+%+E(@*L:Y!%,3Y?_96W(@S
M@>8T"]Q"X%X*O"L"KQ!X%P*W=T7@%P+_L@3_BJ!;"+KW"GJ%H)?=^_QF97>:
M,,4F(RD.2*97:UJZD=F5J?4-#N+TR7I14I\-M$Y-_MARR500K]%GK@U*T ?"
M%0O"!'UA,CVSYQ_1+^C;"T$??OPXLI4N,U7:BX(_S?GN%3Y&3R)6FP3-XR5?
M-NC)#;UK -BZL66+W5.+IZZ1^,*W'>0Y/R/7<7%#A69F^1,[(@]?51.SFO!%
MYR3W&N3S^^5.@YS>+<=#PZWTRH?'RWC^S8<G3!\>/=+$BH6(O^EQ+^%-#XN1
MEXZB#\F6+?C8TL-DPN6>6Y.??L ]Y]<FHR!A)(=U,U@Z'.\GGC<8='LC>W_N
M#V29% A6\\XOO?-;>:>XC)H<,U+:.@8)(^;VN>C(F4P0=E"4#R"NCY;LF#3U
M.LAZ42!8S=5NZ6JWE:O+(%F(7:R0/MK8(8VXMO9"PD@.&YYU2*?C^&[WHD-"
MEDF!8#7K>J5U/:-U-(A9O."%<=DS&Q[1EAWU>YQJ>FJG1EY;[R!AI/=N,,5^
M?W#A'&2)% A6<ZY?.M=OX=RU@=3(:.L6)(R86^?E VG3L E9"PH$JSDX*!T<
MM'!0\O23[/;4:&2V=1021LRM/4V-P]/,B =79T;(:E$@6,WB86GQL(7%-^=%
M(ZRMMY P,FR:%X>7[ZF015(@6,TW[%1?J$X+YPP?%V9.6]- ::2@G4^)/;_K
M7+@&6B:%HM5].TL6L-&W3[$>.'FBC)89$:TM@Z21@E9[B^D[_4O+(,ND4+2Z
M96YEF6NT;"I9O!)RV4&S/]$_3SQZY?+?1M^,G-:^0=((*&T.2J-0M+J_55Z#
MS8%-EO$9ORG,@-;&@D8TH+0Y?I_X8,_QO'K_IE"%UAVK4AILCC%^DT*)^'9_
M!(UI0&D$E#8'I5$H6MW=*JW!YKCFCO[8??_>,'#]^D,Z:[C*=[V+JXBY,JV-
M $U>H&AU(ZKL!9O#E\_&#SVSN'7O,E<%9U]GC1T)LAIS4!J%HM7]JQ(8; XI
M*O_2'R'X@86-/H)F,#>J=#TW(:#UF(/2*!2M;F05Q&!S-C%[_/)('AO- XU;
M0&D$E#8'I5$H6MW0*G;!YMSECBD.-&L!I1%0VAR41@O:^:3?==,?I?<-AKE5
MW.*:XQ;S5&@6MS4+E$9 :7-0&KUQTYLF_;I_5>SBFF.7^Z9",Z2UCZ#!"RAM
M#DJC-V[^=1_MLS4Z$9?K;#55@K(4.E]Q41XM5VP]9NN4+HY/\<,,-QPG^('F
MZ[$J?+X\[(G)=1 G*.0K7933Z>LA0^8KKO(=);;9"J%7H92(LLT-9TLNTPOT
M^940ZK23%E"N>YO\#U!+ P04    " "]@&]8B2"[^^4#  !2"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V.2YX;6RM5MMNXS80?<]7#+3=(@$2Z^)+T]0V
MD-@IN@5V$238]J'H RV-+"(4J24I._[[#BE9ME/'[0)YB"-2<PYGSFB&,UXK
M_6P*1 LOI9!F$A365C=A:-("2V9ZJD));W*E2V9IJ9>AJ32RS(-*$291- I+
MQF4P'?N]!ST=J]H*+O%!@ZG+DNG-'0JUG@1QL-UXY,O"NHUP.J[8$I_0?JT>
M-*W"CB7C)4K#E02-^22XC6_F0V?O#?[@N#9[S^ B62CU[!:?LDD0.8=08&H=
M Z-_*YRA$(Z(W/C6<@;=D0ZX_[QE_]7'3K$LF,&9$G_RS!:3X#J #'-6"_NH
MUK]A&X]W,%7"^%]8-[:#40!I;:PJ6S!Y4'+9_&<OK0Y[@.OH#4#2 I)7@/BM
M$_HMH/\:,'@#,&@! Z],$XK78<XLFXZU6H-VUL3F'KR8'DWA<^G2_F0UO>6$
ML]-'M%PCY='"@V 2SN=H&1<&OC"MF<O)!5S!UZ<YG/]P,0XM'>F 8=K2SQKZ
MY WZ.('/2MK"P+W,,#LD",G7SN%DZ_!=<I+Q=R9[$,67D$3QS\<<.@V?8]J#
MOH<G_2/P^?^')R>BZ7?R]SU?_[_EOT.).;<&_KI=&*NI(/X^XM]=PS<XSN>:
MQ(VI6(J3@+J 0;W"8/KCAW@4_7),J_<DF[\3V8&.@T['P2GV?1TK]QDO24S-
M!'#9=$9J,<?$/$UJ"X29*BLF-V J)8W2!A@,HOC\^:(YQQ;,0JI62&],37EC
MTG(FQ ;H!["LA-H@FAY\DJ!TAAJL@@4""K[D"X%N63%M><HK9O'RC#BW*"BI
M_(F<EFC)<JUH(0VFM2M+*)NZ4CDX,7F*P&3FNRSY2)V"EW7IWCI<4<M,8^8M
M<I[;#12J)I>5;@#Q911%[1Z79Q0XUV2HZ?P-,KUW2 _NMT%1&]K0WS,")?3*
MLA?7;Y&Z!G6/FN2"DIH2ETMP.OKFTD3-!2<'-'ZKVY21//=YCOX& *KOFNX?
M<NF,:BRZW*'7S #5!=TX+IT4#6G'P+ <H6!Z0;'XE'"R+'A:0$$MGQ+A!*1K
MBM3-=@D!IA&DLKM$T'="P=BT<!Z3SE;S1>T.,F=.-:GDU4E"DDE"'$4?&Q:@
M^!L!^Q]W=&T*AF2EI(],XHN%Y,"D=ZQ23WZIWUNI[T1V4*G#KE*')XNJ_7ST
M@<;':O,DS?<VNH9LZ,G<)+2:QO%U1!? :E^7?ULE_<%HU%DU 8=[MVV)>NFG
M%D/QU-(V]UBWVPU&MWX>>+4_HX&IF6]V-,VT]9GI)9<&!.9$&?5^(I]T,\$T
M"ZLJ?Z<OE*4)P3\6-/2A=@;T/E?*;A?N@&Z,G/X#4$L#!!0    ( +V ;UBM
M5A#X2P8   8]   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+6;6V_;
M-AB&_PKA#4,+K+%$23YDCH$T$M$.:Q$DZW91[$*Q&5NH#AY%)RVP'S_J4,FT
M%"8J7M_$ELSOX>&5/D:OR,5C)K[D6\XE^9K$:7XQVDJY.Q^/\]66)V%^ENUX
MJGZYST022G4H-N-\)WBX+H.2>$PM:S).PB@=+1?EN6NQ7&1[&4<IOQ8DWR=)
M*+Z]Y7'V>#&R1]]/W$2;K2Q.C)>+7;CAMUQ^VET+=31N*.LHX6D>92D1_/YB
M=&F?,X<6 66)OR+^F!]\)T57[K+L2W'P?GTQLHH6\9BO9($(U<<#O^)Q7)!4
M._ZMH:.FSB+P\/MW.BL[KSIS%^;\*HO_CM9R>S&:C<B:WX?[6-YDC^]XW2&O
MX*VR."__DL>ZK#4BJWTNLZ0.5BU(HK3Z#+_6 W$08+M/!- Z@!X'>$\$.'6
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M,11-%["UJ6RS3V5.S2IW][Y(4.??JY!<9L*<QJ&F%I3F0VD!E,90-'T!0^N
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M+VG"]E,'.P\;OL;KC=0;W-DD#]?TALK;_)JK-;=66<8IS43,,L3I:NI<X/.
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M*FC)Q<J;>V"8*J%T9&S/63E=L-2_/-SU,VC'AJ?D4FD7VT?PWY-F^1ZPGH%
M+D0KL$>\832HJ#%,RQL[<8N=\0D4->/[5645SC1==7N79./@;C;(1.F<Z39,
MEZQ-HX%@!<C1?#:'NU%5#* QJK2#G-.9DM1I6'LT TL[94+<P;/ZO=CA7A9;
M=>U 564[M(*:H:?Q$^#?9O/<V[3)BWBCBC\J\VEAMR/='+J%W6I6\*6;+XM6
M ,;>Q=EI58G51\%GLF1^\P<'' WHVB^:*\U_V6C0*E-K8)I$CTP;/MVV_-2T
MNF=+LVZG98%K[KU"S7\WSS,FF:9B6[3M_6/.\HL5-R^W?Z'9_5K95QP4F5P=
MO\;FA7[L(M/7(/)5E+M__"*3[/@U-D>[HQ,9-X>,K9/,SCFFM49P7AR2;W Z
M%9N@T63!A>&RF<UYGC/YY#ACZ0V=V#]H=OCM^IP5="',?0L.R6;\E>5\46;M
MJEM(1+-J,_X"V^NF[6'5QN(R9TN6CYNIGDW<,+(#&[6YP&$?N7%7&,%\/!9&
M ,/B8 HP'^^%Q?F?]M-']^,Q3%L_B/11GS[JX[U"R-A]L#AAG\Q>X9UF69*D
M*9;1\3BH8(SE+4WA)\R&:0,/+ Y$^K-<X]7&.^3Y/L!J^ER'8#O%.Q';*9YK
M0,)Y X\L"U<;BP,>6!6PWH'XX3C04V&?)(&J8MJP)QA'L@Q#H!?#/9JF2'92
M^(3K@STE29)E802PL((DP1!X&G$$4P :,"1)W'MP[WT4K]]3\>:_?*/?4$L#
M!!0    ( +V ;UB7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ O8!O6)6)YRJ5!0  HRX   \   !X;"]W;W)K8F]O
M:RYX;6S%FEM/VTH0@/_**D]4.CHAOM&B4@D(/0>IA8B@]K':V!NRJKV;[JXI
M\.L[ZQS:<6)&YV7"$_B2]>>Q/=_LY?U/Z[XOK/TN'IK:^)/1*H3U\7CLRY5J
MI/_;KI6!(TOK&AE@T]V-_=HI6?F54J&IQ\GA83%NI#:C#^^?VYJY,=ZP095!
M6P,[XXXO6OWT?X['37&OO5[H6H?'DU'W?ZU&HM%&-_I)52>CPY'P*_OS7^OT
MDS5!UO/2V;H^&4TV![XH%W2YLWL>(6_EPG=[@ES<2  Y&16'T.!2.Q^Z,[KV
M)3#>*SAYL]4&^U'70;FI#.H?9]NU-G>Q&;B+,;J-+@[/?S=!/';_)XQVN=2E
MFMJR;90)FS@Z54= XU=Z[4?"R$:=C,[MO7+Q?N "E]7FW@) H4BY8PT'W&75
MX7&B&&]K7<'5*W$F:VE*);H0>@28$(#)JP&*@YE$D"D!F>X1<AXAX@^\L$MQ
MO>X]ZHR S%X-\GPE#8+,"<C\%2&_)0BR(""+UX.4?H4@CPC((U[(:W<GC7[J
M#@AI*G$E0^O4P#OYEH!\RPLY;YM&NL<(-==W1L//I GBM"QM:X)&D.\(R'>\
MD!?-NK:/2HD;%>#,&,]SIRH=< H_I'+X(2\@"!F>:'CL'O/%CU:OXP\P'6D8
M9L5<@MW-7;RH./6^+Y8)998)LUK@+7,M?,$7#]"(5STN2B83?IO<Q^HG1FRJ
M%KT'2?ECPBR0>;#E]Y6M*^7\M^X]"X^8C=+&A-D;7Z5SD#EZSY RQ(19$5VL
M(-%V!S 4980)LQ(^2NW$%UFW2GQ6TH,-.F]A/,H%$V897$&[GZSW8J8<E'C2
M*4Q&"6#";(!+4]I&B5OYT,L2"97T$^:D?VZ;1H=-X1'S/F2- !T:94K=AZ1R
M?\*<^V.E(2.6^ 0O7)^+[%0PIWXPN=Z\_6)6]VK?A,K\"7/FOXD[P4@S">F_
M'RTJ\2?<B;]=>/6CC=&ZN-_*& F5]1/FK$^6C[W>0D+)(&&6P7!])@YN)7#X
M-QB3TD/"K(>=0FV0D#)$PFR([8IM$) 21<(LBNW2;0@PI:R1,EOCN4X:!*-,
MD3*;HE<P#=)1ODB9??%"Y?3,B3')82AF?^Q64(.1I%R2,KL$EU*#<)1/4F:?
M;)<K@X"425)FDY"#.CWAI91)4F:3T%Y.,2:EDY19)R\.[(B#J0J]L65**BFS
M5.;01M76W5/^74J<_BXE\.@RI9;L54:A-J'4-<Z1&26:C%LT*)H#%0_&I(R3
M,1MG .V_0,(W[WI3"I1Q,F;CX&CN5F=3C$E.?7#W8! FKM&N; #.&<:D_)/Q
MSWYLE8_XF>.$E%$6RO8QN+4U$(A0,29EH8S;0KTO?=-$Y\V%;8/XBC$I"V7,
M%OI3DO<>=IR[QG5'1BDHVZ."=D-YC><.*07ES K"F+A# :D)PHFGDW)*0?D>
M%71K@ZRCB)PV7I>QDX$Q*07ES K"F ,=((Q)*2C?HX+B1/8=9'1MH(*_5[5(
M!<:D%)3O44$HFK#U=2NWY^3\._>06K\?OIV2,":EH)Q;02B:5W RP%DGH"EQ
M)N$SPIB4@O(]*F@'L]=?RRD%Y=S3\!AS9PSA+XQ)62C?HX7.95VVFW/BYE37
M+5X<0EFHV*.%#LZ444L=WL2>6T2Q>+*AH"Q4[-%"-ZJTIM2U_AW02XQ)6:C8
MHX6F:JD<]-#%GU$DC$E9J&"V4']<:Z>2PYB4A0KV16#$K&&O]UM0%BJX+81E
MV79#7)_CVM&V$3/YB$N/@EP'MD<+[6#V5ZM1%BJXEX+M#&N^U*TL* L5S!;:
MFI3=_HHP)F6A@ME"6Y.T!.819:$C;@MM3]J^.(!T1%GH:+,^NCO9?WA?@<R,
MJJ[@$A[VEV#AF1/QSV8Y5Y;'A1K+MJZCH*_-)RNKYS76S^O#/_P"4$L#!!0
M   ( +V ;UBP!0"]-@(  !PJ   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'/-VDMNHT 4A>&M6"P@N.Z+I!5GU)-,HVP .>6'8AM$T4JR^[:<@7U0
M#WH2<4:H0%Q^,?B$@,>7?&C'?7<JNWU?%I_'PZFLJMTX]K_JNJQW^=B6NZ[/
MI_.133<<V_&\'+9UWZ[?VVVN9;F,>KB=43T]WLY<O'[U^7\F=IO-?IU_=^L_
MQWP:_S&X_NB&][++>:P6K^VPS>.JJC\/U]VEOFS2W7ERM7A^6U7#\UNJZKF#
M!()D_B"%()T_R"#(Y@]R"/+Y@P*"8OZ@!H*:^8/N(>A^_J '"'J8/R@M4<8E
M0=($:P*M$W*="+Q."'8B$#LAV8G [(1H)P*U$[*="-Q."'<BD#LAW8G [H1X
M)P*]!?46 KT%]18"O67RL$V@MZ#>0J"WH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>@
MWD*@MZ#>0J"WHMY*H+>BWDJ@MZ+>2J"W3EZ6$.BMJ+<2Z*VHMQ+HK:BW$NBM
MJ+<2Z*VHMQ+HK:BW$NAMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&V3E]T$>AOJ;01Z
M&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z
M^^1C)8'>CGH[@=Z.>CN!WHYZ.X'>CGH[@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!
MWH%Z!X'>@7H'@=XQ^=F$0.] O8- [T"]@T#O0+V#0.\&]6X(]&Y0[^8G]2[C
MUR&7:\_W&J__DU2/YW/S]?*7Y??.R4VXX%S?5I2GOU!+ P04    " "]@&]8
MX<M&R/T!   ]*0  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VDU.PS 0!>"K
M5-FBQO5O 5$VP!98< &33-NH26S9!LKM<5)  D$%*A)OTZBU/6_BD;Y5S^Z>
M/<7)MFO[N"C6*?E3QF*UIL[&TGGJ\\K2A<ZF_#6LF+?5QJZ(B=G,L,KUB?HT
M34.-XOSLDI;VH4V3JVW^.3:N7Q2!VEA,+G8;AZQ%8;UOF\JFO,X>^_I3RO0U
MH<PGQSUQW?AXE#<4[,N$8>7[@-=S-X\40E/3Y-:&=&V[O(MM6Q;3<TNQW%_B
MBQ[=<ME45+OJH<M'RN@#V3JNB5+7EKNB1_N34[YAVGWR@_/',OL"\\[;X'S,
M$POT^[BWD0RGISX7HI":_:_XGIA+'_Q^-$R[IOJ'V?EZGUS8C/.(;'P<?L<?
M9_Q>_Y=]") ^)$@?"J0/#=*' >EC#M+',4@?)R!]\!E*(RBB<A12.8JI' 55
MCJ(J1V&5H[C*46#E*+(*%%D%BJP"15:!(JM D56@R"I09!4HL@H4606*K!)%
M5HDBJT215:+(*E%DE2BR2A19)8JL$D56B2*K0I%5H<BJ4&15*+(J%%D5BJP*
M15:%(JM"D56AR*I19-4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BR&A19#8JL
M!D56@R*K09'5H,AJ4&0U*+(:%%D-BJQS%%GG_RGKO7.;/XX?GV5GF_XMGXW_
MFCQ_ 5!+ 0(4 Q0    ( +V ;U@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ O8!O6$\+:M7O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ O8!O6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "]@&]8\*[LQX (  !S-0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ O8!O6+*Y_TXA"   RBH  !@              ("!Q!   'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +V ;UA=:Q[G\@,  + 3
M   8              " @1L9  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "]@&]8I9R;RJX%   X%P  &               @(%#'0
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ O8!O6 '_+ /^
M!@  W#$  !@              ("!)R,  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( +V ;UB?2%CK20(  -D$   8              "
M@5LJ  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "]@&]8
MSL:6><((  "%*0  &               @(':+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ O8!O6.'JG+-(!P  _ \  !@
M     ("!TC4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M +V ;U@5=K^M2!H  "A-   8              " @5 ]  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "]@&]8"#-ZTGH"  "E!0  &0
M            @('.5P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( +V ;U@:$)^,K@,  "P(   9              " @7]:  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ O8!O6,'9U.!: P
M!P@  !D              ("!9%X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "]@&]814TN!,X$  ! "@  &0              @('U
M80  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +V ;UA3
MW=]T P4  -T+   9              " @?IF  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ O8!O6%,AM=94!P  "!0  !D
M     ("!-&P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +V ;U@MRP3YD0D  !48   9              "
M@>J'  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ O8!O
M6/5B!Z-[!   2PH  !D              ("!LI$  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "]@&]8D0_-W^D$   !#0  &0
M        @(%DE@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( +V ;UA8-#2J9 ,  %8'   9              " @82;  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ O8!O6+O%MDM[ @  @P4
M !D              ("!'Y\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "]@&]8+3&WKDL"   ;!0  &0              @('1H0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +V ;UC_IX'A
M!1P  $E:   9              " @5.D  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ O8!O6'[=X]H: P  [08  !D
M ("!C\   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "]
M@&]830-T*RL#  ")!P  &0              @('@PP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +V ;UC2VMIBXP(  "T&   9
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M970S,RYX;6Q02P$"% ,4    " "]@&]8EX(U,6L$  "7#   &0
M    @(%!V0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M +V ;UC)(!"<;P4  "0.   9              " @>/=  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ O8!O6$HJ 2<L P  YP@  !D
M             ("!B>,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "]@&]8.XOV(QP%   C)   &0              @('LY@  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +V ;UB"/$AP" 8
M *XC   9              " @3_L  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ O8!O6,OY %6Q P  EA,  !D              ("!
M?O(  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "]@&]8
M+3G'&^@#   ?%   &0              @(%F]@  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( +V ;UC4Z\?[B@(  &H&   9
M      " @87Z  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ O8!O6-78QDBC!   2QD  !D              ("!1OT  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "]@&]8S0VG?(H"  ".!@
M&0              @($@ @$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( +V ;UB$)@FB @,  .0(   9              " @>$$ 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ O8!O6!=+F2R>
M @  N@H  !D              ("!&@@! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "]@&]8&V*U[.H)  !4?   &0
M@('O"@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +V
M;UC2HL+T'0@  #)0   9              " @1 5 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ O8!O6)Q[M_T&!0  3A\  !D
M         ("!9!T! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " "]@&]8D8+//5(#  "5#   &0              @(&A(@$ >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +V ;UB"D!"<NP8  &@Z
M   9              " @2HF 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ O8!O6#5?>?J) P  @PT  !D              ("!'"T!
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "]@&]8?OWZ
M!N4#  !#%0  &0              @('<, $ >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    ( +V ;UCL6.7QU00  &HG   9
M  " @?@T 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MO8!O6(HW_96) P  X0P  !D              ("!!#H! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "]@&]8O?YJ>_@"  #0"   &0
M            @('$/0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( +V ;UC0ITW$4 8  (4R   9              " @?-  0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ O8!O6.<^ L/0 @
M,0<  !D              ("!>D<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "]@&]87)=G?.\"  #4"0  &0              @(&!
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +V ;UB+
MI)M2>@(  &@&   9              " @:=- 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ O8!O6(9Y-39J P  M \  !D
M     ("!6% ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +V ;UC9S8"WGP(  .T&   9              "
M@11D 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ O8!O
M6.-_!8C* @  - @  !D              ("!ZF8! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " "]@&]8':;E8ZD"  "M!P  &0
M        @('K:0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( +V ;UA ,98>$ 4   ,G   9              " @<ML 0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ O8!O6(D@N_OE P  4@H
M !D              ("!$G(! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    " "]@&]8K580^$L&   &/0  &0              @($N=@$
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( +V ;U@@0['>
M"P4  &0B   9              " @;!\ 0!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ O8!O6*:.:7X[ P  \A,   T
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;72YX;6Q02P4&     $\ 3P"@%0  GY !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>382</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/OrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Employee Retention Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/EmployeeRetentionCredit</Role>
      <ShortName>Employee Retention Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/ConvertibleDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/Warrants</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/StockOptions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://azitrainc.com/role/OperatingLeases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative</Role>
      <ShortName>Organization and Nature of Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/OrganizationAndNatureOfOperations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Employee Retention Credit (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative</Role>
      <ShortName>Employee Retention Credit (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/EmployeeRetentionCredit</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails</Role>
      <ShortName>Schedule of Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Convertible Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ConvertibleDebtDetailsNarrative</Role>
      <ShortName>Convertible Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/ConvertibleDebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/StockholdersEquity</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Information about Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/WarrantsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Information about Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails</Role>
      <ShortName>Schedule of Total Intrinsic Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Fair Value Measurements for Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Stock Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/StockOptionsDetailsNarrative</Role>
      <ShortName>Stock Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/StockOptionsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails</Role>
      <ShortName>Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Net Loss Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of (Benefit) Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Payments Under Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/OperatingLeasesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - Retirement Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/RetirementPlanDetailsNarrative</Role>
      <ShortName>Retirement Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/RetirementPlan</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - Related Parties (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>Related Parties (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/RelatedParties</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://azitrainc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://azitrainc.com/role/SubsequentEvents</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aztr-20231231.xsd</File>
    <File>aztr-20231231_cal.xml</File>
    <File>aztr-20231231_def.xml</File>
    <File>aztr-20231231_lab.xml</File>
    <File>aztr-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>form10-k_013.jpg</File>
    <File>form10-k_014.jpg</File>
    <File>form10-k_015.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="831">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "AZTR",
   "nsuri": "http://azitrainc.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "aztr-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aztr-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aztr-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aztr-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aztr-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 338,
   "keyCustom": 44,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 31,
   "hidden": {
    "total": 142,
    "http://fasb.org/us-gaap/2023": 126,
    "http://azitrainc.com/20231231": 13,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 217,
   "entityCount": 1,
   "segmentCount": 71,
   "elementCount": 590,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 831,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://azitrainc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://azitrainc.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://azitrainc.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://azitrainc.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://azitrainc.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://azitrainc.com/role/OrganizationAndNatureOfOperations",
     "longName": "00000008 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://azitrainc.com/role/EmployeeRetentionCredit",
     "longName": "00000010 - Disclosure - Employee Retention Credit",
     "shortName": "Employee Retention Credit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://azitrainc.com/role/PropertyAndEquipment",
     "longName": "00000011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://azitrainc.com/role/IntangibleAssets",
     "longName": "00000012 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://azitrainc.com/role/AccruedExpenses",
     "longName": "00000013 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://azitrainc.com/role/ConvertibleDebt",
     "longName": "00000014 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://azitrainc.com/role/StockholdersEquity",
     "longName": "00000015 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://azitrainc.com/role/Warrants",
     "longName": "00000016 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AZTR:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AZTR:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://azitrainc.com/role/StockOptions",
     "longName": "00000017 - Disclosure - Stock Options",
     "shortName": "Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueOptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueOptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://azitrainc.com/role/FairValueMeasurements",
     "longName": "00000018 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://azitrainc.com/role/NetLossPerShare",
     "longName": "00000019 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://azitrainc.com/role/IncomeTaxes",
     "longName": "00000020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://azitrainc.com/role/CommitmentsAndContingencies",
     "longName": "00000021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://azitrainc.com/role/OperatingLeases",
     "longName": "00000022 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://azitrainc.com/role/RetirementPlan",
     "longName": "00000023 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://azitrainc.com/role/RelatedParties",
     "longName": "00000024 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://azitrainc.com/role/SubsequentEvents",
     "longName": "00000025 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://azitrainc.com/role/PropertyAndEquipmentTables",
     "longName": "00000027 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://azitrainc.com/role/IntangibleAssetsTables",
     "longName": "00000028 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://azitrainc.com/role/AccruedExpensesTables",
     "longName": "00000029 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://azitrainc.com/role/ConvertibleDebtTables",
     "longName": "00000030 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://azitrainc.com/role/WarrantsTables",
     "longName": "00000031 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://azitrainc.com/role/StockOptionsTables",
     "longName": "00000032 - Disclosure - Stock Options (Tables)",
     "shortName": "Stock Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://azitrainc.com/role/FairValueMeasurementsTables",
     "longName": "00000033 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://azitrainc.com/role/NetLossPerShareTables",
     "longName": "00000034 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://azitrainc.com/role/IncomeTaxesTables",
     "longName": "00000035 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://azitrainc.com/role/OperatingLeasesTables",
     "longName": "00000036 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
     "longName": "00000037 - Disclosure - Organization and Nature of Operations (Details Narrative)",
     "shortName": "Organization and Nature of Operations (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-05-17_srt_MaximumMember",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000038 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-01-01",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-01-01",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
     "longName": "00000039 - Disclosure - Employee Retention Credit (Details Narrative)",
     "shortName": "Employee Retention Credit (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2022-04-012022-04-30",
      "name": "AZTR:EmployeeRetentionCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-04-30",
      "name": "AZTR:EmployeeRetentionCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000040 - Disclosure - Schedule of Property And Equipment (Details)",
     "shortName": "Schedule of Property And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000041 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "00000042 - Disclosure - Schedule of Intangible Assets (Details)",
     "shortName": "Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://azitrainc.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "00000043 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "00000044 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails",
     "longName": "00000045 - Disclosure - Schedule of Convertible Notes Payable (Details)",
     "shortName": "Schedule of Convertible Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ConvertibleLongTermNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_TwentyTwentyOneConvertibleNotesMember",
      "name": "us-gaap:ConvertibleLongTermNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
     "longName": "00000046 - Disclosure - Convertible Debt (Details Narrative)",
     "shortName": "Convertible Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InterestAndDebtExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://azitrainc.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000047 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-05-162023-05-17",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
     "longName": "00000048 - Disclosure - Schedule of Information about Warrants Outstanding (Details)",
     "shortName": "Schedule of Information about Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember101770734",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://azitrainc.com/role/WarrantsDetailsNarrative",
     "longName": "00000049 - Disclosure - Warrants (Details Narrative)",
     "shortName": "Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
     "longName": "00000050 - Disclosure - Schedule of Information about Options Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Information about Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "AZTR:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_StockOptionOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000051 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
     "longName": "00000052 - Disclosure - Schedule of Total Intrinsic Value (Details)",
     "shortName": "Schedule of Total Intrinsic Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails",
     "longName": "00000053 - Disclosure - Schedule of Fair Value Measurements for Assets and Liabilities (Details)",
     "shortName": "Schedule of Fair Value Measurements for Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
     "longName": "00000054 - Disclosure - Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)",
     "shortName": "Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails",
     "longName": "00000055 - Disclosure - Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)",
     "shortName": "Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://azitrainc.com/role/StockOptionsDetailsNarrative",
     "longName": "00000056 - Disclosure - Stock Options (Details Narrative)",
     "shortName": "Stock Options (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PerformanceSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails",
     "longName": "00000057 - Disclosure - Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Numerator for Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DividendsPreferredStockStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
     "longName": "00000058 - Disclosure - Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)",
     "shortName": "Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "longName": "00000059 - Disclosure - Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "shortName": "Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareBasic",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
     "longName": "00000060 - Disclosure - Schedule of Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:FairValueOptionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember101773703",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails",
     "longName": "00000061 - Disclosure - Schedule of (Benefit) Provision for Income Taxes (Details)",
     "shortName": "Schedule of (Benefit) Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails",
     "longName": "00000062 - Disclosure - Schedule of Reconciliation of Income Tax (Details)",
     "shortName": "Schedule of Reconciliation of Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "longName": "00000063 - Disclosure - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://azitrainc.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000064 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationTaxCreditsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000065 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails",
     "longName": "00000066 - Disclosure - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)",
     "shortName": "Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails",
     "longName": "00000067 - Disclosure - Schedule of Future Minimum Payments Under Finance Leases (Details)",
     "shortName": "Schedule of Future Minimum Payments Under Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://azitrainc.com/role/OperatingLeasesDetailsNarrative",
     "longName": "00000068 - Disclosure - Operating Leases (Details Narrative)",
     "shortName": "Operating Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://azitrainc.com/role/RetirementPlanDetailsNarrative",
     "longName": "00000069 - Disclosure - Retirement Plan (Details Narrative)",
     "shortName": "Retirement Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2019-01-012019-01-01",
      "name": "us-gaap:DefinedBenefitPlansGeneralInformation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-01-012019-01-01",
      "name": "us-gaap:DefinedBenefitPlansGeneralInformation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
     "longName": "00000070 - Disclosure - Related Parties (Details Narrative)",
     "shortName": "Related Parties (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000071 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r773"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee payroll and bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "AZTR_AccruedInterestOnConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "AccruedInterestOnConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest on convertible notes",
        "documentation": "Accrued interest on convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "AZTR_AccruedResearchAndDevelopmentProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "AccruedResearchAndDevelopmentProjects",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development projects",
        "documentation": "Accrued research and development projects."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r76"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation &amp; amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r193",
      "r608"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r773",
      "r908"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r634",
      "r830",
      "r831",
      "r832",
      "r886",
      "r910"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r94",
      "r122",
      "r368"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expenses of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r64"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r196",
      "r219",
      "r255",
      "r263",
      "r267",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r487",
      "r489",
      "r510",
      "r601",
      "r672",
      "r773",
      "r785",
      "r847",
      "r848",
      "r897"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202",
      "r219",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r487",
      "r489",
      "r510",
      "r773",
      "r847",
      "r848",
      "r897"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "AZTR_BranfordCTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "BranfordCTMember",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Branford. CT [Member]",
        "documentation": "Branford. CT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Operations",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r129",
      "r130"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_CARESEmployeeRetentionCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "CARESEmployeeRetentionCreditMember",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CARES Employee Retention credit [Member]",
        "documentation": "CARES Employee Retention credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizationLongtermDebtAndEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizationLongtermDebtAndEquity",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalization amount",
        "documentation": "This element represents the total consolidated (as applicable) capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r191",
      "r751"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r126",
      "r215"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r126"
     ]
    },
    "AZTR_CertainRisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "CertainRisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Risks and Uncertainties",
        "documentation": "Certain Risks And Uncertainties [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ChangeInFairValueOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ChangeInFairValueOfConvertibleNote",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfCashFlows",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible note",
        "negatedLabel": "Change in fair value of convertible notes",
        "negatedTerseLabel": "Change in fair value of convertible note",
        "documentation": "Change in fair value of convertible note."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ChangeInFairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ChangeInFairValueOfConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in fair value of 2022 Convertible Notes",
        "documentation": "Change in fair value of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r199",
      "r219",
      "r241",
      "r242",
      "r245",
      "r247",
      "r253",
      "r254",
      "r308",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r374",
      "r375",
      "r379",
      "r382",
      "r390",
      "r510",
      "r625",
      "r626",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r659",
      "r681",
      "r705",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r807",
      "r824",
      "r834"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r253",
      "r374",
      "r375",
      "r377",
      "r379",
      "r382",
      "r388",
      "r390",
      "r625",
      "r626",
      "r627",
      "r628",
      "r766",
      "r807",
      "r824"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrants per share",
        "terseLabel": "Number of options exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase of common shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r100",
      "r602",
      "r658"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r331",
      "r332",
      "r737",
      "r846"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares reserved for future issuance",
        "verboseLabel": "Total",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r830",
      "r831",
      "r886",
      "r907",
      "r910"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock, par value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r659"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r111",
      "r659",
      "r678",
      "r910",
      "r911"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock; $0.0001 par value, 100,000,000 shares authorized at December 31, 2023 and 2022, 12,097,643 and 1,043,988 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r603",
      "r773"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock voting rights description",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "AZTR_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCredit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Retention Credit",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r92",
      "r93",
      "r272",
      "r736"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r92",
      "r93",
      "r272",
      "r622",
      "r736"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk and Off- Balance Sheet Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r176"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities due from related party",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r397"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract liabilities - related party",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r397"
     ]
    },
    "AZTR_ConversionConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConversionConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of 2022 Convertible Notes",
        "documentation": "Conversion convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ConversionOfNoteToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConversionOfNoteToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of note to common stock",
        "documentation": "Conversion of note to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ConversionOfNoteToConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConversionOfNoteToConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of note to Series B Convertible Preferred Stock",
        "documentation": "Conversion of note to convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A, A-1, and B Convertible Preferred Stock to common stock",
        "documentation": "Conversion of series A1 and B convertible preferred stock to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Notes Payable",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "AZTR_ConvertibleNotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConvertibleNotePurchaseAgreementMember",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Purchase Agreement [Member]",
        "documentation": "Convertible Note Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "AZTR_ConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock",
        "documentation": "Convertible Preferred Stock [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible series B preferred stock shares issued",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r72",
      "r110",
      "r141",
      "r385"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r827",
      "r884"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r827"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r475",
      "r481",
      "r827"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r827",
      "r884"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted shares",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued to purchase common stock",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r217",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r362",
      "r369",
      "r370",
      "r372"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r105",
      "r106",
      "r162",
      "r164",
      "r223",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r522",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r825"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r349"
     ]
    },
    "AZTR_DebtInstrumentDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DebtInstrumentDiscountPercentage",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount, percentage",
        "documentation": "Debt instrument discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate principal",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r347",
      "r522",
      "r762",
      "r763"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r522",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r825"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r761",
      "r887"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r223",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r522",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r825"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r72",
      "r75",
      "r94",
      "r95",
      "r97",
      "r101",
      "r140",
      "r142",
      "r223",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r522",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r825"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt and Warrant Accounting",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred patent costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r817"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r883",
      "r884"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuances costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r850"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r827",
      "r883"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r155",
      "r183",
      "r480",
      "r481",
      "r827"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r163",
      "r469"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "AZTR_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_DeferredPatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DeferredPatentCostsPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Patent Costs",
        "documentation": "Deferred Patent Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r883",
      "r884"
     ]
    },
    "AZTR_DeferredTaxAssetsDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "documentation": "Deferred tax assets depreciation and amortization.",
        "label": "DeferredTaxAssetsDepreciationAndAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax credit receivable",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refunds tax amount",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pending refunds related to research and experimental development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "documentation": "Deferred tax liabilities depreciation and amortization.",
        "label": "DeferredTaxLiabilitiesDepreciationAndAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlansGeneralInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlansGeneralInformation",
     "presentation": [
      "http://azitrainc.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement plan general information",
        "documentation": "Description of defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employer contribution",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r65"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r259"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://azitrainc.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Warrants Using Black Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r82"
     ]
    },
    "AZTR_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Future Minimum Payments Under Non-cancelable Operating Leases",
        "terseLabel": "Schedule Of Future Minimum Payments Under Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_DisclosureWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "DisclosureWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStockStock",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on preferred stock",
        "label": "Dividends, Preferred Stock, Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r143"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800",
      "r802"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r238",
      "r241",
      "r245",
      "r246",
      "r247",
      "r251",
      "r500",
      "r501",
      "r597",
      "r613",
      "r755"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r241",
      "r245",
      "r246",
      "r247",
      "r251",
      "r500",
      "r501",
      "r597",
      "r613",
      "r755"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://azitrainc.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r248",
      "r249",
      "r250"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. federal statutory tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes using U.S. statutory rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r465",
      "r482"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r885"
     ]
    },
    "AZTR_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt fair value adjustment, percent",
        "documentation": "Effective income tax rate reconciliation debt fair value adjustment tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, net, percent",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r885"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r885"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r885"
     ]
    },
    "AZTR_EmployeeRetentionCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "EmployeeRetentionCredit",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee retention credit",
        "documentation": "Employee retention credit."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r187",
      "r207",
      "r208",
      "r209",
      "r224",
      "r225",
      "r226",
      "r228",
      "r234",
      "r236",
      "r252",
      "r309",
      "r310",
      "r392",
      "r450",
      "r451",
      "r452",
      "r476",
      "r477",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r536",
      "r617",
      "r618",
      "r619",
      "r634",
      "r705"
     ]
    },
    "AZTR_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Changes in fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r507"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r507"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Measurements for Assets and Liabilities",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://azitrainc.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Level 3 Instruments Measured on a Recurring Basis",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r90"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r504",
      "r551",
      "r552",
      "r553",
      "r762",
      "r763",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r506",
      "r508"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r401",
      "r406",
      "r504",
      "r551",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r401",
      "r406",
      "r504",
      "r552",
      "r762",
      "r763",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r504",
      "r553",
      "r762",
      "r763",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2022",
        "periodEndLabel": "Balance at December 31, 2023",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r551",
      "r552",
      "r553",
      "r762",
      "r763",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r508"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option, Disclosures [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513"
     ]
    },
    "us-gaap_FairValueOptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionTextBlock",
     "presentation": [
      "http://azitrainc.com/role/StockOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options",
        "documentation": "The entire disclosure for a company's election to apply the fair value option for measurement and reporting of eligible financial assets and liabilities (as defined), as well as certain other eligible items (as defined) included in the statement of financial position, whether such option is elected for a single eligible item or a group of similar eligible items and is in addition to other disclosures concerning fair value which the company may be required to provide. Such disclosure might be expected to include: (1) for items included in the statement of financial position: (a) the reasons for electing a fair value option for each eligible item or group of similar eligible items; (b) if the fair value option is elected for some but not all eligible items within a group of similar eligible items: (i) a description of those similar items and the reasons for partial election and (ii) information of how the group of similar items relates to individual balance sheet line items; (c) for each line item in the statement of financial position that includes an item or items for which the fair value option has been elected: (i) information of how each line item in the statement of financial position relates to major categories of assets and liabilities presented in accordance with other fair value disclosures and (ii) the aggregate carrying amount of ineligible items included in each line item in the balance sheet, if any; (d) the difference between the aggregate fair value and the aggregate unpaid principal balance (assuming contractual principal amounts and fair value option elected) of: (i) loans and long-term receivables (other than securities otherwise reported at fair value) and (ii) long-term debt instruments; (e) for loans held as assets for which the fair value option has been elected: (i) the aggregate fair value of loans that are 90 days or more past due, (ii) if the policy is to recognize interest income separately from other changes in fair value, the aggregate fair value of loans in nonaccrual status, and (iii) the difference between the aggregate fair value and the aggregate unpaid principal balance for loans that are 90 days or more past due, in nonaccrual status, or both; (f) for investments that would have been accounted for under the equity method if the entity had not chosen to apply the fair value option, the information required for such investments, if material either individually or in the aggregate; (2) for items included in the income statement: (a) the amounts of gains and losses from fair value changes included in earnings and in which line in the income statement those gains and losses are reported whether or not combined with gains and losses from items required to be accounted for at fair value; (b) a description of how interest and dividends are measured and where they are reported in the income statement; (c) for loans and other receivables held as assets: (i) the estimated amount of gains or losses included in earnings attributable to changes in instrument-specific credit risk and (ii) how the gains or losses attributable to changes in instrument-specific credit risk were determined; (d) for liabilities with fair values that have been significantly affected during the reporting period by changes in the instrument-specific credit risk: (i) the estimated amount of gains and losses from fair value changes included in earnings that are attributable to changes in the instrument-specific credit risk, (ii) qualitative information about the reasons for those changes, and (iii) how the gains and losses attributable to changes in instrument-specific credit risk were determined; and (3) certain other disclosures as required or determined to be provided."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r180"
     ]
    },
    "AZTR_FinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "FinanceLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease expense",
        "documentation": "Finance lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_FinanceLeaseInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "FinanceLeaseInterest",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less interest",
        "documentation": "Finance lease interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r530",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of minimum lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r535"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financing lease liability",
        "verboseLabel": "Finance lease liability current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments Under Finance Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term financing lease liability",
        "verboseLabel": "Long term finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future undiscounted lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "AZTR_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "documentation": "Finance lease liability payments due after year four.",
        "label": "FinanceLeaseLiabilityPaymentsDueAfterYearFour"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "AZTR_FinanceLeaseMonthlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "FinanceLeaseMonthlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease monthly payments",
        "documentation": "Finance lease monthly payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r531"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease right-of-use asset",
        "verboseLabel": "Long term finance lease liability",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r530",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease, weighted average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r772"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r371",
      "r388",
      "r497",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r612",
      "r759",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated Useful Life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_FiniteLivedIntangibleAssetUsefulLives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "FiniteLivedIntangibleAssetUsefulLives",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Useful Life",
        "documentation": "Finite lived intangible asset useful lives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r327"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r583",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Amount",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r584"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Amount",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r583"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ForgivenessOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ForgivenessOfAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgiveness of accounts payable",
        "negatedLabel": "Forgiveness of accounts payable",
        "documentation": "Forgiveness of accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ForwardStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ForwardStockSplitMember",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Stock Split [Member]",
        "documentation": "Forward Stock Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "negatedTerseLabel": "Losses on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r684"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible asset",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r321",
      "r322",
      "r323",
      "r760"
     ]
    },
    "AZTR_GrossProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "GrossProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from public offering",
        "documentation": "Gross proceeds from issuance initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_GrotonCTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "GrotonCTMember",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Groton. CT [Member]",
        "documentation": "Groton. CT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r800"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets and deferred patent costs",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r844"
     ]
    },
    "AZTR_ImpairmentOfLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ImpairmentOfLicenseAgreements",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of license agreements",
        "documentation": "Impairment of license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r135"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r117",
      "r166",
      "r255",
      "r262",
      "r266",
      "r268",
      "r598",
      "r610",
      "r757"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r689"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r689"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxCreditsAndAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax credits receivable",
        "label": "Income Tax Credits and Adjustments",
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r461",
      "r466",
      "r467",
      "r473",
      "r478",
      "r483",
      "r484",
      "r485",
      "r630"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfBenefitProvisionForIncomeTaxesDetails",
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total provision for income taxes",
        "label": "Income tax expenses",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r184",
      "r235",
      "r236",
      "r260",
      "r464",
      "r479",
      "r615"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r462",
      "r463",
      "r467",
      "r468",
      "r472",
      "r474",
      "r624"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "AZTR_IncomeTaxReconciliationDebtFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "IncomeTaxReconciliationDebtFairValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt fair value adjustment, amount",
        "documentation": "Income tax reconciliation debt fair value adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes using U.S. statutory rate, amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, net, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit, amount",
        "verboseLabel": "Research tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInCommodityContractAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Commodity Contract Assets and Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r822"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r579",
      "r580",
      "r581",
      "r583",
      "r753"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r168",
      "r210",
      "r258",
      "r521",
      "r690",
      "r783",
      "r909"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894"
     ]
    },
    "AZTR_IssuanceOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "IssuanceOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfChangesInLevel3InstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of 2022 Convertible Notes",
        "documentation": "Issuance of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease remaining lease term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease term",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term renewal",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r219",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r488",
      "r489",
      "r490",
      "r510",
      "r657",
      "r756",
      "r785",
      "r847",
      "r897",
      "r898"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, preferred stock, and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r165",
      "r606",
      "r773",
      "r826",
      "r841",
      "r888"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r190",
      "r219",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r488",
      "r489",
      "r490",
      "r510",
      "r773",
      "r847",
      "r897",
      "r898"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r460",
      "r879"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bearing interest, percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r67"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r417",
      "r578",
      "r616",
      "r649",
      "r650",
      "r713",
      "r716",
      "r720",
      "r721",
      "r723",
      "r747",
      "r748",
      "r758",
      "r766",
      "r771",
      "r774",
      "r849",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r417",
      "r578",
      "r616",
      "r649",
      "r650",
      "r713",
      "r716",
      "r720",
      "r721",
      "r723",
      "r747",
      "r748",
      "r758",
      "r766",
      "r771",
      "r774",
      "r849",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/StatementsOfCashFlows",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r128",
      "r167",
      "r188",
      "r204",
      "r205",
      "r209",
      "r219",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r243",
      "r255",
      "r262",
      "r266",
      "r268",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r501",
      "r510",
      "r611",
      "r680",
      "r703",
      "r704",
      "r757",
      "r783",
      "r847"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r229",
      "r230",
      "r231",
      "r232",
      "r238",
      "r239",
      "r244",
      "r247",
      "r255",
      "r262",
      "r266",
      "r268",
      "r757"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r247"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Expiration [Member]",
        "documentation": "No Expiration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating expenses",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-operating income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r829"
     ]
    },
    "AZTR_ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obtaining a right-of-use asset in exchange for financing lease liability",
        "documentation": "Obtaining right of use asset in exchange for financing lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ObtainingRightofuseAssetInExchangeForLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ObtainingRightofuseAssetInExchangeForLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obtaining a right-of-use asset in exchange for lease liability",
        "documentation": "Obtaining a right-of-use asset in exchange for lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r262",
      "r266",
      "r268",
      "r757"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of minimum lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r531"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, weighted average discount rate",
        "verboseLabel": "Operating lease discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r772"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r772"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "AZTR_OptionsExcercisableSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "OptionsExcercisableSharePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable Value of Stock",
        "documentation": "Options excercisable share price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r195",
      "r600",
      "r785"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r682",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable due from related party",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r667"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_PaymentOfDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "PaymentOfDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred offering costs",
        "documentation": "Payment of deferred offering costs.",
        "label": "PaymentOfDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease rental expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "AZTR_PaymentsToAcquireCapitalizationOfDeferredPatentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "PaymentsToAcquireCapitalizationOfDeferredPatentCosts",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalization of deferred patent costs",
        "documentation": "The cash outflow for purchases of capitalization of deferred patent costs.",
        "label": "PaymentsToAcquireCapitalizationOfDeferredPatentCosts"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_PaymentsToAcquireCapitalizationOfLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "PaymentsToAcquireCapitalizationOfLicenses",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalization of licenses",
        "documentation": "The cash outflow for purchases of capitalization of licenses.",
        "label": "PaymentsToAcquireCapitalizationOfLicenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalization of patent and trademark costs",
        "label": "Payments to Acquire Other Productive Assets",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_PaymentsToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToEmployees",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to employees wages",
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r770"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue price per share of series B preferred stock",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Original issue price per share of series B preferred stock",
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "documentation": "The amount per share used to calculated dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend percentage on series B preferred stock",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r714",
      "r717",
      "r719",
      "r724"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on preferred stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782",
      "r907",
      "r910"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r374"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r659"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r319",
      "r320",
      "r752"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfCashFlows",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from initial public offering, net of transaction costs",
        "verboseLabel": "Proceeds from initial public offering",
        "terseLabel": "Net proceeds from issuance of public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes, net of issuance costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized License agreement amount",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of additional notes",
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r22"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r177",
      "r181",
      "r182"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r192",
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property, plant, and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r599",
      "r609",
      "r773"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r177",
      "r181",
      "r607"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://azitrainc.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r399",
      "r417",
      "r446",
      "r447",
      "r448",
      "r554",
      "r578",
      "r616",
      "r649",
      "r650",
      "r713",
      "r716",
      "r720",
      "r721",
      "r723",
      "r747",
      "r748",
      "r758",
      "r766",
      "r771",
      "r774",
      "r777",
      "r845",
      "r849",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r399",
      "r417",
      "r446",
      "r447",
      "r448",
      "r554",
      "r578",
      "r616",
      "r649",
      "r650",
      "r713",
      "r716",
      "r720",
      "r721",
      "r723",
      "r747",
      "r748",
      "r758",
      "r766",
      "r771",
      "r774",
      "r777",
      "r845",
      "r849",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "AZTR_RefundableTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "RefundableTaxCredit",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refundable tax credit",
        "documentation": "Refundable tax credit on realted to employment in refundable to the employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r540",
      "r541",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r540",
      "r541",
      "r542",
      "r543",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r896"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r689"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r540",
      "r541",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r712",
      "r896"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r541",
      "r544",
      "r631",
      "r632",
      "r633",
      "r687",
      "r688",
      "r689",
      "r709",
      "r711"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r459",
      "r905"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r143",
      "r605",
      "r620",
      "r621",
      "r629",
      "r660",
      "r773"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r224",
      "r225",
      "r226",
      "r228",
      "r234",
      "r236",
      "r309",
      "r310",
      "r450",
      "r451",
      "r452",
      "r476",
      "r477",
      "r491",
      "r493",
      "r494",
      "r496",
      "r499",
      "r617",
      "r619",
      "r634",
      "r910"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service revenue - related party",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r261",
      "r264",
      "r265",
      "r269",
      "r270",
      "r272",
      "r395",
      "r396",
      "r582"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r749",
      "r754"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue",
        "label": "Revenues from related party",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r219",
      "r256",
      "r257",
      "r261",
      "r264",
      "r265",
      "r269",
      "r270",
      "r272",
      "r308",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r510",
      "r598",
      "r847"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset and lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r772"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://azitrainc.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of (Benefit) Provision for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Income Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r77",
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Numerator for Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://azitrainc.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Loss Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r833"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Tax",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]",
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r159"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments Under Non-cancelable Operating Leases",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r685",
      "r686",
      "r689"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Total Intrinsic Value",
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r83"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r140",
      "r142",
      "r143",
      "r197",
      "r198",
      "r199",
      "r253",
      "r374",
      "r375",
      "r377",
      "r379",
      "r382",
      "r388",
      "r390",
      "r625",
      "r626",
      "r627",
      "r628",
      "r766",
      "r807",
      "r824"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://azitrainc.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information about Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r270",
      "r271",
      "r646",
      "r647",
      "r648",
      "r715",
      "r718",
      "r722",
      "r728",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r750",
      "r767",
      "r777",
      "r852",
      "r906"
     ]
    },
    "AZTR_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "documentation": "Series A-1 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_SeriesA1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SeriesA1PreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 convertible preferred stock",
        "documentation": "Series A-1 convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r851"
     ]
    },
    "AZTR_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r851"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercisable",
        "verboseLabel": "Weighed average exercise price",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding period increase decrease weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Excercisable Intrinsic Value Per Share",
        "documentation": "Share based compensation arrangement by share based payment award options Exercisable intrinsic value per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercisable",
        "verboseLabel": "Options Exercisable",
        "terseLabel": "Performance stock options shares",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Options exercisable",
        "verboseLabel": "Options Exercisable Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "verboseLabel": "Stock options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options available for grants",
        "documentation": "Share based compensation arrangement by share based payment award options grants period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "AZTR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding Intrinsic Value Per Share",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding intrinsic value per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding",
        "periodStartLabel": "Number of Options, Outstanding Beginning",
        "periodEndLabel": "Number of Options, Outstanding Ending",
        "verboseLabel": "Options Outstanding",
        "terseLabel": "Options to purchase shares of common stock",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding",
        "label": "Options Outstanding Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r424",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information about Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding Value of Stock",
        "verboseLabel": "Public offering price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueOfWarrantsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "AZTR_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life, Outstanding",
        "verboseLabel": "Weighted Average Remaining Contractual Life, Options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "AZTR_SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm",
     "presentation": [
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average term",
        "documentation": "Share based compensation arrangement by share based payment non options weighted average term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Options outstanding",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r216"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r197",
      "r198",
      "r199",
      "r219",
      "r241",
      "r242",
      "r245",
      "r247",
      "r253",
      "r254",
      "r308",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r374",
      "r375",
      "r379",
      "r382",
      "r390",
      "r510",
      "r625",
      "r626",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r659",
      "r681",
      "r705",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r807",
      "r824",
      "r834"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r187",
      "r207",
      "r208",
      "r209",
      "r224",
      "r225",
      "r226",
      "r228",
      "r234",
      "r236",
      "r252",
      "r309",
      "r310",
      "r392",
      "r450",
      "r451",
      "r452",
      "r476",
      "r477",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r536",
      "r617",
      "r618",
      "r619",
      "r634",
      "r705"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r646",
      "r647",
      "r648",
      "r715",
      "r718",
      "r722",
      "r728",
      "r735",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r750",
      "r767",
      "r777",
      "r852",
      "r906"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r252",
      "r582",
      "r623",
      "r645",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r778"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/BalanceSheetsParenthetical",
      "http://azitrainc.com/role/OperatingLeasesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r252",
      "r582",
      "r623",
      "r645",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r778"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes payable, shares",
        "verboseLabel": "Stock issued during conversion",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38",
      "r72",
      "r143",
      "r363"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r72",
      "r110",
      "r111",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock options outstanding",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Convertible Preferred Stock, shares",
        "verboseLabel": "Issuance of conversion shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering, net of issuance costs of $1,508,791, shares",
        "verboseLabel": "Number of shares purchased",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r110",
      "r111",
      "r143",
      "r625",
      "r705",
      "r730"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options, shares",
        "negatedLabel": "Number of Options, Exercised",
        "verboseLabel": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r110",
      "r111",
      "r143",
      "r430"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes payable",
        "negatedLabel": "Conversion of convertible notes payable",
        "verboseLabel": "Stock issued during conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock options",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Convertible Preferred Stock",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering, net of issuance costs of $1,508,641",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r110",
      "r111",
      "r143",
      "r634",
      "r705",
      "r730",
      "r784"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r143"
     ]
    },
    "AZTR_StockOptionFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "StockOptionFourMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Four [Member]",
        "documentation": "Stock Option Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "AZTR_StockOptionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "StockOptionOneMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option One [Member]",
        "documentation": "Stock Option One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "AZTR_StockOptionThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "StockOptionThreeMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Three [Member]",
        "documentation": "Stock Option Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_StockOptionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "StockOptionTwoMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Two [Member]",
        "documentation": "Stock Option Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets",
      "http://azitrainc.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r131",
      "r661",
      "r678",
      "r706",
      "r707",
      "r773",
      "r785",
      "r826",
      "r841",
      "r888",
      "r910"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r218",
      "r373",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r389",
      "r392",
      "r498",
      "r708",
      "r710",
      "r734"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward stock split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r547"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://azitrainc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative",
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TaxCreditsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TaxCreditsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits receivable",
        "documentation": "Tax credits receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TaxYears2036Through2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TaxYears2036Through2037Member",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Years 2036 Through 2037 [Member]",
        "documentation": "Tax Years 2036 Through 2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TaxYears2036Through2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TaxYears2036Through2038Member",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Years 2036 Through 2038 [Member]",
        "documentation": "Tax Years 2036 Through 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TaxYears2037Through2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TaxYears2037Through2043Member",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Years 2037 Through 2043 [Member]",
        "documentation": "Tax Years 2037 Through 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TaxYears2039Through2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TaxYears2039Through2043Member",
     "presentation": [
      "http://azitrainc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Years 2039 Through 2043 [Member]",
        "documentation": "Tax Years 2039 Through 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://azitrainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://azitrainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock value",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r457",
      "r604"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation value",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r68"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://azitrainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r895"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r275",
      "r276",
      "r277"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r371",
      "r388",
      "r497",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r612",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "AZTR_TwentyTwentyOneConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwentyTwentyOneConvertibleNotesMember",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Convertible Note [Member]",
        "documentation": "2021 Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TwentyTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwentyTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative",
      "http://azitrainc.com/role/ScheduleOfConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Note [Member]",
        "documentation": "2022 Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TwoThousandSixteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwoThousandSixteenStockIncentivePlanMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfTotalIntrinsicValueDetails",
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Stock Incentive Plan [Member]",
        "documentation": "2016 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TwoThousandTwentyOneConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwoThousandTwentyOneConvertibleNoteMember",
     "presentation": [
      "http://azitrainc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2021 Convertible Note [Member]",
        "documentation": "2021 Convertible Note [Member]",
        "label": "2021 Convertible Note [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TwoThousandTwentyThreeStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwoThousandTwentyThreeStockIncentivePlanMember",
     "presentation": [
      "http://azitrainc.com/role/StockOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Stock Incentive Plan [Member]",
        "documentation": "2023 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_TwoThousandTwentyTwoConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "TwoThousandTwentyTwoConvertibleNoteMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfFairValueMeasurementsForAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Notes [Member]",
        "documentation": "2022 Convertible Notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://azitrainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://azitrainc.com/role/ConvertibleDebtDetailsNarrative",
      "http://azitrainc.com/role/EmployeeRetentionCreditDetailsNarrative",
      "http://azitrainc.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "AZTR_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter [Member]",
        "documentation": "Underwriter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://azitrainc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r174",
      "r175",
      "r178",
      "r179"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareDetails",
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails",
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://azitrainc.com/role/SubsequentEventsDetailsNarrative",
      "http://azitrainc.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity term",
        "verboseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "AZTR_WarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "WarrantsTextBlock",
     "presentation": [
      "http://azitrainc.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "documentation": "Warrants [Text Block]",
        "label": "Warrants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, diluted",
        "verboseLabel": "Total, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r247"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfNumeratorForBasicAndDilutedWeightedAverageCommonStockOutstandingDetails",
      "http://azitrainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock outstanding, basic",
        "verboseLabel": "Total, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r247"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://azitrainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "AZTR_YearTwoThousandEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "YearTwoThousandEighteenMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 2018 [Member]",
        "documentation": "Year 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_YearTwoThousandNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "YearTwoThousandNineteenMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 2019 [Member]",
        "documentation": "Year 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AZTR_YearTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://azitrainc.com/20231231",
     "localname": "YearTwoThousandTwentyThreeMember",
     "presentation": [
      "http://azitrainc.com/role/ScheduleOfInformationAboutWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 2023 [Member]",
        "documentation": "Year 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//825/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001493152-24-010091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-010091-xbrl.zip
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MS$G.&7)I ST->8Q#KT3OQWF!(O'K<9I9(J6UI&]24JI(?5*AX\3;7T0/8\@
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MZ%]!>76NJT['0MY ;;DH[9<HC)=!CD>=0CK)8$?UHMCG&S$$DSJ-MEE#'7R
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M3*=DY6:T@LK:WGJ_3+\1Y;6E.CK;^YP0A,1]=( I7-I$I]-9OL[YBAAR8>>
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M]XNX_\"KB=B8C=CJ*KO>NZ=O0WZK]8;+\MJN[MO]XJ IR.(41;A!TK;ZUQ]
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M)\4H+99 LE2'TF@%))R%*4O>=G[X&+-TH9ZDGL+E(US:$0BH@[LOR(^B3>2
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MMIH)8 9AL6T+'M(G=S4WJKPY(@M./D,J!?H;66W6EKF"EU,%1:7IG:7;&DV
MJ&<:G!7VGG6KOU.GPD1*9BL+K0D^:@' Z*_%-ZHW+]&IWZFN:W_W 3\Z$L[!
MT*Y%JWJK&X*6GA+=YH*@[.%0>S#HQP>K<37T(-1RC&Y7'TW^F419\9=;"BRQ
MJ2A';B1*TL_%.T)ID"\=9>/'--YW3?@PB_R8\,/VD^^)U Z?3JZ)1Q\R/&3[
M4B\,H!\O?>H!-&JL+LA95L-)(MX/R_A.TX2*XIV^$.;YD2S)HW%7Z$=&.XE
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MX^F4,&F-"^TN!@=E,\GZ,7&;9H=O)&]=TCB[>G_S&*P3(76*QVQ2#@Y)+8%
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M)N%$[ ,K;Q1@?M2TM'6QI]71728#I&UK!X#3Z92(6C9D]02+R'>])GR)]/S
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M5AI:O'E6T2>@<[Q1Z;9JQQQO;@%-KWE3_TU<5D@7.A6^:4)"::Z4E,;6:W3
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MA,[SM VJ>1\[@VDK>=!YJXX#-XK&T]_3JB/QF%V+%ZTN$Z$A?L)<Y5\=NT%
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MIQR0^S;7K+S+Y?R=,]+ [,\7282"$\&$3$R,3I<2FB!"A ]^\*R']OBYL"+
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MV4K)()01H4H)TXO!HXN S406JD#',U0E)$W8P.JVO"N+US2/U4-FE7@0PBA
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MA1X8RCF %:):HSH<V:-35.*,Y1=81R6 P&8=T4*',KL8%CAX&5<4K$/7^$#
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MDP3(P[L2D\X@,3WO;%(+RS^Y$WKNC77@\TZ*=\JY1@C4DV;3,$_?].O/$;"
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MJ:ADH!!RCVD*8YRTN].+.-ZLZ%8S3B[P,HWE]6/6\A4TON=UE.-G^G%=T'#
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M=>R"7GCRHE%K1G&DP_G<:,(D]^VFKNHH3]+\V:5T1FK!*2MQPLC.@0YL(HI
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M\T<;C:E=M CV1\J=0)?V_\@C><-=*LF8'<;BYR$&38=OJ=/O@=JBW[78#A3
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MP2M'CTO(HL.D3E C%[20U:4+KE@-Y1FH& ?7?C2$%:4 %:\&G+ AW8N&YN\
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M9CI=)I]O&E#-[]LC\^5S3=H)Z;WTP:?"WDMOLO]U:\S-_<(SG.-E*IW-Z34
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MO+4GSWF6PX;U,\PIUE8W@.2#V0NMMQMP#P.L%HN(K;+M^R%*D^+@/4L3&2_
MM[L6"XAMGSW?,6SE;Z(;7.KYU:(D(+%UO!+FT[C5;.WX@=X9+EV@ICX7[5;%
MX3R9^^A]V/=1X@5\IV$TC*DO;UG6PS;WT?NP&Z^$%Q'+=DJ._!7U'FA $]IB
M_^K0>?^;6^$$OR+/)'A_&<8)2^6 \L'-9^$M\5/&A;\\\6)JSV[G3PR'[FQ1
M+%R?8_'QP/._\&:\=9Q-DQO&[RGA\E,T)T%[G+M\9@"+3:O-U4#;.T;77$5D
MX!R?&$(I?#XOSFB0)F1>,8A8X]*ZZWTR^1NART?^WRD_AWE+(GPZ41:ITN5@
MT?,'^Q?(KOPK0[1GUZ:[_M=6+_#30!XA9HN>=->^S][9.B$A6="$7]&?J8A;
MY:I4L@9:<V357>_,\(TG"GV^V>8BW7S:F@]H3[VS<$86A/%==//!7@XI;7KM
MWQAM;],PD@[OG[>_;%MWU?^1*!5FYT\TI*MT=>.MY6@^A_P^?1V%;WP13!N(
M:T[%Q&Y_)NKE.WMD_X*&8E"]LZOK=Q@?BK5C D8^2/2&[5AAU(-$=]@/%4(]
M4/2'O1L'1J\;[A,C,:>5V^(5_\4."7E-")\.\Z(C,6KPHXB$)J)U_E#E[>2-
M>-4BKY;\QZQE/I)B+$'D[WP^$*\_HLHKB^(EC7SC$1/_VV7T_-V<T.^$:,0/
M4D92/OP?O\L/31_XK=;S-Y&4?!$C@>S_=]ZFTN2[/8RJD,0][[%Y4+LMJF,J
MHS9E_B1B?-'BLB[Z\IB_@U7]44S>XKLG&4O_QG^DP0;F!8M6*NGDDH@4 RT+
MBG]B/]*<\N_/Q1@N F_9+,Y*$Z \WV((M)$;+(F>D=AG5%H7#(+=:0F4[SM4
M^3;PMF<Q%W/GEBRI&*\8RN8MB7Y=4)  !?\><Z70<HN$P#0,4R^X)4\1,PA^
MMR50WC]@RKN)-R0Q_V?*#U:$!6N(I&N-@<+^$5/8"@Z1Y'W/O#"F0CX0@==;
M R7^$^K!0\$CDLCO'DD0B.?C7@C2\J;V0+'_C"EV-9\."%[>A\[XU@*7?8D$
M*/Y?7!%_C5LD!&X(H]&<;^D,(/M:8Z#4/V!*7<$AJKS/PSE4VINFX/L/OK K
M["&)^H+&OA=D([K@OXOUXFYH#A4YRIW3R":JV/^+> PL]%)CJ,A1KJ$&%O<L
M\-.4L9W!:%<5=6NHR%$NH"8F]RSS\S"AR5KD&[I.5P];P^FNK.NMH#)&N72J
MF$*1;6%I"!.11DDGWVI+J(Q1[IHZYE#D?,KY82(*<$Y>_X.L=8*N-85*&N6.
MJ64/1=0WC(JG.W?4-R\:];908:/<+/4,HDC[WGN]G(MG1>*-E!"26>A*$JCL
M4:Z5('91(!!!(^PI*IF+3\4[-;8^C>;:)=U "(4#Y;YIP3H**-/YG(LKSO]S
M14/R5@=%8W.PCP@/  V;CHC]G9W8W\'%CG(/-;+IB-C?VXG]/5SL*'=1(YN8
M8C_E/\[8??2B\$ K&T-%CG(7-;"(*7"YT\R8C/G-\K&:I%ZC@(H>\8JJ9Q95
MX;--'J+M14NHO!&OJ\W,8<KY)HH3+_AO^F0Z23:WA\H<\>*J8W3?!L8,=V&T
M4(4259I Y8MR5VUD9]\B%0@SXJG5=[<%5* H%] F9O8LSZM(^#X>HU!KCZVW
M@LH5Y2:I8FK?"Z^()(Z54[_T9W $&\JR6F5CSV+\C=&$CT"\24G#W$:C\(HI
MFD+%BW+]T[*W9U'?R2Q(XH7%)WY"9'2;:7Q7SDWMH$)&N>RI&=NSA&^8?,=*
M^+%;QG&)IP9LMEBH5EY=>ZC$4>YZ9D9Q)7\9QREAMO)OH(*B@'+M@S*][W5&
M)%?@AY^W[Q[NQ8L9Q2I3:P65-<J53\74GF5['=TS3[R,OUNO'J) _3RDL2%4
MPB@7/ UK>Q;RSCB:Q5MI A4LRLVND1VD->'\U9?I6=31"\TMH0)&N>GIF$-;
M>Y>@M7=IN?:BW/A43"')-HL-YS-J]A#0I:=^2:8E +^SP92XAM5]O]^33WY*
M6=(N^ _-8E<TA0H<YXFDCKU]BSJ=4Y&81PXIRQO KU3;BE *J1NIH #@O*$$
M,HUBWO^-!,%_A-%+>$>\. K)/#OJZRS\2A(H"H@^1 .[*!#\&@4IEQ*3@:!,
M,0<43:$B1_0=*MC#B;W,@IHW>T]6*E0G<14%5/"(3D0]LTCQ:0D18Z;/Y,Q+
MO'R$.OFK**#R1W0HZIE%BY]GIWSC649ZGWFE(53:B*&PC:RA"/ENY07!21K3
MD,3:M:72$"IDQ)C71M90A'R^(FS)%[6/+'I)'O.WG3IA*PB@0D>,;-6RBB/\
MU^T[\NS]FU;R#:W!V0D0Q:YD$BOMQJ;HR)VLWLX44M>UA\H=]6&EFM$]2WZ6
M/!)6/C_)P5SR>YLNZ,%,!44!Y;H*91IG;RV]Y-=NK3OMH/)&O)@V,8;S9BI]
M"*A_$42>]ER^TPPJ7\1;: -;*.(]\<(O+'U*_/4-BWQ"A/LDWLPVP(4(V $4
M$L3[J94H<,P%V\SA,A]UN6:&UFB@I8-"@_F($\ XTBDHWC[T(O.3]:U([BS"
M%.[):W+"/_1%?R@"D$/Q0<TH!!;#GF&Z]!=,&KPC-DT2$F=B4P<3Z-I#@4"Y
M$)L914L#PB?N*CEG+&*G$5]$?3T"$#HH$JCYALR,8WB[(G9!V>I2<5>K- &G
MD$/S8U79P1&I.L9CIP%4G#A^V3HK.,*\BGQ-I$&M$52H>+[6.DL-@OW7[VJC
MO^*_*/[:^,>=WFSS?9]X@4B3SR]ZI.3SW<G[_6[R9K+Q"\O$WV$<!70N]OA)
M3C_).^BL'PLO?I (I/&;I><]94I"@B0N?K/5EOP7OV\&-UML'-DW468CT^0-
MS\EAU-TUOQ-GLM0R@(>\G6DVU/2OWREA)=G=V:)@J)S-#AD*/N6(L#LU.5&J
MHR^U=0R2'852";\T_'(J!QP 2G4=UM(&[LF35"RN&=N_3%^I!AB;/D8$F U;
MI;SX^#B>12N^'<'P*MJZ@8N]-FHP*UC;UH# @>8Z"EEI6)^(PIV0MU<T!S__
MVP,TNPI6@4#+;J^GWJ[SQ(1$4UNT5.NV,*@91<=@L_J>!EX<YP5^]5N,AL2-
ME<ON"%#GHE3X P>4\I!,&TA36\=@4*E6!9$F3CKN%_5R5-/_OK_]_8XP2N)I
MJ43]#<N+%<JO*Q<C00TE!JY._5NS->+<E;L--_TL5WH\WG8"Q$R-EKR]#2)0
M80P*R4D71,S$>.G&6R "E07ZEIZ7636:A:KM@&@,A87:_%#9)YKY<T3LN?L<
M*OU:<^B4& H%A7";$%"PB@[$J1<_BBJX_#_G?Z3TV0N$WW::G'J,K6FX_-4+
M4HVE$4@.S@PZ*% J#*(V+#F"7QZ&&-\2G_"Q\N7VFB3J")U"'EHJ[!N[#5H0
M_@?:]>^]UU.^J]'RQQ5[?'-3\!-83#FKA^_(#-C4(->BD+=N;(QM&K'1=PVW
MZ$@4->QE\A41'1?%C:]E\_:*YN#P @?0T'*,C@<_>#]Y='[^^D3"F!@W!45S
M[*NY#1Y:CM'QV.$$>-@%R[__^++6A]P&@3\5=\"KC%WET.2XDBCQ MD2;^I$
M3_SZNA;E[1-^&A0GP2=QW^*G"]T,TE%A6U1 0$(81Y](6?@ N2)>3&[I\C&9
M+3['1/*G!D=+!+Y)HH(#X!L=FQE7'T_$QMNA8R!#-WZ!\ 'QCH[0)9=;N!26
MN8PI/K//7_T@%7'S'Z-H_D*#IJQ?FP,HA!J*U\ W?N-A&BX)=-B*LR;P5&UW
MFAZ@?)\-$(V\H4M</C+,QJ]9N,J-H-(>^$IO6J;J?*'+VB1F6PD/=EFWM+P?
MP%GXBGH/-* ))7"#O8X&"N%@-WPPA&;.\>=-;O^\\=;"%@2V_%;;0T$9[)H/
MD'6SY;>9<W1@RF?U@K>U$1X]%12DP6P!UB!!I( .U>ZQ'0Z6B0X*UV W?FNX
M8)) !XQ/?9;R_;/&GG;=4Y& G9/.P&3D'QVATRB4#/Q&D\?3-$ZB%6'PB06C
MAN(VF$W &C<;J:!#:#.[NDRKP4P UO" YM/83N^-._!U%/JMCB)E0BC @YD6
MP.=XH S0IYQB^X6@!2"%XC68<0*,%U@.Z(B=$4:?/9$]L[1X0/ R$D+1PC=T
M &6 CE4I)/4J"I?WA*VNHX04%TCM<41/",4*WZ(!E $Z5B5- ITZX!@,9L!H
M8U4Z@/.%R,)$$YGM1T1-1C(E(@E]+7):(BB2@UDY+&:3D7?TF71/5B(!$UL+
M3WZR-IMNE0107 8S9X!Q,?#L&B9%9/%T)0R:TR1A]"%-Q'I\']UX^G-$BZ[
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M+13',I/#V)FOO(?-U[1VY::&V/<Q"\TJGS'5/*-?M[**Y829,2FYDQL)L&\
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MVQKH=1DH:BU=<I5;8*!B&1V+XJ';;S1Y/$WY#%T1!DCF:2##3DC0$B60,%R
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M-J+NFRXLI8J8LJE,$I+E"*B^LLHFT@_GCW?P.U.:4Y+4RU3+S-JUI'XX_->
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MN.2679R5ZKO_!;<P$G*!\A:(8&ZH'A!+0"0DJX5T+D+8Y*GA4 \7?I0&8)!
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M:6(L\F%9&,PFC:8;L>=>),M?^F/;:]+W"KDO&J+O(_H?4$L#!!0    ( +V
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M%]7B@6MD6OF<V1V.[%X7GLXZ6;U.Y'JOJB]@> GV50\L<]PVKWM6:?A^T/L
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MET-%*OHK+-%W6O177_X%4$L#!!0    ( +V ;U@7'9*7H @  %\J   )
M97@T+34N:'1M[5IM;]NV%OYNP/^!-[@K[@5DUTF3H4NR H[MML&\QDB,#?U(
M2Y3-5B)5DK+K_?H]AY04.4US5RSMLMT42"U1),_A>7L>4CI]/?]Y^J+;.7T]
M&8[QR^C?Z?Q\/IV\.'T:?O'T:?7X].QB_)9=S=].)S_NI5JY8[8_*!R;RUQ8
M]D9LV*7.N8I"0\2NA)'I'@9BZ.Q+QYVPG)NE5,>,N@Y.F!,?78]G<HFF6"@G
MS!Z4G-W/]/7?[6*>J(4M3KZR,".7*X<EO;QX,V\+Z*4\E]GV^'^)\'VM_$T$
MC3#3V8O)QY5<2-?M'/:/3I^>P5XT^[<RV[TNI?;!WWH1X\G5Z/)\-C^_>-/M
M7+QD\]<3-AK.SN?#*41<C'ZZU_7UG"[\&IN&A79.YU7;UUUM[:]OX:MWI74R
MW5:-4B6")A_TCZ2ZSR4-?Y/.\*C;.5=QG_WG299\*/7)2.<%5]LGQM]%K&K>
MB)LMI:U:&%=)W:A+4[7^EZVX95H)%F?<XBIE5L2ED4Y"2R.6TL)%(F$EUF>@
M9.RD5MW._@%U=2M!377WR<=XQ=52L&'LZ/'^#\\.(X;Y>2XP/(F8PE6V99#/
M8IWG6C'K=/P^8@4W;,VS4K!_#_J#P6"?%1!G5]R(_C_*G5\C0O^2A<Q7HMM)
M=9;IC51+)N%E9LL<:FWKT/#@XF.JY7 *0[3$PC@N%2N,7DN+F&KZ(: T^@Q#
MS/C^E\(Z[G SPBB9RA@WU!TIH4VA#0]!V23'';V:N*=Y[Q)UMLWXQC8)%V[K
MT7WV4AN6:R-8(K".# .D2K7)O1!D:Y$);@622?A%W:62EQOFC]AF)>,50]AC
MOKH/)E]LD8PI,E'%@C)*!(RUS&EOZJ%2)<^@/08@]Q3IER--![V?J$N8U:W@
MI438V,C""R:GJ7JNQSS[DTNZ9]@>^7SI=JZH0GX["O(5%O,/1.6+TG0[=R=U
MZ5;:8(AEI4]3:2W@K2SH>G\PB ;A+X"<KWZ[D-@ 80.-UY#(AG[ S]S$*V1Y
MQ X&!X#:C0"<)^S@>?1\<!A]?_CL,Y.C)#F4.96@<D=L)3)?8)X=AJ<KG0'K
M_2"# FF2Q\KPP)?T.GBLVR'Z=KO'"5$@7#J"*D0@4;ZU=JV@(M3@689E.4?N
M1Z=%Z /V5^ A0H2@9B=&ED()@U';/KMJM7<[-^4ADH1<8W0)($KD6L(4B24H
MR_F6!"4"#)289FITSAP6[+&-?BO!9YJ;A$*7%I>6-#P32Q+.^!H8S!>9H(X
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M9A0QB,[C_M!\A,B,HO/20"?B1BN@-V -H*LIL1%4&1K?*^W,@EUIF3\AF:Z
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M"K3ERNE/&)]RF:@E>AU]_C&,N^ZZKAV'#$R(T!BS=$8Q'^O0JACS4-2=%CF
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M[+M7KWM\K_?ZVSTTNWJ?O\;/B4//Q=2D@E Z 51#P=MV;==6:AON$G"V2LM
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M?C@]_@,QZN7/E[]\>O__4$L#!!0    ( +V ;UB^XI'0IC$# / L&P ,
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M[[C([YG%?3>+F_TYS1;=5*O7ZD^X>VOO.P>$!.CAOU:?>P[\'QZ[K/N]P]R
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MG%G,<7D?\ZX.1-WJKJY1WRQJ=6B5O#_J#UQ_R/DE1R,)OCR ]XN1!3RDA(R
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MG1,/\*6+1T]EQ<'1O>U&B#^??-^Y$Z[[5*@+]SE<2-_FW D0A"OF\O,.?#(
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M*)=PD19ZO=&<6\!@+)VK)27:N<3 /@Z3:[0'IW7'I#.RKN#$4TO_RM%L!ED
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MLN-@"^,FV16><E@7UYQ*)W1BE)'RP6G(UMK^13WG;+6GP;8U"VR7( /NP#(
M$ &PS0< FW*DDQX:NW5,DO9AQ+]Q)H^!M^?"P+W"LYEF!;?5";E\&LS%.P@G
M#3@;W5H_DGG +#H%]S$8D_W,"^CFTXW-!VBIB2-YZUNQW_ J:@?\GPB@/;J%
MOT:\BN>W7+9<UZ=V)BI6G?4G?_$<+N^D@$5.)L?MO?HH.9KP!(A=2@Y/EZ)I
M>MR:2(_X43R*$I=*J<(<MC^@[W'P[_N )CK#DBT:T_R^)W'U[$<HUW&S<2CK
MQGW@K.FO<9;NKVN!Z ]<CF-G]6LR3U:O"N  ]9O@(ER<>*\WF-;\@*F@[HGO
MXC0,TGP8?XQNOU!T!)<6+8)/')1\</)'=E#DZ,WQR]Y->IM^UX"R#,9 @&.0
MX2$HG_O)2LQSDN]&[^*>D]Q#*T[>[:3O,!^GWVX^TULY=7MC:JEMKX,!OC1;
MJN9_A_L)[/'S]3?%;4X3!T+7MY9R<S3L\]N<I2/&#.9DR*KXS6DL\>8TYKTY
MH_D:9[XGQP>^OLK6)9R;=U%&)Y_K;QR Y'[@"EMHV6XYHH_IM;Z72.3T^-IK
MD,V!TBB"C\/T-ZU[$:SMQSV()FV" G3LG2EHWTT$=TG(H\2 1<6 %^<!$R8^
MO['C']^!MT+]Y=DOS-F_&-WG&U>]Q.A L3R\_<!EV)F$EJ5.GQP>L^W JK."
M$AV6 1U>B3L\.NY]]?'AL2UX6_RA1(A%18C7X1"/M5%;?7QX; ?>%'\HT6%!
MT6%^W&%JZL[2.& SH:+&$T)%C7F'BNK%MQ]=>4)\MB+_))!4>UPLHO ]C)MG
MG0T+Q!#J\Y8/DW'V>4UE5Q]IGZU<EEA;/-8^KU?PRB/MLU6>$F<+P5F#A>-S
M7%8!!1\^[[$UOY7#?G@(SNH?_(/K?RM(,&4DVNJ?_N2%K_BQ+X]E_9*;\Z1X
MUAO7W$H;^75=ZD^+L;QUI"UMY 7$VM)&+FWD)<#9TD9^@X==VLB+9R._.!*4
M-O(BV,@O'X<N#<+2('P6]BYP>L",.%\:E*5!^>:POC1(2X/T#>!\:="6R)(;
M64J#>$$,XF5&HM*@?C6#>O'19GP<96F&EV9X83B_6 V=9L3YT@POS? WA_6E
M&5Z:X6\ YTLSO$26W,A2FN&+:(8O&1*59OABF.&+A3;/Z?GTQE6RTOA^W<82
MI?%<&L\K@K6E\5L:OTN LZ7Q^@8/NS0^%\3X?$TD*(W'14B*GM^Q)]Z#;>,]
MH,$=,0*<7)ROP)E'[4 X@LGA%7-Y1MLPE\3K?$W_P'9^_T!FS,K<9M"4Z/#B
M%#^O^3D3_(7E$;\:Q3_!(S@OBI^&&,O336*!-S=AIUOK]9WO@0R_?V;WHA_U
MEY?68!'O+YG7Y8JN\-?,FEZ/=>(>SU-'3AVB\%;O$--K6MU#5(9.>8CS/,07
MLE9+=KJ,AS@A@9Q^6E*%XVEIUIE[7C(MX )>Y(4KX- Y!DX7\E-QB\/: 3>[
M&"U0H\<_#C^SOWU),881+WYZ]4MF +Q:04>),J^/,HM5S#$YMGG0NCRZ.NH/
M7'_(^27';8/M/Y#<,?NTS,AS/1SP\TX+!WMWR9&<"EL^OO)5E>)3L[P?WY+5
MT,%?"#V6S1Q8?'GW#,PM\;1$H4*8W[+;K@O._%[+C%Y\S 5ULAD;W\WE]?;K
M=>0UOIMS]O9GF,$I:V/.P0"Q:OE)_4+ZL#7A\,(%1;+E.?'2/@Z1"Z0(?WS=
M*Z<$3VY\6Q[X*Q_XBXV\3"5(#J*0R[=V[*EDR4GK7W5Z+X]_$8__Q:G_.)*>
M""/)89^.Q3W^M +.TEP8,'T+W@H/*)%@\9#@Q3G!*6<![_FN<](?2/^63.&W
MA@4/[,%;X04E&BPB&KPX-_@8"5BEUWW#6#!]"]X*+RB18/&08.[#!J:GWUQ+
MYO ^DS<K@ 1/2J<8W8#2+_^0""G1Y171Y34+,,N<J]<6$B]^Y*?"QLWSNJVN
MY*NB*#SI^*?NQ,JAPJ/Z0HD4"X44"ZQ!/)K&6^H2BZ)Z+F0R;XDN"X0NKSD0
ML50]7UO?>/$C+[6,A=(R7G<N9HD4"XD4BZ]!U FHK3@).FGB=^:'_"*2=H\%
M/-[#Y4>F!].>9UK]*W$5?5+S$S!/0@5S]?4=?#14?Y][?.3F%6!"+X W>< Y
M];UNR&7_D+?#D93.F8[BC2#QRJ-EB0?3M.7:'G;**N7:HLLU?5(+A@J3&,CU
MG;]Z#&0YY=K4HU@Y)$Y,OKVX^*M$YQ*=BT?G46-U[PE%>GLOU^^PGJK>FDG5
MB9TDNF']JO7IG[LJF >8!X8&Q)=,/X8E"P\2+LXSP:A$]A+9Y]"VL3[O!(E&
MS*T;ZXW=-Z.$+*W4UT>6E_WAX<Y5ZC=C/&JF5-\2CQ88CW*W>-B<6XN'J8,3
M2CQ:?#Q:R#D+)1=:4.S)ZC?-N?H52RZR+'@P]_$<V^OPK_EIHJ%68L3"R95&
M+;]<:;Q<9]8R=+F8H<N7[DQ5XL%BXL&+E::7TF3QI,F"\(,2#Q8'#UZB0'UK
MO;X=_[2SI/T_]3KR*E_I&4/SF_:EB>S8EW=,*B_]%6#1"B0(M7!!(_0T99FO
M9ZF]S""I\I!76%R::.D, =!$I/K7/3\*F.=,TS67'S7F'*3, PI*]A,X>!F-
M9.C,?! K%S-]$'E;JQ:]GQD7)ZY\U0]?<R6] _4W=/C$!!Y:]ZH?_8IG[92)
M,K,TE7F ]:W8Y._YBH%<H"SH$/+7:&XT@_QY,WCX?(E48F$1W'"R_?96L/"E
M#;0WC8>/]O<JC;+E3]E_K2ESI5%7HL[S^$YI%);(,[/R])5A)>0*!#9B),&N
MY>$0IQ?Y'OPZTO4GL]Z5TTRF= (K#WDUH_U3Q$"L>:\@ A1I=ZP2YBV?Y"FQ
M].UAZ2LZ*[]Q)E/1XR/1[86<>\N/;)31@;2:,J8>7.RJ'_A$=K+R:*!M([WH
M<WF)*WL.V9<XF <''U7*2FPLL7&Y%+7).'HF/+X:.#H#FF07NW),ZQF"<W70
M8-%9U8KC8"&"L\3&U<?&91><NBBI)_D*Y(K/@"ECZUTYUO4,\;E2R+#H/&OU
M,;$0(5KBY%O!R>41I1/QMPY(M%/;V6R6"/IF>%9YU&^.%20(LAEWY=O,]#F8
MQ$TIUG;BV;@)MQQ'V8]$&0_\?M_W5B0U"M=WQOK9%@AYMN4UPH]C)_":"+_Y
MA/:!FZ^3&EHB?(GP*\KA'T7X*W&/;J<2V6?>DA+1EP#1#=I^XAZ7S&UY3LOI
M"T\$H61XG$?W SB*%;#' 4']/H_1Z-2W87V^ET6?F7:A1*G94.J2!YQ)NP>[
M><AON>L/B'[?%$+-L <E.LTV.+CD4(O/H19K@/"C*%5RJ,7F4(N%3E,\PQ=<
M=GS99Z  7_687(7^EB,]VF)K8/)*WYYC>,I&Y+<:2R190+/T3>E;12#Y#$ZO
M$M$7U-E8(GLIQ$M$F=UD*!&E- 8>FH"0.UY %YP/T#!;?E1:G'C!%*0>V^V5
M,UX>1<P\D=LWA)PO';DM$33;=2I9][FW KZW8^&!Y!3,G=A%?-)J5^Z@'VTT
M5AYYJ73/Q!& 3;\A](A7^Y8Y0GGD)4=X"#U6HTAD=@1YB[5#Y;&7Y3FY.<.Q
M'\DWA"')<M\R7R@/O>0*D]H1KY+[:BIVO'77T=M(MUB:G(?7['QPS(3\D[D1
M/_$&41B<8D);?<2G'5_SF;,@DI0:%UQR.Y)2>-ULDD.JG$ 72*Y O"_>@(_#
M^,??X"V8!3BD+<ORE0<VM5"/> JNU-$<2_Y/Q#U[. 6H!TZQ6.@>%,Y3$>4M
M4UZCI+SB*:]14EY)>8]1WF9)><53WF9)>27E3:2\DJI*[%U>['VFK;0B"/S&
M3:$51NJGF"%O':E7P\I88:1^BH;_UI%Z-13X54/JU4?8$C$>0HS1"IO2AU\J
MKJ5%.%Z\]#J45_KP2^VZI+S7H+S2AU^: "7EO1CEE5158N_R8F]!MM)X/>R=
M?^![MUR&HNWR,S]<A>S[TG8JG!)G1IRW3)G/L:5*RBQMJY(R%]'6*BFSM+U*
MRGQI6^RM45V)W2N#W66^56EZK3)2E_E6;]5J66&D+O.MWJK"OVI(O?H(6R+&
M0XA1GYW;K0@^S)V!S0<3ZO/NK#*]RW6)$XN$$XO?!KO$GT7&GQ>1+H^.6"AQ
M8I%P8OF:.97XLTCXLQB#N'36CUIG'8YL9[.QO;7,Z##CG./,PDN^,9M6F]FT
M$DE*A;7L%/BZ_>'F[NN805[LU#:7^:RGC!%Y-=)_S<K!2:=;WRU/=S5H]]#O
M\R 4]H$?>:$<+C^;5N.9K]E]*PI[O@2XLZ<\<<%OA9;+TW[SM!VG>K'[;YS)
MH%';W+[N23_J]N#'G1(EGA]-A7=?T"FF$[<>VNY593^Y$/+,/[H?",E6PUI8
M3"P<W^.W@GIDW+<\Y]2WF?M[)$7@"#O9A@E<<2<FT^8*.$0?P\=']N<E^>/X
MQJ\JDH[[2THD+9$T'Y*^8NQQ5OUR[TTAZ:OKE^/;788R9@MEE A=(O3#"+U8
M89='.?0C G.5L?:YND+)$DL,6DP,6BT>]+ _<K=$L]?Q3.Z6;#)7&J8ON>AZ
MI>*82:J;L"EO5&]<2'1^H%*A1.<2G1] YR51033&'MW;;A2(6WXJ;-ASWNI*
M3HE^RX^SF,5RWFEAXDJ7C_2*>&39)2]\F!>6R+.(R+.(G*>^9Y '?M+(HX3$
M]X/6,B)((,,D&_H3][N2#7H"S!.%('IQ[P]:KX4&9L?SH($YFSF@@0KGE8?_
M$@&OT6,L/N!5BT5!+2L*/@*C[/C2.;A>7M[O</'^E'>9>T3 ICC^Z.I>C<77
MGL#B:_/6#P"B+844]%."%)^D'_K>:J)$=FVOAA!Z[W,AA#ZEN2+$7HP0>^N;
MM1(A7A(A]IZ $'A*<Y/^)5]X\48>&0HO7 _(:/7TT^L<XBOIRIE[7M*5?LE=
M>)5S 5"N0(%">C77H&$%C&([P<=A^INLHW%\!TI?S6Q^ZQ)W%@AW%LM5,R4O
MO&6308MMRKBX96U7]\]=490Z\#T;;E85 )<BN/DX_,@]N]=G\B:+2-,VIM"(
MQ_)A^&NFAY>X6N+J$W'U!1IC9HS@D9[D%Y&T>VPLBI"TG>?4RIQ/;&@>C&#Y
M"7P+M\GEQ_"' C"S[6"A&'[J>]V0R_XA;X=)>;SN.S_#";TZN64QX]5(+>-H
MF$N#R3VC_BJB,Y21FMSV(,WDHKME)K 96_J,[=M+8/*S4+<H+E,,7<_1@LCM
MYVO,S<^GR:^Y7@-INI7\E&2Z1NV &B.'1[>)C)M*G$M-6-FECC=3F;@7A:+U
MW&A[7MBLT247-H_<4[P]7.)PB<,SJS8CV%B\:E,8;XV_.0=YUG)=/\1M6)56
M=*N,N7GW03B"R>$5<T''H?=D 9AZ_J48F _A:=/BB^=P>2<%V),E1:X^16+2
MV+4(D0A//$?<"B<R"6-D9XRA0\D'%HL/%*,./D[D4_E#2?W+2_TO0H>OPX:6
M39%^$AV7U/K2U%H2RFL02N0)125?K@Y',;BO9I;MB\!O-NH[[^$2\RCS5>;Y
M^*S)#[_J,<F#:<_7NT37//$% -K%Y)?028YK$'CG6=3GDH7^.*+,OO91\"8\
M,_7&0^[Y?>$]\LY']V/TI1,>:[Y.+__Q;;R 5SQ\2@/X<:8S^N6=N'\/"_ C
M:?, /J$/>IPY2"*_O / ]BN5RB\#*PB'+G#!#F#G>ZM>&X36-5!E8)WQ.^O2
M[S.OJCZH6E> U)T/5I_)KO#>6WAI;6W_EV# O/13UCNL+]SA^\>>0]<&X@=7
MKX4GO<-'P3^#_06#[/_^5WV[]B$+W_]97[>.!7>=]]9EY/+U"];EUOKZ_B^P
MM>:E=\()>_B0VG^O9;YH^Q(.8CWT!^^MCRZS;ZPFP!SXKG"RKQ^$'RQ]<=L/
M0?*9Z^L;6^:.!#X\5?UW"KQW&?@6;&N+/?0/%K+8=>:*+GR$R1JH&<P7$188
MYEW:X?;^E[.3ZZ/#RM5UZ_KHZI=W[>79=;."JZ.#+Y<GUR='5Y76V:%U]-?!
M;ZVS3T?6P?GGSR=75R?G9TNUK(9>UE<6](37#7VO6CG<.-BP&K6MYMY2+669
MZ>+X_/)S13T1Y>^]<_]]K];\SATNUM</?3OJ:W7\NXWI=;5ZK?[]._Y4A_^^
M_Q!?/GN[7SO'VWMU>!S(5\_W2 ,1MJ6UO4O>&<TP#_TD56_-\AC:(%C9D'[?
M&L$C[F_7Z\WM^L[:?KVV_@>)\.05"8J4V#)_F$>QI#&")2W/ X/ED@]\&4[&
MEN/[FI!_]'8<[\G(TO%EGX6(&.'[MN^['$P/&?%)6)2&)XM-NW@ >SO-[0]3
M$ HX[-F7UJEU>71Q?GEM77RYO/K2.KNVKL\M8,/7P&NM^J9U?FG5MWYR?K;.
MCZWKWXZLA$,GW+EU<(U?U_<VF\MUVLN(H<>^K(0];G5$8#/7&G(F+0Y6LV.-
MXN[>".ZJ'B]'RG<[&7E_V_G<^V=7\)UHIQ#L== Y"/?U'#9$2+DW"8DS@"58
MW&R,T^.N7M-!).%AX3%M C:J>7!9=\U/S<.>./QVLEOXLK)+F@97EC;WUO8/
MN:V<(Y@<.Y$^JV,'NCMRH,E;CN&38/+:F6^W6W_:[/X_G0*EU\BK,\MK@.6
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M$$"M@>^ZOD6/HTN^L:"/4R=0&NG+J]9G84N_C0[33Q&ZXIE'I'QU PSC-\Y
M^F_D@N7*%A@914.GOF?]#GM2W_VPN;WYTW:ST?SY?:.QL]YH[&Y8A[[ !6_4
MZXWM=X&Z:8.QL+G9V-ZP+CZ?'+ZW-FO;6UO-QH1<N1+/EQ_/SWOY$$LA]G]
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M3(<X8!.?Y\NPXX-FKTHR)DSWIE*@BD^XIG5CQ)U4_E<\0B).KYY:%40$::H
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MP12T"N#O2DS:*$V:K'>K$,A;95JH+M(SR>#47M!)P<XM=_ ATJ@ ;ER:4GE
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M,SG95J;#"L(JJ?K5!-:8?F1]W5SX)8L.#VUE_,RJ*/1NN#^S7FQR[N^DZ:O
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M5]N7POD(<JH"T_<CFC:L+LCR-9H% JC^]R+3 ;A+*_[$R9 X3;BZ.:.-^=<
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M M_!DVS\30&4'^K1EPR%KB"J@SE0#&+4Q>Z[+CQ_QJ2G>ZZB1TVY7/9B=#G
M"GF!C1AGEL3,<,,<HY+Y^12*'@)69 AM+(W8L\_D_AH'UA$=3(48S\S1LV$@
MU0*EDP'?6P@1<*WBUC(]?(EVKO4=?<MZ8L+'WLN(QZ4]\@\2>B!/6RSRS[HR
M!U%LF+>=E0V,G&&8\H[32:Y7HZW[9EHX#$F<#)'3R@?G,FH0?+0+Q,;55KK
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M(81>+!DI$KC.4%? .05J9F_!&@I+==:E^A 2UD1B4<3BH\1\AW]PF6!=_&-
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MCHZKDP;QW'C7K^DH6* QBP%8#,#_B '@C=T5E+ )--8<J;M8=Y>#&H5.>.\
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ML(% Q8)&-J$EI*@6R9].X!JUU. 2@EMP%_:J:9'+1FB( QR^(GG9W';=D4&
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M90DO1URW&RY_%R(%PYZ%-HD&#PD'OW+>>$6\&:8$O>(H(<!<N<C:I]IKB8Q
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MESMPINI3=^MR>SFT'34)*8)=#[=4U?S C^V/0,I 21\:I5WH[#UI')0Y"Y/
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M'=PB"40VCG)>)A6EW>/BCW-9-D"\.]N*<FHBT M5>\@3 ;(DQP0I"I1@1J+
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M[NBX1V9U[1RQ MR&["\:AF32FX.APR.<IS\0$U0W[C>T;2^184ID SH#D<)
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M_,<#J:@\UZ1C(DE'GQ^?H!.&:5HX3HK&N5Y=4]R8;=*^>:3<5=0W9=O4S+Q
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MMVQ;:HGD+BR _<JK@J2JMCA):@B]YFVMT9HL\,0N<'\*$M=KU,BY:5: 3GB
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M%.S!./>2LI-86)6S=\49RF'%9%13[$_F?M_RA4HB0EF7 )*SO@X3A$BA@T,
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MK?Y<=>RW(@WPAK:@Q'9B\_3:=V5W<2O\/Y4OO F=TCIM\UN/6:-4O!WXNB
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M3QH$D@*!2<!<R%(XS4'.9LOD(!VHNN(6<(IE(?]9%C(2"JP3QGIEMOA/I78
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M9_-C3?21>@BI;2#+OSZ.*,U\-B>O$S.;_%0NM"[V#3B$C*N\NLYQ>+EE]L\
M5LAKH M58$Y)U#TP9YZH*>9QD/ E.:GD@0B]S]W#CVVLK@[W:F)4[:'W0*3I
MH!\F?UP3"*R7XK-M0I'!RW17(:<KV2N<P5&>(BRGH(BG8_1:*(KXG4^4@-F5
M""360GE.HQ%*"3?Q,0$MT?52*A"O50PY7KH7NS.=\[BI!/OJ:IG+$'\MC<T[
M(HG(@EFB8":%(4FX]&K($6\50: P2O7X5VWGXWIP*VHFPE*2KW4S^7V6>';;
M\>\"BZQ?;:H[IZ/QM/DA\6YV&+UN!HWY[-AT?<8%A.0=ZU-?<(A/R=2Y%283
MM07QUHQ58.,H C[7!T9,EH)Z-(B8@TE\Z;+KN65G?TJ6(N(%00+2$R/(# J!
M6S6*A<=VZ8HW]%R^ZSQ]K21)M=BW'8QIQY*)15P1'+U2GV"T005R!^_S]K.$
MUS4LU=:V*>03B9]FG,7$R)#7(Y+=2G]\GE[X'".L25WXU,B![@?0,XNX$@OV
M\!N#X69+.:<W40_N-(6&Q(!0Q%F;HE:6;<Y$<UHP"!&2LD.T2$2:7 G.W;2)
M/(KW[[S/%V<"CZ5F1\0NQ:$$ H*8EO Z62ST)'W#U3[Y>)Y'ZCT/?C$/U$<]
M"G/[XM$"<_N@,+<O%YC; G.[=S;B?CX(IU5>\8F<C)P(3Y)Q,#-BPA(YXW'<
M^4*Q=Q)\ZN0H X><\PL)XAU\D%]\%3AF#YR%401R1(JS2'+H>-R,4K1[D"B!
MUU^3Y+9E_0OK)]'U,^?I^JAF/D% Z;\LW;'6)P)R"NK@4U,0Y9RN[X0ND-,6
MPM09$ .!1"_A)#;1%!M*8?:.P#.(08?I8CX_XD^:K8?)"+S W&S?2S9784QH
M_J)@0],6QV=2=Z(?M&3T[5<\"=->7>U,DQ3^UY@(I#6D&.)?$ O%N=.3 B*"
M,_X5*?R_A6N^],)3-KZ9LQ9'8IAYXS))%T]#&P0B@84ND+3+U+^3UEUU2-Q/
M* [DSKXBTD!+NJ*_)/F1<A*C9TP$F6_H*1I1WE/K*8%>.?^$6N/PEZ<17"+(
M\3J-$=(H4:21O=@& ;7[E)70;DD]=S)OR$X,P-O=YCP-6FIJ30[]$DQ'4IBF
MB\T]KF?X0^GG!@)_;K$.-2?>D)S1GLB;4 16IHZ9@!.[DV1JMBXP\IJW*#6-
M:/(Y&V%9S/T^XO!V0[IK_S][[]H<MY%EBW['KT!T]$38$1";HAZVQ^=,!"W+
M;O6T6[J2/8ZY7VZ@"EDD+!10C0>IZE]_<^U'/E HDJ66[2*-B3BG9585D$CL
MW+ES[[77DO=^PQW]ML?TY!O4KP >(:;5B;-CJ<)KQ15607&2?L>JJ^3Y!,-2
M.CZ>INTHITLOTQXF^\HXH1_2)=2'=&Z"\@I;7EU<0*1R?;>A3W=U>"$'U-@(
M=JR#-,HA^-7#.HUT-@<HKALZ4HT3<@P@W>#/8OJM3I*9>;7M8*K_:'H,$%69
M@NN*VR"?AAI?V87J!M[T$^^C3"")I="&*"V%SX2%GH6*=6WL2CZ-Z1;BIP_=
M&UYY<I=(IQEZV$3'^2^[''!ZV4VH[CCZ$\=*'K>E3U2[$JUV=9?-M3-5.!QQ
M3$Y) &J IE52G:FB%\ >?>=$RJS!":A=\]VZ=4SYG@<0UCR8^.S5*@G4/S3Q
M-+6;W"T(ORE8&POX:<6</,;=DTOV0_%/BN*C]*WZR,E;VW]F)!EF#;8A+U)M
M1WDQ#,*I>04W"8 ^(Y3B#,,[J@?A,^EYO4UX3\^=(OO0;:18HYKK$397<_1K
M*;]'-.09;3<>Y!4<;F\\FR2[10=5T/6$WQY(XR3H!U\VTOK_;3A1VBTY]D$E
M@4X3JF"MO3W.GF=8P!$^"+H-(BOTTM,[;/AJ@'*X)%O10F'(BJTP9<^++5;O
M@9\S-_8#;A:=?!>?HB_NY@O/S7)W^C^I8>=W1%DP5(WZ7QK!5).F"+.@,,W@
MTC! X3 >X(H61'SXA(NA:N!E4Q5'1Y RF_9O:]IZU#S(KJ(^8P4D!3:L\#"@
M*R#B+7^0'B?('_-Q(F?X(\4[#L\SF^0?W"0/(X^2EOFP0U[32/M+5*PW3<7;
MB+'2=Y-<(*564Q/B(:-I]HKCH#I@D(1C] OP(5!XK!GHUET.0!1=UVDQ</*L
M;(+.ZN7W/[PYD" SP+2[AY)>1&Q'X1>X.=*>(;I'2"CF>KP2 -'.X>>0@3@M
MM@E^A'FE_]%7NCW.'V),VL KQ(631N4)$B?;M\P<\OS1K>ZC0I[E9<-\L0"M
M5KW=&RA=:",9DW,?NO8$ABDA_,W!E7-/2S=N'CYH)"&RO!6"6LCW<JU%M77#
M0K)D%6;+GRW_<,MWL%F85 =8)Q4GAYK#=1L_0:#YD2:>1MRUL\W]P6V."_@'
MGB]C&EHY8#:UJ]YZ/7,!^[B>UC;G<K&O:_XEP"(<YF@;"!36LPG_T4TXX&'[
M.!F[",215AQ(V%BA1!%HB78B/0^B[NZ#5J3^N"TL:GWX"%&R3)6*<;$=;BR/
M/Z!J5"T!!=!*RTM3#!6-SYY>JX80'6MCS[7%@0&4C8?*CB!U3FEG#_XDH_/N
M[A'5L2*U!8<]#/LZ+"7JIR#DOO9-=L"EE$+^3S5L.COD:&1 FHI)QF92W[C;
MX?'<[?!)NQV^F+L='G2WPUS7G*D]?[5PI:P)#$)$38=LC6,< K@V*5D>"#K=
MN6W<*?(ICOAC]9V"1#AE]I3@GZ6>"'L,,D;&?S$ ,U\J8XU"<3Q(Z-!L?H0V
MBAM2>78TZ[-F6%TS!@>CRJJ]E]R+R9-[L(@F/;T-D2[+1>DIZ08^[0!QC#"%
MR1"$OB ?]5MSSC30Q%)BPN,[XLPZ&;_VV:1ASF@<2 BQSABB1=ZB(N9P=07_
M!T7>UV4'1K>:.I-_HZH9$JAQ*2QB[@P/"(X98@F.!::Q/&@41,E W"0X"#!5
M$/1&33!9W-%R'7%OJ!@DB/;<0JRWX4+\"/5FGF&BHPC?U;RB'_J*MEO,H8N'
MMB/:;%NSXAW!\]-GNI2YY.UW- $&\5;/$G9EK/Y\&&F\W0ZE5X01B0SZF.+H
ME30TQ0A(!A1M?DW5"Y#2!9TXQ/J"U,#7!T8/^?*2%@2$?=?"1QEHM&(*A$1?
MH;.(&QR//A@A\M:NO*:]R)7@[T!M8?MH+]Z^EA:X4:*#(@<AM:&AV&=5WZ5-
MA;\HU9)KSZO-12/$?H=1M]<%N2MFGH[HT[D'S+/M8L3,^.S'.7N2^^I)"G/%
MYG+P.2 &#%*<RP0]<9\85=7;9B/U3%':XA4[6\T]M1I./AP8.5U/NKC9".ZK
M$1R*>+8!A?2PB/>P.PGO7F:)"!KQ\!1_').DH9GA*+5F9GNYXS _R<%/6ECL
M'\'T>W;Z=91$Z>B/C[^68Q^E/8+>KRA5<[!8(]ODK-]R/]J"I"LZ"?M-N<?N
M5GWW$:,CLR!22WW0-JB @S9B9N/O:I9 "[,X>X%0L[*S$I+F:2<7L?<+C^5)
M>NY.06A1W2=($F!WF8E$5%)(]IFY[H(LA PHMS\H$C[-^0B-^GY7%1TFB!1"
M[FF'@N][TNLXKXK4Z4+;$R>N>;>$<!(EA#%FS@C3LC<?'- X)(X3\FUNW>QP
M2.S+M;R-@+LN[I^CW"@-4SE&/=E?XE_LJ/=3WVFVF\C:E]3&%^TS9.$W(1_#
MY]W>I[X#(XS8:32I+F?RT&^9J1_=N24UH].S;PH-FIP%#.N51A)0 @CAZ;[^
M4[V#HS!5CA3I2;0&5&_3W;G=@RW8)5+EMYMT57/-R'?\<8>.URD%";H7?_S%
M--;F"N5'#$;O"#EU]%U>"4)HW%C;\0-PN-(9IBIL\6.>,$Q1U$.>I;Z!W*D"
M*_A(9CHZ78^H)=9!3G EV3RR6^)D(:.I3%XD?9.EM_8XY])&?+<FYQUC<KH8
M0V57EYV5:DLWUZ5M_3;ZBO<PDN\7MHB?N(SK)3NC8$ L65.F+<V KM+4B-$2
M RSX_FG#]]A6!_CRM%)<ZV96V\SI5@4KPIZ&?9 :+"9NJIXD%Y"F[H6)7VW2
M&DK1SGW61_0@3!'PTJ[NA+?JFYA6;PT4LCU9_C%S;T#6&FJPH56366"XC5_9
M:)P;HGP*7#:Y*-:/J[>9VKT( <VT=T?X(*]6(I0GG?FN I.-/8X8RVWA*'/U
MD@)@2G34\D4G>"*Y:^QL4G9;@VXH9]FAH;8^+>0"V%QN.QLQYF ($&9^W@0O
M35[UR#*#=S'?6C^K1%K(E&.82M'G;WBWD%KXABG1'A 5R$87#&ZF)9CA.S-\
MY\:LO;)=?D0BP\=8N[Q>1Y>-G>WETS18 !UQ=5B^UAY@;%Q"Y^/,ALM4,EX,
M;6'X1,.'-!1M[3'$:8#-!O0@#>C07#_X.6W,JK)NU!(6'*J.OP%L-IK?WF@0
M(UHG4TLT["-4YK<QW;(M%_OT+OQIOD>6U<M-;9J-,@L?,AAD.=HME2V1P\LW
MQ]D<.]OIOS_,C^K\VW_4X70W)]QWDU&S#3U(&SJ\&-ZS03@5>/8U/F>I%!4J
ME\=*",H<?967%:>;R-MQ7[\77SYD*)Z X :QAH6*?QTE.<9LP?_^,*WU'0I!
M7IK"VJ3V-_ >Z0V7\]_"=[%D'=6P1C4FPE!P]F%N>+_)$LOUT%,V?[;9!VFS
MF[9<'@I$8V;5KG_D5#?JX^29F@WD]]B6E]6@8*%&Z37WQWIE'1*FL1,D>0\R
MLZM\N02]^<5@O1])@\]F-IN9_;_(]3A)W.MZI!A.O=,B=M-)H2> *_BN'A8^
MNIB/J _5P*C4^Q&Q/4+[O*U)HX=X&ZT3*L1K<7'2&I@A3E8J-D]CFF8JBYC*
MXFRFLOBD5!9?SE06#YK*XM.6\X_28<RU_7FK_T2]O4-[V'G60UM%:)-CPY)V
M>Q(5!#(<<DN>!\#Z,OO:200=\.1RO1C:CJ&A% =\9*]&A!V"%EB^#G$]Z0^$
M2&JY*,C_419H""ZO@'>3GY<DT=ARD,OB@X<,(GQ,!C!1@LJ+6R'QY G4)(<0
MJ)".9B!=- 1%E=CHT'P#(_[D'D!P=:H][T^+W5%V-LWK^1BJH+E@\U #16_'
MT#]J5H\VS1(8/"D.Y(N.(B:RJCLL\D//$,%BV%DN<T/4_0 D I%Z(T23_+(<
M"[-T06(#A&P&4X*Y(E'CO+#!.5QUA28,2N9'L-,05;H+)*4:?:(6':&G'>8Y
MV*]">;-IH+6.C/L?:+^SXU_9HS)OBB?IZX&874$O2[VF]J%9(MHD H]-'3Q6
M$ 2[NX?H^=HAKLK^-EES;9(*F@'0*F5_L71Y&]3Z(,>Z,$D@)_P C.SAK)8Z
M\4TJ)+/,_0(28DVIEPM9A^]$6S8;XQ!/+KK VW<47>28J4PVU:6D70/)'G,+
M^PQ.TN_ O_HA1U</M0K0QC#NC0(/&E9"DU8-P.BRKI#I5EQW0]1!6!'*G'Q!
MDK44B'F5:]YWW("E*VNJ_0;CZK EE-VEWJ0 FQ2\!K=83;5?V*$%K4<R\5R+
M3J3U@1>^XT&QRZQORZ7P0)$FMK4;O1ZFM.RYFU%HXL ,MV\MP]7XMU!MJ36H
M,O$\)WLXJ:AYBGWI+<!X5-]7YAKCD!XH?;:P-DH=HM<LR6(?,G/.4&Z2:)1)
MO4U04ZX9?W()>,!=.EEP0=85"R:LQHL4;ARZ S>TYA)KH(P&N7A,LTM&CX73
MJ1?M[O-!C#LYIR7Y-3GI=A68QTA<VG)9Y>6ZFU#QH*XP%5R(NT)'>K+:'.HG
M/)#9#MH^[TQLR&N\@I:TZP+LDJ8.O  M?-XHVK)[C\X_&ZAQA%7E;+YY^A8?
MO;0_&'+72?A#J>1+Z3M.^V]IBM^^_.%=1IMB)PKWAA#>Q#FF/&/M<'&2_& '
MCX N\YU(D7=:&,>X5)/IU$W]B-H%2WKS](J")R==[KPM.NF6M=>R<P3*(NI#
M7C55U5PKE50)OY)7B2]>R-AD+&'+)4WS14,5CJ6I\[9LM-O.-ZIR%^:A337S
M9GM$#[+3E>><?4!;=TA/GO8A!WN#W>W(D*QIRO+I! H )S>8(NQ)YX;ML.4\
MX D-XKJ L S-Y'5GQNW[>S&"VC+J1^A<FD][1!L:A<&R+C$3R%*P;A:W8_DH
M.;XNT3&26^+)5:UO6M';G=4\E@4K22#<]\JG0QVRO[O%3M?9N]CF#L5C>Y#=
MY?91/;#RC6#SC/9,W2AA5-01P-@P^X3H]0<AKCT"Q2>E((2K10%!+FZ0/6.\
M6;!]M.+\=:.ED%O&SP0.=!OG 2(#7U&8",D!9CV0D(9.@G;^(';7#131Q\&D
M]*>'R<TWE^B(>3JF-<B$G\/%2'9MME?&/C]MINA-;VKTLP?]6(E"DOD NZ\G
ME-KSI]W<O@7-F1S=C->A.EKF/! Z0I?O\PO\,^GL16QHDJ4%FGS*Q<#O6 8;
M/DO&?1T]J:M0<+%NE&5YV;3%>V,VZM]8\D6V?]<.<N6Z4)DX(YBUI*PI].3P
M[$?B*8F>3*-#^^2N&\G+2! 126[GS6#>NL#MCP,;IGCHT^^;IDA?Z+M\ ])'
M&UYW&O$3VR-%A=^_>&/_I0ME3&JA3=VP3[S#R(QVZ1_D=2#[;2<&\9H_1TF#
M@UT/(FAI#3!!=B5X__)<]OZ\A['Q61?0V!64!K3?(3>OG_ ;*';WS1-T.#H<
MA()WP?UF3#'Z3SN8DI*1@#S;%:E_H#@UUQ8AXN;N-@USD%+YPM1ZT&#[X1DH
MFN5 =YE#N"-Z$ C8PY2L#^3,@-.MIG,YGW1R.J1@^2&_QJF1])N_LQ#VJC=M
MX+<CMA^X[Q6?R';BD]&.02?AT%61$)FT*@:X%RRMC+F3[7CHS,U)"VXS$N-=
M@CD>647?BX3-1S.'A("0-4X$4<0U?P%Z7BRT4FBPK3<J:_:P>A^O"4AY?<GQ
M7U_:W<#8+4+O"R_["*.W8Z(#CS\XTFCYA\I&E>E6(E[V+TV;! R[I%<C[G$[
MKYXC>I"?K4-%L+\1+SZ%\</^<\7N6'7T1.-TLAG.[\3*/\2;L35;/3O;T[Y]
MO.@<8)=PT@Z5(%ME8Z+[C,6!5\9:.A:J/?WW[,*K!HNBRJ\[K4O]5%,FZUW/
M!09T@HHZ6V4N:(^*-G"YBST<V:W"/NA)\FKB.AQ?QDO<:Q!WE)CC<IE?M#L/
MRKPKH2?AC,-/)^].[&9/3F!#U_[6.HKD!_<:SBE%X5G4B7<03H!N(9$T;:IA
M"!U0OHPD:85K+1."#Q&QHQ)U3B!0I=JE[YTD/QO/S.1#/T1GD+9@)2J$R_)?
M_67;#!=\,%O:$39K+:S#!=<&11E(22.W0GH1^<"<7_D";@<O,XAQ,YJ\9N@3
M#TC,_+R=V]CCT7^7R_<+ -[PM@;P?=-GW]D1&QM/4;;N'",.S8&-B._&GI\Y
MWC*AGW:R7O5%YP[5V!:*1+AQ H(5NC"5D'"J^ O7?-CT.<.IT 0E@O/ZJ,99
M+L:L" 6R@?2M6> +;_C'<LKA59"\&S8PK7=."BVPIF\-KJ\<Y_]C[.*#29ZO
M[$&\[0*:N*#*JH&?("BF4QK,X/6!5QQ.#4%H"C\/_C,Z"FBHS:]]RT/Q>1#[
MXBKE4N],Z&BH) A+"XY(X0CH^<03\+3C/29\:#+TDOI .6VH\<B.P@M_QMA/
MTG=B!M&*-!_L$D\I#120L&%,^:2S> #[P,%(U"<S$O63(E&_FI&H,Q+UWOF(
M^_D@48F]O(6Z-$*G<+)%MNT!&T>8?0POX#-:>P/BY'HB%W\3U:ZD6':R;$BW
M,%4:PC\^E%:NM"T5\S .E](E3H^)XU\M4%6'3L(F#$(U!T0)(__<&69!'C6
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M_>N[C(=/@9M3HL)@[#G6/HM]$@C*HVEXT43JO*Q1;2^5!.$C%UWB*FQL]CB
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MQOHYU'S1P,?95K!9:4;\\5>T8!X34%WSD^0@83S8@@@ISC_T &])W,/2N9Y
MFY*DFCP.Z,4/[U((H8T"T"P8B/W-WP;[@FD<&(T@:^A5=6( ]OC_2 B 6R=X
MK;2YJ]U-GN=G=P.S)N);N!0C5-IMQC6AJY$1SV\8KZ=NURX+2N9*W4AK/-&H
MZ"\_H_I+!%;G2_LT4@!Z8?<PBFJKLI.X(N-2:=XG%*#8SR:V7COS)7>"HLV,
M.^32"S)9Z:_[\Y-GPK-B5W=_B>:)@8A9J"-IH"(.]F6Z&WZ(D9Y0P3Z>O#V[
M?R"V;9_YRGZ>:TE+ZSA!(*7H-U=>0U B*5EZ]A/KU;:N,BC9V+B&G"@[DZO
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M8A 1(TD.&DT@3MD@"5 2*874\;IF:'%,V?O.B/]HARF0@Y #7]*-H50PS-W
M* Z&)H%>AR:+A*2&3I.*UP!0MBY*8G7].J2XQJSP6PQZ5JYRT;;LS')H60GD
MH%&XQD<_,67045BVRV%M!U!3>+Z6UDM>\$RKP]4BD]L_\'24==0E>,A@J)&.
MJ6"X=9 20I1Z\D2%*(P-G:R592XH9[=P6#/C.*'#\[GWSNA@W<0.]7DX,#%7
MO#4#$4E1S<U;>%?EY#?!1/XW/.'2S C?HWV0;PP*:2:13#6."@7KE#(+I0N/
M\&F=MVUSS0B],+.-K@=_)&>WZBE:@^Q!)JR;FZ;K2B8(S7NF-.3&]$0@C0X)
M&! J,<1W$>&+G8BBY"6:FLIEI%&@!$9XA)EXZ(@>Y"7O- FQ5K* -\P@)+O=
MAVDELH92.1S"L//NB$S^;5G;.//*)* (Z',.K$0Q_-6$C<;, P$5I@S$83S'
M#[(!7)P">=V;PU&+5AF(O,3R)5M/L'(_9"IX\W*4D0M$=0]8U^>K;ID,$G;#
M@+W6&S7CKYJA+J0%:<Q/*\%,X"!$U&L"C!0^A N0W6D'HEXB7Q:OZS 0HI)D
M%I<I0^8-&^D$R 6'RE\QC^((X$^;5!#3"X_#)-A?#X&:["3PL6<M5J]HWZ&-
M^2H](M#!8% 5N&8\NS3A?@;#R-A+K841KH-#D,%<7S;KY-I3EC;@D7/&QBMA
M]/I@<V4=AGKC!8-W2+"I[<2KT'G7Y@F\ZVCVDZ"_PN.DW+QW.YT5^^?\5W73
MG).[7Q[YTX_Y_RS^ZVW9O>^2MT%!'<T$K^R=2!0=)>PW($!%?N$MA(^ZN4'E
MN!Z$^[)>]>#AQVFR7$)DE/ ;=@MCWRJB N1^RO#=;O3=MO1NV9%=@U2ZAJMP
M6[()=0D\+3G]:&Y;.L('09]>D-(31JR0[BI3OJO,"5EZ!BW[MI$,D01I85;\
M@U5:&UPG;T4?%JJ7H$4G0W @OCYD;'/2YJ)Z%5!S\?E2,C&=N>EJ*:<XL7$9
MNP<V(K&K/U$5:#J,+$J8ZJ5/2R;@7K([V:6],'C(:TW-,%LL!7^\)YH/(%O%
M!M<M0?A.%49.[O*"^>> CNNF#CN&A+Z")9B9>*I>EIN*$K8D!CW4-A+ 78J3
MY(5PJ$(@NG1TK?(<&D&1@'3,TPK&H^!+)/,J;85T!<ZO28PQN<A/TO- WS?Q
MR]S>!;P:XU.?P![#7&:.EB5E@Y+T /TG3>961RCQA$Q467&^>N"P9D!GO=W,
MH$V2^*<29Q*\56TFW;WDI:GHBHU>BE.00PP-PYW6Y;)M%D0'9C^@WHJ()<W:
M22WB;XD\H[-86B)V6HE;B\FR*)5WQ<)/VFWOSB&4=,-3I#RI[',';\F!]4H1
M6W!JGMNL3<(AS4?5(WH0YHJ_@-:WM5HYH@7;8HZC;.%I(&)OMM]DB69-/%)&
M>C(XM+$K69N<19GME:V;MLY+*-B2\,9!LE<IWP@D[3=]W=XW$%GHI<_S@B@N
MV_2],1OZEMHGL6478#*WQR?6^A#&@$'/%?4V_';BO@W)'KM\6/2&O0N6E/A;
M1DU/^HD4R20N:T4>GW8LE\86[GD1V9QP#<G(VSC"0^OM+L%H*).OKX7RE790
MU\;?B8ZYM"D4SA$3]ST)RFQTKQ$&#O@'C(CT+ R<:Y=P?7U$3<YR1\::K Z\
MH43JO,J/Z4'.'>TZ]D@;\< RH+]*#7?$(&O</N_>N'/QL?%25HLV20"'^:4[
M2.2-%)R9P!81>%'B@Q*>1$YI0SKJZ^%\Z4#@K%ZP66*/< E_(:&E8(^FSB@-
M(4JEC=G3E>WN'-VS2[ U4C-<8/F[-^,XDOENUNNF)JWUD_3[%JF(3K24W.]]
MXE;;H^DN8)#+RTH58M;&]#)GB4I3^I1SK!7I4P\$*;*S7-M9KWI$K8NKLADZ
M;2U'[=_4F![6; J'N/M U#E&$8B,E.<CS&DA@8W,LR!65>I! ^J@$TQ>!3ZF
MS<&I1X1U1,J7[,H<O!'/9SW_CVT.R:;V?<)UF<S58-Z]^?%UQH51S*F-3;K*
M!G>DZ:K@6ONF.3D5#) $SX*XAM)TT&9J<U2[-6B1\%!\W2@/M&@*X9O='3S>
M/G$,9%# (#5/<"()PRVI?6".O(V>I.]@YFL#_8&R6[OIMW/VR'S(D9/B=C\H
M-J07;4Y231 >ICP=;,-:&U._^C5;ULXA1]QR=E@G%R>1JP]^)H,)+Z1B6NC]
MXU;=JT9W-?NLZ!==4V9WY2+;&\*!6I*-GF^'LG%UDU:-720"JM[' -O$V[B7
MF4!<;6<:ZEJ)HQX03Q88-A'HADM[=QE0P")G!G8L/Y>D,-9I'E)_GTG/2(ZC
M518D%GQ,D.@30G('?10^YA8%+NK![3-7,\=U,O($>HQP;C2*N)KH9,5F8N>-
MG/E0Y]=P3Q/&GR G&_@_=?Y03\F1\P05TFC:=F=MRB'2!%R3K51@V\A[:AON
MY11.AQW37D+CUKJ5+(G]1)B J6_>/,1$<]PF/#@&E^!A<*>*Q^63U%[G93\H
M+Y XU<$_'I7][<C7KV:0ZZ<%N3Z[CR#7^Q3A/IA0_6=(ST.%LZ8NID>7S;4*
M5]O0H$/+;-^%Z6^76K&NF#8K[C="02Q']^,U[4+7Z .J2G,UY7K+SC.HV[TI
M)Y*#A F#>"_\JTJ3W3 FVGI<KMZ/T.ZDE_;\BB$H;,_8K;/9&FK$7B+2*Y>\
MNNV:!^,>$Y$A\LB5$TDU'IF>K&&@'ZU/G&6)AWU5%@P@I.T*.0V)G*\G*>?W
M9!7BAPI+EG9J2(8M">.;(*X]@1> MP%K/'JP\Y82ML%S<;HXR,(65R7)&;-H
M&^_QF+J!E/=2N_/EDM"-8'@4,R3R7,%O3]*7+OVLU ["\Q >X4H*\&$F_)*%
MZ)^($4>GN'@Z("@+&&*GVF.]M>:$M7:IJTYKQA*43815$9,%)#U[E698FYX6
M2Z5)?4EY.DN/EP"T "7R/$E_L%X1$:0-,(*<3R-,8%BM* ^06H.3E@LB:-?1
MFMF O+]L"GY3:NUS,N.('N35"H:/4S3EPYG6C Z$)4LQ3,26L1V/]<CWGSIH
M!02YZRS.CDL&@_ H0^0CP@6;2;:.OXPPM&PG] .MQ3I2/=%W820(A:]HAYI4
M'F3YR![;!HOY\*]Z%><EZ0SZ]FS%1_0@GGETPO+89ZUPC.,,PDWU;?+4Q-4X
M,K1:Z37((W92>F*53$I_BW)FK$*2<)7=RUGRIB/HZ;DN?H0/ BO28CAO=%VH
M^T1T*YS>9)-2]+) ()S/"CV=MRJI7L;=,=K40K3))#,*@0RH=K9V8$6RV#I]
MI# OV]JPHV6>,9_LT^Z _29NHX9"0J;<9QO#)J$P1Z*UW61A?/Y12J>3CTO9
M'Q^Z:K5*KLIQ',T?]4&C;F*7:\&-'RHAO)3$( E^\T6)>R^1$(7RMU2-AQR]
M#>L6%)UKO.3N3I$[<C"L"4^;@<EK@=IINIVRE"=IE-<?CSNJ(#&3"&^0HG6$
MK7 )X$"/G=3W&^F10&)05(P]A%%S3),O("ZKJ[512G#'H20>9[E_^R7J0%>3
MC+] 9MFZ@6DUKNRZP13I;<5VFD&TDRD04&2GM6XF5Y4#"Z4QM<@6\I)HE)^Y
MH))3E2,MX!LJ(HQ-2D*QW'(55D#V/\.UXL5]\WHPS*8.!E*AF)!W3<W?LD9*
MS(*NL'F.TB<70[R51>Z"TX)3" $W#$3OC]Q90"NXGY@(]FAVBJ-H]9T[?1]"
M2Q,2'0=V*RH.TN^M,Y?+?36  BP^AW)WLKO5LQZ"(PZ+W(F5]26)UZLVE7CC
M.F=W/AO+?346.;4=9"V#M"B$@0EG"#4B"8) W>==B7%#7#W !4F%%\SUG&*F
MXN"A-#/<KJ&Q(8FP4!J0RN/Y]6R:]]4T)5@^U#21_5(:T'5C#T);<F*45.,S
M:G!0DRJT1MM NH@MT6G)??'K ZUR-KH_G-$%Q:.VV>8X>KO"#GE'5T&:V[N/
M]D$(U)6$H"X"Q(9IGC KQ)E1S7S>G'^@+7-A8 J<CC<%'Y1Y9WRD<'N!S2Q9
M(ET@DX-/,6C'IK!QF/=2UC+U+TT9'M+#7O 0\G]KFD0^0?Y/V\A=7H-MW7.K
MQ,RWX="T.,N_D+I*[O()HG5=UISW"DA7/$W)Q%"3NV=TNA!@K>T;UY>&TH,.
M9:20)6G.8%C9TG41.S2VPT1+"B?A!OJHMU<S+"Z%P:!"KPX^RJ'D2W  A#D4
M"))+#B4J;$:H,-\"?FT2Q=45!CW 'YG\Z@2_+J]<.;6CE$W<VC3JDX$NGN"B
M"L-)2U=<SNWB+4JRR)U>V  BZ#"9 F@-K,;=5=]"EXV6GH2DB6SDFB_:B5!O
MS1#NG:*X&$*J96'?>N8%F%"_YO?&Z6AN92:>2YS,9RC[,3U(_ @W@-CLX\X@
MMD\*8GL^@]CF17I7$)OR-W@@-)6-!,4E/:QA4\,Z_\7Z\T79[./ALPZ]:=]S
M'9-3%2AI1,#PH,C7=-Q/-MXS>%.0)E44+]G)H\I%8<Q6_I#I759E%1??HAI,
M6/ J<%PH0OHX@FJXH(Y0V$'GC6\1D597!EJ[Z$1B *EHQ>T&KD3#N9, A:V$
M_4!#$00K#SI*( TRK#=:@'/WY*BI[_/E)8<3AHC%;[@U]5-TTLN'GV=184RB
MM&!<S-C6J#J)#8]-W@K8H+Y"<S%(-="0!Z>2=ZIS$$#0(^RXHU/48NB_,;G)
MOLFE,"F*?WK"E$M_""XM72L_,M;</L[Y9@,EDV^:O"U<KPBWK4Q,1G-EW"))
MI/LD)S _CX(VFP6+;YI-@QB6*$YD+G3"M!K*W09Y)US4"O[[96A=[H23;3P.
M&P/1&&&H*QM"@F J\>W@U $01I1^'H-.:087I2_1]L*]92R2JTWQ68@ &+>5
M[- 3T1PN3)*SK"6']G+BD.SU') =T8,PD,EZ_ EFG:#7'JVJ,/KKMJDOF"GA
MDBKK=A@*!U9],0_?#%M9Y:#KL,,[UX.H-["YUFZ6Z$4I7,M=" Z.H+3-#MZ7
MEE5)7:WV)*)W:V?@TS$^R'D'@IB@'5-]F<*3,M<#S2\RDN*ZOFQXN\!FA?Y)
ML'?P^T9138*5&R,23TL\AATW(:%MQ/!Q7O67).A;NQ429(VHOY1)TP!,9U7&
M*1(Q#4_X^.M66^(8VOQ"X5P!-;)A"_,?C,7,-<-# 4\DPS6]*-+/E$(,B7@7
MB2&XX"[46!;47;'[G' R@7O8&;#Z"WM(1YZBY_F(&(JQWM-HO8^Q^\D.=C]>
M_7L7>_IWOV/)O/N<!FM#&51>'9N+<2S9-VR$B7UG_$O.+^_^^*.VRG3>*H^<
MA8PC\M?7!.,#%]D+<EDVWFR6[]-?>U>YC[QPOVGP A(426!;/[%TA$.=]?M2
M58@#FU4%_L/<I0ROB#R2P^#_;099N=P/6U4LSL0%[BWO3E<VPL;RU*!B7J9'
M]"#[S('C#'L++%H;=P0&<8U6_\ J.NZ8[^R!C4LG5WF+"(,HMZB_33F!.1_!
M.EW;!NGG0=K<FNHD>5?B$"=V.#4,BE^ZIBI\Y%/2!L$B.JSIK<GZ5V]>TRG]
M;T-MTK/3LR=4N_ /^>=G)Z>GP SQ'3,1U69%GP1$8V3M57.==CF8P.B7TP/C
MIK2<,!X4UMN+/_X24_'GTY.S4WOIEH*@[\RB';"KGGV584Q/&6Z^?SDF#0<^
M__C?=R_3<[MM@T25UJC./V4/<MTX20N\'M8+0RWU![V (,#+TL7 '%A*5M0W
M,[1UAK;>[1I_4&@K\PL>"A!#B+LL-Q0VP6]ZCTKY5+=$W9E*4H%:KR-_X?B(
MF>G0U?H.&8NK"\Z8M/MJ@4LFICP476UR$E/I4F1"UUIL;@W5I^M"+&NQ5745
M9DK,JVW7,R@@"!^9,<J^^L-U>O22L_W=5_OC..8P120&F=0^\-DM8\T&<5\-
M(NRT/<0JD*MR[9G<@5DW5[G#/=5V!%,<6<3'17V<L\W<5YL!D QLJA^AZGH'
MJPDM99BMY-Y:"9_X\X.UL:22' 3/&QOH5"5W$%&>7OY-M>_N!LJ,V7CNJ_$(
MAO/0 )6QPOGRDIBE\D"Z65P6R,,K&T0W]:2(\VP<]\$XB#+DL(UG8?IK8_C$
M'@I7<O&,FW>X)9'R?-B'"%)RF9/1N#U)^1&$Y>8C?!MG*H5R%AEYO?9LC_?7
M'ET,?9A50L9,9%)O5HSQL$2IUX X?2V@L*!$NZ D]F&1/!/D^I+_;(?WU0Y%
M^ZUIMP<90&B^G@#&+,M.07?^PI$4GP=%$E7C%8=GK?F%N<P.]8SB=*GGL@R<
M[FR0]]4@/S+;21:U!B6^!^MUV+.#W1I,G=P?YMDOH^-C-J*/:@]SBM*6,Y\A
M_G#6-Q4B0MN^Z<U\S'Q@)@+F]4/, \&[P!>IHX/^X!H/Z=,%TP4$@JJ,0$ ?
M,'$BQF >11 >-@Q?Y8E@EU.&.-$9[JK\^TC?@R_<H;'M\=S8]FD;V[ZXCXUM
M^XSJ*, ;O[,_GM$;O^-^_MYL/>_4O%7?U[<OL/5#P3M*!B"[KJ/!9^IA=_#%
MCHYCJW V-%V(LE1<SVP\]]5XT,QXB.&@<0/9MJNF&M8CP.?7L)W9$NZI)7#B
M_C#<G5DV=;,6D6*I$#@L7A=P1CLPK\_7RI](G3CJPW:T'@<-!6S/Z!="B^W,
M G6L#_(C6J@2??7$B4E:KBU#\ L175N.,/H C:M,6+6=5EOH;P2C"W'21(=6
M IDRTPF!E+5/]/05>EKE#A!J!WQ52U-[UT-93C7LK.&5D"&QMY/;^R:33-']
MW(FXC0Z\C+QO5CV:T&H[_?T M'IPA%U6>=<)9U(D2!ATT(=:L<%/_;?MFE,Z
M+4B%=\0S,&I02P<[^=34B,V?64X%:F G86F<5$5,7^J[U[AL%]+VS(TR1_0@
M7L,BH( B25-5O01;&.2).^%3\GJF"CN)VSC&+8_0+-1?3W29S$W91_@@L3Y/
M9[U%M]I^K$5DJ788\P7:#92T3'H!0'5-(-GX&IP9!&7'>E@GZ O&?19E(>X[
M^':VIX^HS]\;.Q-F(V@%#';7]%2.TANHJ&"6[[%]B IE34*Z5R8Q(MXCWGYO
M7QGI 81"0=N1WH_=G+BCT'K0R]S)NX0]89?6]=N?I=>0$,,CV%\UV&D2I@P1
M^8]@[$I8YS31)TA$ZJWN&9B@VL-_6MK*2!9Y4Y7T"Y('GGS)]&Q0&&ZN=T=N
M+[8P1%J#WQIIL+8VP!)&_S(3VW&+B1(:%?S.WDN97L;7SR+-&_XDX3O31E.T
MS8:HZ!8&P]NQ#D<Y(^8U;5:AMHYTYVMW?#@[>Z^>3,W;O.\=T8/POO<=O=MD
MF6_*W@8\I"/-,65A-T/KHVCE-M?V_--=EANEW^'PC(XORL#(OJ$3:=J@=VEN
M#S["!^']C67#<R? DZH=+)A4BMBL[/KMPQZA3(J=LL##L%U[V.R[1V$#"7]O
M.L1@0G(TQ; 4L4:BC4BBR!^VATIJ6U+](@S'R22#(']G^"M2B \&7YA%'PV=
M>2I&?Q9_'LI7=J:&O#4A5>*\7KS+,;-WNW8;__C2PCX6'3+",A_VG;94ZM<Z
MB==.F!2H[(2XY06&^[Z[92*T/=FK=[K40\ 0W5*#<Z0RFHQ4@UJ[Q=;V/^U.
M3!W'7N.3SX%3*#1@KK78'> K>%)9"%YY52F@H$GD39HVFSXA+B]5!!KFW>.8
M'H1WCW?<S&ZMXZ+$>P*H7J(%*FMC+=^4C% 0?KBLYNWB"!_DO%/->UK.+)S6
M":U"YGB.SK[,OCQ]FCU_^B2@>Q@Q3I [Y/[G'IZ=>0ERG ="'H/(IA0C042-
M& EQ0(-P8=$V[ZVS!$.B=2F=<F@+P,&ZHMI%VD/;#2*B]W:PUWO\]&E&&)VA
MNJ <*W-KXW?OO/\^7_991 ?'$FT)$2B(0^4?^HN:#VA^I)$3QO$#==_:%?#5
MV;/LBR^>[IL<$B:1Y%H#*3W3:MJI-9P6]!,D8TKLF%Z]>9U6]@*/ADW'6B="
M,'H^7%C[$$:*G^4ED>\U*&2M.<EHP__RXF*[ ,"B-1="$PFA0^?F"2W"_%*Z
M3[L=L:9ZA'U5B3TPK QE"/T&&7Q.DVT- (A0Z]]-%[T3?C)[HZT0F!*#HW3U
M!(-:$5J4,36K=-C@MU]ESYZ>9<\>?^7H-5:C<^XYL:S[4$)_O[.I3YF)G%3=
MWW&*E"'P"O *UKG+Q8X"8STTW\;),KN](WH01PN)!6>OB?CV[/1K&RRU)-5R
MT3;7_:5FL.G3QU\'?N1OK[]Y!P\B HD!F[Y3>M2^-8Z)A04.&VB4<!"Z7BPR
M\-I.WI\"6<38:Z1^=@R;!,GSGAG6F+C5)?#G/?<('^2N9I>IW>40SEVI-.J4
M_;G$H/5-N9S/5LX6S0?#K,K2:21T3PG[N)TDF(O5O7'2B8#9"L/:#BPSC.QO
M?B#[;7TB3UR4C(B+TIFXZ%?%OLW0M_N/6L 9^A"8 %=YPW,_I7NW/M6;V\78
MD^*NC=Z$$'5<_7C'?3SIT].GDA,Y:!#O\G:1UZ9[]/I#94-!Z[QV 53[X<DW
M6/1-H.6;%L+M4.:S&<K\::',7]Y?*/-=#7!V\K.3_R3#E)/#8;V;_I01T%GC
MF)V3MA8BP>5 IP0"LM9=KK):U,M$J!X;W7%@*-KN;?/AL Y2;""\;<P0V?MJ
M??[(<-"K%R*#,>QA1<DE%O6MFWI1"L=X<552TNB*NNGJ?>9IS?!  W1EIZ 7
M>47IG0O\N0;C<;Z\1!UTDV_95F<@[[VVU][8L]QA=D*999;64T"C5U=<-:V$
MR82>0:0L+>G08R#]CN427<E<*[7&8WWL+,9ZO _RL^%"\!)U7Y:-V,F82+4"
M'FQA:K,J^] D=O-_81F7T$L^TX*]>.C(3A;-E0G40Q-5#RU7/E/'&3Y2/+HU
MP[<PRQP"U)+X:5&!X"QT%PZ!BLA4UO5W&=T@F;Y!P%"=B3Z:T,SG\EU)-4IC
MQ U5/\>(*UEX2H_+Q=; 90EPV,PIRB-Z$+M6R![M#IZST-C=,N2P *[<K& ?
M6Y.C_R%731F5NR'M 4H<DOA;9ZVTJ2%WK6U95Z8>3$?U-NO3__SXY.S)LW1A
M?\K8;L)&4,61;<A>JD[__%B_@7B606V^1$7P#<+L]I>M,8\P-/'ZA%V0?+VB
MV7'LCZLXLE1HU&7G2GJX3[Z"#!_Q\/*(N_3/7YR>@ER,AI-3"$2\]D].51I8
MRND8QVSZ1_0@'C8NM@EG^&]4B+B-PVXT9<_&6I2H  -"#@ . 7P4G97SD8L@
MLM>&Q!*3<I;A.,8'^8;W8$5/["FQI'M*+ )D+A@ =2<3<]4@+[8UVK:3L/)'
MAE1Z]4]G=.2B.V][$R#!"3.TEP)$6R\N5QUJ+0[1(%NJ3B;:#<-!\TA4=:R!
M)HX7EZN(IM$);OFI(]G(GF#VB-AQHYK^\Y9KJZ0I*U;J4 ]\;$9%.HK^-);C
MGB;UU_C&=6\E4]U;IIA7]!$]B,,$T"D!!K?)2^H,@SACX1":,>S)]\>1/<AO
MTW*]MC$^(20KTJ!MD&C@=A%WQ=FQ'^&#6 / *V-T++M3/182/%JT%S)%3U'F
MP2N(1I^3L(+O[0UT\;Q.H+24L#.A:#L@2C])[*FQ:-@:952P(VH@S;O EMC9
MHJ-4\&S[3!6%D\X8SG%0#!H<3;FMAIH#'-<:8:BS1)IL>CM[F1*> JR&?:7$
M#-@?;BJ[L]"X^,>$C<:I,<JJD!Q@N1@"]<9=\%EX@NQ(0Y ?]"0A*6$\14;#
M["Y96-H.7E6]\>:6AM*(\1Q-K.!Y[1W1@[ +?K5*I#<AX.=@J1&W%H!"Z2[]
M%YK6%RT6S=!';;G^?">2VC8:\!AT5DTA^4T89W-=7Y!0)T(91AUFNUUQ O1D
M]']!A.1F=N='^""0R]N3II)W*(F."NJKHH18*^>\9X=1ZR+'MM<\U2[9!J6W
M/#3%++&&F-..0FY7[)D3DPW)NJ6T:7 RSUU8<%[QU]?KLN?SA-9=U@2X;<L^
M&'V\+H:.).R26ZT9*Z9N)BX#26)^3,YM\H/*G+KGE#77U(997('\WC-KB5MS
MW8@+CQ9M$\X#+U^.^_<OXJ5!ZZF,D@]?\1R,ASLOV2-ZD+%F.T4>2+2W>*UV
M*9;=>^).OYTT8N[ /[X'^6N)' +*H]4VNP/SA_5VG3"&+$#:+ZSFCJ,\=T0C
MGI\D]UYL&IU?4BN@WAI!);I>8%@E9-5L',FL*W9?,*@/:=I$2R^+LG&$PLS-
MLD^&78X%KO&QV"4#E6%Y"I6$]%F!N^(4>D1^0FWH*;IM I:3VW2X<V8XZ83(
MQ).8N*YQ3W0B>0TF0<D2[M_@V^ 98\>)30RG%@(::SL+;WO<Z *:E[!3_]H(
M'@5Q/59T@\P,VLGL_H C!1/L]HCD!]G9G%9]PD+D7]OSPK6QSY-I>D?4;%UC
M$7@^Z,0E$.@":!JJ!'1!DG9# O#,]))I8IYZX[, U3\^$P'YZ!^*SG@H'U(<
MH4]A'VC\$"(HO[9?.4F_&UKL89D01W2<0O)7A>M3C^?Z4>48Q60+S2IQMZ:V
M;L/?/DG/P^J=9 NE.T%S8.Z-T7$(Y#_HV@0!WF@<),'KWA(/E?9VB6$>@#]Z
M,(XU?H2;@*U/9F#KIP6V?G4?@:WWR;8?SB)UY<6EW4RM^=DSW7+P:AO?FBJ_
MQHYF_T=V@<MR4<(- ZXB9\,\IA''T;$K"^(<E!/1'/H>X8.\0=F/=%02.7GG
M:X*M:<S54[\R@A8*$+DCV\8!PBRET=GDKQ9;:S(2[?G&K8V[)2XUMJZ$Q+-2
M3LK:$&^JX1I4>Q13URDK9E/7K$9D*?,PIY2WEOQ%&_PQILR+\%+!;1#P<IP9
M4X:@3SG(E6M:-P>%T;H<UA3KV8]+S1HP#T7X *Z>>..5"V/6"4?6?&*P5UP@
M]0\.#$PQITW"Z53%[T_]!N?VM[DSXF[7^(-V1E"GZ$% W^O+AO92Y!PB=+@<
M$X^O46&VE$_30\,<3(?1Q(_W"CJ]+T"]P46$OL=?.5+G+:"NL2UJS@&IR?#W
MX,ZQESAH$.O\/2X%HNE:0"5<.E6^$-G4;KFUH!J9NPG_LS0%5(P.DWR7YFY.
MKYEB7BP/<K$4S4%60658X>,D*I^PZ89SN(LMU:*0N<4!Q88:L^G,IK-K.O;\
M"T%)1/97#8,EB:#H*%NR9HOY%,.4UW]8N]8E)YW318/RP56^!"33.+CEJJPJ
M)K&G9/EJ5;9K9U7<WF._^@OT2HF UVVF!X["<,,LE3<R*A=@GR4P+C4BY.D_
MAZ8=UG,OV-$^B'!9)&>G3[3?Z]OO7_R=+(F.%^F(U]K4%SDG-% B<L"B9;->
M2(#& +Q<Q*7HR,$M9%));*YM#/?XV7\X.(1D@ *VO$2\'Q<%AYI,2BM8H<0(
MT3""N;PT!?(2Q-CGZ$;3*D<]B5CJI,6%'[(UTI(35$I)J?"2V'Z@H,KMD 2R
MZZ)LAR-"(\RC,)^M[+STK:F7ERI&[5,]]@WF:]%(075JTU)'4#/HA#<;8#*&
M.F0.WP;XC[Y)?)9)Y%TY\/7I'TJ'@LXZMV]*930ZF1+_:_N*_*ML%C2?N<M7
MZ<6TDHJ^>X_X2B8@B7/9ZRX/PN653YP\_UX4>]ZB5O\=:ZK\VFGN3_\@#\:1
M<CGCA6CQ85E--$63%Q!:2VXO[0;IEK'[IQWGFGKG\*U?AN*"BR%@!?7.))!+
MHJ9L\R&\DY[)8\F<!!H%RSYH))&E?% SQUQ(.<('.7?O'D!&^RXW ':(FA?
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MA8DM\'Y,P*>TA;T[Z4=-A2Y+0<W.!;C?G2'RRQDU_FE1XT__0*CQ>?'M 2.
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M3%1]7^W"]*2$FB4>'/,X *7<1,ES"PS&8V!.4H]S3:=QKO0T=GO7;.(TZO2
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M_6D76]EH;(4F<-,*D@CS@B2$43&ZL3!84N!69'-D]-'_PRXNW05+G#C!+L2
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M(\!\/*Z+5+-0&,.Q#ZF63(9_]2:4P2Q;+^%)7Z*SWBMG"#E<OF/,A3MB:<Y
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M8#?.R#3X;"RVD&/V0MBJ$)BF!G7Z4,C>(H)$Q_1G(!R\RKW$P ,,=;,>H<I
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M=X4^L3[786E6%;%2S4%E1[XL3;6HB*79%I#U0Q(#&>L;8S,W0'YLP!!JL^W
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M^'"3<(4@$25&"+I'3O1=1\O 9%4W^D,P90?V$\0];&O4#80UJ20B&'#(:UO
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MY3-$CH5"**E@<TSZMAX/2Q(_A+@(053Y%\*>0<U5I(<()'NBZLD:]=OTE$^
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M<!@8<L;G1)O+GD'!*@&=*63YC1((E8E%)E!:I_7'DQE"#>.*+@U^Q)5P&!W
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M59/\"8BI?;"D YBB_XC:!PS)8JC?#""([V2=BN_ZH!4"H F1H/D] A#T0:W
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M.6W,]]A2FQ7W&0ZQ!MH<884L&.:XOLT)[N;#T>[\O4'! +O:=K(@1P<ALF
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M(*?69Z<,O$023#UZ=<$P?0FA!R\T4J= B$O8"[ZVS=*C&EMZI(&W5W$QZQ%
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MJK1W6!65HBPJM9<.77KU5Y )N\M[AS6QHE1$-9L.K&(4NY^9+6N@GUN.Q_#
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M17(7R^L67MI[IBBKA>%[OSH?NI6'QY;<\6R 6%O*5HO*+Q^@SX/TTPA:;9U
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M62X[F J(GKBV9C#;/H4?61KE^J.9H-J:C2TM02,R' J9W<&;3G2R#3SMO5+
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MZ1I[YA5M;8I?VR;YHU)!SG%'LSKN$*,<';Q1?F#;U1WA-J:HC3@)B%MRR $
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M\L%QOA27!T)WD/UG!JS%U8$UG'J3T_1JI<MN3ON=98!U86K-TL!:.3@NYN+
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M@'^]#$#11QP7/=DQ*C'@@3]LM25W>Z+88D=U6# [R>_>).828.\C#(:T>>,
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M0XP$2GG=%B,SC*S*()MX9AO<BD-084\V*H+!3 VO3L7/IS:4SZKA(A>.:E/
MQ_=US1$-_@Q!)%AS:@&O;ZQ7.4/M#%2_C['H8NSY3".'Z>P8RNXJG7UV#894
M5(JGL6PF5SK,YHG&?!^4(D5;E$//6WC)O0J"\/*Y$A">E(NL!'[%2]__$!G
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M]A[4P7.U0L=*B$R-JW.00QT5#WV8DS#K!NR7,&IE ;5B\>I_D=XI0DUM]E]
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MF*:65E1)EGBS_A2+<;GGF#-,RXX>S2C7CLOB:7983'1-6Y4UOQ4[+[^>1H$
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M]KO:(;,WFFS;G:?:RY UJJ_Y=Y#M8O8\2\$'Q]Z.5LP*$^'!%'1636P50 3
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MU:Y[Q/:GYJIQ&7#B2P#ZC3]DS\H\?!Y?J'=? ON^,06NMP688X SK_NZ]Q<
MZBVQ.'_"VIP3)O=@"E8SSY=9S!X<9W.%=+D8U1A(C"P L*42Y1Y4WYU[(*/9
M-B-7_J5>^\E^7]=R&T]CV%;\BDIY*"Y*>>"ZX+P(/NVP06HV'^QP0S4%_&7\
M\W/3:HJJ@5UD7..V?CNL/_?[ST&.3,-+%? S30G1N#&R"+_>!K)=9&=1J):G
M;B*%?%1#&XYK@2F'=1>^J3AM:FB&J FA"_ <)5[YD>OHLDX5BE>G]AK6FC6L
M<]:VIE2L&+OU!0NW@$RH/@EX#FR-B6*FL'7JF//2\A<'Y_*9G,]W<KG*LJVJ
M7_F>-?IZ^4F_B@VF*8EJ<7(^?><.89M;$!\K%@Z.OU(E7M#;/3HZ1F5HII=L
M%I4CF1*YG%'.>=/RW$U Q&%W4U0J2;SV+$'GA!E@;'4T50^$^#FC>*]DMZ\8
M-WK?J\^_*L."\UR.55/>K9S,.6&<"%D:BGW8LB[.LZR5&,MZ)H=7>):F?54=
M<SA$X8S2(R6\[8BAD@<J386P%,\"*M5T%XV_MFIKP-ZTX9!U-2 &^ JN""._
MIN^B]),DWX;(>_FSCI$C[VJ 4MPW0%ER Y3B?VL#E#U9KK9#Q+Z)R[Z)RU*Z
MK"R[:TOY*&3A4'AZZ5U;]MQESBC>&FAJ/(SZV3580O.SYUK8NO.=9FC]C69H
MP3<U"J%@X5),C7JYFF7][U\'MRS>#$UL2$4?H.0?H+3\ _2_-,< ]9/\\_MS
M4L&P*?@F3D$*-6[4BBXEW'K)WWII6[9>/C@.ZD;RF3@G0*130/8-J#C'$/>8
MXM4#?, ?ZL6\^$V4!43%,BHQ&7=-%2="$@QNJ6T1JI-K(K;/\&/][N*Z<EOP
MD;49<ZCI28C5T/34-YQHI=3W_/74;5^?_72L4I(3)4X C#Q3G'MB:;3[KG*"
M8F5E!UL:9;_O8-6#X_BJGV@7C$>\6&6J*@[OG=SO6ZR/LC!(WWE;]/%<[; :
MI9A0$J)/J\O'Y^:7V\;PYOZV?]<.)K'/[G^6.(MOW?P*B#%W=O-<'#3=FU)Q
MP>;?X#D,MA\7Q=P$T94RRS[%)BBLE,5*I$IL)=)<&MN[!M?;-XK, V%>SC,1
MY#2?F?3/*+Z7?7-6SQH$^[E5^GJ7+7\K98-,B=K4:5::A;-9V5?"B46E8CI3
MC U#I[DM&!261"1 Y*>N-HBXU+W' @#)<?VL)"AR&>^:<^_+?IASS?F"<?FS
M,?CB%OO3):.8<ITH3>%M!XN_;_A?[Z_(-(6E),+/2STH81N$=*502F?FE&?,
MC2&EY!A2D$H\USJ)2?.@X$( U^N>=/BF7Q72TJX 5;1UX$IIY#*CT?[^O<FB
MHI)3O=2X92:*PMZ9Z9(,!)O#* S$@.3YOX/#>:RD<'!<31>JP$S*L<SD2+G'
M.'<0_0ZGF0:--(+&+$I/U2P%&_)&)_.=!Z4]/+C8,,[A"8)I"))X;D(C;3K?
MB@\Z?_W_V7O3YE2QKG_XO9^".\_=_^I39=("*M"G[U2IT<0,FL&,;U(HJ"0H
M!E"CG_[9 Z,"@H)BCE57]963*.R]]EIK_];,-IK?K^<R6W,T$?19Q2('!-;5
MK%Y64$Z3N_]HC.<%8\Q9<*5FR8!\-^B=6")Y;DV24Q;)C=GR(M>^HX2SW&3<
M207)*2N-+/+\D! $+T*U2P77XR.+$HH$=$QI&7&%VS\+*S='&+K),[/X8\JC
M7M5*;XB:S:"N-*A1-*_UO04+_ M-:2( >H$-J/\VFJO_(I0A]DF968.HJ'4D
MJBAK7SN \RWW/#<ZDQL=N'&.'RH54X;8"V7=V'Z=:59T.#*Z;\%R9E19I0#V
MT40-U1!E8)XAK'L&D!^\4),$DP^,.JS20X7(LSD"P03R-W$F:?##8TGKP^\X
M9O?@AMBX&":+=@"_RY(%^[N &A,>,C;>X84H )KW3C+./EN""$F $ASQ/;*P
M#T$1<?7V0!1A+Z:9U8\=W*FP*[;1"=S8V$(7=W!^YHYD8^GNGML9U*(,$\A8
M A14 0IM%^<::4M]X0$Y<*JF-+0VC><IN_:R_"!!"=Q*!JJ.MM0%1\XGT)][
M)[(9?Y/NA9+K%H1MGJVZ.=+=JIOS:::S_)3W>7MZUE'>I'ZKW=MT0E/B9'=L
M)>,"LUC$-2@4!J=U%1BG0 :__N]><Y>[8WFY_#Z?\M1SZW7XW2W;DSP%21O)
M/'@9X$& -QXZ?5$8RV;5KZLGG$88;8/<9(F4Y12>=.'RH8[,P82!PP3MF8$^
M0^00*:<BG-&&H_^^(TB]YLJ!E4&"_-\1M9C-%9 QYO%*KRR))5P4<J+CTN/]
MYN?MS]:I>+;NF&:9P#1;@S>+,%5O.?/.$XDL;LMX!/57X!1#4P@\WV-/*[0L
M&I;TUNUFSQQG7S"S4QJV&F/NQ7E7>JXJ%WJKE"MZMC9S>QL6MUM<V*\Q5Q$3
M:OF_84? ,\55(^ #Z>TM6@D=9"'Z05))'.0Y>UO3E-*L.2?C.\C0?>R\MALT
M)G/;C5B+3'"C]S6Y:Q/MM?;\7.,"\ Z2I&*RLRT=/EU&DU%S 2Y6[DED;WJ3
MSNB6C2 =ZXVF#JGDV-PJ);>/0[WMH\]O4S$&]>Z\;X[;#P],_TI._.BWJ2X3
MC=*Q1Z>%;#&DNMQTC'D"P"_B%/*E^,K.YUK;<E195X7.*V.YR5_D"[?,8E%^
M9,Y?/4H[K-;+1]5Z:9] ;I\4M:[&FQ>HZ[-:Z_'AXG/U066)(6QRG^#@\PT4
M51RZASLZ+:ZM>Y(9@/XBR;7IS<?M[4WGIP] WT)1.LY/R9CS)6'PR"OB9\F2
M^8W24(!(P(@4><=4'_IW5XTA_9+K%9>;W!AO7,7_WN^+/V3J*P(,'$M5+&9S
M9$#S&:\X*1>.:DMAT7RC>$>.9J5AB=\&U3:(>OK3##;L8:AL@?/O;X&;^J'J
M0@%/S3 GCF@!XU*H%>-24#?6A:MW<-$=5LZO)F*!]QYQHJT_XP2]SR?;,C9J
M4D>G$6/TQ2AD,OCN6O@\5[KR=Z7E,PDF$3+%R'3TT2F3Y5C2EU0"RKJQ ^S$
MR@![QAE@/XR\]4IH,KIGXF NA";!0W 9V'_5-01WJ7]2F">^S[N#0>GMN7]?
M[0JI&XO++H_%+;_/GVY:\U&MQO \$&CG3HV\.B,@'F9 ;OJ0Q%["G^8P<\//
M"))Q)CQ;R18H*QJEHP5=[=XLBW[[,)(E,X^Y0!:-I,4"R;S/;UZ[O4\U?W'Y
M9?=MKBGJE%>-'L"$!K\<LCBN<$P6K9^8<&)JK]"M1?.P8)<\!NKXF(1*>7%)
M?EUNT,PCR,E4[K>Y$]RB"KT$_87\_<ML:.7=>23C:&#LS#%%97*PR?H(SM!"
MU5:.27-&:H7XC1-.G.UU4(:*AO*JT(QW#??1\NF-8O5ASJ#7&GV(>4<>&N[>
MXU@9!,QX*6:N%>ZF;W[8@Q0X^V7ISG8'+^ KT'=N>;6IHK9M.%/T5E115J\%
M<A!#V7ZZ$GS=LH/.6(=]ZJ9+[N7IKC9H->BK:X>Y:V\PZ]A_Z)Z!(9;O5Z$"
M&=CTL/FL.<XQATP!8*N3G#]F\,IK+JUY4@L>U:@GU?E\^N(&%Y^SGIR&HW(Y
M0[=Q5$5T5+F P^*-XG1^K/<5%:8_F@H%53%(1G&&9Q5#V?M0\4)*U@/C.LS<
MM-[4+IXZN?N.YV&:&?CV5KQF(GCHYP@'OKBW;1^TUR'#V"!V-P4FROK<$]YC
M([R4\ EA/A,VR<=/L^:@9)"&]E/?B)>0#QQ:KLIT:(W1!:0CIN"F%8TNZ]C&
M)61)'..)2#.@^Q??ZL0<:%;D"$ 2GH#INAFC ;SQ?'R'HQ9?8W"7+3T*WU<P
MFQ$]#5Z%QKA3- C R.'%"978C6D\V/-3/6#T )+HJL+CXC ,B,SO>%YLL" 6
M[@ 5-J#[5(,I*\()\>!]8"AS5$9+=3;V1W\\;B-9Y>%K\*(5F*6<,>8<2U;I
MC2'>#GB VI/9XF[J!=N:<[3"QPH3?D3\%M6.I!G=\F&-&SBS$=A9!_MZO=Z2
M <QMO"6X%2>& ]:(6D!?. 9TB'8[1LC$+/4(MC-W;]V$@/J[7R16<QG$G7MF
ME>RE*572,T&%"B-C3L<BXC:;R\!/0H<E2DZOP(!'%T@='@0'JQ)4('.\OE0R
MA-"W?4/J"NYH&#BQ,/3E/B]_Z/3G0X<4GXHA[^CEDOFS:&\V?'&-#Z$UOYJV
M'\1>^#<G<>W'=J^O[!\1=8'1'(>K%\BM A[!O2!L0!+HLXYL+LP%[OMU*$SO
M&E<?D5!_0/UUA$48_#@47^NSV][SVUTA-:9'G+8%N[+3PKJ+W81-_19+!AA"
MP5QJGY(3A?V$6I'4+SKDQ?"D0 /D'J8&:-Y1U<OY4S4WK9Y?J(SWW3!!C\#I
M!7"LCM91)33P*J0W<3D(X"L*SM6Z>90Z.JWRG3ZVOY=@/P# <.&:TZP!=H4R
M%.'JT=!A:$< @0'H60, N3V0=*-NC3<^XNW"TQS.3A/WFQ.^'-^!2\&6"YJ&
MA9>#>]S!83=H)8*D@A\5U?Z:A4)\G* '0=IR022>-ZP#8Z\/D&!0%-3!M,;L
M*:Q9[X&%JD[0C(G:&%;:F<,L%J[AZDVS-'N^[@S.NH&(3#6>AVSA+GJB%4"-
M<,>$6^,VD!N+^D4423++<?Z>-Q]_3! UK&+G$1!G(("\;!O@T,6!AR:.<(4I
ME.0I#T?&Z5K&Z2G@]>7X[<& WEF_\.*A7WC,_<*+/Z1?^.XY>@_%[M /_- /
M/-9^X EO=IWVX.P)X9\,L[)1^.XE=B_4BC4V[. 1_]D>\;[;(QZ4NN >=+?"
M%UX3B^/6C22(<[MGK#V++K0[O!SY_88'DA^6KNN3F@[;B49Y_XJ>Q4$KV(IU
ME4]@C3&[QMD"M #S-),%_XCJ<LP$.,;]F3&D;URG/X>=M^]<4^?]F"*D>YQ;
M>RD&?]ZUZ);T^7K>^.:B+B7"\>_<3UY,<+U)N,J9&%SE(_<Q'IQ\NYY';N2.
M!O6A=93->2E0W(43=J.T&V_:"97N ;R;CLRU/^5N%;Q80*VT^LI8 ]>^7P<&
M,W7LZ6GXV)QK]^R(]ZQ0''E?BYAJ$>H-PQ(N</!SB.&Z=D%U2!+$=K&Q<4WA
M=;35<R0?&W$#[R9[O)[AEP:!>EZ3!=^[R?%0^SC0-.Z]8>:/:_TF5ZM(Y$<[
M%#,O46S-F]2?=/O!SGX7'K=JAKF=^/:W)AJ\R/PZ7&I;BEP9*J24-95)Z9C$
M+3!]E4N?%Q8:\.'0;M80#A'5YL%' (F82++8 _\,[M '8TM2)_5^DS0LT]8.
M>\9M>RLBBRH?)OE9 PBR,.('I0%'!LT[%CL/X50*= 7C$"2^NW$6L3%A&SQ;
M$+NHS2I4NF.9QTG3C@R!A2(@Q^P#G*=KH*GE%Z%7>+ETZK?-$Y@O#9O!CHPI
MR8M-T"6@V"6K^XEC-+AG17YM)Y"@Y'G=S9GGP26K-Z:7@[YUA3>!BI)@9CK.
MQURXJE%\UU!_BS?\#JYQSWW%>2MSJ(? "54(<RLK'J3[A8+EYHVQ>$-D@PO
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M3E9R.4!<S 2)O53OE5E1[Q7TWK(?K^)*,GVJ@+.&9+>^6%9X53@A8'T<T8%
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MHR4<T)90S4/EB*8I&61 ]<%X@[#/-'B B@G8AE^1! \B^6;N98U\L &/DO"
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MI=B 4_'PDCIZT+NJDO<,:N^]?0#.5UDR$C 2+!IG1')&%:8@H8G=J&@4>[Z
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M](C0._=/(XI/KY$_APP'63G(2G2B)"$MR8[X,W'A7V';()[%,>C.*X!?DX;
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M"<G86'/ULWPO?7W=S2B[@L"+]]U4BK&*/'1[U/"[BC7(P<!(.+>Z#"P]K0N
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M-TYW"+7'(2F2/#IE<EF*C11J^.-/=M>G1L5_:I[74CF):VFY-_Y4J2A#=/W
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MJW0V):?@]F1W>'D:Z[22>U*G^-<A==*2C#/E\\75A1:I$N.MD#E&*6<!F4D
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MVH_Q)J5/$)Q.$!D1&THY1*_P.I#Y-@&3%Y&KHPPT-U!?0I:HM'X3YZJB0[<
M_!E^])J?\'*6N!N+;;'C'3,QGF]8   ]3WB '<= H0!HJV7,]/<;@,D-W,*<
M$#>*IIO?A.$/%%,!T/\;(GZ -M'+G;_$6O\G**34+]I G^#.YX+L9&!43/$1
M.BX9>&1N3H,I\S"]Q6(X@Z5P!- PG>"OC&>9R1O$ *RK#U/%T:\M'.N%2TG/
M]BWP>[?&UR"*(3D3Q9 <1C&:JAMEB/!#YZ("3.]1'T:]#12#JU:.CRNE]_E%
MMS\7"NU.;<I82.7:M;;P'56<2_."(B1G0A'PDP%%\%K>*Z48X 8%5&0A2WF.
MV73V90+FH"JBM !WO1V9^PNF2.$B0&33JB)@!UY>/D\)AF(E'9BX\LR0Z*"R
M9*]+L 440K,+(Q%X/$3]7>C@ UWC&+]>+F;U_I-V]=5>.$:H=XZ"  +N=+/J
M1&"_TG^%L3H%2E43AV'0@GN#[I,BCTZ5(;8#E[",<59(84('5,:LC@#4#X+\
M7FNXQP<(E[(AA6<4RXY?V\/[8=&#PB:G[(;2CEVZR4RM)K.Q<+0+<&M->$F&
M =O#G93>FI#\H28DYIJ0_*$F9$_D\E!D<2BRV(LBB\()L>@:.!1:;-G4HW)K
MF7I>]0TC%5@)ZFR5&>CT.R"K(6/^QFT(:J8A&&P">C>67C0!J9SER,YA9"N(
M$L3#/5ZN H8S>S:8[FMS2966Z:_6&UTESTOEA]=NXE8@E;,<TCFW0WIQ77&8
MA'CH3(ZF5S8SPQ%:9/N986"XE>R"T:@M&(W47_#<S= GS)7O*K#8 XH]"G-A
MXW&!#5 $U>(%)X\"S@0TAP7@JG(,2,H36A_ZDL##86@9!DC!.@B8QZN+,//E
M -6WJ%.@OP\P+AE2KX1P'-F^2<PH^-\^;B-+'#->VN(LG+8@<P5#6X"?5FL+
MO"!;5URTM0_INS!K/WXFKRN HBA@78%^LG6%>U5Q:(K\T2D<^>,UWL@(51F]
M<'G-X4$"![[^.7#6.7!T+NHYC+^U=IF]G4@BNY5SX*QSX([!:A,[A\+1:3'+
M4K[G (7F01SI&"7"%6%?'908E.EB>XN0D'F(50CO'1/=>_=];8I7=*&Z[-^3
MY6E?ONA[^>_^_??E[.7??V_)U_!3A%@:^7[<X:AC>"-EX".S.+=K/((<'#2U
M)(Q7;9.=OUZ-].%,ZY2[7CLWW5,F!>@H% "<!+N_+-# R2!F50QV@?THYU?\
M$>&'3E\4QK+8[-90?>P-D*'!> "80>=E4WL DVXQU@LIZADX9@N4.W#,.5-Q
M8GG=^WQ OWV-AY],[OYCTRE6B9\CWFAF@'=JFP8XP0DF"78@X$,\ZBR^PKC4
MJ 9#>@UFUN%B+Y1.@7R[$LJ\!.*,TN,,M[!9'NX L "_?.N9+LRWQ/*! >V_
M>RT4[BA^N?0^5]KY<W64NY]\V8P!$]-E'KP,T%H\.C59$!(&GPUA<"%A,J!1
M+]MPGXUO4@ B721':WCRAG/)'BV,C7=M^3>1[-3?&(?C6I,B.=I.Q9N39Y2N
M%4F:9NU!QDE._R97W)3FH,J9R2]G8[$!7M.:BO)$O(&H7L-3P*^;U]>W<_59
M?)]_R%.A7FVK"D38/K[R3<[%X 86^N>7]PR(F5^DC/$-ZJ_ X8HFEWD^=FF(
MHOGI_[^]:VM.6UG6[_P*E:O6J:0.(9*0N&3OXRJ,L8/C"S&.DY47ET"#42Q+
M1!*VX=>?Z1F-;DC<C+# >EDK"4C,]/2]>[ZN1+[.IB7.=5W7I77*,VYAPG>9
MT'WQE-2YU%K(>,=K,!ZD66^>S1E^JQY;?_OG]O>+IT%ZPY@)8\EIS\7>"-.X
M=$J;5P#'LUHO2E5Y(:^LP2#U=1D$/.89%OG5FER:-^WJ\'8=%EG'5&!:5W:'
M6X!H:?-+#8A2*4IB7"[SU?RRJ),B:>LGYMB:89<;J_&M7[NXJ$M"RAJENC,\
M H1*FT7J!X=5+&;55#BDN2Z'X$ABAD-^#&Y^W:K]OZWCVO842BUM9EDR,P$-
MT_,G/*]Q/(OZS>*.IP&7UQ+/J%NMCZVR_.UQ+:6_I!3/CDX7Z!3OFR&R$+E=
MM]1\^=7'?H<Z8I8]]=7>M"I?U%>=_"VL,OD[Q"[E-=CE3KO!+.($7<?IQ>WE
M:;]V>=3?DAC?F(ZB,R Y_"[-)GUTB%766-)D)^Q"RO:@S!\<UNHU[#(L#D?6
M8*'*LBST(W!,+9*":I#&]SOMLGVG:G?3JPM-D%J/>D6HOH&F@;5[6#<[KVP^
MO((UDPXJ;3X5#@[E<E&4XB[\K:D /\YAW)/$ IU'":+JID+[SZEUPHMM1]F*
M>IME49&R6P? *0V'($J2="3+$<<KO21JB>LQ+WF,4\UQ3T=+Y796?,M2.C7A
MH-)F31&K4$DN"M7:RKPIKF*<W>[2F+M]@0))HW8WO6P9U<O:"/WM]5Y;T'CW
M71U03"JXX&,<0\";+:PH]FR1OQ6\;.Q7H^"-L;?$IT?C[WWI87@^;,I>H?,J
M_%-0B03OQEW1PMO X9^==XT[7.5[O524:9ZS)B=>T?;ZJDB5*>&J/ZW-/R.0
M?[B.@W4K-#KK?OUWYE *[J%H]DS9FD]4ZS_=7VC0'[AFE3&OE"^0.K;S;V ^
M^G0X:GT=J#<67Y82#VS)VS6QI&<7/8! T5KKJLL/GXZ$H]U2/>G&1Z K;8;R
MS/QS%% Z22)BB)]\6RVR^F/W)Z[Q+W20!0VX0/R1IMZIHR#]S4[SY=QN/1[7
M!HGT#ZUW-0NR>%D;,"WMRQ.LI+&W (&?&)"H#@Y?PH<F'QQ*)3$N%TR.[9_Y
M30D[<:7X[1=Y0L#"4"&N+)MY:[63)M9OQB[/QZ<*8#I (\-7]*PCQ^$ZV'6$
MR8H$Z@Y$'EHB1_ ]JL+6::O&MINU([D,0?CA@CX;:M*;,>/'3R\GXN_N7_ZG
MKY7<E[AKB2XA22TU?M]<?YGS^]NTYQ48^RS%^KAN\Z-FP*4C N##<(V]9KKX
M%CI^)CT0W&RX@2[._C[UCG5;/%:0K"=0.BWKNW"U8>)5L3.48&Q)PYU_E15;
M4H9I-1I;_2%L@D"Y.]C?(]#@#OTR]I<HC?TFGH!3%&-^9R$W@LN?]1ABZ/W[
MZ=SY>:T_=/\\)- [;C';H?_L!L)' +6Q4FVNQ^-A4#.?H4!\G 6NS.Q2@HX"
MH6+(:>D:$_G\6TLO!\;SAHFXDLLR_^>WZZ#4#P[KI4HBE,\"!R5[EFD[79/!
ML_.2%A>*,X99JLF]D74IVALI![ARA9?>3>7K(>JWO_T1+X=Y!V3> >EV0-;N
MIOV7H3H9W8X>1P^O[X!D2B[O>$R_X[$6\$<OSIK_CA]TI::4M]+QR"]20PL[
M'4_.SSO'4VW4NIN>G<MZ0[[__E35\T['> ]@51JGG ^7X&YSM5B5XOR 338X
M2BOP6:BQ,<!>S=YH7*V-C_JZN->-C4O2)VW6$)9FC6WP@]_'&."(0?/DH39Y
M:3R=;;'MZ&W[&)<F5MKL@1U:@2^6I7H:["&LR!Y^VV* .YX?S/;YC_ZOX>DZ
MY=Y,M2TNUW%4$1=V'*W7FQZ77IO?@!9W'NUOS:M?5Q>CYB_IC<KO[[87K0(]
M&=OJ15L8VL[VH 6XY'C04,Y04_M[?)^FU.Y$X]DBZJ6MX\L'AY)<K(FIZ'@Q
M7J^TW<XM4!_3"^VB:O]\^GTA;N>BPOMN*ILI8;"SV R?P8A-K*3F,9P$D)]\
M;%8RA<:QYB)%17E0NOI^XYSSDXF\S6[&O%5LKA9,6_5!_9XO5BN+5=\6^L2$
MN^GY[YIP>G+=>NRI>9_8J^?:84X*-8KY Y1972>V2TR(-UDM^J;X"G/OV)SV
MVQ.C=U%.*"$MZ ^;T<KNSVVQH"Q5 ,5%DA.K14NVAS%[PJU!^W*"LF;OG'L(
M\O32F=:/>NIWOXX77<PJ:BCRH]L\BBK4]JM\==Y1%!8>Q4Z-9ET!3%?.P72-
MS8+IRN\53#?+9C+'S7VWN+F<M]O,<WCZ8XTZM-&J8:A7,#NP8]J.A1S-(IV'
M1^[P\OFSM46^'.G-"-V$6_<7[J;7+>EK_>_CJ7(D1CSVMV^<%2JQHY#&WW\T
M_O*UO]U*&6Y3L&UR'5TQEIF$E#U7?R?CD]F9L$0)P*B;J%<<O/MVC'G10*K+
ME'!F]BG^LZ7H;8/ZG9B1HT-FR)^FTO6M,_A:EEXZBN<?!\Y_A-_%W=-W<9K_
MLKG=@C%38LB?HC*\U++#/G -H #]WF-[9!JV"3V!G,0+'QX^T@63,=5]\XG,
MH1[W;$<Q7)!(N 6!'D>Z.4'(AK"$(RX;="7W<#R&#U8#?X^ ]X(?IL&HV&(!
MAMVZ3W&/^-@!PG>D(QC?^FS"WFT<'L*YT:9ATI=D(^N) <8^F]8#C%-U,SC0
MG82?&XX-U2*C=%4<!PV<"3>$8=[0\40>$(H\S[O_IAG@VFM6!-[8_9$2UV*;
M(N-E'Y4'Q(TL],E17G!X,4 6)JI-\34?$7+8;#Z@N;MKDEMA_=<DLX1?RMB1
M\]DQ ,=-GH:0S;'PT1$L1HJDJG"V,D#<4+&P1TR/1#-<V-6A=@]-U4! K&#)
MV%GO0,BP+9@8[AT$A(F8#_I#6#'PF*7UQG08+% -&LGFOA"3R2!>,'T+A_=/
M"5C^QW^=>P0R_I9I>'UC@ @=^$HIJ2F5UA/<G_176PBM-CZR;<S*<#/P%-#7
M/5<+# V8'Q.&O@>_Y-[ C@U^GR_^7$[_M)76S[HGW.R%(6HNBH!?M[AM!LEU
M;.*$8HU/Q@F/'3DJ;/8DHA-)IZT7[5OYWA"UW]D[B9G!HALX!QD[+6*Y*%66
MNU>XS SAT(#1C%]/>AN?^)K.=N_ &.T;4,F4X@O=8$AYA]S@(&CR"B^]FW:^
MO]@#7C[A93E[GF]UUO.5[J9?Y>&S./K](AR#XTOVRL%FM>5&@&;/A]Q)QY<8
MT8+ETI\.@K?0$S+&"4GA2HA%R1?C+WK=+>3DHTGP$XIR'?L0@[K^?E8Y_=<^
MJ9:%:L!GIFO@!EAXN=!&%JET]NB2X[O=Q^YF5[8)O2T<'%9J%7 \5S.@M:3S
M2![.O;'S>+F5FT_?'T_+O3^IG\?L%.YTST/$=K0FS3V/5QE2KM$G[2^ G@[#
MQTFZ6QVC J&;0VZN!84R5AB#/9TD67+MO8OTBO=CI!$[)Y )LTB0=ZW9#T<3
M' CVAUCO/$3.G"W1?ZM[\BGPTN!?Y6Q\4JTV;#\>3B#1&JP5)<Z\6K;'6(G;
M3Y?SR@>'=?YUBB")%Z*:(*.\,'EROOTQ3?'F]^"M>"&J9-Z(%R1PG^3YS."L
MH'38!5Q.=[LZ-*:I9S1.(5;C!+F,O>RGY@R;I$B/K% C3YSZV1B3B+_.CG\J
M_7*G[E?Y8[>W'I?,W=Q2ZB,=CL APXJ*05CUR%+S%[1IYZQZ_O/VY$S+QI%M
MQY4 ; !Y@6NW@A#O6(2QDV%1VRB$1B2)<^>58<XBW0-@DT:8;37;AA%EA@EY
M:@BP((DZ%P"KZ;_A$C]E=Y0)V)CFV+)<>!_JTI,Q5]Y3T$=P-6A86";O2>HX
M/"DH\M*."YC08#@A,P;\W#3NX:+O,>HY\.[PZVZ>\3,3]E\SNF0FY'^:MTI#
M'.@WXVI0R),(M(10SZ%,@E2')FPM20;WVTOM<A-:H0KCTLKR?$_/'+C9^[DS
MTO:'>UYI=-KXI?CG+,:+CU9OV)T^W'Y[Z>\M+WK&*[SY3;!H#5@4L^=<%@4W
M47%HOEMQ:WB*44!D=!GF7I-^ ^9UDG(47234I>+&Q()"QIJZ4>0:G[ =!!-X
MQ'4L4DG#"K?KF/T'MW<1E.J'+D(<$(.K?@2\%PWB<(<6U,!11VIAGCM$7M>V
M[3%2*<Q2!_^\J79A8*A-R0VM" 2XAI&^B_J $J%Y:18VA# J7UT'LRD<:NOO
M&*\(=FH:4-^+,&V33"4E2UE6"N:S_=(BOJ1&/QD89XWSP<F/4[^&0@]"(Z1C
M !!]CV"+!.EU=$_*#]59?HB*').+6?K&2TP:%H"@PW@"1O<7EC&HFQ4K]6I1
MJB?+&)E@:P=&V-J$_*2L[%.=@6]$M!J%EQIA,D-572<RQ>[5Q*)[-19+".GX
MS 7$%9!OE[]NA?NO5]^%E 5D.;+OD'S,,S\5G@R4E<K%JIA8S<P+DK&3)L<]
MF[0-.ZTG$*CX\F.E/J?\F/B*NVF[\2+(_]X>(3DZ$?+MZ2W49HN-1W=3^[[1
MMK_J1^6)?G#H;XVC>\OKC5M;])51.$$]B_8TR231(85C:];AI<((]W%/QR)A
M#K#[!PH46ZMYHW;GNA5XC>0C:I4D7A1D8I7</R4QOA_))'UCQJBL;]>FG?-F
MX[%6J=YJ?H8,*P;(0D#3F><&1 CS*G_+(TRLW9 ^\2+6QOZ?/.L03X9$J[(I
MCZD"*"F58J52G1N6^+32'#OL-BD.1"(>4V'/J(]B':%@LINLI -?96#+_:PQ
MCSFY>40/@Y[]TX]VR;+=+8XP%Q&R+&07;Z^Q,>U;, )V#CIQS" >'/*E<C(;
MX#T7R)XI&BA3,BPZY.XMT[;!8^XCI!)V44;X;R]X$0[2)['.<6 2MVUWW$=!
M7$",X,):FR+H=8B07KE\=C<R*D8ET\JG_^/<:4Y_U/[>>_QS&J8/2<HOJ7S(
M+<K5:)0)#?2IX@%Z5N:YI^6#PT2P<0Y;1YW@T4*S+')6X;#@'?E5N$O.-'>%
M?T-3->P!=!683DZ^%7G^"H<4#5TW'?BM*X+YR[CT2JC_N31;OVN_?93=RR"%
M"8]J+K'6,)89X5;ODT1:+,O/\G+\+ %^?MR<JQ!'%SD"XX/?KX[[9)X$@19]
MAM 3&U.&ZD+1@AG)/[$ZGGOQUPYKXWL<?L.GX 9Z;\._ 58:A@NPS3/T9[@E
MP-"? ?A<54D/O*+/)/M.]LD[O+,MY].G&V#YJT';4+4G31TK>CAE\<.GWZ8E
MC[_YVK>;O\Y.1Y5DYY0=C+H+/BE+:<P2;5/"M]B=E0\.Q:*\(,F>[,T6">0Y
M9/UF8Z49TR+NE$.[*<9=4VZF5^,IXL\[W]IFS>/W3H3*F?*L%W-M(L-OU"FO
M+';**;DX'4">(FK?JP4Q6U)TYR-(\B=5F<#36$\4D &H -R%@O4-)]9I*H'<
M+,.$-1"E/@&TCI&.<,K!S=)BLQ)9"A8N.V!>N)"I\RX^@54L*-RS FED)V2=
MH@(8!&IKZHJ-C_TG?>S*N@9D'JI/,8=[V=PF-G](/9JXW[/=+WH]?2E([)M(
MF_QK^M#]AAY?1.1)&]MSB*:!*@CEO455V]?1>0."NB5QC!/%ZL%AI5(I5FJO
MR)2@%V3U-1O-R91(B_BZY;Z#Z#[O0X_(0LHVZ$TX^A?_U;*OKB87EVJ4HZ,T
M7=J K$7<W6'A)(M2(Q:EFAQO^R8%(H:883K!>RN,0 U#I12Z&CMP5QD,BC?;
MY>5\KYA14HV?WVNM'_6_8HQZQ9O^\N77\:\O7SKRO\MCG-:%@T.8\A NH-"9
M/=1,E^:7O@+5)T&\FUX+TU.\U6'7N,\XY%IA/BA2)0=%VC H4F570)'V' =I
MT^O[;R\P6475[G@!ZWIWN6T<.!;J):XYA/8,,GX&LDK'FNW-NG-GUKC7,X@R
MPS;3_2MXZ?  Q9&#F3;^Y5F*Z9-Z[=3]1PTK9'@I7Y(U(^O'^R8;N32=@C(:
MX2 -1'BWT/(RM;Y9@:I'!*KAW@,R=9JE)0EO%<N$G9I0,+8IETO2* JBGKGC
M2'W1_]4./R@?"RV &%;80$-?-R4=#T"AY$HK0QNY&EL%_#V%]@X6 ^DF#\3(
M/5QS;'']H88&$/FYD$7F8(#C-8L<,OULX!DJ]AFB+.(61Q##!3+8##;\6M7C
M&PI]P_AFY/$-Y$Z@CD5R4]<PC4PH*SBN^H ^NH/AX.6MESZQL]AZ.I#W I:,
M Y0E7^X#.!*B':>*PY9),F'/"*L>Z,(>:*2)!^J<%NSI&;M?9.'XY9KCWNVR
M*6X1<8"A-JIBSP[&2MH(F_A[CWZ*;]$'8X->!2AQ/Q'I9#5([DXS^A8!L\6A
M'*:><5^ X\ ^ Q I\+QF#"S%=JQQGTPBL,= :@U1Z@RP&ZUKD+(&^I&H<O%"
MZ&1,DT,&\<])?1?']? 2"SUIZ+G@'A5INS4((-;(0IA)D!HX<YMERO'.CJ"$
M0AM\"5HO=EGO39*X7)>3,&\0H$ZU0$XLS#E<$N<\(X8,Y4%2);'&CNG@G34<
MO8^%@$/,6(J=(,U_^,>/V<RT@%USXY&QC9"9. 57P+B^>Z18C00UQ<)C)24*
ME8)3 3\$U?L@4;U3%=#OC\FM&MJ>3B"LL?*UH/2>A&9!'APJ +CGJG4 ]R.Z
M :E%0-"#'!SH81.4X833M0?H<L';FGF@&+O3PAP&WBE9W5D%T_]8N/"<&J\:
M1\\!HNOHB=FYSMF5C< -N8)B&&/OE#C5Q&\ "T\'U&/[[AWU@'N<Y0/%MK$/
M1]IQP"^R5.I3+:FNB(: ,>W8\W.(4U7P?PW4 7ZG9M/;U6[--NAQ:=8C 0<@
M/J./?NDFFSEX)W[&'N*G>Q/.PKK09K>B_$H?\7$\=0A5=,V&ZS0%*#,;Z!F\
M,_K3?5(@UDCDE=5X?^?R$2(?R4<<E3B"R<(%T&?S]%RV-I*GYU(3!R$B#LU2
M,!5T[>G8$QP#XB/GSK :LU7-#3V)0]8AD'T.%B"*$X(_R 4H6QO990%:4.RL
M_H>C)6K["_Q.EW*@5P&M5O,2:+@$NDX!M%K-"Z 9U2#>8)'-&8FPA1 ]"]%I
M7-\4VNWV3JF/3*UOUOZ6P_97X,'^6EB)F19^3\M+LE[11"H-'YJFA:,6R/">
M0JA#YI3E)C=;&[D9HD)@= :;L:!Z23$-ZA#H$2MG78<Q%!"\*BR1!C$C]']!
M_>UEPGEM[!0_P^8@>X=C3!PU,U:@,2= U8!FSG':MK#H66F6(M(LE (BW RT
M;&])6G?RB'+)?)?'GJYDRA')%$LL)S?AKIX-;%F'V@BR=4WL<>/#YNA\(I(_
MI)^3 _93T^2O;'0 Z:(=FCKPSP6D%ZUMA< [>=2YA+_+8T]7PBL1"2^7/%DF
M8@HI BSC=DAP@^".1;>_DWK?7!OSR@@JD=MSKG?R5'-A?I?'GJXP5R/"+)7P
M 3(,0;_?FCM!;D6M2T?BY68WE]3LI7WV( OHWXN@6<#;]T7M=+5=I$=>D"%M
M,-1ZFHMDXE\A\:6BVQ\B%5H,-J_QWM-A0"?\24P3[!ZHX[VQ*]=,Q1<T&'2K
M(@:6 "[Z2Y*$V*[9 9'B:F!A *>7:[>))2'8]M#]B-]C(TXU^V/Z$ &&@":@
MZ.W1+'%MYJ6J%RM5G.TKK9WGRKT1+^^@"C$'1>0!::1#"OKT/)_.'3_G_3WH
M^(&?Y_;[,\\.IF5#89VX;7&W#N"%!# <.H$M!+<A--WS'9.$>+=D=$$K0RWO
M6MALUT+M774M^#^7,4F GF[FS^Z!OMP;Q0_Q.F)Q!G&IL.)NT/[L:Z_A_@2K
M=?S IV_$%-C(@?M@SA#'[[KY3*$4W9=P&O''\'^Q\,/E.J3TAX$N;MJ?#>/6
M3,L'L#*M26&D ]HB7-_P9B'XE@6OK(=<:P"(6 ;[O6WDYMZ"F7Q]'=3/4?V]
M\F9#ZCM1S1^ F@KH\F7??^"J-U^G+[96RZ\]:E'H2[T]U?[9<(!.$;I"H34V
M&-$=NL?A;9%LSB?T/_[QQCR<)GEF#&[$IDKRI@GFZG>RR6-D]RUM--/GL$L4
M9 RV52)>(&=HJF2;.#X]T6!T7Y2"Q&G9E(B^BL-25(.!PY[' ,LO/U:S[_B>
M%@I]^K6*U_$CMD)88N\M$\=X8(E,ZPMGW?<^B+Q4%,NUHBC+'S/,L^62D F&
M5;BA!?!U0\<9V5\^?WY^?B[9J%^Z-Y\^-ZS^4'M"]F>DWBO69QQ^*Y^%*B](
MU=IGGL?_KY<%613+O"C4Z[7/Z*7\22@-G4?/O2#X:W@MX+9]88[7)JG81=@K
M5+G&([WT2XOS)"V@DOJ]-B#.)"C$ME?Z"<P;NR97]@!)SCL,95^DK1VH=9&5
M0])#,T)E+Y8+C<XR=.="1AWY&O;CJ2MMPF4> W'B#(3"YJ7ZYU!S4*9%6<R$
M*&_.F=BP4A"740KS1/EHHBO/=IS0*K$.8BZT;RZT.V2*I8R8XHS)KU"M5&0L
MO])R1KT[ F!<9(3LKH5&%K(1O0+OHS53^'?:^)K+<%"&B<1V/PD1B17*N9F5
M,F)F-R)<O"S+ A&NI8SC!NMUP&!8!!F:MS] H&-I3R"S'5WITR0JFWAMY\YQ
M1F1TIZQJ.1/BFE&K*BQG59FX7C-#JL!M,(\5F133RCAU[G@7[\J7[)NA9CS0
M&3;<^7DSM[@9D>;L6UPI%^&H"$L\7RFG)L+^A.$*'0N4+,;<!\5Q%&BU@0^]
MN0G@:3<8QCC70\XS0D8D;B;1=>!U1?*^Z JH!$@?<WVQ:I3MTU!RASOE/@%5
M*'(F% I3 ^!_RT2&-[C)0 &3Q+K*2'-(:RD)=O?-D3X!GB=+1CKJ.Y9IP KT
M"1$I0#%^SP94X$O"_V:"XS-E0D6^+%>$VF?0ES CJKJ,&6U,-?Q/4,8I894J
M5*A P=\AO?1$XE8C-U49<6UWR"AA(15S(8W+4=7$J@1^+N\:R94D%$>@N81F
M6$)WP':6<[%<:#OKRTBF#R/4>ASIYH2$AGZ02 ._QLC2=$X4">L)\R+'$PLN
M8-A]DSLN<5U%?U)RJ<Z(5.^6W95R 8_++XGU>IG:76ECTGTVQC&9[*:&YV6%
M+.5)LXEUP-RKYX*]0+ 5@R9ZZNDG>G; 8LNY0"^TV)55DL9P2?G1@(SO4CE=
M<F?&'8>M,B10^DETXI*=BW9NL]<0\4HNX8LDO/;:?L<V:[QPV9.CL[YGC'H7
MC1PZY4B@55]^&>4 'WFM'61(.QG1!Z*2ZX0WT0FQA$G! 4B9UJ*PY4[*K"D"
M/V<F+ED</L<""C+9'?=L3=442T-;[W/>H@2N+WT%+'T7"CX&K\%EZ^*W23N=
MMB1N^TY"*I*(Q8A='CALF@;T3H!LG%J*;6O<_RB/^)B:9JG(-3L-_+Y.J8G_
M["-O.JX$D8E<'3H6*S!>_42S'G=:L+98>MT3 U7>"P.%7LK,NASZS?;0;D#A
M;MPI-ER9%[T)<HK54PQD?[IZT=&$S-'$GX@\+^82\%YM!!:&O; 16!C$7!BR
M* R9-P?BGI@#,=8<V-CIL>RQ0L?#,T&H\Y7%@E#DA!KWH]3%'I7WH%"6^5Q
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M8CL>#GN-SW'87X_#7N/7Q&'?2:CT_W[NF>H$_C]T'O7#_P=02P,$%     @
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MO[A@/V-_%;CY 5Y3M DZ)#P$&8F01X=<"[UA@C93^&MW$[#]:UA+P=STNG^
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MQT,E,DH<(;%57?R^.:)*:IS9"DLQH3[=V"R"=#N6LM:;?I&"SVR""1,&#_]
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M_!QXP<6O. ;#FE'=OQWSVU*T]]@ 8)M](OGE#$D1INB^X-36.$AGD0443-/
M8\T'[*UH?-SG<X0J4\Z2SJ>2;Q*I^$4'X;FFYLR*F:;/0_*<TP=%!84A,;Y/
M<(H:G:ABACEMEP5P&M'&*04>[<Q^RH&I'L(!<3@2S/R-D_U/GA]7'DM2[^"&
M<CHNWA+= S7+>94>P]")R< ,XM=9P$P<=M9P^T?[3G]"^X@ZI0\CY C]X',0
MB_3)Q3?I6_:::*7MC!RZ_&Y ZFL#6B'-4UBB<NI@1P"W_/KG9!WO@5@0?A&M
MB@A/QZA32G-V1@2^Q44G5<RO;J)0^D5%-Z1OQMRS2GPJE:8J'KW58CPSW;5_
MFV;\ZPAH(,:D-FFQ.: BB"KC"[GV8DJQX=WU3YYYV,RI J?2.>WNGE04W=ID
MB!10[Y()7:6?1OI*9$H=6TK[.C3& \8T(E/O2>:X/,X*^F1S-%/ZC*50<I<K
M'H E[>SS8;N,L5\&F6+8J5N$O8L&6#.#O\8D8-,X8H  XR48:%6Y.$+'+CA9
M 2+_KNDE:H%E L?2F:JPK .0_?E<DM9#>%N1^L3-4"A%9>;U\7>RMQ%H?+<A
M1GML<FRC,J<R6]_E]*S_[2F<VL[:SRD#%L ;C_TP7,L"%L"TVKT=A)1ZK_R\
MZ6CHFH<[O:Y]N_JH44:_2Y%&?L/8;O/(]_$O<7+$-4<O;QM4F,98VX#,5:_?
M[P" ?X$GC*&V \;;I:"S=^*933819%_I1]Z2#*N:8?Z4X 'ER8OIY:3&^_'(
M1ES=$P7]Y[NN3ZMQBC0D1XGRQR8'2:]RKAU&MFCHX]!T2>J<M</X_&O=)T%[
M\29>.6+1;Q1:DL2,/D0[:G-Z;'I==I?K+LYY.+\!)IK\5F$A3H/JFOGKA0,]
M!++3R/21+6I9_3@#N=#2DCVP9_;4_8\3OW,XK19V-CSS&'F;_U0O)*#[X1<=
M@ VN8(J@ZS+<R0?+-4OP9$*?261>JX/.]N_%*HIM=D^<!MKJY7;V-9V\JHT9
M*V@;:NP^#G/,)JQB!2- F7Q</?BC8E5HSF,Z)UKW_251QF77AOA+X*_CPG"F
MA9&K>TPZ'B*/Y[0CL3>5XDIRRW)--,W9)0([?"'1;\+7S1WM'HW,A\W%J;*3
MJZG.^_>9)O'*^Y7F,K06%YH'Z827GOUDS?!&5Z.25>C&TKLO;+:\=P: Z#KP
M1TB^RWR+%S<_RIR44Z (W,+ @MVIF0;W<R)\W+K:5/Q;K*X<O"EH0_2IWW:$
M;N%8 +\L'<SP1I4I*DRV7 J.*7&"F@*>>V=)#@Q.V*+/:)0(A/&-!?1 ,1^P
MV[;QMBP@$<<(7LFEJ<#7JR@WB3$;(428$.CXU);RP.CFW2&#G2\0WYS7E8_*
M'NP&L*\&4]VS  9X#"0G,P=+)3J.8*;FS2DJJ4S9M>+YU+A)> "^,272>?UY
MR^WF!U1_Q [7:QR31Y-NRK"C:5'T!EP[C,C>3XG99S\K2(0L3QR>?F'TFW#9
M<L&=X.V]+(#4H1M_;,S<(%Z3<CRI:7CMS[5"9W=;C2OBJ;EJ1Y=OOR%ZHG(>
M#6.D&:#7)0<R8FD7:[PL0Q;6<B57U Y[)+CT_-9VJ,[Q'/#S4<2$KI]Q%V(8
MPQP]"1MNPJ\G4=ZO>CTFWQPX^FE@T]0L,F4KL+/N YYV5&M]BZ).VJGKJB*'
MI1CX"#475,[UQ&L@"-081%@J!JWBA['&.SPJ$^C%3J.H5K1A\B;U.2V*I"7,
M,)X"P^_^'ZZM'6TMLS)'0Y8<+R\GY4,7?5I$G$[*8/NP:2:P_K!T<WFR0P8Q
MMM$K=+0FU/0%1^8#T3P>#J@U[^H9>=V4%)]4/ R_\  K9<Y%2_XN'<9+H"WW
M5%C3C[027[FVN?G)I!5R?%;2S GE-TRY6[L0"O\@"AIQ'&U#K.L_>V)0TU2+
M&"9K$7.XIZLR:.JI(NQ4?:U]@AG='+RHCF(T&&!\T(Q1M(E8L(=,#<<:2(K9
MGZ=D&%W,5AIX S2^E!<\]1KS&=31^P),%[Y1N!Y&?MQ^YHP1:5J(L49U9?+,
M@CGY(;0Z]3RY-+4=0=RW[(FCIALL54ZVW?/V,&EZ5V"]MOI*V:GT8IC=GF\6
MH%KQ_V]E??H/4$L#!!0    ( +V ;U@/:0KTY2$!  4R 0 0    9F]R;3$P
M+6M?,# R+FIP9Z2Y>U12Z?\O3EF9F9I:6II0>:LQI?(V>8$Q,S,SNGI-J:P4
MB9A*DQ2A,N^94TXZ:4KF+5.D$C05)05U&L?P"HDIMYG*^]Z3XDX!#W/.6>?W
M6^=SUEF_]?MN_H&]-V^>]_.\GM=EL_QQ60+;<.20WR'8BA4K8.<T+]CR",S[
MWT__I>/?(O_5&BN6W\$,U\+:5MIHK=@!6VFX0LMPQ3(/AH#!5JS^'S? _N>Q
M8J76JM5KM-?JK-/5W,#: %NY0DMKY2JMU:M7K=)<3=)<AZTR7&VT?:_7&N,3
MY[5W7-NX[\[#DK66!UZW;3K9!U@Y7KA^5V>=B>GF+6;6-K8[=_W@Y.SB^N-^
M-^^#/H=\#_L=.77Z3&!0<$AHY,5+EZ.B<3$W8N-NQI-N)23?2TE-2\_(?)3[
MZ^.\_-^>%#PO+2NOJ'Q1]?)-'9-5W_"VL:F=R^OH[/K]_1_] X-# N''89%4
M)O_K[\]?OHY/@/]\FYM7+$#?%__M:P5,ZW^U_G_LRU#3U\I5J[16:?_;UXJ5
M\?_>8+AJ]?:]:XR\3FB?OV:\8]^=M1L//"QYW:9CZ7@2V'3A>M\Z$RLGJ37X
M;VO_O;/_;XW=_?_5V?]J[/_I2P1;K[5"LWA:AC T3*W>^3)^,24U'^^L*+^%
MKQP.*WF4V#TL8['NK("QZ_X<WXC/TW)XERC<0[$DH[3LY31MQ@N4==\=[=YE
M6,7\_#/]#[]--VAMX<.?2)[JK[5-[EH%3IX]#^4"4W?14@^ NNV!1T"I%H2H
M!Y+T(L>@R7>N!MOA[L"5ZA\VQN;RFO1Y9WQ$I4DC,SZ_.%7_9J'L)/ J^GZ"
M^]=0!.B5<Y@LK%'K^DF.8>RH;B=V'<IT'+W9@Q)WYU8YA&^'KQ;&7>YSZI[&
M=[K6*]06=8-C?T\CRX$E\7MZ6+2H-H6.N6126/NUP2V%8*=X!>E6D0K5AL$H
M>]*AD9!F02Q=B_L(C[(<F%O"P,7X8EU@X8%3!L5"'('!GY=[H@@&':%G6E1C
M:=?B+U5,=LJ/Y/T]2[C:3C:5(2 ;SA2#/EFG//@&FI0EV<DI53(5IDOM G%N
MR9%I:H>A5BM26^MVTBF9[STD&R<UV#A>P.!FC2+?N4;H]7JX2GKTQ6VOQD5!
M*7,T?9SPVFB/-!M.V#MFLPR[BZ.\C]@+?.%9F'>(3>/L8Q9DEQBI$A"=_EQ(
MT8]&;3L<:V &R3L77Y)N!FBU"1(H]SP(5+F%XR'P6'[9\/A-L_PTLHZD>FW9
M@+G_(]EQ@T8BAX <3O0?G')*G,WAZ#T*\&Z'(\$.UB?*SH'ROFFE); 4W.MD
ML 4O>E"WZI_Q>D.<:!F6X11N-"90_V.N\CXQ=(50,WW)U- QK'\9AN<,"T-!
M5QYU=:@R"C@*WP$%540G\!_4S%LD#&#2C@++L'2VK12Y=3QB>QVG"?]CG,4Z
MHBYIH5U(?_EQMV)"=/]XP)X_+ZI_)D6J=?!+SB0SA.XHR5V1,\CVE"-T)DPB
M;/J40:7#:OZ&L#"2&'-[?#$J\R_@S.SM><2ZLZ/C*/.T8\#HX_J2RDE#7_T,
M*2'!MY WMJF/91<]H-8)6_HQ-#3;UEM5XW%+N@PS&"_>E=8)-^N3<E2T6LL!
MYZPB.V[$%B&=%7Z(F,:HA?AMBXQDLCM>^I&M)U.=.@$(DG\6NM7F5+[W,-/I
MNXWV9<<M75;_*=9GVGOS(I#0$M!UN(^)78%#&\U^AMN\:FW!:DTV+%Y^^!PJ
MMG?U?]L\Z# W&G9*$(MW7U-?GQ?RH 3_0T?]Y]6YO?;H:.S=A ?ED:7C-%,U
M8BRF(.=^F+3UR26BK&=E8A&F2Y 7E%#T)<5IY'Q"@ZGH4P*A_.^1D=#=Y03Z
MC-7ZL8-MZ#UD\V78JCY5L7*3I!J=YA8TC7QIL!HGBFJ/CB7HT3E1G>Q7 K4)
MHVWREO/D,FPC1I(H-IK8!W&/04BIO]Z-@_G!22O_\!=OC( H_&/JOM?U;R;1
ME]"0+74J=\F2?*0.*I%0,US@-B J7TI/Y+I9\#,N0VBB24IY!#;:OR1B%_#A
M3FFX&"KENJ&*:J,U*]7(S@H99.8@H+_G]SM\'A1L_@G5"_"G'RXY0W7^(*6Q
MG'P%.!N*Y?+3F_CMM"W4*WB716M!LKS'M#/TRQTK0#645R$0=LY,=E LAIA+
MNK1M(V,V--*52T7VLX%B#F@[O1K M.7IT$D<V3*,J]DK!)?2+2T"-N'9N$#/
MYLE+O^<QM"CV6[;7CP.L=*N!N-7'?8KZ]_QZZZ<>[,,$H=((K[@!;DJISV50
MA"CW0;I]7%'4B26/7 K?)<]5 ;<"B3GJ;:3,D?"Z ;+VQ:8O&7'H=,0FCSC9
M[Y3M,1P"6.8B4M<]X[_\'M3OI+J^#&M#<B[U^/L)-%!%BW3/@JVY+\B.8%H[
M>GUPS )GU15[%()DW%F\&7HH=>]!<[$?U?IWT-)M]4RH4-;\EASY4E7',YYP
M^S6HH2&_/R34.V;%(JZ2TB^&L1R?^50J"1".5&S5  9\29W9 <ZF7<X*9P&[
M!B^ V1WW^V(PZP7%9DFF9]2")@=[.J>.9;FUP3"D>V\;532BN.)RLV$QOBLG
M->$YWDP[TR.@Q*N4],U+0)Q7F;>[) P)TRL =7YDTC7J2X??6N&"H[+.L>O3
M%1_J.V\=O(;^8IM-E>2CW_ ?H+8MP]JI5>K>T#^"ZYL9>+HDFH%:RY4VQPOM
ME>?/)Y5^?>@K#6:PT=+4 0]\]4_D_>4Q#\>%H;R;3:.?[N)'#P<*6!J4OE/E
M.(]3K$='E:?R/E S6YT'E>=EN-@ K-2"/M_R>(P&<GU? \<RR!YV.DQ@[+%T
M-@>U"VBI/CO"&JM\AH-O[H][+A"%Y/VE-1\D_<(KTI414ZYXX*2[XO Y!A/(
M%]Z7XJO&W?)RX^)<<A-$E^3T%%69\=IS30\2+],2#PZ$?7@1W#XT\6(DWW;+
MUJU;OW52T@;CM#._,R0/TH!(B6N[6%MI"^3D*#U1R9))^P.Z^):P#A0BR?\X
M6Q"7[<TSZZQ\48C_;9MK06I==4S\P-IG#_9:RU?YK+LQA0;>4"R68;T+DEGE
MKEBB^N@S?4&FC".]J'1?AI7,MHFADU_%RD)?Y6Y:&G7.$]*<71>NV;BYT5JL
MYV\94 A:?QGV-1&(5V]L<EV&V?0MPW1MI6*5 45SOCW_T#+L+Q%L.H8NWY3U
M<US.JJN[K_USD<@]]_A=E^6#PE?[:T^I33!<SB)<J1E$BD/V,NP]*_";#'$[
M*J4TK2O"P#I3NRLC%CU_X6#46<^!JK&7QU,W[^0KPZ*UVEJ=U +:.I0.2=@N
MUF>'+,-T! PY>O-7L\I,)FT]2>N=>B<HJ#:]YT0(Y1X<]/"J[GH6\LDAH^Q3
MA%@WT4YUP#^N*4\TO9W_JW_$&U4M)\J\Q?*4P!:2 T*?'+\!)XLHGL!L&9;M
M9+%#TX@+W/:MR>+18NN!V5G"C!)M/5B3M6.L\ZC18;V^%%O6+25&[CO5L>2J
MO EJQ(9B2UKH1)DW@C?K@,-D0^!RE>JUA' $>U=Q/<9-T? "DDL)'UBK1[ZJ
MW=E#+'^=-8W6S >TCZ&81:<\1:I=S@.*@V9S6J,O<++,J/<(\]1,$T$07+\!
MG*_(OT5 MA$BS']3VV&JO< ?[&]X@]HI+ O+H$80D3K2%K%U $F<ML'JARD=
M 1]%0=Y" :7$H6G%8C:#,L"I6TAQQAA&4ZR@+X#<9TAIL=6U>$??/'H+=+/[
M5.\%VA3N:D%/_DC!82-9P"F_PT/+,*IYS,UNIR.RTUD9(&*Z;LD5.O"%=Q-E
M [5(Z3;?N&,NO>RU>=?#W2-(I;P(V[1WCL/>DNIH(W_:%EQ"@C( (+M]8$GO
M#<[U&/TS&\0:K"UQV[14^=>7NQQ)?H*_T@>,OT^Q5/=35@ 5-*F!&:G[C"I_
M&W0F":CK$''NQF(R*+NA]PQE0"-8""W#I"8YN"37K%A&EET9;G$-&V4=03);
M:"\V'53:R;_:,^WL;=!^0JKDD?A-:D-DU5>S^&F$/$<7\L8.&!\!35.?@ZYM
M29<3(2>"OTQ0(DEE@L?JI!;>'69NI/WJO5#JVFFF1:1?^,U)+GS%("NK^B/9
MFAA9?9M")VDI4B$,:*S!D4\):<'KD9"KWMK+QL@#;$\(=L<&W) *GLCH)GQ>
MPA7L!J?F)6A&:9M(J/Q#?H8E\"@LVO=/I[KS[\B"T5(R'B&:5%SD#,0%7!Y0
MI$/>U.=??QE_-)%0U,!#ZGK6TO0K7_14A/@ENBH>E3>(YL-P5TX?C=S#A!.Z
M?\H5%>:D4! :9'ARHM K0M2#(C*'Z=(H^XV#U]NBM),UJ["A$)I00_)O>P-]
MZ50[P3<"GTM+("*F\,2;>R2-#3K@3S-%IC^)M0OXH4_Y7<;.F\V &!I^>Z7*
M;=T9@C<C-'2U1$H_F0E*P8AE6%#.NV_D-:R!OUD07XXVTRQ YP;O<C%D>>*-
MJ=]+J/08$_C\XK6*PS4CWE'N6I/O<2/T[-FQVY1\*%=1H7I*MD8U5Y(*Y0OM
M2 ,LR<7<GV$4.B'>H'2^(#KJVC<>Y)(;8W>C:C>809_O^8&T(QK<,VA?FG7M
ME\?3'O9@HE28/5^4V*[6A^Y($490%M=E,>!S8QDID9<0P7H1?;-@;M>-DD\Q
M]0I3XX!-+:H: &,QTYFLLME<_CBXBLA#I-  ?_1*1A8YZB7Y)M0"O%EH-[//
M[R"N(6L!F-LL\6HHG134)C:1JYZ-\!8;TN,X&Y1N *69\#*I3MY2RWD&Q7PY
M RY"[A%0HC3$*6=KQ+A+H)L+3>$[E;UD2M91_8+:0?:!\J7\!PNT#60_^>RZ
M8-*N2G"& ="O,AGZXY1=0\H3EV(*^"ES=.W30MNP[$.Z.K7SU556^4?[8\M(
MS]\V$"2(E]?>L]?KNUA&;?OR\X<?Y^:5"88GA08('C4M.I,#%)'V;'A9ALR(
M/7MQ_;D+"\_V=['0_T&8S!6BOK-!_TG0FNNYP*PZC:--E?J74O\AP&XR@S;]
M'_@9_;^S_4\6]$T=U/;W4/PRS%N<S '*^SC?77+^@^Q[M8O4?52F*1<[G"6E
MIJ/VDB,$2#(:6.*:PK>\&7(.=S\R%-<]-,C&RE0&[XJWO*KO=_(/&STV$WZJ
M V[5[S3:&_J;?4K_I[$ (G[]HP<&_JHWZ"A[K R;TVH40@X'Z)R<5G.E-S#;
MCC".;FI][F2'0^TB5;8ONMYG<M+&$!Q!Q^.T=.6Y8KAP#J_"^/3.$&OG+*MQ
M@4U_X!82Z/<=+U &:;KJ=>HAK/XT:C,DEJ4^KH1.Q&4519ZNZ_7 2KO=Z9=J
M/:QE8ITNW*UK\=9_%.*UP2BEE0)^HKX L0%*//@4\U>'TSZEJ[;2&*F(9@T1
MG+/0(CO>ZXF"\K\[A#S[R-,"BAZI,@RZ2YZ])V+G-U5P9%C=F%#!'8:8U"!I
M2/8(>@GEMP>9F90RSGK%1[W869]U-!B&/G1.5<6)RIH^Y&D7H+'AJ0O'WV:=
MCG:"4-NA<\P^B&+5*HPPS3D9G3%08_7(_[O'P*;7]8W?QG;6S%STOXE@"J>6
M82^[I=5A" T"UCO4*D.DT_X=*+/ZY"X*(JSG!C<A 7LV)F(;L\'M@:+_RJ'<
MERK&\1T_2@ANBLUC7EL?H+>P.) U+24.G>42ZINB1BE_A/R7[$GQ$O$=MK%4
M9?<N0<Q]0G&(H3@"B';,9K(YD),^_Y:%3>D-QOT233&!*L% .<]D&C3O*-X*
M9:'OSUP8)*]^-F8]1J]:+$, ?HR/<O6F0RU Z6E(6#5YG)0;GLM+8&1>'%2O
M]ZKY-#82K;;.\NW_TO :Z,@KC),V(S:31CK$&R[WVM0]&C@+KFFN&L&+KPP@
MS4QAJE7-JK?+L$LMCKPF=(JYW#>UO%'HL5/M-,#Z2DP1)M/9UIOR&N)1=8DR
MUHF2X?*7."0QWF(4RM/3P/MP?R<QSBZZ;!YK3$Z"]DJF'=M#&^ZC]I#=@/I\
M^5L"DFU<-=GJW#?G3S09[B%<\@A2FQ6>:&)EA3$+//V/C7@F8ZZ&J@6..WH\
MKB&ZAI=ADASTFY_ZY^WT[!398%3JS'QPK>7@K).%MR0[]6$UBB7CZ)$:>/T3
M$?IP(ZINQ$C,HCC5J7#H5:'?FOY%@3C4=-_$N/7OB]<7% C5;_.CII*<-+(O
M:,8-ZD.M)",!TW;L6ER#J++]_6X64A^RZZ)H0[F)+R9-Z-+/J?;83O@NB"CI
MSME@D^M<=._AN%[4)4)D94S!HU?:PS1@D%KWJ>IZI$;=:\P-M+Q!Q/$3\MGU
M-:)X[LCCPS*PAZ?S<F_ 2N*^3>$^R3OS9CX@=Y_]--)F106&:'7)11'GEWXB
M6_FC#<2X4$KC3BA-6DZP63A^^/.K.G9ZC-6(^;U')I'7+VQ)?'MQ+Z9RK,/@
ML_ >YU^?S4AA8==A-,SR+7!(Z2B9W0I%RJX62A*7.'>1)3%P]  9 ]!X%"<A
M&Y-$E-IA#2>;HCI,H%/Z#V4,[8FQ;8-*]\JOZKW@X\I[T[$K7H;6/OGFFL:1
M/#33YMDCNES$S*!I7ZGG%F=_/#&M50\0MWEBI'!6&4ZL'=N,S'CDI5$97L0^
MR%VJYQT"FKR64>_#D6!XCZ+\.5XTDUTE"OGT"1)WFIJ6S/4:B%21BCI(KU0/
M9T^QA6[P%M1;A>>!A70F;4V,CJPGDKM8(UCL&?"J'D_8_K:9:0*2$K%+ISRN
M]/J5C1WXW3K5!U,V]_VOPNZ;@6O![>LD7?NV6(;\&J#+W?C:[]4OOTL>G[N^
MG]&5M@R[2Z"\MY.AM2<?*B-:O:49L4--=5D=B/61;T#[\IR<5GORD=9<WO41
M4HS=TK0_SVVA"YW9=(Q!<7;'-V>;=ISZ_4WYS)-*9TIM3GHQ#-G"CI.NMNSY
MF2JU[LO?/<FT?)@03]@LZIJY=]SMYQ5?-P89H:R4'C M.5][*\Q1XX4=LOD<
M)66A_+\D C=0.X<D?4[5JHB9B\Q7?5.S<>%'%G$F[G@["Y>^689#K56(;M<F
M5MF^L_N7G+X;/M;)/W7Z/^J<I>9X^$BPIM"I"&"4T5&$;A\@I1T4Q!YF^TN1
MYM$BW\Q8K9?C#2ZZ-1#^M*MQ5^7DXNG^BM*R\+-AGT([7H2%%3:'%6+=ML!0
M& "AW%BI. 1V+,/28@.AJAN2Z: .Q8T8BFZ]1HBQ)F1WC!ET5&,1BO>A]@*=
M=)F]S8#WD'*_:0K;6D8X0(CQ#-PX,.,4UH(XF<D/2O3WSXD$D=/92X[0*6X3
M(\,9_8"F?_E57ZM%#'5C14,_^TS%I%EVUVVG0E].84=@H%O<WQV*DDJ?&(?+
MV#K>MU$O(G77/0O+$YD#WX+.:%;\+'G=D-/O= <.GK^YMBZ1CB^H?5TSOFO)
M,UIT['D<W?S=HDU%CB0,O8IQ9[<#^50Y9'&EU08?&I5F[TS-J)81DI2APJ\%
MZ\U,MP/5:IV] +)=()I-^]<?&Y)&WA%!':6?%+EF_!^E67\_00L#M(B38PNQ
M<%)R !"173V1D$>7VB=VF;FT//OXJ4-2C5,&);T("0X_M@S;ICTAJ%S"JC\T
M(;F_4VQH6<5&0TK+6]>D!)?.;URWCLIT)&,^!Q[QZ2/)_]";OKF!6R\^Q2R.
MCM*5)C?7F02((JH5R5>=ENX6Z55.(P']&:XOIPX:!RH4W3R**QNZ52+VDHOU
M67G-<KKSF2@@[_'/SENV<P:_WSV4*3HWO6FH)/#\K:NYE-!Q-'"4.#P;!#6#
M05T1*(@E;1[5"A62]6I(V@& .-L#C:-75)<HPT'.M+%L&;:5=)<X96^' 1K2
ME1@0W:4K74JR?)=R93<*3D+[#=3.)QT1\YHT:-@N OA*8XPB$9AK1;S-4N0+
M&'&;R=8R:AK*45 L5!#ZYPW,E7N$9 O ]UU@A,X#OC^$PS]7NN?[ @WO#-)>
MA9$&I,4T*7;+IXB/W7&W7I[]],EYZ#?M\3(T\\L['0*A5@X- TUX@F]7#M#:
M*3. DW#T.$1ZZX4#Y$V1UVQ>!G[AZ3F6G<#UWMF>4OKTO5FWN86]J5SCU:F&
M7B\^?:694! Q]6K$H'.V>7C^4?!F]DW1,8:TY]21/E:SWJ&#K<7F_BVF9\ U
M:943>W['=C<*F"7&?S;DR; ]!@::*JZ<*+IN^(#'<1KS\7Q7!HV[A_PC6%]1
M@)GJJQ@F":5K<BNA**[:3-.4=-I5RD1M@6Y51L--@4$S'TX&RCQ:;0K6_(*Q
MY*0?;;I\K_[Q=@U<KRJ-X.:0!@,812N8K<@'EF$'ZX#CA^V789>G=Q W*IV!
M+UFM:Z"1MM:5H/.';&!,(.EX/DFMXW.K1[T[ H,,H8:.H UX' -?)YKT/EH/
M4[GD*)(A>]N[K-ETD!P"K.<8L&U?8LI(M,XJ6=%>MGW)1+U0(#HK2E)4?4DJ
MMO":MYMT#S-/S(A4#X6-! V<'(\Z>FF"QM)^U^R).=/['*J6C-[@P<VIJVD;
M2%1NJ)I62TH^U ".<4J@1&Y!7F49;D%?4'"I0\VI.#LZ-NJW,>'RPY^=\7_?
M'?:A)(QIYFT_]7+1*06>J2I@J#W\T:E3:E<<QX*INF4);2IWR:>+<-G/1-"Q
M@7>AQ&2F.+6K373H87P5%N?F+$R]:I"J/.,1L;,W0J3H/OBZGQPIY2N-@A24
M?I2Y2(F"[BP=X5>-%U JP=+C0%<J>5,2$,^E; ;64[<2V1=;=Z8=&IHF&YZ7
MT8RZB<]).3ZO^AS(X:A*O/2%TOY\&73C6#]YS_G^*[?1)Y262Y'J'K4GZ% E
MX6N3KT'79'I$?\&4QVX0-[:SO]:>96 HCG89LTWV U1@8VIW6'/ ND7>IY&0
MHQ=#D/:1O_A:3Q><Q6)&3!5AM_[<H^ZG:GW^M>?2U5Z#3+@)_'13ZILFBT??
MDX]OTQT]*3/W#[I5L/\OI--)W<WE33G_+ 1JL.!+>:^V!>.683R#+>K>T+0,
M#QR]D]OAQNY5?Q!M&/P\\-,R[-Y)K"Y.;0; <TN5GF^![*&\AS8/7T*N ?W$
MV1HGM%YH#-]:<&?]/PD5#?_]P>Y]%FG>+IBLP6'&+2*ULG,QG-^6O@RKF_.\
M(<UYQT].F$VKB2QL?]3>=(@!<"27:!J*63 UV1-,_@F<']2Q^% .2]>:-MA(
M&:'5\9,K ,%CF4%Z?5[K;C"B)#'J.>0@^/#M)-C3T5);+K/?,_$/A.J[)-@]
MM^4R,#W1)3/OOM@WUD>(6T&R1];\E2]6&H"V[\3&3C=!;2[?Y"O*L6_'8)R>
M$0'+31BM8$3A7N*"EP(+;]C7-!AVO BMZU!DW;+2S_K!KY'-&_UNC-=TQ%4]
M/=<$%&*6CI$TE,,=TQL\![ID/SL[@=6R*E)O/TNR;:>L$+ )=-*CV;:@""L!
MI]X)H_OG&RCRU""BW>Q@JZ50_TEID9O,<P>ZCGJ1DXQ8NPR[R$^Y0?X!:.@8
MM>T(M>!GQ6$WCWR"TDY"<<\KLE35%5]%5U!F #]-J5<.80\ 7]*<)L/M?5C9
M]*=9!/=/[V-,='D-KV!+?SC^UO?FV%^![_>C]V@SY)A:.%HSU0:&FZA2=R!A
M^K@+S3CZ2[36"F]GR068Q.1[>IM5P6.4I1+U\+$EV'7OXLUS+Q]"68?C+T?>
MWG1RZI'?U&K8S=C3Q_EZ[5:_''[3M4/;SW*[/,X65GV_:ORC*OJ9M@=NQZ\/
MSPS="0P\_JYJV^/M=U8?6^.U:NMUO=,NZ?KDMT^\?ERS<SA]O];+ZX>\K'*?
MFMTL22)6B (28S_4*R8_'^WC7OM9ZOJ#T2\BKL<_&_[D6)UP-WRT9H7E8VPZ
MW.S'GLYG*RPP:>RC;Q?3^H(0![RT'S!7#"856'8-/_^24[#V&K_6^,?YKICO
M6,5+U4L4G/)>L^W2,L@$*2&QXP;TK>LF5I]M+:5JARL=^EA%6)XIR@)$9LW\
ME10I-^ 9I* -YGI<?0'&/;*/S.*D)N;WI+2/BP(^OG[3VKBW"^N%0$!1VJ9!
M?RD0'^&6?ZG-?,BTI0#E6@B]= J19B\G;B4?!YB<]1Z^#*B06Z=$$>*Y_WS"
MD@K;$F:YTQ$6P>&DL-.9,SKDO;* F,Y1P<[:J8NMQ;(_9#IA<; ;< V?W_U5
MK3'R0'ZJ1J+!H(. \ZR&HTGF,C)57TD@FA2"=OZ]ZFWCB_!*Z:C+ E?D/5F_
MV) ^\QST39.%(]M%%1SCKA<=U*A;MRI^S^_!1F@J9E-ZU' H5RI.G6FU&ASA
M+:#,,KNZ$BP8=QA*K?,XV626G:?Q">%\B <65TN*<<_*@?PW[69Q]$,G>Q!<
M_F;#YQ@G-ZO09=AM' ?PYWQD<"G6_62LA$Z5<^YHC(==MOXW:07K&30KVS^H
MWA@1W;I%0PF[*B#J"WP!G'&KLK9*LI0=QC6[EW!O\>FNYY/Q@H+8FVO<M]@G
MAE/5.N#2#BAU(7QH9IZ3-2X+N$IBK9"]]3@#KB(Q H13,^RXQ K2<X,-_+)/
M$Z$Y&<PE<09\3Q,!'Y$?V#KD$)?57!01-I+Q]\-WJ$Z ,^V]M!\:D<'+@?QV
MJK'26(9-7W3)EWGB0X'ZW.L.,W/9Z/:(W:#!'>6!15Z>XMLPSG%\;#=0F1$;
M5-?2^& &-V<?,BUY&A)0UUZFF;DG:J[A),6T3PJ-2/&%:-/H"$_A'-]H^&,X
M^MXC@[36'0#R'@OOWG(S<><SM7"(Q<F F]0#G8^C+/Z>35\E-![V^2L,7?@0
MR%5XJIY2]$B+ S+$/6601A5 O<K;\[.P V,V((U71.)KWX\;]C@AIQK'!-W
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M4?LPYZMQBGBMA%*?;=K)D*MZW6H <9R3XP4QRJ$L!1Y,Z<J)S4D51253G .
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MU[#*QUWVG(T)=/F<R+PU:__,SP9C",PJ-QHHSH/:'8S[Z+4YF5:]\XB[Q19
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M7I<_&?Q#&0_%O=!SX/H-AC 3TP3G!G/# O;.C2#U/XV;! 6.[1C\*R#^T*,
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M)5G_,MQ",UW<7$%Y,NK&$(I7![IRREY8%(:^O97^<RFY./?RF&TF?"I2$H7
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M:/1=.SD*5[O[NV#Q1?6(K!TXI9)-=$N;27K$ >0]A%+3[/^!H/Y_$YK'$VH
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MA[9T<XZ6!"%:&M3M\^F-;ER$9^'TRF$=K#$5#P4C&^'&D*-T5AA;=(FX,/\
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M$IKJF4\LNW143S06Q>+#M3PGO)3E_H"&]$M.N2SK2Q_U:''_!-8D_JPPS%I
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MV>U[HAR=E'()%B(DSU)N(VI2?]%SFBT8R"8Z@0<[@C_UOOB!UL G]Y0*U"6
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M>#81,6YV/."\MN?W&><6W6WX%_YJ=UO3-L 09?+ $3FGN(S%ARPV#<M,"%:
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M(5XJ^D;L1NT7ZD^*):<OPJ0[Y7\AK"51:]CDIIAV= LNI]'>%=&+5D5MI2A
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M&:VINZ/MXY[:DS=]_79H]&Y9DZ2H\&32#5$4B !.4'@!DN-C=DO05A%:<=J
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M*V 8'/?HB[GHJGV&:5H]Y'7LG[L^WRRYZ,_OG!;3'Q0;!7:B79RTM, 3MVE
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M(&*N:=IVV:G[0\::R("MK<0/Q"O$XY!-Y -5D,C<.^:<<WH!^G):X8'1;JG
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MIY7#G:_B 2:5(:=9XH&(2L:G?A;DQ,&OHG Z;.B($/\E]*AA[9:_>D*6]0O
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M23+3< I%I<63))UFBQ%'*4,)-N<,6K.3QZS!WXUT!V +RW2Z">P=%T&*C;5
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M(X?<%J &%1:&Y9K7LEPX T1^HRI995:+=V=4.),'X&\=5:#9/XYW"-=@"X[
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MG<X0'>F</(IATK<C+[<.U8 "B=F2619BU+VE?][/H^X;. 7E6-[PBKOVUF.
MY@<2I,'MAEFBA7E$?A;#?F Q?[IJO3]_6-CI"ID5OJ$JS5AGN^':VJ$J-43N
M;(6C$>O#'&$F^<FJ;M3J3\(F,N+ZR:6]N0:#,UC=T$=4GLR,1=_9*9E@GAR:
MRSX"VQ>$XO"-0&T1\ZKX#4<O<F6/R&V(HRHE*4\M+28@4*9_7:3O5E$_DUUF
M5E'[2E^/TPEW"5\7ZQ4>R @]@F7/G<U#'X34@(5E":8-DX17LR9IA,9TS][
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MUB_Z)^K&H]^F:]T^TF,?:&:,$0P5PYN032%7#;HG0:^G[842@L6BA$71.NF
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ME@+MH+ HW$ &D_M\)K-#A#Z'3^2&L%,P>C2"@2\N32<>=LF'EB:D!C&8Q$=
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MWKLR/) (N<7X-"GO5QLECZ0^ENF#V_!M9EZI)3[<?Z#]-V3_[X"%_G]"]C^
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M=ZPH5.A;"](N]+["Z@,;Y,XF.XW*.@%7ARI4PQ L7^%]Q<':@X9$W5G:H:$
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MOGV!.#M@F\2QA'(XN=[P^P+G;*[D.REB;:M]Y.]\F/H![N7DU'#Q99X3^Q.
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MU@'$FH*FFKXT0:.!-4L?&%=57?":Q@#Z%^2)\C!PQSAR,??'.W";#?@#5G5
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MF[^!ZZ< M&+)6U^&V4YOB-#:F\OE+7#'G:!NJR,GY!7UQ$)&KE@4BO^*GY,
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M2>WBXER%4;1FVD!(OO65M'S0V[166?QV<P;MBZCS"PG9F1CJ6*=*:ZJ':WY
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M*YX*/NH-?5NE/'7OH#L\"6F3*)O9Z]_1O1SJ&&0GC@])R&K7OL<*B?@7F/J
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M[$_%E (M6'/K3:UL)YW8*'1-_K\19)]W_!D^[^."!=3T>N)[7,: @$35<?,
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MIJ?F1&A9S>BK^19"FVW60 C R(Y1J*]66KQ 1%7#A2BV%<Q]CG<NC*H&O6K
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M=O$N-4$&U]!%F90X8L-<>8B/%GH& ;,+:@GISK<L2_!L+#5+%]#BBM<1&]P
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MB<:1R_%OS D;J(DXV8J_>I\"!QC6I<8OREE'<5!7%_M^M[;3BY_0C."FLM*
M*W,D>!TF(,?<5:\-M:@CA865TA@YPM3^C#(HI"@^B["!<M)7J!)*AJ24F^EI
MNE!V+ZJ\TU(E.\S12.&VC,\#?*1+-WAKL\'#C'S %8ND*WH\D1SXTUE:9IA1
MV2G_Q8!C5(/8-Z00+7GPK_>O.-AJDQ+U-*K 3S(M5+(D!I*UU4RA'5#*JMVI
M,X",(@T9>ZWZ%J7^:.O+/FH#Q:%\)8*49VNNY2.1"_-O2*,"_HBQOV)K9BSY
M.$F6I?[N372USF"/Q7WC^$BXK]\OP^]1K:F/[_;7TGVTDJ*7KRLM?>TL\)*
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M65A1::^[1"\KT S=<-O9C=;'HI#[H 1[CT:05:Q>[#&5B9-K>;O?F[LJ[S<
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M*(<W6=()(EZJQGNJ!@?S.KE/YL7T6NQ9VEOLSA3)B6N9U-NH4[=-)3T3':E
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MU\R_M&HXKQY1FYICG/N,_ _S8':6?/FHY0IGB?HPD!-'8RP/I'4K)KH&D?B
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M6QWS9;T==2%7A/0>>=PA+&I3Y:U"J*D^&<E;%[&*.A@/H4"&'HS&A;=*W34
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MS9LPRT\M^K>24R^)SK/%+W=N$8_D!Y"G.%;N-N[O.(:A*3M0D;L!#;"+&SP
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MO_*_D_W*JZVPF0PRX^2)X('ALEC< QNGLK*(RB^GYIW,!*R%U@-5_TS]5U9
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MR.J>GMR>4#O#RT??1!O.(2)DTCF$RNY+V,Q!2/?#5.L<(H=1Q1C?#91I#=3
M'$)3""T%&A2A?&#41J^%8-RKN9@G=@T8=\1<_P1%7:: G!;94ORVUK((O@V\
M(=_YMH*1;%5[1R%C2IVOQ&;''- 9'!9_KW8!5:ABI6DWTSME2R2J@!S\QGY(
M7VLP->- BX(H9;28)+L6=2GM),1)F@F)Q&_JG2QH-X08S7G21W=I- .Y,5XE
M!-HHQI4W%0-X^\4.GWBO7G+5<1QH$^>+\<.H0>-.+/(Z?64T6A1J#*DK?%51
M_$51FM %4+R"?24A7-@6K/3/ RWF$$% #SM>[F9_#ZG$),/>C\CU%2E6Q S8
M'9N7OIH]XW+T/:4F2JMKW-?^H(M=7=)P\4KB8MKA]]J-4%[S',($K33BZ0$A
MJ9-YU^$ 1>/:7F%"24^J8H9C04:M?%^#-(48N\'!JTK'^*:+8_HBO/E[KH]%
M0T6$E4U:I62K_B>&@ UMLAS/ -HU@<#@$W#'<6BIBFA*=B:]F!+:()6E(I6J
M7VU-"X$:=%FW!P+&6T#+%KQ]%9,$!0-\ 0_=$4NR'*3A@=RKB2K9 O)40/W>
MJJ#12Y)A_"K ,K-49TFOR6C^+Z'X^[3@]UH4_1]-!S5+8)4MO@?HAX!U.260
M(BGQ(;W)-6_\#[YE;%F!/NL 'T)R(*4>0/+L*@+^K3O</^*2WUB758.Q#(W4
M(@'9^- 50@2A+UQUID[40&'R37DKJ-_W0-[NM64@2CVS12H3\&Q> +.?^24?
MJ&TU)+/A_/BT2;[Q</P< HGS+AF1F>+<+Y1#8?OK >?G)1_&G(D*833EQY""
M+3VJ-3BJQ.3(EC(BJ#B?94$<01'P:4*&&LN366)XYJ$07X46D&Q\8\IA#&3@
M%%]K1<ET8ETM1';KPH.].K66(]/'. *&*7OYELK8D!A1P@A"KETSAVCV841Q
MKB2KL%,B?C(!@=]PG+:NEQ#!8M8F()L+6)G3+NEPH(J1+*NR%&*D65Z@D0O*
MB=?M-(/6\RZ&-*3YU+*#K^K8QVJS!/4<UI?)\6V8+3B[$I"^2C?%S[1=^#6=
MM-UE?;3UL_>V5/-3\$NA;-!0>;!1/Z.&;:KSALNYUG),-F$A'NU)!@J1:7.(
MI=JUPWC]GIH*I++G6?Y]T"Y'NQ:3"H?(J2FY0849JDV.7)?I.XR96'J+56@)
M:&;=SI(9+NP5E/W:#5,8X=&/1YTO%1_F 934TUG"P37/WF.<*&CJM6ABJQ8!
M5!;=IQK^"A(R42HQ:BG0^+EPRNKKW=*!=CE;JM8X@*3DH1ZN 1BO6#B4'.OG
MZ"D=R=_5,3&NY]L(/7=IKBH='';AK7S.WN=#=VJ)D?N.FPWM"W3D7C#N<GU4
MF&?Q?<4N@CU.;PZQT&WV 6RNTID?AC%^6Q2[*D"T&!<RXP.'0P&@H8BWTK6$
M*1HW6\PXCUZI;9.9T$SX!K&L%2S+B/A0%##.8M984ZS)/#VHYM&81=[T<GZ+
MHYM"G&6L;D&;)LK&C6>BZ!WH)7,(,H7%UM>:#J--L"J%#;IE<.>U,96-^GH<
MR7B89PVYSZRFFJL*RQY2CWH #@GK)VN+5&QS:@[19.!?692THO8N+B]T2TUM
MUY;R?H&TM-NJ='QH!C'R?2QT=3?>!;;S\VX:W,'<6PA#;J2&WM;K<.!)57?.
M6/-\]/R0L<+M>2U6%%VY9UQJ4_*9(TI'MQ.U4(PR9'O2Q8_4\Q&**GUX&4%C
MTD6S*:?Y/9LMTEJ-H99+XBHLA?'UGV_>ATI#NR@87* \Z6BKJ\V[NX_(6K-&
MT#N+MHT#[P2&TG'$*)6CB3 0N%0LYQM1F;_>%CF60)=&OC01MN((NCDVGGV\
MIH/K44F]@W-["F^#WL[LH9WJQ!NWE<I&\PEB4JJKW56\O?9=_%9=^. RJ[W:
M1;TX:\M4W@8JISG7M)\:BC3/)GA+L%D<"]*)T=Z;P[3X)@:TB3B.4;%,:/H0
MZ2EM+^0!>K1JG4%OYA8*W19VZ<:2H/U:Z\C#]*[ITJ8R3!JAAIWJ>.[\1,8D
MRX8L+6%FQHY;"S1\$ZS[41\H'$0*:V^\C2XE%^YHF-W7R9<7$YX/<E0$-+2_
MOV706@(3 (:(A^V@KX8]P>6/F H6,\BF-(6G3W73I';APA4AWL=3S5OQR[JX
MYLI&XU,]7.OPQY==-!3L[!_UGK+423=M!H'"_J#O50=\KF3;\$R'?4'SH"Y>
MTQK@W?/BR&]1],4@D<E#CP4,NG2V)D?'J1<,4.U;!C$ FXG-IBBC^6D201YJ
M(_"I;?+3'5YC2?OO\P!*.B.*U$__KC'2%7$ ? IRC <DFJNS3_D11*MA*_1U
MFF/QF"M12$B6K9R<4?<E:FZ#<5-IM.B*D#[H&E$_D!K0BEH J--Q%XJ&S2-<
MI*P<VG*7*Q-C?*,1Z;C(-9PXLYK^+Q[9"%78I>$WTJ792A82*M-LA;:IB":E
MXW:/:?:0G6J,(V6(2"@=S$D+:;% )LTYIU>@EL\AK"%+4>AR0"8HD"5+]]9+
MJ69(XP@KIP"KGJ(G_$RN]XP/ZN[)T\^"/$M&-+XG+^ TM9KII.SZXZ'MZYNY
M]56^5%M?WX:[=@TS?MW/<A+37C6:[Y]#1+TR^SQ(/2H(RNX*J&>ET-8\ENV^
M.'5C<!2U#!B?_!)PRW?(Y[+-0,]=K"#4EZ#^5!^X4'2;KO&Q(N9?(=S5J5Q9
M+7O\B8K1]V .$0B-S^SIH[\EK*I1][$UQWH89[.)K;RU0#@3CX3]H!!PAXH@
MT&&8=G&V F: B7Z0N^JQ@Y8@?#PJ@3"!4#SF2EX3H0K%U''(O+'ZVMM*;U!;
MHF(CZ6^T.HE7?3 /;-!<EJQK!/^0<D1J$S+#0LS#JC/H-A!'B5XZS%L,E8)V
MBIQLL%3(<P)D5^E603HP8U794<V6O80E- 9:2#(B\]:]=WP@F4-4G3_O-%:0
M-Q,ZY-E!B;[U9FIO!\6AN(HK"7O>T#'17[:Q>L!K7?(AR9JJPA[?B-BV/8._
MC*LGAA_XVO=3'US[;' R>VF, VRC<'<1!="W2+C8HA'MQD: QY1G<4R/C]36
MYA=#&*%+?6W)?:KG%D?5]7Z(LJ\K;OSL=*M7S?%SJQNZSI>:KCP=< CY.5C!
M'I^<"7P[LP.B*$GC;F"QB#2/9\<0_*G#XN^06OXUO9=A_ G0%\OZ5$K&N..,
M*X31%,R6T2ZK1KB.T6?*:,'=CK!'!414LH7SG9 FVG_0)K@015*DN/]8#_?<
MH.N+Z3)-W>PKGCUF?)O*GM@WI'+,+9XQ)/,7S"'.8LRTG83JH68;AJ*TQ9[?
M%]Z,7P=]G]E%M5.VBM2ITZ=&4':2FCF$Z<!((0HX>QL,;K7**5:&V&NBH4 %
MWXQV*%GQM;%RY/T>0NSYV!"3::FAVZS^;MZ+VKK\=SV"&8].2KG#EZ\6RUX^
MKWK14)7?T_GF3$U-8+2C,E-Z.#S\LY?L=.VW8@GLKAA8VQE-V <,,9VR\<I-
MXU]C9^V$TUONGHRAQ S-/I*.OA&(!WL^]PR-!Y#(-86;'+\:MS7GN^QXR]63
ML_K2:;Y@WCAKYK!LA%W-$:O1VG=\_?,X#'#T &#'PJ+34&N RCJ0+Y:B4WG;
M=6XHU*@71P!Z!5J'*H#9K&;2'0']:[@-=2B[WL\@(9VV6V7L+9J*;Q5*3[S0
MTGZNVESCPA1(#?ICDMF&7+N9'2%C)%.>+;RJ$V\!Y6O'E-81@ZL M(B_3-LY
MN+(W#KT2PK]M*6TMM.V!3?EZ7+O''A1.A$SO*T<-QUED/X%\A:X[(NCK&[7)
MCA6.#C=:SY#)9U;>.- 1&-3?)Y*DKZV=\?".7K5OBA!>5W?EWQ<%R<8UU6?W
MU +IPT'4>&%]DC!D1+L*^,RF3@58?@L=T:([RBD/^0U_A83(&L=+KKL0&7&Q
M%E\_3SYR.3JP^<1;^W=9JQ%:1C4#VHQN)5WG.<[^46UOXRNG-.WDALWLT0H*
MC4"98*H'Y\T 94I-%LCV8[7,(9;1C@', ^#R)Q*2)C'MR^B@7E06'SD:NC:8
M9 A]'CH"JM-PNXOZR"Z\NZ"]YL'LPPDBM!'9@DS1;@8Y&5I+NA!O-5O&/RM#
MC!%6<9VU2'XOUU%%22>\T!EFM#7L/%N -?0C"J9<&$;T1;0+4&/9J/,<PHSN
M]O9RY5A>J!/(3Z&;1M05+NB@$>.4T78:V8S^+I=<5Q9L.XC2ON^L\,NY\Y@A
M(!0G->Q_ML.0_8P<P#XYXW7WU)9CYW/?B'T3?ZU'DX^G_+@AS14(E&XOS\?.
MXC];?[>.7!IR//!$RV.G/4O-(Y>V+\BB=23E=XEZ3YW-KG 86-)XKVKO//A'
M,*-Y%P\/U6ETM'PM/(I?9=>"24-7YXVW@OI*I)"RA'8>(CRA^4,QBD9O\?37
M5S,NVHX$WG.%SN*0/M1:%98"0H\J*%5!,(&R0M-DNX':LLN5T)[VYEI+:=A8
M_""Q@[$$_PL<#)JPYA +N&!["C]2UX_,:7I@LG)(3)I'EVA70LE <#/= FI3
M$3(37)KX4NO60GM _WILA?,O1^6)-%/HB1P)!>2BY\,V1=+V1S(JQ:NF06>S
MLBJX_;K:U=9]@ ($"2'_2M/N*# &Y*#4?\1*U:%.KJ-B=L>A0OG=X^W8R;0"
M2MPZ4?O.[=7B/>%_?OV'TW#XW+FE=V\)B5Y1KR87G7Y6=42:_2_%>/!ARV\+
M:^Q?G\DU;-M=E1A/<>J9VO%V0:=8CKY)>LX>+P:+E=Y9!/F#0LSL?>X.D*30
MI (,(=N([D1SAW: 1^6E6?@5@? 2*"X>*!7S5C="E)C*%H6CAXCN#L8I(2^"
M&>S56UW&6-Z^X55%I(9D$EM!%"9X7:O/^QLU7Y>'9JT$;<[%*AN("ZGFFL!N
M7)2<@H1#H3RE,7WL$-@]E(+%,!DFA-.L5'ZU]D[I"-T&((E(5J-!E/2X@:.M
M"4/">>5C6JQY8+/BNS+)M]F5D.D8U\[<QO BK[KPUF%DF3U.>[SPPH*U45>7
M+%98FOV@GVF]C0ICMI.-#G.?H+IR#_UP1ED#[^XLZ1_!KP!XM^?WN^<+2Z"H
MW9('P3L7-MUJ"WLAN;\[?'5#@YDT>@;WX.L7'W/#LJNK]94R 0G:B&YAL_BU
M[5_Z@,%>$5N?OHJ& ^U$:FF>8-!^]IY3".EH-S^B%U +9'VC4R*\"5@GWH@-
MII8[<O542//(H/!L&I*0YL0R^BHYSS5T"%T'MO S8.]%V3/4QE\6&!4:+,BY
MO.#:[M4?S1X^V6G_36XT7!UB9;-[,J(ZVLH]U#<Q<2<VMJ/Z8??@N\Y-JZNK
MDXXY]!ZZU=,Y&.@8[3CXJ:BFYN9X=*=;?$1.^HH5-OIZZPKU$3&%",2\]PA$
M$^+0_ [/98B>.822,7$N;JQC5M=0Y\TA.LBA>V0P49N=TYA J&?("=..&^?O
M_WG3[W?.4L9K?]+T)TMMUOZ)H/_R*T+T@-N@E(GY*6@$C E7L;+G$.:XE4!Q
M<STS$\;*HY!FT-"):D![.TF%7$EBG*4&"/WS\LK7% 3T<.K6WWFYX/+6@9 3
MON2HD^XM";?7W6SP7OO"]=;*XZ8>>M<0[L^KM3N'/1'KEW]#M_+[[16]7X;
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M9UL5M$(+L+((Q!R':I2L*U)]Y@3+F.K=FNLL7<@>GP=F\PRII"/0':5C>#-
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MWIC?6P<%!SDJ-L9*?M$?1F<R3C(^,(1H(\X<(ER6(ZMVF!;??A+),^WFDL)
MDHJ@$Y$(2"BJU5K,7E<S3HV;^W6/Q]ZS:]Y&K@W@S\<\Z#K]2N*4Y':X 0SA
ML576T;L"[8-.1,*VNFX<0W^-7PQ89I^?(&0%Y5V/1:-HMI $((@9ID[1%#DI
MN=I:EU%M1Z$IY"9OVX-E)*,6 -[" ;3(F;X*(LMW*&PBW9WMQRF!(/9S0X6G
MTDUM2HZR?%?/^6((.NKB;4]G(W 4@-#,1]-M(9)F<O:N%DMFU!"SG62IA6M
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M%]Y*8$I,3)/&?]&-4&9#YAM@"7ID&1*+26&5#A,6E-,,GTA#A^N];G/\0-]
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MRLO@#NV,S8JLJ#'X\38D[V/XJMC2<<4IV&.Q_E' [,-Q)[.8A(A=-!%=I8L
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M-@7ON+G'KJ;UR /)KE*(2+Q?2TYHC&?USBN9\*.X%QBM@]%7)&AIN QAR02
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MM8<9$3U;LCY9$+>*Y)KMFG6*Z?HR]O[]T?(CO[O]]T_T6)C;_P%02P,$%
M  @ O8!O6(F.#JE;*P  %C$  !    !F;W)M,3 M:U\P,#0N:G!GQ7EU5%5=
MU^^FI05!:9"6[CYP .D&:1 14$*ZRX,T1Y 24*1;*>F4D&Z0[@;I;CCG'O1Y
MWM?GO=^XXW[?_>-NQF3LO5?L.7_K-^>:<QWX!'P!N*LHJR +("$A <\0?P!\
M&I &L# P,#'0L3#O8&)C8^'@D][%Q\/#I[K_@)"4GH:1@8Z&CI:979B+F46
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MQ(ZDESX9I$),Q2ZPO+I9=."APCK*45[FN6FN3*:U&[8K]X.R@JZ'ZLI(>!H
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MZZ?D3VL#2R3?ST[,2-:LJ>>G"3<MUU^4H="5M2F3,_S#-#RU/\\&\B/.5>
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M2[%U-5&O:<^5X4"O5P\"#_$#_+!CPP%*(^/I3;<!NS'NM"@)M  *Z(ES.L)
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M:I0!)!F /"521S:@\E\<T/PM&/#)_P502P,$%     @ O8!O6!6EV'^2-
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MU["._439[\'A' _$-4V&!1&.Y<K)7FX/!=2U9S3B5J<:SB)=Z][\03534><
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M-A_71/\JN!-H.PNHG8V4##CLI>K=>S,APF+K62S33/0(V+U\GL9_MATTUB0
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MRV^]P'%Z^'D6Q@&FL_FH(]YU0Z.!)]Z1H-.\C'N@AV: Z2&/:86!X8(*78A
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MMQ=ZX\)<@X&OV?<W_U4B+#U/ @0.^.ASK"O->84"4%A/3(S3L=XVDJ=V'>/
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MD,0W--X;F'"VF?=V7:*/$EX8<:W7X=;Q-J44._69D418M"<$I_14&S-$R[0
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M8(T3_G-HN-V/],WQT.M@I=AY!'D C=>SH"E^VS:VEFD_'J:>64)# Q((N=8
M]\" ^F(;&6CZF5XF]M<*,<:"VIX38JA,MQ< (2NG?.CI>]ZJ1_VU'Z;3=SWK
MIVGEB)H2LRQ:+D__.%4(S5*_(V\,6D#Q_)3T;EQ-3H47U7549\[/#IK,QIQ>
MS6Q+K,FS"N'AS_@0F8"J2 4!4Z4%I*Z7+K0J:4$AHRSV<JADCKJZJ4+$@V9W
MH-.'J9"+2L[9 #9P2'<;PXR#@UDP>ML<,-.PY]57):H$!>&2K./O]]K[YG!
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MT[G#*_>@U39:?,7?(<IS58FLBZ!@\9*&>V[[K%N2<]6[T\"^;W77X^"&1.\
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M@N5[+Q\QGA0 YY!6<*5ZSDH2:$@8D='@W^3T*6/.0IOF^,S908[T>JP-=WR
M/_4SV;A9O[[%?.A/9NL#:432'O_R>3UVBFM E\BI+^+P3#GQIB/?J<#RCEJA
ME;7^[)ZA&X%;=VFG;<O+V6Y9O>ELC5-U1*3V8ER"9#ME8@Z/!5('HNV?.D4^
MR3T]SS\0V\:&W>\@VKAQ5[>2B5.HZ!6"KNV:&3[D;^5(3"88VCJ3$<G3K;>H
M9>QF&A7FXJ8WGZ1A]<'N!2WTDALUUG81UCI7MR/NH%!7UHB,^18]NDTXG1X(
MSYCBQT^]7_WQ4;E"(7=\WBT>MDDPG'/$V8?_TRU*9/YMZS2Z+59\<W<TD$^E
M\^S,'T2MD7@S4(FL:KO6"GQF@LP*G.=6:8.UOLPN/"@4NM#(1@-F+>6XWQY:
M^:OX40L/ZFS;N^T, ,H&Y.81/"03N]0-<],L.C]ZJE]TP'=N2EZ5/#OS5E_U
M50CJU.:;(^/0[C2+.%04X0_=YC&N#1:.P-WX12+S]-T!B.-0XITV; ;A41TH
MQNZO<GB7>H-=G"IRJ";%$66DIA;*3] I->L-=8@O/OM]XXB5  HJA_A7W=^N
MY#PCMY]NS;'_TF=W[WL?@4/_U\=Q]I[P-8D7L[:5-YPCUK%#O1/Y!GLQ#IHZ
MT%K)C?F.=;?B+##?M]]#-7C]C0J_L"$?#V=:<[DI@T4%%^A<-YAW>C9R>DXR
MH!)DAT>4=!Q!1;UW'VUP#'DIB;N)'9IC2RQUQ')LS+RF[ A& U8UL8-3?;4A
MC2-B^A^BF5K.$XAXK55ZSVWBH4+0HJ!R1<E=GR6-DH0BSJ=E%8?[:3 )<_EO
M:0J"_5MK\C4R;&N-+UH*I"J^V560VO:WK5$_C \_>?KK5*BTB6'-Y<,7; IA
MH8N;Z@T^K.^-["-<Z66A2YK%X45KB8O#3^:AI]\^=O]B;//H]Z-^3L&J4A:L
M$;$=R_6E@BM,_\$4(Z5^YFQFG#N'37A:C"#9Z&L@Q-]%Z(%BO./AH%W@V>VR
M,$=7-2I\MD-0#".UN].-TP:,E./C6$71K>W<[";CR6#[8KT:+7@T5W\O,LE!
MZWW@#ZO)+N<'^5L#V7*%QF-5L:(<X Y*\;-IQ<HL0Q&#<Y]^20<JPH1?2VL?
MKE#8\8XM T_C5CD>*D-P*R=V.6'E9-)ESQ<ZT8#%_:1%/E>;^&?+>X.B*^6&
M%5+&HO?X8'8^P=[V=\59I2I"C*4U)Q0^?&FF4':(]W0M\+Q++"!%94!J/A5A
ML0/-U9Q/>&G\"?QT6T"0]><1Y7/0(#E;1$VGM)U"&=(_*$<NBR,SS\C>B24]
ML:^G-N1FX@$IB$G3)N&E(TZA78-#<.!8F%(@F,N2U0U2*9Y[NV53/.?QV'*5
MK*I06H@AE1&!M]6C3O)A95Z!H4[*MQG7L58GHE0M.=H5:V$S&/ JFNMXV3&K
M@3^1]]=@]^N&AT>5(/V_Y0HDLI_H4!7M4:DWECZ?3_/,7% PS S#VPAV&_'8
MB;I>.3HB6@I0"B0-9LAU,\*O>#&36'U\TW"D%*!4Y9?VC,3<"/>=)58QM3'H
MA:U0,M$<9B]5[611Z:EW+EL*0+.USC6XJV:A,7W](_!&UZXX\L$:@T5F\/->
MR94]2J15.L;!UEX+IDZ$[XA;P;,<TOU#M*"A1T=&YUV]8AT]Y_Z.:64^I,'L
M<C_'^A3HJ32"LYN7;86VFE,<+YV4\X@L2<4R6N\^O&Q2LK$$!LN0T7Z>-.71
M%X-)]C'J <I5YM9I=OS%! J;+\_3VE(6)0P2W'ZK8#:?_-?5" XCI6AAS%V[
MG-%U?]7DDS7O<^%U[O"CZT49_LQ*V\*%DM1=O: *F5ZAY4^V0J>975ES;67&
M]U-DV]^H 8_Q$&$VUC^P$ALYAV?4_$NRHB#@/5RP9=CMN>!^832@T7U^<R!N
MJ822+U>L:ZK8%;@.NWR15"&#!FB7CN:*+II.;PX:='4>D;Z_8]3:M<8R_?QA
MV ^,F*T.Q5--Y]4^!:M#9+GGTOZU>#;VDWK#E-PR@:*LKY-#ER^3]NS@T% [
M[HUKK1:,#+Q8.3&]U%=EY;$-P1#BV.T'90N=.,X#=5;]#NUF$,,+CZQ$-L5\
MZ(SF(Z/SM,.P7F$ES)HYE)WX@@=^=QP/EU@EC#?6).831>S-;Q44-F0M+ 9I
M%NUEUAT^V.D)-3$[U"V6>P[VJY2@2IF=WH3H,.1V69#84]QB^5ZX '\A:O\6
MS ,3*19" V+#V%O_D/WPZS+XO!0S^QQ[! NB92D;A:KP%Q$L0"C?4W$ECZ=5
MD3M/3H7+4C*RV^W_NE4M?:0N\+J-W!BP/G8*EFCKHDWC7S-XV&0&ONNAB9SR
MOU++TUN2S#9_0EQO*V.Y[=Q;FJ/UQ&^]"MK+<SKZ:E?(E)Y3\(5]4DEAX(52
M6\-;\_HG\";"K5B_LSDHR!\*A2;7:80X/.4HLF'\\)Q45P%?&>S\DZKQ:SX'
M71NENJ];CM[6!33#KS/K>75]Q"3.MT(F O+^[]E42]@'U/$ KS<;- YJCIU3
M(.UEY;(C5RTXKHP7[34 /GQ[$G9)?:6%!G+NIND7Z+^[Y$,#/:*3X%T'I-E-
MNDB(>\7?+]%_B/=<(\'#0RT 'IV7?3]IMXA+@TY'2W45<ZAHI,*(C5S3Y -T
M1VP<+_V(<<=!.(%M]'E$U&$9S]C2M'G6X@U^I9G1QRX*#-HGCR.+K1)/6J[(
M)SCYP_P3J:-WUX^UNDC[S)@'@W$B)2X_%RZ2'B('83TIVJTYM%H]XF,EEH$L
MF:;_7I=_H,FL=]J16&%2("G[/ML'X%J)*(9QN^N1XQRRJA<BN?J\^2;A:C]O
MO2II9L:C/MUHT,G54%_9IGC,OM7P)CJDM[A[^PZ][S[;"PG]L-,?*)])\#W'
M!='6"X.@>A5XS_$G)52&875M6>C%X>\N!^/==6ZVV78RF1\\7 > W7T<#=AR
MTRRC;"W*+A5R473:6>#@R;%0WH0(1<F_J[FG!.7V-S?VQTE(-K9]MV&39,1#
MIBP;T]I4&N;M0;4\<_4L4Z;P94K%N$MQRW6#N_8DG/FH?;@IKE:8J(F7Y[M.
M2C>S1,!R$\X6&.0A:):\*5!@ECG'6ZT>M1XAXV+!%"''Q'XHN]^_NR_/RXUI
M)8,DKJ.<6$Z*,"F27ZVN#.Y4X)6*R).%\N@QUL:F[.<@DL B*D!:99PGW@<+
M1Z-<X\>_1 'LDKI>:RSK*A@#><,_N)84M]W+5,2+7UR*-;H94,:+O:+IC%UD
M'>Z>=5RP7IM:L+Y3.S0FB -KAHRJ0?IW?]N KJQJ_6YD3Q:>63/J>\M!'VLI
MU;#9D2\GQ:3K]-0D,3X"CT_:-L1^2O.0JOD1/?!4*R,U<+CY?_(]PO]#]=!H
M;,$ZB^B;2]IRK+6F_Y@(:/RX^:=8_\>K]DL!*FPAIO<GVBN*^4F<,C"5[LPJ
M[ $O#JY3A40*)&N.7=JVW?FES--%$X%#L^LH'O8 \33F"G>:X$Z3I;FYE-]3
M/4N59UU[$'A(812\3YRA][1/V\>X+E*9:'.K_-FW%R8[=1%*DJ'G1>K7L3=/
MYCU>H/32YK<-TR;A/BR%HU8!SH=M3-7-:$#SB]Q>!/C+%(=(292<9*[XQ8R)
MNYL'=ZG^;IS\^X4&$=HIJ??D,NOS<:\N?]]HYJA#YS^'!X>Z3RG))V+QDS[Z
MC@8<O1Q#'JMO=?).>C])37WH_S'9_AGC3UD=:J.I D#QO_VA(ASBB)V- 0;$
MACI?+3!HOGDX@@:*U\O*QD]"8 K#HX?78MT%T>O;0HEZ<3$.N;PD.-X&IO8\
M6;$HF\N7,LQMXHR:2&AB@4O.O"5E8?0H2J=-.SJ'*,0(QA_WI@]"E$G'VWL7
M)\ZAVF^P+4P#:?;E.(S*?,S\8C_.)F\KLI1W=H'>F#V45O#4Q$E=G3I'6?I.
MMV^K@ @HX+CZ& R2-#/*LOCY17-ZEQ"Z9/AZTVV(,7[CJ;?8PU,8ZAKNR=9<
MF_YP*U' !4;F&KO,7_29O^_+'&<=C,%G9*;X+FFS,;/]<Y,/^>D@!33@_Q,1
M<'W+PQ-3VVD'7_EJHP'"*U[(<@.S^LB'B8\39F':$_QRIR'^MQN;JALT ZVM
M<'1"XJH7BN,YWX0N#A[2O"*-7=3<\/-7EXWG24HAP5H'(\9H[Z&!9*6P)L2"
M:P :^&Y!=?H3$9@#GI&0:/X=B=AII\=" ][\.]37$)Y+Y;*20\6]?H%4.1P[
MMT.<I<=X!.F)Z6:AF#AV1@,57)_YV8(N/\G;4,W/:_9S%*X$-%->-I1G\OV0
MH2?3DN;NHUI>W@M7>L4F>4-IU$IWC(\\NZ$JPL@_)(:ZNK0B42!=Y&254TXG
MPC52,TP#]IS]U91IDIE9>8F5X)6;_\+A-:+.E7UAM)N.WODT&<3VSQYYLU3>
M]:6D,VP5<\P[_M6C7Z1F.E?C2G1=T](ILQ6OC/>][5+-E1*JNJHHKT19F0$E
MTG@XT[5,XY89*$R8;[UURM&;__'',WKKPSD:8IW(TPB$K\-UY.K^3S00X;*"
MA<G$WTI,C&Q)W/=50E6LT#V$6:3-6];2_LJ$F9)@P>7E@\YQYGSMJ9>@V.9=
M4>/[K:=-?$$S,*)1<Q 1DKD3Y-_(72$/M6E-Y!G?"V_+=TDBKM@BN6<O!*$S
M6-.48$)5P/OT7LUI(P8C5S^)FTZ"GRS'P0^^XI /[[,__A[T0,."726 16XY
MQP0LW4,1;A<>?T:1>RBU5O*DN'I77+PGHX]F+T\@E"&WM*FV5F"O\((6'PT0
M6\#71XWD/'A7(5P/>J!V3A:I W!BC3WR9_@A>N,%)2J/+#ZJ#KX'<0M"NXN8
M4'B7MI ;=F1FEN'* MD*E%\M_5N]:)J^P8"-/\#8<4O^\>#N_BP>[96G>(&Y
MB&/2 SX;2J7"V=FY37?UC-0!FZ<+<?OKQ3$./?4XQI>4(5\>+#K;"QP-;S:2
MCSH&Q7T[OI:8[-7)!/%-3NY0_"IU8[)W/SG;T7R?I>H0I%JNOE.S;8C\J<W'
M.I8G]T:UBJTQ>T5I[PE<0)>&N6O>$8PHO'HY=",[U@1/KZ?OU]R2D!#[@ 8Z
MZI!X:(!^*D\&/PPLX+#+RA;D5Z6WW\((1(=_!3Z8Q6YO&;551DM8H."7)A:T
MV(B V6/%A^U*.0,L/@L>+^$A[^2J%M5"%6+4D6S?21(".[[BK +?ASZC@4JI
M@-!Z!NMZJ6370/&W%,&J:* 5#/?44*NT)Z$.J*R,4KYJ^VW:O7Q,/Y7M\19!
M'G#SS,"5R')JUN.4TJOD:0YI2+\%CV7@K.="<0B6U;TFR(-]K*8)QPW;K2N:
M-!2L];34/)'65ZFTJN0Q;6O;1T)[:2]C@[KXC?#(^"G!LIRA@8']4_&,KZV>
M,M.7X$7]JZFMV:YG&$2YX: +'-0EIC;U%79^.PQE$78'-LS<M82RKI=$ ]W\
MVS-B%^J>ZQEWXTOXQX,(9'<HRX-)R$T)LD6CF98!X4+?+K$LU>M<,5!::XS@
M::) 295;:J66M1?=#C(G6HN,)0UG>M6A>S.P0>O7BQYZM9/KC'K&:M]TU#%M
M'0RNA_(5.NF:=M"!W:\7M4 RRE 26([,+&S--D;F*]2]+O09O"'L4%?LJ^J_
M%!AN7[9>\ =R-F/:8]^[>[CL9&M5_ A;Z[(O*_HQJ!F2<N0C3^1ICNW[SWM9
MYHJOZPMX\^'JP96@_F,T\)OR>*F<3)VUKGJAA3K,&I;(VG3Z1=Z5(U&-G(=1
M-MR&ZI<TU@>1/9SLH3R0R@M:C1RO\<7;PXYS#3(J9<@&_P0SPGG=A04/\-1*
MX)UA:Q<7R+W<W.2(=F^@R#!4B5?L P@)ANO#D$;RHUXL5W3(I !PU>YQ'X>#
M7/V(@?K=B"[+L?9A,D9;G!Q87;79H^X!9^)\K39/&XLG_<]<'"F6O:N7&++[
M2&F0B7;QQNZ!P&1FA>GT]J3[CQA\"R?B/AU9PY^2#$U1]$(LS=0^XJ "BX=_
M_RZ*_R__+@K=;%Z\#]))II$B4?=^5_NA))M5QXZM:LJW*VNCP^/7I1@*KQU&
M=*7W-"L'!58>&_#WN9 N<(.LR5XL',>6EW'T6GETIPK3.H=7?N?\VKF\+5%K
M?N;"6(4SKI 1=?/QT?&'VYA\*$]\$_LWR <-8#DUH90X"RH.[EK24HU%RB-O
M)Q5:1KO[:C>6\"]65ZF7RO"Q,]G,L_<;L(Y<9WU@=<':00.E=%^<DFYA+BAW
M/<!%,W*9$!'G,.**B?@V$%%0? X%(_BFR7!7WII<U+6':=DN<C**W-IM$#:T
M<4."Q>8L$3_5NU1)WKITW_52.521J_7(-9/BBJ9H4UU"OOUN0IX>%:^9LTLQ
M*WE/W%E0A*]$=5&N)NUS.]F1C;DF$JRCL#TMQ(8RJ@'!K#G"P;=GICQY7)<G
M4%4>:$'O?VH<>YO'2IU0S%RP^(&))*==C5K,9K>&M=)9J-)D;,E>SZ!2#O5-
M%$](O:DW66JD>(VXM]BDP5<QJ4R4AESMA%/0I1Z;0GGP@,.G3R)M1-RAA?OM
MN"J)<LOJX"M,QGI'Q@F.HNN@?!33;N=VP0"SD$Q0%<^=V_/?[:_3TV%Y9/AY
MB ]K/9$89>0);YK=Z?1ZYK-XHP?21F0$5EQ/S$=V3N5\<FED.2LYG&!XOL)'
MX&M';_(SR27L@+8M$_Q0BW+C:WD3P>99;65)MHZ%B%JZ@7E-4]./ES@L(F5U
M]W*!+E76*Q<YIH^OC8T_4&AIWI.!3V5?;=[:4QGGZ)C(+RXKEV/@X0NOG-0-
MK=E[5][B\'W&P&AH;#)"3N!0&AABNG1.!GTKAWT6&?(YGF: X5DF/D9,QB&5
M-"?W^;2R!%VT_8(GR;DE[3O="'7I)#2GR\.J5YG#8R\T3ET0C67+29\E  0:
M^%IVW9"Q*2"@T9)^1#! 35 8AP:"<.['QQYC^0^5;/)(OP6=[PV8S*'B9.-T
MFT8*G.2?G>@(I<7N*(;"M3^Y_IYG, M^T%VH5AD!B+[E?4&#ZQ:S1[C,BV1;
M3@KQ$%(]M.#BBTL/G.W<AYA61_9XAI>]WNZ@J/3YLF<8]:%75L+O-"S\YU6*
M^Z7[T5@HC'6@!"D0F6L96_C+*%=SP=)=7KK6+U[PSN%,^5<:G.Z[FWV/B>J\
M>[]+2P$>#BL'/HW<XW$M)46^^TZB-6+,<'&>WCVSD-M^GD:YA'$S!NQBR0S<
MQ:R@7Z=V=$YX)=?Q-R2HM%8P^8,S%43Y+)&V5\(*(51#-=K8:9)S_R3%R4(D
MZJ,Q[8M?/1_$RNS*LND]Y=8]6F3/J#<^AS8<C1V1ZHMV/ZU)G'R69K&"E1ZB
M::.X'!ZUG;Z<*".VV@CPQ0S;BM)9(I1FT^!Z2^W/)!Y9:D,34W(L*?%"CO4D
MNZMJPS_XX]1_RZJ.H&^A,[:<-L7)-IOS:9^J:YVKNG9(6KOXF!XN[PAM\@,\
M'J^"O&'W*@;D5W"CH^!NNQ4[>5PTC*XAA9-\XT;CZX&*/#,&SKKGYE]=@.+K
MGT3!P57M=+A.EUL5UY9<?C$N$O?&^3G4RM' ;320A@^=];PU.2CJ_SF>U2:6
MZ@>S,_PTB=M;5?:RJ8>F>L.VBY2@E=SG').V72G1_AP '!J!41M'@X ;RM$3
M+879@L0X"-2-H49T73:<2;3V>ODMC!(3-70>9%-<31:*+ATB)"XC??D>0A..
ML#U(T)8VE<Y9XMANR>N,[B\?A0W.+'DDHWL8&G]JGI9L" L+;URA@9,<;3"W
MK'#+C@\&11HX&O"I/8GJ],N71Y0>3K74>F5E5*8L7\W]LM:FN;T_J#6Y8,QR
MR1P]@X5G1[8BU>O'YZJQ#&JG(5=&P8SR7/4A"^Z3;<V;8E*G$Z['J.,>T\AW
M%6;SLJ(TWW&(RCR33Z;?7(\/[W]4^_76GOL$CTXR;'Q\46X#+['AXL81ZS!@
M%X8H:E\"7;W<V)$@2VH[U$2!WX[P*[ZR&.DLR6ES<&.J(JSX%N[<F__$BNRH
M$@WT24B4Z*\N^@79O*N+/Y*OLO%8C\0J^L]3_D"6@G]*)1%#<X(OQZ\4+SFO
MWHPZ>@KL:$T4\5FD58SM%BRZ940&LYM[1ULO8T7ZHCP\LZY J 0C9&1+E2*\
M0')7 @LICS)K+;N.-JVB-(C,T95Q12DP&2MFZ<0,#D,K]W]_OE#C8Y"FMN?A
M$5D^V<B^>G:CM?!]>B,1/.0.7&TB_7V1X XZ7(]W&5*95Y(310<2-/,R*Y<T
M[E0Y:4GM_CH?@K+2O??ID&?A9C=A97V;=HF-XCHK[4OEF:&GE;0BQ</T$T7E
M>9=:J>.9)1'-6U903E)O'7X#\;<"C&]*61Z\D61-RKOA]) N1[U<=JM7@5E(
MI-F0KH5\J_*+THK=/J0RL7:%9Q%Y_EBER(<%TU&EH)3R747E;_INQAN1_"<=
M(75]GTC3E<O5#VP[Y9C@+V6_TJ87%0!N56T&=U%H0/KZZZ*>R$'[NROM<;&G
MUF>N/H<6A5-J II2[VL^%I>69N/[Z;4Y$)48_:XE3NH0A048[E<<?)U-\GN*
MU/\^6V]K[EZ8D/\RZSIAX&RZORJ&,K@DSK_R@=5<.?LZ<7<;+1I8"9NM:TNZ
M.R=G0ZDCDZ)C2<E_4WEFMYC13Q ]]A(O(C]>GCW$[I&:[E&7:G+7BM+LPW8O
MBE(4S &&&%,IC>O40&Y53KZS=![ILW%B>M<?KE"_?&[[0%9,L-<<>[T)'[6Z
MPN<LTIEE!FX'W=O*710?X8B87]1?:/.(L4,#IETB.1Q4J5(\:8T3P='*?75X
M&8;(B-%5#20.'2)>MP^>1.PJJ5TYNG!PWTGGJ[K-GCR82]0T5E;+-P?G/%'.
M6HWX$QIH0P/!B_?*)BH6"#PEIIJGAE&)XG=UU.Y;-4[L[STX/_W9-<3F5J@U
M=\##+18[A #MJ:5=*4S6"Z>ZNKRJ;YIR(@PZ@D&H<T)H!R?W/_$ZV)Z?>_30
M,_ !9=;B@"E )WKUP7=5.@GATCJ)A+6Z>AC!X T:[>\6S$NW(X.@^EIIU4%O
MN6>A3MSI823R?/Y <3&WZ#W+I" ^NL E1*D$$R2:3((%L?ZKR-6W]1 B$AV7
M9M#'7AF43/JS@R;^N]Z;')<U)I]9Y2W?>-P/7GEEURGE<44S72JH^EBIE2T!
M$:?UU%GKM:,$:.Q[8XIELL-0WM#4$GZNV;)788JHSP5;[ORG%? FG&E>2\J.
M_/#S=Y9WZN(4O>WUU7"QO]_*L4W??Y0,2KJ2@S<%QV8$6SCE7<G&RH-\9S-3
M+)Q,JV+E>PJ[7!H[A3_ZK*A!2NZ.<]<7'@(= >P5,AVTA,C.N (/C7&^;@]8
M*N1B,@N^(+\WZYE98 =QLKA.L*R2W8'PO<WEO!_>D7+YAN7.5P8<KCDT /*0
M<UL%@4+>["CXON%ZRA!*\XIMS9'@^:*QC+6DM:[Q]6#]E/IP=!C5-/4'0;N#
MDV30L^N8_7H5)P17:]$JF^+;OG8Y:Z3NTS+'*7)[5D6&+O;0D<YSQSNH"/YP
M2:A=C9Q$@Z(:6Z+#V^1;@2S_1K'CVQ#5#]R;*9N%6M:W9,YD1M.U"TBZPF(^
M3R5&\?3L74R60*HO'HPH+-TX2*.!H]BQGY*;F39H0#@-=CY W2P1:/JG5Q -
MQ(_T8__W.&YA>_B(H7>H&D21,F(RTM,F<YMGR>)L6%>O\_!U <03=UA=;8/X
M-_1T(<ERI9'>@P;9U0XU:A:9S%Y\&''6ZIXQ,3L]@'.DM2#)'QP]9^#23Z&0
M<33&FD9MVNAC2NS;*248.KT5.M-!W>PQ@60\?3G6*.SJVQ(;T$ZE1[>K31N>
M.PTSW>SCN]_FX&R([X!M#'6=%.Q<]C)5I\XNV+S!1W7I(L):+L'DKIEMVDB0
MCYCDW8)/^5*6(R%OA0JL"X9_,.W^"/K";O_2F,F('N2R&@NF*^)SP%IQA[4T
MW3.7X$/2UF19UK[TU4,6%'VU9F@LX>5SMMM"ZHAQ<X.9.F5]\8%E7B*'V"-,
M@@,N:9AJ67KH"NN0()FTVKU2N2[)45SQ-]<K.%F0V(:O:S+I1D2T_?2HPL.*
M&KSCK'U1QEQR-6B^:BT2&I\X[H!U1!MV*8):&3IUF&J\NP"1H(N4'^=+D%$,
M4 _%;QPE[NOMW0]8$SIZ(;3A;5F8=$G;LYQ UT%+AI!:_VR&.-,?V2.]XBJT
M*,K6ELS5^?EC/K<\J/%9ZC><P"Z[[VYQAYIT.4U=8M0JNV\=IA*),;@9-,.^
ME'DPCUVIGKV;CFNZ#XF$.&AM3G;.M@XD"JT>+@>7;#/<W;NR%ZV\_2I,.SL*
MDUY<;&%B>]!\'>OXW5^1T'2U'OJ!3HH7$PA4_R?&9#HFZ!0MQ)NTW\K>>GO\
M7E6Q_)(V0-P\GSKJC-;?@W-1^ZIK/\N](I8E%4P1,R/I4G46MB%]>H.\VDRM
M_4J\=[UZ/M+05 \384G&_@1SO7&TL3F@&PQD 1:7%L$)5'.774>85ZS@OYOE
M_?_/)**N1//4TIC6WFW>*] 1B8J4_4..(?3,_P)02P,$%     @ O8!O6,=(
MEP*B)   KRH  !    !F;W)M,3 M:U\P,#@N:G!GK7IU7%3MVNZBI5%:0$"&
M#J6D&4)*1+I3 >EN4(80!*01E!"D<T"D6Y1&6D"&#DE)AV9FOC'V?F/[GF^?
M\SO#^H?U+&;===W7=3\\J,^H!8#LCJ**(H"!@0%8H'\ U#0@#Q#@X>'CX1+@
M7\(G)"0@(J4E(R4A(;U&17V%%L3$QLK"Q'*=@U?L)@?7+>[K+ *W!6Y)2,G(
MR+#=5%15D+XC!I:10KT#""]AX&+*8&!<!E = ", 8.!@_/@ OSX8F%C8.+AX
ME_ )"-$/U) !F!A86)C86#@XV-CHU<?H=0#[,LX59GY97'+-^WC7W2@$@A.R
M+['(5;93:HWL@00?N(?@$U!1T]!>965CY^#D$A*^)2(J)BY_6T%125GECK:.
MKIZ^@:&1I97U0QM;.WL/3R]O'U\__] G8>%/(R*C$I.>)Z>\>)F:EI.;EU]0
M6%1<\K:JNJ:VKKZA\?V'CLZN[I[>OM&Q3^,3DY^G8(M+RRM?5M?6-S;W#[[!
M#X^.3T[/4##@TG=_P,"1/4=.U/_;Q9VPWQ;S<*_*J-/Z_M'&B@I[LLCVP:)L
M"F02+OS)R%0AP([X(W$C9X*5XJ&6 -<_O">O7,EDWZS4;JDRQT[\\:L/B&A3
MP9F94QG,3E=1Z?'\1<;+X$C/8N>'->="PR92U47E#(3,[5RSW2W.(PH4FK^_
MF-<=0EOWS HK?)MT/E4($\:(?WY7ZYWS.9?V>ON-)J9E]AK'$^J[GZK52<I?
ME."P#2K%XF-AK<IG9(NNN[K%V6_\@\/QDYF^'][7P;*BQ[35,,<,JZBNDW(%
M9)-TS]W;R<P(%*Y9(";4'/8,B!!FY&--^?(E9%2,Z)D#[7IPG-GA^#^8^O__
MTL/-7PH;\^+DO38A-]^DK'HEQX\^N.8>?]=B4J84%S&XRUN_U2J)V\@8Y,2<
M:8,AJQ;<#F_W6FL3KBIPN!I81=A?,"?O=?56EVVZ*UZYX,DX[)_2SYDHW3/U
MIMMVD,(J*]_M\LFTGA?/F?WMQ15M<I8=0# (LL"L[W,^\Z#:>C]U#-X4T+1]
MZTAYQ:2EL]JB(TM,YMYJSQ!>&[:^]C_XH4O80J[>FKK:6&L(LH:I\B\7LF22
M8B4,41C;^CME0%E;,I0_A@@&=XW$\H^].5MX^%:2[=FUBB5K!8)<31K  E(<
MV_BKY.[$E#,;3N"F\ N&]-/>;PC:E"D65/W[^UC9^M8>!?(OO))'3J& ]<[R
MQ']Y6O)"')J<T:H[\(E?6K!F&H\2?Q_]72B G-#Y'JX5@QUI1'6RM7:Q$:YS
ME#4M6%9_,9D]C#4R-#>ZE+/G>M9?7N)A1HD"XH<B4<!7$!A^UVOT9PTGZZU*
M3'K=JB/K>+FB<ME='0'GCOG43,Y[W,$@8?1"JW-&4Y"K#,3>(T/O/+2?\0W6
M1.A;,>KJS.>T\JPQ#T=]K?XW26IHBV \ &TR'@VA $5>S^?_,L'BY#T*,!CS
MI'66!#^HJUM\SG/;!LB\)R (+P-3VOH_C817D/1*?86IC9K<'NO$LN)^LX8G
MI1,:NN, [MA[-T\C>6O7H5@RAX\ULLU3S-$F=F9GQ57!7WE#];]Q5-/D8>GK
MS4G&*W"H(O']I<I8/%Y[P1ZMIG!QAND721OP\AY73MO_*+15)!.D)ZD(,@U&
MT-2,_GJ%KI?82LWH3F%$T+[<3@,M+8%R&<>.L%X,S:8ESVL4T/T6!<3<>%7"
M>!H9=X%KOE]B]#PM\OS:]FU&>/T^,CJ7P:^T-; 8!<BB$QG4CQ3Z\R_"TB_\
M'L$::AL:R;N</H8>RUYB#MH^A&[^85.YDOD^5:%U!9V$[U5N=1"YZW *D,I"
M=+I1HQMGA@+N/+N]+UWJQ0/U<0!U,MF<"UUV>A23;D#%].C\Y4+6XI$P.(3O
MVLYYAT>ODW"5]&O\<$<7]5EVDRM@HZV?C09>9G@XG=?:4!?2SFI S^Q=/Y6H
M:UPPAMAT.=I& 0@L9A3PK@WYOFB@;)[!>00%5.7TA%C@P5J648 -K +B/(\"
MA@48+PC1X>>L6"+LJ:V&N7-1WV9U]KG<$+)&Y[=E#/\;VB:<2E36N8(FX5V7
M])"?P_7NG[?WF!7NM9?%T9LH>2U(3+WV2F2_G.PEANWWS/37'U$J&:.33)6-
M LQ&(>MLE8LH0)/Z//141WNNT_&<X2$[;9_<1_!-?AV7BJ7G1E^COGYMB)E&
M7+T'#*JK^[\23E>A]@P,*'=K<)J)1KCI6[KQV&\U$0D(7 (GK&850'IZP%L#
M;7#A\J@_M9Q+ VSM)FMAD!7!)<CYI3@$.8-G]7=;5$S048BO+40!YFBG<W(+
MQ\70S]BA !,VI-MX'Q2" J[E(IOD44"N7F/?W^K+H?P+$SWY_&A#JB0I]LZ0
M\->/!V*):D4EA!<=9!(6#:*[AJU">U^@A:'Y+WM=OTUCP]X_U'WPD$A%QCO3
MX)!R]E<,=;S:3C'L&0^WV9$A#M<8#R^C@'IPLB2]OE2NKRX<JFK0^$*[H4%-
M.6NVLCN%)&"M0A0OE@M">/)@\GWM%9CA@&0QJ$!N--,CVN)!;;'GT"DM'L*O
M#AE>,_+G-.D++YJ?$IUD(=^C7;G=;<K[_::6OL#\ =4G%+"U %DOVJPM9EVH
M3N.^E"?82WYI5:L^9K^=*=-OM?[<E+1C[,1=E=C(X6FC9S+5JIC&6UP.F5ZF
MA(/:Q['<.7LUR7,)N;"-.A4W0;E"D2OBF2O+M.P,87;F/^$T:0N!V^L;_KUQ
M4@Y<R*" !'8-%% +.>-WR/L5UJ(MR 'F)_ 63!V!/2$)WK1$ :X0KL>849R_
M<XZ5 BL-8X V;T8*!7"M27*C .8L<A3P61FR_G(K_V<;7XV["/,"GYV8(R@9
M)#45]-I00)PN"B@?1O?K3^5O_Y)3QVB]6_>C@S,=!JF74EY7?I!L)*Z;RE=Z
MX>F?YXPT(JJ<CJW_ZI:9O+Y?"R<2O]E3DF963%)A/TFUV/' D/E#-$//%]+-
M@O))D7TLY.W_H(1<* KH(4 !R)8\--#4+#^@JVO_1[JE@U5450O0JW\O7DZZ
M?+][N8L,<EO&33'5,8HJ-JV"O%_]$U3=\!\EU'G+3B<$B<-%R\N'3-7Q3VS4
MU"\+P]29K#6_M'P(PH?1%(DQWXD^%K*59C<G\ZU== 0UB'MZ<]WI=QX)YON6
MX0P@9C27&.@T6B:D1ZQ=F*(5J2#S07SD_OPR@NWOWZQA9?E#<VT#F2L3?02Z
M^-0:=-+\B!(J)6YQ:G@<A+EE2A\_&H_#XEV:\XVPOX']0EX#L2R3KY'%*8ZI
MLA&U]:,=)S:D?(=7\;_A-3JB6X$"EJ<@6]7@,V'NLK\ JGBS,;DUH6#@L>_'
M-W(8#TH,,C( 8%.%2?]&X= B7079S,;1F:3;K(E@:=^1!$N]E9@7D2)-B(!2
M45E;9*VF\:RA*;'\5RW3RIB"^I8T40VN%2 ALW!R>J[QQM.]3I=%PMLAJ[ -
M$>4YKZJFW"LK&=2G<5(><XWVOZ6)WZ&RK0_-R@&C&UD' J1GWUP0Q XY_S(^
MY'0UMLNG-EI57'& WFI! N/=A9H?M"+6:ZO%: *&U>I[$?'EK;ACR9B@Y<"#
MM8CWB?[[77X#WM?$ZS/GVX\/C%4DW1<I[Q+7#)HJ8D%(/&)FJ]+Z]WCS!VJV
M1QK>CO,&1UO,V9=Z%V:^(X^#>E?_$YHA*[PED$DT3Z/1?.>.$;0(\D_XL_1M
MA%3Y:FL^GV)=O^R!%:(;S&05/(CK[C9$KT^[R,L/-Z>"==]X"G5*VZ0UM(E:
MM8/=K.__<J+K$81'W#/@>-(WIM7<6I4RP ?M+#@R+@WP=?9Q!L@LW4F=WZW6
M-DM:FV+>$-]1+=;WWC ;ENE8V;,$+!FA'B-;9FR)V(FBK-:N'TN./KMFB?")
MXP*<!.([W6PY^P^S2WL7"E1C^/.B=-7%UWLJ7Z* 1[=6!0>5"7P/RY%_QA A
MNFE4V('AY 9[** H#M%^40S7A$69BB 59=&LXH0"LJ&>.O]B_-WE-&/"B.W\
M@T+?*<OXZ*\/1,'!%=+J1/-3Q-<X#AU&H!+=[%.KGPP3*;0DC["01ECKD!93
M]MA$_L7>_*9,T)LXW"5.I[M;'#.W0BC":43%*/M]R8V&>80;>!;&MLN<^3"[
MJN1=)!\HBC$KQ]_WB!43JU"CJ!GPU4?*2[.C@#?Q*&"$?_*GSDG^6'<15O.K
M%ZFHJ/Y PR?(]Q0]0*>(,NM6,OUH=8R'?WZLZPN^UX\!23W<2$B^@]%<:2',
M@3I)U88)AVI3MMH"*S0ST#%JP\E1;\Q[RADTBP*DK&VZQZ2XQO^58V5_/2Q)
M?_6HR1N20]#:X:;P'LF7O0L!<1.5@>Q3L%Z[@EFSUI</ZI+;PY$^D=8S]8M)
M&=$V-$B=-I)FT3,YJ1D1*G?#6>,"Z5[!GCBV8]#%_*Q6:68A_:1;L,E:!T8<
MCOW?)*(N@PM2QN@I(D %!;Q.ZWZ*N W9B?NBGO/[OJTD5-F.G72W_7J,:I.(
M E:B0\1DL]-B5Y3$++O6V(ZP[]3].J8=I_)->HP=<+*+;P\,!;R_X7>T['G]
ME/](,]5GUS1=ZMAIJQOJ/D<_1J<[07=N[^0F+/$P?"5_LXM*.>%E%^X@?UO2
M/,MH4^KA,T)#JZBE'9J5&,EN/4>RUK:B0F/[%/TDH5N3&OW77[L7+;PJS$8H
MK1FT_DY]LGKPHEG%21W92HT"%)2T?C&(]2\&&4<S""<WENQP]:R(V41Y6=ER
MN-^J.?\GKSYNQ@(5]JCU/^9>[HY&*W1DRK_>CX6IL&E@SNP>#-(PIM\GGJXL
M5WV?B=D\W"Q+##\R(E*Y^F;>UIDHE(7>Y4%;OF<FZ][*V<J$(,Q>K7#&L"HY
MP6G49 >X'+Y<H[1H3CSGZP8*?_Q =<N[5SEMEN52YS/^OL->X1']_P,)_19
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MCSG^U8KV[GC3!>!M=(4 >-0@S@X H*,#W $ @!0@"'\/7,-?$0#_+%<+@"I
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M[PIXQOL,=$8^'Z8 YJ!VOKT,(5?M!?#LC)4&:[(,@LVV?H9C4U.PKE67D5?
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MJ'#HDHRZ67%@*:Z I%>K5O4]\?C@N2;D<L%:L@I_"3NX#\6[3E72%SQXE+@
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MIF%;^2[+YW>6PA3T]S[G[>N=OM,[=2),Q P=8#G1IY>Q\]'XD&RBU-<,FO7
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M[-1<Y[H,Q52'3.$=WPN_^G#&K6OJ.<0<V4#_K997)_PC6,%&L1'L,R[>_2M
M+W-P1<FQG1FSKXU1^#R VN].PJJ.VJ+=R]QRALLQ,696F!2^_F_)<A]N?BC2
M69@B^V% V(!L%IFUU&YL=VP.]!,RWJG(1U.WG4J.#?W*?YIEN=,DM.)./L?^
M52QN!>^G9?_>3TOP?EKR/_'3OT.DX9]H>$2P%7NJQJN?'L$PG4.MM"KP#X+8
M6DSSAR#^AV#H D//K[8]@ UPHO<O8\\3<<G:%NE_IXPB4+&XW@6KRVMA"H,Q
MM]M[E<GJ\I*:0$]<S(_*!9 ;"3LX%JP4FB9F?]&V?GPGO_&L^:M^+8R).U0\
MC_GI8UHCM_S;<K=^^""6^RHPQG#ZEA!$IK!P9";")*?&[;GVNVS$:$T2\4+G
M$YF!'WM36U\'?G'SV;0(G,A@8,$KL/ FBQ^E<+0>Y.6RY90=K&6&F224YJ*X
M$D9^ZC3CDHV=QKSODC"WKIK8,VUOB?'VCE_3T?VVH-4QT*MIQOAM&:J+BLP,
MX<_:B!67TVYXG_\57/PP(4YZ?M",>T,^F*UGM )MUEV-J4:,1-6XVB\K7+Y&
MJ9?VV&>1?_ZV.=W2?Z*-(82A-+J8:;=E7Z=G%'X2@'N1MSV/0(^)#4AO+:*D
M68HE$N>WNS(LRX(=FM1;@]+V!N_MC(\AWMWR1E<V$+\[D?Y5>01:2.ED.TEE
MQ,%S(=E[/Z#O\YGJAC[2%95U[!656=_Q?+<JV;H6H-\W5129QG1O+$7G=,)V
MTS[1Y4]J>=LR)!_K@E+_9.\F!RE1KTJV,Y*L-\UJ&F92/K-X](;R@?1 >3]X
M4KC65=I#^!Y/4^T'U5YQ:DY.,'<DQPTU=\_Y>3;Q_^.TL6!NV&W-Y9;.%QP^
M(S.L1_MG?J47(5)/:ATA;KNK;LWF^4Y%CIZPN3[9D_[5$IZ]M]X=J_6%@;C4
MLRM@E89D&\=>??EYA[\)K1'] E8O+^,3&')'/ETJ(S!FR6PR=DC75'HUD"'_
MN8T$;\K'L)!#ATH-<C[2XAL@;C4"9:4 P+\7 M]YK(3L:?BA@>7#\6[@5J52
M-V#5B^T][T.IMT10A5371Y0S>\];FBBY)")/!&?4Q4#59X(-2;KU[[^QT+RM
MN-9<,6NV"T>-2.;IWF??QVA*(#Q?G)YQ>9S4+ET!(K#A>G^O#."<[&]"\,\T
MVQ4PISG5?O2L-21N>1(FB]E>L<+&@=C:=_)=\ >OFV:C)'@:09K/*^Y^IL;^
M^?\2^#\:)SW,#K/+#GMZECUWS@8\86J[>5D=^L 9QX-)17B$S[]C]C=UVZLH
M6G*ICXF_&R 9>(_GF5ZS5]*UI-]BVXEUD)2]KRLKAQ\#RNE65]HCW-MNTT1)
ML;G\A!2\, *';]D8J]!5UW]3BGC?+CP#$"3XS+PJ?O+ZYU;A3E;9<I[,]D.?
M&#W_J9!^5U>V;O>HDO7<,":E/?3$?+G&SXO).\T,80$<!T$G^T\BZNT</^'"
MK@!3Y/13MRR0Z#"KPS>W%O_M!:S0@4B/)3%J(ZKM =2V<:I%J<#%B+=?]N/#
MX!+!];?<3M\(/FBQ;"RD]$N<'RS[SJPSX@E ;"TZ'=>_J'_6;T!"YG.A@)5K
M2M8"==6Y_%A LVNQO4J&D'< 8J/^A;!N&:S4-G[9:]M"?KW#958NUP9)GX45
MX"-W)F8; 7OEN_RF[6:P!]GORB&W G/QIY?A#WX_9;JCFM0L VQ(G%M=T.%M
MDX?E78-C"G?.\4Q"U"I[F4YI+1M3@NN4LKT"N-LQ1K\U=G3P<)>(2L3U-BM=
M,@@2+GS^][\(%E;VOYA@TIGCMJ.6C0'28@ZH;/OAC&5^KM]\KX (4[?+=SZR
M9HM:R)Z(0N4>WG>2_<[/Q>(^.K)*#$- J_6](E%<]!,M:@50KAH+)=VHX6M+
MD#*>='?-L_2=?A+>8P:"(W[&U()%"TOGNH-E4^&L[:X*A2^/^6DU#9B49]G#
M!%@[?L@:YGZU3AH&A/_GF=;L/R=PFS$UQIQP/!>\7K57VOKXO%^MOJ&]O3GR
MQ_@B%,^0^#3SXL6F/JX0L^P%&]9"''<#$5G:O2!24RHY]28TS[S+O-LE+MKQ
M1IK%PS[VAOS&E[;2=&GQX+T#J>?DP'&K@&'E=.ENQ='"-S\*H3 V]A)G0\UU
MRT"COR(YP:;HBMDX-PS3*A&L%XR\EX?+8T[MA=)@'-$2BC2+11''-1A="1K&
M;=G6A,QRB)\'?]W$O7OYP:X^)%DL+\/<%E2D%^,"2F T5X##%1 /IX3*^BJ0
MK(8F4L-/AIIWZ[F(3=B'&QJ2D?KPNB,1H>?^.32?9X]'"%]E8/97K!2Y,1,+
MN'M_\[;=?L;?_0B/78H9''/]FP>RL%Z@/1';-D.%@,V)($]?[<FK*&:B^S7I
MMN=KYA?1F1UC;=L?GC$.7@$%V)*HF83 D3(@2'+I# A1X_"7P:IY2X$ G/3\
MPL!-S ;B0$\;@!)R43\ *[U MC2?6%1B$!>/H;2H*Z!'!6W;C>.R,-DS<%Y&
M1?3[K =*T:G"Q79O-RM:[C>)?O29#E-06I4DZ5P&^5P!#TYR12</704*_*V^
M;H"J0%UZ,UR@NBM@U/4UFGFG&YW7DPV:$G==3C!EK9HL_5790(NA98SS[AMK
MHUF0EC,^- SEPOUH9V]CQ@AHH-)>H8=4$]7'RFRKJA-6.TKX8NDH!1TNGO_T
ME$6&*6:[L]!W<*2<'5<,A01W-IWV),9:,>[OM=V&/ASM?1/G<;3@*LS>(V:V
MH$II\^#3C0V.QLT^8'5F!XVJ/WD]HL0)E8;M*5OA="IN55]&M-UR;DIK_ZR&
M[OY+*NA7L60E=&3E_:Q$SR?55)#KF1&I]$:KQ"^2(>;E2JL(/]<!#Y$6LU7M
MA<9,WW1FMB_RR2!#FX\9I<M?V\.E?)!@)BY9SH>\<&P$_-O,C!2\$MXK9V92
MJ,1>D^:TZ@A@N.Y37_>Z D#0$-?O,/OE5U< HY*SR$L<%R9*4<@)Q\76V$CX
MY IX_5 .+C38D PZACOIS!V<AHS-<!V;$JRWW<*(?,8H=00-_TI'!R#CM/,W
MJW5<G;)O)5D_3*K.C7C&8E[B*^_0KG(%V"[:ZL[ [.$1&0G%P5Z?EW]B0L=-
MRLL+G>U3XVSO_NA)#AFHH)UNMX9%9W./[1\U+\?/FYDLFVD[2R=V"L;9)I%_
M);) >8(EYK *EQ]Q4E@1U)-HA##%:OD;KOC<>0U[AW0N(A,^6NZN2(^ZN(_4
MM4#(H^$(F16C=<:98;3MZFUY&@S83P7>)[^*'EFW<H=UE5]^:L1CY#[BYVHB
M)H=Y 0=W[6U'+(4JN;E:3,$0 ;.7U6:3OZ8JP-B;2;NNT?[[=Q2G#E[5X#$Q
M]DCO%1SZ] K()JBP:[L,P\)L'<6O %33T:E3GB,YE.65_W6OWAF0Z:'57.*)
M&^;5A2;>?Y=[P!C3((\W?94G<<[=7<5>ZX%&=*JXZEVRO[T7[T;2X*@O9HC]
M&&4B^$Y)SG4:@6\IH.EVE78;JS/QQ-?/O940[%5XUJEMI; -0CV!<;J:*IQ\
M\$-7@R73ZP[,_J+O_%QJZW>G U3[9YVV0/B-[FB5 *+$TN="P \Q&Y_Z\WY/
M>\W.\^&(C+SH!)]1+KNQ2G,Z$6ZFI;B36&;);$&N@.,9N,MRC497._56NJQ[
M,5JHB\T]S_5F3+#V<-#T;1NO*1-3957JE4-S,/;.\CQS>[\'M=1,!P4>_:<.
MZVJO *)&]*U6I ZLARVQ=_?6OOZ,!&NM]L MU*,G\IMF/B\6?1^7!]WS%"3\
MS;Z_<'@2-+%_JSX36?YFX^$":.A!T\9<*JGU'AG#,@;BN+/5@+=.<=[A[Q3X
M99&5C-45T"E\W,PNLP%B$O=W6G6^!B=4EGKNR&&.J_VU7 W:D:L('5LFQ$J@
M:7!,U+$(=)GP"%9;XQ6B\0#:',V]CCVF@@L%+(*".:N503G^[;4!G:Y#FO?R
M,+4KJ3'/2[,#HH1Y7W!],'Q+>\0K\?O\7J5MA;-_4\*'0(]B8POUJLX 1\&T
MV[IQD1J6K& ;Z8J1[1$,/W5%B*./JT!O/#\=4C)Z7H3H85E-^<2KDVS9DPI_
M#.Q"#NJ.<5S)HND*8N[7H19F5ZN.Z1J^)T]:I<D3_[#\UX73OZ!'VT=O5X2;
M=V![?>T#=_YO3>]@I1YGOT/ .;SH"E=\\+.Z>(B^ I@7NAUG% 'SU0F<4LF/
M/9BM4LQI.KVY%KI;Z\$PK^8:A$O>_GVVTOCE;\*8PT+CP=*#N&+S-Q[*8C.?
MK[W^D.3?MTOY'%N99VW$>5])=K,6/+N!S(;;^OE= 135FF^[Z34-,#SWJ0D4
M0N?Z58<#9W9&4([(HEU&E&JWU8TK .'Z&P?"S9LL7(A#%.42!88:DCE8J0;W
M1M*;]Q);$WV>^W)!6T+/'775C6!M(2$E.WBY=_H1(Y%#H@X71#)WO7V^&@T-
M7S!B#=QI^BYY25BO@!@N^8_^5T!BT[YOXBLXR%?AW@2X%K.+.*ZKC;X9)Q6F
M^_9+CG_K2?'S$);AFL/Q1%,\\<4Q>NR2+H;*00)8-O&,Y=H%;&(W:.:E;UFP
M.FHX%1Y=^PVJ4=[%OFM:4!95E>!_3Y/GQGXU^<-5K\WL8YKGLLS_1=Z&0$_<
M.C- -8Y.=K)&E_"9?YP7AO+I*JH@-XR>ZZCO;>E+3\WCHP+'^=E^EF%(>W]%
M?#)$0&VF!G:]J^TFYH-' >?C"97ZEWO\QG\5LWY(\LKZ]*''++7@8,[H5I@P
MUNXROX47!:9U06UE]![YQQ>;.Y\+%\T7UE0^E%H<^6:,U,?^-2<000FI4$'!
MHVK C$Y?74)!DR]J=>Z\>%]><V9HG#GSZZEZB.OALB4^%D;A1"$3W6FG;9Q3
M/&C<)S<O/\<OD,(E3MF1/G_)Y/QVZRG?!2,12D+N;KXY&9U2:B\K1WPPNS[2
M:46XY'PJ)7D:-%U9_-,UHR;M_AF3:Z#BXJ8;,[8ZXMH=P:V'>_*5.31&_:TL
MI_]0??J%G7?P^!ZGW+D1(5IN]?HK5.2R1C-::>'N49:V;J)VB*&TMJGQ +>B
MV<^!_E3V^V2_0._$!/D<Q8$K@ -JA0)WU[99T4%2P.-VE34Z#Y%+SH1/OHIG
MFTI'J_@O"@Q*AFM[RI3!B#%YC]#U$4>[P=U2=>>%T2$L&=-[/Y3'OA6UJ0=R
MO%KF?F5U8[L^6^RRH(U;X[-:X<(F%S<*5WGB*NBVRZL#ZZB_HU77U$1U4_N"
M(I7@O<A0;5**E[Z5+58$XUB(59C8YYKN&WDR>1R=KCM]<_RT+&59W$D@F>4]
M7-@BW?_Z RW;- <^PF9#RD8B9#K7$?693$$.47^K^G<-PA1<2/%Z8P=KA3 &
MC1Y2QY @0N0L9W;W,_]JF42,KS=5OODA::.[L4N=94+O8"PHD$W0F4.,[UJB
M@Z%8N0#3N319%I3,#GQ>F#77*.C>T+DVJ$G/TG^7X657>. *V[8\_2H--6:U
MN^Z\/N+8E<I#(_WRV5*FK ZM- GK4\]N7NX#N9F-PC<ED(U>KEM*5'Z)S.:0
M+R(W7$S!\,].31&+QUV,PC(SXD.%B0.U"5+&AMK>[,Y1*^N1^RVA-["LJ/9.
M$/70)\S#/@NQOS(0Y:9+VM&W]&X_,[1?>B+U@M(KS+C:]JX38?OQKS]:WW8B
M$-W7'> 547-@&2$*-:C26O]ZID4RL6V>V%/!YJQ(C++ %9=NCV)<;JEX$&,'
M?NTTP-*XD^(^6 6RQ%TS8^G,H>"21O]Z@]K72#%"<^[XLP5]>UL:P:61IO&<
M3GJ,H29!"V% WQ?B592S9>I>5I1_;M$CQ=3(+7Z75'_QB>S]/1K%VK.9O-EM
M*V9YW0S.>8U5EN/B%-.6R#Z<IN_"U,A<>D_&(^0S4J-AVL79#P3K=7[#(<TH
M^I7R#RCFCEW$Y8-G\%WFY"WFIZHOTKZRYI.S#[Y4--8G;5#)7DO^K@4<88/'
M$H-,!?%*ZM@8Y=S*RJ[]CAGJ9P-U+S)9./:<]T:^S._R;_V5Y_M6G>6(_7V8
MUD9""X=#& ]Z)K%%";6LDFZ!EBR^GEK0,1@O/\=7+3GZY0N%''T8(P%?=JIK
MI^*M4:P]PD+.'#5U7)?WR4IMP]1B[JM3P4/PG=!&K(\5+:;;%#VSJX4LTWY8
M/\T,?O77M%M1;/>\F1I348'I<^'R]J)EDKE@PC?I09Z4[K_)!VK@93@RK' L
M@N;5VKB1?LJS;.2>]G9FXDUAQ*&YX&TB6NS;GD^,AA(_[@?R)2LKL',=V2ZE
MQ0#@OI3I_W7FX>\:G3_?\?PC_C@@],TH9X2KMA-J@Y9L12A%*#Z8A@H7UI4A
MW>2T&IHF=@S%>'4>])DPJ-^W2CHE&+)UDOE-\-/MD-6J[;[L)2RG(A.J<B&Z
M946-U9'J$7D]7]"/%:A>U+K7[(JD...K0_.7)IB4;:00=:$)+Z)Y"8<Z#"E+
M=<161OIVZ<$IB/TWI?)^Q5#+-O1D>D!BJ19_VZ6DM%M+WS*1:'&"\.9Z6/?-
MM4Y;R_H*B)0^VC'AKGNMW#&88C-2J$3GWM0'KJT=R4?UE*2+'!!#X_Y!X^LO
M4G5S:%!*G>W7(20]&?M11S24FTT:4;6;&:N&D\*KWT\?R 4F-HX,AZ_521-]
M3,K8RU/E\EZH\DF9V7R2&+%:"#XL%@0*W>4J$Z??U5$+C;0)05U0RYW!"KRZ
M:.U%D]\SI^A9[9*[<F7B!RL[:5M_(05C@<P1@O>.A'R G#EF>&68!"F9NJ+=
M?L-,(/;XD;-PC:]1FLTGUE-I-47C.W$JWH0ON.UFTK @3!:R(B%H)J%%&$W1
M(7D.>_VI/CC8L'6BG,ATMQDL[O#B\2>Z6_$,@4^T#QNP^8Z9"<M(6&0H#Z2^
M1Y$.U9;XY2?FH$\HLYUFB^U(LBDAUH=<HL:(R]=!12+O-<WKLZ18-U9A>$XH
M \;'%)78#:=V6N*9+D S-=I:,[:>E(G:S.@3<]E]\'@?/M<IP.?M1"B'$.C,
MHD!01W#!"]B;9R*5JCM#OC2-!#)^]H>XR:\0BM_?MX\WSBKI<QU-NY]'6'0%
MF#&L6S1N\'T\*AHET&W)]*:Q0DLSX$%C-2X!>\15.X@Y1#*_"67]75R*R3-X
MHS;.!MF-W^W;OW.;8U=GA\# '-WX-6>5SR%,>CD6Q'JW1FX;3@SQ,/YJ%7T>
MF<4WKY.UWG*XT'F3:FW(=TR(U,9!-7S=I[Z!!,2-$>A+7Y(=K0AEPB0<]@09
MQ9?7-CNMC;]P,(,SW*KD>&MNL?W@&SC)S2:ZEH>\@%6&^'U82#JRJ",$M&I^
M&RW64<?,]8#K#E.UA1-;4=2]&@MVO03!+.ZF;/'70[S<LT1NM<:2FL-!IQWP
M\$T4'.^>XML+47Z)#)OGYD'VTRTVUYU7#1UOO+$Q[V;7'(S9@1#*'RJS+9.$
MDF.,5CQ>VZ-F7KDY3M2H-P2_JTW>T@K7W/H4DV:CS!_PG*NTOS6(P2O*X,[E
MV,1\*K.#AGFR\Q&@SQKSE45 X?(.DUM9G%?"$]A(NT0?UAC=EXZ/]!VGYS^*
M2^,9312'7/TX\RPUW?G/;(Q7E"T#1.II<_@K)UAS2!7Y(2D&5D28<242B;+3
M>-_%6ZZQPO)- W?,WW]<<$^\++(4ZW;K?^*Z)L3IVGD%L,D3KM"\R0#U@!DA
MZ7V*?)/M-1ZUVO'FBM4(N1)7$\H4'1>5 _KO5&31=<5TR:6:1"?PZI"LC>Y+
M[^Y>18J96YBQ%9IH9B')$F3D(]SDA!]W)F5UR+@;V<-"^LB7D0PW-"M*R[!*
MUHY^/H$>CAX>@3X]I[1=)7P-/Z3NL[JW'BA\)DS 2*'20*]QM"'<+E7;S&(6
M6GX2$X^^\HA]^9Q JKL;SO\HWE!BA7A@@&\FGV=75_9BM*1>?N/CQ&>@L-JM
MGU7QW1S?08><UL;7BAOX2)M[T1TD$@V567EDX8&,KTMKBF/C+[W^RUC8%"F=
ML59$D$4[_^CUVW&6]X+6RER):,*^>:/N=E(72_X9/DC-$&FWG"IMFA;%?8-X
MAFLF61\, )F[Q% )1(A'KQ5KB^LG8PS,L@G-7Q==L63I=+IT>T)ML2_:V_K#
M/?%AAT46FMMYCI*G7BFO#K"SJS-XN+9!,T=CM0JQ8NB1-[4E-3-W120HA#W,
MT\:%'VOF)GE[W"V;#$E4M#G3\+)=AS=UK,Z$DF.)1T-)-\7F-Q\L;054YWMJ
M?]GZGFS9VJ)=1\KVZ-G@HQ;!XWN!=W4 +934RG!%YS+P^YQ7H>RDR*GZ@T?9
M+A%IFU_W3_G[A5H)Q(&DF@>>C,%Q,X5]!3YIPBG9P<'ZJ?X;/W]E_5>O$/['
MQ-:UO#2PL$]<8AFO5FTC"\M%3YP1_^I^E"ES]Q5 OIUQ4A$0J\,T7+&'J.=Z
M@>0NRK=--LLAPL.':B_7G4J45:2?U0V7TI-SRW17B=W):/IF/CTAN:^Z#T*?
MV>)D*K(EP 28Q$>8K!Q,?]>W9=HV+DRFOHZ!R>+PAA:B9 YAQY:59A$P7_48
M.N3M+<4$;E$+?-9:$86["35O&[LUH<B]&?2L+S_]8/-@.:K6@T(G^->+MOJW
M8MT!A8.\2781W>\M0C=)&(\\=N"HTUXE2AQ=XG5,P7 /&U-1@'VNQ>.Q#WOB
MM2F2XX\KDS]C^("B" -Y.F5@)Q2$%1N'\KI>YOHJT<QCZLX%?U27.)T;^,/=
M&[IJDKT.&1V)PQRD5V6X,_;2%+ZHR'"@CXMI_<O%X$%^@'K,LT 9Q>YKV?V<
MQ:X]H7*A8V^QO-.E\G)YF% 8"Z1O&]PPS:P>N2<DD=!%;"O1DS)T($@$,-B_
MWXB[IDQBA!9;97J)BO?5:GE\RN3/5K \F_+4N-K1553_J_EC3>-7=;3:SYF>
M2V];"JVTSVL\P>2A5WM %"WZ>3_GG$U_O=R8AWCTG!O-W?L$&=((=+W3>/O!
M +O&G2JFAR4"\I1G[3W"MOW+G!*__82E'J-3ER.ASZSSEC >.C%+3*BC>=_?
MD3@J$Q9L%6*MFVF5U(9[#9Z/%;B0PP1WG\->NME/^L5;0VD#?!2CYE.G3\.T
MV7LJJR.H>#08(L67/R:8>74"[.WD;52_K4A]V4-$-(.'EJM*%DR77)(I8DN"
MK43S$\8<N67"'_3PB$ISU?YV:< >:L;0>BK\P3R3DV..H'$QMQUP1:TU)M,\
ML;N)ZU.Q#G'O=W__JI_BDEJ_=.[D,MVF@]%_I*0)K2&(0+OVF+Z)Q'%APD.N
MF^DA(ZL:$M7JFY.,=MG>).]ZD$=*.SI21.#N@LJ@\!4X(U0:DX6 $V#E6Z8E
M1F(S$F,E)!K0EDD5VP\RA[FTS0("%>><KC^/<(S7[4#H5K*(U,.UFE 6T[7(
M1&JH-497&&N"6&;2<BYV562?$J"B/'MV8\O?P5#(P^\:;:,Z803%P=?AX/IP
M+ ^.<T)_]U1O:WXMMN[46-)S8=A?A=^DQ^6Z,G? YG(98(JR>GVT3X0QTAZM
M*81?B.F\%"XS1 9\F.8'>/9M3,)T@0%Y @MR035R66IBGF+SM0T!I<<A ".[
M)O-GZ;U@ V&O>DPP_>;$<M&V.4F?1\Q;[$W41TO^UC$)85NUA$WNR;V:]RV;
MX@M&? H+ZHH!\=1=G80W\NM(+97%<?R0/!RM%?%6@.Y6D'MZJ0Y1VKFVRXQ>
M)V7Z]]<JK(XWM43J$\ D9=  !(@%8M4'I_$5 <Q<N?C0 CW[3"Y4SD@S"Y=S
M9PD8A85PZ8 /C.-)@9LAL\?BZ@M'SWFMZXTC& ULR(6*4Y/AAS(G,4BW^M2O
MYD84. ;[J&S=RADL[CU$G5N':!O@2]*XB(UXYA#W^HR,+Z0:Y8C(Q(IB G*=
MF-G*?K07&\_SU_:5?;YQ.%POI]OV8/##?'/L#6# -EE9#$>"I1\/)8?X[XT/
MPG:I] T:I>:SOW G+.RFT-::JW+QQA'-A_$D,-"GI%AF<=A(3VFHL8">3/&4
M_SS\^'>P$,\T8QD6DESZ:?01LHTLC"[:9K8D_XI63[='4Y_J-#2,'Q47JC<X
M&L_FD4:?-;(N3(:!591985R*MUUP!%;DO]M8)VIV57M#[TRV5XM/3;O'M\;9
M6R<[\Z6^8WI.)]GC)"7#38TYVUI&E%<BEN=-E[;5)AW0# &F:5FE6!54:#1D
MNDAGLC ^;5E7JV"!OS?YG;=;/<(_DN+'('S%JJ^,]^0;*A-['Y.5'U+1(^GO
MY1*+I&(RU#99CU.';IM,4!'_O*7+R;!.C4@F8SR"=UT!X><T7;53!1/N$L)&
MSZ8*$G0T3*8K,@Y.=OHD^ZH>_]Q5^V; HDNVFO*6 D>+T5ZY H!MT^EJQ C5
M9I-D1=F34]G4X[*JTIFGS>Z. 7VK:7RKA<%&[B6U7G\]N],@X'7<4>STWWM[
MX"E"50CZG:6"V%.SWRL;.]/)18 A#,C!38Q!@I%^<4'+"S67EDXM%FO:=Y<D
M(E=>2 9\)]-4'&8:KD21&7]X_#'R$K 7SO:\0\_B,,"U;%6Q)D@X$DJ/)4/!
M.Q>"UU%KS&42B'C'IBF1PK:LW#A:!AZM#^_57R9,D1 J;(_E)0[I-BXF;)21
M-QNQCBBM&;S[^YU*HP3<.*@:_D;)F8:X+;;TR[R+X:>"\=HHA%':H#?I#QHZ
M]>YUB-FZ'Q]M5FE;KU9B$-")^I$94H"!Z51/WBO;.Z8(-D8T9"\M?(O48@3N
M)KG+,63[KZT\=XSY^6P!_M>OCS4U>,;6]AP8V 9_.72LVI,#KT[$ ,@6>[1/
M5QM9-9JH*;+28::).EVQ.K!@X2=?>HDK'9,S$?=>'V.D)J'"Q4PO?+9II-<C
M;EM\B6#2%R/QR149/$)E#GG[&+7P QI5._S@0,"JZF??M=*3L]E!(UM%LO+Z
MKO;J[)(5T'QF]R@F>="*'F)IUFIF,@$UK[-RFKSG7LY]L#1BV,"7&GWS'F_7
M%T5:\*+,N2O"HQ-$@+UY$0P1ZSH)Y;JPO?UQ8<]FL''VY8>$V1D9TJ+G?"N$
M&< O)?LKX/7Y?F?[M>VV&U,BMUK&W"06^E$7BS_JF7F?^!NIB!%3- Q.?-65
M5E>9D=@=Z@L<D> 0C9I\^7,-17)0_#<K0X;/EH.1)(DUB9&AS"UHZE;YM!.F
M=7HF5,VACE"#YJ<8">+\I,541N4!!T"7N)T!TOT0%1^SY'H^G/#&:3R?PNNS
M!1^IG0.!KAB'.U^<B'XOU ,%6@V( O>5M#+)7*\O@I183O:5K,@()%MH=_V5
MS'CA</;^+,VG?([4_$Y-AVJ#NUZ'I=:JU7SX]E]?93O1D6GSZZN8X)X;F]=#
M)%ZLTW#^2BI[6,8Q[9/O&O'!6-3H>1RA>T53&SU6[@J("%ZQ$%!O;+-PU*NO
M,W:74'V1]$'9YAE@F90C1^OMGROX0UV3.#&RG0*K@*I0:1R7%W:8=TA2V)E!
M]F@.4](]7LBR5D<*GKHKFH81.'2PEL\9J.>0/[(HB4O;:%4,(X\H6-B"C("W
MQPLKR"X+84ZO,10%O\DHV?1=FB8/U=R\D%3*L\YUVY3J)FPF73*+-6Z:8R8_
MZPE?*7,:Q;?QFY1@*KK:.*;*X/W3LD3G^9+!E,L.@TE$R:OK0 .1T'T'8.4&
M&0C F!E.M;N Z?C.+6*'T&1N/.UH2B;%FRE_C1W?3AO9.9DO2.UQLC.+(MKB
M?QEY_?%;S6%?+@JW $M,%JP<>J=N4CXP?W$;M" &@1F(.7L[S1^AWX3OZSK;
M:L>6B:OS)R\'>!:'*?/N*T7@B/'.0M,1Q/5&:';8S_$%77"\%#BAB^R61X8)
MW9)2VOT]DYC#@;4,0)$!<PM,@)5!3;_R42B;.HZ/$[58G%LHI37_Z:8OWDFB
M<^#N@6&6*1^4$/U,'!L,+U#X'PO/.&K5 !^< .',]W[+YGTUNL$Q_WV@\]]7
M6AQR<S-/^\1IGCI^V<0])>*7YN[^[QEWZG='Q; '^@)IM\=_;^DQKUCVSO[N
MXL)_;\49KP27R[^[N.,_0UEWPRN8:M<#I2)WC__>DF=_=]$#JZX\H"9SH*H"
MV4"CMO\,KWN:_>%&^=2;E4NYQNY)MWG^\E_]6GN@H=) 0W;P+3,6_2=4-^78
M#.V$#[9URYEV\,O7)'[X?KBV^O LNUW?!>(K&I>W>Q]1<2TNE,H7.Q1V)-.D
M65%P1KY"XZ498O^4:J(^G#\LRQ]QY>M;/^N22VMF!\ZZIKSOR2$C<P[W<XZ*
M#0K)3VT^%'X*[[9)_>C\:/F1;OL?D[,O_U _$C8M7,IV:N^6<*GBFW>CW62?
M['9)S"[.53YM...$99=JC]FGPT+2_6+_+M\7JK%__%K7Z+S31[[YI:7+7E0]
MF\ZSOOSAS,MG/I><%XBTGF]D^?@.R\2WG_X<OMD<?L.>Y9]PYG\&]AKF_(=_
M39-[3-97VI2MNGA+]4B+R:);0F<4VNN\CK1G]<V9Y,%JW[B?\4M^DY7O&[-R
MHZQ?]Q8D6\W;7LP3Z%_Y5*%/X+30*@V/ P&B[D5%$9-?:>PN/IDSY[-OZ*=/
M3-_5/Z\$AO2E'7R+9H/BI!<8"3'LX9:/]3EN5EQWW'59_SJGEKQ>:J^4=Z7A
M)U_)TH1-BD^C9>2R%\(BA'UVC?(/_<5_%-M#LV/=0S[R[5SC-UUJV=[U?MO%
MMZ_K4.ZQ;@T0%71:I<'H\/*D^J70LH]S+B)L(BV-F'Q?7/AER=VW7?X)RO5[
M77GJ\J:$E:5PK-U]X[ODR[=^=U^?=;+^Z_Y)I/O>QN#,Z?N>]MEJ/+ZT<-'J
M6X8W9O=[67Q9D;'XEL%&<[DIA2\#+KIO24S*@RCHSSATY$Y5X/&ESJYR%UL[
M=WQ9W._5UF6[F%NX\*6[W%1>D6HW,;7'E_ILM:0TOO7H^!Y?*E,58A+X5B)B
MXO1BYFD27]9/LM.O8?W1GI[_F)_G1]FAXX_J@9TS*<D\^XU[0E=[YINWE[(G
MU/Q0/VQ]^YV:OV[9+J.:'F:I7Z=_9$XJ^]7_3&OO8EYKF?1#^]O*YO/_,<^4
M/3]U9<4J7[MSEV,^,AW:>"?K\T&NX\_/')Z6_%D@8AKCKNNE4AT''ZM\\C.<
M_#I@^5W[X#]GM2Z^E7@3 7&C5NUB45(\03!L]E29RJ0M?)>UY_[K]LN_KGBM
MWG;H=M*5GO("BZ.B40_#S_Q>O'RI:,V*TS/G_[\) %!+ P04    " "]@&]8
M%N]A"P5:   '8   $    &9O<FTQ,"UK7S Q,"YJ<&>LNP=84]NV-KSH*$V0
MWH*"H-)[)R*;+ET!J=)+1#J$&A %Z0)21 24I@)&N@@2>D!$I".]]Y)00H"0
M_''O?<X]]]S[_<_]_ONO9#Y9=<XQYIASO.\8<X4P09@'+NEIZ6H!)"0DP /B
M!R LD&#= P)\E,3%'_F+.3A[.[J(.7E[B4,=?,0EQ23$ 14PU,?!">(2P.?H
MXN;Q2%5HKPDAQ.?AK"ID(6L@8>"CX>+NH1/JYV(6:GC7*13BI.@L!%:CNZ@"
M58)Z^7BY!#CP0;T>/O)7@JI>_;-V)>+^[]/B5]54_)Q=E4S_T/K[#N*1ZM6_
M90D.#A8+EA;S]G,3EU145!27D!*7DA(EWB'J'_(HP $J^LB?_^\*_G#Q=_+S
M\ GP\'[$]_O8P=$[,$#U:F"@A[.2JX.KK*.SLZRHHX.TLZBDI+.#J(.SM*2H
ML[2TL[RLI(*4JZ3CU;^;=W;Z9^L^@7X/_VS;V4G<Y:&+E\NC ']B;TC^EMG9
M2<G/P\T]P/^OUM4?!OSOQ'_H\?MYI8<.C]Q4KT)%G5U<'0(?!A OBO]U]>\=
M8CO$7KUPX8**^+]((/YO'?#W&6*?$O?^:8'?YOBG%5T>$4T73+0180&XJ@GU
M< 4  P/@)@  U #)XQR E+A' OR]$:8 #8",E/3WE[B1$[\4U!04Y.04%ZFH
M**EI+]+2TERDH:&C9[I$1\](3T-SB?42XV5F%A866@8V=E9F=B9F%N;?E9"0
M$9\AI[A 07&!F8Z&COG_>B.T HS4P!:I"AG)58"4D82,D830"8"(LE*0_+G]
M0V024J*,E%34%R[2$&^HNP20DI"1D9*3_9::>#6">!T@9Z1@NB*I3GG9Q('J
MJB^S5'3:&VK^VU5M+*:#* %I1[_'%RZRLK%S<%X3%+I^XZ:,K)R\@J*2QA^:
M6MHZNGIF=^^96UC>MW(BFLK-W</3/R P*!@:$AKSY&ELW+/XA/2,%YE9V3DO
M<]\6%9>4EKU[_Z&ZIK:NON%SXY?VCLZN;F1/[[>AX9'1L?&)7Y,+BTO+*ZMK
MZQN;Z/V#PR/,,?;D]+=>)  9R3^V_U8O1J)>I.3D9.14O_4B(0W^?0,C.<45
M24HF=1,J!]_+5Z6BJ9EOI[VI:KO +VV*8G'T&[S(*B"S< W]6[4_-?N?*?;X
M_Y-F_U3L/_2:!&C)2(C&(V,$P,"YKF6ZQ <V=-DSI"(PG!::,O/^6UT6W)R5
M8SE53R5MP]2KR$N9!)2N>GU?NX1V"M:+\]@Z(#MZVRK=R_LBA'^H>$IK4H0\
M4N>PJ)<W4W#R?6 (75[86I:"&=^CM,=)&5&*QZTX]T^73_B'4@5"[[FV)"AF
M"05H/WQBVB&B;4QE-E>X[:D0F"C<F\LN-I][3\%]*?-^-$</O]J()4W+7Y7J
MGUD-[R0^?'3E3%\HYY-(5(]%D]=62J;\9)J;9:)X7NNG5)_I6YNWME(*<MZV
M&OTEM;%!('=8</4[UXFF'-J&!ZH#GN9?-!W?/*]._MX4>ZN- )"=<(J0S_[5
M@-6 :7W+O;#[2XU:/0PTL:;:#U.4A\<V!,SW)W18ZNO'N+GG4SL*OB62R/_5
M"^ITR_*,%6DZZ5J_.LI)F[E!/</@6M&QT4=)[T1S'EUF)9%;4J[)<^(>?" :
M\J?:IAI\:61D';0I<2=WF]P_,?[5&7=?N4]I1J7^M]TH-_B G]@2K\[A>[G!
M^L1_]+]N?7*M)34N;4,[7?6F0:W7VU;M_[ 2*RE8(-2$>)SAQ?7_7R-UY!G4
M(S67F/TL44!WZ. #T%\-WDL^_S(5_[WGTR7JS!SRMFZU1WFK+P5+O+P#69H;
M))'^$J+<M/,Z\X%7C(1XVQ-)_/\2X+V-9U9] ROFP$:3^<!9DSO]NAL_Q\4+
MO2J8 ;UT_9ZE_0ZI<ITIISZ2S_//J536J$I820?^[G/9=FT./Y]H?6]'TNBD
MY8PIW$UEU=MSQD\,(#+!$O5!O32Q5.0Q/<=O6ZW_4NF=PY<4E^DG4OE)97RI
MQF$IF6R8DO+[Y^]=S>LG[7^890*TR_ESR:RD<W_5;_;*]/&LQ+XNLZ_$B7,(
M8!H&P,2_.\G*'-. Q.ZQ\5&ZMO8JD*%53!X(_E7]A_X(SCM7Q-ZZVO8Q@A4Y
MR!1XJD-'WQ$ :".^D3(1R/^_-^1*JKI)K1,X(++.R>N:OE%IS$_-LDI)CZU[
M/,\E/2HZ@_J5WKJ<U&!!9;*%J;&(^>(6!6]FNW!%+%<)-FNJ0WY6:D1M_+UG
M@_0STV_?+NG52#HD[P<<[??L"M<0@,</<>Z?L25G:FUO/<?+@Q>-*&=ZW]CK
M"#*]O$?OD.TCY',]:)>*_$VEJ#^&![76.3#)U05BQ OJNRTEJV':1<&Z/Q]5
M6FJ6:14S3<7@M@VWN6D?J>KTVV/%SW@GPDFPQXL#[%!ATX9!',<B#;77*BI)
MKE.;=C"*O*H%3T4?M+-U92T!.+W+/31LH1RR95A(VN)Z_K7Y.EX)JUR$]14O
M'1884S$JL;RVTO0":J6+*2>5@#J6<>S8WQDS?%,T"8$\:L $'3^>=?[\Q.:/
M:NH5C1>^:1UD/?SDQE1M5O:=E?9+<4COZ'SAK_EA83#ZV=Z%L"W)KR9'#<-B
MQ2.4[91[(AT7YU,NJ!6.DZ$*VJ4]\'3G^8&B1NVS["B[U ^>6>EEG<EBBQZ!
MK#EZ SQUW:,F7#;S;X+<DECY]ML1NEXXNH6SD*(L43;#%,L]@1'&]"$)\Y4V
MICOTX#$)5UH"$-+ G>L$9>@8A@8Q,+3$E[9$ ^J\V=?R#!Z^8I=BY+ M+ <Z
M4AA4W<GFX4S:"WOTV")[]+!\',Z[%,1=D;[%VK#O$2DSN-N_6%A[[WGDJ<)
MSZ?'^<[7/A4IRN,%PLW&BK GY>'N-3^;U4,6[$DAQNZ@R2PX"..-,65+-'>S
MEY#NJ?[.8=A! 'A;W?)2ZW9;F*!B!UV#T _>%]?ABY8_+"PCU/@#&-C5'&R6
M29*.R-ZP5#(\"4B,H/=B$A7[ILKK<%.WK+):A+Z::8B,G<MPL3-?L7= (!=
M@R?[K&J&PZ5137:Y&&4OU@'D%]&9KN.7U>SS(IL"P52\]\6:\R4ZAIKA2_6-
M"W.LX7>PG:!N@\+U*BA(9V@O7-/5:I%'*>3H@MX%E9IV">%5[B2M7SWDG&=,
M6^U?#([CYC0^#U<*#>9?(=O8MRZRKGW@Y)"4Y+54XH)U6H ]:>8JG'$/!<4&
M) MI-<X*#6\_=(R]0'8^W_.!)1ITHV<9H/>]!>*$@A8%T\[ 6P67'EU#C<?*
M] >-MY.9)1C%Y;Y_]<?(M.'5NOL5/704W]._?TCZ-5L2Y;2R^AY',4+5'@;F
M" =C"]@25#@6]BYC@XP8!SY V'1Y.NP_>(U9S5KR8&)GF M)J2E0E'01+]_@
M>%#B3[?=:H9P/(434T9*MOIT]:^8!#+XJ5*TC!5='ES,1Y8*!YN@6K(K[*UG
M[#<P#>-R35W-#1(BR4#@]3/VI(_+RH8,_/R-A0P#7ZU^=+2='J<T<S$.UNZ1
M>>8.//DH%-/>\'#2T?W 5D8A3_*;C0V@,IS\\96AGSS/602HXW*X94SKT'F^
M48PPFG1WED=.EPKC\-F 5;&E+Z8M^1'-9XW]>)(V#GAM .P)_B(*'_W>7<GM
M2:VJLN9(HNQN@4>9!C/;M19T&LLMQX@N;:%V>TJ#>?3"#94;;_L6GBR[[Y1U
M>DGW]B0^^NGG_UPZW2@4.$!,[.[KPQ]OIDWWAA19;856EB;["L0:G(9;5)>T
MC MDWRJOTQ5:N;<M/%LNKCWL5:NJ1D.C[.XE4CFB3?>UV5%AZ98$RUT?8!W8
M21@I)$VX_C\KG\(=%LM!Y%@+"S1EZ9#8JQ(K_3"_P2M!C%HE>5%*>61=WA99
M^*%!.$YZK_-K1\S":^W@OKQHKRO+\V<_J9(\P"BS@>C<FONZ8F_@'J$1TXE,
MGE:Q\2I!";JM@L;49*KGR1$6;B$L1\W!EY3ZR!-X%5FB+4Q):*EW8NP33J/1
M$>/;;(5B9>B&=OG("W4)7+'8 *=8.JT_K*O#4V7]KSC.R1L6&,+L\?1;/Z%%
M"^"8ND3;FUY,DP1 I[8Q\<[GF991*Y:K_$T%+[C]-V[Q?&4VN441@D2N[N,I
M<7_XG%&C5M]J.-.":G1C\IMY<^#:'SBS"KP_6/5! IF#68>U!O5I/W#PL#\H
M)QOA!'!PM&MCN>Z9<&I,Y3L;2=3KBDC!YF;'8(/BZC;5!#8\WS&;EHJ;0O07
MBU)<<!5JF5<"V[CXR[J#5ZEVV-O)RV[<;$1@2,7DC3ZY9+7@:^7DI)>\SK=(
MON9\M(FQ#S1 $8 .>9-^;CQH:$VWTJDZS>Z'' ,YS(\_[=N-]:\49N-JE[#"
MG;E'I8T?L/H:(W6O#!!N(X]J)UP^)WJ<R/5\TYF:&JZ_3K8(2[&"Q1X-L(7K
MH2'@6!4(!%(RT?=A/?)F\RO=\</K8_T"21O!Y%)E.>PZ%S_L9OOM"7#++R%3
MFW719EVYYD7S]@S8<AL0?0 73U!WF+F6Q-;E"@M>6\P&<R.K$T3P N7"%]^"
M^G!=5'9;I,18Q5$RK#U7K.[#KTRY\?')<#,#>GJM<1>!!X=K"9/#./DR#VD[
M72<GB+NWJ_1T#M\]:1WC*\%\X?UU=YTQ[(4,^03 W8@-ZK2(W.XH]%SKRHKD
M_1ENXE_:YQ'RCC)":5';X:K57.V=)J_EP/UEY2@.OE.+% \P8_;\0%RDC(<5
M0ZS,#/\BV<1&/49.C7+4:D_K:TNSE/6D;#/%W2E#-=,>+3FM)$-%L ^L_?(;
M6+L<GE=)+?^4[$U\+:)&Z%?"Y?12$:\V@73)5,_>G\3>%6K'R&&LP$\.;<5^
M<%6]T_"&E'5Q:ON1F$B0^#93\LD;TY-T2Y"@X1VJUNUSM'ANG#Y6$ZT S6Z=
MI1ZN?(!FB<-\G<N(\'^P^W:7#ZVSD@GG]ZVR]J\<^RDY!,?Q?>J;QP;F!%2R
M&:%*$4NON*:\GQ" 270;]UBOAX 'V?-9T^EO"X\,FABYF"]VUD-VC1AQJJB!
MI!SY9RK@$DA2U<FM35:3@:<B[/#O#%PON,UE8*1XWLEUB\EK#8]5E+V+[95T
M YUXLR]V*)<&21?:2-KD,4E)/U=?C5*[BIJMFC^#/\6@L/".G] "LXRN2+[A
M<(KY$-G ;'WHG00I9Y&K86$/>_*#@KKEJ=L$. \'GH%H]IKY44A,B)<^,C?[
M6=E/G';AQIF(M[]3A/3,S=KO1OUB7=<N^SL!3%+04PM++/\\72C2J'H$Q[)P
MKM5G&+>-,6\(M6'J\F*57.FN>')SZ1.HQ\EUKLV*I32QS./2.H;1(S<\K<_#
MM;[G2@-TRD^*C]VT[+FVQBT07^3@):R9+O:-VQ*,8=9C_'0V<\E64/RR_)0+
MYPY" DE7F>3U9/^^@'F:-FWE#?+GOIC)CZ/=P7XA! "\)ML_&RZ+^OAF<<N;
MV0;KK5?0F?6!E<Y*__KD)A\)V</B1^SD*0P:"9N904G&9._>)@#7_Z7<4"PI
M7GUK#73]R?'TE*]4>=[@\E8X7+Y;1_MR4^'A);6OY>H<!YYC657] @=(ZJ?Z
MWVW;3SRE#^1\G\[/Y]>9;W5QWDN4R#:MC1(@W9C5?T+B($1Z6W=!&J<-8 3&
M>V:5L&R+82".\ =?:H9D4QG=E4J;%E[;68>]QP\*PB&TZ:I'%>K/%NX6,B:1
M,M/N0\JQ;F?"]5]1D33VS-&EGI/9<8(_U^IR1Z^%0:V.=KT:\G#]3-7737T4
M"QG>C]TY)"N EPV5FM/UP 7PL^C@.+S".I[[ZTA WQP=Q"KP?+36>*)67JZ2
MI($L(-_AOO1J TI,=6LL&S$6Q:/);$SRORRD;I/5=?VL'9U6MKO9[R:1$65S
MMS'C<M6ER[F"IAQ<$['@UR%SW:G)ICBAL6:Z,NV%OADG/%-$Z+ F9!U5/T;J
M07I!X)'A=D&F[\&#?<F!G(XS>\\O[=BGM7#JJ5Y:\X,Y]SW5)=:FNOJ1Y*>]
M:>0/BN(H1M4?/I;2!(*^>&\;H81T6Q+VQQ>,8AT_QZI?5;8L=XC^X?.+98?U
M4TGS59F+'YJ!#T#K/"V#>C36(M.= '#7[LB;HA.@L\?:J.2/&1]Y;G[;W#]R
M3$&K#3!_."N>.@C?R>3H!GJ[(:->'XN:GPK&C^DL&V]<E7!QX>=[K)0 -/S?
M=I)NOZB0+-,$I:BJ1Z*1E<DOND3COJ=[,2D7.,@:CMZ7MX(]^C6Z<M4:4>E;
MM]'DDZX9X*3:+3HSH]H&NFO;IKVI^3:[.B-DS[\&[_L(J_.N"$[@3;JE]]?0
M W#>V=JC-(N+2DZ-6X='I^,="+H]_-5P2S1;H@I8_-G1YSKY^MR]NW6YNSH.
M0][S8SG6&APT9YD0A0XIH3EVH3V+3_!V&"_\*<ZC9-;3;,[@P]QY]1#$Z]ZB
MLW.&CY"?W&CX.TDX>RK'23S DYTHU[!S!;4>)7T>7[&6BJG8&F-MB8@]ZQR*
M'.(EKT%39D \Z/)C/FC3ET&"5VDVI%U6Y3,_A6@H*DR/'EX\GP0"?T/P_ZJ8
MNU956$%A^DTC@1>RQMJ'!//#XAGZ.*]?RUGZ1!HEH1*"6M+#)O,^Y?TH*+D^
M^?5C V2Y9>"P/'B.T?O>S&C8?$ %B!1'##LZ"E@]6ZX,OOUB78X6@=!UKNJ(
M\F<YJ0RVQCVY?\TU+4Y1*,F"%U$?W/&R67KA:R35Z$>92A\; V[T+] AQ%TL
M:U+_9:Q?6DA*%&.Z!KVPZQPF[6<IN@0>ZSQX! G;J+-.OO[RS3WJP6J^;(X5
MGN);RO-K[(7TV4LE>?+V%#AHS1_5'];E=V(!7/LO5,BN*L1[X>T.-GCAT=K9
MS7$A]H%=T^9C)(A15,47E;VX\\(\F#-B-JUTT]Q//5RE(?!,Y:WBXR/&WKJ$
MC!':\;?ALGPX952+=.IVDUT1:+_7G:SD;<)UX/^]:!SV Z+,+S'%TQ'7249,
M- 'FWR5O:,C?1#3*<7@LI_:HA.?Y1)V=T<ML%9+I?.FI+?.;-R[<$Q+P":6'
MJ%\2\:RP%+NPTKB5:JJ$E^5GL2MV4ED^7(.OV5^#OL(\P\:[+8G'JW%^KA\*
ML$X4OP0-TQQ<33;X6=LPXIQFM>J4.;W"YF-(FDXB6(*:ZS)*XE5 T67'RSPY
M6/HRE"5O"S9,CFI.-'$7S)+HS%C]HZD>]$6J8YIL7.7>0>1@ 7W5S_7< 6/U
MLS%8VI9=;=W!46JBT#C"'4YB:><16E):7H8-NRM?;52F3U>;7E4]L_RM Y+\
M:QVRSK*FEC\";%Y_&W7Q_UB*15-&@%HS^5.TUIY)@AS)H9E*F_X7HI>4D3PL
MH9+Y2#JHR=QZ_=_ XV;QV)9/1<J'];ZZM*@K<6^.N$>_7"=;4=7 ""0<="BI
M);6(YTXJ%"&J1DJMF45#7 +?B:*3I0A 8T @-?<C=J&59:<YL19VJ.GIP8[_
M.F=XMJ-%P0ZOSH$*4IVK?K<PTU@ZOV.HMEESL1_4#GN@U%+D55IY/A)DWN_/
M9Z\4K* S/I)ATW^,] 8LZYNX\V\._W'*_7-JT[ABJK@^_3ZY;_G-QWX_;B>1
M970!?C#>%GJL%@&8'TBQ\F)B31>5.C:YSZK+F+0%X=-RK*"AX*80B-ZPRT;-
M%<3A.9U&:_M,87O?+%C0RDA.^42U2SC#.-VO^K\.S_E-ZAHU:5\)L.[C$!)<
MC:924E+4V[Z3X?($(#UL(<D/7+WC.X6W+ $"_CF\_@]%.OBKQ">[D54K-#P1
M4>N:C<KN'/LBNIKZWK.F'X+YA(DTUK27=J5?I5(D/PWX&#KZ)B[FO;F>I.W]
M%A"#Q643TQ*V&VK/-HF1BA$KU,E@I(X]8(9SL7OJ!=/LMVH) 9+GGYXKG8VM
M)@K%"WR![81YB=%$((3OV^CSKPF]<Q]/[6YQ11_OI!5[MM"-BFH_E>TZ,-$*
MMEX&M@B @7 (PJN?+5B-=2S&;;5#G0 @A;_?[[YH]:%\3Q5^!).>FNC;57MI
MGYNN>0+=LH.A8A:[4KL( ,- ^0;&(HBQPV^LN@-J%OKE0P/7!7('I.* U5ZV
M<J1O?^C(IE;QW?G=_'<H3[/7'-]>:WIH_BJ;KM%D-B^F$)*IS1O1?\!>>U1*
M1 MM9SE1V1?YL;D##7 C>Z-*URVK,HS8J[#PGP8!69^:^^FJ]S+;WWN]:W9)
M4>"H)'?8 M&$"RU>&[>XBSI*WM]Z?]$ST1> U57\D1.S]O%[7FA093);QRDL
M+J!)55B_-LYHN&+)LK+2JXCZ>2'[168?2H4->QF#,Q]IZ.4_T-R15%\>ZY>,
M>N_5;DT-THX%<89O,>\EQP4@0]- 9'ND./^QCK,_()>A]EWCL(DO 9PI&<'L
M=2F+)Z;"KX)(?F6FGO8R25VXQUUU;ZD2"%032;;&I&#]FB)WDRO2\H-P8Q&J
MPF,62>,QL/; M] ^3"P6*M.O-[N+ 3%X5L_<O\!L8[4G=^>M^_X=KX$9E83C
M3.58][]]E8'KU"1Q3IJE+VMS2=+M)V6:-'YQ ^B/OMF$WQT6=:U/,5"VNB]V
M/YU%Z5ZW\X,+K2>J)(7TLPE=@X'K1^5!F:+BHD&-&CPK3>WXQ@X2I"'$2HY)
M;-Z/X3:].ZG>O[J#9+R=IUXR<F4H.2H^1XR&-N-.V+O*)7'^"AU$R.M/5".Y
MY94]8[FVTSU!O=QWOG6\:Q5$R*Z@&Y)4= N1& 3;YKCIM%:J0+ %Q8)KJ\")
M$UEE.-[CU6 ?LZWS]AE(-WW9,FG3+/G"M;[I<U$OJV\J64U/?<<#HAP+Z#J#
M+\*Y*J(.71YT'+"<6(DT:[,<CL=U"H6G4>OE:$E<4%10.?HXW(%71 =E1Q3^
MD2\V]BF[ONKD1O"SBQQ+W[:1MZ4D\X\6AQ>;KWFFE1F*-BI'K/U<5 "!;K_X
M\$-OT.(L=2C@P0P#3V.9N&$=L^)D<5[^T<UC^.?D+Z#7H:EO$VY&_;N+NT'C
M6.1!BAXY=7;];!DIP*$F98.E]MC)"6"O0S2<%$&\/Z>#Q!\I$ "+O+46R6YW
MLK3S-VIT?6CENUC?<@^,N3^$EP-M^/I#Q(=5 SA%[AW.>6W\\,WHO92WS5L+
ML.V&B@ELC64]6H\8O;=+TZ64E5I-6TY?ECV=V>R/_+AI<1QI>3-'>5]=D4=X
M\SW7NS[:&#S,Y!ZXMF),Y_*.<7$-TU7;K9<2AK=/#U6ODW6TB(4S#A-#J.!%
ME1;0N&PJP]?1IT?G;5595P5,R+_SG2PY7IW>]5'LX_6-4@U;:'J$#5N(^<DC
M-K(T?*S?Y4\ .&2%PQ"/$9>>,"&5-=]XWKC:_>MZ^^2=<I+791/C&J@Y$ H>
M+D'2@^^K6\-/$#U<[=^>C&_#P/6DR@;<"7\FA:47%=X^-?,\5GK:88UDFV2]
M),G5J,A' ()YE,?3H$V8N+'M0(%GUFUO0=?ETP0&IYET%1[N<+LEA86-':*.
M;HJY"[\-R=R.$&["K6;O!<%?X"Z?&4!3+5-UTS>\=EU?D_6YEC@*I+UNPLQ'
M0'ZID*'UMKIF!1H'O6N%AL2NU+(]-JHKWMRT=Y7Z(/G#8Z1CM+2QA(<J8$#O
M;4:@J+^-@R:SV3_H  E72;C!F8,;GHWUY6,JG&[($CZ?LV4"SXE]A>GV*F"7
M*2( QM[GGSU/U 01F$#]D$BW7ZA47/+[< + O[;'[+^PM9 O1T_E_1IB>JOI
M5>C>NE'?U%"-BG%3N'*H?U[A#GYRK":K[\%2B@*\K4CHVY?-8W#92:1X=MI1
M]K9&]#SH$K<37LAT#8]3M]>&WX:L,4RD@E'1V+CQ,T^C<T:*"-[F&Z?CAW9&
M^!6C05#O_35<4CDL'N_\PD0S3/O)/TG+."-:>O%I=ON,VK?-8TTT97VV:8XY
MF&'#=*XGCJ.OXL&.C5M&=%?0EIWOV2W/<4Z&-C#/IEQHYH_4,(^W=@84YWE:
MNH6!\<^<37YL1P\\7+OZ(DC#[94'F+,.E@#B;2:CCUX@ )SN>/;:FI$YJPS+
M0:'JVK1<A<CO-$K[P52M"D?P8HG[_H.(299]Q/;4 @_$ "V76>X928[NCG4>
MCG]EAJ9*&;>H<^PIRTG:[L^/KJ=]X*,<8<(;=##0N E1Y^4HC^S)IQB3H5&]
MJAOX3%1TMXXKSMT[J-<G>YQT<?."M7?_Y1[FG?GD0M>OF0&O-.-Z67]2*U**
M7_=:CAE&X;92L6_01>T%5-FW[!GGN,*2PTSB](:]KF@(C,LS*17>4Q^A^R54
M2/IYQQI3C7)]]0$R^5#"<_Q82?];R9NZ3@M]VG*6X=;EA3&J!]6\@!"9# FL
M<]*K#KYS8Y[C;7WLC5T9+X?2S"NW]I]CH-.MCQ1.ER:_QH<=Y*(KS>XF6F%W
M4 UF];1C#9&@T=+X3_YU_1FDT$/9[?*Y.D#I=QHQYYOU<]_N&X?)MT W-K_0
MI50MPMD- H'/C?C)SSJS'L[M !L921323G4KLP7K%A$15F;3&U%<=/_[\,W*
M%X5JQA\9]L[I@F$'4M"F@I.4&=BU]U\66^9H;K]8U_Q\J.@B%,8]ECG_ZFYT
MAFG*T*X-+A7"G49ATLK=@^3+F&V)PMX<$&J'76QJ4I9[?4'DN^Y94:-@<Z8"
MK.,TX6C@,7A?5^4: 7BP#CMDM#.'&#*/*-Y+?K ;+&.B&;[QSD23&?A=S+AP
M-PZ["<#%.[0(1@+00TD \)]["4!A+J[S)P%89G ;/M>#K5]%&.(T"0 ?%P$X
M7226"_#O!E3X6QC841?XD-$^RQ>.6M@DSAJ,/3TXV6*0+7N/,P*.BZWU/J,F
M.K[UPU(88QEQIP="9&B?DN'X5#W<E @!""O#7SLIPH0OG7]KP-HO1[ZR)@#O
M$TJ-FHRG_MZQ'SK$7\9.AJ4/:K)4_7OT2?4#7*\=TWQ#*&JJFW/MJ2C.X)U'
M)<7K1L28F,R6LDMN8%*_KX!!I\G)TXD=IZB(\LL8711O_ *"$9IP=J<&ZT_7
M.6;<.:Y&@Z;[42ZMQ?VZ^N3D%Z^?EG*&+<-.5(/5<30REO_GD>Z5S[EC)[(3
M,AD?)B9[*;[I5J].*I)7/!%R$1X(9[P+<WD=9C "/VH4/1*/'6<ZH;[6@ I*
M%,P,8V407+UA#[7))S'YX4[&MG3</L?A">(4&@^7]O\X:V./O6P[7 D+PS\M
MLY.Z+=KY .!/F^C1J.KMIO3M!K>"?Q&=TZB@T26QEX'S_<KZ8TY??A[NF%YP
M^JQC/C:ME\P!RU(4,]6EGL_C[<\](\G.R(A27/93/=#_]GXIQ?<'4,B0%WDM
M7!H-CHZ\C#-\U3&9E4AN55>Y<[22.5,Q<#&V/OL']%E&\&MAIJZ<3':0:%AP
M1Z0:+];IXV]^VP0_?;%U'\S%Y=U6 /I$!+]X"KS28U^O:U[A\K8(AG )\":'
M%P%XFQ6EI'2CJ8G>@$.MH%(X:M,;;9*Q<3KT?J9?0B5UJ0WLA7)8=C+)?L./
MMRWYR"GGWCJY7?0K.=B>%[RTU8; ,&83 -V2CVQ8[:$6I-!8"E+6Z!DL9[LH
M(&EBWOF0I0Z5BM>KG+T%1O-3;>'3+ LZK&'4Q#'YP98 3%##-C0AN1YQS^?/
MEV:^*A\8\FRHWM .Q3Y"WB*BEN4_(FM:6;3\SO,W+6(>MKIX)#L &^ZSF))%
M@W>>-[6(>Y )/!I$$X ,.GO1SH)]L8*^ ^U)GV0"4+=A/;"O%HF^FT:<0'/O
MTFAV:!J@/X(K/6O3ZL_3B_+</#\)<1_<+1X\/(L7"#D\NY\HW]\BX7\RDG5J
M^SI1VGI2@\:KS7V8$D'=K"B2_Z5@1*5./@QDA^^$[5_!/B$ (ZY_^G_0AKU"
MY)_GXO =4K#U9\+K"W-;]C]_@<\RP:BB$Y : 4A+]D9+65U_^[6H_:*AAX?B
MNZQ620@2X2&J85B'"C>?1'2"&; TABT'7D*IG8,:U[+><[VQ:'BNDE9/#=[O
M[_"?_?H4TH>7@[Z1X8I@9&ME0-/O+ZZDTZEQB&19/KO=K<DFUC@/HS2XOAT[
MP'2>&<Z_8"O4;2(?&P FV=1W>_BSX!*4OTMZ!NGYU(=QN\15<J\5B'481Y]B
M6&>;OD)68"18#7MT-G* %CHYM2!C3Q/@16,P(KHG)I@_O,/9-$W=Z?-L)P?W
MS+C1@\'F ;W_$=,G.\#IAU0'B@" ]7YJDZ&+%ARP50OGXD8I1P$;VX%A="9N
M$O$T-)!W99(/TI["A#U.8WY(0$'4^&]RG.*==$:6HW6R8[6D@8+#AV7U^]_M
MO;^D;*ZX/%<\L/B>?/MQT45 L2O49:";@<(#P\K6H"8R)+H-W[,VK/N<CI'(
ML"E_Z/Y\C;8MFHK[XC.<)\IQ([3EK>R9F4?Q;++2Z9V"Z6E6ZJJE]]>>D7'\
M@/8#/E_BH@.,:/$C=O0CM7UR=2TCM;8VMDH#_/P4$-$/537,MQ06;L&A5OOB
MS'<JSS3#%0/7 U2=][6,^MVZE3+L"@(C6%X7CTM_3J!VDNKEYR6-SE+Q;RVD
MB4ORU;$&\GQ/QW,]"UA5Q.$;T5YU7TU;]<A*1I.?=*'''SLZ/!9.K4%C7LLG
MR";>"/=>]*Z:U/ 64 Y8Y/*/E\[ /-("*LZ+PU*^'P^>1#*[[7^D,L!6+N2P
M_FC=M#"[,^5P_V-%::J_R]U'3NQ NF9PPK3K>UW5I_5KWPG ;ZS!=S2 >SU=
M=HP)P/?>Q;TS^FD"<.U]=EUD?#21QJ6^Z17MLC\JB#MBV2H@ARVG8?7Q;40L
M6+_:G P;BP2-6'P,)T)%NO:"^!F5!A$J$M UE840(Z?&M[G]#?4>R7QVS7Y4
MJS["*\GQ[J472 C T5#YHP%F8/-&Q<1'F-VX+)V8NV/USX]U/IOW9V?=C06I
MV4]F=%76$H#U#W+KX(OSAZ!GN07//F'P=*/\T6YA(8)9JS_)G2.2="ZS\ET*
MI1^=>323(CDL\X7DU2+X!)B#C5,1@)\&D8[KX'VJ&@+P\<9OH<Z5T&RX*&_$
M5B)1=$&$9 #HA(SH4\>9B?=J1EIW%W24_2MB;8PA]CD'$=O\$ )0-/3*L(X
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MV8RY5,!K=OU+(@2@G0ON['1.&@G>>651@*ULB!PL8*!&]K^%"!4.S-8@50F
MB@5LR>CD<B 17=8O$TOI^ZSO]%P=X'T1]P(,0SW1_=VPDGW]GQ'UY+WGKSD>
M\UBV%,3R_6Q\"]$NAQ]N8BX29Q\/K*=&_#SB/@'8N'MOFV5S'D^65;KV'7$@
MB6WX:]4A<,<8]AVY./<WI&X=W0&=-4<P*!F96)R[+9QKALZU@4\$(AF)]@P
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MZOK1UC4P_XY:C28)(:?6Q8RI<UL*>D<3C+CWB=4H$^DXBM3<,=MR8^H;5H%
MBK7PJ4\LB2@X8FLZ!W=:<_J3OYV:%#0*#[:9,(CN88BVTQ1(R4U-T2 *X+*I
MJM32NL_495J;D=O66.Z$4$)-5G!.>*C)*T&]S!:[]Y6)8,035MS701C(,$V9
M2'^7_*&+B_=6VR[>M!U88NQO!E\+!A%0\475KR^T2,;[1'N(#L/,]>]>@\5Z
MH7HP@;V*M78G,$L75SJQJ92B+GNHT)PB:R4W!65U>O.4CD$^YV8NW["6:K\:
M%X.Z!D_6U$JG)$TWM.8<,% = >_-5BL*GRH$J[;BMZ*P1]V<T_2.FF]:&NI'
M-S,$E[9O1"]=)+WW 5-('E$2_^$7.RG2=F_=</:[^^$SIU&1=']/^A^HRC#Y
M5D=;'2:U\<3M!UT?+CA4)GCN"NDIXIB0UJZ:I&_SY&>6.!;%_4%C:!P%X!YV
MX"B]PY76LW.O!3,35M[669X)'>%8B]QV[)V+S?:%6=Q1)30.#D.G#XFM%WS<
M/3W)*(H@(LVYEN#4G3X 95@' AU(5#3V(K@^?N_1QU'+?JS)=;;Y>J5I*\?'
M]SL?/.79'L0"_VF;\7 K;X,\'G1Z#H@]3W9N!]IN_W'-Z/A"+ QD2.<JD?YM
M-^:6_C>A'YX6+$;_]S@KLH\6]E"&\Q!*L$IC?7J_&_WDNY,W]Z#&*>L Y_@#
M9=_9EG+':]GW+Q?(F>_0#H#[-0USEL)R/K6Y-@RXSO+-7_(;V&E55YY*/G[)
M,)<NA%ZUP9>3^=P!DGV;@(?4OV]WA)7?:4[KQ:S4>K[=^MN80F;MJ=CR>W7D
MLZ+V62[Y%^L:&%A"%-Z'\+<%]2R;]$(4G4IM?_+YCGS:]IW(RO)PS:]D/HLL
M08K/O4R#^W7NG>#@05Z7#6Y/MCM=4#;A8BE[K9T#S/<$\$O??9J_+&%UD7\L
M/O<H1C) >G2VOZ_*5GD(^^ .70EJRW4U.@1[H[N2-_RL60?I6'C#:?>_G@.\
M&2]>*[\Q4WY#>CA'OC.U$L%(JK4X%CCL.6X3=SXU52;P@T\,YA:>KZ!(=XC1
MQ;^F?T^37DRPSL[RQ<C(TR??,E'A^G!8">FU^:R$(3!;8"9E1N*;ZXZJI\\^
M6(CR]TO4ABYTZ#6)'I^:QF:]6+>O3BG4*A9P'\GK\Z4U]Y!GC\<L)Q[N*SW#
M;F7Q#JN>@')T!7AL&7ID>1U\X=XY(1M_2+:G=!L-\O2#&6S?0K2/+#H3H- !
M3NGXQ\F-S+6(]Q(C]="JS1LO#5860QL?TY&PUCDAKS^%T9):SO1[#I"GVZ&3
MY/;E+?/2X.3)T&]$FUCR[8=6&SY,XV28JHUZ(7<KP4891G/1'],N;EF<'OYB
M]M!&V+'7D:\V9!,<;NW1EJ4@L\43N@-XP'C&I+H9UZD-(V)N8,4:H<G%S4:]
M+DI; NZIUK>2<>8)BDUEH]>#8^*UIIN(2@[Q,6)LS[Y('SOP3Q[5K/5/UQYT
MRW\LQT#D3L8WQA1_%/U-3<EXZP9BS:GK1J$%-V.Z"^*%5?_C3-N7S$]XEC(_
MPV_]U+(]]LEXH5"5MT(TAP!M89.=%\ AH&BJ:M6.:*4I)&GC-['\&.<T?R/)
MOOQ8B3[4W=LY@RA* YKOL[P$MK=AKME!RK06^N"HJKKITZC)5Y:K+QLQF?HO
MK:ND765KEPWS/W[@++ISE?W7_4DP?2AX;8XN&.RP,,/[1R:[\N^>!Y<T4D$B
MP#X<&)"8%P3E 10&P1)$^T*2,+ZX+;+HKGC/"&1P-6Y704&!ZW:T8=,T;1X5
M)4#E7\K^!-<T! B5&+XQX6NV]'-,;E O;\K^"+3B<O67OY;7YP8Z\>33U3PI
M%Y&\UYNX:_)^21SR@#="#0BN)>0>1H1QNK*U4>*W!K%^#54OE6M:M5!]9(?N
M=<VK?&JJRG<-T#R=@_!ME40MSR=$FE/EWZ0[X]MBGH[U$\$Z)=&OUS;14U>E
MO<S;1_-!1]HZ*1@!CLYW>13E^)%YMFBE&QL6GPKSIZ7%8$RWWT9$U2<^MC6@
M^/G7K=8A[L'P#ZJ@C,H?ZKXJE_/*=@/ 5L;7G[!!ROU/]N GKTJ+WFM,P$^S
M3--(3XC'"\JQY66_K=</AQ:YE; *F-'!_#N[2R(UM:R=91)&+1^C9Z+['"V
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M_(/91H$8VK-S6$1(0@6@^QIR.,8][-_6O>[V]DG^+-7%QP"W$Y;O9YG16A1
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M-R#ONA8 RCA&J>%'X.> "R-[*@&-_OMVX8N(%B76I_\?1_W[[TUMD%Z/@,$
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M7%YO3#&J,D_QZUGV#8J;)28=J_(4V*+_X<[HOXHL*+"D./_];U!+ P04
M" "]@&]8_I#KB&)'  #B2@  $    &9O<FTQ,"UK7S Q,2YJ<&>DNV58'<VV
M+MJX!'>'X![</<'=78*[>T*P &'B[A+<">[N[I-D8L$MN/OE^_;9:Z^USSKG
MWGM.S>?]T5U=_=2H&O76.\:L?OGY\AO D).2E0*@H*  D]<?\+($O >0$1"0
M$."1D1"1WKQ!1D$GQ$!'0T,GP\/'(J2FH*6AHJ"BI&?A9Z-GY&&BI.+XP,$C
M*"PF)D;+)B4O*2+'+RHF_-=+H-Z\>8..BDZ*@4$JS$#%(/S_N[QT YB(P#.T
M& P4)0"-"06#"?72#Y # !0<U-\%^!\%"AH&%@X> 1$)^<WK PT8 #04# PT
M+ P<'"SL:ZW?:ST BPF']99='!Y;]2,"I0L.1V#<=T0JB9H>7+694VI.4]<@
M)&0\? )"(AI:.GH&1BYN'EX^?H'W'R2EI&5DY=0U-+6T=73US,PM+*VL;6S=
MW#T\O;Q]?(._AH2&?0L'Q2<D)B6GI*:EY^47%!85EY26U=;5-S0V-;>T]O;U
M#PP.#8^,SL[-+X 7?_Z"K&]L;FWO[.[M'YR=7UQ>7=_<WMW_91<4  /UG^7?
MVH7Y:A<T+"P,+,)?=D%!>_WU "8LW%MV>"QQ582/+MB4'(&(.!)QWVMZD*@X
MU4YQ35UGD/&HN=9ISOXR[6_+_K\9%O1_9-D_#/LONR  "@S4Z^3!8 *BP#4;
M< 0R4(%CH<!V(+:QSH5=DH+HT4/QS#0F@P#%>H?"O !L!P*<>J]<^#,IZ087
MO=#J,M%PIZ.W+>W1JS $X@Z6-##.NW0-F@OM[ZOZ_$H*FYE(. ;L,XOA:B[<
M)I7WTZO4A/.D_0./Y ./# K(N!NC7X _;M)O=5+[+XYA[T M_*I+C7XV*:LL
M72_ UR\.$DMR\12:9$C4'A86EC#4:&&0%"8T[RQ/A 8ZW(02.X=B'<@(3?F(
MA^L8B>=!'\WP)-+^4.7'U=ODY^M-Y:8?H?+:\4>YK;"E%HP<&MB#[)/6V\3I
MTE:!1[(QA29&A]K)JPQ!/0Y]>MSEDY,$\-3D_A<3JC%#UJ?C:R9NS$Y8WS:3
M]#TO H<W^0_HMTUWI0T#I>!<ZVY76#;9)\QGUI#&X>$3 43#7VMS!.4G&WQA
MH5(-I.VS4BJ\B?B[))L(>Y]F1H?&TYH"I1 :7!4W#LM3+UN8*S$J)W;C*+#*
MHYJG8+_XAR ,N!F.V9LVID-6JCLG=K J=V)EJ$C%-BM)*HQF2)W(YEU>!^H+
M#THY<^OGFJ6QG0HU?(1/TO%2@E8D1*##0:S.-.<)&^'(P5^.W^W+CR6ZL:,#
M+J9G1ONR2$,1&@C(%L;'-J'@#GOM+:S?9@OZ./)6P?#!DG@(VX"-F'E3KN/>
M(*FMGNM2!;ENHM;Q4WN0TF^;[4K+@GAF00PZW_]UVO_7_E"8CP.D5E0ZZ2OB
M.D2(S3;T=ZH%](CQ35&?@<#<H[>K.-EO4)=D0?Z<9MVS^;_)$(TKN1IHE8;]
MIB)-Z_#*7:RU[-+D&)&2 E07(M!$T1IHPB+K#\=T'0L_.D"/?XPJL$]#/ D<
MKB"V:_-HF=M.YOJJIW1.<&1/HVDR%OW5HXRC!_V7?3*#):<^5__.K*8V%I9O
M8&8,N#R)\&+XA&ZQ?LQF/=1N#T\WP)RX\U08?5.VT"[9=[B9QUZF*;'_CF#+
MZUX;W]YTKBJP)O&.HX")/D,Y#O3G^3?5]YM]/3VI4KOBH9(^]F9K1RL?,P8K
M"@O4>3)!E8W0HB7>G'Z(3/1^?COHO6W(E@8_'UEV5XAVS !;4TATX_5D#=KG
MCM^9YBB[9U5*"V^CWH;Z;+'KZ4_ M43WJDRUF[T;<K*=;>NL;3D-LCY89*(<
M(+%\;T4[JQ&9:=:)BDJA9KFR&\',<GGF82OYD[.R1><G \H*A[+<9Q&*%2\+
M!^&, 9HE@2(:;1CK$7[<T8,W9I_</+<FWS:W!ID1UB80JYB4;G;H=+75Z4\(
M^&%Q.ESSQ'[;JDTQ<P3(@+QA.?O]!A:W/RG['^UL:%8VI7=29X*^*FS2Q.#:
M*7<^.,0O"W'H8\?.C -,,7-D5P-&Q@T3L\85.?LQ4$TMX15%YX42KFR^08RK
MP2Q1C5&LL1>&0BGVFZZ0X;*,V^ZICR?R2;CCQ^XJMS&RV?Q;H?<(^BZM:N@K
M9%W*OME#VC7S_:&C._SM^6$07VTV(5(_[HP^-S=K%$_:46PL7!0D!+=G0SB'
M_58FG4-\;8OI(2[V#YA2B/1LBGCOE23%-_T8TCDJ5M4G3^O# D*DW([1;6<2
M^@4,V,2Y4J:9W2Z('8<_'NKB?<%M"7U&B-?W#%J]UD^"4MH@E>DYBE542^EN
M^O+A#>E &T<?-1;3,;)F9J.42/.0G.>'56G' HX@-O$M3/G ?54]"99*TZ^N
M5&(YL0.*JF:J_^N%,(LAS# ?&H"C-HNLAP&'HZH #:+/_0=BKUX;L!T_LMAX
M^0O_;NX(LNF^$ H?A0D,["ZE.5WYNF.ZH6:5S)]Y(E1OXO"L62W%L&Q0,D!&
M\(,H,L66!EZ:]<PG;(Q9"FGI0%*</-B]OZ&Y<6),F@/QQQSV=BX_E#!_51B.
M:<2/;2F+G7 '_^(!&V<+BS [:7I7:BU2 EZ#>9YGXKDCD7$S7?FET3DFSOC)
M/VRZ,;X_'1?Z#;Q35 Q=-1X^R*G=L6CU64U16SWK655W%>,PQ?^)CE&9MK]B
M&CYV%)IBI[16&J(0X-6DK'%JQ[:[%D?-/&>JZR4M2LQ9R;>"F;[7$+!L*1LK
MU>$>F'?57S&<LC<][X9@\_%?;12>&268N53NS<H[5MSP&AD4T^VJA 4K?Q3D
M_H2_U)MN%4NUQA<K9WGQN+F30@5[?.^BG2';X/?6_?0<$3H$A?KM+?_DB=YZ
MU>]Z95Q;EW'W^F@&2@W]7X0RAL$A/?LJ1DL&G=\_%>ES?JL?(5>/"EP/[-&\
M]SOPI$MC#;/!#^':6_^@E3.N'^BQ<]?%GT P(JK$Z'ZZ GJ/8DN]A#K2JIQS
M.R):+,P45=<ASAI183BR)>U7HN@\L 2E[8A#/MJ!/'F]^KRL:"/DUJ\$DV].
MI"R1;^FF]059AFO_PVP:ZW"J= HM];N<U'=FP>J_O%D'67B'VVP*XV6P\,T8
M!#5,UH7AI>R*!HAM#!-S(WV$>#_29;68B[B?+?.0W\X1^Z/!F>UG8[<V+OYN
M2_JMP[(5_T%G9=(KTH1AW?>ZJN^O.746X\N+5)NEI\\# ?\SX@/P0#:.-N4<
M@K7ET,/.W632X  R&W89 \9X9^!8D5*NEL+=PMSQ/<,P%W P#/8HK7\HUY>7
M5VXP7#ZF#^FE1^:0Y2ZYD";C'0;I-D8V<OB)-$AKS%1<Q>%#%FX^R,I2N4:V
M_/X-LE9V0/.]&" *22YW8](37)*T(#D7FZ5GV\J\6%X8.OLRX<E$7@=#4KU=
M$<&JY'F\Y4D>;7MW.IFQ-881\&V[2=\2:FK9*"@OIA>B9_2F9--YPY@+B@%"
M3D!'RAE=?\E9WY8&7N5[AS7E87*J/^+ TJ]$C:(CY2Q.6@<).ZM('F'OG(/@
MR9LWB]7!KY+^R%]:K2\\/<YR, >!:MYX4X?2)M66D5>)'W#J^HH&@>%;GF>M
M+61S=7@^&!.H9_VBH]@E&%)0S?TT6)501:JMW!KWW=JBB;D*:KDX,JBXN4+G
MLY4+?!IV!#]K>QM-:[IVG,81L_@FJ5UAS6QE_8,LR_H%H3E-YO!V6OAFO&WU
M(^6]Z9(L=.^J0?+&0NC%<P5)X/UL*^,X-[@Y1^)3&_&( Q%?9'=9<-OV, +W
MN+)_A;A=WJ9J9UKU3($+BHS!Y]QU<8)!NSHF*Q=K^\_#$-ZH_)\DYB4$HDD:
MK:>3.5ZH!6K,9<R+]O#\NKI2[/.?U!74(GPS5YZ;2O9JEF2%!\98)NI+B98'
MRS8^1Z4!GQ94-X3-_JAUWT@ZN2_)0HX:8]+%NM_NQ_@>9O0)N">#I^7B1Y/G
M?,[2:"PMG$IW3XMEUX^XM^8MO)TA02'-#K?+".=Y>P8Q+;Z#4O&#2"3;J]RF
M?K*X)FZZ E^BS/*<7C=3#:8@RZPT#?32C0;<GAXU1*'@0[4)C#-)VF-Z5+$A
M517BD@_9QAED3TN>QX23G#&C1?"O'OE/S!?7JC;+*Z< _'M>_ <DG)G(U<^T
M8O)7_-*?+]^+3'%:#IKBS_\F04,%[#'30RKS.'TZU7SR QZD3B;C)\^)'V2J
M*LVQ>CC"HA;S&?9LF8[4YI23(4PM8+JVA-$PK[-. 1787L3!E1H*B"R!:H^P
M3#'!PC?F@"1^V.C0W/KY2J?*S62(AWN"()JS$AHZJ3?%?(Y=</W,O=^9&,PO
M?9F!@J;PU"OF@'3O(#9Y'VN"J(+?YC%RH$\/GZR-;*PDHU2&E?X\YIKGN(#B
M(1N"Y=[%(3<#C&%2I#V$.,B]Q#J$N$2(O_"/2U4#+W%N-Z)QE[ 8W]UHF*CO
M6Q.H2N( _SNHJ<V(H0K;!0;I+S8UR=N55NYV+A1%'VBHZ$"UP<0- :9MYYR:
M#A44]<D^;Q4K!>_B??$&.>_5%=*8,H6KRLN5RZ?LW)RWX+,9*%QFN8V3 I9Z
M3C(O-*1J_#Z:%;VW$QZG)?9&^E8]O)ZQTSVH']T>J5WL0)*)DGU; !%&V%9.
MS99>OOC9_\/(4((V71:ML2WYP^0"52C)E\X% =O6%^#7%2Z938I<X*;EKS@7
M!J>DL"K\;,%%GQ]6?.1)!"<#)#TC.VYDF)T=74WM^/B*+EA)F'(^)G+GG 'H
M(LO:PD5K!KI[UYXG)2OZ2]SSAQ[.V"S8T'+52C >U=*(T+\!A-Q\DTLCWS-P
MTM#H'Y?%1=ZF%P#EF+I3RB[TVR9#J#/QMD-G@<E&"6N3#V[AP8"_CW!9/1+I
M5#)NW)+@(K5S/JG+H-VT7/!/-5B22!2RGWF_?Z^ICV^?H?UHM6@/O3?(5T#4
MA,PZ."6&,H7R'0W:26WJ+TQ]FZ5)^VUX^BW78T/CXT4\L'6U2X6[:D\67.6K
M6H\];07.X<"G.O:9^)H D2&"LV BRZ>LB8GMJ6U_ 3+G:P_2MZ,J'EB/68T4
M19BRI@C&[?51FV"F+ZO%Z(7QSPL1$12^:+@AT*5-W%K>G^_*=?I4"5U%_11G
MATN-:MD-;$.8;7E?<B 0'5C>X^+A(<C2.K9#Q]3G*@!=_)1C>WD:X Y _43F
M>4=EO9LPP!23H#@)[7/B6,$]@G>_\4E?!],D*A_.8CD@7HI_)_U^-3>]?N:]
M'W\V4PE5Z+ADHCMC6ZW+$O751@>0"T- (+*@MZ345)^]8:W"G(*^(^.6V<C^
M&"(8$7?#%R'\22U%317U<I&7W#Z=MIX]*H@& 3566.Q$L]+CR>7RL 5N/IXM
M1,^^:*?)]-8TWXF M.6J6KQVKK)^SXA)YYJJ3::/_RYU*V>RXBO)*?_AJQL,
M/V1;5Z=>?2IQI&GVZ&RP^Q2.C[(;N,?90]G!AF9;.? 57Q$JC=<'"PG#"F#[
M3=Y;"5)<+AGLG9'$ 2'3YP7\#:E]>9D5!C8H>1D&:S$<54FV?]3\ P7"]% $
M9P:#I?F'=,;-\UQI[D]-/!&.^^[5<?4UPT,/"W-D2>.W&?W: I+S[.)8L9LN
M5B3D'U4%0,A_6MVWU0QJN-L%BSICUA](173Q9%F^Z_R:-\$29HP!M;-ET]K!
MIANS$ML020VMCDC@E/X1IWC&K3;C;ZD+M50+_8"B<5U!3G1P'YID8^O>\E'6
M(C%TK;Y%I> Q\!OL@U6Q7,%QN.WD(&YU7\2>R%"7>I!4N(K0 /&X1,7XY[I,
M8*G3_F$N93U2'K4LC:4.A8TJ*VS'/;:MZ1&1M+Z1',.))@T#(NY-BU?3;>9/
MWS:*IA.<B1*LW'0+.HLCG<C):*AC#I)4PQDW@]*^_4;A?J0@J7WK4,(%7O(@
M_DC:6LMP_I--O6M[RB6,/,FKU;#TQ^P1"VE?/4:!9)AK&;R_W$;&1J1+7\ME
MXPJ%.G+%>N!8XMTP.1W37(?\"X#TV 1)3G,RLZ:(_I1*F3FYZ8U6^*-TD<3O
M #CNP;%L'HO!-";'6NUN#0G)Q%,?0(9,Y@A/7DV*3TJY!09&\Q><>H&J'\5+
MA+S"G8@BN%.II?G,J*J-\Z+I81KR8MT+_PWW_RM@\W'J5:!-07KO9P,(F<M1
M++9,RO*ILX/R&]I"C]]Q(&'.+2A)2I?HLGXW8ZG_&A)K$@<IV_/EV -78PV;
MLRY%D(G*3;2X^> E^GC-=[FYD%9@*7+"@FA8CWT!@?3AFK,O,5]JZK4EA7[A
MT?</SZ0P<[2Y\L.B;&E5_D%UL^)"?B#2,$?3X%F.M$((OJRB7%R?G_[ZSL<N
M]5C-/(1"1.U(K4*,>CW#4XGOMXL>AB>,3@TO"]#RK;;H?"ETFC.F8X[_2/VI
M\6>[+>O;%8I1U$V6_1B]WPWH86X]Q?MG-I5.5+VQ?93M8E1'"9]D^CI]S2HY
MT,.\PLMA?=;QPG%TFS$?U[]6;)ON;I$$7N:BW2M*S=)3IQU_Q)22\5QE0SRZ
MNB[#)Z.?8ZG/,)3<\0PZ(1.3&1-J(;S3</7>:1%T"N70@R3JW]+$62SG6<M3
M58$-6G>3[^IR5/6M>KW8;(A(M'B'4R "1]&ZILOQT&TZN)-2TM]SW\S<MDEE
MC)R?Q*4[O3,%O#YOA0P?Q2-6CFY2GTI.#%;"/=Y'JHV+3,[)@'\+UBOI1[K#
MDGR!;A,Z$X/#,5>-$X,CR*>,?-6B?X5$./6JKW?_"53NA06.B:E 80%./<7K
MFDW]EUI:G\(J_:$+6[QLDD]9/)<0+H[!65R#NE)G-G3'>JAYR^#99KXK&YK;
MY&M/W_'9;^^),VP,/WRN'L.QF_]!1=.F]1Q>961+E'44FE]<F7E=%G/^JALK
M,]T"]\6(K0HEN0OPWWZ^5;W.C.KCXYJ0^/,3TOZL/HQA_O4P1D^?*=C#,3X5
M(MPGJ%_YWJ93M6!VATX3F0WNO4\QY(#MCK=Q>EDR\T\2#,H3J@Z.YK<2K@Q,
M#OEK07]NZ*_^S!823\ODC@N*G[D+JZJ?\J_YHKK%0'(HM 29@3^W8[AK9$'
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M8,QSAT??@R<%?\VK .O,%P67J>KI3&)[>4EUNNAJ^58.3%8*%R33LL/SRN[
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M>!4AX'\L6+'IY ^O=)>789YX8"2H",95G;]KN?/N>8+S'<;=OO8D"GY4BS^
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M^+?);AQ>\MTB67"?'&][8G*4>%#X;;^TM]*:HG4*[%%OE8!\TAZGW1/GJ:4
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MZOI8#!E>](KQ8@L[643\RU7G#_O?&YWQ7(%8.0+P+90 8.0:"< 2?#.;0U7
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M.DM3R01O#;PJ;!-)%2H2R!E[DUF'_+1PW;@.!'6W-$]=[1R@?HB);4\G6V>
M.OE!P<$F>.$%7RJWIZRVO)8QVV;%JT)L&W%;UDN'X?8+#71,CBP!:='>O3@K
M+I8I<[EY&H&A_@^4M)?T5Z@XW= O;B[)#GEE)M1A+V+N/T"))CX7W7&KV>(>
MAZ28L7S\$<IZOIQG\JLUF55GRX,#"@U/+PL"<-%*H56<.I\L<YR*I_T3 ND&
M;05.-#>-Z-Y]+&<IJ)<FCTH6</M$VWAA2+C;C#&[Z]L_H+,JF2;/-K/P=\,[
MY>Y#U]G9R^V,2:LJ#>\]R+R@3AX0*F+Q%WZF;'_83P!2]#!P F U>H2/=CJ
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M.E,:FHM81-Z7K!'<!3$[A4)$7TOSNM<L7WET?K!3;;'8+Q9/M8<"=3*H31&
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M\6+HZY.]$U?CY;"U'X"TRF7S#\0W#GVY7V/=9H@.$$5R"\C-F2/ !1^]QEW
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MH HU*+_S>;4,?@\]VP=7RU4)MJ7E,M@[K;MT +<- %KG>H>3QOW#3MK;>S<
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M/]KC++,$W"[GJ 3YC2)$NPMD:_?@"B%$NV,H0K -G4XIG8 8*%$S .I0HX/
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M9)5&S?PLN&IWNLJ'U$JJI+7PI+M)%]\!-VRV_)S>#0H#/"7-%EAZ5_10B'?
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MOE0_2[9L+>A"N(HU ?L>'[]'GR<L;9>;V 5V3<V&ST2%QI>WA'R;B)M[UYC
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MG1S7S?2TU!:].MW8[]E1%&0AI'*\%<1?/1H%=KWUYBX<ZK9@UH0;_#6BSIR
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MUU7O7C 8%%Y[_:ZFI[;_H]]Z:VP@S,G&\ZL26O?1#V#VV4O_%&P\3@XNV,+
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M\X  !_8)+06F#-;C^KDG4)KBCS=9OHR7]9_KC:O0(KP[ ?F?=4);"D!_$#(
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MTD$::KN$J,ITP/SY3"YO$V4/5H;3A8@2>SYC-2EE>E"L9X_T\?;JGDEG\7&
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ML"TX:X NJ7MKA?@RYY1=DBC'*7ADYR"R/*W\M[,<'4DNTK/Q]&R]#]LV%=%
MW^M^[=/YZ[\_')FU2C,WB-!D-+;N^UIM<RB2@8S;1:X=2L:[26O7V"",@4:\
M__UOH7*K672#[^VV3P$9_*?2FGLO [\N=F>:>:\JK#?8_R!N'RKH-!,+#^M=
MVO?W4&H_VI+:%LQ=J["#'DGI/XH_AV<S1ZDTT]U Z26*)1F+W4+>W2UN']D!
MIIT^77P:H8$4Z[\EAT)9$IYZ4\XL \*2W23VZZ,/2"1+]VRFV;4./E[[R)OD
M\R"T,E+;^(I5U&AOH+#JINA3WC'6<-=#&$'EZ@;(5MIZEN\#-N52C,?/DQU!
M=(74)T;@3&$Z\F*D:86)H6!-*;,*;VK83VU(LI93#?'$34&HTEVUFU\'!EF\
MUKUWH/]Z(-.HMV#[BW7/?,]'SHY9X2T[*KP2&_R/=.ET1B(/UGLY@.+(NL,/
M[+)($LO VO5ZNP*MI-;.<]7KNJL][VW.<YA\YI4);DZ=#>RK_<9[1_P;:2C#
M:2G?%T.]TE.U$O$JY6N$,8H I!V /MQ3OFX6=_+6#Y-B(]\XB'*Y"([R)6@V
MW7GY#/*%<BNU_0$P\L38?9!K23VNZ@Y79C0_T>&/I.$4'GKCRHJ%I2KN3PH=
MB"_?0K(_N%3-F ^#\.!9W- :M!79BRX9O(S>SLZ#=-HI&@,HG4+[CA%=\ !M
M.ES)M+L2X>WMPQ>L_01%UA>RKI;8L Q"=+PU+#I*POON#>3=;*TZ5G4X:,PP
M@-\\5Q5RU=HOJ236LLV*LM#R+E_*J=*X\<NWT,#:O/91,/2H28A7.;\CZ-'3
MMS];O*[<OB<;EU%I,*ES[8;SYK)?][67X)V782T?2R?@_W7^0:\ ->5Z-]">
M/[*ZNQYM!D5(U:9#[BK<E^Z@K<GZ2^7H'0H7*/UWLLT !44BM*'7]I+#;D'-
MDVWHK3R@B39;9^L=WMQ'WHO)G9V9XFF^#1L?;.;>>>A^*Z[WU2PNES=:/83-
M.@6^YMVEB*AZ9U79K WB,KG&E!Z$P6QKK&1I/@M(D=)RXE'6YBO,2Z/E_@)B
M!=:8[%*EPQL'7@YZ&T#Y+3F6Z8,4CM#C'X2ZZ;UZ77(^LJ,DQ/MM1Y7/W9=Z
M>(N^QEL^YZW8EH&?2L+NH[8ZGZNU\:HTVEURVLNZ6*,STBFWG:]G<P9XT9OE
M=;U.DG"61'I=<L:M)/S7,W;F6E8.P*^IORX^584:Y'614/5;( N[*N=6./-S
MRM_ +X0\1@4T;MP=>)RF2FBZT-^U2,0"$Y>CD"T8\WP9MI9-'#IKP=T<IUS7
M@][!I"O4\#*>AL<H73]Z(GIKW^R^)*PV5F),-Q1*K*?1@X+%ZCN.^<1-0M:!
MV=?5_Y)5Z))18A[:B4BK=*@428C3#()</TY_X\CGG=^"P.3!/(6QQ &LK/R*
MRPEHETYV!*<<'IHX-'!4O]1Z'HN\'5Q:_&E]A55>UE*]NT] 0$:M^LM=)4A_
ME/*O>_=RVS<EW&VJ71]W+'$(%<O_*OP%8!E)YHZZ"+HV^F=OVQ?75RO2TW3C
M!]XP01TZU],>.,_&=Y N/JFBL7)N6K4SAE0N\+_2Y<)*TZ5F)-R$-!G<BS:E
M_,DSYJ0!-!^H58J]%",KS>))X'T.ZEQS*/C3-^^!DXSV75 6AU!#MGL,FA6,
M&+9"SZC5!R2N3@$8?%]EKX<GT@$'F;.F34#Z_'4H$307B#=SX(@L)%R#' N5
MCZ;#_1JX &>(4J52:QW-RFSROC-D#(L0HEY/VN#JV.L&;GB6]&01FX=4I[(Y
M>VV__/HI\&5-5%[UX?K4AUG[_.:W@"5Q=O7@INMX5NSZAK)K"4M_[:Q]S7"P
M7UN>,,$''?WR.R5[%+9Q4-[;?GJ2%5^MH$C?VS;3/*=T@'#\KE_%?DLVC74X
MM,#UHO_]6V'[/(96-H/XK^T9%<,U7E)1X>CON7(K1?12\YEE6%P\7+AHT$;,
M8^C=9V/?B3HP/RHWXY7&(/8RVICL]100?JDP$/#6A4*)'>'!=T=,#W,>MAPY
MNR.M*W3:SO1"Q0/Z._3*$JYF,AQ0R[>?'5Z&J1-2T.K +PIDOK2SR P4M;\R
M4MF:E=.CS?FIKRJX-* K$LRB"<2Y Y4;'H&GZ$X"5X_G(X9]VX#WL7[ZP$3O
MN'.!_E+R>9ND$S*W=S&1YOXEQ#JOE*KPZ[N^E5A=9?EF/KOS*#!HOUNEWHGW
MEEV5MJ:.Q@)31,7FX#_-<UY8#O"/)SP-.W7UUF8I$-K\ZT3@HR3S*X*8GVO;
M+UZPGSS&FK*26/8&3?+?>@;BF)C_,K@$3U01>(SW@V>]4*+!^H'4A 7_I+)9
M!<NPDU&X]J:4Q1^C/O. 2R3T-ZE'+G?/R%'['(S&E-(X8AAZ[=*?&5<<&J=_
M0=IV-NHZ>7QEZ<1I* WT]@!Q-(7&[X3HM0.*%( @&RSDQ<*-HTDM$O/\&;)[
MG6([E,XBO?@+I/+I&Z JP8@E%%&+K<:?)S6U#SD)EF$;AB.@XB,]<QII?]3/
M_%[J4;[YQ/<2GV#]..N2E_%MAW>77PF@R,^B&H+L=6>\D%8>OP5<<UVOP/,=
M; T_O4T)IG0'_%X5%E3K?W/WIB3_"J.$K#"LEHUS(3[@HS"0+YE(<RX9KZ4\
M_EOZO12C$A*CMRF6CZ #P(W5D"MHKTJ;"LG,.[71L6E;.994_'P!H85"G!RM
MU^BL7!]%\?%RT4H+!2H94H01Z;(#2QNB82'JZ ?'=Y@&V^XS?SW!__S(5R1
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MSXTQ_8/2[TS*XH+J_/V9 0R]\ >Q_D]V]]9Z%88C(NMS%^O#-Z?^&I)=>[!
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M8L:3!>%)]&OZ(B[=T"017N:'U@1+VO'*D)9Y=C=+3@C;$KK+""X_/E7(<4>
M BH3&[^#J']W__+WZF4)0](VT#&NZ9!7MD/*4Y]L:MQ,B[.K@R]NM,<5XXHO
MYF]-BJA8B@P9*\/7# 9.'EP_0G4PE"V/U;SKF7&QT:+_>>AIM\7%PFM[L+EU
MQ^DFY[(W*THIYC\_]^'[Q-?XW,Y7SX^CWEU_<W/']L\O8#=/D\W0FOP[0AB>
MKB3H)L/I7OH;%S 2HO;X)Y-"H2+H/E(&;M$=ZY5)3PFWB+K%;\H%;Z:D1ILT
M &OG.&9+0J4EV-.A"\9U3NV"E/(5^;G5QW Q)(4/5R#2<ZB[HV$[U8=WB$]I
M45^@UGEW4"?([--QT2BS9_XX*;2X;\L&0(^*9^)5)PFN70K3&XRF-Q'=GO<W
M1=XJ+DD@RA=]R]<'I29C"B"7[Q/6("=OZ["1CO/."P]J"[R7RR8+RX<76>F-
M_5IAJQ-9;OWAY!ZH8'7_QZFXB\;A)\:L#RC?BI:_L.D/MYQXL=M:2IMOGU'W
M4L/?*+]4,;M]>_06+?%#^WVW;'WO<6'7SS6YNQ][R4<PHAHXDX5!&-(AC>GN
MOC%K5EP;?>.8H+]E+V0RHX/90&#8@?1V&TO;T18T9,!L:6:ZPN-W$-C,N&C>
M(5;2L3Q9M^%0G263+JI<(-&.G7,/-!KN[2I17WBZBWQ2H$UJ0SA4<"T%K_,/
M0/;RTPS:V 2S*XV(X9H3E0%*HBO#'0:E/"9*-U-9E,70(C^!A,*H;J4+\1"T
M5$Z([I#M+IS^1I\PU9T!A+!4#%,+*#>.T*CW#*O/S!TO' ]S<1F/[#O%<6W>
MN/PK(AP7M.XKW]PQW[M=]EW96O;^PAO-@C^?'?\6P7Z\8JCL_P!Q-J!$YO5%
MR[VQQU-QW^_]^=BI#KAM%3A&NTV_CO_(9F"J9SOA'Z>[QND,VB;H/3R:BBP&
MQ3M=^^3?<];JJ)NU(!/P23M.<OQX+B%M )N"F&VGR-7%>OLP3<;%Z/'AOQI^
MK\TM#QEP%/B/5BBI=,"N;]?\%&RP*(OS<)#NGX.,QBD8TI/)TD3)BH_?II56
M^N NT";&!^(I8+E]68[4+X1M"[T8A5Z7&PGXCO)DPN/6X-+T8H*B8W/5RYJ0
MM,@W^JYK-;3:\>DK 2N.OPK6SCM/*?K$%+UY /-*/J$=ZL M?ZUXL^S*[3.P
M&=:3'UY"6/[A6?]:5-W[CV]V&AO_>''?_/GK"UO5$3PI8)0G:\VR3,1X*)&V
M\&PA*^"I?[X2O[9%@N@$.3[RBYB.K3#"PTE]M;\?G?2V7A[?PNB< UXY$[<#
M:\FHJ!G,%N*U_E#L-IX80+N#5B'\9*QW/8PLAS"GH&@V1:5)T"EB#8XDQ 1-
MG/A/>$>!A<Y1C 1*'$1RJ+]W^81FF=@$E!A[K@G#HL9,2]*]R&($<9$JVV%$
MEYA;]@_W?K(PM7.8IZ]7PL1)]$E-/62KE8RWE3*,\A\'2Q[3_^H6<2PPDQ]8
M^;WZY<\3X1,EH6O(EU8!P6I_I4Z%AYY^D+'OP4./&[MV/[U\[\8)AZZ1S3MN
MG#CJ4IQ5O) =P*&4?9R8=W$O"N1DK4>-*]8UW'FMN_NV?.BU4.>]V5I62[-G
MONM^2?49."T@\8*X6P2?6@SXV8(=!#S+.T:PG>@//2[R1P)V;M[=0MAV'*LO
MD:@+D$] 3*X]Z4-#72=R;(V3 Q2FVY3@%A#D-O+V24(.(QL>5S1J2$F8WF)(
M3S0@1#/1CZ/8M"V=^'!N'?!VHLL!LUV@[,RS]-\")7@"/ULYN!W*9UOHPR%U
MX'!)S$HC6<GX8>E\741L6>G<$FO_JN;+H=!CW*6SZT.=X>1;H:$'!U\;IC6D
M1=04B]IY_Z)UK8J:CT:19;KAOKR*67[($16L]=!*'M9\H,;&SS_*:\3W($F>
M9S^DYE]7G[GL_P;H8;E8:M Y5 YMC&D=6>I9@U4ZN,-][+(O52:DQ[7"?A!U
MB!4RFKG>Q7E3C97]EH*')Z!,4*RO 8=='^A_7"ZOY+VRH#&;K[A^LGZT ##D
M3.:D>HO>&2-&\LKF3,-UV,T6^CM/5$);VE:^U"'\33J0._U>3/0^AF2/9W]T
M;_S$?YZD3%&Z[,2^\&&%6ZPPOEE2/"F4GWG(UQC!<U<9+ 9MZYG+N^2&JJ?A
M$,ZJ90"U2_.QQFL0EWS=2,=)5S]4"%.<<F.?1ZLV6T<&F!\'5G]43!65G@Y@
MVT3MH5,LG@^.GGXV75N[NC068I":]C+<9I[ZS+;/X=<%J)K>OJS^<.&%N>'G
M\AT]!OL_M>\?/UDV>'#'S@TH;Z4^N:W>APQ[-O=N4Z'M3TGV^T2LT#3>]/:N
MB;=Z1"*O4P3E.X)>I!P:1: R-1N9???RI?A%)%4(RUSNIDCXX380;X%U'?2-
MU2I(MG['&8$*N3V77^@!FL3I%C?7#Z%W3!!PW>Z[*1<^Z!TD[>>9U4(I06QR
M]'(PBZMU^Y9XJA#F@1VW=N<_7\$E<M9-8D++_A8<(;W&[$0AN9>L07J70LM!
M/I4$X\D"68PE)">=GX8Z"O0Y5;> R$3B[UW:28I0:6@PH:%I2@4LQU4;E["P
M25G]A#*F94Q7^9 ]U\[%Q'^A:&5U,&#Z5']!@%G#^)KEXIO8H+0K#T]VO7QQ
MZ/E&XZXQ^&ZU0+=*DL/KMJ.['.Z&3C=(9/5<]#4YQ>YQ/O2">F!;V>< K_;<
MV])G^G[2@1R!!(-[@V#.H4'!H&0'7:8Z<OJVZM;?VS[QB/R:@*;==+F:LDFO
M*2Y;".N@I[2H#E>_*?\2M^@X!0?PK17*,_3X)JV9O_8=TX]'[A)HCUN\H-UC
MI3$QUY"0IA"VQ  B.7_S_R*&@_8LXP=E/!E^+@G#BX#H!9!#'RNSOGR^-I-<
M0VNCC2N?@B:+H+OM/A[/P4 J$Y/40&[%["1J#O[=PX\I(>*@YVK&W>V'<KZR
MY<DDO;?K.,>Q6VM+(^V-D:>7 T:RYP66*V>O+\L/&%?7.VML]["X>W[@.JRE
M4SMK?*MNW;$3FP'?)R/?7@-)_M&']WO'F^]]</&V^6&Q3\].;%: 78G^Y/@3
MST4+86V'A3#?OFV"UG]95U-? 8*WD62@3C9YIZ 3RZ*I3$%5,\M)U?#X"/UV
M_?%-#%5#B!Y>AIW!;X5PG>Z&@Z.MM6@-*A?)MJVC+9 PB(X6^2S'*AM'YS2\
M\["H@%/)U:I) 'YFC8&3(1Z&;G'MH4U,_4[JQ%>6B(/#AP5&_E0Q]&Z(CH76
MP)T+'9B7X5T4^ E?!5H!$5W+IZ+TC>N8%4@FFAJNN]S60XXWS4IJ@;NY0]VM
M+4HOFXYZ\,#FI9$)?&\-S;,EJ^6UGA"6!5HN.Z7:5\F\/I?JD;S9H^7X1:7!
M9(.[;[=5GCGXB/*W9Y&3N 92YKGE,5N9]S=2@V(\:IXKBW_1>D3KIB:37YHL
MW6+K8,?CVO-E1HB[KGIR;8@;1/ (%[R/H"4:(1.G=QHIZTM"'DR+"G $/J'F
M-+@<>FP9<E7,4M6 R.P>^!;(LF. D#C-PB7AFVR0"49N83V.P)>I9W5H92*2
MWR"0\Z<^]T[DV<U@)7EAHK9LF7N$-(1Y6=>E78U/C2#?98*GJ0DMVH+>'40X
M]$4&K*0^Q208J>"8F-8H:Q?0*^ZI1Z<J$L0D+!L6-C68*&:9;'O[?L!FH?@-
MMVYRCM[0V&A4H#(=..G8]QUS1:VF(2N^HE)][Z779Z[=E/EAESI\Q!&68;9U
MSN[7S8#I+V^JR!GTGJC\JY\MZ<KA#UY?GMW-EH?$N5A!&[G:NQ,'.P%4V4&2
M(I'#QD?SL%PB:50(JX:G-EF03'SRQ:%Z)GYLC:78 ;+[8H4P*<%VB-:)N/Z<
M()(/G=LCD'%H32C=YI5-))/.F(3C1&:BV34@+F$%)P?9STOBQZ8YW1C ;A+)
MJ57,WS!(@K4Q7Y$];PDD2E*;K(++?86PJMWT;1BF018+X219#(62V9'P\78=
MPR1;00].J0>H/#J D3$\UR#?RE8F^C::7*-:.Z-[)YL#KM5,;L27!_QTFYZC
MO>-?21N9W[>YMD[FBUOWP^U)&<D;E^X^RCA^(@QYX/.UY$3?NS<>O+[RMZ5V
MQP6E7/5[*UNY8?5'CFRS.H*ZX0^FM^( VXI()O(.*N 13QO0NHV2$$E P;:'
M@#4GOHHL34BS,=+@4P1PTH#[)HCRB& :^8JMNSE_-R!&35DRQ,;MD=QK7**7
MJ"[CIV<I.T/]B..4?!#H$)U Y;E\^0]$\TJ"OF";6"$DFA))-=!@A3]I+[_:
M<DFETB^;NE@T(X0I$39&Z>WBB5_E'OE6UX!.DEI+J"RN@BZBM.#W6K:E8%NG
M#$&SX8>>O)[(ZP+L+&WRZ]WE.A;E4V3/_LJ*RNNARON_'US>6_^\J:JEUFHI
M<.EKRJ/FEPVU>:K*\9Z)%K'SX]>N$2;33NV-IQG6-+Z"@H/]"_T5[2<)TM]9
MDDAI0NJZKYX><6]P\+Z)CY!]IV.506_0XT_O0!<"MC,\[=C$68Y@%RC7&S9N
M6U%&BB*WF="O]8W[<UQ >&>  ;LO=9&T%]I+VB3H(DN@Q?T'H%H1M[8<KNY'
MPWVFE6OHRA"NN^O'UJM-PR0DE,.:I#-PD@36QS?!H"R3%HV2J23$6H*76AH/
M3C^9TAWYVI1/WD@@]=@,\TZ7^5;P*U2KO!JR8GF'F+UGCU9<&T&Y7>E#^/TQ
M?R@IQP;>3KH6[G[P52I+6[7G1-5(38K9,:V"EB17HT$WKAEFW[7%RI7PE_,3
MD3JZ;EPBQY+TNU_?<__$YATGVI3VJ!:\$A_:IJ/,&#^(WOVA.FKCU$_[H8 5
M-^.^<W>%,.<F?[[##YTC#G*OAO3&[-_79UPTC%&+E6,=V1,KEVHT5NCTWUVK
MVK%D#OE#<E (6QB \Q5JOLK/K5OR[JX(8>LKT4+8Z0J83_^_KF@]VZ*QQR\E
M37P=94:B.>U2+?@I/S_H-'89\]"L?.>;VXV?$W;5)L\HJ*EOS]U(>--YFI]>
M3.Z+H?%_88%'<+W7J\B_2_>JO8][(&@0$>A*O_\@^65(WZ_?.U31M05R9,^Y
MLI^2RN<M]\3;JZET[Y;YR#'<\)/2?L8+L[U)^I3!'VADS9[R"W^HA31OO2 5
M@7R X0%4 :]'E.5+I:3M1*5,*TTJ4Y]AY95OI97I3!1C^FID.KL5BEXKQ>%I
MSBJ%#SYEAGN%:?R=CN1IX^^25\Z0E,A,.E BA!WPB6@LFQ"U'P\DK-334M*L
MEU:LR/H/X/]P#3O.K6[K6]W\Y^E"6'PIG6E-E!7"GI@#(L4N)83%8'[96_Y'
MJX):\F<,N9K\@RPX%;?X4PCK:Q+"UKYB!?LH^\B_F!C^KZS_F]94A3!1C_59
M".,E_/:.VR>$D3R%,-;^'UI"&/66$+;\CLX[;2-JI%QGJ/R=R%@DA.=I"V%O
MLS'_V456JX2P/6M<2R%,]/7/9X@)0MCLO=\NXOZ7N)A'#I+.\KA5.G^SN\1W
M/*I\K6X]ABMIK:-\S"G;/Z>QL93W*F"I@F69Z5L4DGID^.'?,!N";<6S^:G#
M0R$4G=/9OP+SS5Q;T;"AQPU5-F>/Z<2_0\H+#II_X5>=!KPR0C_W,<E;+[?Q
MBZ)(NGJT@Y_!R[4(?#0I)7IFN:W1:NG[4HL<T;BFOC9?.<?U*4J<2="JJ[][
M.GN*->6S4I2FS<S8Z>29DL%^<*D_>K^:M3-T"6!TN-S+KHLG[884W8>]$I5O
MA9KYM[M(ESVUPE^_9@Q819*O!MT$CGO]Q9 \XQ'?HWW:7NV+$.8X3Z^LTRBU
MQH;;YO_@+BM/1/H,1JP,OF\R8BH *R;I6-WO-;0%@\XH%F[GM,O?RZL]T(."
MF.1#<4G8@6K(K<+01GI8P"AP5HA%FG[UGYAX3UW\N<)%02L_KHE2>V":IPV_
M.RV*LZ(0QMS Q HN_FZ4S6?J1/F-$<*@XP1[(2S#,/:OM)?GN5\$I[%5(E2@
M16B;?HB!$E'_F-,*(:S]/J0KA)V*8Y(%.U3EA+ O-DB@$"U)[M\+X82P>^*_
M,WN<+X1]C_HAA.TK&9M5T9U%<MK_'6;+R/_A2Y;_P<T/(BBLH7^1']B_I@H(
MV'^#*A<EA/U<QO"A]/^FH=^8SY?]/4XRE%CWG\6$_!]'NV%9" M>SOHE_T^!
M:9KH:%%OKF^A W6Q^*60GB7CZ27WPV#,3&V %G/JKY%VX UF(L@CG+70:Y;R
M-:/07=:CP/=[_G[PK%X&/Z.8D#Z,89XA*OS+#*$+85OAV\@_BNL&F=.WU3YH
M KDD<>">NT*]K"1U>S>S&8&!7Y9,B.EMI9ZVWEO\3NO5QEL=F;U?WVU."PST
MV5(XB,V(.!HU7B$[/]),R4$=8N[GV7B6'/!57"<SI(P7N-8G/H0>"?P\W++7
MKR^(_VCJ&#B!*_!3#'/,CN/9K%3H.$H]]:_K4TS@G4^TR"H8XV(?W+#RNCM3
MM=,Y^7":E?KGM'JM_)**RYC-),GT="")>4>K%+T!>*PU;YMFQ?/]3\9Q1T-C
M $FDJY>WX,H"2_Z9%-?Y^<3U7X?)H#Q>(!?7AE]7QT@*8<#M_X,/1$2Q%W 5
M),#;172P!_4O1"3^;PE ]_TK@:G_]Y/Y?]JZ]K\8&)1_FDS_#_PZNH _*H35
MBB(D=TOD4I_$OW*TZW\6F_\D^+?7A+#ZM1Y>8OXIT;1I)W-_Z@MA,I;_6/[H
MT 6D&/W;?9[HD_9-[51>:<%_D@LXF4LETE__Q.^$TNUL3A/W,H\L?2?B@OWE
MOTQV+NJC'\PTJS(_IV)D"*ER!/>OKG&Q/DTFS*>S=<V@QHJLK&YFG$?9/,=4
M@ "^YC&CS,K+"^L;\N?GW2P=AU>U+\PZ@UM>W'A1-%)3X;[O5)W)FH3<^2>G
MY10<%,Z[^$:X%:5F>7AZBU=\RY< \+$!ZH,\$R9&"@IK]X]KRNXY^6%E4G7
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M\-5U/9U#I:[[*W*B_)1R&PQH)Y6(6D,^?Y9UONI\1L1!NL&1P<4$^Q, _5Y
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M\<M051M.H4715PB3Y,ER??RI-<A67+SH6HN:_ *T*B&.<Q' +*Z!*B$IQQR
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MJAY([U ]"GAWT!!]++P,0YJ*3$&+ZB5(OB>*NA"V@Z#5C=RUJG^O10D,RXE
M]_"?"6$SF=0JRA(9K.WY?;LP3HDTT+(5NDT58_/SC7Z1-OY^;$).L&DN_QAT
M@.A,(PQPF:.4@)9=_BW(1A 3&YJ'[\C.64"$?EEO(V^H2CVUT\G%6BX;Q]M9
MQ;$"2CKQ,.)%R+N(=PXR1DD^)DH 2\L,7+0(5,0@8(V)Z:@PX. &8Q]P40P0
MUXY0*-L$36%B(LZ>*'!RF?*[[T3H9G BR+%H+1?"+,,E-/,!3+PW.XZGV,U1
M? [Y,^D)L=,LMA-4QAP5A47)-V++X]\/0Q17>;-IXY(L:N?T/32,3R4ZED)L
M%B6&!Y]!IH0)M" QL.0\F)=%(5YE4N/06X 2!GXG1.T0S2/#)3T=;1J*WCX-
MN%.B1?JN0I/&I$@MH+7Y.4;4CT(84[&3$K<>'L,[$DH;=^V:KL%T(B<B6;1%
M; #WL(^J4A683(>O3D:015,/OH0R>>+NJ[J'VHZ(+3);2ZD@:>*(!R(Q"HXC
MT\ L\J/?X'%HH1 *;U/5!0+KP&5.20V_.E2$CAW@2,T3GCD@OB1?Y!=16\=<
M5N9I@.HV:@35488I/8'H&?X$<E!V79;HQK/IRCZC#;J<.RPWR[,9XW2>S!K'
M#!3+0>YX T[@P L\%2@2B&6P8FNXQWEV0P(]GW3B ?Z3)BS7F8B!7HAPD9 5
MP6O1ZT<?)CAR[H!A-':O;)=I8$F ;]%$5%+K."G.'YA_CY2 P8V'R#.U&!@K
MFC&.B17"O)$3QUCPS@ENWWBZ!5BWN#9#CG&'#:,/$55 R\7 :4D]P3'(E160
M(81U+NFT<L;S4YC4Y/R-8-:]&J0X8;F+I BE/_;/OE3"6-X!976BU8&X6-[I
MWDD1X]RB7VN<W@GA3XFJ4!*G&NI_#$UWD[<(Y"!Q%I*A'Z,J5P]HI;3HD/K)
M5=@XC!_U-EG:T'I9241B8?7^+&PB4HIHJ5(N"\4=_\ S ]8Z$.Y%(FI,=X,"
MF F&%#F_&J*'$+;Y.(0I)UI ^I6$8VS';E&=RU<"'&/HUTN@9M:T!/$*R$G@
MGB6&0#7<JU.\#90NC!S*&^P^.U+^?56RD2+)D\=+^(WK"F+""UR^C:)EL9L_
M$BP66O,5&@9(V0"=MS.8HP<8]=W%M;F+@UHQ(7UQR&I,*WP<W]JBTL\+H&G&
M,.DBH%1I+4X6D]YBMBXMZ59ZUS<T I4I /[,RP$C,]E+S4-(]^'^FB4'#MO.
M8P_LE^VR0!KY^W;NN75R:X"K_3!)\UN#=Q=]&\&U*YLWI=[?M(EIO7P[ IG4
M<I10P D8M.R"2T,E+(<D5HJKXW.H;P:O+-(04TA(Z@D1/XI2*R387X026%&8
ML]!5XPRVC>4Q%IVGF#6S%MNB2 P1E4G:&)V3-=ID/X.Y0ZWM[B1''R;,BG@8
MWJ0,C+)'JKCBA+?8.'JU7C03HZ#5J6OMG&0-.9>_"6")Y,Z"R13BI0E2NGQU
M%I"BIPC4?1. J=EO.'%1CA$8#VI<^+04K45EBD>&HD0]J> ]]]3P$A$."F$L
M_9@ DA[!@DR9WH'Q;=9JPRDYGAX^^!7$QZ$,P$A628>NJWEJ5Y3D);(4H<H9
M(E?Z98_>T?<&%O/"1*G>_!<_Q8@J07!M;>B.X?F7$ES;T1+\9H&J[_CE%O1H
M0,L@$P-I8^(#B=9<>]_QF.]Y&AD\&DN2VW@/R/O2/%PQ&QU0.%'X7C-5FPWS
M7C+A1A&B9^)XL@6V?-HB6L$X&LQA><>@=WS#B+6($>U'FHZ6])!!+B=F%&4@
MF@>J8B"IE$E5\$/L^W:?0.\<#ZQ@330C.[F+3?"BA8;<[,R'9AD]8[Q5H%$@
M:0^P'?F9=$]:DKLQI /F=..4!09$%+3*PB<AQ<A>]*T^ LP02>H3J2N[INX.
M^3IFUT)W1[XI\*6FCH&)I>_4>M&/T@KPIHD*'*8C'N4XP\7'H67 D8*G[UY$
MI;/QD);^8A_X^TED!H!E9U)8^'%)9MQB4>5<OA: O8<^YC\'8BW V?@0Y 8H
MBSD:9X1/:2 G5G,7D$F*[KL_$)W++OOTL/Q]'T6[&F=W )\FQUI[?K&Y6'+;
M=I&VB#X1;<Y/K!3L%O1F.[Q@4\=U.MVU@>9VP8=\66 YKH+N2X\1PJ1(NXDG
M/PAVU"TV<H\+WE<1S)FI!4$ M6WJ#Y"^^(NE@Q'5*BBGXJ-%\6AKW-):]E/Q
M0,P,750$KP)UB4TW!9OX14LH&29F"^F]NWHCV$(#EMM(J@#Z,8LV/L'$B4J
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M1RA7N2D%8*H B]_Y!+I/XL77, 6!U&8-4$SZ-,#%R)X-J 62-_L GUJA C"
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M3)=EC]$?*'!5787YJCT<=W@MO;Q[:Y).>O"N]'*=AS;<I7]F0].%N:F<5'P
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MO!-0KM=:XP$S]Y#[\[NMTY>WN]<3H&F]1R!-\EK^0DU@,^9!"<([F4JA6*X
MFSC:CR8W+?7+]O=]4VM;*($%IGSH<9"Q_X/[ZW6QOPO)T3JS\G8^W#PX_0UR
M5V#O*PA,<9=_2T=TV@>B@?WW5\K<H+J</,W,>7L[5'3.6?P(5,P^ F",PMH7
MT-3XZ^@/.Z(X)^!+S7$YV)YTE+MSV=LM^<V.1X!/\>$&(P6AC5)Y*9Q"MZE1
M;(.OT+:R[1'@-7P$6D0 K=/EIW4*'@%O!-XKT&8A:/%-P7T:RO4JT?T)]2TO
MT6FWP.V:' R8G^AZ)_UR.!O\X<$C[_Z,)GUZZ4F.Z1%8)(W\;X%S.:.M8]X_
M!V.([1V!P-B/P&&TW"!< G9W2I9^",E>Q[CG,.Q'2:@"E1CF'#T_T>=*E>6C
M51LNE7X3L* F0^"E,O$+L7)UU.7W9%'Y3]B:"R7W:41_X_4JM&_G/\1; <?Q
M[WRI?Y^>=^$FL!D&NNS-_HV7(-8OC"R1RH@5B;$^]1R QX]Y:CM6SOM/QB!=
M2B.UHY!Z!)I>?=])=_>[EZ'QK?'Q0V)ZLDBELDFPOEZ=@2)7D&&?XA8(S(HT
M^6>FE21J26$*;;C?FP7E@PBS\O['W::M;N@8Z&RXA6QF;B@<%"UT1IG/5RS5
M2AH\YU#J#XU;V&N<XBB:;BG4__7:6-?VM NP<C]Z"F:E)^% 0B^!TQ\"AYGJ
MQ_15??7Z0A'/:)CSAL?33?T?W'H> :]0H/Y77*/_+J7XBZ3\+W=D(*;]'4GL
M[_>#LL#O%(G^\W#].ZLT;1_*!SG P:"!O\TR;8)EV9@%(KCSESC/!%:5X_6E
MQ\AI1E[>=M*>BGHF ]-_8=5GUM/"=/)1[M#4&XE_$3"1?[=P(>@W@OQ@N+OC
MR(=K=(C_;/3]7P>&BZXB9U+)22==O^7X4#9UJUS\E(B'81IHOL@6W&WUG0ND
M II9A48WZ4-A?[I @2XO^$+D$2!*)!)YJ.83PKI[K^6-=3-^!D'0V3XS83Z%
M5BXZ^H(["A:4Z^BRP!JA*<N^*EU7$_?15"WI1ZT8#XQH+^>..X%;:?);=4.W
M>6&R A6X.C)H%>VR("=-6I6:VJ_AI*9B9.1KF3!<5.50D#XLK<ML51+51FFC
M9D&?BWOH.,0Q:HY: J+]57*/GW>^>%MI_I(RDZUG>J7J-.J 1]+4C1,*^)%[
M=!%5J35X@3U](!^C/4U<A/^U;0M^;;69T<U4#->]'%-R#8=WSH:G]FR^D6N(
M,P-IX[@Z*S?SEOSV8/*2*89Y%![:FFC\97HNN0YKD-($.2:SNX9&O];UQ\3I
M2:@:2STS#S5,0*T=-FVVQ.T14+(/"PWWXLK);)PU8Y\/>OGE8N:VY1*GAQ4B
MFBBB1":2H8 ^;-<:YIN?27B"=$ ^2=T.\S?/E]KTQ6![<Z31;\.\P3A9#HB4
MGOBN^41B8VM!&U35P@1]*DF>7'( U9'\M?)8WR" '@"K4 P!YX?BH1&AKH(^
M-\W%B<!=?H8.H2 >QBR:T@N]@L,=+S#/GU4BQ/&Y)'YFRZ5N#Z5:63G!/9(S
M-IMQ^\7#SB-0O6.Q9Y\C'R 42  #R>C<BM&193$Q@6+*NL\-]]V*&7:I";G8
M?8LFYSU7=:S<.#U_%X/5Z/( //K!B:AF1#9?4>XM1>MLPF6_;E7Q>[G8.JU-
MHE1E;LR$Z<$X$$=*.HC50/8[ JS1S%7K?K)(]9J&53C;W JBISW-^E3I@6;&
M-_"ZA@KN</.X0N?, %+WL-97$SC;(;DR@I-7<$%5OGD$ GM)-0OX)-$A*@3/
MN'KO7HE]8 U,FS"J4(KY 6T79]"HRM4#E^:^X<-4V@32-\9GEK6T*V"6Z9_&
MAJ6<]?.TX:,Y>W@5RL(J/SU(WZXE;(VN'^=>1GH 1>4#P)'?*-=[<66#;88E
M\]J/F;G1]:,_Z'T7P 0>,,AO,),<T8\'3,(J*ZI2A>BR$1RG?!=\6,IXM2WS
MV.,)]INB9$&O@KNU96/]T!.(E\*[Q BK"_3S<^\FCW-DT@WKV?<TLU]D5O"U
M6!1[L62QTB*:?V6FTWD7I+6OM>GG@7^:5LV+RYYN73!8(&Q;<> @58I]U^G#
M+&K_&4(0:RLK^A--@@&D;XRL!5!D_R*8-U-8M..R/"W (])#S9BIR:X22P+6
MP'&2\,.=!1<Y"X;+&[GT>9$%X1WOPD[&.$H)Y.V40XZ\KQ<90NX.-2Z*\\P)
M:H;F"!$Y$,D;]%[>ANPI&&<7L9KMETR:"70XHN=S>&2EW"^X5959Y<&(3]U
MA A-OZ?_N!*<3"7CS!OKL8$J8S<L?-%^QF<W"+!Z>1%5$Y$BCOBA;*K&D71P
M"5#62 M=P?@>XS%N[<^J^=[U[:TK&J+''#! Q)$>\(CE->ORXXRHL[.G0 $I
ML.M]\G6U<+7D::\&E_<I#C8:/,G-OXB*&4CTZ@=]VX]NZP(X.FZ&)ZM&/&HV
M8 S8"^S6PJ!F=Q7-<8L]NG(24=M8(2C=WDDQ3BOZ1\_DC%7-2M,L]E:$]6 Z
M5M5;V4=LY-96^XT0Z(6)ENZ30<Q'*@J^5."F"Y8?9X[V>TXOPMK^ A:1QRZ?
M.U808X:Y-.&$J:_/3_XR+J+G[E2QC2FJR0&@"/.9VO)^E@_$#AJK/'?HN(PQ
M#.[)*))_^[4;%8Y @D_BG/79P#%F,]&'XHSZ&"B.5.YOA?B4\$@.$OLG$]K@
MR*I=D0]#M741$OO+=1%4V(8;[/,MG9Z3$HZFMB[Z'"^*T][ZJ5VB-"R]0%F3
MW937VE;AB)&DZ*H0/R7-"7@$T KF,NY16)$&'X& TH%;3\51#(+-K_Y#%.+\
M)K#J2J9<^,[GQ1O'YPW;+Q:]_:1'Y^Y3^D]5:5P.^OA:XAOO?7.N!SFFB$^U
M<TR]6UFP;J_Y9"Q>+FNCSR*"OH;[Z?+PS+K<60_M;>:A0_ ]%$YP,X[S]Y'G
M%):'$(C.7=*Y 1X_BFBC/0UMG<K[L)/9HLC]D>IQV@BK80XB]?.W!_1=;2BK
M%7)$OWN4R5C,,9&_R&'R0T6G\7/\=ID!-^[XII(:.MZ82Y5 :3P>NJ*2*PB-
MXQ%XF18LT.U#K$@FOI=!_UT-#>+2B* 5;%&+5,1+2VKZ?%?9,-Q$EX'WH]Y[
MD\-7-S?*PS^?NQ$ &6("A5>E!+0ZM:/)0^9I1F*+>,A0_&V!.W;NG%NO$OA9
MQVS/,2L$=^D,EG/G1YD0K<EO-O.[;#Y*.K=PM%/<*HJ2,E].(0O>]16&9YK;
M8B58C9E,J^*?1==RWLE2^G[ZN#K U<39T(GI*!ZT-%OE.4DMQO/I# @CZB[N
M69G*F[2NJK/&"1L6$4C9*(5LL8_4LF;SD'V^-2I"KJL7@B:JJH^IN"%?1<@T
M&^K@YODN] 0OOP23*_-M! L>!H0JCRA$&Q15"< A/S$F/5YL35X=/[K?:6"L
MAX&]"?CW;6M4O]L4_]K4['>R,FU4YT^H&>/60Q;Q ;9T&$).^B7<:>:W.&2A
MK=7A1R!<5FD]WE2%HF:F;,'FQ!/%=E/P>81Q$%M=I(")XRG)S@?.U5F^PB,<
M8N1S#>ID475C[4S0CZ[[1<?#N\)!P+%OI6Z&MK'V:RKK%J9"K>;X=1!9$(1C
M-/A=D?.JV]D]_\K*I61]J*6K#U]#0_VK5^U?B5<GR69J%#MNI%QCY^D#=)QV
M!DBXB(-NYYQP#B.J>KW8LF=GJJM<4*_I27O;0JPJ[N=BMV=\F#17,-,O)&Q&
M)UQK(N4D44FC@^8? 7JX6S*XDR_IP>R1^@1SF"SB,0O-.9ZI2NP_Z%OY Y!I
MK9^2(D7Z-):,C^8:1P(<#H+2^X!0L:/NT(N1V7M?-.JUTQ>B72XU\_701#+4
MD($]81DUQ]"XPM/B1G'"IR%8_M3D>LZ<;8.21*'"L]H+(%,I.OT(U5 0$\A[
M_3,CXN=(JXE8LP;'7B-+)5-^';6U]/G[(>\*"XJCC:C*>2DZ0Q2GXI@T.V&'
M;\C^?,>"&"O'RF$M9-4CD!5S6IKP'9C8"J)+ <Y#S" $)WZR(&LBZ?' JBR>
MZU'H-Z)*E1A]%RO%I?ZY%/US)6&D3M'&ZBYW;7'6^.?;W=Q*+BVX(WNQQLTQ
M6? J<HTA"$LQSZ"/^U@A%!:[>&;5+%/Y)3VMZ25B-@=5Q?2'OHD=&^*<]6(
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M-/",E<PR2R D',T<J]IZ*R<J@,DWE;8V$<Z$_9[T:)R0S)O+)DD*L[*JXNU
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ME1Z!#/J\^SL+X,)VCX_JP==%]W(9U![YA]^;3!^PA@J>$I:F[.W5.*C]^H?
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M#>Z"09LQSG '$?,"-#&_?XWRKQB0.#;[&7J56B)XJ)]Y?$ :IA?AD7</FH_
MXH]' /<(]+<G'HZ/ ,/?GH[89[=/[AI_T9%EJVZNR1(/E3#BE$(*OX(.NSC/
M0"ELK;(";9XL/CR478W<9QL^ @()C\#E.:B[Q9@?&!<9[(13'.-HX]9LH73@
MG1AZ>>"\NJUVX8&QOI'K;-R"C3O,5)=@SH2OKVE.'G9)_)X5XCSQ'\@(_ X_
MV9^H\W+"FMC<N':(X:$[/[)^1NIE>X1]6[$"0KEBE% ;7#4Q?]?#2/DCD#X
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MR:E##":8MM)W/%)8D& !)1>C>^=&-_A@Z8<UW?SJK?$X!>7IQ;4]G; ]7/Y
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M,P3:?MU0@8BR-L7FJ5M"\5H=6VA.MN#OY^WI6B%0_EA8<#F>,"LW:JSIG+9
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M-.N&\]:^-4ZD6'^V/$M0ZBH++&R;F :QY@IRB<J(CXKN[1%WT!56=S/[\Q;
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M0U/]>Q,0C)L;S@L7X^,34Y>5D%7_MVNW"1"  28 $PPZ"' (@, "H-TV0!H
M0)R@'P7\62 .,(23"PKCYN'=,U3N SA 8# '!,S)"8'LJ;?W=  BP"DHJW::
M2\CZ,O3@#6'UR)1G,#FCE\TBYP<8\AI7;M[EYA'=+W8 J:"HI/S3(4VMX]HG
M3NH8GT&A34S-S&TNV&+L[!T<7=W</3RO>EWS#P@,"L:'A$;=BXZ)C8M/2$U[
M]#@]XY<GA-R\_(+"HN*2TE?E%955U36U=2VM;>T=G5W=;P:'AM]11T;'QJ=I
M,[.?/G^9FU]@+J^LKJUOL#:WOG.! ##HK_J'7 )[7!P0"!@"_<X%X@C^;A"
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M-%TK3O%?TB*70C2M#1&Y"<K@W;&_ 5!+ 0(4 Q0    ( +V ;UC93<M)\Q$
M ,+4   1              "  0    !A>G1R+3(P,C,Q,C,Q+GAS9%!+ 0(4
M Q0    ( +V ;UA/'=Z\-1D  (M5 0 5              "  2(2  !A>G1R
M+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "]@&]8/:EV 4\X  #0Z@,
M%0              @ &**P  87IT<BTR,#(S,3(S,5]D968N>&UL4$L! A0#
M%     @ O8!O6-7-IN;<=P  O"$' !4              ( !#&0  &%Z='(M
M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +V ;U@X'T2*-%4  ,'B!0 5
M              "  1O<  !A>G1R+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4
M    " "]@&]8@,*L[7@#   O%0  "@              @ &",0$ 97@R,RTR
M+FAT;5!+ 0(4 Q0    ( +V ;UATH7:S.@@  +)'   *              "
M 2(U 0!E>#,Q+3$N:'1M4$L! A0#%     @ O8!O6'%@ 8PN"   ED@   H
M             ( !A#T! &5X,S$M,BYH=&U02P$"% ,4    " "]@&]8?PI
M$I,%   !,P  "@              @ ':10$ 97@S,BTQ+FAT;5!+ 0(4 Q0
M   ( +V ;U@7'9*7H @  %\J   )              "  95+ 0!E>#0M-2YH
M=&U02P$"% ,4    " "]@&]8U('BVS,@   I/P$ "@              @ %<
M5 $ 97@Y-RTQ+FAT;5!+ 0(4 Q0    ( +V ;UB^XI'0IC$# / L&P ,
M          "  ;=T 0!F;W)M,3 M:RYH=&U02P$"% ,4    " "]@&]8^''I
M\P@9  !5&P  $               @ &'I@0 9F]R;3$P+6M?,# Q+FIP9U!+
M 0(4 Q0    ( +V ;U@/:0KTY2$!  4R 0 0              "  ;V_! !F
M;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @ O8!O6'!9K OP3@$ Q5<! !
M             ( !T.$% &9O<FTQ,"UK7S P,RYJ<&=02P$"% ,4    " "]
M@&]8B8X.J5LK   6,0  $               @ 'N, < 9F]R;3$P+6M?,# T
M+FIP9U!+ 0(4 Q0    ( +V ;U@5I=A_DC0  &0X   0              "
M 7=<!P!F;W)M,3 M:U\P,#4N:G!G4$L! A0#%     @ O8!O6$T12^24+P
M!S(  !               ( !-Y$' &9O<FTQ,"UK7S P-BYJ<&=02P$"% ,4
M    " "]@&]8NWI-&K4L  !3,   $               @ 'YP < 9F]R;3$P
M+6M?,# W+FIP9U!+ 0(4 Q0    ( +V ;UC'2)<"HB0  *\J   0
M      "  =SM!P!F;W)M,3 M:U\P,#@N:G!G4$L! A0#%     @ O8!O6*5Q
M!4==10  4DL  !               ( !K!(( &9O<FTQ,"UK7S P.2YJ<&=0
M2P$"% ,4    " "]@&]8%N]A"P5:   '8   $               @ $W6 @
M9F]R;3$P+6M?,#$P+FIP9U!+ 0(4 Q0    ( +V ;UC^D.N(8D<  .)*   0
M              "  6JR" !F;W)M,3 M:U\P,3$N:G!G4$L! A0#%     @
MO8!O6/'.>V9,-   CC\  !               ( !^OD( &9O<FTQ,"UK7S Q
M,BYJ<&=02P$"% ,4    " "]@&]81>KR]AT3 0!7-@$ $
M@ %T+@D 9F]R;3$P+6M?,#$S+FIP9U!+ 0(4 Q0    ( +V ;UC<&VD<UTL
M #Q>   0              "  ;]!"@!F;W)M,3 M:U\P,30N:G!G4$L! A0#
M%     @ O8!O6!0P>H;)#0  F@\  !               ( !Q(T* &9O<FTQ
A,"UK7S Q-2YJ<&=02P4&     !L &P!V!@  NYL*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AZTR="http://azitrainc.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aztr-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-012023-06-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-17_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-17</instant>
        </period>
    </context>
    <context id="AsOf2023-05-17_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-17</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CARESEmployeeRetentionCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:CARESEmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AZTR:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AZTR:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-05</instant>
        </period>
    </context>
    <context id="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-05</instant>
        </period>
    </context>
    <context id="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-05</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwentyTwentyOneConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-05-162023-05-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-17_custom_ForwardStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AZTR:ForwardStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-17</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ForwardStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AZTR:ForwardStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AZTR:TwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_SeriesA1PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesA1PreferredStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AZTR:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YearTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YearTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YearTwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">AZTR:YearTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember101770734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandSixteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:StockOptionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AZTR:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AZTR:TwoThousandTwentyTwoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember101773265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember101773703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember101773718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2036Through2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2036Through2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_NoExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2037Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2037Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2036Through2038Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2036Through2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">AZTR:TaxYears2039Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_country_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_country_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BranfordCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:BranfordCTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_GrotonCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_custom_GrotonCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_GrotonCTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AZTR:GrotonCTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AZTR:TwentyTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_UnderwriterMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AZTR:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="ixv-12788">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="ixv-12789">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="ixv-12790">0001701478</dei:EntityCentralIndexKey>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:EmployeeRetentionCredit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ForgivenessOfAccountsPayable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0475"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0477"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0495"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ForgivenessOfAccountsPayable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:PaymentsToAcquireCapitalizationOfLicenses
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:PaymentOfDeferredOfferingCosts
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ObtainingRightofuseAssetInExchangeForLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ConversionOfNoteToCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ConversionOfNoteToConvertiblePreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-012023-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0815"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember"
      id="xdx2ixbrl0825"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember"
      id="xdx2ixbrl0863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31_us-gaap_LicensingAgreementsMember"
      id="xdx2ixbrl0873"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31_custom_TwentyTwentyOneConvertibleNotesMember"
      id="xdx2ixbrl0976"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31_custom_TwentyTwentyTwoConvertibleNotesMember"
      id="xdx2ixbrl0980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1241"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1243"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember"
      id="xdx2ixbrl1298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember"
      id="xdx2ixbrl1299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1346"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1348"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1497"
      unitRef="Pure"
      xsi:nil="true"/>
    <AZTR:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1525"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2021-05-31_custom_GrotonCTMember"
      id="xdx2ixbrl1583">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2021-05-31_custom_GrotonCTMember"
      id="xdx2ixbrl1585">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1629"
      unitRef="USD"
      xsi:nil="true"/>
    <AZTR:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember"
      id="xdx2ixbrl1691">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="ixv-14617">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="ixv-14618">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-42">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-14619">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="ixv-14620">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="ixv-14621">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="ixv-14622">001-41705</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="ixv-14623">Azitra, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="ixv-14624">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="ixv-14625">46-4478536</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="ixv-14626">21 Business Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="ixv-14627">Branford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="ixv-14628">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="ixv-14629">06405</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="ixv-14630">(203)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="ixv-14631">646-6446</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="ixv-14632">Common     stock: Par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="ixv-14633">AZTR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="ixv-14634">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="ixv-14635">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="ixv-14636">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="ixv-14637">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="ixv-14638">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="ixv-14639">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="ixv-14640">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="ixv-14641">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-12-31" id="ixv-14642">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="ixv-14643">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="ixv-14644">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="ixv-14645">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="ixv-14646"
      unitRef="USD">20042404</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-15"
      decimals="INF"
      id="ixv-14647"
      unitRef="Shares">28804643</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14648">The
registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended
December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="ixv-14649">606</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="ixv-14650">GRASSI &amp; CO., CPAs, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="ixv-14651">Jericho, New York</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14652"
      unitRef="USD">1795989</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14653"
      unitRef="USD">3492656</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="ixv-14654"
      unitRef="USD">8255</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="ixv-14655"
      unitRef="USD">7820</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-14656"
      unitRef="USD">90000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-14657"
      unitRef="USD">175000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-14658"
      unitRef="USD">90000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-14659"
      unitRef="USD">175000</us-gaap:AccountsReceivableNetCurrent>
    <AZTR:TaxCreditsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14660"
      unitRef="USD">118383</AZTR:TaxCreditsReceivable>
    <AZTR:TaxCreditsReceivable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14661"
      unitRef="USD">69666</AZTR:TaxCreditsReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14662"
      unitRef="USD">6836</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14663"
      unitRef="USD">13722</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14664"
      unitRef="USD">67859</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14665"
      unitRef="USD">216886</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14666"
      unitRef="USD">448257</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14667"
      unitRef="USD">160133</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14668"
      unitRef="USD">2535579</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14669"
      unitRef="USD">4135883</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14670"
      unitRef="USD">710075</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14671"
      unitRef="USD">846958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14672"
      unitRef="USD">40002</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14673"
      unitRef="USD">828960</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14674"
      unitRef="USD">1116697</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14675"
      unitRef="USD">210881</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14676"
      unitRef="USD">219567</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14677"
      unitRef="USD">742229</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14678"
      unitRef="USD">800831</us-gaap:DeferredCosts>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14679"
      unitRef="USD">47760</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14680"
      unitRef="USD">47507</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14681"
      unitRef="USD">5115486</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14682"
      unitRef="USD">7167443</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14683"
      unitRef="USD">897272</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14684"
      unitRef="USD">784687</us-gaap:AccountsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14685"
      unitRef="USD">14600</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14686"
      unitRef="USD">307655</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14687"
      unitRef="USD">287384</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14688"
      unitRef="USD">383668</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14689"
      unitRef="USD">993961</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-14690"
      unitRef="USD">156000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14691"
      unitRef="USD">1603195</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14692"
      unitRef="USD">2222032</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14693"
      unitRef="USD">26169</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14694"
      unitRef="USD">537523</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14695"
      unitRef="USD">840896</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14696"
      unitRef="USD">35453</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14697"
      unitRef="USD">70283</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14698"
      unitRef="USD">6600000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14699"
      unitRef="USD">2202340</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14700"
      unitRef="USD">9733211</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14701"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14702"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14703"
      unitRef="Shares">205385</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14704"
      unitRef="Shares">205385</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14705"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14706"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14707"
      unitRef="Shares">205385</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14708"
      unitRef="Shares">205385</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14709"
      unitRef="USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14710"
      unitRef="USD">3337506</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14711"
      unitRef="USD">3272944</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14712"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14713"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14714"
      unitRef="Shares">380657</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14715"
      unitRef="Shares">380657</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14716"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14717"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14718"
      unitRef="Shares">380657</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14719"
      unitRef="Shares">380657</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2023-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14720"
      unitRef="USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14721"
      unitRef="USD">14274638</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14722"
      unitRef="USD">14100533</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14723"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14724"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14725"
      unitRef="Shares">851108</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14726"
      unitRef="Shares">851108</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14727"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14728"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14729"
      unitRef="Shares">391303</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="ixv-14730"
      unitRef="Shares">391303</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14731"
      unitRef="USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14732"
      unitRef="USD">17000159</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14733"
      unitRef="USD">16321065</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-14734"
      unitRef="USD">16321065</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14735"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-14736"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14737"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-14738"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14739"
      unitRef="Shares">12097643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14740"
      unitRef="Shares">12097643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-14741"
      unitRef="Shares">1043988</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-14742"
      unitRef="Shares">1043988</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14743"
      unitRef="USD">1210</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14744"
      unitRef="USD">104</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14745"
      unitRef="USD">51510269</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14746"
      unitRef="USD">1054138</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14747"
      unitRef="USD">-48598333</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14748"
      unitRef="USD">-37314552</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14749"
      unitRef="USD">2913146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14750"
      unitRef="USD">-36260310</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14751"
      unitRef="USD">5115486</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14752"
      unitRef="USD">7167443</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14753"
      unitRef="USD">686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14754"
      unitRef="USD">284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14755"
      unitRef="USD">686000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14756"
      unitRef="USD">284000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14757"
      unitRef="USD">4493332</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14758"
      unitRef="USD">3639666</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14759"
      unitRef="USD">3809063</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14760"
      unitRef="USD">6097938</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14761"
      unitRef="USD">8302395</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14762"
      unitRef="USD">9737604</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14763"
      unitRef="USD">-7616395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14764"
      unitRef="USD">-9453604</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14765"
      unitRef="USD">1577</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14766"
      unitRef="USD">4818</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14767"
      unitRef="USD">167726</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14768"
      unitRef="USD">251891</us-gaap:InterestExpense>
    <AZTR:EmployeeRetentionCredit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14769"
      unitRef="USD">229813</AZTR:EmployeeRetentionCredit>
    <us-gaap:OtherIncome
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14770"
      unitRef="USD">65849</us-gaap:OtherIncome>
    <AZTR:ForgivenessOfAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14771"
      unitRef="USD">56285</AZTR:ForgivenessOfAccountsPayable>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14772"
      unitRef="USD">-3630100</AZTR:ChangeInFairValueOfConvertibleNote>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14773"
      unitRef="USD">-1250000</AZTR:ChangeInFairValueOfConvertibleNote>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14774"
      unitRef="USD">89886</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14775"
      unitRef="USD">-25351</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14776"
      unitRef="USD">-3650078</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14777"
      unitRef="USD">-1226762</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14778"
      unitRef="USD">-11266473</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14779"
      unitRef="USD">-10680366</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14780"
      unitRef="USD">17308</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14781"
      unitRef="USD">-11283781</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14782"
      unitRef="USD">-10680366</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14783"
      unitRef="USD">1355347</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14784"
      unitRef="USD">2768984</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14785"
      unitRef="USD">-12639128</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14786"
      unitRef="USD">-13449350</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14787"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14788"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-14789"
      unitRef="USDPShares">-12.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-14790"
      unitRef="USDPShares">-12.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14791"
      unitRef="Shares">6924453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14792"
      unitRef="Shares">6924453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-14793"
      unitRef="Shares">1055399</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-14794"
      unitRef="Shares">1055399</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14795"
      unitRef="Shares">205385</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14796"
      unitRef="USD">3272944</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14797"
      unitRef="Shares">380657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14798"
      unitRef="USD">14100533</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14799"
      unitRef="Shares">391303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14800"
      unitRef="USD">16321065</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14801"
      unitRef="Shares">1043103</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14802"
      unitRef="USD">104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14803"
      unitRef="USD">868163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14804"
      unitRef="USD">-26634186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-14805"
      unitRef="USD">-25765919</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14806"
      unitRef="USD">184465</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14807"
      unitRef="USD">184465</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14808"
      unitRef="Shares">888</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14809"
      unitRef="USD">1510</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14810"
      unitRef="USD">1510</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14811"
      unitRef="USD">-10680366</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14812"
      unitRef="USD">-10680366</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14813"
      unitRef="Shares">205385</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14814"
      unitRef="USD">3272944</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14815"
      unitRef="Shares">380657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14816"
      unitRef="USD">14100533</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14817"
      unitRef="Shares">391303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14818"
      unitRef="USD">16321065</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14819"
      unitRef="Shares">1043991</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14820"
      unitRef="USD">104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14821"
      unitRef="USD">1054138</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14822"
      unitRef="USD">-37314552</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14823"
      unitRef="USD">-36260310</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14824"
      unitRef="Shares">205385</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14825"
      unitRef="USD">3272944</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14826"
      unitRef="Shares">380657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14827"
      unitRef="USD">14100533</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14828"
      unitRef="Shares">391303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14829"
      unitRef="USD">16321065</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14830"
      unitRef="Shares">1043991</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14831"
      unitRef="USD">104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14832"
      unitRef="USD">1054138</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14833"
      unitRef="USD">-37314552</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14834"
      unitRef="USD">-36260310</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14835"
      unitRef="Shares">23432</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14836"
      unitRef="USD">1124759</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14837"
      unitRef="Shares">1846020</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14838"
      unitRef="USD">185</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14839"
      unitRef="USD">9494887</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14840"
      unitRef="USD">9495072</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-14841"
      unitRef="Shares">-205385</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14842"
      unitRef="USD">-3272944</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14843"
      unitRef="Shares">-380657</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SeriesA1ConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14844"
      unitRef="USD">-14100533</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      id="ixv-14845"
      unitRef="Shares">-414735</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      id="ixv-14846"
      unitRef="USD">-17445824</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14847"
      unitRef="Shares">7707632</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14848"
      unitRef="USD">771</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14849"
      unitRef="USD">34818530</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14850"
      unitRef="USD">34819301</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14851"
      unitRef="USD">1508641</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14852"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14853"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14854"
      unitRef="USD">5991209</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14855"
      unitRef="USD">5991359</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14856"
      unitRef="USD">151505</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14857"
      unitRef="USD">151505</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14858"
      unitRef="USD">-11283781</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14859"
      unitRef="USD">-11283781</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14860"
      unitRef="Shares">12097643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14861"
      unitRef="USD">1210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14862"
      unitRef="USD">51510269</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14863"
      unitRef="USD">-48598333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14864"
      unitRef="USD">2913146</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-14865"
      unitRef="Shares">12097643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-14866"
      unitRef="USD">1210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-14867"
      unitRef="USD">51510269</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-14868"
      unitRef="USD">-48598333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14869"
      unitRef="USD">2913146</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14870"
      unitRef="USD">-11283781</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14871"
      unitRef="USD">-10680366</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14872"
      unitRef="USD">129653</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14873"
      unitRef="USD">125885</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14874"
      unitRef="USD">7981</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14875"
      unitRef="USD">295896</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14876"
      unitRef="USD">280092</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <AZTR:AccruedInterestOnConvertibleNotes
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14877"
      unitRef="USD">166019</AZTR:AccruedInterestOnConvertibleNotes>
    <AZTR:AccruedInterestOnConvertibleNotes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14878"
      unitRef="USD">164611</AZTR:AccruedInterestOnConvertibleNotes>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14879"
      unitRef="USD">151505</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14880"
      unitRef="USD">184465</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14881"
      unitRef="USD">-34830</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14882"
      unitRef="USD">-821</us-gaap:FairValueAdjustmentOfWarrants>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14883"
      unitRef="USD">-3630100</AZTR:ChangeInFairValueOfConvertibleNote>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14884"
      unitRef="USD">-1250000</AZTR:ChangeInFairValueOfConvertibleNote>
    <AZTR:ForgivenessOfAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14885"
      unitRef="USD">56285</AZTR:ForgivenessOfAccountsPayable>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14886"
      unitRef="USD">-41417</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14887"
      unitRef="USD">-7923</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14888"
      unitRef="USD">351360</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14889"
      unitRef="USD">-84565</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14890"
      unitRef="USD">21953</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14891"
      unitRef="USD">288124</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14892"
      unitRef="USD">49844</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14893"
      unitRef="USD">253</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14894"
      unitRef="USD">-694</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14895"
      unitRef="USD">-48717</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14896"
      unitRef="USD">103645</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14897"
      unitRef="USD">-68684</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14898"
      unitRef="USD">420752</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14899"
      unitRef="USD">-6886</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14900"
      unitRef="USD">15024</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14901"
      unitRef="USD">-283102</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14902"
      unitRef="USD">-268509</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14903"
      unitRef="USD">156000</us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14904"
      unitRef="USD">-141000</us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14905"
      unitRef="USD">-7362375</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14906"
      unitRef="USD">-8349469</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14907"
      unitRef="USD">26544</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14908"
      unitRef="USD">33101</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14909"
      unitRef="USD">4250</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14910"
      unitRef="USD">214152</AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts>
    <AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14911"
      unitRef="USD">180802</AZTR:PaymentsToAcquireCapitalizationOfDeferredPatentCosts>
    <AZTR:PaymentsToAcquireCapitalizationOfLicenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14912"
      unitRef="USD">65510</AZTR:PaymentsToAcquireCapitalizationOfLicenses>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14913"
      unitRef="USD">77563</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14914"
      unitRef="USD">61598</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14915"
      unitRef="USD">-318259</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14916"
      unitRef="USD">-336761</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14917"
      unitRef="USD">4350000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <AZTR:PaymentOfDeferredOfferingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14918"
      unitRef="USD">216886</AZTR:PaymentOfDeferredOfferingCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14919"
      unitRef="USD">7392</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14920"
      unitRef="USD">5991359</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14921"
      unitRef="USD">1510</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14922"
      unitRef="USD">5983967</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14923"
      unitRef="USD">4134624</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14924"
      unitRef="USD">-1696667</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14925"
      unitRef="USD">-4551606</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14926"
      unitRef="USD">3492656</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-14927"
      unitRef="USD">8044262</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14928"
      unitRef="USD">1795989</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14929"
      unitRef="USD">3492656</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <AZTR:ObtainingRightofuseAssetInExchangeForLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14930"
      unitRef="USD">1418502</AZTR:ObtainingRightofuseAssetInExchangeForLeaseLiability>
    <AZTR:ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14931"
      unitRef="USD">46452</AZTR:ObtainingRightofuseAssetInExchangeForFinancingLeaseLiability>
    <AZTR:ConversionOfNoteToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14932"
      unitRef="USD">9495072</AZTR:ConversionOfNoteToCommonStock>
    <AZTR:ConversionOfNoteToConvertiblePreferredStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14933"
      unitRef="USD">1124759</AZTR:ConversionOfNoteToConvertiblePreferredStock>
    <AZTR:ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14934"
      unitRef="USD">34819301</AZTR:ConversionOfSeriesA1AndBConvertiblePreferredStockToCommonStock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8418">&lt;p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zyGpxj2Qg7gb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
&lt;span id="xdx_826_zzgaE43ZUfg2"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Azitra,
Inc. was founded on January 2, 2014. It is a synthetic biology company focused on screening and genetically engineering microbes of the
skin. The mission is to discover and develop novel therapeutics to create a new paradigm for treating skin disease. The Company&#x2019;s
discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced
and engineered to make cellular therapies, recombinant therapeutic proteins, peptides and small molecules for precision treatment of
dermatology diseases. On May 17, 2023, the Company changed its name to from &#x201c;Azitra Inc&#x201d; to &#x201c;Azitra, Inc.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains a location in Montreal, Canada for certain research activities. This location and operations conducted there remained
consistent throughout 2022 and 2023. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
Stock Split, Change in Par Value, and Initial Public Offering&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company completed its initial public offering (IPO) in which it issued and sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230601__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNTL6bAsINvb" title="Shares of common stock"&gt;1,500,000&lt;/span&gt; shares of its common stock at
a price to the public of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zW1UvWuhXVsl" title="Sale of stock price per share"&gt;5.00&lt;/span&gt; per share. The shares began trading on the NYSE American on June 16, 2023 under the symbol &#x201c;AZTR&#x201d;.
The net proceeds received by the Company from the offering were $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvhItHSJllvl" title="Proceeds from initial public offering"&gt;6.0&lt;/span&gt; million, after deducting underwriting discounts, commissions and
other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Immediately
prior to the effectiveness of the Company&#x2019;s registration statement, the Company effected a &lt;span id="xdx_901_eus-gaap--StockholdersEquityNoteStockSplit_c20230101__20230630_z83ahAlzuYhj" title="Forward stock split"&gt;7.1-for-1 forward stock split&lt;/span&gt; of its
issued and outstanding shares of common stock (the Forward Stock Split). On May 17, 2023, the Company changed the par value of its capital
stock from $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MaximumMember_z6I6mWIxmA3e" title="Sale of stock price per share"&gt;0.01&lt;/span&gt; to $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20230517__srt--RangeAxis__srt--MinimumMember_zr05IHCaqIei" title="Sale of stock price per share"&gt;0.0001&lt;/span&gt;. Accordingly, all share and per share amounts for all periods presented in the accompanying audited consolidated
financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the Forward Stock
Split. Refer to Note 8 for additional details relating to the Forward Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Going
Concern Matters&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation
for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to
continue as a going concern. As of and for the year ended December 31, 2023, the Company has an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zhK13gazNIp2" title="Accumulated deficit"&gt;48.6&lt;/span&gt; million,
a loss from operations of $&lt;span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zNIDC5NrkPkd" title="Loss from operations"&gt;7.6&lt;/span&gt; million and used $&lt;span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zUa4erHCXZp7" title="Net cash used in operating activities"&gt;7.4&lt;/span&gt; million to fund operations. These factors among others raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
plans to continue to raise funds through equity and debt financing to fund operating and working capital needs; however, the Company
will require a significant amount of additional funds to complete the development of its products and to fund additional losses which
the Company expects to incur over the next few years as the Company does not yet have product revenue. There can be no assurance that
the Company will be successful in securing additional financing to meet its operating needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
conditions and events create uncertainty about the ability of the Company to continue as a going concern for twelve months from the date
that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary
should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-06-012023-06-30_us-gaap_IPOMember"
      decimals="INF"
      id="ixv-14935"
      unitRef="Shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-30_us-gaap_IPOMember"
      decimals="INF"
      id="ixv-14936"
      unitRef="USDPShares">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-06-30_us-gaap_IPOMember"
      decimals="0"
      id="ixv-14937"
      unitRef="USD">6.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-01-012023-06-30" id="ixv-14938">7.1-for-1 forward stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-17_srt_MaximumMember"
      decimals="INF"
      id="ixv-14939"
      unitRef="USDPShares">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-17_srt_MinimumMember"
      decimals="INF"
      id="ixv-14940"
      unitRef="USDPShares">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="ixv-14941"
      unitRef="USD">-48600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="ixv-14942"
      unitRef="USD">-7600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="ixv-14943"
      unitRef="USD">-7400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8491">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zu2k2EAJDC54" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
&lt;span id="xdx_826_zo2DKJIjEhE9"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zMtiHuRO9Al6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_867_zZqaCW4rAPe7"&gt;Basis
of Accounting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S.
GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zuAKEAiSIOZi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_z5isAYtCIGSh"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
These estimates and assumptions are based on current facts, historical experience, and various other factors believed to be reasonable
under the circumstances, the results which form the basis for making judgements about the carrying values of assets and liabilities and
the recording of expenses that are not readily apparent from other sources. While management believes the estimates and assumptions are
appropriate, actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbhO8K0SBAj5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_ziWQJ4TFc4bh"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6JZhm12qyoe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zUG5HvOzVEsb"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zxxdutHi8g2c" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt; to &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zYHSrbr4mOdl" title="Property, plant and equipment, useful life"&gt;10&lt;/span&gt; years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zilBeWaVDAg7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zXgQuPq5jsw"&gt;Accounts
Receivable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries its accounts receivable at cost less an allowance for expected credit losses. On a periodic basis, the Company evaluates
its accounts receivable and establishes an allowance for expected credit losses based on a history of past write-offs, collections and
current conditions. There was no allowance for credit losses at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zXnFt8Rbwac4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zfbgB7kzjFId"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&#x2019;s initial public offering. In June 2023, the Company consummated its IPO and recorded
such amounts against the gross proceeds of its IPO within the statements of stockholders&#x2019; equity. During the fourth quarter the
Company incurred $67,859 of costs related to a follow-on offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zNXhjUSSL1Oe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zZGESRvACDc4"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02, Leases (&#x201c;Topic 842&#x201d;).
ASU 2016-02 requires lessees to present right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either
operating or financing leases based on the economic substance of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$&lt;span id="xdx_90F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220101_ztnyfb3ehQyi" title="Right-of-use asset and lease liability"&gt;1,418,502&lt;/span&gt; as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&#x2019;s
option to extend certain leases ranges from &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zSeo4zMg8uZj" title="Lease term"&gt;36&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_z2il98dePDgc" title="Lease term"&gt;52&lt;/span&gt; months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. The Company utilizes a weighted
average discount rate of &lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zcnGnCh3Kx9i" title="Operating lease, weighted average discount rate"&gt;4.25&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zJ7LSKGJNpPa" title="Finance lease, weighted average discount rate"&gt;9.60&lt;/span&gt;% for its operating and finance leases, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company had operating right-of-use assets with a net value of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zMn2w1U4xA33" title="Operating lease right-of-use asset"&gt;828,960&lt;/span&gt; and current and long-term operating lease
liabilities of $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zx5EewTQfpAl" title="Current operating lease liability"&gt;307,655&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zd3AkaCmHbAc" title="Long-term operating lease liability"&gt;537,523&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has
a term of &lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtM_c20231231_z2QaJxzUGq8j" title="Finance lease term"&gt;36&lt;/span&gt; months. At December 31, 2023, the Company had financing right-of-use assets with a net value of $&lt;span id="xdx_906_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_zuCS5CAC1OXl" title="Long term finance lease liability"&gt;40,002&lt;/span&gt; and current and
long-term operating lease liabilities of $&lt;span id="xdx_90D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zP39DMziATy4" title="Finance lease liability current"&gt;14,600&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zskZ2wli7W8j" title="Long term finance lease liability"&gt;26,169&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziNUhc5MFc5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zOMApwqfbtN7"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were $&lt;span id="xdx_900_ecustom--ImpairmentOfLicenseAgreements_c20230101__20231231_zWv6Tn88ESZ" title="Impairment of license agreements"&gt;78,606&lt;/span&gt; and
$&lt;span id="xdx_909_ecustom--ImpairmentOfLicenseAgreements_c20220101__20221231_zfjusyt3FGCc" title="Impairment of license agreements"&gt;0&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively, and are included in general and administrative expenses on the accompanying
consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DeferredPatentCostsPolicyTextBlock_z4b4ly3qt0Z" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_zxQIkWopin63"&gt;Deferred
Patent Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating
to deferred patent costs during the years ended December 31, 2023 and 2022 were $&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqi1vsaTWV6" title="Impairment of intangible assets"&gt;272,754&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHx7Xqou0uCe" title="Impairment of intangible assets"&gt;0&lt;/span&gt;, respectively, and are included in general
and administrative expenses on the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUr7PcCCf6Pf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zq5aIFmoUVhl"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC Topic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets (ASC 360-10), the Company&#x2019;s policy
is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets.
The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition
of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value
of the net future operating cash flows generated by the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
Summary of Significant Accounting Policies (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zPW2TWZB4w42" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zjkuYKwT7Bxh"&gt;Convertible
Debt and Warrant Accounting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)
and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income (Expense).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
debt&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &#x2013; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&#x2019;s
conversion features require bifurcation in accordance with ASC 815 &#x2013; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
The Convertible Notes were converted into the Company&#x2019;s common stock on the Closing Date of the Company&#x2019;s IPO. Under 815-15-25,
the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825.
The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to
be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change
based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized
as a non-cash gain or loss in Other Income (Expense) on the statements of operations. The Company elected the fair value option for the
2022 Convertible Notes and recorded the notes at their initial fair values with subsequent changes in fair value recorded in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ConvertiblePreferredStockPolicyTextBlock_zoDaQ41gDDYe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zWfXmquYxeSi"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted in Note 8, at the Closing Date of the Company&#x2019;s IPO, the Convertible Preferred stock converted into shares of the Company&#x2019;s
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zSZKzFW576J" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zlP1wXMBJkAg"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the &lt;i&gt;five&lt;/i&gt; steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers
(&#x201c;ASC 606&#x201d;), which are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;1&lt;/i&gt;: Identify the contract(s) with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;2&lt;/i&gt;: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;3&lt;/i&gt;: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;4&lt;/i&gt;: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;5&lt;/i&gt;: Recognize revenue when (or as) a performance obligation is satisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z5TWStwucIwl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zBHxvW101E84"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, &lt;i&gt;Research
and Development&lt;/i&gt;. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Advance payments for goods and services that will be used in future research and development
activities are expensed when the activity has been performed or when the goods have been received. Research and development costs incurred
were $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zroj86IPyoQb" title="Research and development"&gt;3,809,063&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zE3vq10NMPol" title="Research and development"&gt;6,097,938&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company has a state tax credit receivable of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20231231_ztPBBt1if2c1" title="State tax credit receivable"&gt;86,778&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20221231_zyQ9FwNbN8xl" title="State tax credit receivable"&gt;32,459&lt;/span&gt;, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2023 and 2022, the Company has
$&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_z3MIXlO8Zl1c" title="Pending refunds related to research and experimental development"&gt;20,040&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zJUPVx5KHOC" title="Pending refunds related to research and experimental development"&gt;28,925&lt;/span&gt;, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits.
At December 31, 2023 and 2022, the Company has also recorded $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20231231_zwPd68iTdYma" title="Refunds tax amount"&gt;11,565&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20221231_z8DHBFkcmAy5" title="Refunds tax amount"&gt;8,282&lt;/span&gt;, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLmBzSEROH7k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zLzLqCWaK226"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved. The Company recognizes the effect of forfeitures when the forfeitures occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&#x2019;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, &lt;i&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;, which expands the scope of ASC
718 to include share-based payment transactions to non-employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;. The expected volatility of the Company&#x2019;s shares is estimated based on the average volatility of peer companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Underlying
Common Stock Value&lt;/i&gt;. The underlying common stock value of the Company&#x2019;s shares is estimated by a third-party valuation expert
up until the Company&#x2019;s IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-free
Interest Rate&lt;/i&gt;. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Yield&lt;/i&gt;. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zUHeCzIdfisg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zK0UNWqj7YP5"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, &lt;i&gt;Accounting for Income Taxes&lt;/i&gt;. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2023 and December 31, 2022. The Company&#x2019;s income
tax returns have not been examined by tax authorities through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zc2sDqE0Fo3l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_z6nfOQDLexIc"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per weighted average share attributable to common stockholders using the weighted average number of shares
of common stock outstanding during the period. The Company computes diluted net loss per weighted average share attributable to common
stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period.
Potential common shares outstanding consist of stock options, warrants and preferred stock and are excluded if their effect is anti-dilutive.
Diluted weighted average common shares did not include any incremental shares for the fiscal year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--CertainRisksAndUncertaintiesPolicyTextBlock_zxGQWdOD9QCh" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zTVzLJ61m7Gg"&gt;Certain
Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding
to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical
industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on
key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztEoDnBavlIc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zVmQr5aENLK"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 &#x2013; Inputs are based upon observable or quoted prices for identical instruments traded
                                            in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 &#x2013; Inputs are based upon quoted prices for similar instruments in active markets,
                                            quoted prices for identical or similar instruments in markets that are not active, and model-based
                                            valuation techniques for which all significant assumptions are observable in the market or
                                            can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 &#x2013; Inputs are generally unobservable and typically reflect management&#x2019;s estimates
                                            of assumptions that market participants would use in pricing the asset or liability. The
                                            fair values are therefore determined using model-based techniques that include option pricing
                                            models, discounted cash flow models, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1wB1vi2kIA7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_zVuLsQuwtdtg"&gt;Financial
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term
maturities of such instruments. The estimated fair value of the Company&#x2019;s long-term debt approximates carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z4b5eMa24sd1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zLSkO6OaZs5e"&gt;Concentration
of Credit Risk and Off- Balance Sheet Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash
equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and
accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated
with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The
Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances
in the form of a money market account with a financial institution that management believes to be creditworthy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCsompK9GpOf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zY6TggQUom35"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740): &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.
This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing
additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted
this standard effective January 1, 2022, which did not have a material impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 1026-13, &lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (ASC 326)&lt;/i&gt;, which replaces the incurred loss methodology with the expected loss methodology. This standard is referred
to as the current expected credit loss (&#x201c;CECL&#x201d;) methodology. CECL This standard is effective for the Company on January 1,
2023. The Company has adopted this standard effective January 1, 2023, which did not have a material impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_zhfFJXBdUUYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8497">&lt;p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zMtiHuRO9Al6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_867_zZqaCW4rAPe7"&gt;Basis
of Accounting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S.
GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="ixv-8507">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zuAKEAiSIOZi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_z5isAYtCIGSh"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
These estimates and assumptions are based on current facts, historical experience, and various other factors believed to be reasonable
under the circumstances, the results which form the basis for making judgements about the carrying values of assets and liabilities and
the recording of expenses that are not readily apparent from other sources. While management believes the estimates and assumptions are
appropriate, actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8517">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbhO8K0SBAj5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_ziWQJ4TFc4bh"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8527">&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6JZhm12qyoe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zUG5HvOzVEsb"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zxxdutHi8g2c" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt; to &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zYHSrbr4mOdl" title="Property, plant and equipment, useful life"&gt;10&lt;/span&gt; years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="ixv-14944">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="ixv-14945">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2023-01-01to2023-12-31" id="ixv-8539">&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zilBeWaVDAg7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zXgQuPq5jsw"&gt;Accounts
Receivable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries its accounts receivable at cost less an allowance for expected credit losses. On a periodic basis, the Company evaluates
its accounts receivable and establishes an allowance for expected credit losses based on a history of past write-offs, collections and
current conditions. There was no allowance for credit losses at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <AZTR:DeferredOfferingCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8549">&lt;p id="xdx_849_ecustom--DeferredOfferingCostsPolicyTextBlock_zXnFt8Rbwac4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zfbgB7kzjFId"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&#x2019;s initial public offering. In June 2023, the Company consummated its IPO and recorded
such amounts against the gross proceeds of its IPO within the statements of stockholders&#x2019; equity. During the fourth quarter the
Company incurred $67,859 of costs related to a follow-on offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AZTR:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8559">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zNXhjUSSL1Oe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zZGESRvACDc4"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02, Leases (&#x201c;Topic 842&#x201d;).
ASU 2016-02 requires lessees to present right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either
operating or financing leases based on the economic substance of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies (continued)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$&lt;span id="xdx_90F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20220101__20220101_ztnyfb3ehQyi" title="Right-of-use asset and lease liability"&gt;1,418,502&lt;/span&gt; as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&#x2019;s
option to extend certain leases ranges from &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zSeo4zMg8uZj" title="Lease term"&gt;36&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_z2il98dePDgc" title="Lease term"&gt;52&lt;/span&gt; months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. The Company utilizes a weighted
average discount rate of &lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zcnGnCh3Kx9i" title="Operating lease, weighted average discount rate"&gt;4.25&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_zJ7LSKGJNpPa" title="Finance lease, weighted average discount rate"&gt;9.60&lt;/span&gt;% for its operating and finance leases, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company had operating right-of-use assets with a net value of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zMn2w1U4xA33" title="Operating lease right-of-use asset"&gt;828,960&lt;/span&gt; and current and long-term operating lease
liabilities of $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zx5EewTQfpAl" title="Current operating lease liability"&gt;307,655&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zd3AkaCmHbAc" title="Long-term operating lease liability"&gt;537,523&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has
a term of &lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtM_c20231231_z2QaJxzUGq8j" title="Finance lease term"&gt;36&lt;/span&gt; months. At December 31, 2023, the Company had financing right-of-use assets with a net value of $&lt;span id="xdx_906_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_zuCS5CAC1OXl" title="Long term finance lease liability"&gt;40,002&lt;/span&gt; and current and
long-term operating lease liabilities of $&lt;span id="xdx_90D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zP39DMziATy4" title="Finance lease liability current"&gt;14,600&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zskZ2wli7W8j" title="Long term finance lease liability"&gt;26,169&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-012022-01-01"
      decimals="0"
      id="ixv-14946"
      unitRef="USD">1418502</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="ixv-14947">P36M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="ixv-14948">P52M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14949"
      unitRef="Pure">0.0425</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-14950"
      unitRef="Pure">0.0960</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14951"
      unitRef="USD">828960</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14952"
      unitRef="USD">307655</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14953"
      unitRef="USD">537523</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2023-12-31" id="ixv-14954">P36M</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14955"
      unitRef="USD">40002</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14956"
      unitRef="USD">14600</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14957"
      unitRef="USD">26169</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-8623">&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziNUhc5MFc5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zOMApwqfbtN7"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. Impairment losses relating to license agreements were $&lt;span id="xdx_900_ecustom--ImpairmentOfLicenseAgreements_c20230101__20231231_zWv6Tn88ESZ" title="Impairment of license agreements"&gt;78,606&lt;/span&gt; and
$&lt;span id="xdx_909_ecustom--ImpairmentOfLicenseAgreements_c20220101__20221231_zfjusyt3FGCc" title="Impairment of license agreements"&gt;0&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively, and are included in general and administrative expenses on the accompanying
consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <AZTR:ImpairmentOfLicenseAgreements
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14958"
      unitRef="USD">78606</AZTR:ImpairmentOfLicenseAgreements>
    <AZTR:ImpairmentOfLicenseAgreements
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14959"
      unitRef="USD">0</AZTR:ImpairmentOfLicenseAgreements>
    <AZTR:DeferredPatentCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8640">&lt;p id="xdx_841_ecustom--DeferredPatentCostsPolicyTextBlock_z4b4ly3qt0Z" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_zxQIkWopin63"&gt;Deferred
Patent Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Impairment losses relating
to deferred patent costs during the years ended December 31, 2023 and 2022 were $&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqi1vsaTWV6" title="Impairment of intangible assets"&gt;272,754&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHx7Xqou0uCe" title="Impairment of intangible assets"&gt;0&lt;/span&gt;, respectively, and are included in general
and administrative expenses on the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AZTR:DeferredPatentCostsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-14960"
      unitRef="USD">272754</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-012022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-14961"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8652">&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUr7PcCCf6Pf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zq5aIFmoUVhl"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC Topic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets (ASC 360-10), the Company&#x2019;s policy
is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these assets.
The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual disposition
of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the present value
of the net future operating cash flows generated by the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
Summary of Significant Accounting Policies (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8688">&lt;p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zPW2TWZB4w42" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zjkuYKwT7Bxh"&gt;Convertible
Debt and Warrant Accounting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)
and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income (Expense).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
debt&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &#x2013; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&#x2019;s
conversion features require bifurcation in accordance with ASC 815 &#x2013; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
The Convertible Notes were converted into the Company&#x2019;s common stock on the Closing Date of the Company&#x2019;s IPO. Under 815-15-25,
the election can be at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825.
The Company has made such election for the 2022 Convertible Notes. Using the fair value option, the convertible promissory note is to
be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. The Company evaluates the change
based on the conversion price at the current market value. When recognized, changes in the estimated fair value of the notes are recognized
as a non-cash gain or loss in Other Income (Expense) on the statements of operations. The Company elected the fair value option for the
2022 Convertible Notes and recorded the notes at their initial fair values with subsequent changes in fair value recorded in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <AZTR:ConvertiblePreferredStockPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8716">&lt;p id="xdx_841_ecustom--ConvertiblePreferredStockPolicyTextBlock_zoDaQ41gDDYe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zWfXmquYxeSi"&gt;Convertible
Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted in Note 8, at the Closing Date of the Company&#x2019;s IPO, the Convertible Preferred stock converted into shares of the Company&#x2019;s
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AZTR:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8730">&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zSZKzFW576J" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zlP1wXMBJkAg"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the &lt;i&gt;five&lt;/i&gt; steps to recognize revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers
(&#x201c;ASC 606&#x201d;), which are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;1&lt;/i&gt;: Identify the contract(s) with a customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;2&lt;/i&gt;: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;3&lt;/i&gt;: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;4&lt;/i&gt;: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step
                                            &lt;i&gt;5&lt;/i&gt;: Recognize revenue when (or as) a performance obligation is satisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
earned under these grant contracts are recorded as a reduction to research and development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earned. The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="ixv-8817">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z5TWStwucIwl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zBHxvW101E84"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, &lt;i&gt;Research
and Development&lt;/i&gt;. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Advance payments for goods and services that will be used in future research and development
activities are expensed when the activity has been performed or when the goods have been received. Research and development costs incurred
were $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zroj86IPyoQb" title="Research and development"&gt;3,809,063&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zE3vq10NMPol" title="Research and development"&gt;6,097,938&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company has a state tax credit receivable of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20231231_ztPBBt1if2c1" title="State tax credit receivable"&gt;86,778&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsStateTaxes_iI_c20221231_zyQ9FwNbN8xl" title="State tax credit receivable"&gt;32,459&lt;/span&gt;, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2023 and 2022, the Company has
$&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_z3MIXlO8Zl1c" title="Pending refunds related to research and experimental development"&gt;20,040&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zJUPVx5KHOC" title="Pending refunds related to research and experimental development"&gt;28,925&lt;/span&gt;, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits.
At December 31, 2023 and 2022, the Company has also recorded $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20231231_zwPd68iTdYma" title="Refunds tax amount"&gt;11,565&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_c20221231_z8DHBFkcmAy5" title="Refunds tax amount"&gt;8,282&lt;/span&gt;, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14962"
      unitRef="USD">3809063</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14963"
      unitRef="USD">6097938</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14964"
      unitRef="USD">86778</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14965"
      unitRef="USD">32459</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14966"
      unitRef="USD">20040</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14967"
      unitRef="USD">28925</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14968"
      unitRef="USD">11565</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14969"
      unitRef="USD">8282</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-8840">&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLmBzSEROH7k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zLzLqCWaK226"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved. The Company recognizes the effect of forfeitures when the forfeitures occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&#x2019;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, &lt;i&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;, which expands the scope of ASC
718 to include share-based payment transactions to non-employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;. The expected volatility of the Company&#x2019;s shares is estimated based on the average volatility of peer companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Underlying
Common Stock Value&lt;/i&gt;. The underlying common stock value of the Company&#x2019;s shares is estimated by a third-party valuation expert
up until the Company&#x2019;s IPO, at which time the Company utilized its trading price on the NYSE American on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-free
Interest Rate&lt;/i&gt;. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Yield&lt;/i&gt;. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8914">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zUHeCzIdfisg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zK0UNWqj7YP5"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, &lt;i&gt;Accounting for Income Taxes&lt;/i&gt;. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2023 and December 31, 2022. The Company&#x2019;s income
tax returns have not been examined by tax authorities through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8952">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zc2sDqE0Fo3l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_z6nfOQDLexIc"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per weighted average share attributable to common stockholders using the weighted average number of shares
of common stock outstanding during the period. The Company computes diluted net loss per weighted average share attributable to common
stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period.
Potential common shares outstanding consist of stock options, warrants and preferred stock and are excluded if their effect is anti-dilutive.
Diluted weighted average common shares did not include any incremental shares for the fiscal year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <AZTR:CertainRisksAndUncertaintiesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8962">&lt;p id="xdx_848_ecustom--CertainRisksAndUncertaintiesPolicyTextBlock_zxGQWdOD9QCh" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zTVzLJ61m7Gg"&gt;Certain
Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding
to properly execute the Company&#x2019;s business plan. The Company is subject to risks that are common to companies in the pharmaceutical
industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on
key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AZTR:CertainRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-8972">&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztEoDnBavlIc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_zVmQr5aENLK"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 &#x2013; Inputs are based upon observable or quoted prices for identical instruments traded
                                            in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 &#x2013; Inputs are based upon quoted prices for similar instruments in active markets,
                                            quoted prices for identical or similar instruments in markets that are not active, and model-based
                                            valuation techniques for which all significant assumptions are observable in the market or
                                            can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 &#x2013; Inputs are generally unobservable and typically reflect management&#x2019;s estimates
                                            of assumptions that market participants would use in pricing the asset or liability. The
                                            fair values are therefore determined using model-based techniques that include option pricing
                                            models, discounted cash flow models, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-9007">&lt;p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1wB1vi2kIA7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_zVuLsQuwtdtg"&gt;Financial
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short-term
maturities of such instruments. The estimated fair value of the Company&#x2019;s long-term debt approximates carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="ixv-9017">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z4b5eMa24sd1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zLSkO6OaZs5e"&gt;Concentration
of Credit Risk and Off- Balance Sheet Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash
equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and
accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated
with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The
Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances
in the form of a money market account with a financial institution that management believes to be creditworthy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. Summary of Significant Accounting Policies (continued)&lt;/p&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9052">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zCsompK9GpOf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zY6TggQUom35"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740): &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.
This standard simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing
additional reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted
this standard effective January 1, 2022, which did not have a material impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 1026-13, &lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (ASC 326)&lt;/i&gt;, which replaces the incurred loss methodology with the expected loss methodology. This standard is referred
to as the current expected credit loss (&#x201c;CECL&#x201d;) methodology. CECL This standard is effective for the Company on January 1,
2023. The Company has adopted this standard effective January 1, 2023, which did not have a material impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9073">&lt;p id="xdx_805_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zBvN6RCxo9V9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.
&lt;span id="xdx_82B_zQ2fuRdozvYf"&gt;Employee Retention Credit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CARES Act provides an employee retention credit (&#x201c;CARES Employee Retention credit&#x201d;), which is a refundable tax credit against
certain employment taxes of up to $&lt;span id="xdx_900_ecustom--RefundableTaxCredit_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zFUbl7aEOpT1" title="Refundable tax credit"&gt;5,000&lt;/span&gt; per employee for eligible employers. The tax credit is equal to &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MinimumMember_zc0neqHDL2j" title="Tax credit percent"&gt;50&lt;/span&gt;% of qualified wages paid
to employees during a quarter, capped at $&lt;span id="xdx_901_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_zAUFQSnawIF3" title="Payments to employees"&gt;10,000&lt;/span&gt; of qualified wages per employee through December 31, 2020. Additional relief provisions
were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September
30, 2021. Based on these additional provisions, the tax credit is now equal to &lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember__srt--RangeAxis__srt--MaximumMember_zycnb2CGuTx5" title="Tax credit percent"&gt;70&lt;/span&gt;% of qualified wages paid to employees during a quarter,
and the limit on qualified wages per employee has been increased to $&lt;span id="xdx_900_eus-gaap--PaymentsToEmployees_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CARESEmployeeRetentionCreditMember_z78u0QxiVU68" title="Payments to employees wages"&gt;10,000&lt;/span&gt; of qualified wages per quarter. In April 2022, the Company
determined it qualified for the tax credit under the CARES Act and recorded a receivable for $&lt;span id="xdx_90B_ecustom--EmployeeRetentionCredit_c20220401__20220430_zBKsn1N6sBGe" title="Employee retention credit"&gt;229,813&lt;/span&gt; and recognized the amounts as other
income on the statement of operations. The Company received full payment for the amount in September 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <AZTR:RefundableTaxCredit
      contextRef="AsOf2023-12-31_custom_CARESEmployeeRetentionCreditMember"
      decimals="0"
      id="ixv-14970"
      unitRef="USD">5000</AZTR:RefundableTaxCredit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-14971"
      unitRef="Pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:PaymentsToEmployees
      contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember"
      decimals="0"
      id="ixv-14972"
      unitRef="USD">10000</us-gaap:PaymentsToEmployees>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-14973"
      unitRef="Pure">0.70</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:PaymentsToEmployees
      contextRef="From2023-01-012023-12-31_custom_CARESEmployeeRetentionCreditMember"
      decimals="0"
      id="ixv-14974"
      unitRef="USD">10000</us-gaap:PaymentsToEmployees>
    <AZTR:EmployeeRetentionCredit
      contextRef="From2022-04-012022-04-30"
      decimals="0"
      id="ixv-14975"
      unitRef="USD">229813</AZTR:EmployeeRetentionCredit>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9089">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zslLWzaeL29i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.
&lt;span id="xdx_821_z6zNl2UHX9r9"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvzIVcCNTZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zhpgQy9pfYuk" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zNAL2YgfmwE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zIjSyKKYbC0b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zuC6SM2kvHa1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,013,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,034,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVm6VIlXmUW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computers and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd02iNHTOvzk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1lRbxZsED2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znhsWhNZQxMf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Building equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFzA_zDejBdfUkalj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,112,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,133,507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFzA_zqxxiUqswxzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation &amp;amp; amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(401,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(286,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFzA_zQii0gDfTlD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total property, plant, and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;710,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;846,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zGcz3xiuQAn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;4. Property and Equipment (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_90C_eus-gaap--Depreciation_c20230101__20231231_z3s2fT1ANBLd" title="Depreciation expense"&gt;122,010&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20220101__20221231_zJZC3Q4S9AVc" title="Depreciation expense"&gt;120,651&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022 there were losses on disposal of property and equipment recorded of $&lt;span id="xdx_905_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20230101__20231231_z4yIhyN2T153" title="Losses on disposal of property and equipment"&gt;41,417&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_di_c20220101__20221231_zGRV3dcPaiK2" title="Losses on disposal of property and equipment"&gt;7,923&lt;/span&gt;, respectively,
and are included in other income (expense) on the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9095">&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvzIVcCNTZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zhpgQy9pfYuk" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zNAL2YgfmwE5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zIjSyKKYbC0b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zuC6SM2kvHa1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,013,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,034,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVm6VIlXmUW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computers and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zd02iNHTOvzk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1lRbxZsED2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_znhsWhNZQxMf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Building equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFzA_zDejBdfUkalj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,112,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,133,507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFzA_zqxxiUqswxzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation &amp;amp; amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(401,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(286,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFzA_zQii0gDfTlD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total property, plant, and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;710,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;846,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="ixv-14976"
      unitRef="USD">1013134</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="ixv-14977"
      unitRef="USD">1034579</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="ixv-14978"
      unitRef="USD">30825</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="ixv-14979"
      unitRef="USD">30825</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="ixv-14980"
      unitRef="USD">24316</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="ixv-14981"
      unitRef="USD">24316</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="ixv-14982"
      unitRef="USD">28855</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="ixv-14983"
      unitRef="USD">28855</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="ixv-14984"
      unitRef="USD">14932</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="ixv-14985"
      unitRef="USD">14932</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14986"
      unitRef="USD">1112062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14987"
      unitRef="USD">1133507</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14988"
      unitRef="USD">401987</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14989"
      unitRef="USD">286549</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-14990"
      unitRef="USD">710075</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-14991"
      unitRef="USD">846958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14992"
      unitRef="USD">122010</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14993"
      unitRef="USD">120651</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-14994"
      unitRef="USD">-41417</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-14995"
      unitRef="USD">-7923</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9229">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zVdcVEe2kTi6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.
&lt;span id="xdx_82E_zIAL8Gb7y7hl"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zM3kuxjk4HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zxrrCXioz30b" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDbfGwolEBIg" title="Estimated Useful Life"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zy3fFZEzZ4i6" style="width: 9%; text-align: right" title="Gross Amount"&gt;57,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztfG906mrQC5" style="width: 9%; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zS0kweJv22ek" style="width: 9%; text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1FgkZk9Spm" style="width: 9%; text-align: right" title="Net Amount"&gt;57,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziHF1SdrAmua" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zksXf151TqY3" style="text-align: right" title="Gross Amount"&gt;169,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zTz2l95V2Oil" style="text-align: right" title="Accumulated Amortization"&gt;15,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeWgY3CSdip5" style="text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztiUx2PBENf2" style="text-align: right" title="Net Amount"&gt;153,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;License agreement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zClj2XepS3we" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQavO1GiYWxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zFFzyn5mP5Ud" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpW3Pt6wclrf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9vZYtq0A4Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_zVQsw5yPtnz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount"&gt;305,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zRMH75DR6O5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;15,783&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231_zJqlewJv4bIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_ziaQ7SuYurh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount"&gt;210,881&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_90D_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV1YCRMn1jC" title="Estimated Useful Life"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQyNzZsqxFLb" style="width: 9%; text-align: right" title="Gross Amount"&gt;53,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zzP801sPs0a5" style="width: 9%; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zH1tv1jdc154" style="width: 9%; text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zitqpRkuAcJ9" style="width: 9%; text-align: right" title="Net Amount"&gt;53,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zspge0w8Yn3g" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCCQnEujbfj" style="text-align: right" title="Gross Amount"&gt;108,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJgplqHK3zK6" style="text-align: right" title="Accumulated Amortization"&gt;8,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6B2SLwkSvza" style="text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNMXtmTPYg7a" style="text-align: right" title="Net Amount"&gt;100,058&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;License agreement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_znZcSRqWHOJ6" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z7zYmOdIk2i3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount"&gt;65,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zNALvIHma669" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSywPZlK9lof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zdlSqPfJUS27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"&gt;65,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zf2Zzk4pJClh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount"&gt;227,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zB30cLLzzPJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;8,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231_zUDcSeorX2J2" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zEymGA2twQPj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount"&gt;219,567&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zn1DKLlaTTL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, amortization expense related to intangible assets was $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z9eSQ5cwYqp" title="Amortization expenses of intangible assets"&gt;7,643&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zvKGvxYdD9Zj" title="Amortization expenses of intangible assets"&gt;5,234&lt;/span&gt;, respectively. During
the third quarter, the Company recorded an impairment of $&lt;span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_c20230101__20231231_zwA8EYqjk4gk" title="Impairment loss"&gt;78,606&lt;/span&gt; to licensing costs, recorded within general and administrative expenses
on the consolidated statements of operations, as there is uncertainty as to the likelihood of the patent being granted. All subsequent
licensing costs have been expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9235">&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zM3kuxjk4HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zxrrCXioz30b" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDbfGwolEBIg" title="Estimated Useful Life"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zy3fFZEzZ4i6" style="width: 9%; text-align: right" title="Gross Amount"&gt;57,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztfG906mrQC5" style="width: 9%; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zS0kweJv22ek" style="width: 9%; text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1FgkZk9Spm" style="width: 9%; text-align: right" title="Net Amount"&gt;57,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziHF1SdrAmua" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zksXf151TqY3" style="text-align: right" title="Gross Amount"&gt;169,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zTz2l95V2Oil" style="text-align: right" title="Accumulated Amortization"&gt;15,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeWgY3CSdip5" style="text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztiUx2PBENf2" style="text-align: right" title="Net Amount"&gt;153,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;License agreement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zClj2XepS3we" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQavO1GiYWxi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zFFzyn5mP5Ud" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpW3Pt6wclrf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9vZYtq0A4Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_zVQsw5yPtnz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount"&gt;305,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zRMH75DR6O5c" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;15,783&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20230101__20231231_zJqlewJv4bIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"&gt;78,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_ziaQ7SuYurh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount"&gt;210,881&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_90D_ecustom--FiniteLivedIntangibleAssetUsefulLives_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV1YCRMn1jC" title="Estimated Useful Life"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQyNzZsqxFLb" style="width: 9%; text-align: right" title="Gross Amount"&gt;53,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zzP801sPs0a5" style="width: 9%; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zH1tv1jdc154" style="width: 9%; text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zitqpRkuAcJ9" style="width: 9%; text-align: right" title="Net Amount"&gt;53,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zspge0w8Yn3g" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCCQnEujbfj" style="text-align: right" title="Gross Amount"&gt;108,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJgplqHK3zK6" style="text-align: right" title="Accumulated Amortization"&gt;8,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6B2SLwkSvza" style="text-align: right" title="Impairement of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zNMXtmTPYg7a" style="text-align: right" title="Net Amount"&gt;100,058&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;License agreement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_znZcSRqWHOJ6" title="Estimated Useful Life"&gt;17&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z7zYmOdIk2i3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Amount"&gt;65,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zNALvIHma669" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated Amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSywPZlK9lof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zdlSqPfJUS27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Amount"&gt;65,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zf2Zzk4pJClh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Amount"&gt;227,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zB30cLLzzPJa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;8,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--GoodwillAndIntangibleAssetImpairment_c20220101__20221231_zUDcSeorX2J2" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of intangible asset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zEymGA2twQPj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Amount"&gt;219,567&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <AZTR:FiniteLivedIntangibleAssetUsefulLives
      contextRef="From2023-01-012023-12-31_us-gaap_TrademarksMember"
      id="ixv-14996">Indefinite</AZTR:FiniteLivedIntangibleAssetUsefulLives>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="ixv-14997"
      unitRef="USD">57474</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="ixv-14998"
      unitRef="USD">57474</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      id="ixv-14999">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15000"
      unitRef="USD">169190</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15001"
      unitRef="USD">15783</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15002"
      unitRef="USD">153407</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      id="ixv-15003">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="ixv-15004"
      unitRef="USD">78606</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="ixv-15005"
      unitRef="USD">78606</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15006"
      unitRef="USD">305270</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15007"
      unitRef="USD">15783</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15008"
      unitRef="USD">78606</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15009"
      unitRef="USD">210881</us-gaap:FiniteLivedIntangibleAssetsNet>
    <AZTR:FiniteLivedIntangibleAssetUsefulLives
      contextRef="From2022-01-012022-12-31_us-gaap_TrademarksMember"
      id="ixv-15010">Indefinite</AZTR:FiniteLivedIntangibleAssetUsefulLives>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="ixv-15011"
      unitRef="USD">53999</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="ixv-15012"
      unitRef="USD">53999</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      id="ixv-15013">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15014"
      unitRef="USD">108198</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15015"
      unitRef="USD">8140</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="ixv-15016"
      unitRef="USD">100058</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember"
      id="ixv-15017">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="ixv-15018"
      unitRef="USD">65510</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="ixv-15019"
      unitRef="USD">65510</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15020"
      unitRef="USD">227707</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15021"
      unitRef="USD">8140</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15022"
      unitRef="USD">219567</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15023"
      unitRef="USD">7643</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15024"
      unitRef="USD">5234</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15025"
      unitRef="USD">78606</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9471">&lt;p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z0gkRTPy8i7f" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.
&lt;span id="xdx_823_zYTs3kO8NeK4"&gt;Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAYvX5tAdQO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z5Gx6qiSRuXl" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zBRNgjoHnx2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zksyM47zs8Mg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_maALCzSIF_z2R8dtyly0m9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Employee payroll and bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;207,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;371,010&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_maALCzSIF_zbcqAwmeI9x3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedResearchAndDevelopmentProjects_iI_maALCzSIF_zV6cWh29dGqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;316,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestPayableCurrent_iI_maALCzSIF_zNQEbXEkezP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzSIF_z4EFnNrFEoz4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzSIF_zzaR84ou17L9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzSIF_zbJBjtGopUVi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;383,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;993,961&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zJZThjKQ5he6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;6. Accrued Expenses (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and
efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and
non-clinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of
services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services
will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced
any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9477">&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAYvX5tAdQO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z5Gx6qiSRuXl" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zBRNgjoHnx2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zksyM47zs8Mg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedBonusesCurrent_iI_maALCzSIF_z2R8dtyly0m9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Employee payroll and bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;207,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;371,010&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_maALCzSIF_zbcqAwmeI9x3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedResearchAndDevelopmentProjects_iI_maALCzSIF_zV6cWh29dGqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;316,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestPayableCurrent_iI_maALCzSIF_zNQEbXEkezP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzSIF_z4EFnNrFEoz4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzSIF_zzaR84ou17L9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzSIF_zbJBjtGopUVi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;383,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;993,961&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15026"
      unitRef="USD">207556</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15027"
      unitRef="USD">371010</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15028"
      unitRef="USD">31074</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15029"
      unitRef="USD">27082</us-gaap:AccruedVacationCurrent>
    <AZTR:AccruedResearchAndDevelopmentProjects
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15030"
      unitRef="USD">85767</AZTR:AccruedResearchAndDevelopmentProjects>
    <AZTR:AccruedResearchAndDevelopmentProjects
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15031"
      unitRef="USD">316389</AZTR:AccruedResearchAndDevelopmentProjects>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15032"
      unitRef="USD">223792</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15033"
      unitRef="USD">35624</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15034"
      unitRef="USD">24502</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15035"
      unitRef="USD">23647</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15036"
      unitRef="USD">31186</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15037"
      unitRef="USD">383668</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15038"
      unitRef="USD">993961</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9604">&lt;p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zB4NxjGNUwD5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.
&lt;span id="xdx_826_z1Y1bwMuhc82"&gt;Convertible Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zsuFUQHPerUi" title="Convertible promissory note"&gt;2,000,000&lt;/span&gt; of convertible promissory notes. On the
same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for $&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zVyS6HtvEZl9" title="Convertible promissory note"&gt;1,000,000&lt;/span&gt;. The 2021
Convertible Note bears interest at a rate of &lt;span id="xdx_909_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20210105__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zHJjg8kupXyc" title="Bearing interest, percentage"&gt;6&lt;/span&gt;% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note
automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal
and accrued interest divided by the conversion price of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zIE6kvIzX2x3" title="Conversion price per share"&gt;48.00&lt;/span&gt;, which is subject to adjustment as defined in the note agreement. The
2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in
control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of $&lt;span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210105__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zfos0GvtY81e" title="Debt issuance costs"&gt;15,613&lt;/span&gt; related to the 2021 Convertible
Note, which has been recorded as a debt discount and will be amortized over the term of the 2021 Convertible Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zmRQNoH25j6c" title="Convertible promissory note"&gt;4,500,000&lt;/span&gt; convertible
promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors
totaling $&lt;span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwDCSA3ABfW" title="Convertible promissory note"&gt;4,350,000&lt;/span&gt;. The 2022 Convertible Notes mature on &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0vTRnHLAF71" title="Maturity date"&gt;January 13, 2023&lt;/span&gt; or the occurrence of an Event of Default (as defined) and
bear interest at a rate of &lt;span id="xdx_908_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zoHoqlUjg6k8" title="Bearing interest, percentage"&gt;8&lt;/span&gt;% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding
principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of
a Qualified Financing resulting in gross proceeds to the Company of at least $&lt;span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pn6n6_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z0I1sjOfHoIk" title="Gross proceeds"&gt;20&lt;/span&gt; million into securities issued in connection with the
Qualified Financing, at a discount of &lt;span id="xdx_901_ecustom--DebtInstrumentDiscountPercentage_iI_dp_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zmHenJ7sYyod" title="Debt discount, percentage"&gt;30&lt;/span&gt;% per share; b) upon the closing of a Change of Control event into shares of capital stock of
the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued
to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public
offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the
holders, at the maturity date into a new class of Company&#x2019;s Preferred Stock (Series C Preferred) equal to the quotient of the outstanding
principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of $&lt;span id="xdx_90A_eus-gaap--CapitalizationLongtermDebtAndEquity_iI_pn6n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zcedl9DQgwUe" title="Capitalization amount"&gt;30&lt;/span&gt;
million divided by the Company Capitalization, as defined in the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company elected to convert the 2021 Convertible Note, including interest accrued but not yet paid of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSr0jJyHaTK8" title="Interest accrued"&gt;124,759&lt;/span&gt; at a
conversion price of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp0p0_c20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3wCAXeZOA2" title="Conversion price per share"&gt;48.00&lt;/span&gt; into &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0p0_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyblRmCvggv3" title="Issuance of conversion shares"&gt;23,432&lt;/span&gt; shares of its Series B Preferred Stock in accordance with the terms outlined in the Note Purchase
Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2023, the 2022 Convertible Notes were amended to extend the maturity date to&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zY3frpMLGlN1" title="Maturity date"&gt; March 31, 2023&lt;/span&gt; and to change the conversion price
upon a Qualified Financing or Change in Control event to $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn6n6_c20230201__20230228__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zfV9vY8m4tv7" title="Conversion price"&gt;30&lt;/span&gt; million divided by the number of shares of the Company&#x2019;s common stock
issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;7. Convertible Debt (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
April and June 2023, the 2022 Convertible Notes were further amended to extend the maturity date to&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zC791egVMhRe" title="Maturity date"&gt; &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zgKSytheB3v" title="Maturity date"&gt;September 30, 2023&lt;/span&gt;&lt;/span&gt; and allow for
the sale of additional notes of $&lt;span id="xdx_908_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230401__20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zJtomlTHO8R4" title="Sale of additional notes"&gt;&lt;span id="xdx_903_eus-gaap--ProceedsFromSaleOfNotesReceivable_dd_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zvMDubOEXtr6" title="Sale of additional notes"&gt;500,000&lt;/span&gt;&lt;/span&gt; for a total aggregate principal of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230430__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zSKRImPURgTb" title="Aggregate principal"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dd_c20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z2EPv5hSuP65" title="Aggregate principal"&gt;4,850,000&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
June 21, 2023, the 2022 Convertible Notes, including accrued interest of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230601__20230630__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFr6MT17Q612" title="Accrued interest"&gt;265,052&lt;/span&gt;, were converted to &lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_dd_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z34nLXIhKu5g" title="Converted shares"&gt;1,846,020&lt;/span&gt; shares of the Company&#x2019;s
common stock equal to $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_iN_ddi_c20230620__20230621__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z6puenIbVVSe" title="Conversion of convertible notes payable"&gt;9,495,072&lt;/span&gt;. Upon conversion, the Company recorded a change in fair value of $&lt;span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20230101__20231231_zx8NOxYGl8Fi" title="Change in fair value of convertible note"&gt;3,630,100&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--ChangeInFairValueOfConvertibleNote_iN_di_c20220101__20221231_ze9bQ2dD0vuc" title="Change in fair value of convertible note"&gt;1,250,000&lt;/span&gt; for the years
ended December 31, 2023 and 2022, respectively, which was recognized as a non-cash change in fair value in Other Income (Expense) on
the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the
accounting considerations under ASC 480 &#x2013; Distinguishing Liabilities from Equity, and ASC 815 &#x2013; Derivatives and Hedging.
The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company
also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria
for bifurcation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zbwDcoZihTbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
notes payable consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zwa2WTYnxfB9" style="display: none"&gt;Schedule of Convertible
Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;2021 Convertible Note&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zQAWEoHtTA06" style="width: 16%; text-align: right" title="Convertible notes payable"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zG8PFsoAyOz1" style="width: 16%; text-align: right" title="Convertible notes payable"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z9Ve8MgvcpP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwROubSS7hKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231_zCulOaH45P72" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231_z52LDFTUSHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable, net"&gt;6,600,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zXilFwMjPPMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
expense was $&lt;span id="xdx_900_eus-gaap--InterestAndDebtExpense_c20230101__20231231_zShQKNn3X0g6" title="Interest expense"&gt;166,019&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestAndDebtExpense_c20220101__20221231_z4N6Q1pyAnAa" title="Interest expense"&gt;172,592&lt;/span&gt; and included debt issuances costs of $&lt;span id="xdx_902_eus-gaap--DeferredFinanceCostsGross_iI_c20231231_zmHfnCGKve5a" title="Debt issuances costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DeferredFinanceCostsGross_iI_c20221231_zLdkGoflxCTe" title="Debt issuances costs"&gt;7,981&lt;/span&gt; during the years ended December 31, 2023 and 2022,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember"
      decimals="0"
      id="ixv-15039"
      unitRef="USD">2000000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember"
      decimals="0"
      id="ixv-15040"
      unitRef="USD">1000000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2021-01-05_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyOneConvertibleNotesMember"
      decimals="INF"
      id="ixv-15041"
      unitRef="Pure">0.06</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember"
      decimals="INF"
      id="ixv-15042"
      unitRef="USDPShares">48.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2021-01-05_custom_TwentyTwentyOneConvertibleNotesMember"
      decimals="0"
      id="ixv-15043"
      unitRef="USD">15613</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember"
      decimals="0"
      id="ixv-15044"
      unitRef="USD">4500000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15045"
      unitRef="USD">4350000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      id="ixv-15046">2023-01-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="ixv-15047"
      unitRef="Pure">0.08</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-09-012022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="-6"
      id="ixv-15048"
      unitRef="USD">20000000</us-gaap:ProceedsFromConvertibleDebt>
    <AZTR:DebtInstrumentDiscountPercentage
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="ixv-15049"
      unitRef="Pure">0.30</AZTR:DebtInstrumentDiscountPercentage>
    <us-gaap:CapitalizationLongtermDebtAndEquity
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="-6"
      id="ixv-15050"
      unitRef="USD">30000000</us-gaap:CapitalizationLongtermDebtAndEquity>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="ixv-15051"
      unitRef="USD">124759</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="ixv-15052"
      unitRef="USDPShares">48.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_TwentyTwentyOneConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="ixv-15053"
      unitRef="Shares">23432</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember"
      id="ixv-15054">2023-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="-6"
      id="ixv-15055"
      unitRef="USD">30000000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      id="ixv-15056">2023-09-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      id="ixv-15057">2023-09-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2023-04-012023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15058"
      unitRef="USD">500000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15059"
      unitRef="USD">500000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-04-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15060"
      unitRef="USD">4850000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15061"
      unitRef="USD">4850000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-06-012023-06-30_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15062"
      unitRef="USD">265052</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="ixv-15063"
      unitRef="Shares">1846020</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-06-202023-06-21_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15064"
      unitRef="USD">-9495072</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15065"
      unitRef="USD">-3630100</AZTR:ChangeInFairValueOfConvertibleNote>
    <AZTR:ChangeInFairValueOfConvertibleNote
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15066"
      unitRef="USD">-1250000</AZTR:ChangeInFairValueOfConvertibleNote>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9691">&lt;p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zbwDcoZihTbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
notes payable consisted of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zwa2WTYnxfB9" style="display: none"&gt;Schedule of Convertible
Notes Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;2021 Convertible Note&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zQAWEoHtTA06" style="width: 16%; text-align: right" title="Convertible notes payable"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyOneConvertibleNotesMember_zG8PFsoAyOz1" style="width: 16%; text-align: right" title="Convertible notes payable"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_z9Ve8MgvcpP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zwROubSS7hKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes payable"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231_zCulOaH45P72" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231_z52LDFTUSHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible notes payable, net"&gt;6,600,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31_custom_TwentyTwentyOneConvertibleNotesMember"
      decimals="0"
      id="ixv-15067"
      unitRef="USD">1000000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15068"
      unitRef="USD">5600000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15069"
      unitRef="USD">6600000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15070"
      unitRef="USD">166019</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15071"
      unitRef="USD">172592</us-gaap:InterestAndDebtExpense>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15072"
      unitRef="USD">0</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15073"
      unitRef="USD">7981</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9749">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfmmAZWhREfd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.
&lt;span id="xdx_82B_zVMTzpFF7aa2"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 17, 2023, the Company effected a &lt;span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20230516__20230517_zMYfgkr4HJqd" title="Forward stock split"&gt;7.1-for-1 forward stock split&lt;/span&gt; (the &#x201c;Forward Stock Split&#x201d;) of its issued and outstanding
shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#x2019;s preferred
stock. The par value of the common stock was adjusted as a result of the Forward Stock Split from $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230517__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zXVQFmTN3KL" title="Common stock, par value per share"&gt;0.01&lt;/span&gt; to $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_zckVq9mHkygl" title="Common stock, par value per share"&gt;0.0001&lt;/span&gt; and the authorized
shares were increased to &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--AwardTypeAxis__custom--ForwardStockSplitMember_z0wIOsHVc0Rc" title="Common stock shares authorized in connection with forward stock split"&gt;100,000,000&lt;/span&gt; shares of common stock in connection with the Forward Stock Split. Fractional shares resulting
from the Forward Stock Split were rounded down to the next whole share and in lieu of any fractional shares the Company will pay a cash
amount to the holder of such fractional shares. The accompanying financial statements and notes to the financial statements give retroactive
effect to the Forward Stock Split for all periods presented. Shares of common stock underlying outstanding stock-based awards and other
equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately
decreased in accordance with the terms of the agreements governing such securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, per the Company&#x2019;s amended and restated Certificate of Incorporation, the Company was authorized to
issue &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zBjt3kSc1eV6" title="Common stock shares authorized"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNjdTzKwbSeg" title="Common stock shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zd9xYndwQNKj" title="Common stock, par value per share"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zneYIyPgWZQ5" title="Common stock, par value per share"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockVotingRights_c20230101__20231231_zJzVE0wEGHr7" title="Common stock voting rights description"&gt;Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zEMOAyWLcmDf" title="Common stock shares reserved for future issuance"&gt;1,611,991&lt;/span&gt; shares of common stock reserved for future issuance for the potential exercise of stock options and warrants
outstanding at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;8. Stockholders&#x2019; Equity (continued)&lt;/p&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preferred
Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, per the Company&#x2019;s amended and restated Certificate of Incorporation, the Company has authorized &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zFe6uTMidezb" title="Preferred stock shares authorized"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zanALIvFt061" title="Preferred stock shares authorized"&gt;1,437,150&lt;/span&gt;&lt;/span&gt;
shares of $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zt3kncZx0Ota" title="Preferred stock, par value per share"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zQT3TikYGNx9" title="Preferred stock, par value per share"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company issued &lt;span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zVVnUOzsR8pa" title="Convertible preferred stock shares issued"&gt;23,432&lt;/span&gt; shares of its Series B Preferred Stock related to conversion of the 2021 Convertible Note at
a conversion price of $&lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneConvertibleNoteMember_zjLtM0FCi1jb" title="Convertible preferred stock conversion price per share"&gt;48.00&lt;/span&gt; per share (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A, Series A-1, and Series B Preferred Stock had the following rights, preferences and privileges :&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversion&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preferred stock was converted, at the option of the holder, into common shares based upon a predefined formula. The holders of preferred
stock converted such shares into common shares upon the Company&#x2019;s IPO. For purpose of conversion, the initial conversion price
was $&lt;span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7WmJ8tNwJmh" title="Original issue price per share of series A preferred stock"&gt;16.25&lt;/span&gt; per share (original issue price) for Series A Preferred Stock, $&lt;span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zbKyqBCcOQ3d" title="Original issue price per share of series A-1 preferred stock"&gt;37.50&lt;/span&gt; per share (original issue price) for Series A-1 Preferred
Stock, and $&lt;span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7BoPie7HAK5" title="Original issue price per share of series B preferred stock"&gt;43.45&lt;/span&gt; per share (original issue price) for Series B Preferred Stock, and was subject to adjustment as described in the Certificate
of Incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Company&#x2019;s IPO in June 2023, all of the outstanding preferred stock converted to common stock, resulting in the issuance of
&lt;span id="xdx_900_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqmhSe3ZQBh6" title="Convertible series A preferred stock shares issued"&gt;1,458,233&lt;/span&gt;, &lt;span id="xdx_90C_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFRdpE43WVj4" title="Convertible series A-1 preferred stock shares issued"&gt;2,964,849&lt;/span&gt;, and &lt;span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zJMxbiTAyI5c" title="Convertible series B preferred stock shares issued"&gt;3,284,553&lt;/span&gt; shares of common stock in exchange for outstanding Series A, Series A-1, and Series B Preferred Stock,
respectively. There was no gain or loss upon conversion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Voting
Rights&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of the Series A, Series A-1, and Series B Preferred Stock were entitled to vote on any matter presented to the stockholders of
the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of preferred stock was entitled to cast the number of votes equal to the number
of whole shares of Common Stock into which the shares of preferred stock held by such holder converted as of the record date for determining
stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock were each entitled to elect
one director of the Corporation. The holders of the Series B Stock were entitled to elect two members of the Board. Each class of preferred
stock could have removed such directors from office and to fill any vacancy caused by the resignation, death or removal of such directors
under certain circumstances as described in the Certificate of Incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A Preferred Stock were entitled to receive dividends at a rate of &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLw0zrVdj0B2" title="Dividend percentage on series A preferred stock"&gt;8&lt;/span&gt;% per annum of the Series A original issue price
of $&lt;span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znVMn8l6vnl5" title="Original issue price per share of series A preferred stock"&gt;16.25&lt;/span&gt; per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends accumulated
from the original date of issuance of the Series A Preferred Stock, were cumulative and were payable upon declaration of the Board of
Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series A Preferred Stock as there
was no longer any Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A-1 Stock were entitled to receive dividends at a rate of &lt;span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_ztBd3BNB8Gu4" title="Dividend percentage on series A-1 preferred stock"&gt;8&lt;/span&gt;% per annum of the Series A-1 original issue price of $&lt;span id="xdx_902_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesA1PreferredStockMember_zzkCvOlJPWl3" title="Original issue price per share of series A-1 preferred stock"&gt;37.50&lt;/span&gt;
per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends were cumulative and were payable
upon declaration of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on
Series A-1 Preferred Stock as there was no longer any Series A-1 Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;8. Stockholders&#x2019; Equity (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series B Stock were entitled to receive dividends at a rate of &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaVJD4xCAc8j" title="Dividend percentage on series B preferred stock"&gt;8&lt;/span&gt;% per annum of the Series B original issue price of $&lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zH19oPIj8Ws8" title="Original issue price per share of series B preferred stock"&gt;43.45&lt;/span&gt;
per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to the Series B Preferred Stock). Dividends were cumulative and were payable upon declaration
of the Board of Directors or liquidation of the Company. At December 31, 2023, there were no cumulative dividends on Series B Preferred
Stock as there was no longer any Series B Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock were entitled to receive,
prior to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock
original issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment
of all preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation
available for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock,
pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted
into Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-05-162023-05-17" id="ixv-15074">7.1-for-1 forward stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-17_custom_ForwardStockSplitMember"
      decimals="INF"
      id="ixv-15075"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ForwardStockSplitMember"
      decimals="INF"
      id="ixv-15076"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ForwardStockSplitMember"
      decimals="INF"
      id="ixv-15077"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15078"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15079"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15080"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15081"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="From2023-01-01to2023-12-31" id="ixv-15082">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15083"
      unitRef="Shares">1611991</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15084"
      unitRef="Shares">1437150</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15085"
      unitRef="Shares">1437150</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15086"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15087"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember"
      decimals="INF"
      id="ixv-15088"
      unitRef="Shares">23432</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyOneConvertibleNoteMember"
      decimals="INF"
      id="ixv-15089"
      unitRef="USDPShares">48.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-15090"
      unitRef="USDPShares">16.25</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-01-31_custom_SeriesA1PreferredStockMember"
      decimals="INF"
      id="ixv-15091"
      unitRef="USDPShares">37.50</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-15092"
      unitRef="USDPShares">43.45</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="ixv-15093"
      unitRef="Shares">1458233</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_custom_SeriesA1PreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="ixv-15094"
      unitRef="Shares">2964849</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="ixv-15095"
      unitRef="Shares">3284553</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-15096"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-15097"
      unitRef="USDPShares">16.25</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember"
      decimals="INF"
      id="ixv-15098"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="From2023-01-012023-12-31_custom_SeriesA1PreferredStockMember"
      decimals="INF"
      id="ixv-15099"
      unitRef="USDPShares">37.50</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-15100"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-15101"
      unitRef="USDPShares">43.45</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <AZTR:WarrantsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9913">&lt;p id="xdx_80D_ecustom--WarrantsTextBlock_z7ZL09p17T2i" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.
&lt;span id="xdx_828_zNloBHkOS3R8"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued warrants to purchase &lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl8FR2llnrmh" title="Number of warrants issued to purchase common stock"&gt;6,745&lt;/span&gt; shares of common stock in 2018 in conjunction with convertible debt financing that have a redemption
provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it has converted into)
at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent appraiser.
As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based on ASC 480
&#x2013; Distinguishing Liabilities from Equity. These warrants have an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zGUeVATmqlV2" title="Exercise price of warrants per share"&gt;0.48&lt;/span&gt; per share and a term of &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zVNTfymJH4qc" title="Maturity term"&gt;10&lt;/span&gt; years. The
warrants are marked to market each reporting period. The fair value is $&lt;span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znlBQpdkEen9" title="Fair value of warrants"&gt;35,453&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3p8YgMIYdDl" title="Fair value of warrants"&gt;70,283&lt;/span&gt; at December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead
meet equity classification criteria. The &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsZMXNdQLIKh" title="Number of warrants issued"&gt;11,466&lt;/span&gt; warrants issued in 2016 had a weighed average exercise price of $&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpW4FIoFM0d3" title="Weighed average exercise price"&gt;0.01&lt;/span&gt; and a weighted
average term of &lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm_dtY_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkfifuOkytud" title="Weighted average term"&gt;9.7&lt;/span&gt; years and expired upon the initial public offering in June 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQBju39i6ktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about warrants outstanding at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zPZXVjgU03Q2" style="display: none"&gt;Schedule
of Information about Warrants Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants at 12/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants at 12/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zkCdwpqzeEc" style="width: 9%; text-align: right" title="Exercise price of warrants"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zqwmz86hzsfi" style="width: 9%; text-align: right" title="Number of warrants outstanding"&gt;47,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zZQB7cZI9yQd" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDzgr0Jg8Ltd" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_ziu9fUMDi1jc" style="width: 9%; text-align: right" title="Number of warrants exercisable"&gt;47,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zFum6EmXhFEc" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDZIfgEPrF4g" title="Weighted Average Exercise Price, Exercisable"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zp59YIvl2e7l" style="text-align: right" title="Exercise price of warrants"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zI69yuzjnSla" style="text-align: right" title="Number of warrants outstanding"&gt;215,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zlnYOwUWtjh6" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;2.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zIDZkPocI7ah" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zRxszl8YDn92" style="text-align: right" title="Number of warrants exercisable"&gt;215,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zO4D9DbLSszc" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;2.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zYZ23YLUv4n5" title="Weighted Average Exercise Price, Exercisable"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zoUrwgmKzUhk" style="padding-bottom: 1.5pt; text-align: right" title="Exercise price of warrants"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zyvRh2JSCFQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zt1XkaHM9rfl" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;4.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zh8jG0wWUC5k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zAJs7XeX8rM4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_ztKvjweQ94Y1" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;4.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zCfJMwwPkhC2" title="Weighted Average Exercise Price, Exercisable"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7xK4duS2j36" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRNfZFq6smlb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;4.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBz0QE0X97Hb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxcQjjPXULUg" title="Weighted Average Exercise Price, Exercisable"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zSFicp98Qbg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</AZTR:WarrantsTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15102"
      unitRef="Shares">6745</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15103"
      unitRef="USDPShares">0.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-12-31" id="ixv-15104">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="ixv-15105"
      unitRef="USD">35453</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="ixv-15106"
      unitRef="USD">70283</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-15107"
      unitRef="Shares">11466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-15108"
      unitRef="USDPShares">0.01</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <AZTR:SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm
      contextRef="From2023-01-012023-12-31_us-gaap_IPOMember_us-gaap_WarrantMember"
      id="ixv-15109">P9Y8M12D</AZTR:SharebasedCompensationArrangementBySharebasedPaymentNonOptionsWeightedAverageTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-9935">&lt;p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQBju39i6ktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about warrants outstanding at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zPZXVjgU03Q2" style="display: none"&gt;Schedule
of Information about Warrants Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants at 12/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants at 12/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2018&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zkCdwpqzeEc" style="width: 9%; text-align: right" title="Exercise price of warrants"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zqwmz86hzsfi" style="width: 9%; text-align: right" title="Number of warrants outstanding"&gt;47,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zZQB7cZI9yQd" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDzgr0Jg8Ltd" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_ziu9fUMDi1jc" style="width: 9%; text-align: right" title="Number of warrants exercisable"&gt;47,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zFum6EmXhFEc" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;4.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandEighteenMember_zDZIfgEPrF4g" title="Weighted Average Exercise Price, Exercisable"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zp59YIvl2e7l" style="text-align: right" title="Exercise price of warrants"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zI69yuzjnSla" style="text-align: right" title="Number of warrants outstanding"&gt;215,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zlnYOwUWtjh6" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;2.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zIDZkPocI7ah" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zRxszl8YDn92" style="text-align: right" title="Number of warrants exercisable"&gt;215,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zO4D9DbLSszc" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;2.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandNineteenMember_zYZ23YLUv4n5" title="Weighted Average Exercise Price, Exercisable"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zoUrwgmKzUhk" style="padding-bottom: 1.5pt; text-align: right" title="Exercise price of warrants"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zyvRh2JSCFQf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zt1XkaHM9rfl" title="Weighted Average Remaining Contractual Life, Outstanding"&gt;4.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zh8jG0wWUC5k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;6.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zAJs7XeX8rM4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_ztKvjweQ94Y1" title="Weighted Average Remaining Contractual Life, Exercisable"&gt;4.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--AwardDateAxis__custom--YearTwoThousandTwentyThreeMember_zCfJMwwPkhC2" title="Weighted Average Exercise Price, Exercisable"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7xK4duS2j36" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRNfZFq6smlb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;4.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBz0QE0X97Hb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxcQjjPXULUg" title="Weighted Average Exercise Price, Exercisable"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_YearTwoThousandEighteenMember"
      decimals="INF"
      id="ixv-15110"
      unitRef="USDPShares">0.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      decimals="INF"
      id="ixv-15111"
      unitRef="Shares">47890</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      id="ixv-15112">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      decimals="INF"
      id="ixv-15113"
      unitRef="USDPShares">0.48</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      decimals="INF"
      id="ixv-15114"
      unitRef="Shares">47890</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      id="ixv-15115">P4Y6M</AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandEighteenMember"
      decimals="INF"
      id="ixv-15116"
      unitRef="USDPShares">0.48</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_YearTwoThousandNineteenMember"
      decimals="INF"
      id="ixv-15117"
      unitRef="USDPShares">5.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      decimals="INF"
      id="ixv-15118"
      unitRef="Shares">215846</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      id="ixv-15119">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      decimals="INF"
      id="ixv-15120"
      unitRef="USDPShares">5.28</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      decimals="INF"
      id="ixv-15121"
      unitRef="Shares">215846</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      id="ixv-15122">P2Y4M24D</AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandNineteenMember"
      decimals="INF"
      id="ixv-15123"
      unitRef="USDPShares">5.28</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_YearTwoThousandTwentyThreeMember"
      decimals="INF"
      id="ixv-15124"
      unitRef="USDPShares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      decimals="INF"
      id="ixv-15125"
      unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      id="ixv-15126">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      decimals="INF"
      id="ixv-15127"
      unitRef="USDPShares">6.25</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      decimals="INF"
      id="ixv-15128"
      unitRef="Shares">60000</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      id="ixv-15129">P4Y8M12D</AZTR:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_YearTwoThousandTwentyThreeMember"
      decimals="INF"
      id="ixv-15130"
      unitRef="USDPShares">6.25</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734"
      decimals="INF"
      id="ixv-15131"
      unitRef="Shares">323736</us-gaap:ClassOfWarrantOrRightOutstanding>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-15132"
      unitRef="USDPShares">4.75</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734"
      decimals="INF"
      id="ixv-15133"
      unitRef="Shares">323736</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember101770734"
      decimals="INF"
      id="ixv-15134"
      unitRef="USDPShares">4.75</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:FairValueOptionTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10146">&lt;p id="xdx_80F_eus-gaap--FairValueOptionTextBlock_ztthSgv6sYdb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.
&lt;span id="xdx_820_zvYjWmmeT4s2"&gt;Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023, the Company&#x2019;s Board of Directors and stockholders approved the 2023 Stock Incentive Plan (&#x201c;2023 Plan&#x201d;).
The 2023 Plan allows the Committee to grant up to &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230301__20230331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzPMcaWcSdL"&gt;2,000,000&lt;/span&gt; shares of Common Stock in the form of incentive and non-statutory stock options,
restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and non-employees. As of December
31, 2023, options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEeOuRQC5yHj" title="Stock options granted"&gt;40,000&lt;/span&gt; shares of common stock had been granted and were outstanding under the 2023 Plan and &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEtzj3orjm1" title="Stock options available for grants"&gt;1,960,000&lt;/span&gt; shares
of common stock were available for grant under the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2016, the Company established the Azitra Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options and
restricted shares to the Company&#x2019;s employees, officers, directors, advisors and consultants. As of December 31, 2023, options to
purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD9scnGAjqX3" title="Stock options granted"&gt;1,248,255&lt;/span&gt; shares of common stock had been granted and were outstanding under the 2016 Plan and &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CfoIW3sj06" title="Stock options available for grants"&gt;242,340&lt;/span&gt; shares of common stock
were available for grant under the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recognized stock compensation expense of $&lt;span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgh4WNwNWMni" title="Stock compensation expense"&gt;125,555&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--StockOptionPlanExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFuIFefi7ape" title="Stock compensation expense"&gt;25,950&lt;/span&gt;, included in general and
administrative and research and development on the accompanying statement of operations, respectively. During the year ended December
31, 2022, the Company recognized stock compensation expense of $&lt;span id="xdx_90B_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZdNmpXreBda" title="Stock compensation expense"&gt;131,185&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--StockOptionPlanExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRjfKE3yoZE5" title="Stock compensation expense"&gt;53,280&lt;/span&gt;, included in general and administrative and research
and development on the accompanying statement of operations, respectively, relating to the issuance of service-based stock options. At
December 31, 2023, there was $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQWLNqwXgBUl" title="Performance stock options shares"&gt;326,438&lt;/span&gt; of unamortized compensation expense that will be amortized over a remaining weighted-average period
for the 2016 Plan and 2023 Plan of approximately &lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zt124Q1nIaK8" title="Weighted average period"&gt;1.32&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember_zRIjwwgBicja" title="Weighted average period"&gt;3.58&lt;/span&gt; years, respectively. At December 31, 2023 and 2022, there were &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z9dtWmEXgX76" title="Number of stock options outstanding"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNNUGhdowyf4" title="Number of stock options outstanding"&gt;13,120&lt;/span&gt;&lt;/span&gt;
performance-based options outstanding with a fair value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5EfcXfS8wZ6" title="Fair value of stock options"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDliqpi9yO6" title="Fair value of stock options"&gt;109,551&lt;/span&gt;&lt;/span&gt;. During the years ended December 31, 2023 and 2022, the Company did
not recognize any compensation expense for performance-based options. The Company determined the options qualified as plain vanilla under
the provisions of SAB 107 and the simplified method was used to estimate the expected option life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_z0IW86DeXVh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about options outstanding and exercisable at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zIyC4GBKAWC3" style="display: none"&gt;Schedule of Information about Options Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_z8alUhhaGHvf" style="width: 11%; text-align: right" title="Number of options exercise price"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zxyowzgtjtj" style="width: 11%; text-align: right" title="Number of options outstanding"&gt;246,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR3Ann5Ixp79" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zt9pjLBKdbci" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zo8WiVuiKYZ7" style="width: 10%; text-align: right" title="Number of options exercisable"&gt;246,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zYT3Df1fOJ71" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR9c35belXWj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_z230LJtrVUte" style="text-align: right" title="Number of options exercise price"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zG1uZTAAOHKi" style="text-align: right" title="Number of options outstanding"&gt;202,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEpD9VstCDi4" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zTBl3sDX1S83" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEz0aNcZOps9" style="text-align: right" title="Number of options exercisable"&gt;202,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zaBAK7ymcR3" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zebXAPfhb2Qj" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNplBbt1s6i" style="text-align: right" title="Number of options exercise price"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zjdmUFeW7k" style="text-align: right" title="Number of options outstanding"&gt;800,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNyXrER7XRx2" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;7.3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zQpwkXxVK3rf" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zTTtxALwWwpl" style="text-align: right" title="Number of options exercisable"&gt;572,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zhRU9mi8Ph2b" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;7.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zu2hHQ7pyKbi" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_ziJR95ZKgtO6" style="padding-bottom: 1.5pt; text-align: right" title="Number of options exercise price"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zmQXbPGAObYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding"&gt;40,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zSRjIM5YVT7h" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;9.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zinJOCaNbm2l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_z7fmXVkMUUQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable"&gt;4,167&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zNrZYLH8kxX3" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;9.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zg0wp74KBlKi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zurrTuXFjww2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;1,288,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z5EguCpa9YGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;1,025,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zsBU4Knl9oV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znzMZ8DIaDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
stock option activity for the year ended December 31, 2023, is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z8jQ1C39P195" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zSNcOmTFKIEk" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning"&gt;1,381,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zugnGEAh2Rc4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zC3Aneb4tN5i" style="text-align: right" title="Number of Options, Exercised"&gt;(888&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zCIG5MDvbj1e" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_zesRlD2lIsAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(90,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zL7rTaF8BFSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;5.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zV4J4DYMImTi" style="text-align: right" title="Number of Options, Outstanding Beginning"&gt;1,290,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_z0zusWSFR2l4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zyVwOyA2CMY9" style="text-align: right" title="Number of Options, Granted"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zEW8hL496vA8" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zUM7hFyG2jj2" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zXJUrtb9U9Y5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zi0Q53h4PbQ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(42,063&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zxDSVZ0EUXHg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;0.87&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z2xIL8GpDF76" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending"&gt;1,288,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOGJvImz7sfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z6oqf11p9Ps7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;10. Stock Options (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBKxZCmf8BQh" title="Shares available for future grant"&gt;242,340&lt;/span&gt; shares available for future grant under the 2016 Plan and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeStockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z83BldKcWmz4" title="Shares available for future grant"&gt;1,960,000&lt;/span&gt; available under the 2023 Plan at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_zh1YyAYYvNZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
intrinsic value for the 2016 plan for the year ended December 31, 2023, is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zyUPIhhTgClk" style="display: none"&gt;Schedule of Total Intrinsic Value&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Value of Stock at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zrkBRiqqQy2i" style="width: 16%; text-align: right" title="Options Outstanding Value of Stock"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OptionsExcercisableSharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zOoksrDCpKWd" style="width: 16%; text-align: right" title="Options Exercisable Value of Stock"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zb8PSyGiExx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Exercise Price"&gt;0.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zNQKltQxeIx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable Exercise Price"&gt;0.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Intrinsic Value Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zEuooQLcCDTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Intrinsic Value Per Share"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z78JkwIjJ5Yg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Excercisable Intrinsic Value Per Share"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options O/S&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zyBSUf7Rfjac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding"&gt;246,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z2BQQGDGzlWh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable"&gt;246,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Intrinsic Value at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zPFMR5g23Ftb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Intrinsic Value"&gt;108,300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z6O0lcqKxIFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable Intrinsic Value"&gt;108,300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zh8qcwh0tcE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOptionTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15135"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15136"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15137"
      unitRef="Shares">1960000</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15138"
      unitRef="Shares">1248255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod
      contextRef="From2023-01-012023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15139"
      unitRef="Shares">242340</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsPeriod>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-15140"
      unitRef="USD">125555</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="ixv-15141"
      unitRef="USD">25950</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="ixv-15142"
      unitRef="USD">131185</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="ixv-15143"
      unitRef="USD">53280</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ixv-15144"
      unitRef="Shares">326438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandSixteenStockIncentivePlanMember"
      id="ixv-15145">P1Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember_custom_TwoThousandTwentyThreeStockIncentivePlanMember"
      id="ixv-15146">P3Y6M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ixv-15147"
      unitRef="Shares">13120</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ixv-15148"
      unitRef="Shares">13120</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="ixv-15149"
      unitRef="USD">109551</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="ixv-15150"
      unitRef="USD">109551</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10180">&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_z0IW86DeXVh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about options outstanding and exercisable at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zIyC4GBKAWC3" style="display: none"&gt;Schedule of Information about Options Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weight Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_z8alUhhaGHvf" style="width: 11%; text-align: right" title="Number of options exercise price"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zxyowzgtjtj" style="width: 11%; text-align: right" title="Number of options outstanding"&gt;246,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR3Ann5Ixp79" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zt9pjLBKdbci" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zo8WiVuiKYZ7" style="width: 10%; text-align: right" title="Number of options exercisable"&gt;246,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zYT3Df1fOJ71" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionOneMember_zR9c35belXWj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;0.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_z230LJtrVUte" style="text-align: right" title="Number of options exercise price"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zG1uZTAAOHKi" style="text-align: right" title="Number of options outstanding"&gt;202,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEpD9VstCDi4" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zTBl3sDX1S83" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zEz0aNcZOps9" style="text-align: right" title="Number of options exercisable"&gt;202,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zaBAK7ymcR3" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;2.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionTwoMember_zebXAPfhb2Qj" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNplBbt1s6i" style="text-align: right" title="Number of options exercise price"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zjdmUFeW7k" style="text-align: right" title="Number of options outstanding"&gt;800,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zNyXrER7XRx2" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;7.3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zQpwkXxVK3rf" style="text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zTTtxALwWwpl" style="text-align: right" title="Number of options exercisable"&gt;572,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zhRU9mi8Ph2b" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;7.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionThreeMember_zu2hHQ7pyKbi" style="text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_ziJR95ZKgtO6" style="padding-bottom: 1.5pt; text-align: right" title="Number of options exercise price"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zmQXbPGAObYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding"&gt;40,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zSRjIM5YVT7h" title="Weighted Average Remaining Contractual Life, Options outstanding"&gt;9.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zinJOCaNbm2l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_z7fmXVkMUUQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable"&gt;4,167&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zNrZYLH8kxX3" title="Weighted Average Remaining Contractual Life, Options exercisable"&gt;9.7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--StockOptionFourMember_zg0wp74KBlKi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;2.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zurrTuXFjww2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;1,288,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z5EguCpa9YGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;1,025,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_StockOptionOneMember"
      decimals="INF"
      id="ixv-15151"
      unitRef="USDPShares">0.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionOneMember"
      decimals="INF"
      id="ixv-15152"
      unitRef="Shares">246137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionOneMember"
      id="ixv-15153">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-12-31_custom_StockOptionOneMember"
      decimals="INF"
      id="ixv-15154"
      unitRef="USDPShares">0.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_StockOptionOneMember"
      decimals="INF"
      id="ixv-15155"
      unitRef="Shares">246137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_StockOptionOneMember"
      id="ixv-15156">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionOneMember"
      decimals="INF"
      id="ixv-15157"
      unitRef="USDPShares">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_StockOptionTwoMember"
      decimals="INF"
      id="ixv-15158"
      unitRef="USDPShares">0.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionTwoMember"
      decimals="INF"
      id="ixv-15159"
      unitRef="Shares">202040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionTwoMember"
      id="ixv-15160">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-12-31_custom_StockOptionTwoMember"
      decimals="INF"
      id="ixv-15161"
      unitRef="USDPShares">0.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_StockOptionTwoMember"
      decimals="INF"
      id="ixv-15162"
      unitRef="Shares">202036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_StockOptionTwoMember"
      id="ixv-15163">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionTwoMember"
      decimals="INF"
      id="ixv-15164"
      unitRef="USDPShares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_StockOptionThreeMember"
      decimals="INF"
      id="ixv-15165"
      unitRef="USDPShares">1.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionThreeMember"
      decimals="INF"
      id="ixv-15166"
      unitRef="Shares">800078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionThreeMember"
      id="ixv-15167">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-12-31_custom_StockOptionThreeMember"
      decimals="INF"
      id="ixv-15168"
      unitRef="USDPShares">1.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_StockOptionThreeMember"
      decimals="INF"
      id="ixv-15169"
      unitRef="Shares">572968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_StockOptionThreeMember"
      id="ixv-15170">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionThreeMember"
      decimals="INF"
      id="ixv-15171"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_StockOptionFourMember"
      decimals="INF"
      id="ixv-15172"
      unitRef="USDPShares">2.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionFourMember"
      decimals="INF"
      id="ixv-15173"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionFourMember"
      id="ixv-15174">P9Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-12-31_custom_StockOptionFourMember"
      decimals="INF"
      id="ixv-15175"
      unitRef="USDPShares">2.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_StockOptionFourMember"
      decimals="INF"
      id="ixv-15176"
      unitRef="Shares">4167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_StockOptionFourMember"
      id="ixv-15177">P9Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionFourMember"
      decimals="INF"
      id="ixv-15178"
      unitRef="USDPShares">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15179"
      unitRef="Shares">1288255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15180"
      unitRef="Shares">1025308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10375">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znzMZ8DIaDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
stock option activity for the year ended December 31, 2023, is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z8jQ1C39P195" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zSNcOmTFKIEk" style="width: 16%; text-align: right" title="Number of Options, Outstanding Beginning"&gt;1,381,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zugnGEAh2Rc4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zC3Aneb4tN5i" style="text-align: right" title="Number of Options, Exercised"&gt;(888&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zCIG5MDvbj1e" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_zesRlD2lIsAe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(90,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zL7rTaF8BFSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;5.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zV4J4DYMImTi" style="text-align: right" title="Number of Options, Outstanding Beginning"&gt;1,290,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_z0zusWSFR2l4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zyVwOyA2CMY9" style="text-align: right" title="Number of Options, Granted"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zEW8hL496vA8" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zUM7hFyG2jj2" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zXJUrtb9U9Y5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231_zi0Q53h4PbQ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(42,063&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zxDSVZ0EUXHg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;0.87&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_z2xIL8GpDF76" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding Ending"&gt;1,288,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOGJvImz7sfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;1.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="ixv-15181"
      unitRef="Shares">1381908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="ixv-15182"
      unitRef="USDPShares">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15183"
      unitRef="Shares">888</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15184"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15185"
      unitRef="Shares">90702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15186"
      unitRef="USDPShares">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15187"
      unitRef="Shares">1290318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15188"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15189"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15190"
      unitRef="USDPShares">2.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15191"
      unitRef="Shares">42063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15192"
      unitRef="USDPShares">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15193"
      unitRef="Shares">1288255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15194"
      unitRef="USDPShares">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15195"
      unitRef="Shares">242340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeStockIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15196"
      unitRef="Shares">1960000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10505">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_zh1YyAYYvNZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
intrinsic value for the 2016 plan for the year ended December 31, 2023, is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zyUPIhhTgClk" style="display: none"&gt;Schedule of Total Intrinsic Value&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Value of Stock at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zrkBRiqqQy2i" style="width: 16%; text-align: right" title="Options Outstanding Value of Stock"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OptionsExcercisableSharePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zOoksrDCpKWd" style="width: 16%; text-align: right" title="Options Exercisable Value of Stock"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zb8PSyGiExx6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Exercise Price"&gt;0.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zNQKltQxeIx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable Exercise Price"&gt;0.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Intrinsic Value Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zEuooQLcCDTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding Intrinsic Value Per Share"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z78JkwIjJ5Yg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Excercisable Intrinsic Value Per Share"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options O/S&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zyBSUf7Rfjac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding"&gt;246,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z2BQQGDGzlWh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable"&gt;246,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Intrinsic Value at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_zPFMR5g23Ftb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Intrinsic Value"&gt;108,300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenStockIncentivePlanMember_z6O0lcqKxIFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable Intrinsic Value"&gt;108,300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15197"
      unitRef="USDPShares">0.92</us-gaap:SharePrice>
    <AZTR:OptionsExcercisableSharePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15198"
      unitRef="USDPShares">0.92</AZTR:OptionsExcercisableSharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15199"
      unitRef="USDPShares">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15200"
      unitRef="USDPShares">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15201"
      unitRef="USDPShares">0.44</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare>
    <AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15202"
      unitRef="USDPShares">0.44</AZTR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15203"
      unitRef="Shares">246137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="INF"
      id="ixv-15204"
      unitRef="Shares">246137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="0"
      id="ixv-15205"
      unitRef="USD">108300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_custom_TwoThousandSixteenStockIncentivePlanMember"
      decimals="0"
      id="ixv-15206"
      unitRef="USD">108300</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10572">&lt;p id="xdx_802_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zpZPvJubsqMj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.
&lt;span id="xdx_823_zqiV7bvlq3G6"&gt;Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBKPHKKuW5vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_ziY5xp84EIgb" style="display: none"&gt;Schedule of Fair Value Measurements for Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2e8yspYLvIh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zk6TsCYXF1Rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zstjytY83pPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKGa7vl2qWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zHlPqQZ1mqmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1284"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z3EYgVVW1NU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFv6jSbplQ79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoS2fezKmjEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxPBFbWHocb9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9zxz54b4MHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zIEMn0IQf2l3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;70,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;70,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNoteMember_zYi48rZhccb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z8XA51UIyGpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,670,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,567,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zuTmJjT7RD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z0kZpwkZv4If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zncfXAazObO" style="display: none"&gt;Schedule
of Changes in Level 3 Instruments Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_4BD_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1p34BQtPLUl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_z1q7e27CglDj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;71,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zurp5fkLQ478" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IssuanceOfConvertibleNotes_z1NKCLvE1QTh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zH3s99L4a9gi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_ztNUsYSMFtuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,670,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zXKBGPbrt20d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,830&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zvSvJ0XeOJO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,630,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConversionConvertibleNotes_zHJuLjed3EO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Conversion of 2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,230,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zve30gNh3qe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zmd6jwOWj7Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;11. Fair Value Measurements (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zoOSLa7v7TR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zhFxpIcLF5B4" style="display: none"&gt;Schedule
of Fair Value of Warrants Using Black Scholes Option Pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Underlying common stock value&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zUDDyoy1CJh3" style="width: 16%; text-align: right" title="Dividend yield"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231_zXTl2VrkBAci" style="width: 16%; text-align: right" title="Dividend yield"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zYkWaZCcl9El" title="Expected term (years)"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zpLwB0ubkzwj" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_z7tZJPnP41E4" style="text-align: right" title="Expected volatility"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zfcaq46ibAla" style="text-align: right" title="Expected volatility"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zN4HKuQkBTmk" style="text-align: right" title="Risk free interest rate"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zm0mVHMFB1P2" style="text-align: right" title="Risk free interest rate"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zePJz5kqEL6l" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zOnRUNZeT7x1" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zY5Wyo7xpau6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fluctuation
in the fair value of the Company&#x2019;s Common stock is the primary driver for the change in the Common Stock Warrant liability valuation
during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to their redemption, fluctuations in the various inputs, including the enterprise value, time to liquidity, volatility, and discount
rate are the primary drivers for the changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the
enterprise value, estimated time to liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible
Notes generally increases.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10578">&lt;p id="xdx_895_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBKPHKKuW5vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_ziY5xp84EIgb" style="display: none"&gt;Schedule of Fair Value Measurements for Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2e8yspYLvIh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zk6TsCYXF1Rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zstjytY83pPf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKGa7vl2qWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zHlPqQZ1mqmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1284"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z3EYgVVW1NU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFv6jSbplQ79" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoS2fezKmjEh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxPBFbWHocb9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9zxz54b4MHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--CommonStockWarrantsMember_zIEMn0IQf2l3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;70,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;70,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--FinancialInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNoteMember_zYi48rZhccb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,600,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueNetAssetLiability_iI_z8XA51UIyGpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,670,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,567,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      decimals="0"
      id="ixv-15207"
      unitRef="USD">35453</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      decimals="0"
      id="ixv-15208"
      unitRef="USD">35453</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="ixv-15209"
      unitRef="USD">35453</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="ixv-15210"
      unitRef="USD">35453</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      decimals="0"
      id="ixv-15211"
      unitRef="USD">70283</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_CommonStockWarrantsMember"
      decimals="0"
      id="ixv-15212"
      unitRef="USD">70283</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember"
      decimals="0"
      id="ixv-15213"
      unitRef="USD">5600000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_TwoThousandTwentyTwoConvertibleNoteMember"
      decimals="0"
      id="ixv-15214"
      unitRef="USD">5600000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="ixv-15215"
      unitRef="USD">5670283</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="ixv-15216"
      unitRef="USD">5567283</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10762">&lt;p id="xdx_89B_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z0kZpwkZv4If" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zncfXAazObO" style="display: none"&gt;Schedule
of Changes in Level 3 Instruments Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_4BD_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1p34BQtPLUl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_z1q7e27CglDj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;71,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zurp5fkLQ478" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IssuanceOfConvertibleNotes_z1NKCLvE1QTh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zH3s99L4a9gi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_ztNUsYSMFtuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,670,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_zXKBGPbrt20d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(34,830&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInFairValueOfConvertibleNotes_zvSvJ0XeOJO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of 2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,630,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConversionConvertibleNotes_zHJuLjed3EO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Conversion of 2022 Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,230,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zve30gNh3qe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15217"
      unitRef="USD">71104</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15218"
      unitRef="USD">-821</us-gaap:FairValueAdjustmentOfWarrants>
    <AZTR:IssuanceOfConvertibleNotes
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15219"
      unitRef="USD">4350000</AZTR:IssuanceOfConvertibleNotes>
    <AZTR:ChangeInFairValueOfConvertibleNotes
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15220"
      unitRef="USD">1250000</AZTR:ChangeInFairValueOfConvertibleNotes>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15221"
      unitRef="USD">5670283</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15222"
      unitRef="USD">-34830</us-gaap:FairValueAdjustmentOfWarrants>
    <AZTR:ChangeInFairValueOfConvertibleNotes
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15223"
      unitRef="USD">3630100</AZTR:ChangeInFairValueOfConvertibleNotes>
    <AZTR:ConversionConvertibleNotes
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15224"
      unitRef="USD">-9230100</AZTR:ConversionConvertibleNotes>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="ixv-15225"
      unitRef="USD">35453</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10856">&lt;p id="xdx_899_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zoOSLa7v7TR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the
following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zhFxpIcLF5B4" style="display: none"&gt;Schedule
of Fair Value of Warrants Using Black Scholes Option Pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Underlying common stock value&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zUDDyoy1CJh3" style="width: 16%; text-align: right" title="Dividend yield"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231_zXTl2VrkBAci" style="width: 16%; text-align: right" title="Dividend yield"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zYkWaZCcl9El" title="Expected term (years)"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zpLwB0ubkzwj" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231_z7tZJPnP41E4" style="text-align: right" title="Expected volatility"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zfcaq46ibAla" style="text-align: right" title="Expected volatility"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231_zN4HKuQkBTmk" style="text-align: right" title="Risk free interest rate"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zm0mVHMFB1P2" style="text-align: right" title="Risk free interest rate"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zePJz5kqEL6l" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zOnRUNZeT7x1" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15226"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15227"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="ixv-15228">P4Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="ixv-15229">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15230"
      unitRef="Pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15231"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15232"
      unitRef="Pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15233"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10937">&lt;p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zBMkOwBVb9Cg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.
&lt;span id="xdx_82C_z6xU1tXD7XL3"&gt;Net Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share were calculated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zJNFCSMaVIi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
numerator for basic and diluted net loss per share is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zfpFVNqOTC3h" style="display: none"&gt;Schedule of Numerator for Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zCPJVc2TksLi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zFZDXGfH5KHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILFCzCGP_zULqagYfRwO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(11,283,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,680,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DividendsPreferredStockStock_iN_di_msNILFCzCGP_zLM3gIHiY3X5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dividends on preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,355,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,768,984&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_iT_mtNILFCzCGP_zyXj41tpGmj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(12,639,128&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,449,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zxpTpRC9P2D5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zGsT9DCsnp34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
denominator is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zLTGJPpLz6f1" style="display: none"&gt;Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Weighted average common stock outstanding, basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2coApmHoYv8" title="Weighted average common stock outstanding, basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNNh9KEXWE6" title="Weighted average common stock outstanding, diluted"&gt;6,919,081&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtNwCylC15" title="Weighted average common stock outstanding, basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRK3MfNeG5cg" title="Weighted average common stock outstanding, diluted"&gt;1,043,932&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;$0.01 warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYb2ti6mWI6" title="$0.01 warrants, basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRX72Go7aqmb" title="$0.01 warrants, diluted"&gt;5,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfL9UvMbNNf" title="$0.01 warrants, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuNTI8EmtUc" title="$0.01 warrants, diluted"&gt;11,467&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zz3A9PtZqQIb" title="Total, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z8ZlPbMj0mz2" title="Total, diluted"&gt;6,924,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zCJ9KcRdEP7h" title="Total, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zGwOsO0x3oxg" title="Total, diluted"&gt;1,055,399&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zkKnj9BZ0Eq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;12. Net Loss Per Share (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zzHwGgy3Dqw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share, basic and diluted is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zQbWsCUzCHU6" style="display: none"&gt;Schedule of Net Loss Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net Loss per share, basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBYfdHL8e44c" title="Net loss per share, basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zUH004Uqwkt5" title="Net loss per share, diluted"&gt;(1.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zB02apJBBhYe" title="Net loss per share, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_z6yPSgVg12Z6" title="Net loss per share, diluted"&gt;(12.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zJ90GOUSIsv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRfdJ1Q0gWp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zbnsigDYV59l" style="display: none"&gt;Schedule of Calculation of Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zsXLrmvpRAp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zQGqz7S0BhKb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_ziBSQNCoJAC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,288,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,290,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z03y5jLiEog7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263,743&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zAc0GXMqIWO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,611,991&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,554,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zEsyP8793r51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-10947">&lt;p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zJNFCSMaVIi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
numerator for basic and diluted net loss per share is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zfpFVNqOTC3h" style="display: none"&gt;Schedule of Numerator for Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zCPJVc2TksLi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zFZDXGfH5KHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_maNILFCzCGP_zULqagYfRwO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(11,283,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,680,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DividendsPreferredStockStock_iN_di_msNILFCzCGP_zLM3gIHiY3X5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dividends on preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,355,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,768,984&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_iT_mtNILFCzCGP_zyXj41tpGmj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(12,639,128&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,449,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15234"
      unitRef="USD">-11283781</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15235"
      unitRef="USD">-10680366</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15236"
      unitRef="USD">1355347</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15237"
      unitRef="USD">2768984</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15238"
      unitRef="USD">-12639128</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15239"
      unitRef="USD">-13449350</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11007">&lt;p id="xdx_89B_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zGsT9DCsnp34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
denominator is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zLTGJPpLz6f1" style="display: none"&gt;Schedule of Numerator for Basic and Diluted Weighted Average Common Stock Outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Weighted average common stock outstanding, basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2coApmHoYv8" title="Weighted average common stock outstanding, basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUNNh9KEXWE6" title="Weighted average common stock outstanding, diluted"&gt;6,919,081&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8TtNwCylC15" title="Weighted average common stock outstanding, basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRK3MfNeG5cg" title="Weighted average common stock outstanding, diluted"&gt;1,043,932&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;$0.01 warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYb2ti6mWI6" title="$0.01 warrants, basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRX72Go7aqmb" title="$0.01 warrants, diluted"&gt;5,372&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvfL9UvMbNNf" title="$0.01 warrants, basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQuNTI8EmtUc" title="$0.01 warrants, diluted"&gt;11,467&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zz3A9PtZqQIb" title="Total, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z8ZlPbMj0mz2" title="Total, diluted"&gt;6,924,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zCJ9KcRdEP7h" title="Total, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zGwOsO0x3oxg" title="Total, diluted"&gt;1,055,399&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15240"
      unitRef="Shares">6919081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15241"
      unitRef="Shares">6919081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15242"
      unitRef="Shares">1043932</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15243"
      unitRef="Shares">1043932</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember101773265"
      decimals="INF"
      id="ixv-15244"
      unitRef="Shares">5372</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember101773265"
      decimals="INF"
      id="ixv-15245"
      unitRef="Shares">5372</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-15246"
      unitRef="Shares">11467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-15247"
      unitRef="Shares">11467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15248"
      unitRef="Shares">6924453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15249"
      unitRef="Shares">6924453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15250"
      unitRef="Shares">1055399</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15251"
      unitRef="Shares">1055399</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11096">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zzHwGgy3Dqw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share, basic and diluted is as follows for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zQbWsCUzCHU6" style="display: none"&gt;Schedule of Net Loss Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net Loss per share, basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBYfdHL8e44c" title="Net loss per share, basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zUH004Uqwkt5" title="Net loss per share, diluted"&gt;(1.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zB02apJBBhYe" title="Net loss per share, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_z6yPSgVg12Z6" title="Net loss per share, diluted"&gt;(12.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15252"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15253"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15254"
      unitRef="USDPShares">-12.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15255"
      unitRef="USDPShares">-12.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11132">&lt;p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRfdJ1Q0gWp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zbnsigDYV59l" style="display: none"&gt;Schedule of Calculation of Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zsXLrmvpRAp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zQGqz7S0BhKb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_ziBSQNCoJAC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,288,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,290,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z03y5jLiEog7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;323,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263,743&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zAc0GXMqIWO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,611,991&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,554,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15256"
      unitRef="Shares">1288255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="ixv-15257"
      unitRef="Shares">1290318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember101773703"
      decimals="INF"
      id="ixv-15258"
      unitRef="Shares">323736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember101773718"
      decimals="INF"
      id="ixv-15259"
      unitRef="Shares">263743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15260"
      unitRef="Shares">1611991</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-15261"
      unitRef="Shares">1554061</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11192">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zoJBeGCYKQrg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.
&lt;span id="xdx_823_z92Mn21tNel9"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zpfbBNL4YGPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
(benefit) provision for income taxes for the years ending December 31, 2023 and December 31, 2022 consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zIOjfXsCBFq7" style="display: none"&gt;Schedule
of (Benefit) Provision for Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zGYtHGstCgd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zIgjC1BHdPmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzw8s_z4hkGu6sJr1f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1414"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1415"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzw8s_zUhSNJnkiHp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Foreign&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzw8s_zyeb7u5WOyHa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1421"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzw8s_maITEBzwVq_zB0CcPiU7ny4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1424"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBz8IL_z8oA38GMc7rj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBz8IL_zaTfkcSR9up2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBz8IL_zB05kIboZfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1433"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBz8IL_maITEBzwVq_zvyM8uXgmD7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzwVq_zCoJbq6tBkO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1439"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zKkc3ULkV2R3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8TNnX7OuLJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax computed using the U.S. federal statutory tax rate compared to that reflected in operations for the years
ending December 31, 2023 and December 31, 2022 consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zr6AjcBdvpN2" style="display: none"&gt;Schedule
of Reconciliation of Income Tax&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Income taxes using U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20230101__20231231_zBQWfu5NiH14" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount"&gt;(2,401,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20230101__20231231_zFQvJdlBxaKh" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zqldSVBsjYSl" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount"&gt;(2,205,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20220101__20221231_zAwHWYPwvQP6" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt fair value adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20230101__20231231_zT1v6mNoWBh9" style="text-align: right" title="Debt fair value adjustment, amount"&gt;762,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20230101__20231231_zgKlhvb28D4d" style="text-align: right" title="Debt fair value adjustment, percent"&gt;(6.67&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20220101__20221231_zI8sHpMERyk8" style="text-align: right" title="Debt fair value adjustment, amount"&gt;262,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20220101__20221231_zoNgeEc5sgYg" style="text-align: right" title="Debt fair value adjustment, percent"&gt;(2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zNPf6YVQdqC5" style="text-align: right" title="State taxes, net of federal benefit, amount"&gt;(538,268&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20230101__20231231_zCyc8KELZeT1" style="text-align: right" title="State taxes, net of federal benefit, percent"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20220101__20221231_zRZzEZj1GPF7" style="text-align: right" title="State taxes, net of federal benefit, amount"&gt;(602,211&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20220101__20221231_zl6sZEUwzwI7" style="text-align: right" title="State taxes, net of federal benefit, percent"&gt;5.73&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zmt64MMj3WUk" style="text-align: right" title="Research and development tax credit, amount"&gt;(356,237&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20230101__20231231_zSRVv2461cDi" style="text-align: right" title="Research and development tax credit, percent"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231_zJk1BxhkFHU9" style="text-align: right" title="Research and development tax credit, amount"&gt;(433,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20220101__20221231_zYx5r1gOzZol" style="text-align: right" title="Research and development tax credit, percent"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_z9PXm5o8mZp5" style="text-align: right" title="Change in valuation allowance, amount"&gt;2,502,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20230101__20231231_zOZZNI679Ft" style="text-align: right" title="Change in valuation allowance, percent"&gt;(21.88&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zlk32p46zGq5" style="text-align: right" title="Change in valuation allowance, amount"&gt;2,889,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20220101__20221231_zjfN5GrkvOh3" style="text-align: right" title="Change in valuation allowance, percent"&gt;(27.51&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zE16s75wjxec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount"&gt;48,335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20230101__20231231_zvrRd69wLQ6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent"&gt;(0.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20220101__20221231_zKZfGx0xO2H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount"&gt;89,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20220101__20221231_zQ6NWxkGQcEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent"&gt;(0.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expenses (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_zpyz6dkPwVt9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20230101__20231231_zL0JtloCgzrf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="U.S. federal statutory tax rate"&gt;(0.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231_zP9O6vp9zrB" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;p id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20220101__20221231_zf6GfF1mv82j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1497"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zY4expNN5Ga3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;13. Income Taxes (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhpaIW6z2iL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_ziXVB3Yf6517" style="display: none"&gt;Schedule
of Deferred Income Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zocL4cblOKt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zQ4I8w2dCtHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zOv3kUhmi6Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_zMbnYKMXCjah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,755,690&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,870,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_ziW2rjLHPgd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,155,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,729,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_maDTAGzRjT_maDTAGzJN6_zM2Ib0xs56Se" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,372,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,189,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzJN6_z9YiDw1wHPg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJN6_zfEkFsSKHIDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,572&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJN6_maDTALNzcbS_zIm003X3ZEN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,402,912&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,899,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zmBM7rBQJGs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzJtH_zVpXKUZeRN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1525"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzJtH_msDTALNzcbS_z78OE6dfDKr4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1528"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzcbS_zJkpwGa5FF7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,402,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,899,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcbS_zOn5cvxwIoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1534"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1535"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zVyNMELdCeEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has federal net operating loss carryforwards of approximately $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZh3XhJkHwc" title="Net operating loss carry forwards"&gt;32,529,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmqoxOoMuZI5" title="Net operating loss carry forwards"&gt;29,192,000&lt;/span&gt; for the tax years ending December 31,
2023 and 2022, respectively, of which $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2037Member_zBlYMv8JZY95" title="Net operating loss carry forwards"&gt;1,285,000&lt;/span&gt; will expire in tax years 2036 through 2037 and approximately $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--NoExpirationMember_zIeXdvwHMsr4" title="Net operating loss carry forwards"&gt;31,244,000&lt;/span&gt; which does
not expire. The Company has state net operating loss carryforwards of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_zOLPNzCv4gEj" title="Net operating loss carry forwards"&gt;32,484,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2037Through2043Member_z4Sg90sEegR3" title="Net operating loss carry forwards"&gt;29,374,000&lt;/span&gt; for the tax years ending
December 31, 2023 and 2022, respectively, which will expire in tax years 2037 through 2043.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has federal research tax credits of approximately $&lt;span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_z4chqDCa37m1" title="Research tax credits"&gt;1,524,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_znkq3rpIqId2" title="Research tax credits"&gt;1,235,000&lt;/span&gt; for the tax years ending December 31, 2023 and 2022,
respectively, which expire in tax years 2039 through 2043. The Company has state research tax credits of approximately $&lt;span id="xdx_90A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkZR3vZ6PAf2" title="Research tax credits"&gt;466,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zxEm7BwfiKWg" title="Research tax credits"&gt;350,000&lt;/span&gt;
for the tax years ending December 31, 2023 and 2022, respectively, of which $&lt;span id="xdx_901_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxPeriodAxis__custom--TaxYears2036Through2038Member_zzPIAC2tvgEi" title="Research tax credits"&gt;312,000&lt;/span&gt; will expire in tax year 2036 through 2038 and the
remainder can be carried forward indefinitely. The Company has Canadian research tax credits of approximately $&lt;span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zCjOgZ53X0yl" title="Research tax credits"&gt;263,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__us-gaap--TaxPeriodAxis__custom--TaxYears2039Through2043Member_zfOX7ceMxKYa" title="Research tax credits"&gt;218,000&lt;/span&gt; for
the tax years ending December 31, 2023 and 2022, respectively, which expire in tax years 2039 through 2043.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
U.S. Internal Revenue Code Section 382 imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership
change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company undergoes an ownership
change exceeding the 50% limitation threshold imposed by Section 382, the Company&#x2019;s net operating loss carryforwards may be significantly
limited as to the amount of use in a particular year. In addition, all or a portion of the Company&#x2019;s net operating loss carryforwards
incurred before 2018, may expire unutilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;13. Income Taxes (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
realization of deferred tax assets is dependent upon the Company&#x2019;s ability to generate future taxable income during the periods
in which the temporary differences become deductible. Based on the Company&#x2019;s recent earnings history and projected future U.S.
earnings, management believes that it is more likely than not that its federal and state deferred tax assets will not be fully realized
in the foreseeable future. As a result of this assessment, management believes that a full valuation allowance against its net federal
and state deferred tax assets is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 740-10 to account for uncertain tax positions. ASC 740-10 addresses the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the
Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be
sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that it
has no significant uncertain tax positions requiring recognition and measurement under ASC 740-10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income tax, Connecticut state income tax and Canada branch tax. The Company has not been audited by
the IRS, state, or foreign tax authorities in connection with income taxes. The Company&#x2019;s tax years remain open to examination
for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statute of limitations
have expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will recognize interest and penalties related to unrecognized tax benefits, if applicable, as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11198">&lt;p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zpfbBNL4YGPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
(benefit) provision for income taxes for the years ending December 31, 2023 and December 31, 2022 consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zIOjfXsCBFq7" style="display: none"&gt;Schedule
of (Benefit) Provision for Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zGYtHGstCgd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zIgjC1BHdPmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzw8s_z4hkGu6sJr1f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1414"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1415"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzw8s_zUhSNJnkiHp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Foreign&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzw8s_zyeb7u5WOyHa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1421"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzw8s_maITEBzwVq_zB0CcPiU7ny4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1424"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBz8IL_z8oA38GMc7rj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBz8IL_zaTfkcSR9up2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBz8IL_zB05kIboZfGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1433"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBz8IL_maITEBzwVq_zvyM8uXgmD7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzwVq_zCoJbq6tBkO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1439"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15262"
      unitRef="USD">17308</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15263"
      unitRef="USD">17308</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15264"
      unitRef="USD">17308</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11351">&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8TNnX7OuLJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax computed using the U.S. federal statutory tax rate compared to that reflected in operations for the years
ending December 31, 2023 and December 31, 2022 consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zr6AjcBdvpN2" style="display: none"&gt;Schedule
of Reconciliation of Income Tax&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Income taxes using U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20230101__20231231_zBQWfu5NiH14" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount"&gt;(2,401,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20230101__20231231_zFQvJdlBxaKh" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c20220101__20221231_zqldSVBsjYSl" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, amount"&gt;(2,205,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20220101__20221231_zAwHWYPwvQP6" style="width: 11%; text-align: right" title="Income taxes using U.S. statutory rate, percent"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt fair value adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20230101__20231231_zT1v6mNoWBh9" style="text-align: right" title="Debt fair value adjustment, amount"&gt;762,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20230101__20231231_zgKlhvb28D4d" style="text-align: right" title="Debt fair value adjustment, percent"&gt;(6.67&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxReconciliationDebtFairValueAdjustment_c20220101__20221231_zI8sHpMERyk8" style="text-align: right" title="Debt fair value adjustment, amount"&gt;262,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate_pid_dp_maABC_c20220101__20221231_zoNgeEc5sgYg" style="text-align: right" title="Debt fair value adjustment, percent"&gt;(2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20230101__20231231_zNPf6YVQdqC5" style="text-align: right" title="State taxes, net of federal benefit, amount"&gt;(538,268&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20230101__20231231_zCyc8KELZeT1" style="text-align: right" title="State taxes, net of federal benefit, percent"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_c20220101__20221231_zRZzEZj1GPF7" style="text-align: right" title="State taxes, net of federal benefit, amount"&gt;(602,211&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20220101__20221231_zl6sZEUwzwI7" style="text-align: right" title="State taxes, net of federal benefit, percent"&gt;5.73&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zmt64MMj3WUk" style="text-align: right" title="Research and development tax credit, amount"&gt;(356,237&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20230101__20231231_zSRVv2461cDi" style="text-align: right" title="Research and development tax credit, percent"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20220101__20221231_zJk1BxhkFHU9" style="text-align: right" title="Research and development tax credit, amount"&gt;(433,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_msABC_c20220101__20221231_zYx5r1gOzZol" style="text-align: right" title="Research and development tax credit, percent"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_z9PXm5o8mZp5" style="text-align: right" title="Change in valuation allowance, amount"&gt;2,502,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20230101__20231231_zOZZNI679Ft" style="text-align: right" title="Change in valuation allowance, percent"&gt;(21.88&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zlk32p46zGq5" style="text-align: right" title="Change in valuation allowance, amount"&gt;2,889,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20220101__20221231_zjfN5GrkvOh3" style="text-align: right" title="Change in valuation allowance, percent"&gt;(27.51&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20230101__20231231_zE16s75wjxec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount"&gt;48,335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20230101__20231231_zvrRd69wLQ6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent"&gt;(0.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationOtherAdjustments_c20220101__20221231_zKZfGx0xO2H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, amount"&gt;89,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_maABC_c20220101__20221231_zQ6NWxkGQcEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other, net, percent"&gt;(0.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expenses (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_zpyz6dkPwVt9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"&gt;17,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20230101__20231231_zL0JtloCgzrf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="U.S. federal statutory tax rate"&gt;(0.15&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231_zP9O6vp9zrB" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income tax expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;p id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_mtABC_c20220101__20221231_zf6GfF1mv82j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1497"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15265"
      unitRef="USD">-2401761</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15266"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15267"
      unitRef="USD">-2205649</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15268"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <AZTR:IncomeTaxReconciliationDebtFairValueAdjustment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15269"
      unitRef="USD">762321</AZTR:IncomeTaxReconciliationDebtFairValueAdjustment>
    <AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15270"
      unitRef="Pure">-0.0667</AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate>
    <AZTR:IncomeTaxReconciliationDebtFairValueAdjustment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15271"
      unitRef="USD">262500</AZTR:IncomeTaxReconciliationDebtFairValueAdjustment>
    <AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15272"
      unitRef="Pure">-0.0250</AZTR:EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustmentTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15273"
      unitRef="USD">-538268</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15274"
      unitRef="Pure">0.0471</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15275"
      unitRef="USD">-602211</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15276"
      unitRef="Pure">0.0573</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15277"
      unitRef="USD">-356237</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15278"
      unitRef="Pure">0.0311</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15279"
      unitRef="USD">-433674</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15280"
      unitRef="Pure">0.0413</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15281"
      unitRef="USD">2502918</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15282"
      unitRef="Pure">-0.2188</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15283"
      unitRef="USD">2889667</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15284"
      unitRef="Pure">-0.2751</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15285"
      unitRef="USD">48335</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15286"
      unitRef="Pure">-0.0042</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15287"
      unitRef="USD">89367</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-15288"
      unitRef="Pure">-0.0085</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15289"
      unitRef="USD">17308</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-15290"
      unitRef="Pure">-0.0015</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11537">&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhpaIW6z2iL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_ziXVB3Yf6517" style="display: none"&gt;Schedule
of Deferred Income Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zocL4cblOKt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zQ4I8w2dCtHe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zOv3kUhmi6Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_zMbnYKMXCjah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,755,690&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,870,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGzRjT_maDTAGzJN6_ziW2rjLHPgd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,155,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,729,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_maDTAGzRjT_maDTAGzJN6_zM2Ib0xs56Se" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,372,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,189,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzJN6_z9YiDw1wHPg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJN6_zfEkFsSKHIDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,572&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJN6_maDTALNzcbS_zIm003X3ZEN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,402,912&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,899,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zmBM7rBQJGs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzJtH_zVpXKUZeRN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1525"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzJtH_msDTALNzcbS_z78OE6dfDKr4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1528"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzcbS_zJkpwGa5FF7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,402,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,899,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzcbS_zOn5cvxwIoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1534"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1535"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15291"
      unitRef="USD">8755690</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15292"
      unitRef="USD">7870665</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15293"
      unitRef="USD">2155118</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15294"
      unitRef="USD">1729421</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <AZTR:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15295"
      unitRef="USD">2372070</AZTR:DeferredTaxAssetsDepreciationAndAmortization>
    <AZTR:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15296"
      unitRef="USD">1189975</AZTR:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15297"
      unitRef="USD">89462</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15298"
      unitRef="USD">81876</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15299"
      unitRef="USD">30572</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15300"
      unitRef="USD">28057</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15301"
      unitRef="USD">13402912</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15302"
      unitRef="USD">10899994</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15303"
      unitRef="USD">13402912</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-15304"
      unitRef="USD">10899994</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="ixv-15305"
      unitRef="USD">32529000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="ixv-15306"
      unitRef="USD">29192000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2036Through2037Member"
      decimals="0"
      id="ixv-15307"
      unitRef="USD">1285000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember_custom_NoExpirationMember"
      decimals="0"
      id="ixv-15308"
      unitRef="USD">31244000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member"
      decimals="0"
      id="ixv-15309"
      unitRef="USD">32484000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2037Through2043Member"
      decimals="0"
      id="ixv-15310"
      unitRef="USD">29374000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member"
      decimals="0"
      id="ixv-15311"
      unitRef="USD">1524000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_custom_TaxYears2039Through2043Member"
      decimals="0"
      id="ixv-15312"
      unitRef="USD">1235000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="ixv-15313"
      unitRef="USD">466000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="ixv-15314"
      unitRef="USD">350000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31_us-gaap_StateAndLocalJurisdictionMember_custom_TaxYears2036Through2038Member"
      decimals="0"
      id="ixv-15315"
      unitRef="USD">312000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member"
      decimals="0"
      id="ixv-15316"
      unitRef="USD">263000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember_custom_TaxYears2039Through2043Member"
      decimals="0"
      id="ixv-15317"
      unitRef="USD">218000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11769">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zifvlu3ZAqx1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.
&lt;span id="xdx_82F_zvhYM1tSkWi1"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions
or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on
its financial position, results of operations or liquidity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License
Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 26, 2022, the Company entered into an Exclusive License Agreement (the License Agreement) with an unrelated third party. Under
the License Agreement, the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how.
The License Agreement continues until the later of the expiration of the last to expire licensed patent or ten years after the first
commercial sale of the first licensed therapeutic or non-therapeutic product. The Company may terminate the License Agreement at any
time by providing at least 30 days written notice to the third party. The License Agreement is also terminated upon breach of a material
obligation under the agreement or bankruptcy. Upon any termination of the License Agreement, neither party is relieved of obligations
incurred prior to the termination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, the Company capitalized payments made under this license agreement in the amount of $&lt;span id="xdx_909_eus-gaap--ProceedsFromLicenseFeesReceived_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_z72gFpn1c2T6" title="Capitalized License agreement amount"&gt;13,096&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--ProceedsFromLicenseFeesReceived_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsZqhBt4Ty41" title="Capitalized License agreement amount"&gt;65,510&lt;/span&gt;, respectively. During the fourth quarter, the license agreement was subsequently written off as discussed in Note 2.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="From2023-01-012023-12-31_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-15318"
      unitRef="USD">13096</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="From2022-01-012022-12-31_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      id="ixv-15319"
      unitRef="USD">65510</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11797">&lt;p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zFSlWNltB9S3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.
&lt;span id="xdx_82D_z5r1stsCw0kd"&gt;Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company&#x2019;s leases expire at various dates
through May 31, 2027. Most leases are for a fixed term and for a fixed amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2019, the Company entered into a new lease agreement for office and laboratory space in Laval, Canada. The Laval lease required monthly
lease payments of $&lt;span id="xdx_901_eus-gaap--OperatingLeasePayments_c20190101__20191231__srt--StatementGeographicalAxis__country--CA_zHfhzd5bcFw7" title="Lease payments"&gt;5,221&lt;/span&gt; which increased approximately 10% per year upon renewal. The Laval lease is initially for a &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zqXHyIhVsKqb" title="Lease term"&gt;one year&lt;/span&gt; term with
additional &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dc_c20191231__srt--StatementGeographicalAxis__country--CA_zy288uYbnRn6" title="Lease term renewal"&gt;one year&lt;/span&gt; renewal terms available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"&gt;15. Operating Leases (continued)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2020, the Company entered into a new lease agreement for the Company&#x2019;s primary office and laboratory space in Branford, CT. The
Branford lease requires monthly payments of $&lt;span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20200101__20201231__dei--LegalEntityAxis__custom--BranfordCTMember_ztNfo4aiBSYf" title="Lease payments"&gt;13,033&lt;/span&gt; for the first year of the lease, which increases approximately 2% in each of the
following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments
of $&lt;span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210501__20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zHbsjix5ybUk" title="Lease payments"&gt;4,234&lt;/span&gt;, which was increased to $&lt;span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210901__20210930__dei--LegalEntityAxis__custom--GrotonCTMember_zuxsbB8Pvie8" title="Lease payments"&gt;6,824&lt;/span&gt; in September 2021 upon leasing additional space. The Groton lease is initially for a &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zJhR1BwhlHhb" title="Lease term::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1583"&gt;one&lt;/span&gt;&lt;/span&gt;-year
term, with up to &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20210531__dei--LegalEntityAxis__custom--GrotonCTMember_zYKptnyscBfb" title="Lease term renewal::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1585"&gt;three&lt;/span&gt;&lt;/span&gt; additional years renewal available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zm3Zqunk70Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zob4Grp0Rvqj" style="display: none"&gt;Schedule of Future Minimum Payments Under Non-cancelable Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231231_z1D2ts613384" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrWe_zjlwdIEbroUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;338,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrWe_z7DrqcLsQMvf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrWe_zXEyNoTI7hVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzrWe_zTrAKc8MM941" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzrWe_zUfTXVdcqED8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzrWe_zS79ur35KmVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrWe_z7zMVNGc8NBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zOMi14Eml617" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_z1IjGrF02Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;845,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zNEn7N8peqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense for all operating leases was $&lt;span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231_zBuQc4khLhC5" title="Operating lease rental expense"&gt;338,856&lt;/span&gt; for the year ended December 31, 2023. The weighted average lease term for all operating
leases is &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhpEHfdTr034" title="Operating lease term"&gt;2.9&lt;/span&gt; years. The weighted average discount rate for all operating leases is &lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zoPCxLsEmD8f" title="Operating lease discount rate"&gt;4.25&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company entered into an agreement with Hewlett Packard to lease equipment. The lease requires monthly payments of $&lt;span id="xdx_90E_ecustom--FinanceLeaseMonthlyPayments_c20230101__20231231_zDvxF2ZSq0Wf" title="Finance lease monthly payments"&gt;1,478&lt;/span&gt;, including
tax. The lease is for a &lt;span id="xdx_900_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtY_c20231231_zvbDls2Dae5l" title="Finance lease term"&gt;3&lt;/span&gt;-year term with option of purchase or extension at term end. The remaining lease term is &lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20231231_zZvLtWRlkSjk" title="Finance lease remaining lease term"&gt;2.8&lt;/span&gt; years and the discount
rate is &lt;span id="xdx_901_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20231231_zSny5LKEl3Ei" title="Finance lease discount rate"&gt;9.60&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z5RhecIKj2Nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zcxhdypVpmpk" style="display: none"&gt;Schedule of Future Minimum Payments Under Finance  Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231231_zMJCYukla8a3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzipE_zJL5lA5gQv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzipE_zCbpu78uBcl2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maFLLPDzipE_zfCFk8yxAvJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_maFLLPDzipE_zwkoILUcXhGa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_maFLLPDzipE_zIKCOXOMpCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1631"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzipE_zDfAaJeCiqDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FinanceLeaseInterest_iI_zMiM7sWvZM2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_zM4OQTtL0yy5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zLZ81GFREmbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
expense for the finance lease was $&lt;span id="xdx_901_ecustom--FinanceLeaseExpense_c20230101__20231231_zbDozcIynbM3" title="Finance lease expense"&gt;6,450&lt;/span&gt; for the year ended December 31, 2023. Interest expense for the finance lease was $&lt;span id="xdx_903_eus-gaap--FinanceLeaseInterestExpense_c20230101__20231231_z5zNtz9BbdQi" title="Interest expense"&gt;1,707&lt;/span&gt; for
the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;AZITRA, INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the Years Ended December 31, 2023 and 2022 &lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-012019-12-31_country_CA"
      decimals="0"
      id="ixv-15320"
      unitRef="USD">5221</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-12-31_country_CA" id="ixv-15321">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2019-12-31_country_CA" id="ixv-15322">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-012020-12-31_custom_BranfordCTMember"
      decimals="0"
      id="ixv-15323"
      unitRef="USD">13033</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-05-012021-05-31_custom_GrotonCTMember"
      decimals="0"
      id="ixv-15324"
      unitRef="USD">4234</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-09-012021-09-30_custom_GrotonCTMember"
      decimals="0"
      id="ixv-15325"
      unitRef="USD">6824</us-gaap:OperatingLeasePayments>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11852">&lt;p id="xdx_899_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zm3Zqunk70Rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zob4Grp0Rvqj" style="display: none"&gt;Schedule of Future Minimum Payments Under Non-cancelable Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231231_z1D2ts613384" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrWe_zjlwdIEbroUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;338,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrWe_z7DrqcLsQMvf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrWe_zXEyNoTI7hVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzrWe_zTrAKc8MM941" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzrWe_zUfTXVdcqED8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzrWe_zS79ur35KmVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrWe_z7zMVNGc8NBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zOMi14Eml617" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_z1IjGrF02Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;845,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15326"
      unitRef="USD">338254</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15327"
      unitRef="USD">279475</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15328"
      unitRef="USD">206423</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15329"
      unitRef="USD">74273</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15330"
      unitRef="USD">898424</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15331"
      unitRef="USD">53246</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15332"
      unitRef="USD">845178</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15333"
      unitRef="USD">338856</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="ixv-15334">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15335"
      unitRef="Pure">0.0425</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <AZTR:FinanceLeaseMonthlyPayments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15336"
      unitRef="USD">1478</AZTR:FinanceLeaseMonthlyPayments>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="AsOf2023-12-31" id="ixv-15337">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm contextRef="AsOf2023-12-31" id="ixv-15338">P2Y9M18D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-15339"
      unitRef="Pure">0.0960</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-11942">&lt;p id="xdx_895_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z5RhecIKj2Nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zcxhdypVpmpk" style="display: none"&gt;Schedule of Future Minimum Payments Under Finance  Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231231_zMJCYukla8a3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzipE_zJL5lA5gQv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzipE_zCbpu78uBcl2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maFLLPDzipE_zfCFk8yxAvJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_maFLLPDzipE_zwkoILUcXhGa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_maFLLPDzipE_zIKCOXOMpCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1631"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzipE_zDfAaJeCiqDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--FinanceLeaseInterest_iI_zMiM7sWvZM2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_zM4OQTtL0yy5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15340"
      unitRef="USD">17740</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15341"
      unitRef="USD">17740</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15342"
      unitRef="USD">10349</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15343"
      unitRef="USD">45829</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <AZTR:FinanceLeaseInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15344"
      unitRef="USD">-5060</AZTR:FinanceLeaseInterest>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-15345"
      unitRef="USD">40769</us-gaap:FinanceLeaseLiability>
    <AZTR:FinanceLeaseExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15346"
      unitRef="USD">6450</AZTR:FinanceLeaseExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15347"
      unitRef="USD">1707</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-12032">&lt;p id="xdx_806_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zRE4H9qmGaB2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16.
&lt;span id="xdx_82D_zuQUAq08qS63"&gt;Retirement Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 1, 2019, &lt;span id="xdx_90F_eus-gaap--DefinedBenefitPlansGeneralInformation_c20190101__20190101_z4RVtfH34xPa" title="Retirement plan general information"&gt;the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed.&lt;/span&gt; Total employer matching
contributions was $&lt;span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zwMjNzjIaEW9" title="Employer contribution"&gt;11,803&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zExiK3gn2iZ9" title="Employer contribution"&gt;23,466&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlansGeneralInformation contextRef="From2019-01-012019-01-01" id="ixv-15348">the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed.</us-gaap:DefinedBenefitPlansGeneralInformation>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-15349"
      unitRef="USD">11803</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-15350"
      unitRef="USD">23466</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-12045">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPQxsf05F055" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.
&lt;span id="xdx_824_zH5hw2pZx1D"&gt;Related Parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
related party revenue was $&lt;span id="xdx_906_eus-gaap--Revenues_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQJ6GYsF7317" title="Revenues from related party"&gt;686,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--Revenues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zxV5CvQmG3bj" title="Revenues from related party"&gt;284,000&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively. Accounts receivable due
from the related party was $&lt;span id="xdx_904_eus-gaap--OtherReceivables_iI_c20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfYaJuF77Asa" title="Accounts receivable due from related party"&gt;90,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_c20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zyvtKjoo2TZf" title="Accounts receivable due from related party"&gt;175,000&lt;/span&gt; at December 31, 2023 and 2022, respectively. Contract liabilities from the related party
was $&lt;span id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2XJDWac3P93" title="Contract liabilities due from related party"&gt;0&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ContractWithCustomerLiability_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zizPJ7LWVFJi" title="Contract liabilities due from related party"&gt;156,000&lt;/span&gt; at December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2022, the Company entered into a convertible promissory note totaling $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zjCVaA2flTu7" title="Convertible promissory note"&gt;4,350,000&lt;/span&gt; of which $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--TwentyTwentyTwoConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmrbhSzkVKxc" title="Convertible promissory note"&gt;4,000,000&lt;/span&gt; was attributable to an
entity who was also an investor in the Company&#x2019;s Series A, A-1, and B Preferred Stock financing (See Note 7). This entity received
&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zFfnJALfFUG9" title="Stock issued during conversion"&gt;1,697,490&lt;/span&gt; shares of common stock upon conversion of the promissory notes for principal and interest of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220901__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleNotesMember_zKNXV1gHOQ19" title="Stock issued during conversion"&gt;4,243,726&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15351"
      unitRef="USD">686000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15352"
      unitRef="USD">284000</us-gaap:Revenues>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15353"
      unitRef="USD">90000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2022-12-31_us-gaap_AccountsReceivableMember_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15354"
      unitRef="USD">175000</us-gaap:OtherReceivables>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15355"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-15356"
      unitRef="USD">156000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15357"
      unitRef="USD">4350000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-09-30_custom_ConvertibleNotePurchaseAgreementMember_custom_TwentyTwentyTwoConvertibleNotesMember_us-gaap_InvestorMember"
      decimals="0"
      id="ixv-15358"
      unitRef="USD">4000000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="ixv-15359"
      unitRef="Shares">1697490</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-09-012022-09-30_us-gaap_CommonStockMember_us-gaap_InvestorMember_custom_TwentyTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="ixv-15360"
      unitRef="USD">4243726</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-12069">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zIAx15YVBe5j" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.
&lt;span id="xdx_82B_zsgAIsHlB3yl"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2024, the Company completed a public offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPLCAm867Vii" title="Number of shares of public offering"&gt;16,667,000&lt;/span&gt; shares of its common stock at an offering price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoyTmekfbsWc" title="Share price per share"&gt;0.30&lt;/span&gt; per
share. The Company received gross proceeds of approximately $&lt;span id="xdx_90A_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn6n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPcULtCzU8qg" title="Gross proceeds from public offering"&gt;5&lt;/span&gt; million and net proceeds of approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zO19jNoEZ8Zk" title="Net proceeds from issuance of public offering"&gt;4.4&lt;/span&gt; million, after deducting
underwriting discounts and offering-related expenses. The Company granted the underwriter an overallotment option to purchase an additional
&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0THcsCXJGp6" title="Number of shares purchased"&gt;2,500,000&lt;/span&gt; shares of its common stock, at the public offering of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zOuze0LPKIo8" title="Public offering price per share"&gt;0.30&lt;/span&gt; per share less the underwriter&#x2019;s discount, for a 45-day period
ending March 29, 2024. In connection with the public offering, the Company issued to the underwriter, as additional underwriting compensation,
a warrant to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z5XzkSKemx2e" title="Warrants to purchase of common shares"&gt;666,680&lt;/span&gt; shares of its common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zX0HrsOOyMNd" title="Warrant exercise price per share"&gt;0.375&lt;/span&gt; per share over a &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_z4dnWQ8EU9q2" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1691"&gt;five&lt;/span&gt;&lt;/span&gt;-year period.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15361"
      unitRef="Shares">16667000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-15362"
      unitRef="USDPShares">0.30</us-gaap:SharePrice>
    <AZTR:GrossProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-6"
      id="ixv-15363"
      unitRef="USD">5000000</AZTR:GrossProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="ixv-15364"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-152024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_UnderwriterMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="ixv-15365"
      unitRef="Shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember"
      decimals="INF"
      id="ixv-15366"
      unitRef="USDPShares">0.30</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember"
      decimals="INF"
      id="ixv-15367"
      unitRef="Shares">666680</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-15_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwriterMember"
      decimals="INF"
      id="ixv-15368"
      unitRef="USDPShares">0.375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
